<SEC-DOCUMENT>0001144204-11-062961.txt : 20111110
<SEC-HEADER>0001144204-11-062961.hdr.sgml : 20111110
<ACCEPTANCE-DATETIME>20111110160555
ACCESSION NUMBER:		0001144204-11-062961
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20110930
FILED AS OF DATE:		20111110
DATE AS OF CHANGE:		20111110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeoStem, Inc.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33650
		FILM NUMBER:		111195450

	BUSINESS ADDRESS:	
		STREET 1:		420 LEXINGTON AVENUE
		STREET 2:		SUITE 450
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10170
		BUSINESS PHONE:		212-584-4171

	MAIL ADDRESS:	
		STREET 1:		420 LEXINGTON AVENUE
		STREET 2:		SUITE 450
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10170

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHASE III MEDICAL INC/DE
		DATE OF NAME CHANGE:	20030819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORNICHE GROUP INC /DE
		DATE OF NAME CHANGE:	19951117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FIDELITY MEDICAL INC
		DATE OF NAME CHANGE:	19951025
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v236875_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: PR Newswire-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED STATES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington, D.C. 20549</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_______________</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FORM 10-Q</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="hangingindent"><!--EFPlaceholder--></a></font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">x</font></div>
</td>
<td align="left" valign="top" width="85%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2011</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OR</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">o</font></div>
</td>
<td align="left" valign="top" width="85%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the Transition Period from __________________&#160;&#160;&#160;to _________________________</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission File Number 001-33650</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEOSTEM, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact name of registrant as specified in its charter)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DELAWARE</font></div>
</td>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">22-2343568</font></div>
</td>
</tr><tr>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(State or other jurisdiction of</font></div>
</td>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(I.R.S. Employer</font></div>
</td>
</tr><tr>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">incorporation or organization)</font></div>
</td>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Identification No.)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="45%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="45%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">420 LEXINGTON AVE, SUITE 450&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEW YORK, NEW YORK</font></div>
</td>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10170</font></div>
</td>
</tr><tr>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Address of principal executive offices)</font></div>
</td>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(zip code)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Registrant&#8217;s telephone number, including area code: 212-584-4180</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former name, former address and former fiscal year, if changed since last report)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes<font style="DISPLAY: inline;" face="Wingdings">&#160;&#160;x</font> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No<font style="DISPLAY: inline;" face="Wingdings">&#160;&#160;o</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No<font style="DISPLAY: inline;" face="Wingdings"> o</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="54%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Large accelerated filer<font style="DISPLAY: inline; FONT-FAMILY: wingdings"> o</font></font></div>
</td>
<td align="left" valign="top" width="36%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accelerated filer<font style="DISPLAY: inline; FONT-FAMILY: wingdings"> o</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="54%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="54%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-accelerated filer&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font>&#160;&#160;&#160;&#160;&#160;(Do not check if a smaller reporting company)</font></div>
</td>
<td align="left" valign="top" width="36%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Smaller reporting company<font style="DISPLAY: inline; FONT-FAMILY: wingdings"> x</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;&#160;&#160;&#160;No&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">107,324,573 </font>SHARES, $.001 PAR VALUE, AS OF <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">November 8</font>, 2011</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">INDEX</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="part_1_2_1"><!--EFPlaceholder--></a><a name="item_1_3_1"><!--EFPlaceholder--></a></font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page No.</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" colspan="2" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Part I&#160;&#160;- Financial Information:</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1.</font></div>
</td>
<td valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated Financial Statements (Unaudited):</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated Balance Sheets At September 30, 2011 and December 31, 2010</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated Statements of Operations for the three and nine months ended September 30, 2011 and 2010</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 39.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated Statements of Cash Flows for the nine months ended September 30, 2011 and 2010</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Notes to Unaudited Consolidated Financial Statements</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 2.</font></div>
</td>
<td valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">26</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 3.</font></div>
</td>
<td valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Quantitative and Qualitative Disclosures About Market Risk</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 4.</font></div>
</td>
<td valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Controls and Procedures</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" colspan="2" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Part II - Other Information:</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1.</font></div>
</td>
<td valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Legal Proceedings</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1A.</font></div>
</td>
<td align="left" valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk Factors</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 2.</font></div>
</td>
<td valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unregistered Sales of Equity Securities and Use of Proceeds</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">40</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 3.</font></div>
</td>
<td valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Defaults Upon Senior Securities</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">40</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 4.</font></div>
</td>
<td valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Removed and Reserved)</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">40</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 5.</font></div>
</td>
<td valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other Information</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">40</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 6.</font></div>
</td>
<td valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibits</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">40</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Signatures</font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">43</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PART I. FINANCIAL INFORMATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_2"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item 1. Consolidated Financial Statements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEOSTEM, INC. AND SUBSIDIARIES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CONSOLIDATED BALANCE SHEETS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Unaudited)</font></div>
</div>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div>
<div>&#160;</div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31,</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ASSETS</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Current Assets</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Cash and cash equivalents</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,713,338</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,612,391</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Short term investments</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">555</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">512</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Restricted cash</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,427,827</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,381,369</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Accounts receivable trade, net of allowance for doubtful accounts</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">of $437,443 and $210,977, respectively</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,944,803</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,871,474</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Inventory</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,582,284</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21,023,388</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Deferred income taxes</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">621,105</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Prepaids and other current assets</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,808,695</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">993,711</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Total current assets</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">45,098,607</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">46,882,845</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Property, plant and equipment, net</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,571,589</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">36,998,241</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Land use rights, net</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,870,549</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,807,834</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Goodwill</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32,586,656</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27,002,044</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Intangible assets, net</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30,461,547</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24,466,597</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Other assets</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,625,734</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,867,188</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="74%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">168,214,682</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">143,024,749</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LIABILITIES AND EQUITY</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Current Liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Accounts payable</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,896,278</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,286,929</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Accrued liabilities</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,863,031</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,772,019</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Bank loans</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,810,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,034,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Notes payable</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,766,272</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,568,398</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Mortgages payable - current</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">187,935</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Income taxes payable</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">589,230</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,242,911</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Deferred income taxes</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">338,054</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">232,075</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Unearned revenues</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,066,851</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,708,280</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Total current liabilities</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31,517,651</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32,844,612</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Long-term Liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Deferred income taxes</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,655,744</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,959,508</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Deferred rent liability</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,743</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">45,489</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Unearned revenues</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">180,808</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">282,518</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Mortgages payable</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,487,175</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Derivative liabilities</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">910,318</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,571,367</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Amount due related parties</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,534,147</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,301,361</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Total long-term liabilities</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30,778,935</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,160,243</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Commitments and Contingencies</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Redeemable Securities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Convertible Redeemable Series E Preferred Stock;</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,582,011 shares designated, liquidation value $1.00 per share;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">issued and outstanding&#160;7,838,527 and 10,582,011 shares,</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="74%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">at September 30, 2011 and December 31, 2010, respectively</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,475,567</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,532,275</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="74%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,475,567</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,532,275</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EQUITY</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shareholders' Equity</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Preferred stock; authorized, 20,000,000 shares</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Series B convertible redeemable preferred stock</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">liquidation value, 1 share of common stock, $.01 par value;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">825,000 shares designated; issued and outstanding,</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,000 shares at September 30, 2011 and December 31, 2010</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Common stock, $.001 par value, authorized 500,000,000 shares;</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">issued and outstanding, 100,361,443 and 64,221,130 shares,</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">at September 30, 2011 and December 31, 2010, respectively</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100,361</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">63,813</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Additional paid-in capital</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">192,575,872</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">141,137,522</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Accumulated deficit</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(124,116,505</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(95,320,620 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Accumulated other comprehensive income</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,001,635</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,779,066</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Total NeoStem, Inc. shareholders' equity</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">73,561,463</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">48,659,881</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="74%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Noncontrolling interests</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">26,881,066</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,827,738</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Total equity</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100,442,529</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">86,487,619</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="74%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">168,214,682</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">143,024,749</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td nowrap valign="bottom" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">See accompanying notes to consolidated financial statements.</font></div>
</td>
</tr></table>
</div>
</div>
</div>
</div>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEOSTEM, INC. AND SUBSIDIARIES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Unaudited)</font></div>
</div>

<div>&#160;</div>

<div>
<div>
<div>&#160;</div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="24%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Three Months Ended September 30,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="24%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Nine Months Ended September 30,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,756,144</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,475,558</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">55,857,980</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">51,716,260</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cost of revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,840,744</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,232,819</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">41,636,950</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,015,540</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Gross profit</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,915,400</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,242,739</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,221,030</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,700,720</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,483,261</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,679,945</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,766,988</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,113,487</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Selling, general, and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,812,458</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,306,622</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31,828,451</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23,442,282</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Operating Expenses</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,295,719</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,986,567</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39,595,439</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">28,555,769</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Operating loss</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,380,319</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,743,828 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(25,374,409</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,855,049 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other income (expense):</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Other income (expense), net</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,383,826</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">45,829</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,721,419</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31,326</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Interest expense</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,305,820 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(10,663 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,168,118 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(25,380 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">78,006</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,166</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,446,699 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,946</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Loss from operations before provision for</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">income taxes and noncontrolling interests</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,302,313</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,708,662 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(26,821,108</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,849,103 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Provision for income taxes</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">26,151</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left">&#160;</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">285,976</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">907,628</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,191,179</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,328,464</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,994,638 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(27,728,736</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(13,040,282 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less - net (loss) income attributable to noncontrolling interests</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,971</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left">&#160;</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,145,588</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">559,079</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,085,743</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss attributable to NeoStem, Inc.</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,346,435</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,140,226 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(28,287,815</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(17,126,025 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Preferred dividends</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">150,655</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">508,070</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">153,469</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss attributable to NeoStem, Inc. common shareholders</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,497,090</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,140,226</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(28,795,885</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(17,279,494</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic and diluted loss per share</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.08</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.13</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.35</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.36</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted average common shares outstanding</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">94,102,589</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">56,777,430</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">82,775,215</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">48,599,359</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td nowrap valign="bottom" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">See accompanying notes to consolidated financial statements.</font></div>
</td>
</tr></table>
</div>
</div>
</div>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEOSTEM, INC. AND SUBSIDIARIES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Unaudited)</font></div>
</div>

<div>&#160;</div>

<div>
<div>
<div>&#160;</div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For Nine Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash flows from operating activities:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Net loss</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(27,728,736</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(13,040,282</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Adjustments to reconcile net loss to net cash used in</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">operating activities:</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Common stock, stock options and warrants issued</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">as payment for compensation, services rendered and interest expense</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,164,814</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,399,842</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Depreciation and amortization</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,754,953</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,556,994</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Loss on short term investments</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,215</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Amortization of preferred stock discount and issuance cost</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,903,703</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Changes in fair value of derivative liability</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,661,049 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Write off of acquired in-process research and development</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,150,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Loss on disposal of assets</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">396,635</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Non-cash interest expense</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">328,425</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Charitable contributions paid with common stock</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">607,363</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Bad debt expense</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">50,024</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,311</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Deferred income taxes</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(678,211</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(182,417 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Changes in operating assets and liabilities, net of the effect of acquisitions:</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Prepaid expenses and other current assets</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(647,674 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(461,743 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Accounts receivable</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,489,064 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,278,573</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Inventory</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,136,189</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,405,838 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Unearned revenues</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,361,697 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(392,040 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Other assets</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,014,566 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(128,225 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Accounts payable, accrued expenses and other current liabilities</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,433,540 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,175,902</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Net cash used in operating activities</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(17,522,431 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,175,708 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash flows from investing activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Cash received in acquisition of PCT</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">227,942</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Purchase of short-term investments</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(27 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,424,132 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Proceeds from short-term investments</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,452,015</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Change in restricted cash used as collateral for notes payable</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,098,114</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Change in restricted cash used as collateral for bank loans</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,463,710</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Acquisition of property and equipment</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,453,931 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(12,510,648 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Net cash used in investing activities</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,127,902 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,019,055 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash flows from financing activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Net proceeds from the exercise of options and warrants</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,100</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,101,850</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Net proceeds from issuance of capital stock</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21,167,682</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,138,948</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Payment from related party</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">644,414</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">566,775</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Repayment of mortgage loan</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(109,492 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Proceeds of bank loan</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,149,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Repayment of bank loan</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,557,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,203,650 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Proceeds from notes payable</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,950,616</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,256,799</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Repayment of notes payable</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(17,154,753 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(16,644,465 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Repayment of debt to related party</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,406,043 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Repayment of preferred stock</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(175,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Payment of dividend</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(222,924 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Net cash provided by financing activities</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,516,524</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,993,333</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Impact of changes of foreign exchange rates</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">234,756</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">108,754</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net (decrease)/increase in cash and cash equivalents</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,899,053 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,092,676 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash and cash equivalents at beginning of year</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,612,391</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,159,369</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash and cash equivalents at end of period</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,713,338</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,066,693</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Supplemental Disclosure of Cash Flow Information:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash paid during the period for:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Interest</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,238,400</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">219,376</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Taxes</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,463,100</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,784,325</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Supplemental Schedule of non-cash investing activities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Acquisition of property and equipment</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">348,488</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Capitalized interest</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">235,700</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">307,200</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Supplemental schedule of non-cash financing activities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Common stock and warrants issued with the acquisition of PCT</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,200,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Common stock issued pursuant to the redemption of Convertible Redeemable Series E 7% Preferred Stock</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,785,400</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">622,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Financing costs for capital stock raises</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">75,466</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Conversion of Convertible Redeemable Series C Preferred Stock</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,720,048</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="74%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Dividend to Related Party reinvested as loan payable</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,726,100</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">See accompanying notes to consolidated financial statements.</font></div>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>
</div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEOSTEM, INC. AND SUBSIDIARIES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 1&#160;&#160;&#8211; The Company</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><a name="FIS_UNIDENTIFIED_TABLE_13"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NeoStem, Inc. (&#8220;NeoStem&#8221; or the &#8220;Company&#8221;) was incorporated under the laws of the State of Delaware in September 1980 under the name Fidelity Medical Services, Inc. The Company&#8217;s corporate headquarters are located at 420 Lexington Avenue, Suite 450, New York, NY 10170.&#160;&#160;The Company&#8217;s telephone number is (212) 584-4180 and its website address is<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;www.neostem.com</font>.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NeoStem is an international biopharmaceutical company operating in three reportable segments: (i) Cell Therapy&#160;&#8211;&#160;United States; (ii) Regenerative Medicine&#160;&#8211;&#160;China; and (iii) Pharmaceutical Manufacturing&#160;&#8211;&#160;China.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Through the Cell Therapy&#160;&#8211;&#160;United States segment, NeoStem is focused on the development of proprietary cellular therapies in oncology, immunology and regenerative medicine and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally<font style="DISPLAY: inline; FONT-STYLE: italic">.</font> Within this segment, the Company is a provider of adult stem cell collection, processing and storage services in the U.S., enabling healthy individuals to donate and store their stem cells for personal therapeutic use. In addition, the Company collects and stores cord blood cells of newborns which help to ensure a supply of autologous stem cells for the child should they be needed for future medical treatment.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company strengthened its expertise in cellular therapies, for its Cell Therapy &#8211; United States segment, with its January 19, 2011 acquisition of Progenitor Cell Therapy, LLC, a Delaware limited liability company (&#8220;PCT&#8221;), pursuant to which the Company acquired all of the membership interests of PCT, and PCT is now a wholly-owned subsidiary of NeoStem. PCT is engaged in a wide range of services in the cell therapy market for the treatment of human disease, including, but not limited to contract manufacturing, product and process development, regulatory consulting, product characterization and comparability, and storage, distribution, manufacturing and transportation of cell therapy products. PCT&#8217;s legacy business relationships also afford NeoStem introductions to innovative therapeutic programs.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In March 2011 PCT&#8217;s wholly owned subsidiary, Athelos, Inc. (Athelos), acquired rights and technology for a T-cell based immunomodulatory therapeutic in exchange for an approximate 20% interest in Athelos. Athelos expects to initiate Phase 1 studies in autoimmune disorders in 2012.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company further strengthened its breadth in cellular therapies through its October 17, 2011 acquisition of Amorcyte, Inc.&#160;&#160;Amorcyte is a development stage cell therapy company focusing on novel treatments for cardiovascular disease.&#160;&#160;Amorcyte&#8217;s lead product candidate, AMR-001, is entering a Phase 2 study for the treatment of acute myocardial infarction (AMI).&#160;&#160;Amorcyte is currently recruiting trial sites in connection with the launch of this Phase 2 clinical trial which is expected to start enrolling patients by the end of the first quarter of 2012.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company views the PCT and Amorcyte acquisitions as fundamental to building a foundation in achieving its strategic mission of capturing the paradigm shift to cell therapy.&#160;&#160;(See Note 4 and Note 14)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Through its Regenerative Medicine&#160;&#8211;&#160;China segment, in 2009, the Company began several China-based, Regenerative Medicine initiatives including: (i) creating a separate China-based cell therapy operation, (ii) constructing a stem cell research and development laboratory and processing facility in Beijing, (iii) establishing relationships with hospitals to provide cell-based therapies, and (iv) obtaining product licenses covering several adult stem cell therapeutics focused on regenerative medicine.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company acquired its Pharmaceutical Manufacturing&#160;&#8211;&#160;China segment on October 30, 2009, when China Biopharmaceuticals Holdings, Inc. (&#8220;CBH&#8221;) merged with and into CBH Acquisition LLC (&#8220;Merger Sub&#8221;), a wholly-owned subsidiary of NeoStem, with Merger Sub as the surviving entity (the &#8220;Erye Merger&#8221;). As a result of the Erye Merger, NeoStem acquired CBH&#8217;s 51% ownership interest in Suzhou Erye Pharmaceutical Company Ltd. (&#8220;Erye&#8221;), a Sino-foreign joint venture with limited liability organized under the laws of the People&#8217;s Republic of China. Erye was founded more than 50 years ago and represents an established, vertically-integrated pharmaceutical business. Historically, Erye has concentrated its efforts on the manufacturing and distribution of generic antibiotic products. In 2010, Erye began transferring its operations to its newly constructed manufacturing facility. The relocation is continuing as the new production lines are completed and receive cGMP certification. As part of its plan to focus its business on capturing the paradigm shift to cell therapies following the January 2011 acquisition of PCT, the Company is pursuing strategic alternatives with respect to its interest in Erye.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 2 &#8211; Summary of Significant Accounting Policies</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Basis of Presentation: </font>The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;generally accepted accounting principles&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of September 30, 2011 and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2010, 2009 and 2008 included in our Annual Report on Form 10-K for the year ended December 31, 2010.&#160;&#160;Operating results for the three and nine month periods ended September 30, 2011 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Use of Estimates:</font>&#160;&#160;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Concentration of Risks:</font>&#160;&#160;For the&#160;three and nine months ended September 30, 2011, three major suppliers provided approximately&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">29</font>% and <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28</font>%, respectively, of Erye&#8217;s purchases of raw materials.&#160;&#160;As of September 30, 2011, the total accounts payable to the three major suppliers represented <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14</font>% of the total accounts payable balance.</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the three and nine months ended September 30, 2010, two major suppliers provided approximately 17% and 20%, respectively, of Erye&#8217;s purchases of raw material.&#160;&#160;As of December 31, 2010, the total accounts payable to the two major suppliers was&#160;18% of the total accounts payable.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Approximately <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">80</font>% of Erye&#8217;s revenues are derived from products that use penicillin or cephalosporin as the key active ingredient. These products are manufactured on two of the eight production lines in Erye&#8217;s manufacturing facility. Any issues or incidents that might disrupt the manufacturing of products requiring penicillin or cephalosporin could have a material impact on the operating results of Erye. Any interruption or cessation in production could impact market sales.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition, over 70% of these drugs are on China&#8217;s essential drug list and any policies that might lower the pricing of these drugs and any policies that could reduce the consumption of these drugs could have a material impact on operating results.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Inventories:</font>&#160;&#160;Inventories are stated at the approximate lower of cost or market using the first-in, first-out basis. The Company reviews its inventory periodically and will reduce inventory to its net realizable value depending on certain factors, such as product demand, remaining shelf life, future marketing plans, obsolescence and slow-moving inventories.&#160;&#160;The Company includes in work in process the cost incurred on projects at PCT that have multiple deliverables and therefore cannot be recognized as revenue until the project is completed. The Company reviews these projects periodically to determine that the value of each project is stated at the lower of cost or market.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inventories consisted of the following (in thousands):</font></div>
</div>

<div>&#160;</div>

<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30, 2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31, 2010</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="66%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Raw materials and supplies</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,839.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,043.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="66%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Work in process</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,136.5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,792.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Finished goods</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,606.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,187.2</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total inventory</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,582.3</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21,023.4</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Income Taxes:</font>&#160;&#160;The Company recognizes (a) the amount of taxes payable or refundable for the current year and (b) deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company&#8217;s financial statements or tax returns. The Company continues to evaluate the accounting for uncertainty in tax positions. The guidance requires companies to recognize in their financial statements the impact of a tax position if the position is more likely than not of being sustained on audit. The position ascertained inherently requires judgment and estimates by management. As of September 30, 2011, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify">The Company classifies taxes related to witholding taxes paid on dividends declared by Erye to the Company that are reinvested into Erye as general and administrative expense. </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company recognizes interest and penalties as a component of income tax expense. There were no interest and penalties recognized for the three and nine months ended September 30, 2011 and 2010, respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company files income tax returns with the U.S. Federal government and various state and foreign jurisdictions. The statute of limitations has expired on all consolidated U.S. Federal corporate income tax returns filed through 2006, and the Internal Revenue Service is not currently examining any of the post-2006 returns filed by the Company.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Comprehensive Income (Loss):</font>&#160;&#160;The accumulated other comprehensive income (loss) balance at September 30, 2011 and December 31, 2010 in the amount of approximately $5,001,600 and $2,779,100, respectively, is comprised entirely of foreign currency translation adjustments. Comprehensive loss for the three and nine months ended September 30, 2011 and 2010 was as follows (in thousands):</font></div>
</div>

<div>&#160;</div>

<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Three Months Ended September 30,</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Nine Months Ended September 30,</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,328.5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,994.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(27,728.7</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(13,040.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other comprehensive (loss)/income</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Foreign currency translation</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">712.1</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,483.4</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,222.6</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,651.1</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total other comprehensive (loss)/income</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">712.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,483.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,222.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,651.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Comprehensive (loss)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,616.4 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,511.2 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(25,506.1 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,389.2 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Comprehensive (loss)/income attributable to noncontrolling interests</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">366.9</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,864.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,648.1</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,877.8</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Comprehensive loss attributable to NeoStem, Inc.</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,983.3</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,375.2</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(27,154.2</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(16,267.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Goodwill and Other Intangible Assets:</font>&#160;&#160;Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company&#8217;s intangible assets with an indefinite life are related to in process research and development at Erye, as the Company expects this research and development to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Amortized intangible assets consist of Erye&#8217;s customer list, manufacturing technology, standard operating procedures, tradename, lease rights and patents, as well as patents and rights associated primarily with the&#160;&#160;&#160;&#160;&#160;VSEL<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"> TM</font> Technology. These intangible assets are amortized on a straight line basis over their respective useful lives.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. The Company tests its goodwill and indefinite-lived intangible assets for its Cell Therapy&#160;&#8211;&#160;United States, and its Pharmaceutical Manufacturing&#160;&#8211;&#160;China reporting units on October 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing a discounted cash flow model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit&#8217;s estimated fair value. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Derivatives:</font>&#160;&#160;Derivative instruments, including derivative instruments embedded in other contracts, are recorded on the balance sheet as either an asset or liability measured at its fair value. Changes in the fair value of derivative instruments are recognized currently in results of operations unless specific hedge accounting criteria are met. The Company has not entered into hedging activities to date. As a result of certain financings (see Note 8), derivative instruments were created that are measured at fair value and marked to market at each reporting period. Changes in the derivative value are recorded as other income (expense) on the consolidated statements of operations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Evaluation of Long-lived Assets:</font>&#160;&#160;The Company reviews long-lived assets and finite-lived intangibles assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset or its eventual disposition, and recognize an impairment loss. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Share-Based Compensation:</font>&#160;&#160;The Company expenses all share-based payment awards to employees, directors, advisors and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Advisor and consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of certain share-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant. See Note 9.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Loss Per Share:</font>&#160;&#160;Basic loss per share is based on the weighted effect of all common shares issued and outstanding, and is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period. Diluted loss per share, which is calculated by dividing net loss attributable to common shareholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding, is not presented as such potentially dilutive securities are anti-dilutive in all periods presented. For the three and nine months ended September 30, 2011 and 2010, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share. At September 30, 2011 and 2010, the Company excluded the following potentially dilutive securities:</font></div>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="32%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="66%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock Options</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,749,895</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,558,214</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="66%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,208,817</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,352,028</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="66%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series E Preferred Stock, Common stock equivalents</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,693,730</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Revenue Recognition:</font> The Company recognizes revenue from pharmaceutical and pharmaceutical intermediary product sales when title has passed, the risks and rewards of ownership have been transferred to the customer, the fee is fixed and determinable, and the collection of the related receivable is reasonably assured which is at the time of delivery. The Company recognizes revenue for its cell development and manufacturing services based on the terms of individual contracts.&#160;&#160;In certain cases, there are multiple elements that cannot be considered separate deliverables and therefore the Company recognizes revenue on a completed contract basis for these arrangements. In other cases, the Company is paid for time and materials or for fixed monthly amounts and revenue is recognized when efforts are expended or contractual terms have been met.&#160;&#160;The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is twenty four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments. The Company earns revenue, in the form of license fees, from physicians seeking to establish autologous adult stem cell collection centers. These license fees are typically billed upon signing of the collection center agreement and qualification of the physician by the Company&#8217;s credentialing committee and at various times during the term of license agreements based on the terms of the specific agreement. These fees are recognized as revenue ratably over the appropriate period of time to which the revenue element relates. The Company also receives licensing fees from a licensee for use of its technology and knowledge to operate an adult stem cell banking operation in China, which licensing fees are recognized as revenues ratably over the appropriate period of time to which the revenue element relates. In addition, the Company earns royalties for the use of its name and scientific information in connection with its License and Referral Agreement with Ceregenex Corporation, which royalties are recognized as revenue when they are received.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenues for the three and nine months ended September 30, 2011 and 2010 were comprised of the following (in thousands):</font></div>
</div>

<div>&#160;</div>

<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revenues</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Prescription drugs and intermediary pharmaceutical products</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,513.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,384.5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,806.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">51,528.7</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Stem cell related service revenues</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,529.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">91.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,266.9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">187.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Stem cell related services - reimbursed expenses</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">714.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,785.1</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="48%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,756.1</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,475.6</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">55,858.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">51,716.3</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Fair Value Measurements:</font>&#160;&#160;Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 1 inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 2 inputs which are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company determined the fair value of funds invested in short term investments, which are considered trading securities, to be level 1 inputs measured by quoted prices of the securities in active markets. The Company determined the fair value of funds invested in money market funds to be level 1. The Company determined the fair value of the embedded derivative liabilities and warrant derivative liabilities to be level 3 inputs. These inputs require material subjectivity because value is derived through the use of a lattice model that values the derivatives based on probability weighted discounted cash flows. The following table sets forth by level within the fair value hierarchy the Company&#8217;s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2011, and December 31, 2010 (in thousands):</font></div>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="85%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="10" nowrap valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">September 30, 2011</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="10" nowrap valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Fair Value Measurements Using Fair Value Hierarchy</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Level 1</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Level 2</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Level 3</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Money market investments</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,500.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Short term investments</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Embedded derivative liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">783.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrant derivative liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">126.9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="9" valign="bottom" width="45%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31, 2010</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="10" nowrap valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Fair Value Measurements Using Fair Value Hierarchy</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Level 1</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Level 2</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Level 3</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Money market investments</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,501.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Short term investments</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Embedded derivative liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,281.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrant derivative liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">289.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subsequent to December 31, 2010 the Company reevaluated the characteristics of the money market savings account, currently recorded as other assets, and determined it is not tied to underlying securities and has been reclassified to level 1.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the three and nine months ended September 30, 2011 by type of instrument (in thousands):</font></div>
</div>

<div>&#160;</div>

<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="87%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="24%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For the Three Months Ended</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="24%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For the Nine Months Ended</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="24%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30, 2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="24%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30, 2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="11%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Embedded</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="11%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="11%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Embedded</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="11%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Derivatives</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Derivatives</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Beginning liability balance</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,933.7</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">342.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,281.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">289.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Change in fair value recorded in earnings</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,150.3 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(215.4 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,498.4 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(162.7 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Ending liability balance</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">783.4</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">126.9</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">783.4</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">126.9</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Some of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, restricted cash, accounts receivable, accounts payable, notes payable and&#160;bank loans.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Foreign Currency Translation:</font>&#160;&#160;As the Company&#8217;s Chinese pharmaceutical business is a self-contained and integrated entity, and the Company&#8217;s Chinese stem cell business&#8217; future cash flow is intended to be sufficient to service its additional financing requirements, the Chinese subsidiaries&#8217; functional currency is the Renminbi (&#8220;RMB&#8221;), and the Company&#8217;s reporting currency is the US dollar. Results of foreign operations are translated at the average exchange rates during the period, and assets and liabilities are translated at the closing rate at the end of each reporting period. Cash flows are also translated at average exchange rates for the period, therefore, amounts reported on the consolidated statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheet.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Research and Development Costs:</font>&#160;&#160;Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To further drive the Company&#8217;s cell therapy initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for government grants as a deduction to the related expense in research and development operating expenses when earned.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Statutory Reserves:</font>&#160;&#160;Pursuant to laws applicable to entities incorporated in the PRC, the PRC subsidiaries are prohibited from distributing their statutory capital and are required to appropriate from PRC GAAP profit after tax to other non-distributable reserve funds. These reserve funds include one or more of the following: (i) a general reserve, (ii) an enterprise expansion fund and (iii) a staff bonus and welfare fund. Subject to certain cumulative limits (i.e., 50% of the registered capital of the relevant company), the general reserve fund requires annual appropriation at 10% of after tax profit (as determined under accounting principles generally accepted in the PRC at each year-end); the appropriation to the other funds are at the discretion of the subsidiaries.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The general reserve is used to offset extraordinary losses. Subject to approval by the relevant authorities, a subsidiary may, upon a resolution passed by the shareholders, convert the general reserve into registered capital provided that the remaining general reserve after the conversion shall be at least 25% of the registered capital of the subsidiary before the capital increase as a result of the conversion. The staff welfare and bonus reserve is used for the collective welfare of the employees of the subsidiary. The enterprise expansion reserve is for the expansion of the subsidiary&#8217;s operations and can also be converted to registered capital upon a resolution passed by the shareholders subject to approval by the relevant authorities. These reserves represent appropriations of the retained earnings determined in accordance with Chinese law, and are not distributable as cash dividends to the parent company, NeoStem. Statutory reserves are $2,300,900 and $2,234,600 as of September 30, 2011 and December 31, 2010, respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Relevant PRC statutory laws and regulations permit payment of dividends by the Company&#8217;s PRC subsidiaries only out of their accumulated earnings, if any, as determined in accordance with PRC accounting standards and regulations. As a result of these PRC laws and regulations, the Company&#8217;s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets either in the form of dividends, loans or advances. The restricted amount was $184,500 at September 30, 2011 and $214,200 at December 31, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 3 &#8211; Recently Adopted Accounting Pronouncements</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In December 2010, the FASB issued an update which addresses when to perform Step 2 of the goodwill impairment test for reporting units with zero or negative carrying amounts. The update modifies Step 1 of the goodwill impairment test for reporting units with zero or negative carrying amounts. For those reporting units, an entity is required to perform Step 2 of the goodwill impairment test if it is more likely than not that a goodwill impairment exists. In determining whether it is more likely than not that goodwill impairment exists, an entity should consider whether there are any adverse qualitative factors indicating that impairment may exist. The qualitative factors are consistent with the existing guidance, which requires that goodwill of a reporting unit be tested for impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. This update is effective for fiscal years, and interim periods within those years, beginning after December 15, 2010. The adoption of this guidance did not have a material impact on the consolidated financial statements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In December 2010, the FASB issued an update which addresses the disclosure of supplementary pro forma information for business combinations. The update requires public entities to disclose pro forma information for business combinations that occurred in the current reporting period, including revenue and earnings of the combined entity for the current reporting period as though the acquisition date for all business combinations that occurred during the year had been as of the beginning of the annual reporting period. If comparative financial statements are presented, the pro forma revenue and earnings of the combined entity for the comparable prior reporting period should be reported as though the acquisition date for all business combinations that occurred during the current year had been as of the beginning of the comparable prior annual reporting period. Amendments in this update are effective prospectively for business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2010. The adoption of this guidance did not have a material impact on the consolidated financial statements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 4 &#8211; Acquisitions</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 19, 2011 (the &#8220;Closing Date&#8221;), NBS Acquisition Company LLC (&#8220;Subco&#8221;), a newly formed wholly-owned subsidiary of NeoStem, merged (the &#8220;PCT Merger&#8221;) with and into Progenitor Cell Therapy, LLC, a Delaware limited liability company (&#8220;PCT&#8221;), with PCT as the surviving entity, in accordance with the terms of the Agreement and Plan of Merger, dated September 23, 2010 (the &#8220;PCT Merger Agreement&#8221;), among NeoStem, PCT and Subco.&#160;&#160;As a result of the consummation of the PCT Merger, NeoStem acquired all of the membership interests of PCT, and PCT is now a wholly-owned subsidiary of NeoStem.&#160;&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Founded by Dr. Andrew L. Pecora and Robert A. Preti, Ph.D., PCT became an internationally recognized cell therapy services and development company.&#160;&#160;They sought to create a business for &#8220;as needed&#8221; development and manufacturing services for the emerging cell therapy industry and to prepare for eventual commercialization.&#160;&#160;With its cell therapy manufacturing facilities and team of professionals, PCT offers a platform that can facilitate the preclinical and clinical development and commercialization of cellular therapies for clients throughout the world.&#160;&#160;PCT offers current Good Manufacturing Practices (cGMP)-compliant cell transportation, manufacturing, storage, and distribution services and supporting clinical trial design, product process development, logistics, regulatory and quality systems development services.&#160;&#160;In addition, through its network of contacts throughout the cell therapy industry, PCT is able to identify early stage development opportunities in the cell therapy field and opportunistically develop these cell therapies through proof of concept where they can be further developed and ultimately commercialized through NeoStem&#8217;s developing commercial structure. Dr. Preti now serves as PCT's President and Chief Scientific Officer and Dr. Pecora as Chief Medical Officer of NeoStem and PCT.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PCT is engaged in a broad range of services in the cell therapy market for the treatment of human disease, including but not limited to contract manufacturing, product and process development, product and regulatory consulting, and product characterization and comparability.&#160;&#160;PCT&#8217;s expertise in the cell therapy space, which includes therapeutic vaccines (oncology), various related cell therapeutics, cell diagnostics, and regenerative medicine, creates a platform upon which NeoStem intends to build a therapeutics strategy.&#160;&#160;NeoStem&#8217;s goal is to develop internally, or through partnerships, allogeneic (cells from a third-party donor) or autologous (cells from oneself) cell therapeutics technologies that, in the aggregate, comprise the Cell Therapy &#8211; United States reportable segment.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition, PCT has assumed NeoStem&#8217;s adult stem cell business based on PCT&#8217;s strategic advantages in meeting cGMP regulatory requirements in an industry that is widely dispersed with a range of quality issues.&#160;&#160;NeoStem believes that PCT, as a quality leader, is ideally positioned to become a leader in cell collection, processing and storage (cell banking) which is synergistic with NeoStem&#8217;s roots in this business.&#160;&#160;In addition, PCT&#8217;s leadership in the transportation and distribution of cell therapy products is complementary to NeoStem&#8217;s strategic vision of working with the industry leader as the partner of choice.&#160;&#160;These efforts are being bundled together into a new service with PCT&#8217;s cord blood banking business into a multigenerational stem cell collection and storage plan that the Company calls the &#8220;Family Plan&#8221;.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the terms of the PCT Merger Agreement, all of the membership interests of PCT outstanding immediately prior to the effective time of the PCT Merger were converted into the right to receive, in the aggregate, (i) 10,600,000 shares of the common stock, par value $0.001 per share, of NeoStem (the &#8220;NeoStem Common Stock&#8221;) (reflecting certain final price adjustments agreed to at the closing) and (ii) warrants to purchase an aggregate 3,000,000 shares of NeoStem Common Stock as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(i)</font></div>
</td>
<td valign="top" width="83%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">common stock purchase warrants to purchase one million (1,000,000) shares of NeoStem Common Stock, exercisable over a seven year period at an exercise price of $7.00 per share (the &#8220;$7.00 Warrants&#8221;), and which will vest only if a specified business milestone (described in the PCT Merger Agreement) is accomplished within three (3) years of the Closing Date of the PCT Merger; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(ii)</font></div>
</td>
<td valign="top" width="83%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">common stock purchase warrants to purchase one million (1,000,000) shares of NeoStem Common Stock exercisable over a seven year term at an exercise price of $3.00 per share (the &#8220;$3.00 Warrants&#8221;); and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(iii)</font></div>
</td>
<td valign="top" width="83%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">common stock purchase warrants to purchase one million (1,000,000) shares of NeoStem Common Stock exercisable over a seven year period at an exercise price of $5.00 per share (the &#8220;$5.00 Warrants&#8221; and, collectively with the $7.00 Warrants and the $3.00 Warrants, the &#8220;Warrants&#8221;).</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Warrants are redeemable in certain circumstances.&#160;&#160;Transfer of the shares issuable upon exercise of the Warrants is restricted until the one year anniversary of the Closing Date.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In accordance with the PCT Merger Agreement, NeoStem has deposited into an escrow account with the escrow agent (who is initially NeoStem&#8217;s transfer agent), 10,600,000 shares of NeoStem Common Stock for eventual distribution to the former members of PCT (subject to downward adjustment to satisfy any indemnification claims of NeoStem, all as described in the PCT Merger Agreement).&#160;&#160;As of September 30, 2011, approximately 974,000 shares have been distributed to the former members of PCT.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The issuance of NeoStem securities in the PCT Merger was approved at a special meeting of shareholders of NeoStem held on January 18, 2011 (the &#8220;NeoStem Special Meeting&#8221;), on which date the PCT Merger was also approved at a special meeting of members of PCT.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The fair value of the net assets acquired in the PCT Merger was $12,416,200. The fair value of the equity issued as consideration by NeoStem was valued at $17,200,000 resulting in the recognition of goodwill in the amount of $4,783,600. The fair value of the equities issued by NeoStem included 10,600,000 shares of NeoStem Common stock valued at $15,900,000 and NeoStem warrants to purchase up to 3,000,000 shares valued at $1,966,200.&#160;&#160;A portion of the consideration paid is contingent upon the accomplishment of a certain milestone for the $7.00 Warrants.&#160;&#160;Such contingent consideration has been classified as equity and will not be subject to remeasurement.&#160;&#160;The goodwill that has been created by this acquisition is reflective of values and opportunities of utilizing PCT&#8217;s cell collection, processing and storage (cell banking) resources and production capacities, as mentioned above. </font></div>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The preliminary fair value of assets acquired and liabilities assumed on January 19, 2011 is as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="40%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">227,900</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts Receivable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">442,400</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other Current Assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">166,200</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Property, Plant &amp; Equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,769,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Intangibles</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,100,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Goodwill</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,783,600</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other Assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">654,100</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="72%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts Payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,370,900</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other Liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">540,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred Revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">247,400</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amount Due Related Party</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,000,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Mortgages Payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,784,600</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The total cost of the acquisition, which is still preliminary, has been allocated to the assets acquired and the liabilities assumed based upon their estimated fair values at the date of the acquisition. &#160;It is expected the goodwill will be deductible for income tax purposes.&#160;&#160;As of September 30, 2011, the preliminary fair values of the deferred tax liabilities were reduced to zero, from an initial estimate of $4.3 million, due to the finalization of the tax treatment of the transaction. As a result, the tax provision for the nine months ended September 30, 2011 reflects a $178,000 adjustment related to the portion of deferred tax liability recognized in the first and second quarters of fiscal 2011. In addition, the fair value of the equity issued as consideration by NeoStem was reduced by $666,200. The net effect of the updated values reduced the preliminary goodwill by $4.9 million. This estimated purchase price allocation continues to be subject to revision based on additional valuation work that is being conducted.&#160; The final allocation is pending the receipt of this valuation work and the completion of the Company&#8217;s internal review, which is expected during fiscal 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 18pt"></font>For the period since the acquisition (January 19-September 30, 2011), NeoStem recorded $5,571,500 in revenues and a net loss of approximately $4,043,300 or $0.05 basic and diluted loss per share attributable to PCT.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 18pt"></font>The following supplemental table presents unaudited consolidated pro forma financial information as if the closing of the acquisition of PCT had occurred on January 1, 2010 (in thousands, except per share amounts):</font></div>
</div>

<div>&#160;</div>

<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Nine Months Ended September 30,</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Three Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Nine Months Ended September 30,</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(As Reported)</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(Proforma)</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(As Reported)</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(Proforma)</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(As Reported)</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(Proforma)</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">55,858</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">56,240</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">16,476</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">18,883</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">51,716</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">57,575</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Cost of revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">41,637</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">41,961</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">11,233</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">12,996</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">35,016</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">39,561</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Gross profit</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">14,221</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">14,279</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">5,243</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">5,887</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">16,701</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">18,014</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Research and development</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">7,767</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">7,767</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,680</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,679</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">5,114</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">5,111</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Selling, general, and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">31,829</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">32,218</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">9,307</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">10,905</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">23,442</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">28,120</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Operating loss</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(25,375</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(25,706</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(5,744 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(6,696 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(11,855 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(15,217 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Other income (expense), net</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(1,447 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(1,482 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">35</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(47 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">6</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(208 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Loss from operations before provision for income taxes and</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">noncontrolling interests</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(26,821</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(27,187</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(5,709 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(6,743 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(11,849 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(15,425 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Provision for income taxes</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">908</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">908</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">286</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">286</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,191</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,191</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(27,729</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(28,905</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(5,995 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(7,029 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(13,040 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(16,616 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Less &#8211; net income attributable to noncontrolling interests</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">559</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">559</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,146</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,146</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">4,086</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">4,086</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Preferred dividends</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">508</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">508</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">154</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">154</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net loss attributable to NeoStem, Inc. common shareholders</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(28,796</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(29,162</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(7,140</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(8,175</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(17,280</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(20,855</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Basic and diluted loss per share</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(0.35</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(0.35</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(0.13</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(0.12</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(0.36</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(0.35</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Weighted average common shares outstanding</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">82,775</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">83,513</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">56,777</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">67,377</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">48,599</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">59,199</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The unaudited supplemental pro forma financial information should not be considered indicative of the results that would have occurred if the PCT Merger had been consummated on January 1, 2010, nor are they indicative of future results.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Athelos Corporation (&#8220;Athelos&#8221;) is a subsidiary of PCT pursuing the development of T regulatory cells (TRegs) as a therapeutic to treat disorders of the immune system.&#160; Pursuant to a Stock Purchase and Assignment Agreement dated March 28, 2011, Athelos issued approximately 20% of its shares to Becton Dickinson and Company (&#8220;BD&#8221;) in exchange for the rights to certain intellectual property relating to TRegs that BD owned pursuant to a license agreement between the University of Pennsylvania (&#8220;Penn&#8221;) and BD dated September 28, 2005 (the &#8220;Penn License&#8221;), and a license agreement between ExCell Therapeutics, LLC and BD dated September 16, 2005, as amended August 31, 2007 (the &#8220;ExCell License&#8221;).&#160; Pursuant to a Stock Purchase and Assignment Agreement dated March 28, 2011, Athelos took assignment from BD of its rights and obligations under the Penn License and the ExCell License, including, among other things, obligations to pay royalties on net sales of licensed products, maintenance fees and milestones on initiation of clinical trial stages, license application filings and regulatory approvals.&#160; As expressly anticipated by the parties, Athelos replaced the assignment of the Penn License with two new direct licenses: The Amended and Restated Patent License Agreement between Penn and Athelos dated September 12, 2011, and the Patent License Agreement between Penn, Athelos and the University of Minnesota dated September 12, 2011. Athelos and ExCell are in the process of negotiating a direct license that would replace the existing assigned ExCell License.&#160;&#160;Pursuant to the Stockholders&#8217; Agreement dated March 28, 2011, Athelos, PCT and BD have agreed, that, among other things, BD will have certain anti-dilution protection for the first $5 million of new investment in Athelos and certain&#160; board of directors&#8217; observer rights.&#160;&#160; BD has assigned to Athelos, and Athelos assumed, all rights, title, interest and obligations of BD under a consulting agreement dated as of September 16, 2005 between David Horwitz, M.D. and BD, to be paid retroactively beginning as of January 1, 2011, for services rendered in advancing the Athelos TReg research and development platform<font style="DISPLAY: inline; FONT-STYLE: italic">.</font>&#160;&#160;PCT had preliminarily valued BD&#8217;s share of the contributed intellectual properties in the quarter ended March 31, 2011 at $927,000 and characterized this acquired intangible asset as in-process research and development which has been recorded as expense within research and development expense.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the quarter ended September 30, 2011, PCT finalized its valuation of the intellectual properties received, and revised the fair value to $1,150,000, which is recorded as expense within research and development expense for the nine months ended September 30, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 5 &#8211; Goodwill and Other Intangible Assets</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The changes in the carrying amount of goodwill by reportable segment during nine months ended September 30, 2011 were as follows (in thousands):</font></div>
</div>

<div>&#160;</div>

<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pharmaceutical</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cell Therapy -</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Manufacturing -</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">United States</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">China</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance as of December 31, 2010</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27,002.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27,002.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Acquisitions*</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,783.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,783.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Foreign currency exchange rate changes</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">801.1</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">801.1</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance as of September 30, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,783.6</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27,803.1</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32,586.7</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">*Goodwill associated with the PCT Merger</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of September 30, 2011 and December 31, 2010, the Company&#8217;s intangible assets and related accumulated amortization consisted of the following (in thousands):</font></div>
</div>

<div>&#160;</div>

<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="23%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="11%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="10" nowrap valign="bottom" width="31%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">September 30, 2011</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="10" nowrap valign="bottom" width="31%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">December 31, 2010</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Accumulated</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Accumulated</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="23%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="11%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Useful Life</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Gross</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Amortization</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net</font></font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Gross</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Amortization</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="23%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Customer list</font></div>
</td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">10 Years</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">19,666.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(3,598.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">16,067.7</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">17,740.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(2,069.7</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">15,670.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="23%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Manufacturing technology</font></div>
</td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">10 Years</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">10,251.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(1,247.4 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">9,003.9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">4,220.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(492.4 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">3,728.2</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="23%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Tradename</font></div>
</td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">10 Years</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,313.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(284.8 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,028.2</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">983.9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(114.8 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">869.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="23%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">In process R&amp;D</font></div>
</td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Indefinite</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,779.9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,779.9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,219.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,219.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="23%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Standard operating procedures</font></div>
</td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">10 Years</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,098.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(210.5 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">887.9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,066.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(124.5 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">942.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="23%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Lease rights</font></div>
</td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2 Years</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">841.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(806.4 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">35.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">817.2</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(476.7 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">340.5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="23%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">VSEL patent rights</font></div>
</td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">19 Years</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">669.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(132.0 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">537.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">669.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(105.6 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">563.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="23%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Patents</font></div>
</td>
<td valign="bottom" width="11%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">8 Years</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">203.1</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(81.2 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">121.9</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">164.4</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(31.2 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">133.2</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="23%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Total Intangible Assets</font></div>
</td>
<td valign="bottom" width="11%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">36,822.4</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(6,360.9</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">30,461.5</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">27,881.5</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(3,414.9</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">24,466.6</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In 2011, Erye commenced sales of two products that were previously accounted for as In Process R&amp;D which has resulted in a reclassification of approximately $505,500 from In Process R&amp;D to Manufacturing Technology.&#160;&#160;Certain of the Company&#8217;s intangible assets are recorded on the books of wholly owned or partially owned subsidiaries and affiliates in China, and denominated in RMB. &#160;As a result, the balance reported fluctuates based upon the changes in exchange rates.</font></div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the acquisition of PCT, the following intangible assets were acquired (in thousands):</font></div>
</div>

<div>&#160;</div>

<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="65%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="77%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Customer list</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="20%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,400.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="77%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Manufacturing technology</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,400.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="77%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tradename</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,300.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="77%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,100.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</div>

<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="85%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" colspan="6" nowrap valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Cost of revenue</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">388.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">87.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,126.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">259.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Research and development</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">401.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">41.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,185.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Selling, general and administrative</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">547.9</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,611.4</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8.8</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">949.8</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">488.4</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,779.2</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,454.2</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Estimated intangible amortization expense on an annual basis for the succeeding five years is as follows (in thousands):</font></div>
</div>

<div>&#160;</div>

<div>
<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="25%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="right" valign="bottom" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td align="right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="45%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">880.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="right" valign="bottom" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012</font></div>
</td>
<td align="right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="45%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,380.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="right" valign="bottom" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2013</font></div>
</td>
<td align="right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="45%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,380.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="right" valign="bottom" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2014</font></div>
</td>
<td align="right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="45%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,380.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="right" valign="bottom" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2015</font></div>
</td>
<td align="right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="45%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,380.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="right" valign="bottom" width="45%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thereafter</font></div>
</td>
<td align="right" valign="bottom" width="8%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="45%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,061.4</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="45%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="8%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="45%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30,461.5</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Note 6&#8211; Accrued Liabilities</font></font></div>
</td>
</tr><tr>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued liabilities are as follows (in thousands):</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="65%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="65%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">September 30, 2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" colspan="2" nowrap valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">December 31, 2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="65%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">VAT and other taxes</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,081.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">126.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="65%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Salaries, employee benefits and related taxes</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">911.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">210.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="65%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amount due on patent infringement</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">770.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">758.5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="65%" style="PADDING-BOTTOM: 2px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,099.8</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,676.3</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="65%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,863.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,772.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>
</div>
</div>

<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 7 &#8211; Bank Loans, Notes Payable and Mortgages Payable</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Bank Loans</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In November 2010, Erye obtained a bank loan of approximately $3,124,000 from the CITIC Bank International with a variable interest rate that is currently 6.06% and is due in November 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In May 2011, Erye obtained a bank loan of approximately $3,124,000 from Commercial Bank of China with a variable interest rate that is currently 7.02% and is due in November 2011.&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In July 2011, Erye obtained a bank loan of approximately $1,562,000 from the <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Agricultural Bank of China</font> </font>with a variable interest rate that is currently&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.56</font>% and is due in May 2012.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Notes Payable</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Erye has approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">3,571,000 </font>of notes payable outstanding as of September 30, 2011. Notes are payable to the banks who issue bank notes to Erye&#8217;s creditors. Notes payable are interest free and usually mature after a three to six month period. In order to issue notes payable on behalf of Erye, the banks require collateral, such as cash deposits which are approximately 30% - 50% of notes to be issued, or properties owned by Erye. Restricted cash pledged as collateral for the balance of notes payable at September 30, 2011 and December 31, 2010, amounted to approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,428,000 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">3,381,400</font>, respectively.&#160; At September 30, 2011 and December 31, 2010, the restricted cash amounted to <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">40</font>% and <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">35.8</font>%, respectively, of the notes payable Erye issued, and the remainder of the notes payable is collateralized by pledging the land use right Erye owns, which amounted to approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">4,870,500 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">4,807,800 </font>at September 30, 2011 and December 31, 2010, respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has financed certain insurance policies and has notes payable at September 30, 2011 of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">38,700 </font>related to these policies. These notes require monthly payments and mature in less than one year.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Mortgages Payable</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On October 31, 2007, PCT issued a note to borrow $3,120,000 (the &#8220;Note&#8221;) in connection with its $3,818,500 purchase of condominium units in an existing building in Allendale, New Jersey (the &#8220;Property&#8221;) that PCT uses as a laboratory and stem cell processing facility. The Note is payable in 239 consecutive monthly payments of principal and interest, based on a 20 year amortization schedule; and one final payment of all outstanding principal plus accrued interest then due. The current monthly installment is $20,766, which includes interest at an initial rate of 5.00%; the interest rate and monthly installments payments are subject to adjustment on October 1, 2017. On that date, upon prior written notice, the lender has the option to declare the entire outstanding principal balance, together with all outstanding interest, due and payable in full. The Note is secured by substantially all of the assets of PCT, including a first mortgage on the Property and assignment of an amount approximately equal to eighteen months debt service held in escrow. The Note matures on October 1, 2027 if not called by the lender on October 1, 2017. The note is subject to certain debt service coverage and total debt to tangible net worth financial covenant ratios measured semi-annually. The next measurement date for compliance with financial covenants is December 31, 2011. PCT was not in compliance with such covenants at the measurement date of June 30, 2011, and obtained a covenant waiver letter from the lender for all periods through June 30, 2011. The outstanding balance was approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">2,736,100 </font>at September 30, 2011 of which $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">112,700 </font>is payable within twelve months. On December 6, 2010&#160; PCT Allendale, a wholly-owned subsidiary of PCT, entered into a note for a second mortgage in the amount of $1 million on the Allendale Property with TD Bank, N.A.&#160; This loan is guaranteed by PCT, DomaniCell (a wholly-owned subsidiary of PCT, now known as NeoStem Family Storage, LLC), Northern New Jersey Cancer Associates (&#8220;NNJCA&#8221;) and certain partners of NNJCA and is subject to a financial covenant starting December 31, 2011. The loan is for 124 months at a fixed rate of 6% for the first 64 months. The loan is callable for a certain period prior to the interest reset date.&#160;&#160; The initial four months was interest only.&#160; The outstanding balance as of September 30, 2011 is $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">939,000</font> of which $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">75,200</font> is payable within twelve months.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 8 &#8211; Preferred Stock</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Convertible Redeemable Series E 7% Preferred Stock</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On November 19, 2010, the Company sold 10,582,011 Preferred Offering Units consisting of (i) one share (&#8220;Preferred Share&#8221;) of Series E 7% Senior Convertible Preferred Stock, par value $0.01 per share, of the Company, (ii) a warrant to purchase 0.25 of a share of Common Stock (consisting of at issuance an aggregate of 1,322,486 warrants, adjusted to an aggregate of 1,452,925 as of September 30, 2011); and (iii) 0.0155 of a share of Common Stock (an aggregate of 164,418 shares). Each Preferred Offering Unit was priced at $0.945 and total gross and net proceeds received by the Company were $10,000,000 and $8,876,700, respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the holders of the Preferred Shares are entitled to receive, out of the assets of the Company available for distribution to shareholders, prior and in preference to any distribution of any assets of the Company to the holders of any other class or series of equity securities, the amount of $1.00 per share plus all accrued but unpaid dividends.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dividends on the Preferred Shares accrue at a rate of 7% per annum and are payable monthly in arrears.&#160;&#160;The Company is required to redeem 1/27 of the Preferred Shares monthly.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Monthly dividend and principal payments began on March 21, 2011 and continue on the 19th of each month thereafter with the final payment due on May 20, 2013. Payments can be made in cash or, upon notification to the holders, in shares of Company common stock, provided certain conditions are satisfied or holders of Preferred Shares agree to waive the conditions for that payment period. If the conditions are not satisfied, the Company must make payments in cash. Payments which are made in stock will be made in shares which are freely tradable. The price of the shares will be calculated based on 92% of the average of the lowest 5 days&#8217; volume weighted average prices of the 20 trading days prior to the payment date, and the shares are delivered in tranches beginning in advance of the applicable payment date.&#160;&#160;As of September 30, 2011, the Company had issued 3,462,559 shares of Company common stock in payment of monthly dividends and principal, including required advanced payments.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company may pre-pay the outstanding balance of the Preferred Shares in full or in part (in increments of no less than $1,000,000) at 115% of the then outstanding balance, reducing to 110% after November 19, 2011, with notice of not less than thirty days and adequate opportunity to convert. If the Company chooses to pre-pay, the outstanding balance must be paid in cash and the premium may be paid in cash or shares of Company common stock.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Upon issuance, the Preferred Shares were convertible at an initial conversion price of $2.0004. The conversion price is subject to certain weighted average adjustments upon the occurrence of specific events, including stock dividends, stock splits, combinations and reclassifications of the Company&#8217;s common stock and if (with certain exceptions) the Company issues or sells any additional shares of common stock or common stock equivalents at a price per share less than the conversion price then in effect, or without consideration.&#160;&#160;As of September 30, 2011, the conversion price had been adjusted to $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1.67</font>.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An aggregate of $2,500,000 of the proceeds from the Preferred Offering was placed in escrow for a maximum of 2.5 years as security for the Company&#8217;s obligations relative to the Preferred Shares, and is included in other assets.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The characteristics of the Series E Preferred Stock: cumulative dividends, mandatory redemption, no voting rights, and callable by the Company, require that this instrument be treated as mezzanine equity. The Company bifurcated the fair value of the embedded conversion options and redemption options from the preferred stock since the conversion options and certain redemption options were determined to not be clearly and closely related to the Series E Preferred Stock. The Company recorded the fair value of the embedded conversion and redemption options as long-term derivative liabilities as the conversion price is not fixed and the forced redemption option contains substantial premiums over the stated dividend rate for the preferred stock. The Company also recorded the fair value of the warrants as a long-term derivative liability as the number of warrant shares and exercise price of the warrants is not fixed. The Series E Preferred Stock was discounted by the fair value of the derivatives liabilities. The fair value of the preferred stock (net of issuance costs and discounts), the embedded derivatives, and warrant derivative were approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5,475,600</font>, $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">783,400 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">126,900</font>, respectively, as of September 30, 2011.&#160;&#160;The Company will report changes in the fair value of the embedded derivatives and warrant derivative in earnings within other income (expense), net. The discount and issuance costs on the preferred stock will be amortized through May 20, 2013 using the effective interest method and will be reflected within interest expense. For the nine months ended September 30, 2011, the Company recorded a decrease in the fair value of the embedded derivatives of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,498,400</font> and a decrease in the warrant derivative of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">148,400</font>.&#160;&#160;For the three months ended September 30, 2011, the Company recorded a decrease in the fair value of the embedded derivatives of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,150,300 </font>and a decrease in the warrant derivative of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">213,000</font>.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 9 &#8211; Shareholders&#8217; Equity</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Common Stock:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The authorized common stock of the Company is 500 million shares, par value $0.001 per share.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 3, 2011, the Company consummated a private placement pursuant to which five persons and entities acquired an aggregate of 2,343,750 shares of Common Stock for an aggregate consideration of $3,000,000 (purchase price $1.28 per share). The investors included Steven S. Myers (one of the Company&#8217;s directors) (who purchased 390,625 shares) and Dr. Andrew L. Pecora (the Chief Medical Officer of the Company&#8217;s subsidiary PCT, who is also now the Chief Medical Officer of NeoStem, and the Chief Scientific Officer of Amorcyte) (who purchased 78,125 shares). On April 5, 2011, the Company consummated a private placement pursuant to which nine persons and entities acquired an aggregate of 1,244,375 shares of Common Stock for an aggregate consideration of approximately $1,592,800 (purchase price $1.28 per share).&#160;&#160;On June 13, 2011 the Company consummated a private placement pursuant to which one entity acquired 781,250 shares of Common Stock for an aggregate consideration of $1,000,000 (purchase price $1.28 per share).&#160;&#160;On July 6, 2011, three then key Amorcyte stockholders (including a fund managed by a then Amorcyte director) invested an aggregate of $728,000 in a private placement of 568,750 shares of Common Stock (purchase price $1.28 per share).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 22, 2011, the Company completed an underwritten offering of 13,750,000 units at a purchase price of $1.20 per unit, with each unit consisting of one share of Common Stock and a five year warrant to purchase 0.75 of a share of Common Stock at an exercise price of $1.45 per share (the &#8220;Offering&#8221;).&#160;&#160;The Company sold securities in the Offering under the Company&#8217;s previously filed shelf registration statement on Form S-3 (333-173855), which was declared effective by the Securities and Exchange Commission on June 13, 2011.&#160;&#160;Lazard Capital Markets LLC (&#8220;Lazard&#8221;) and JMP Securities LLC (&#8220;JMP&#8221;) acted as representatives of the underwriters named in an Underwriting Agreement, dated as of July 19, 2011, by and among the Company, Lazard, JMP and such underwriters.&#160;&#160;The Company received gross proceeds of $16,500,000, prior to deducting underwriting discounts and offering expenses payable by the Company, for net proceeds of approximately $14,667,000.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On September 28, 2011, the Company entered into a Common Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Aspire Capital Fund, LLC, an Illinois limited liability company (&#8220;Aspire Capital&#8221;), which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $20.0 million worth of shares of the Company&#8217;s common stock over the 24-month term of the Purchase Agreement. At the Company&#8217;s discretion, it may present Aspire Capital with purchase notices under the Purchase Agreement from time to time, to purchase the Company&#8217;s Common Stock, provided certain price and other requirements are met.&#160;The purchase price for the shares of stock will be based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice we submit to Aspire Capital from time to time, and will be based on market prices of the Company's common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the agreement.&#160;&#160;&#160;The Company and Aspire Capital shall not effect any sales under the Purchase Agreement on any date where the closing sales price is less than 75% of the closing sales price on the business day immediately preceding the date of the Purchase Agreement. The Company&#8217;s net proceeds will depend on the purchase price and the frequency of the Company&#8217;s sales of shares to Aspire Capital; provided, however, that the maximum aggregate proceeds from sales of&#160;&#160;shares is $20.0 million, and the maximum number of shares that may be sold may not exceed 18,747,906 shares unless shareholder approval is obtained.&#160;&#160;The Company&#8217;s delivery of purchase notices will be made subject to market conditions, in light of the Company&#8217;s capital needs from time to time and under the limitations contained in the Purchase Agreement. As consideration for entering into the Purchase Agreement, effective September 30, 2011, we issued 990,099 shares of our Common Stock to Aspire Capital (the &#8220;Commitment Shares&#8221;). The issuance of shares of common stock to Aspire Capital pursuant to the Purchase Agreement, including the Commitment Shares, and the sale of those shares from time to time by Aspire Capital to the public, are covered by an effective shelf registration statement on Form S-3.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">17</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Warrants:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has issued common stock purchase warrants from time to time to investors in private placements and public offerings, and to certain vendors, underwriters, placement agents and consultants of the Company. A total of <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">35,208,817</font> shares of common stock are reserved for issuance upon exercise of outstanding warrants as of September 30, 2011 at prices ranging from $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">0.50 </font>to $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">7.00 </font>and expiring through January 2018.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the three and nine months ended September 30, 2011 and 2010, the Company issued warrants for services as follows ($ in thousands, except share data):</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="85%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Three Months Ended September 30,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number of Common Stock Purchase Warrants Issued</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25,000</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">370,000</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">627,000</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Value of Common Stock Purchase Warrants Issued</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32.9</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">289.5</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">772.2</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The weighted average estimated fair value of warrants issued for services in the three and nine months ended September 30, 2011 was $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">0 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">0.78</font>, respectively. The fair value of warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term is based upon the contractual term of the warrants.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The range of assumptions used in calculating the fair values of warrants issued for services during the three and nine months ended September 30, 2011 and 2010, respectively, were as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="34%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="3" valign="bottom" width="32%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three Months Ended September 30, </font></td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="3" valign="bottom" width="32%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended September 30,</font></font></div>
</td>
</tr><tr>
<td valign="bottom" width="34%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="34%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Expected term (in years)</font></font></div>
</td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3 <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">to 5</font></font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3 <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">to 5</font></font></font></div>
</div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">to 5</font></font></font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="34%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected volatility</font></font></div>
</td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">81% - 83%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">91% - 96%</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">80% - 86%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">91% - 99%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="34%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Expected dividend yield</font></font></div>
</td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="34%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Risk-free interest rate</font></font></div>
</td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.42% - 1.53%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.27% - 1.60%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.42% - 2.24%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.27% - 2.04%</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Activity related to warrants outstanding was as follows:</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: center;">
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" colspan="2" nowrap valign="bottom" width="13%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Remaining</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number of</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" colspan="2" nowrap valign="bottom" width="13%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Contractual</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Aggregate</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Exercise Price</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Term (years)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Intrinsic Value</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Balance at December 31, 2010</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21,843,507</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.62</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,812,939</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">*</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.23</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expired</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(447,629</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.18</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cancelled</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Balance at September 30, 2011</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,208,817</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.41</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.9</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,600</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Warrants Exercisable at September 30, 2011</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">33,933,317</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.29</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.7</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" colspan="16" nowrap valign="bottom" width="84%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">* Includes 3 million warrants issued pursuant to the PCT Merger Agreement - See Note 4, and 10,312,500 warrants issued in the </font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">July 22, </font></font><font size="2">2011 offering</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s results include share-based compensation expense of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5,600 </font>and a benefit of $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">147,300 </font>for the three months ended September 30, 2011 and 2010, respectively, and an expense of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">247,500 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">417,300</font> for the nine months ended September 30, 2011 and 2010, respectively.&#160;&#160;The total fair value of shares vested for warrants issued for services during the three and nine months ended September 30, 2011 was approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">60,100 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">235,800</font>, respectively.&#160;&#160;As of September 30, 2011, there was approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">93,300 </font>of total unrecognized service cost related to unvested warrants of which approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">49,500 </font>is related to warrants that vest over a weighted average life of <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">0.25</font> years. The remaining balance of unrecognized service cost of $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">43,800 </font>is related to warrants that vest based on the accomplishment of business milestones as to which expense begins to be recognized when such milestones become probable of being achieved.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Options:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="FIS_UNIDENTIFIED_TABLE_27"><!--EFPlaceholder--></a>At the 2011 Annual Meeting of Shareholders of the Company held on October 14, 2011, the shareholders approved an amendment to increase the number of shares of common stock authorized for issuance under the 2009 Equity Compensation Plan (the &#8220;2009 Equity Plan&#8221;) from 17,750,000 to 23,750,000.&#160;&#160;Effective October 14, 2011, concurrent with shareholder approval to increase the number of shares of common stock authorized for issuance under the 2009 Equity Plan by 6,000,000, the Company&#8217;s Board of Directors authorized a decrease in the shares available for issuance under the Non-U.S, Equity Plan from 8,700,000 to 5,700,000.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s results include share-based compensation expense of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">831,400 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">2,453,100 </font>for the three months ended September 30, 2011 and 2010, respectively, and approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5,631,400 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5,982,500 </font>for the nine months ended September 30, 2011 and 2010, respectively. Options vesting on the accomplishment of business milestones will not be recognized for compensation purposes until such milestones are deemed probable of accomplishment. At September 30, 2011 there were options to purchase <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">654,928 </font>shares outstanding that will vest upon the accomplishment of business milestones and will be accounted for as an operating expense when such business milestones are deemed probable of accomplishment.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 4, 2011, the Company entered into an amendment of its May 26, 2006 employment agreement with Dr. Robin L. Smith, pursuant to which, as previously amended (the &#8220;Agreement&#8221;), Dr. Smith serves as Chairman of the Board and Chief Executive Officer of the Company. Pursuant to the amendment, (i) the term of the Agreement was extended from December 31, 2011 to December 31, 2012; (ii) Dr. Smith will receive cash bonuses on October 1, 2011 and 2012 in the minimum amount of 110% of the prior year&#8217;s bonus; (iii) a failure to renew the Agreement at the end of the term regardless of reason shall be treated as a termination by the Company without cause; (iv) the Company shall pay Dr. Smith her base salary and COBRA premiums (a) for one year in the event of a termination of the agreement by Dr. Smith for other than good reason and (b) during any period during which she is bound by non-competition, non-solicitation or similar covenants with the Company (such payments shall not be made during the time Dr. Smith is also receiving payments under (iii) or (iv)(a)); (v) Dr. Smith was granted an option to purchase 1,500,000 shares of Common Stock at a per share exercise price equal to the closing price of the Common Stock on the date of the amendment, vesting as to 500,000 shares on each of the date of grant, December 31, 2011 and December 31, 2012; (vi) all other unvested options held by Dr. Smith were immediately vested; (vii) any vested options previously or hereafter granted to Dr. Smith during the remainder of the term shall remain exercisable following termination of employment for the full option term until the expiration date; (viii) the Company agreed that, with the exception of the period of time during which Dr. Smith is a Company affiliate and for 90 days thereafter (during which time any shares owned by or issued to Dr. Smith will bear the Company&#8217;s standard affiliate legend), the Company will not place legends on shares on Common Stock owned by Dr. Smith restricting the transfer of such shares so long as such shares are sold under an effective registration statement, pursuant to Rule 144 or are eligible for sale under Rule 144 without volume limitations; and (ix) if Dr. Smith ceases to be employed by the Company and for so long as she continues to own shares of Common Stock the sale of which would require that the current public information requirement of Rule 144 be met, the Company will use its reasonable best efforts to timely meet those requirements or obtain appropriate extensions or otherwise make available such information as is required. Except as set forth in the amendment, the Agreement remains unchanged.&#160;&#160;Pursuant to the modification on April 4, 2011 of Dr. Smith&#8217;s stock options, the Company recognized $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">723,000 </font>of incremental compensation cost during the nine months ended September 30, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The weighted average estimated fair value of stock options granted in the three and nine months ended September 30, 2011 was $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">0.50 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1.10</font>, respectively. The fair value of options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term is based upon observation of actual time elapsed between date of grant and exercise of options for all employees.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The range of assumptions used in calculating the fair values of options granted during the three and nine months ended September 30, 2011 and 2010, respectively, were as follows:</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="34%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="3" valign="bottom" width="32%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Three Months Ended September 30,</font></font></div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="3" valign="bottom" width="32%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Nine Months Ended September 30,</font></font></div>
</td>
</tr><tr>
<td valign="bottom" width="34%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Expected term (in years)</font></font></div>
</td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1 <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">to 6</font></font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2 to 10</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1 to 10</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2 to 10</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="34%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected volatility</font></font></div>
</td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">76% - 84%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">91% - 99%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">75% - 85%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">91% - 122%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="34%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Expected dividend yield</font></font></div>
</td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="34%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Risk-free interest rate</font></font></div>
</td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.13% - 1.82%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.42% - 3.00%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.13% - 3.45%</font></div>
</td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.42% - 3.58%</font></div>
</td>
</tr></table>
</div>

<div align="center">&#160;</div>
</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">19</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div>&#160;</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="59%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Activity related to stock options outstanding under the U.S. Equity Plans was as follows:</font></div>
</td>
</tr></table>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div align="center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td nowrap valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Remaining</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number of</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Contractual</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Aggregate</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise Price</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Term (years)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Intrinsic Value</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at December 31, 2010</font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,932,214</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.87</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,544,600</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.54</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised</font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.42</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expired</font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cancelled</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,071,919</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">) </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.74</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at September 30, 2011</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,399,895</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.73</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7.5</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options Exercisable at September 30, 2011</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,812,002</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.84</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.7</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Activity related to stock options outstanding under the Non U.S. Equity Plan was as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div align="center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Remaining</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number of</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Contractual</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Aggregate</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise Price</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Term (years)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="3" nowrap valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Intrinsic Value</font></font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at December 31, 2010</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,100,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.02</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">650,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.74</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expired</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cancelled</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,400,000 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.02</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at September 30, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,350,000</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.94</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8.6</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options Exercisable at September 30, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">950,000</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.07</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8.3</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The total fair value of shares vested during the three and nine months ended September 30, 2011 was approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,169,300 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">3,973,800</font>, respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The number of remaining shares authorized to be issued under the various equity plans at September 30, 2011 are as follows:</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non US Equity</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">US Equity Plan</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Plan</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares Authorized for Issuance under 2003 Equity Plan</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,500,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares Authorized for Issuance under 2009 Equity Plan</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,750,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares Authorized for Issuance under Non US Equity Plan</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,700,000</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,250,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,700,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding Options - US Equity Plan</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(15,399,895 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised Options</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(97,500 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding Options - Non US Equity Plan</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,350,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Restricted stock or equity grants issued under Equity Plans</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,479,085 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(885,000 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total common shares remaining to be issued under the Equity Plans</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,273,520</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,465,000</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of September 30, 2011, there was approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">6,515,400 </font>of total unrecognized compensation costs related to unvested stock option awards of which approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5,776,100 </font>is related to stock options that vest over a weighted average life of <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1.9 </font>years. The remaining balance of unrecognized compensation costs of $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">739,300 </font>is related to stock options that vest based on the accomplishment of business milestones which expense begins to be recognized when such milestones become probable of being achieved.&#160;&#160;Effective October 14, 2011, concurrent with shareholder approval to increase the number of shares of common stock authorized for issuance under the 2009 Equity Plan by 6,000,000, the Company&#8217;s Board of Directors authorized a decrease in the shares available for issuance under the Non-U.S, Equity Plan from 8,700,000 to 5,700,000.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Changes in Stockholders Equity:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The changes in Stockholders Equity for the nine months ended September 30, 2011 were as follows:</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Series B Convertible</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Preferred Stock</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Common Stock</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Shares</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Amount</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Shares</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Amount</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Additional Paid</font></font></font></div>

<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">in Capital</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Accumulated</font></font></font></font></div>

<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Other</font></font></font></div>

<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Comprehensive</font></font></div>

<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Income</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Deficit</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Non-</font></font></font></div>

<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Controlling</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Interest in</font></font></div>

<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Subsidiary</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Total</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Balance at January 1, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">10,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">100</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">64,221,130</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">63,813</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">141,137,522</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,779,066</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(95,320,620</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">37,827,738</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">86,487,619</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Exercise of stock options</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">5,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">7,095</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">7,100</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Share-based compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,394,530</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,395</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">8,162,419</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">8,164,814</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Proceeds from issuance of common stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">19,678,224</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">19,678</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">21,148,004</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">21,167,682</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Shares issued for charitable contribution</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">408</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">606,955</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">607,363</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Repayment of Series E Preferred Principal and Dividends</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">3,462,559</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">3,462</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">3,404,477</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(508,070 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,899,869</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Foreign currency translation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,222,569</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(9,652</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,212,917</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net income attributable to non-controlling interest</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">559,079</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">559,079</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Dividends to related party</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(11,726,099 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(11,726,099 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Technology contributed to Athelos by Non-Controlling Interest</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">920,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">230,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,150,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net loss attributable to NeoStem, Inc.</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(28,287,815</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(28,287,815</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Shares issued in PCT Merger</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">10,600,000</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">10,600</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">17,189,400</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">17,200,000</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="28%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Balance at September 30, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">10,000</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">100</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">100,361,443</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">100,361</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">192,575,872</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">5,001,635</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(124,116,505</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">26,881,066</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">100,442,529</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 10 &#8211; Income Taxes</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><a name="FIS_UNIDENTIFIED_TABLE_33"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Tax Reform Act of 1986 enacted a complex set of rules limiting the utilization of net operating loss carryforwards (&#8220;NOL&#8221;) to offset future taxable income following a corporate ownership change. The Company&#8217;s ability to utilize its NOL carryforwards is limited following a change in ownership in excess of fifty percentage points during any three-year period.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since the year 2000, the Company has had several changes in ownership which has resulted in a limitation on the Company&#8217;s ability to apply net operating losses to future taxable income and future ownership changes could result in additional limitations. At December 31, 2010, the Company had net operating loss carryforwards of approximately $39,590,500 applicable to future Federal income taxes. The tax loss carryforwards are subject to annual limitations and expire at various dates through 2030. The Company has recorded a full valuation allowance against its net deferred tax asset because it is more likely than not that such deferred tax assets will not be realized.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The income tax provision for the three and nine months ended September 30, 2011 and 2010 is related to foreign taxes for our operations in China.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 11 &#8211; Segment Information</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s financial information broken down by reportable segment was as follows (in thousands):</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Nine Months Ended September 30,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revenues</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Pharmaceutical Manufacturing - China</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,513.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,384.5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,806.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">51,528.7</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Cell Therapy - United States</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,177.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">61.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,837.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">157.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Regenerative Medicine - China</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">66.1</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">215.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,756.1</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,475.6</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">55,858.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">51,716.3</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="40%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Loss from operations</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Pharmaceutical Manufacturing - China</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">717.9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,552.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,480.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,302.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Cell Therapy - United States</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,996.1 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,304.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(9,957.7</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,917.2</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Regenerative Medicine - China</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(681.8 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(321.9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,847.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,058.7</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Corporate office</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,420.3 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,669.9</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(17,049.7</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(13,181.4</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,380.3 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,743.8</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(25,374.4</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,855.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="40%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total assets</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30, 2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">December 31, 2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Pharmaceutical Manufacturing - China</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">124,045.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">125,458.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Cell Therapy - United States</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">28,445.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,101.9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Regenerative Medicine - China</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,640.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,949.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Corporate office</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,084.3</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,514.9</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">168,214.7</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">143,024.7</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">21</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 12 &#8211; Related Party Transactions</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At September 30, 2011, Erye owed EET, the <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">49</font>% shareholder of Erye, $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">20,534,100 </font>which represents dividends paid and loaned back to Erye.&#160;&#160;At September 30, 2011 the interest rate on this loan was <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">6.56</font>%.&#160;&#160;In <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">June</font> 2011 Erye paid EET approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">875,100 </font>consisting of the net of the following: $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,115,000 </font>of unpaid accrued interest at June 30, 2011, approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">408,700 </font>repayment of a non interest bearing loan due in 2011 and recovery of cash advances to EET of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">648,600</font>.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the terms and conditions of the Erye Joint Venture Agreement, dividend distributions to EET and the Company&#8217;s subsidiary will be made in proportion to their respective ownership interests in Erye; provided, however, that for the three-year period commencing on the first day of the first fiscal quarter after the Joint Venture Agreement became effective distributions are made as follows: for undistributed profits generated subsequent to the acquisition date: (i) the 49% of undistributed profits (after tax) of the joint venture due EET will be distributed to EET and lent back to Erye to help finance costs in connection with its construction of and relocation to a new facility; and (ii) of the net profit (after tax) of the joint venture due the Company, 45% will be provided to Erye as part of the new facility construction fund and will be characterized as additional paid-in capital for the Company&#8217;s 51% interest in Erye, and 6% will be distributed to the Company which has not been paid from the 2010 distribution and is in the amount of approximately $130,000. For undistributed profits generated prior to the acquisition date: (i) the 49% of undistributed profits (after tax) of the joint venture due EET will be distributed to EET and lent back to Erye to help finance costs in connection with its construction of and relocation to a new facility; and (ii) of the net profit (after tax) of the joint venture due the Company, 51% will be provided to Erye as part of the new facility construction fund and will be characterized as additional paid-in capital for the Company&#8217;s 51% interest in Erye. It was contemplated by the Joint Venture Agreement that the construction would continue for three years.&#160;&#160;As such, 45% of the dividend we would be entitled to by reason of our 51% ownership would remain in Erye through October 2012 to complete the relocation while EET would loan back their dividend during the same period at a prevailing bank interest rate.&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Upon a liquidity event of Erye, as contemplated in the joint venture agreement, the Company will be entitled to the return of its dividend reinvestments to the extent of the proceeds generated by the liquidity event.&#160; </font>Repayment of such loans from EET&#160;would occur gradually after the relocation is completed.&#160;&#160;In January 2011, a dividend totaling approximately $13,671,100 based on earnings for&#160;&#160;Fiscal Year 2009 was declared and approximately $6,698,800 was distributed to EET and lent back to Erye and approximately $6,972,300 due the Company was reinvested and re-characterized as additional paid-in capital in the business. In April 2011, a dividend totaling $10,259,700 based on earnings for Fiscal Year 2010 was declared and approximately $5,027,300 was distributed to EET and lent back to Erye, and approximately $5,232,400 due the Company was reinvested and re-characterized as additional paid-in capital in the business.&#160;&#160;A 10% withholding tax was required on dividends payable to the Company.&#160;&#160;As a result, Erye withheld approximately $1,220,500 in taxes related to the Company&#8217;s Fiscal Year 2009 and 2010 dividend amounts, of which approximately $526,600 has not been paid to the local Chinese tax authorities as of September 30, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the PCT Merger Agreement, NeoStem agreed to pay off PCT&#8217;s credit line with Northern New Jersey Cancer Associates (&#8220;NNJCA&#8221;), in an amount up to $3,000,000, shortly after the closing of the PCT Merger. On January 21, 2011, NeoStem paid NNJCA $3,000,000 in full satisfaction of all of PCT&#8217;s obligations to NNJCA arising from the underlying line of credit and security agreement. Dr. Andrew Pecora (who was PCT&#8217;s Chairman and CEO prior to the PCT Merger, and who became PCT&#8217;s Chief Medical Officer on January 19, 2011 pursuant to an employment agreement effective upon the closing of the PCT Merger), has served as Managing Partner of NNJCA since 1996.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 13, 2011, NeoStem entered into the Agreement and Plan of Merger to acquire Amorcyte.&#160;&#160;Amorcyte had originally been incorporated as a subsidiary of PCT and was spun off to PCT&#8217;s members prior to NeoStem&#8217;s January 19, 2011 acquisition of PCT.&#160;&#160;At the time the Agreement and Plan of Merger was entered into, Dr. Pecora and Mr. Goldberger were officers of both PCT and Amorcyte.&#160;&#160;The Amorcyte acquisition closed on October 17, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In order to accelerate Amorcyte's commencement of its Phase 2 clinical trial of AMR-001, NeoStem agreed to provide loans to Amorcyte prior to the closing of the Amorcyte Merger to be used in connection with the Phase 2 trial. Pursuant to a Loan Agreement entered into on September 9, 2011, NeoStem loaned Amorcyte prior to the closing of the Merger an aggregate of $338,500 which was applied towards the commencement of the Phase 2 trial.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective March 10, 2011, Matthew Henninger entered into a consulting agreement with PCT, pursuant to which Mr. Henninger was engaged for a three month term to serve as an advisor to PCT with regard to the development of the &#8220;Family Plan,&#8221; a multi-generational stem cell collection and storage service. In consideration therefor, Mr. Henninger was granted an option to purchase 150,000 shares of NeoStem Common Stock under the 2009 Plan at $1.60 per share (Black Scholes value $129,000) vesting over the term of the agreement. Pursuant to an amendment and extension of this agreement in April and May, 2011, respectively, Mr. Henninger&#8217;s term of service was extended through September 9, 2011, for which he received 75,000 shares of NeoStem Common Stock (market value $115,000), $5,000 per month for a three month period and reimbursement of health insurance premiums; in September 2011 the PCT management with approval of the Audit Committee extended&#160;the term&#160;further&#160;through December 31, 2011, in connection with which Mr. Henninger received a $25,000 bonus related to prior performance, a monthly fee of $10,000 and continued insurance reimbursement. Mr. Henninger is in an exclusive relationship with the CEO of NeoStem.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the nine months ended September 30, 2011, the Company contributed to The Stem for Life Foundation, a Pennsylvania nonprofit corporation classified as a tax-exempt organization under Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and as a public charity under Section 509(a)(1) and 170(b)(1)(A)(vi) of the Code (the &#8220;Foundation&#8221;), whose mission is to promote public awareness, fund research and development and subsidize stem cell collection and storage programs, 407,600 shares of previously issued restricted common stock with a fair value of approximately $607,400. The contribution of such securities was subject to the approval of the Board of Directors and the Audit Committee.&#160;&#160;The Company&#8217;s CEO and Chairman is President and a Trustee of the Foundation, its General Counsel is Secretary and a Trustee of the Foundation and its Chief Financial Officer is Treasurer of the Foundation.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">22</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 13 &#8211; Commitments and Contingencies</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company leases office and laboratory facilities and certain equipment under certain noncancelable operating leases that expire from time to time through 2015.&#160;&#160;A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of September 30, 2011 are as follows (in thousands):</font></div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Lease Commitments:</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: center" align="left">
<table cellpadding="0" cellspacing="0" width="30%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: center;">
<td valign="bottom" width="60%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Years ended</font></div>
</td>
<td align="right" valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" colspan="2" nowrap valign="bottom" width="37%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Operating Leases</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="35%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">383.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012</font></div>
</td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="35%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1259.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2013</font></div>
</td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="35%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">898.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2014</font></div>
</td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="35%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">629.5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2015</font></div>
</td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="35%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">587.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="60%" style="PADDING-BOTTOM: 2px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thereafter</font></div>
</td>
<td align="right" valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="35%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">857.2</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="60%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total minimum lease payments</font></div>
</td>
<td align="right" valign="bottom" width="2%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="2%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="35%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,614.9</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Expense incurred under operating leases was approximately $535,300 and $1,672,600 for the three and nine months ended September 30, 2011, respectively, and $522,800 and $1,139,400 for the three and nine months ended September 30, 2010, respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Contingencies:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products.&#160; The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the issuance to investors and service providers of many of the shares of the Company&#8217;s common stock and warrants to purchase common stock previously disclosed and described herein, the Company granted the holders registration rights providing for the registration of such shares of common stock and shares of common stock underlying warrants on a registration statement to be filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) so as to permit the resale of those shares. Certain of the registration rights agreements provided for penalties for failure to file or failure to obtain an effective registration statement. With respect to satisfying its obligations to the holders of these registration rights, the Company has been in various situations. The Company had previously filed a registration statement as required for some of the holders, and in May 2011 filed a registration statement for all of the holders (except for holders whose shares of Common Stock were currently salable under Rule 144 of the Securities Act or who waived certain rights); such registration statement was declared effective by the SEC on September 30, 2011. The Company has certain obligations to maintain the effectiveness of this registration statement.&#160;&#160;Certain holders who had outstanding registration rights had previously waived their registration rights or were subject to lock-up agreements. No holder has yet asserted any claim against the Company with respect to a failure to satisfy any registration obligations. Were someone to assert a claim against the Company for breach of registration obligations, the Company believes it has several defenses that would result in relieving it from some or any liability, although no assurances can be given. The Company also notes that damage claims may be limited, as (i) most shares of Common Stock as to which registration rights attached are either now registered or currently salable under Rule 144 of the Securities Act or are otherwise currently subject to other restrictions on sale and (ii) the shares of Common Stock underlying warrants with registration rights are now registered, and during much of the relevant periods the warrants with registration rights generally have been out of the money, were subject to lock-up agreements and/or the underlying shares of Common Stock were otherwise subject to restrictions on resale. Accordingly, were holders to assert claims against the Company based on breach of the Company&#8217;s obligation to register, the Company believes that the Company&#8217;s maximum exposure would not be material.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Xiangbei Welman Pharmaceutical Co., Ltd. v Suzhou Erye Pharmaceutical Co., Ltd. and Hunan Weichu Pharmacy Co., Ltd.</font>&#160;&#160;involves a patent infringement dispute with respect to a particular antibiotics complex manufactured by Erye (the &#8220;Product&#8221;). The Changsha Intermediate People&#8217;s Court in Hunan Province, PRC in the foregoing case rendered a judgment on May 13, 2010 against Erye as follows: (i) awarding plaintiff Xiangbei Welman damages and costs of approximately 5 million RMB (approximately $778,500) against Erye which was fully accrued for at September 30, 2011; and (ii) enjoining Erye from manufacturing, marketing and selling the Product. On March 21, 2011, Changsha Intermediate Court issued a civil decision suspending the execution of the Preliminary Injunction. Therefore, Erye is currently free to produce, sell or offer to sell the product.&#160;&#160;Following the filing of the patent infringement dispute, in 2009 Xiangbei Welman brought a copyright infringement lawsuit against Erye claiming the package inserts with respect to the Product infringed upon their copyright and Erye was enjoined from copying and using the package inserts on the Product and selling the Product with the package inserts and Xiangbei Welman was awarded 50,000 RMB, or approximately $7,800.&#160; &#160;In July 2011, a new copyright infringement lawsuit was brought by Xiangbei Welman against Erye claiming that Erye was not complying with the earlier judgment enjoining them from copying and using the package inserts for the Product. The Changsha Intermediate Court was applied to for property preservation and it issued a civil decision freezing Erye&#8217;s bank deposits of up to 50 million RMB, or approximately $7.8 million, or sealing up or detaining Erye&#8217;s other properties of equal value. Currently this case is pending.&#160;&#160;As of September 30, 2011, approximately 13,744,700 RMB (approximately $2,140,000) of cash had been frozen in six bank accounts, and is classified in Other Assets.&#160;&#160;Erye is working with their counsel to respond.&#160;&#160;Erye has contended that jurisdiction is not proper.&#160;&#160;A similar action was recently instituted by Welman against Erye in the Guangzhou Intermediate Court to (i) enjoin Erye from copying and using the package inserts from the Product and selling the drugs with the aforesaid package inserts and; (ii) award Welman economic losses of approximately 2,000,000 RMB (approximately $312,400) against Erye and the case is being reviewed by the Court. Welman made an application for preliminary injunction to prohibit Erye from copying and using the package inserts from the Product and selling the drugs with the aforesaid package inserts and Welman's application was denied by the Court on September 6, 2011.&#160;&#160;Welman subsequently obtained a preliminary injunction from a lower court Guangzhou Haizhu District People&#8217;s Court in Guangzhou Province, PRC (the &#8220;Haizhu District Court&#8221;)&#160;on September 14, 2011.&#160;&#160;But on October 28, 2011, upon the appeal by Erye, the Haizhu District Court issued a decision withdrawing the preliminary injunction.&#160; The Company cannot reasonably assess the possibility of additional exposure above the amounts previously accrued as of September 30, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">23</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Chinese regulatory approvals</font> &#8211; The Company has determined that it did not obtain all Chinese regulatory approvals (and associated registrations) required to reflect the legal title of its interest in Erye as being held by the proper entity within our group which is its current beneficial owner as that term is used under U.S. law.&#160; The Company believes it has now determined what governmental approvals (and associated registrations) will need to be issued by the Suzhou Municipal Bureau of Foreign Investment and Commerce and the Suzhou Administration for Industry and Commerce to remediate these deficiencies and the Company has had counsel in China prepare these filings.&#160; The Company&#8217;s management believes these regulatory deficiencies can be remediated within a reasonable period of time and should not delay a possible divestiture of the Company&#8217;s interests in Erye that is currently under evaluation.&#160; However, the Company requires the cooperation of the officers of Erye, as to which no assurance can be given, and we could be compelled to seek to replace those officers or&#160;to commence legal action to obtain the required consents or otherwise move forward with requisite filings.&#160; In addition, even if the filings are made, no assurance can be given that any unremediated regulatory deficiencies would not have an adverse effect on the operating results and liquidity of Erye and the Company and will not impede or delay efforts to divest the Company&#8217;s interest in Erye.&#160; In addition, the remediation process is expected to trigger certain tax liabilities and penalties, however the ultimate liability will be based on future discussions with the relevant Chinese authorities.&#160;&#160;The Company cannot reasonably assess the exposure as of September 30, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Amorcyte line of credit &#8211; </font>On May&#160;19, 2006, PCT entered into a line of credit agreement with Amorcyte Inc. (&#8220;Amorcyte&#8221;), an entity which was spun out of PCT in 2006, whereby PCT agreed to loan Amorcyte up to $500,000 at an annual interest rate of 5%.&#160; The line of credit agreement was a condition to Amorcyte closing a Series A Preferred Stock Financing completed during 2006.&#160; The Company has not loaned any amount to Amorcyte under this agreement through September 30, 2011.&#160;&#160;The line of credit agreement expires on the earlier of (i)&#160;the date on which the Company declares the outstanding principal and accrued interest due and payable based on an event of default as defined within the agreement, or (ii)&#160;the date of closing of the first debt or equity financing of Amorcyte following the initial borrowing of the principal. These events have not occurred to date.&#160;&#160;On October 17, 2011, the Company acquired Amorcyte pursuant to the Amorcyte Agreement and Plan of Merger, and this line of credit was cancelled.&#160;&#160;&#160; (See Note 14).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE_36"><!--EFPlaceholder--></a><a name="FIS_SUBSEQUENT_EVENTS"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 14 &#8211; Subsequent Events</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">The Amorcyte Merger</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On October 17, 2011 (the &#8220;Closing Date&#8221;), Amo Acquisition Company I, Inc. (&#8220;Subco&#8221;), a newly-formed wholly-owned subsidiary of NeoStem, Inc. (&#8220;NeoStem&#8221; or the &#8220;Company&#8221;), merged (the &#8220;Amorcyte Merger&#8221;) with and into Amorcyte, Inc., a Delaware corporation (&#8220;Amorcyte&#8221;), in accordance with the terms of the Agreement and Plan of Merger, dated as of July 13, 2011 (the &#8220;Amorcyte Merger Agreement&#8221;), among NeoStem, Amorcyte, Subco, and Amo Acquisition Company II, LLC (&#8220;Subco II&#8221;).&#160;&#160;As a result of the consummation of the Amorcyte Merger, Amorcyte is now a wholly-owned subsidiary of NeoStem.&#160;&#160;Amorcyte is a development stage cell therapy company focusing on novel treatments for cardiovascular disease. Amorcyte&#8217;s lead product candidate, AMR-001, is entering a Phase 2 study for the treatment of acute myocardial infarction (AMI). We are currently recruiting trial sites in connection with the launch of this Phase 2 clinical trial which is expected to start enrolling patients by the end of first quarter of 2012.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the terms of the Amorcyte Merger Agreement, all of the shares of Amorcyte common stock and Amorcyte Series A Preferred Stock and all options and warrants to acquire equity of Amorcyte, issued and outstanding immediately prior to the effective time of the Amorcyte Merger (the &#8220;Effective Time&#8221;), were by virtue of the Amorcyte Merger cancelled and converted into the right to receive, in the aggregate:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(i)</font></div>
</td>
<td valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,843,483 shares of NeoStem Common Stock (reflecting certain adjustments taken at the closing, and subject to further adjustment following the closing in accordance with the Amorcyte Merger Agreement) (the &#8220;Base Stock Consideration&#8221;);</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(ii)</font></div>
</td>
<td valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">the right to receive 4,092,768 shares of NeoStem Common Stock (the &#8220;Contingent Shares&#8221;, and together with the Base Stock Consideration, the &#8220;Stock Consideration&#8221;), which Contingent Shares will be issued only if certain specified business milestones (described below) are accomplished;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(iii)</font></div>
</td>
<td valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">warrants to purchase&#160;1,881,008 shares of NeoStem Common Stock exercisable over a seven (7) year period at an exercise price of $1.466 per share (the &#8220;Warrants&#8221;) (such Warrants are redeemable in certain circumstances, and transfer of any shares of NeoStem Common Stock issued upon exercise of the Warrants will be restricted until one year after the Closing Date); and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(iv)</font></div>
</td>
<td valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">earn out payments equal to 10% of the net sales of Amorcyte&#8217;s lead product candidate AMR-001 (in the event of and following the date of first commercial sale of AMR-001), provided that in the event NeoStem sublicenses AMR-001, the applicable earn out payment will be equal to 30% of any sublicensing fees, and provided further that NeoStem will be entitled to recover direct out-of-pocket clinical development costs not previously paid or reimbursed and any costs, expenses, liabilities and settlement amounts arising out of claims of patent infringement or otherwise challenging Amorcyte&#8217;s right to use intellectual property, by reducing any earn out payments due by 50% until such costs have been recouped in full (the &#8220;Earn Out Payments&#8221;).</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In accordance with the Amorcyte Merger Agreement, NeoStem has deposited into an escrow account with the escrow agent (who is initially NeoStem&#8217;s transfer agent), 5,843,483 shares of NeoStem Common Stock for eventual distribution to the former Amorcyte stockholders (subject to further adjustment following the closing, including in connection with any indemnification claims of NeoStem, all in accordance with the Amorcyte Merger Agreement).&#160;&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Contingent Shares will be issued to the former Amorcyte stockholders only if certain business milestones are achieved, as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#167;</font></div>
</td>
<td valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">One-third of the Contingent Shares (1,364,256 shares) will be issued upon (a) the completion of Phase 2 clinical trial for Amorcyte&#8217;s product candidate AMR-001 and (b) issuance of a statistically significant analysis demonstrating satisfaction of the primary clinical end points from the Phase 2 clinical trial, which primary clinical endpoints are described in the Phase 2 clinical trial protocol submitted by Amorcyte to the FDA on July 5, 2011.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#167;</font></div>
</td>
<td valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">One-third of the Contingent Shares will be issued following a Type B End of Phase 2/Pre-Phase 3 meeting with the FDA wherein AMR-001 is acknowledged in writing by the FDA to be ready for Phase 3.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#167;</font></div>
</td>
<td valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The remaining one-third of the Contingent Shares will be issued upon the first dosing of the first patient in the pivotal Phase 3 clinical study for AMR-001.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The merger consideration described above will be distributed to Amorcyte&#8217;s former securityholders consistent with applicable liquidation preferences contained in Amorcyte&#8217;s governing documents, all in accordance with the Amorcyte Merger Agreement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The issuance of NeoStem securities pursuant to the Amorcyte Merger Agreement was approved at the 2011 Annual Meeting of Stockholders of NeoStem held on October 14, 2011 (the &#8220;NeoStem 2011 Annual Meeting&#8221;), on which date the Amorcyte Merger also was approved at a special meeting of stockholders of Amorcyte.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The description of the Amorcyte Merger contained in this Note 14 does not purport to be complete and is qualified in its entirety by reference to the Amorcyte Merger Agreement, which is attached to NeoStem&#8217;s Joint Proxy Statement/Prospectus dated and filed with the Securities and Exchange Commission on September 16, 2011 (the &#8220;Joint Proxy Statement/Prospectus&#8221;), the Warrant Agreement between NeoStem and Continental Stock Transfer &amp; Trust Company, and the form of Global Series AMO Warrant attached thereto, which is filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K dated October 14, 2011 (the &#8220;Form 8-K&#8221;) and the escrow agreement, which is filed as Exhibit 10.1 to the Form 8-K, respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Amendment to the 2009 Plan and 2009 Non-U.S. Plan</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At the NeoStem 2011 Annual Meeting, the shareholders of NeoStem duly approved an amendment to the NeoStem, Inc. 2009 Equity Compensation Plan (the &#8220;2009 Plan&#8221;) to increase the number of shares of NeoStem Common Stock authorized for issuance thereunder by 6,000,000 shares (that is, from 17,750,000 shares to 23,750,000 shares), and NeoStem thereupon effected such amendment to the 2009 Plan. Persons eligible to receive restricted and unrestricted stock awards, options, stock appreciation rights or other awards under the 2009 Plan are those employees, consultants and directors of NeoStem and its subsidiaries who, in the opinion of the Compensation Committee of NeoStem&#8217;s Board of Directors, are in a position to contribute to NeoStem&#8217;s success.&#160;&#160;Concurrently therewith, NeoStem decreased the number of shares authorized for issuance under the NeoStem, Inc. 2009 Non-U.S. Based Equity Compensation Plan by 3,000,000 (that is, from 8,700,000 to 5,700,000).&#160;&#160;The reduction in shares available for issuance under the 2009 Non-U.S. Plan was effected in light of the Company&#8217;s plan to focus its business on cell therapy manufacturing and development and other related activities in the United States, and the Company&#8217;s consideration of the possible divestiture of its 51% interest in Erye.&#160;&#160;Persons eligible to receive warrants, stock appreciation rights or other awards under the 2009 Non-U.S. Plan are those service providers of NeoStem and its subsidiaries and affiliates providing services outside of the United States, including employees and consultants of NeoStem and its subsidiaries and affiliates, who, in the opinion of the Compensation Committee, are in a position to contribute to NeoStem&#8217;s success.&#160;&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">25</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="V179493_10K_HTM_EOLPAGE26"><!--EFPlaceholder--></a>ITEM 2.&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; herein and under &#8221;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2010 . The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this quarterly report and in our Annual Report on Form 10-K for the year ended December 31, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Overview</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NeoStem, Inc. is an international biopharmaceutical company operating in three reportable segments: (i) Cell Therapy&#160;&#8212;&#160;United States; (ii) Regenerative Medicine&#160;&#8212;&#160;China; and (iii) Pharmaceutical Manufacturing &#8212;&#160;China.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Through the Cell Therapy&#160;&#8212;&#160;United States segment, we are focused on the development of proprietary cellular therapies in oncology, immunology and regenerative medicine and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally<font style="DISPLAY: inline; FONT-STYLE: italic">. </font>Within this segment, we also are a provider of adult stem cell collection, processing and storage services in the U.S., enabling healthy individuals to donate and store their stem cells for personal therapeutic use.&#160;&#160;In addition, the Company collects and stores cord blood cells of newborns which help to ensure a supply of autologous stem cells for the child should they be needed for future medical treatment.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company strengthened its expertise in cellular therapies, for its Cell Therapy &#8211; United States segment, with its January 19, 2011 acquisition of Progenitor Cell Therapy, LLC, a Delaware limited liability company (&#8220;PCT&#8221;), pursuant to which the Company acquired all of the membership interests of PCT, and PCT is now a wholly-owned subsidiary of NeoStem. PCT is engaged in a wide range of services in the cell therapy market for the treatment of human disease, including, but not limited to contract manufacturing, product and process development, regulatory consulting, product characterization and comparability, and storage, distribution, manufacturing and transportation of cell therapy products. PCT&#8217;s legacy business relationships also afford NeoStem introductions to innovative therapeutic programs.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In March 2011 PCT&#8217;s wholly owned subsidiary, Athelos, Inc. (Athelos), acquired rights and technology for a T-cell based immunomodulatory therapeutic in exchange for an approximate 20% interest in Athelos. Athelos expects to initiate Phase I studies in autoimmune disorders in 2012.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company further strengthened its breadth in cellular therapies through its October 17, 2011 acquisition of Amorcyte, Inc.&#160;&#160;Amorcyte is a development stage cell therapy company focusing on novel treatments for cardiovascular disease.&#160;&#160;Amorcyte&#8217;s lead product candidate, AMR-001, is entering a Phase 2 study for the treatment of acute myocardial infarction (AMI).&#160;&#160;Amorcyte is currently recruiting trial sites in connection with the launch of this Phase 2 clinical trial which is expected to begin enrolling patients by the end of the first quarter of 2012.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company views the PCT and Amorcyte acquisitions as fundamental to building a foundation in achieving its strategic mission of capturing the paradigm shift to cell therapy.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Through our Regenerative Medicine&#160;&#8212;&#160;China segment, in 2009, we began several China-based, Regenerative Medicine initiatives including: (i) creating a separate China-based cell therapy operation, (ii) constructing a stem cell research and development laboratory and processing facility in Beijing, (iii) establishing relationships with hospitals to provide cell-based therapies, and (iv) obtaining product licenses covering several adult stem cell therapeutics focused on regenerative medicine.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">26</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We acquired our Pharmaceutical Manufacturing&#160;&#8212;&#160;China segment when on October 30, 2009, China Biopharmaceuticals Holdings, Inc. (&#8220;CBH&#8221;) merged with a wholly-owned subsidiary of NeoStem (the &#8220;Erye Merger&#8221;). As a result of the Erye Merger, NeoStem acquired CBH&#8217;s 51% ownership interest in Erye, a Sino-foreign joint venture with limited liability organized under the laws of the People&#8217;s Republic of China. Erye was founded more than 50 years ago and represents an established, vertically-integrated pharmaceutical business. Historically, Erye has concentrated its efforts on the manufacturing and distribution of generic antibiotic products. In 2010, Erye began transferring its operations to its newly constructed manufacturing facility. The relocation is continuing as the new production lines are completed and receive cGMP certification. As part of its plan to focus its business on capturing the paradigm shift to cell therapies following the January 2011 acquisition of PCT, the Company is pursuing strategic alternatives with respect to its interest in Erye.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To support our liquidity needs, the Company raised an aggregate of approximately $5.6 million in private placements of Common Stock from March 2011 to June 2011.&#160;&#160;In addition, on July 6, 2011, three then key Amorcyte stockholders (including a fund managed by a then Amorcyte director) invested an aggregate of $728,000 in a private placement of 568,750 shares of Common Stock (purchase price $1.28 per share)&#160;&#160;and on July 22, 2011, the Company completed an underwritten offering of 13,750,000 units at a purchase price of $1.20 per unit, with each unit consisting of one share of Common Stock and a five year warrant to purchase 0.75 of a share of Common Stock at an exercise price of $1.45 per share (the &#8220;Offering&#8221;).&#160;&#160;&#160;The Company received gross proceeds of $16,500,000 prior to deducting underwriting discounts and offering expenses payable by the Company, for net proceeds of approximately $14,667,000.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Results of Operations</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Three and Nine Months Ended September 30, 2011 Compared to the Three and Nine Months Ended September 30, 2010</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Revenue and Cost of Revenue</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Three Months Ended September 30, 2011 Compared to Three Months Ended September 30, 2010</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the three months ended September 30, 2011, total revenues were approximately $17,756,100 compared to approximately $16,475,600 for the three months ended September 30, 2010. Revenues for the three months ended September 30, 2011 and 2010, respectively, were comprised of the following (in thousands):</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div align="center">
<table cellpadding="0" cellspacing="0" width="85%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Three Months Ended September 30,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pharmaceutical Manufacturing - China</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,513.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,384.5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cell Therapy - United States</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,177.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">61.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Regenerative Medicine - China</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">66.1</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,756.1</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,475.6</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenues for our Pharmaceutical Manufacturing &#8211; China reporting segment were approximately $15,513,000 representing a decrease of approximately $871,500 or 5%. The decrease was primarily due to a strategic decision to adjust the product mix, decreasing sales of certain pharmaceutical intermediates to other pharmaceutical manufacturers in order to create capacity for higher margin products in the future, which resulted in 5% reduction in overall sales.&#160; As an example, in Q1 2011 Erye&#160;&#160;introduced two new products, omeprazole and cloxacillin which are expected to contribute to higher margins than the discontinued pharmaceutical intermediates, and we have several other products under development that may be introduced over the next three to four years.&#160;&#160;Revenues from sales of antibiotics, cephalosporins and other therapeutic products declined approximately 8% compared&#160;&#160;to the same period for 2010 due primarily from the impact of specific policies on volume control for certain drugs, including ongoing restriction on antibiotics, and the average price of antibiotics and cephalosporins decreased revenues by approximately 2%, which were offset by increased revenues resulting from changes in foreign exchange rates between the Chinese RMB and United States dollar by approximately 6%.&#160;&#160;We recognize that there will be continuous price pressure on Erye as over 70% of Erye&#8217;s manufactured drugs are on China&#8217;s essential drug list. There has been evidence of such price pressure&#160;&#8211;&#160;i.e., on March 2, 2011 the National Development and Reform Commission issued price cuts for medical insurance drugs which substantially impacts two of Erye&#8217;s drugs. We anticipate that Piperacillin Sodium and Sulbactam Sodium will experience as much as a 50% price decline while the price of Ligustrazine Phosphate may be reduced by approximately 75%. As of September 30, 2011, the price reduction experienced by Erye on these products was approximately <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20%.</font>&#160;&#160;During the three months ended September 30, 2011 Piperacillin Sodium and Sulbactum Sodium accounted for approximately <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4%</font> of sales and Ligustrazine Phosphate accounted for approximately <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1%</font> of sales. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recently, the Ministry of Health issued, for public comment, a draft policy &#8220;Administrative Measures on Clinical Use of Antibiotics&#8221; to curb their overuse.&#160;&#160;The proposed guidelines set forth three categories of antibiotics, which include 1) restricted, 2) non-restricted, and 3) special-use only.&#160;&#160;It has been projected that the limitation of antibiotic usage in China will reduce the historical compound annual growth rate which has been approximately 20%.*&#160; It has been estimated that China&#8217;s population consumes about ten times the global per capita average of antibiotics.*&#160; These regulations have not been finalized but issuance of a draft policy has created uncertainty on the part of distributors and has reduced purchases by distributors and in part has contributed to sales reductions in Q3, 2011.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">*&#160; Derived from the October 12, 2011 China Healthcare report, published by Deutsche Bank, AG.</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">27</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The increase in revenue for our Cell Therapy &#8211; United States reporting segment is due to revenues generated by PCT which was acquired in January 2011, and whose revenues totaled approximately $2,151,200.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The cost of revenue was approximately $13,840,700 representing an increase of approximately $2,607,900 compared with the prior year period.&#160;&#160;The cost of revenue in the Pharmaceutical Manufacturing &#8211; China reporting segment was approximately $11,905,100 and increased 6% over the same period in 2010. The strategic decision to discontinue manufacturing low margin pharmaceutical intermediates in order to free up capacity for higher margin products in the future decreased the cost of manufacturing by 2%.&#160;&#160;This reduction in cost was offset by increases in the cost of manufacturing of antibiotics and cephalosporins and other therapeutic products of approximately 2% due to the impact of the increased costs associated with the new plant and an increase in amortization expense associated with intangible assets acquired in the Erye Merger. This increase in manufacturing costs is expected to continue to have a negative impact until an increase in sales of higher margin products is realized.&#160;&#160;Increases in the exchange rate between the Chinese RMB and the United States dollar increased cost of revenue by 6%. The cost of revenue for Cell Therapy &#8211; United States reporting segment was $1,891,300 an increase of approximately $1,870,200 principally related to the cost of revenue for PCT and the cost of revenue for Regenerative Medicine &#8211; China reporting segment constituted the remaining balance.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Nine Months Ended September 30, 2011 Compared to Nine Months Ended September 30, 2010</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the nine months ended September 30, 2011, total revenues were approximately $55,858,000 compared to approximately $51,716,300 for the nine months ended September 30, 2010. Revenues for the nine months ended September 30, 2011 and 2010, respectively, were comprised of the following (in thousands):</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div align="center">
<table cellpadding="0" cellspacing="0" width="85%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Nine Months Ended September 30,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pharmaceutical Manufacturing - China</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,806.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">51,528.7</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cell Therapy - United States</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,837.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">157.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Regenerative Medicine - China</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">215.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">55,858.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">51,716.3</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenues for our Pharmaceutical Manufacturing &#8211; China reporting segment were approximately $49,806,000 representing a decrease of approximately $1,722,700 or 3%. This decrease was primarily due to a strategic decision by management to discontinue selling certain pharmaceutical intermediates to other pharmaceutical manufacturers, in order to create capacity within the existing production lines for higher margin products in the future, this reduced Erye&#8217;s sales approximately 11%. Revenues from sales of antibiotics, cephalosporins and other therapeutic products increased approximately <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font>%.&#160;&#160;The balance of the change in revenue year over year is due to increases in the exchange rate between the Chinese RMB and the United States dollar which increased sales volume 5%. Overall the average price of products sold for the nine months ended September 30, 2011 increased approximately 1% in comparison to products sold in the same period last year. However, we recognize that there will be continuous price pressure on Erye as over 70% of Erye&#8217;s manufactured drugs are on China&#8217;s essential drug list. There has been evidence of such price pressure&#160;&#8211;&#160;i.e., on March 2, 2011 the National Development and Reform Commission issued price cuts for medical insurance drugs which substantially impacts two of Erye&#8217;s drugs. We anticipate that Piperacillin Sodium and Sulbactam Sodium will experience as much as a 50% price decline while the price of Ligustrazine Phosphate may be reduced by approximately 75%. As of September 30, 2011 the price reduction experienced by Erye on these products was approximately <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20%</font>.&#160;&#160;During the&#160;nine months ended September 30, 2011 Piperacillin Sodium and Sulbactum Sodium accounted for approximately 1<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">% </font>of sales and Ligustrazine Phosphate accounted for approximately <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4%</font> of sales.&#160; </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recently, the Ministry of Health issued, for public comment, a draft policy &#8220;Administrative Measures on Clinical Use of Antibiotic Drugs&#8221; to curb their overuse.&#160;&#160;The proposed guidelines set forth three categories of antibiotics, which include 1) restricted, 2) non-restricted, and 3) special-use only. &#160;It has been projected that the limitation of antibiotic usage in China will reduce the historical compound annual growth rate which has been approximately 20%.*&#160; It has been estimated that China&#8217;s population consumes about ten times the global per capita average of antibiotics.*&#160; These regulations have not been finalized but issuance of a draft policy has created uncertainty on the part of distributors and has reduced purchases by distributors and in part has contributed to sales reductions in 2011.&#160; </font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The increase in revenue for our Cell Therapy &#8211; United States reporting segment is due to revenues generated by PCT which was acquired in January 2011, and whose revenues totaled approximately $<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5,571,500</font>.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The cost of revenue was approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">41,637,000 </font>representing an increase of approximately $6,621,400 compared with the prior year period.&#160;&#160;The cost of revenue for Pharmaceutical Manufacturing &#8211; China reporting segment was approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">36,207,100 </font>representing an increase of<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#160;4</font>% over the same period in 2010. The strategic decision to discontinue low margin pharmaceutical intermediates and free up capacity for higher margin products in the future decreased the cost of manufacturing by <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">12</font>%; however, this reduction in cost was significantly offset by increases in the cost of&#160;&#160;manufacturing of antibiotics and cephalosporins and other therapeutic products resulting from&#160;&#160;the&#160;&#160;impact of the increased costs&#160;&#160;associated with the new plant and an increase in amortization expense associated with intangible assets acquired in the Erye Merger. This increase in manufacturing costs is expected to continue to have a negative impact until an increase in sales of higher margin products is realized. Increases in the exchange rate between the Chinese RMB and the United States dollar increased cost of revenue by <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5</font>%. The cost of revenue for Cell Therapy &#8211; United States reporting segment was approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5,336,100 </font>and the cost of revenue for Regenerative Medicine &#8211; China reporting segment constituted the remaining balance.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">*&#160; Derived from the October 12, 2011 China Healthcare report, published by Deutsche Bank, AG.</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Operating Expenses</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Three Months Ended September 30, 2011 Compared to Three Months Ended September 30, 2010</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the three months ended September 30, 2011 operating expenses totaled approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">11,295,700 </font>compared to approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">10,986,600 </font>for the three months ended September 30, 2010, representing an increase of approximately $309<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,100 </font>or 3%.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Historically, to minimize our use of cash, we have used a variety of equity and equity-linked instruments to pay for services and to incentivize employees, consultants and other service providers. The use of these instruments has resulted in significant charges to the results of operations. In general, these equity and equity-linked instruments were used to pay for employee and consultant compensation, director fees, marketing services, investor relations and other activities. For the three months ended September 30, 2011, the use of equity and equity-linked instruments to pay for such expenses resulted in charges to selling, general, administrative, and research expenses of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,530,700</font> representing a decrease of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,205,672 </font>over the three months ended September 30, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the three months ended September 30, 2011, our selling, general, and administrative expenses were approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">8,812,500 </font>compared to approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">9,306,600 </font>for the three months ended September 30, 2010, representing a decrease of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">494,100 </font>or 5%.&#160;&#160;Equity-based compensation included in selling, general and administrative expenses for the three months ended September 30, 2011 was approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,647,500</font>, compared to approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">2,750,300 </font>for the three months ended September 30, 2010.&#160;&#160;Overall, the increase in selling, general and administrative expenses was primarily due to the following:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A decrease of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">451,800 </font>in the Cell Therapy &#8211; United States reporting segment, comprised of (i) a decrease of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,102,800 </font>related to employee, director and consultant equity compensation; and (ii) a decrease of approximately $576,100 in selling and marketing expenses in connection with our adult stem cell collection efforts.&#160;&#160;These decreases were partially offset by an increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,119,300 </font>related to new operating expenses as a result of our acquisition of PCT in January 2011.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A decrease of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">287,300 </font>in our Pharmaceutical Manufacturing &#8211; China reporting segment.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">244,900 </font>in our Regenerative Medicine &#8211; China reporting segment.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the three months ended September 30, 2011, our research and development expenses were&#160;approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">2,483,300 </font>compared to approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,679,900 </font>for the three months ended September 30, 2010, representing an increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">803,300</font> or <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">48</font>%.&#160;&#160;Equity-based compensation included in research and development expenses for the three months ended September 30, 2011 reflected a credit of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">116,800</font>, compared to a credit of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">14,000 </font>for the three months ended September 30, 2010, which is primarily due to the fair value remeasurement of consultant equity awards.&#160;&#160;Overall, the increase in research and development expenses was primarily due to the following:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A decrease of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">139,400 </font>in the Cell Therapy &#8211; United States reporting segment as a result of reduced internal research activities in our VSEL&#8482; Technology, subletting a portion of the VSEL laboratory and focusing on supporting VSEL research activities with our external research collaborators.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">536,900 </font>in our Pharmaceutical Manufacturing &#8211; China reporting segment as a result of increased clinical development efforts on products under development.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">127,000 </font>in our Regenerative Medicine &#8211; China reporting segment due to the recovery of certain expenses incurred in prior years that were refunded to us during the quarter, offset by increased costs of operating the Beijing laboratory.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">29</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Nine Months Ended September 30, 2011 Compared to Nine Months Ended September 30, 2010</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the nine months ended September 30, 2011 operating expenses totaled approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">39,595,400 </font>compared to approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">28,555,800 </font>for the nine months ended September 30, 2010, representing an increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">11,039,600 </font>or <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">39</font>%.&#160;&#160;For the nine months ended September 30, 2011, the use of equity and equity-linked instruments to pay for such expenses resulted in charges to selling, general, administrative, and research expenses of $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">7,985,800</font>, representing an increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,135,400 </font>over the nine months ended September 30, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the nine months ended September 30, 2011, our selling, general, and administrative expenses were approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">31,828,400 </font>compared to approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">23,442,300 </font>for the nine months ended September 30, 2010, representing an increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">8,386,200 </font>or <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">36</font>%.&#160;&#160;Equity-based compensation included in selling, general and administrative expenses for the nine months ended September 30, 2011 were approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">7,485,100</font>, compared to approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">6,123,200 </font>for the nine months ended September 30, 2010.&#160;&#160;Overall, the increase in selling, general and administrative expenses was primarily due to the following:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5,968,100 </font>in the Cell Therapy &#8211; United States reporting segment, comprised of (i) an increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,361,900 </font>related to employee, director and consultant equity compensation, including approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">722,900 </font>related to the modification of stock option awards to our CEO in April 2011; (ii) an increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">3,022,800 </font>related to new operating expenses as a result of our acquisition of PCT; (iii) an increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,562,200 </font>in legal, accounting, and other professional fees, including expenses relating to the Company&#8217;s strategic shift towards cell therapy initiatives; (iv) an increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">607,400 </font>due to a one-time charitable contribution paid in equity during the three months ended March 31, 2011 to a foundation for which our CEO is President and Trustee, General Counsel is Secretary and Trustee and CFO is Treasurer; and (v) an increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,240,100 </font>related to administrative activities. These increases were partially offset by a decrease of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,219,000 </font>in selling and marketing expenses in connection with our adult stem cell collection efforts.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,672,000 </font>in our Pharmaceutical Manufacturing &#8211; China reporting segment, comprised of (i) a $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,186,100 </font>increase in taxes related to withholding taxes paid on two dividends declared (in January, 2011 and April, 2011) that were retained in the business, (ii) an increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">518,800 </font>in selling and marketing expenses, and (iii) an increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,153,100 </font>related to administrative activities.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">746,100 </font>in our Regenerative Medicine &#8211; China reporting segment, comprised primarily of an increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">732,300 </font>related to administrative activities.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the nine months ended September 30, 2011, our research and development expenses were&#160;approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">7,767,000 </font>compared to approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5,113,300 </font>for the nine months ended September 30, 2010, representing an increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">2,653,700 </font>or <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">52</font>%.&#160;&#160;Equity-based compensation included in research and development expenses for the nine months ended September 30, 2011 was approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">500,800</font>, compared to approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">727,300 </font>for the nine months ended September 30, 2010.&#160;&#160;Overall, the increase in research and development expenses was primarily due to the following:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 446pt; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,347,400 </font>in our Cell Therapy &#8211; United States reporting segment, comprised primarily of an in-process research and development charge of approximately $1,<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">150,000 </font>related to the acquisition of certain intellectual properties in the area of T-Cell regulation from Becton, Dickinson and Company in March 2011.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,152,200</font> in our Pharmaceutical Manufacturing &#8211; China reporting segment as a result of increased clinical development efforts on products under development.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An increase of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">154,000 </font>in our Regenerative Medicine &#8211; China reporting segment due to the recovery of certain expenses incurred in prior years that were refunded to us during the quarter, offset by increased costs of operating the Beijing laboratory.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Other Income and Expense</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the three and nine months ended September 30, 2011, the Company recognized interest expense of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,305,800 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">3,168,100</font>, respectively, compared with approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">10,700 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">25,400 </font>for the three and nine months ended September 30, 2010.&#160;&#160;The increase is primarily related to amortization of debt discount of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">574,500 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,903,700 </font>for the three and nine months ended September 30, 2011, respectively, associated with the Convertible Redeemable Series E Preferred Stock that was issued in November 2010, which is being accounted for as mezzanine equity.&#160;&#160;For the three and nine months ended September 30, 2011, interest expense of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">329,500 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">855,700 </font>respectively was recorded as a result of a loan to Erye from its minority shareholder of which approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">0 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">235,700</font>, respectively was capitalized as part of the cost of construction of Erye&#8217;s new manufacturing plant. For the three and nine months ended September 30, 2011, interest of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">343,500 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">474,300 </font>respectively was interest expense associated with bank loans obtained by Erye totaling approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">7,810,000 </font>at September 30, 2011. In addition, interest expense includes, for the three and nine months ended September 30, 2011, interest of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">49,800 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">144,500 </font>respectively for mortgage loans for PCT&#8217;s Allendale facility.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">30</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other income for the three and nine months ended September 30, 2011 net totaled approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,383,800 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,721,400 </font>respectively which primarily related to the revaluation of derivative liabilities that have been established in connection with the Convertible Redeemable Series E Preferred Stock.&#160;&#160;Other income for the three and nine months ended September 30, 2010 net totaled approximately $45,800 and $31,300, respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Provision for Taxes</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The income tax provision for the three and nine months ended September 30, 2011 and 2010 is related to foreign taxes for our operations in China.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The provision for income taxes and the realization of deferred tax liability for Pharmaceutical Manufacturing &#8211; China is based on, for the three and nine months ended September 30, 2011, a statutory rate of <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">25</font>% and, for the three and nine months ended September 30, 2010, a statutory rate of <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">12.5</font>%.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Dividends on Preferred Stock</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Convertible Redeemable Series E Preferred Stock calls for annual dividends of <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">7</font>% based on the stated value of the preferred stock and for the three and nine months ended September 30, 2011 we recorded dividends of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">150,700 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">508,100</font>, respectively. In the nine months ended September 30, 2010 the Company recorded dividends of approximately $153,500 on the Convertible Redeemable Series C Preferred Stock which called for an annual dividend of <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5</font>% based on the stated value of the preferred stock. The Convertible Redeemable Series C Preferred Stock was converted into NeoStem Common Stock in May 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Noncontrolling Interests</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with accounting for the Company&#8217;s 51% interest in Erye, we account for the 49% minority shareholder share of Erye&#8217;s net income with a charge to Noncontrolling Interests. For the three months ended September 30, 2011 Erye&#8217;s minority shareholders&#8217; share of net loss totaled approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">53,200</font>.&#160;&#160;For the nine months ended September 30, 2011, Erye&#8217;s minority shareholders&#8217; share of net income totaled approximately $796,200.&#160;&#160;In addition, the Company acquired rights to use patents under licenses from Becton, Dickinson and Company in March 2011, in exchange for an approximately 20% interest in PCT&#8217;s Athelos subsidiary.<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font> Noncontrolling interest also reflects Becton&#8217;s share of losses incurred by Athelos during the three and nine months ended September 30, 2011 of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">35,000 </font>and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">237,100 </font>respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Liquidity and Capital Resources</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At September 30, 2011 we had a cash balance of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">11,713,300</font>, working capital of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">13,581,000</font>, and shareholders&#8217; equity of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">73,561,500</font>.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the nine months ended September 30, 2011, we met our immediate cash requirements through existing cash balances, private placements and a public offering of our common stock which raised an aggregate of approximately $21,167,700, the issuance of notes payable for our operations in China and the use of equity and equity-linked instruments to pay for services and compensation.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We incurred a net loss of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">7,497,100 </font>and approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">28,795,900 </font>for the three and nine months ended September 30, 2011, respectively. The following chart represents the net funds provided by or used in operating, financing and investing activities for each period indicated:</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div align="center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Nine Months Ended September 30,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net cash used in operating activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(17,522.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,175.7</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net cash used in investing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,127.9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,019.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net cash provided by financing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,516.5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,993.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Operating Activities</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our cash used for operating activities in the nine months ended September 30, 2011 totaled approximately $17,522,400, which is the sum of (i) our net loss, adjusted for non-cash expenses totaling $9,481,800 which includes, principally, common stock, common stock options and common stock purchase warrants issued for services rendered and charitable contribution in the aggregate amount of approximately $8,772,200, depreciation and amortization of approximately $6,755,000, the write-off of in process research and development of approximately $1,150,000, amortization of Preferred Stock discount and issuance cost of approximately $1,903,700, and (ii) changes in operating assets and liabilities of approximately $6,810,400.</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Investing Activities</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the nine months ended September 30, 2011, we spent approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5,453,900 </font>for property and equipment principally related to the construction of Erye&#8217;s new manufacturing facility.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the&#160;nine months ended September 30, 2010, we spent approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">12,510,600</font> for property and equipment. Erye was building a new production facility and during the&#160;nine months ended&#160;September 30, 2010,&#160;$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">10,821,400</font> was spent on construction.&#160;&#160;In March 2010, we initiated construction of our stem cell laboratory in Beijing and spent $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">852,200 </font>for the nine months ended September 30, 2010.&#160;&#160;The balance of our capital expenditures was spent on equipping our laboratory in Boston and other Company stem cell operations in China.&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Financing Activities</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 3, 2011, the Company consummated a private placement pursuant to which five persons and entities acquired an aggregate of 2,343,750 shares of Common Stock for an aggregate consideration of $3,000,000 (purchase price $1.28 per share). On April 5, 2011, the Company consummated a private placement pursuant to which nine persons and entities acquired an aggregate of 1,244,375 shares of Common Stock for an aggregate consideration of $1,592,800 (purchase price $1.28 per share).&#160;&#160;On June 13, 2011, the Company consummated a private placement pursuant to which one entity acquired 781,250 shares of Common Stock for an aggregate consideration of $1,000,000 (purchase price $1.28 per share). On July 6, 2011, three then key Amorcyte stockholders (including a fund managed by a then Amorcyte director) invested an aggregate of $728,000 in a private placement of 568,750 shares of Common Stock (purchase price $1.28 per share).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 22, 2011, the Company completed an underwritten offering of 13,750,000 units at a purchase price of $1.20 per unit, with each unit consisting of one share of Common Stock and a five year warrant to purchase 0.75 of a share of Common Stock at an exercise price of $1.45 per share (the &#8220;Offering&#8221;).&#160;&#160;The Company sold securities in the Offering under the Company&#8217;s previously filed shelf registration statement on Form S-3 (333-173855), which was declared effective by the Securities and Exchange Commission on June 13, 2011.&#160;&#160;Lazard Capital Markets LLC (&#8220;Lazard&#8221;) and JMP Securities LLC (&#8220;JMP&#8221;) acted as representatives of the underwriters named in an Underwriting Agreement, dated as of July 19, 2011, by and among the Company, Lazard, JMP and such underwriters.&#160;&#160;The Company received gross proceeds of $16,500,000, prior to deducting underwriting discounts and offering expenses payable by the Company, for net proceeds of $14,667,000.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the nine months ended September 30, 2011, the Company&#8217;s Erye subsidiary borrowed approximately $10,801,000 in notes payable, and repaid approximately $17,021,900 over the same period.&#160;&#160;Notes are payable to the banks who issue bank notes to Erye&#8217;s creditors.&#160;&#160;Notes payable are interest free and usually mature after a three to six month period.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the nine months ended September 30, 2011, the Company&#8217;s Erye subsidiary borrowed approximately $6,149,000 in bank loans, repaid approximately $1,557,000 over the same period.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the PCT Merger Agreement, NeoStem agreed to pay off PCT&#8217;s credit line with Northern New Jersey Cancer Associates (&#8220;NNJCA&#8221;), in an amount up to $3,000,000, shortly after the closing of the PCT Merger. On January 21, 2011, NeoStem paid NNJCA $3,000,000 in full satisfaction of all of PCT&#8217;s obligations to NNJCA arising from the underlying line of credit and security agreement. Dr. Andrew Pecora (who was PCT&#8217;s Chairman and CEO prior to the PCT Merger, and who became PCT&#8217;s Chief Medical Officer on January 19, 2011 pursuant to an employment agreement effective upon the closing of the PCT Merger), has served as Managing Partner of NNJCA since 1996.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Liquidity and Capital Requirements Outlook</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">With our acquisition of a controlling interest in Erye and expansion into China, and our acquisition of PCT and Amorcyte, we have transitioned from being a one-dimensional U.S. service provider with nominal revenues to being a multi-dimensional international biopharmaceutical company with current revenues and operations in three distinct segments: (i) Cell Therapy&#160;&#8212;&#160;United States; (ii) Regenerative Medicine&#160;&#8212;&#160;China; and (iii) Pharmaceutical Manufacturing&#160;&#8212;&#160;China. The following is an overview of our collective liquidity and capital requirements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Capital Requirements and Resources in China</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Erye has substantially completed the construction of its new pharmaceutical manufacturing facility and began transferring its operations in January 2010. The relocation is continuing as the new production lines are completed and receive cGMP certification.&#160;&#160;Further, an additional two production lines are believed to be needed for growth at a cost of approximately 40 million RMB (approximately $6,305,900).&#160;&#160;In January 2010, Suzhou Erye received notification that the SFDA has approved Suzhou Erye&#8217;s application for cGMP certification to manufacture solvent crystallization sterile penicillin and freeze dried raw sterile penicillin at the new facility. In June 2010, Suzhou Erye passed the government inspection by the SFDA to manufacture penicillin and cephalosporin powder for injection at the new facility. In May 2011, Suzhou Erye received cGMP production certification for freeze dried powder for injection issued by SFDA at the new facility. The facility is fully operational with respect to these lines. The combined production lines now certified by the SFDA were responsible for approximately 99% of Erye&#8217;s 2010 revenues with two of them responsible for over 90% of Erye&#8217;s 2010 revenues.&#160;&#160;Eyre has incurred approximately $39 million on the new facility,&#160;and is substantially complete at September 30, 2011. It was contemplated by the Joint Venture Agreement that the construction would continue for three years.&#160;&#160;As such, 45% of the dividend we would be entitled to by reason of our 51% ownership would remain in Erye through October 2012 to complete the relocation while EET would loan back their dividend during the same period at a prevailing bank interest rate.&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Upon a liquidity event of Erye, as contemplated in the joint venture agreement, the Company will be entitled to the return of its dividend reinvestments to the extent of the proceeds generated by the liquidity event.&#160; </font>Repayment of such loans from EET&#160;would occur gradually after the relocation is completed.&#160;&#160;We have agreed for a period of approximately another year to reinvest in Erye approximately 90% of the net earnings, in the form of dividends, we would be entitled to receive under the Joint Venture Agreement by reason of our 51% interest in Erye and EET has agreed for a period of approximately another year to loan back to Erye all dividends it is entitled to for use in connection with its construction of the new Erye facility.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">32</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are also engaged in other initiatives that would expand our operations into China including with respect to technology licensing, establishment of stem cell processing and storage capabilities and research and clinical development. In June 2009 we established NeoStem (China) as our wholly foreign-owned subsidiary or WFOE. To comply with PRC&#8217;s foreign investment regulations regarding stem cell research and development, clinical trials and related activities, we conduct our current stem cell business in the PRC through domestic variable interest entities (&#8220;VIEs&#8221;). We have incurred and expect to continue to incur substantial expenses in connection with our China activities; provided, however, that the continuation of these activities is being reviewed periodically.&#160;&#160;Based on, among other things, the changing regulatory environment in China we could conclude that it would be in our best interest to discontinue them.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We expect to rely partly on dividends paid to us by the WFOE under the contracts with the VIEs, and under the Joint Venture Agreement attributable to our 51% ownership interest in Erye, to meet some of our future cash needs with respect to continued operations in China. However, there can be no assurance that the WFOE in China will receive payments uninterrupted or at all as arranged under the contracts with the VIEs. In addition, pursuant to the Joint Venture Agreement that governs the ownership and management of Erye, for 2011 and approximately the next year: 45% of the net profit after tax due to the Company, in the form of dividends, will be provided to Erye as part of the new facility construction fund, which will be characterized as additional paid-in capital for our 51% interest in Erye; and (iii) only 6% of the net profit will be distributed to us directly for our operating expenses which has not been paid to date from the 2010 distribution and is in the amount of approximately $130,000.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The payment of dividends by entities organized under PRC law to non-PRC entities is subject to limitations. Regulations in the PRC currently permit payment of dividends by our WFOE and Erye only out of accumulated distributable earnings, if any, as determined in accordance with accounting standards and regulations in China. Moreover, our WFOE and Erye are required to appropriate from PRC GAAP profit after tax to other non-distributable reserve funds. These reserve funds include one or more of the following: (i) a general reserve, (ii) an enterprise expansion fund and (iii) a staff bonus and welfare fund. Subject to certain cumulative limits (i.e., 50% of the registered capital of the relevant company), the general reserve fund requires annual appropriation at 10% of after tax profit (as determined under accounting principles generally accepted in the PRC at each year-end); the appropriation to the other funds are at the discretion of WFOE and Erye. In addition, if Erye incurs debt on its own behalf in the future, the instruments governing the debt may restrict Erye&#8217;s or the joint venture&#8217;s ability to pay dividends or make other distributions to us. This may diminish the cash flow we receive from Erye&#8217;s operations, which would have a material adverse effect on our business, operating results and financial condition.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our interests in China are subject to China&#8217;s rules and regulations on currency conversion. In particular, the initial capitalization and operating expenses of the VIEs are funded by our WFOE. In China, the State Administration for Foreign Exchange, or the SAFE, regulates the conversion of the Chinese Renminbi into foreign currencies. Currently, foreign investment enterprises are required to apply to the SAFE for Foreign Exchange Registration Certificates, or IC Cards of Enterprises with Foreign Investment. Foreign investment enterprises holding such registration certificates, which must be renewed annually, are allowed to open foreign currency accounts including a &#8220;basic account&#8221; and &#8220;capital account.&#8221; Currency translation within the scope of the &#8220;basic account,&#8221; such as remittance of foreign currencies for payment of dividends, can be effected without requiring the approval of the SAFE. However, conversion of currency in the &#8220;capital account,&#8221; including capital items such as direct investments, loans, and securities, require approval of the SAFE. According to the<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;Notice of the General Affairs Department of the State Administration of Foreign Exchange on the Relevant Operating Issues Concerning the Improvement of the Administration of Payment and Settlement of Foreign Currency Capital of Foreign-invested Enterprises</font>&#160;&#160;promulgated on August 29, 2008, or the SAFE Notice 142, to apply to a bank for settlement of foreign currency capital, a foreign invested enterprise shall submit the documents certifying the uses of the RMB funds from the settlement of foreign currency capital and a detailed checklist on use of the RMB funds from the last settlement of foreign currency capital. It is stipulated that only if the funds for the settlement of foreign currency capital are of an amount not more than US$50,000 and are to be used for enterprise reserve, the above documents may be exempted by the bank. This SAFE Notice 142, along with the recent practice of Chinese banks of restricting foreign currency conversion for fear of &#8220;hot money&#8221; going into China, limits and may continue to limit our ability to channel funds to the VIE entities for their operation.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">33</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Neither Erye nor our other expansion activities into China are expected to generate sufficient excess cash flow to support our initiatives in China in the near term.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We recognize that there will be continuous price pressure on Erye as over 70% of Erye&#8217;s manufactured drugs are on the essential drug list. There has recently been evidence of such price pressure&#160;&#8211;&#160;i.e., on March 2, 2011 the National Development and Reform Commission issued price cuts for medical insurance drugs which substantially impacts two of Erye&#8217;drugs. We anticipate that Piperacillin Sodium and Sulbactam Sodium will experience as much as a 50% price decline while the price of Ligustrazine Phosphate may be reduced by approximately 75%.&#160; <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of September 30, 2011 the price reduction experienced by Erye on these products was approximately <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">20</font>%.&#160;&#160;In 2011 Piperacillin Sodium and Sulbactum Sodium accounted for approximately <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1</font>% of sales and Ligustrazine Phosphate accounted for approximately <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">4</font>% of sales.&#160;&#160;Recently, the Ministry of Health issued, for public comment, a draft policy &#8220;Administrative Measures on Clinical Use of Antibiotic Drugs&#8221; to curb their overuse.&#160;&#160;The proposed guidelines set forth three categories of antibiotics, which include 1) restricted, 2) non-restricted, and 3) special-use only. &#160;It has been projected that the limitation of antibiotic usage in China will reduce the historical compound annual growth rate which has been approximately 20%.*&#160;&#160;It has been estimated that China&#8217;s population consumes about ten times the global per capita average of antibiotics.*&#160;These regulations have not been finalized but issuance of a draft policy has created uncertainty on the part of distributors and has reduced purchases by distributors and in part has contributed to sales reductions in 2011.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Capital Requirements for Recent Expansion</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NeoStem, Inc. acquired Progenitor Cell Therapy, LLC (&#8220;PCT&#8221;), by means of a merger (the &#8220;PCT Merger&#8221;) of a newly formed wholly-owned subsidiary of NeoStem, with and into PCT pursuant to an Agreement and Plan of Merger, dated September 23, 2010 (the &#8220;PCT Agreement and Plan of Merger&#8221;).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the terms of the PCT Agreement and Plan of Merger, all of the membership interests of PCT outstanding immediately prior to the effective time of the PCT Merger (the &#8220;Effective Time&#8221;) were converted into the right to receive, in the aggregate, 10,600,000 shares of the common stock of NeoStem and warrants to purchase 3,000,000 shares of NeoStem Common Stock (the vesting of 1,000,000 of such warrants being subject to the satisfaction of certain conditions). Immediately after the PCT Merger closed, the Company made a payment of $3,000,000 to repay certain indebtedness owed by PCT.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NeoStem, Inc. acquired Amorcyte, Inc. (&#8220;Amorcyte&#8221;) by means of a merger (the &#8220;Amorcyte Merger&#8221;) of a newly formed wholly-owned subsidiary of NeoStem, with and into Amorcyte pursuant to an Agreement and Plan of Merger, dated July 13, 2011 (the &#8220;Amorcyte Agreement and Plan of Merger&#8221;).&#160;&#160;Amorcyte is a development stage cell therapy company focusing on novel treatments for cardiovascular disease.&#160;&#160;Amorcyte&#8217;s lead product candidate, AMR-001, is entering a Phase 2 study for the treatment of acute myocardial infarction (AMI).&#160;&#160;We are currently recruiting clinical trial sites and expect to start enrolling patients by the end of first quarter 2012.&#160;&#160;Pursuant to the terms of the Amorcyte Agreement and Plan of Merger, all of the outstanding equity interests of Amorcyte outstanding immediately prior to the effective time of the Amorcyte Merger were converted into the right to receive, in the aggregate, 5,843,483 shares of Common Stock (currently being held in escrow for eventual distribution to the former Amorcyte security holders, and subject to further adjustment, including in connection with any indemnification claims of NeoStem), seven year warrants to purchase an aggregate of 1,881,008 shares of Common Stock at $1.466 per share (the transfer of any shares issued upon exercise of these warrants restricted until one year after the closing date),&#160;&#160;up to an additional 4,092,768 shares of Common Stock to be issued if and only if specified AMR-001 milestones are achieved, and additional consideration in the form of an earn out based upon net revenues of AMR-001, if AMR-001 is commercialized.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company expects to incur substantial additional costs in connection with its transition to a cell therapy development company.&#160; In particular, Amorcyte is currently recruiting clinical trial sites for an expected 34 site, 160 patient, Phase 2 clinical trial for Amorcyte&#8217;s lead product candidate, AMR-001, for the treatment of AMI.&#160; The trial is expected to start enrolling patients by end of the first quarter of 2012 and to cost approximately $12 million over the first two years and anticipated to cost up to approximately $17 million over a five year period, inclusive of manufacturing costs.&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Liquidity</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We anticipate that we will take further steps to raise additional capital in order to (i) fund the development of advanced cell therapies in the U.S. and China, (ii) expand the PCT business and (iii) build the family banking business to meet our short and long term liquidity needs.&#160;&#160;We currently expect to fund the anticipated expansion of our operating activities through a variety of means that could include, but not be limited to, the use of existing cash balances, the use of our current or other equity lines,&#160;&#160;potential additional warrant exercises, option exercises, the 6% of net profits to which we are entitled from Erye but have not yet received, issuances of other debt or equity securities in public or private financings, sale of assets&#160;&#160;and/or, ultimately, the growth of our revenue generating activities.&#160;&#160;In addition, we will continue to seek as appropriate grants for scientific and clinical studies from the National Institutes of Health, Department of Defense, and other governmental agencies and foundations, but there can be no assurance that we will be successful in obtaining such grants. As the Company grows, it may not be eligible for SBIR grants.&#160;&#160;We also review and consider from time to time restructuring activities, including the potential divestiture of assets.&#160;&#160;In this regard, as part of our plan to focus on capturing the paradigm shift to cell therapies following our January 2011 acquisition of PCT, we are pursuing strategic alternatives with respect to our 51% interest in Erye.&#160;&#160;We plan to devote our resources and management efforts to cell therapy manufacturing and development, and other related activities, including adult stem cell collection and storage.&#160;&#160;We believe the October 2011 acquisition of Amorcyte described elsewhere herein is in keeping with this strategic mission.&#160;&#160;We also believe that if we could monetize Erye, we would have additional capital needed to pursue the development of multiple cell therapies.&#160;&#160;To that end, in June 2011, we engaged a financial advisor to lead the effort to pursue the possible divesture of our 51% interest in Erye.&#160; Marketing efforts are underway which have generated interest from both financial and strategic buyers; however, in addition to the factors set forth below, it is too early to determine whether this will lead to a proposal to purchase at a price and on terms that the Company would consider acceptable or whether, in the event a proposal or proposals on prices and terms acceptable to the Company are received, whether a transaction would be completed.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">*&#160; Derived from the October 12, 2011 China Healthcare report, published by Deutsche Bank, AG.</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">34</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any sale of our interest in Erye would also be subject to a right of first refusal held by Suzhou Erye Economy &amp; Co. Ltd. (&#8220;EET&#8221;) pursuant to the terms of the Joint Venture Agreement between a subsidiary of ours and EET.&#160;&#160; EET owns the remaining 49% interest in Erye.&#160; A number of issues have arisen between EET and NeoStem with respect to the operation and financing of Erye.&#160; For instance, while EET is required to lend back to Erye dividends received by it to finance Erye&#8217;s move to its new facilities, Erye has recently reported to us that such arrangement is no longer tax efficient in light of the ratio of Erye&#8217;s shareholder loans to its registered capital.&#160; In connection with exploring ways to remedy the additional tax burden caused by the level of shareholder loans and in preparing for a sale process, other issues have also surfaced, including the issue of us and Erye needing to obtain all Chinese regulatory approvals (and associated registrations) required to reflect the legal title of our interest in Erye as being held by the proper entity within our group which is its current beneficial owner as that term is used under U.S. law.&#160; We believe we have now determined what government approvals (and associated registrations) will need to be issued by the Suzhou Municipal Bureau of Foreign Investment and Commerce and the Suzhou Administration for Industry and Commerce to remediate these deficiencies and we have had counsel in China prepare these filings.&#160; Our management believes these regulatory deficiencies can be remediated within a reasonable period of time and should not delay a sale of the Company&#8217;s interest in Erye.&#160; However, we require&#160;&#160;the cooperation of the officers of Erye, as to which no assurance can be given, and we could be compelled to seek to replace those officers or to commence legal action to obtain the required consents or otherwise move forward with requisite filings.&#160;&#160;In addition, even if the filings are made, no assurance can be given that any unremediated regulatory deficiencies would not have an adverse effect on the operating results and liquidity of Erye and the Company and will not impede or delay efforts to divest our interest in Erye.&#160; In addition, the remediation process is expected to trigger certain tax liabilities and penalties.&#160;&#160;At this time the Company does not expect such amounts to be material.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have not yet determined to sell our interest in Erye, and we will not do so until we can assess the level of interest generated, the potential price and transaction terms we might be offered and any regulatory impediments to a transaction.&#160;&#160;A sale of our interest in Erye, if a sale can be consummated, would have a material effect on our business, results of operations and balance sheet.&#160;&#160;Factors that may impede a sale may include, but not be limited to, EET&#8217;s right of first refusal and the significant time and money that exercise of such right could cause a potential purchaser, the need for any purchaser to negotiate a new Joint Venture Agreement and a shareholder loan repayment schedule with EET if EET does not wish to either sell its interest or exercise its right of first refusal, recent regulatory changes in China which reduce prices that may be charged for certain of Erye&#8217;s products and limit use of antibiotics, tax or regulatory issues affecting Erye, including those described above and other tax&#160;&#160;increases&#160;&#160;described in our filings which will adversely affect Erye going forward, availability of financing for a potential purchaser, and other factors typical of any sale process.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To support our liquidity needs, the Company raised an aggregate of approximately $5.6 million in private placements of Common Stock from March 2011 to June 2011.&#160;&#160;In addition, on July 6, 2011, three then key Amorcyte stockholders (including a fund managed by a then Amorcyte director) invested an aggregate of $728,000 in a private placement of 568,750 shares of Common Stock (purchase price $1.28 per share)&#160;&#160;and on July 22, 2011, the Company completed an underwritten offering of 13,750,000 units at a purchase price of $1.20 per unit, with each unit consisting of one share of Common Stock and a five year warrant to purchase 0.75 of a share of Common Stock at an exercise price of $1.45 per share.&#160;&#160;&#160;The Company received gross proceeds of $16,500,000, prior to deducting underwriting discounts and offering expenses payable by the Company, for net proceeds of $14,667,000.&#160;&#160;In August 2011, the Department of Defense (DOD) Peer Reviewed Medical Research Program (PRMRP) of the Office of the Congressionally Directed Medical Research Programs (CDMRP) awarded NeoStem approximately $1.78 million to be applied towards funding the Company's VSEL&#8482; Technology, which award will support an investigation of a unique stem cell population, Very Small Embryonic-Like (VSEL) stem cells, for its bone building and regenerative effects in the treatment of osteoporosis. &#160;In addition, in September 2011 we entered into the Purchase Agreement with Aspire Capital which provided that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to $20 million of shares of the Company&#8217;s Common Stock&#160;&#160;over&#160;the 24-month term of that Agreement.&#160;&#160;Also on September 28, 2011, the Company gave notice to Commerce Court Small Cap Value Fund, Ltd. (&#8220;Commerce Court&#8221;) of termination of the Common Stock Purchase Agreement dated as of May 19, 2010 between the Company and Commerce Court.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and our negotiating position in capital generating efforts may worsen as existing resources are used.&#160;&#160;Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability to operate as a business, our stock price may not reach levels necessary to induce option or warrant exercises, and asset sales may not be possible on terms we consider acceptable.&#160;&#160;If we are unable to raise the funds necessary to meet our long-term liquidity needs, we may have to delay or discontinue the acquisition and development of cell therapies, and/or the expansion of our business or raise funds on terms that we currently consider unfavorable.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">35</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At September 30, 2011, we had cash and cash equivalents of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">11,713,300 </font>and restricted cash totaling approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,427,800</font>.&#160;&#160;In addition we have $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">2,500,000 </font>recorded in other assets for restricted cash associated with our Series E Preferred Stock, which is held in escrow and not available to meet current cash requirements. The trading volume of our common stock, coupled with our history of operating losses and liquidity challenges, may make it difficult for us to raise capital on acceptable terms or at all. The demand for the equity and debt of small cap biopharmaceutical companies like ours is dependent upon many factors, including the general state of the financial markets. During times of extreme market volatility, capital may not be available on favorable terms, if at all. Our inability to obtain such additional capital on acceptable terms could materially and adversely affect our business operations and ability to continue as a going concern.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table reflects a summary of NeoStem&#8217;s contractual cash obligations and commitments as of September 30, 2011 (in thousands):</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div align="center">
<table cellpadding="0" cellspacing="0" width="85%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Total</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less than 1 Year</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1-3 Years</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3-5 Years</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">More than 5 Years</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="25%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Long-Term Debt Obligations</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="25%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series E Preferred Stock<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(1)</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,326.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,107.7</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,218.9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="25%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Mortgages Payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,373.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">187.9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">410.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">456.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,318.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="25%" style="PADDING-BOTTOM: 2px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Operating Lease Obligations</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,614.9</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,363.6</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,649.7</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,165.4</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">436.2</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="25%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,314.9</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,659.2</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,278.9</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,621.8</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,755.0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="25%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1) Amounts include dividends.</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other significant commitments and contingencies include the following:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products.&#160; The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At September 30, 2011, Erye owed EET, the 49% shareholder of Erye, $<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20,468,400 </font>which represents dividends paid and loaned back to Erye.&#160;&#160;At September 30, 2011 the interest rate on this loan was <font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.56</font>%.&#160;&#160;In June 2011 Erye paid EET approximately $875,100 consisting of the net of the following: $1,115,000 of unpaid accrued interest at&#160;&#160;June 30, 2011, approximately $<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">408,700 </font>repayment of a non interest bearing loan due in 2011 and recovery of cash advances to EET of approximately $<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">648,600</font>.&#160;&#160;The repayment terms are not specified regarding this loan.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Seasonality</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NeoStem does not believe that its operations are seasonal in nature.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Off-balance sheet arrangements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NeoStem does not have any off-balance sheet arrangements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="item_1_3_4"><!--EFPlaceholder--></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This Quarterly Report on Form 10-Q includes &#8220;forward-looking&#8221; statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or industry results, to be materially different from anticipated results, performance or achievements expressed or implied by such forward-looking statements. When used in this Quarterly Report on Form 10-Q, statements that are not statements of current or historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; or &#8220;continue&#8221; or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. Additionally, statements regarding our ability to successfully develop, integrate and grow the business at home and abroad, including with regard to our research and development efforts in cellular therapy, our adult stem cell and umbilical cord blood collection, processing and storage business, contract manufacturing and process development of cellular based medicines, and the pharmaceutical manufacturing operations conducted in China, the future of regenerative medicine and the role of stem cells in that future, the future use of stem cells as a treatment option and the role of VSEL<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font> Technology in that future and the potential revenue growth of such businesses, are forward-looking statements. Our future operating results are dependent upon many factors and our further development is highly dependent on future medical and research developments and market acceptance, which is outside our control.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">36</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Forward-looking statements may not be realized due to a variety of factors and we cannot guarantee their accuracy or that our expectations about future events will prove to be correct. Such factors include, without limitation, (i) our ability to manage the business despite operating losses and cash outflows; (ii) our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including meeting our financial obligations under various licensing and other strategic arrangements and the successful commercialization of the relevant technology; (iii) our ability to build the management and human resources and infrastructure necessary to support the growth of the business; (iv) our ability to integrate our acquired businesses successfully and grow such acquired businesses as anticipated; (v) whether a large global market is established for our cellular-based products and services and our ability to capture a share of this market; (vi) competitive factors and developments beyond our control; (vii) scientific and medical developments beyond our control; (viii) our ability to obtain appropriate governmental licenses, accreditations or certifications in the United States and China or comply with healthcare laws and regulations or any other adverse effect or limitations caused by government regulation of the business; (ix) whether any of our current or future patent applications result in issued patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business; (x) whether any potential strategic benefits of various licensing transactions will be realized and whether any potential benefits from the acquisition of these licensed technologies will be realized; (xi) the results of our development activities, including the outcome, timing, enrollment and/or results of any clinical trials;&#160;&#160;(xii) factors regarding our business and initiatives in China and, generally, regarding doing business in China, including through our variable interest entity structure, including (a) costs related to funding these initiatives, (b) the successful application under Chinese law of the variable interest entity structure to the Company&#8217;s business, which structure the Company is relying on to conduct its business in China, (c) the ability to integrate the Company and the business operations in China successfully and grow such integrated businesses as anticipated, (d) the need for outside financing to meet capital requirements; and (e) the ability of the Company to realize on its investment in Erye through distributions, divestiture or other strategic alternatives; and (xiii) the other factors discussed elsewhere in this Quarterly Report on Form 10-Q, and the other factors discussed in &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010 under the heading &#8220;Part I &#8211; Item 1A. Risk Factors&#8221;, our definitive proxy statement filed September 16, 2011 and in other periodic Company filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;). The Company&#8217;s filings with the Securities and Exchange Commission are available for review at <font style="DISPLAY: inline; FONT-STYLE: italic">www.sec.gov</font> under &#8220;Search for Company Filings.&#8221;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not applicable to smaller reporting companies.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;Disclosure Controls and Procedures</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Disclosure controls and procedures are the Company&#8217;s controls and other procedures that are designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that the Company files under the Exchange Act is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of the end of the Company&#8217;s quarter ended September 30, 2011 covered by this report, the Company carried out an evaluation, with the participation of the Company&#8217;s management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company&#8217;s disclosure controls and procedures pursuant to Rule 13a-15 of the Exchange Act. Based on that evaluation, the Company&#8217;s Chief Executive Officer and Chief Financial Officer concluded that the Company&#8217;s disclosure controls and procedures were effective, at the reasonable assurance level, in ensuring that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">37</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following material weakness had been identified by management in connection with its assessment as of December 31, 2010, which as of March 31, 2011 the Company had concluded had been fully remediated.&#160;&#160;The Company had determined that it had a material weakness in its accounting for share-based payment arrangements as a result of errors identified with respect to the Company&#8217;s accounting for awards to employees and non-employees. Such errors were the result of ineffective controls primarily related to the application of accounting principles generally accepted in the United States. With respect to both employee and non-employee awards, the Company did not timely evaluate the impact of modifications to certain awards and the effect such modifications had, if any, on recognized compensation expense. With respect to non-employee awards, the Company was not consistently subjecting such awards to re-measurement at each reporting period consistent with the guidance in ASC 505-50,<font style="DISPLAY: inline; FONT-STYLE: italic"> Equity-Based Payments to Non-Employees.</font>&#160;&#160;With respect to awards to employees, the expected life used in valuing such awards previously was based on the contractual term of the options rather than through the use of the &#8220;simplified&#8221; method, as prescribed by the SEC under Staff Accounting Bulletin No. 110, which the Company had determined to be more appropriate given its limited historical experience with respect to option exercises. In addition, certain employee awards that contain performance conditions were not appropriately evaluated and accounted for in determining whether or not the underlying performance conditions were probable of being achieved. Expense associated with certain awards was initially recognized on a graded vesting basis rather than a straight-line basis consistent with the Company&#8217;s accounting policy.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company had taken steps during 2010 to remediate this weakness, including (1) the adoption of the &#8220;simplified&#8221; method for estimating the expected term of share-based awards issued to employees; (2) undertaking a complete review of all share-based payment transactions with non-employees to ensure that the appropriate re-measurement considerations were taken into account and were reflected in the financial statements appropriately; (3) the organization of an internal management committee which meets at least quarterly and consists of senior members of the accounting and legal departments, as well as the CEO, to review share-based awards with performance conditions to assess the probability of the performance conditions being achieved; and (4) the implementation of a new share-based management system which will integrate the administration and accounting for the Company&#8217;s share-based payment arrangements, which is expected to be fully implemented in 2011. The adjustments that were recorded to correct the Company&#8217;s share-based compensation charges for the weaknesses noted above were not material to its financial position or results of operations for any period during 2010 and 2009.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In its assessment of internal control over financial reporting as of March 31, 2011, the Company had concluded that the above material weakness has been fully remediated.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;Changes in Internal Control over Financial Reporting</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There have been no changes in the Company&#8217;s internal controls over financial reporting, as such term is defined in Exchange Act Rule 13a-15, that occurred during the Company&#8217;s last fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. </font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">38</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEOSTEM, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PART II</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OTHER INFORMATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_6"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 1. LEGAL PROCEEDINGS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="item_1_3_7"><!--EFPlaceholder--></a>There are no material changes to the disclosures provided in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2010, except as set forth in Note 13, Commitments and Contingencies, of the Notes to the financial statements included elsewhere herein.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 1A. RISK FACTORS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_8"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As previously reported in the Company&#8217;s definitive joint proxy statement / prospectus filed with the SEC on September 16, 2011 under the heading &#8220;Risk Factors&#8221;, and as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">The PRC government does not permit direct foreign investment in stem cell research and development businesses. Accordingly, we operate these businesses through local companies with which we have contractual relationships but in which we do not have controlling equity ownership.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PRC regulations prevent foreign companies from directly engaging in stem cell-related research, development and commercial applications in China. Therefore, to perform these activities, we operate our current stem cell-related business in China through domestic variable interest entities, or VIEs: Tianjin Niou Bio-Technology Ltd., or Tianjin Neo Bio-Technology, and Beijing Ruijieao Bio-Technology Ltd., or Beijing Ruijieao, each a Chinese domestic company controlled by the Chinese employees of NeoStem (China), Inc., our wholly foreign-owned entity, or the WFOE, through various business agreements, referred to, collectively, as the VIE documents. Tianjin Neo-Biotechnology conducts operations formerly conducted by another Company VIE, Qingdao Neo Biotechnology. We control these companies and operate these businesses through contractual arrangements with the companies and their individual owners, but we have no direct equity ownership or control over these companies. Our contractual arrangements may not be as effective in providing control over these entities as direct ownership. For example, the VIEs could fail to take actions required for our business or fail to conduct business in the manner we desire despite their contractual obligation to do so. These companies are able to transact business with parties not affiliated with us. If these companies fail to perform under their agreements with us, we may have to rely on legal remedies under PRC law, which may not be effective. In addition, we cannot be certain that the individual equity owners of the VIEs would always act in our best interests, especially if they have no other relationship with us.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Although other foreign companies have used WFOEs and VIE structures similar to ours and such arrangements are not uncommon in connection with business operations of foreign companies in China in industry sectors in which foreign direct investments are limited or prohibited, recently there has been greater scrutiny by the business community of the VIE structure and, additionally, the application of a VIE structure to control companies in a sector in which foreign direct investment is specifically prohibited carries increased risks.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For example, if our structure is deemed in violation of PRC law, the PRC government could revoke the business license of the WFOE, require us to discontinue or restrict our operations, restrict our right to collect revenues, require us to restructure our business, corporate structure or operations, impose additional conditions or requirements with which we may not be able to comply, impose restrictions on our business operations or on our customers, or take other regulatory or enforcement actions against us. We may also encounter difficulties in enforcing related contracts. Any of these events could materially and adversely affect our business, operating results and financial condition.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition, the Ministry of Commerce, or the MOFCOM, promulgated the <font style="DISPLAY: inline; FONT-STYLE: italic">Rules of Ministry of Commerce on Implementation of </font><font style="DISPLAY: inline; FONT-STYLE: italic">Security</font><font style="DISPLAY: inline; FONT-STYLE: italic"> Review System of Mergers and Acquisitions of Domestic Enterprises by Foreign Investors</font> in August&#160;2011, or the MOFCOM Security Review Rules, to implement the <font style="DISPLAY: inline; FONT-STYLE: italic">Notice of the General Office of the State Council on Establishing the Security Review System for Mergers and Acquisitions of Domestic Enterprises by Foreign Investors</font> promulgated on February&#160;3, 2011, or Circular No.&#160;6. The MOFCOM Security Review Rules came into effect on September&#160;1, 2011 and replaced the <font style="DISPLAY: inline; FONT-STYLE: italic">Interim Provisions of the Ministry of Commerce on Matters Relating to the Implementation of the Security Review System for Mergers and Acquisitions of Domestic Enterprises by Foreign Investors</font> promulgated by MOFCOM in March 2011. According to these circulars and rules, a security review is required for mergers and acquisitions by foreign investors having <font style="DISPLAY: inline; FONT-STYLE: italic">"national defense and security"</font> concerns and mergers and acquisitions by which foreign investors may acquire the <font style="DISPLAY: inline; FONT-STYLE: italic">"de facto control"</font> of domestic enterprises having <font style="DISPLAY: inline; FONT-STYLE: italic">"national security"</font> concerns. In addition, when deciding whether a specific merger or acquisition of a domestic enterprise by foreign investors is subject to the security review, the MOFCOM will look into the substance and actual impact of the transaction. The MOFCOM Security Review Rules further prohibit foreign investors from bypassing the security review requirement by structuring transactions through proxies, trusts, indirect investments, leases, loans, control through contractual arrangements or offshore transactions. There is no explicit provision or official interpretation stating that our business falls into the scope subject to the security review, and there is no requirement for foreign investors in those mergers and acquisitions transactions already completed prior to the promulgation of Circular No.&#160;6 to submit such transactions to MOFCOM for security review. The enactment of the MOFCOM National Security Review Rules specifically prohibits circumvention of the rules through VIE arrangement in the area of foreign investment in business of national security concern.&#160;&#160;Although we believe that our business, judging from its scale, should not cause any concern for national security review at its current state, there is no assurance that MOFCOM would not apply the same concept of anti-circumvention in the future to foreign investment in prohibited areas through VIE structure, the same way that our investment in China was structured.<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#160;</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">39</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As previously disclosed, and as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has agreed to issue equity to certain consultants for services.&#160;&#160;Effective August 16, 2011, pursuant to a three month agreement for consulting services in corporate development and investor communications related activities, the Company agreed to issue 170,000 shares of Restricted Common Stock, vesting as to one-half upon NYSE Amex approval and one half six months after the agreement effective date.&#160;&#160;Effective October 17, 2011, in connection with the Company&#8217;s acquisition of Amorcyte, Inc., pursuant to a two year agreement for advisory services as Amorcyte&#8217;s Chief Medical Officer and in connection with Amorcyte&#8217;s Phase 2 Clinical Trial for AMR-001, the Company agreed to issue a four year warrant (the &#8220;Warrant&#8221;) to purchase up to 200,000 shares of restricted Common Stock (the "Warrant Shares") at $0.64 per share (the closing price of the Common Stock on October 17, 2011, the Commencement Date), to vest over the term of the agreement as to 25,000 Warrant Shares on October 17, 2011 and each third monthly anniversary of the Commencement Date through and including July 17, 2013. The issuance of all such securities to consultants was subject to the approval of the NYSE Amex.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The offer and sale of the securities described above were made in reliance upon the exemption from registration provided by Section 4 (2) of the Securities Act, for transactions by an issuer not involving a public offering.&#160;&#160;The offer and sale of such securities were made without general solicitation or advertising to &#8220;accredited investors,&#8221; as such term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_10"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 4.&#160;&#160;(REMOVED AND RESERVED)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_11"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 5. OTHER INFORMATION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For information with respect to certain recent issuances of equity in unregistered private transactions, see Part II &#8211; Item 2, Unregistered Sales of Equity Securities and Use of Proceeds.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_12"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 6.&#160;&#160;EXHIBITS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Description</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Reference</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.1</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Agreement and Plan of Merger, dated as of July 13, 2011, by and among NeoStem, Inc., Amorcyte, Inc., Amo Acquisition Company I, Inc. and Amo Acquisition Company II, LLC (1)+</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.1</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.1</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Registrant&#8217;s Amended and Restated Certificate of Incorporation, as amended (as certified March 25, 2011)*</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.1</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.2</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Certificate of Amendment to Registrant&#8217;s Amended and Restated Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on October 14, 2011*</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.2</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.1</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrant Agreement, dated as of July 22, 2011, between NeoStem, Inc. and Continental Stock Transfer &amp; Trust Company, with the form of Series NA Warrant attached thereto*</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.1</font></div>
</td>
</tr></table>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">40</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.2</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrant Agreement, dated as of October 17, 2011, between NeoStem, Inc. and Continental Stock Transfer &amp; Trust Company, with the form of Global Series AMO Warrant attached thereto (2)</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.1</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.3</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Registration Rights Agreement, dated as of September 28, 2011, by and between the Company and Aspire Capital Fund, LLC (3)</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.1</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Underwriting Agreement, dated July 19, 2011, by and among NeoStem, Inc. and the underwriters named on Schedule I thereto (4)</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.1</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Second Amendment of Lease, executed July 11, 2011 and effective as of July 1, 2011, by and between Vanni Business Park, LLC and Progenitor Cell Therapy, LLC (1)</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.3</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Guaranty of Lease, executed July 11, 2011 and effective as of July 1, 2011, by NeoStem, Inc. for the benefit of Vanni Business Park, LLC (1)</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.4</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common Stock Purchase Agreement, dated as of September 28, 2011, by and between the Company and Aspire Capital Fund, LLC (3)</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.5</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Escrow Agreement, dated as of October 17, 2011, among NeoStem, Inc., Amorcyte, Inc., Paul J. Schmitt, as Amorcyte Representative, and Continental Stock Transfer &amp; Trust Company, as Escrow Agent (2)</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.6</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NeoStem, Inc. 2009 Equity Compensation Plan, as amended (2)</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.7</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NeoStem, Inc. 2009 Non-U.S. Based Equity Compensation Plan, as amended (2)</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.3</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.8</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amendment dated August 17, 2011 to Employment Agreement dated September 23, 2010 and effective January 19, 2011 between Progenitor Cell Therapy, LLC, NeoStem, Inc. and Andrew L. Pecora (5) &#160;</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.95</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31.1</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31.1</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31.2</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31.2</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32.1</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32.1</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32.2</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32.2</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.INS</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Instance Document***</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.INS</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.SCH</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Taxonomy Extension Schema***</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.SCH</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.CAL</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Taxonomy Extension Calculation Linkbase***</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.CAL</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.DEF</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Taxonomy Extension Definition Linkbase***</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.DEF</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.LAB</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Taxonomy Extension Label Linkbase***</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.LAB</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.PRE</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Taxonomy Extension Presentation Linkbase***</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.PRE</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*Filed herewith</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">**Furnished herewith</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">***Users of this interactive data file are advised pursuant to Rule 406T of Regulations S-T that this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">41</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">+The schedules to this agreement were omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. NeoStem will furnish copies of any schedules to the SEC upon request.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Filed with the SEC on July 14, 2011, as an exhibit, numbered as indicated above, to our current report on Form 8-K dated July 11, 2011, which exhibit is incorporated here by reference.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Filed with the SEC on October 17, 2011, as an exhibit, numbered as indicated above, to our current report on Form 8-K dated October 14, 2011, which exhibit is incorporated here by reference.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Filed with the SEC on September 30, 2011, as an exhibit, numbered as indicated above, to our current report on Form 8-K dated September 28, 2011, which exhibit is incorporated here by reference.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(4)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Filed with the SEC on July 20, 2011, as an exhibit, numbered as indicated above, to our current report on Form 8-K dated July 19, 2011, which exhibit is incorporated here by reference.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(5)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Filed with the SEC on September 2, 2011, as an exhibit, numbered as indicated above, to our Registration Statement on Form S-4 (File No. 333-176673), which exhibit is incorporated here by reference.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">42</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEOSTEM, INC. (Registrant)</font></font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;Robin Smith M.D.</font></font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Robin Smith M.D., Chief Executive Officer</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%">&#160;</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: November 10, 2011</font></font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;Larry A. May</font></font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Larry A. May, Chief Financial Officer</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%">&#160;</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: November 10, 2011</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By: </font></font></div>
</td>
<td valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;Joseph Talamo</font></font></div>
</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Joseph Talamo, Chief Accounting Officer</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: November 10, 2011</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">43</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>v236875_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<html>
<head>
    <title></title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="50%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Delaware</font></font></div>
</td>
<td valign="bottom" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PAGE 1</font></div>
</td>
</tr><tr>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">The first State</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">I,&#160;&#160;JEFFREY W.&#160;&#160;BULLOCK,&#160;&#160;SECRETARY OF STATE OF THE STATE OF DELAWARE,&#160;&#160;DO HEREBY CERTIFY THE ATTACHED ARE TRUE AND CORRECT COPIES OF ALL DOCUMENTS FILED FROM AND INCLUDING THE RESTATED CERTIFICATE OR A MERGER WITH A RESTATED CERTIFICATE ATTACHED OF &#8220;NEOSTEM,&#160;&#160;INC.<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8221;</font> AS RECEIVED AND FILED IN THIS OFFICE.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">THE FOLLOWING DOCUMENTS HAVE BEEN CERTIFIED:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">RESTATED CERTIFICATE,&#160;&#160;CHANGING ITS NAME FROM &#8220;PHASE III MEDICAL INC.<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8221;</font>&#160;TO&#160;&#160;&#8220;NEOSTEM,&#160;&#160;INC. <font style="FONT-WEIGHT: bold; FONT-STYLE: normal">&#8221;</font>,&#160;&#160;FILED THE TWENTY-NINTH DAY OF AUGUST,&#160;&#160;A.D.&#160;&#160;2006,&#160;&#160;AT 5:49 O&#8217;CLOCK P.M.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">CERTIFICATE OF AMENDMENT,&#160;&#160;FILED THE EIGHTH DAY OF AUGUST, A.D.&#160;&#160;2007,&#160;&#160;AT 11:08 O&#8217;CLOCK A.M.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF AMENDMENT IS THE NINTH DAY OF AUGUST,&#160;&#160;A.D.&#160;&#160;2007,&#160;&#160;AT 10 O&#8217;CLOCK A.M.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">CERTIFICATE OF DESIGNATION,&#160;&#160;FILED THE FIFTEENTH DAY OF APRIL,&#160;&#160;A.D.&#160;&#160;2009,&#160;&#160;AT 5:05 O&#8217;CLOCK P.M.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">CERTIFICATE OF AMENDMENT,&#160;&#160;FILED THE THIRTIETH DAY OF OCTOBER,&#160;&#160;A.D.&#160;&#160;2009,&#160;&#160;AT 8:01&#160;&#160;O&#8217;CLOCK A.M.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">CERTIFICATE OF AMENDMENT,&#160;&#160;FILED THE THIRTIETH DAY OF OCTOBER,&#160;&#160;A.D.&#160;&#160;2009,&#160;&#160;AT 8:02 O&#8217;CLOCK A.M.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="19%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td rowspan="5" valign="bottom" width="48%" style="TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><img src="ex3-1pg1.jpg"></font></div>
</td>
<td valign="top" width="33%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/ Jeffrey W. Bullock</font></font></div>
</td>
</tr><tr>
<td valign="top" width="19%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Jeffrey W. Bullock, Secretary of State</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="19%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">0899444&#160;&#160;8100X</font></div>
</td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">AUTHENTICATION:&#160;&#160;8650602</font></div>
</td>
</tr><tr>
<td valign="top" width="19%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="19%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">110343404</font></div>
</td>
<td valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">DATE:&#160;&#160;03-25-11</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">You may verify this certificate online </font><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">at corp.delaware.gov/authver.shtml</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="50%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Delaware</font></font></div>
</td>
<td valign="bottom" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PAGE 2</font></div>
</td>
</tr><tr>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">The first State</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">CERTIFICATE OF DESIGNATION, FILED THE THIRTIETH DAY OF OCTOBER, A.D. 2009, AT 8:03 O&#8217;CLOCK A.M.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">CERTIFICATE OF CORRECTION, FILED THE NINTH DAY OF DECEMBER, A.D. 2009, AT 2:24 O&#8217;CLOCK P.M.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">CERTIFICATE OF DESIGNATION, FILED THE EIGHTEENTH DAY OF NOVEMBER, A.D. 2010, AT 10:30 O&#8217;CLOCK A.M.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">CERTIFICATE OF DESIGNATION, FILED THE EIGHTEENTH DAY OF NOVEMBER, A.D. 2010, AT 10:31 O&#8217;CLOCK A.M.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">CERTIFICATE OF DESIGNATION, FILED THE EIGHTEENTH DAY OF NOVEMBER, A.D. 2010, AT 10:32 O&#8217;CLOCK A.M.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="19%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td rowspan="5" valign="bottom" width="48%" style="TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><img src="ex3-1pg1.jpg"></font></div>
</td>
<td valign="top" width="33%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/ Jeffrey W. Bullock</font></font></div>
</td>
</tr><tr>
<td valign="top" width="19%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Jeffrey W. Bullock, Secretary of State</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="19%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">0899444&#160;&#160;8100X</font></div>
</td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">AUTHENTICATION:&#160;&#160;8650602</font></div>
</td>
</tr><tr>
<td valign="top" width="19%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="19%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">110343404</font></div>
</td>
<td valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">DATE:&#160;&#160;03-25-11</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">You may verify this certificate online </font><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">at corp.delaware.gov/authver.shtml</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">State of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Delaware</font></font></font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Secretary of State</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Division of Corporations</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Delivered 05:49 PM 08/29/2006</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">FILED 05:49 PM 08/29/2006</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">SRV</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"> 060805812 - 0899444 FILE</font></font></font></font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AMENDED AND RESTATED</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATE OF INCORPORATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OF</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PHASE III MEDICAL INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phase III Medical Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &#8220;Corporation&#8221;), does hereby certify as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The name of the Corporation is Phase III Medical Inc. The date of filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was September 18, 1980, under the name of Fidelity Medical Services, Inc. The name of the Corporation was changed to Phase III Medical Inc. by filing a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of Delaware on July 24, 2003. The name of the Corporation is being changed to NeoStem, Inc. in connection with the filing of this Amended and Restated Certificate of Incorporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Amended and Restated Certificate of Incorporation of Phase III Medical Inc., in the form attached hereto as <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A</font>, has been duly adopted by the directors and the stockholders of the Corporation in accordance with the provisions of Sections 242 and 245 of the General Corporation Law of the State of Delaware.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Amended and Restated Certificate of Incorporation so adopted reads in its entirety as set forth in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A</font> attached hereto and is incorporated herein by reference.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Amended and Restated Certificate of Incorporation shall be effective on the date of filing with the Secretary of State of Delaware.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">IN WITNESS WHEREOF, the Corporation has caused this Amended and Restated Certificate of Incorporation to be executed by its CEO on this 29<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> day of August, 2006.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Phase III Medical Inc.</font></div>
</td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="55%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td align="left" valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ Robin L. Smith</font></div>
</td>
<td valign="top" width="15%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Robin L. Smith</font></div>
</td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer</font></div>
</td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT A</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AMENDED AND RESTATED</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATE OF INCORPORATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OF</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEOSTEM, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FIRST: The name of the corporation is NeoStem, Inc. (hereinafter sometimes referred to as the &#8220;Corporation&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECOND: The registered office of the Corporation is located at 2711 Centerville Road, Suite 400, Wilmington, New Castle County, Delaware, 19808. The name of its registered agent at such address is The Prentice-Hall Corporation System, Inc.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIRD: The nature of the business and the objects and purposes to be transacted, promoted and carried on are to do any or all of the things herein mentioned as fully and to the same extent as natural persons might or could do, and in any part of the world, viz:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To purchase, take, own, hold, deal in, mortgage or otherwise lien and to lease, sell, exchange, convey, transfer or in any manner whatever dispose of real property, within or without the State of Delaware.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To manufacture, purchase or otherwise acquire and to hold, own, mortgage or otherwise lien, pledge, lease, sell, assign, exchange, transfer or in any manner dispose of, and to invest, deal and trade in and with goods, wares, merchandise and personal property of any and every class and description, within or without the State of Delaware.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To acquire the good will, rights and property and to undertake the whole or any part of the assets and liabilities of any person, firm, association or corporation; to pay for the same in cash, the stock of this company, bonds or otherwise; to hold or in any manner to dispose of the whole or any part of the property so purchased; to conduct in any lawful manner the whole or any part of any business so acquired and to exercise all the powers necessary or convenient in and about the conduct and management of such business.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To guarantee, purchase or otherwise acquire, hold, sell, assign, transfer, mortgage, pledge or otherwise dispose of shares of the capital stock, bonds or other evidences of indebtedness created by other corporations and while the holder of such stock to exercise all the rights and privileges of ownership, including the right to vote thereon, to the same extend as a natural person might or could do.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To purchase or otherwise acquire, apply for, register, hold, use, sell or in any manner dispose of and to grant licenses or other rights in and in any manner deal with patents, inventions, improvements, processes, formulas, trademarks, trade names, rights and licenses secured under letters patent, copyrights or otherwise.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To enter into, make and perform contracts of every kind for any lawful purpose, with any person, firm, association or corporation, town, city, county, body politic, state, territory, government or colony or dependency thereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To borrow money for any of the purposes of the corporation and to draw, make, accept, endorse, discount, execute, issue, sell, pledge or otherwise dispose of promissory notes, drafts, bills of exchange, warrants, bonds, debentures and other negotiable or non-negotiable, transferable or non-transferable instruments and evidences of indebtedness and to secure the payment thereof and the interest thereon by mortgage or pledge, conveyance or assignment in trust of the whole or any part of the property of the corporation at the time owned or thereafter acquired.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To purchase, hold, sell and transfer the shares of its capital stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To have one or more offices and to conduct any or all of its operations and business and to promote its object, within or without the State of Delaware, without restriction as to place or amount.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To carry on any other business in connection therewith.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To do any or all of the things herein set forth as principal, agent, contractor, trustee or otherwise, alone or in company with others.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The objects and purposes specified herein shall be regarded as independent objects and purposes and, except where otherwise expressed, shall be in no way limited or restricted by reference to or inference from the terms of any other clause or paragraph of this certificate of incorporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOURTH:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A.&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;The total number of shares of stock which the Corporation shall have authority to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">issue is 505,000,000 shares, of which 500,000,000 shares are designated as common stock, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">having a par value of $.001 per share (&#8220;Common Stock&#8221;) and 5,000,000 shares are designated as </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">preferred stock, $.01 par value per share (&#8220;Preferred Stock&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Preferred Stock</font>. The designations and the powers, preferences and rights, and the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">qualifications, limitations or restrictions thereof of the Preferred Stock are as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Board of Directors is authorized, subject to limitations prescribed by law and the provisions of this Article FOURTH, to provide for the issuance of the Preferred Stock in series and by filing a Certificate pursuant to the Delaware General Corporation Law to establish the number of shares to be included in each such series. The Preferred Stock may be issued either as a class without series, or as so determined from time to time by the Board of Directors, either in whole or in part in one or more series, each series to be appropriately designated by a distinguishing number, letter or title prior to the issue of any shares thereof. Whenever the term &#8220;Preferred Stock&#8221; is used in this Article FOURTH, it shall be deemed to mean and include Preferred Stock issued as a class without series, or one or more series thereof, or both, unless the context shall otherwise require. There is hereby expressly granted to the Board of Directors of the Corporation authority, subject to the limitations provided by law, to fix the voting power, the designations, and the relative preferences, powers, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, of the shares of each series of said Preferred Stock and the variations in the relative powers, rights, preferences and limitations as between series, and to increase the number of shares constituting each series, and to decrease such number of shares (but not to less than the number of outstanding shares of the series), in the resolution or resolutions adopted by the Board of Directors providing for the issue of said Preferred stock.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-3-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The authority of the Board of Directors of the corporation with respect to each series shall include, but shall not be limited to, the authority to determine the following:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The designation of the series;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The number of shares initially constituting such series;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The increase, and the decrease to a number not less than the number of the outstanding shares of such series, of the number of shares constituting such series theretofore fixed;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The rate or rates and the times and conditions under which dividends on the shares of such series shall be paid, and, (i) if such dividends are payable in preference to, or in relation to, the dividends payable on any other class or classes of stock, the terms and conditions of such payment, and (ii) if such dividends shall be cumulative, the date or dates from and after which they shall accumulate;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Whether or not the shares of such series shall be redeemable, and, if such shares shall be redeemable, the terms and conditions of such redemption, including, but not limited to, the date or dates upon or after which such shares shall be redeemable and the amount per share which shall be payable upon such redemption, which amount may vary under conditions and at different redemption dates;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The amount payable on the shares of such series in the event of the dissolution of, or upon any distribution of the assets of, the Corporation;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Whether or not the shares of such series may be convertible into, or exchangeable for, shares of any other class or series and the price or prices and the rates of exchange and the terms of any adjustments to be made in connection with such conversion or exchange;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Whether or not the shares of such series shall have voting rights in addition to the voting rights provided by law, and, if such shares shall have such voting rights, the terms and conditions thereof, including but not limited to, the right of the holders of such shares to vote as a separate class either alone or with the holders of shares of one or more other series of Preferred Stock and the right to have more or less than one vote per share;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Whether or not a purchase fund shall be provided for the shares of such series, and, if such a purchase fund shall be provided, the terms and conditions thereof;</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-4-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72.35pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Whether or not a sinking fund shall be provided for the redemption of the shares of such series and if such a sinking fund shall be provided, the terms and conditions thereof; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72.35pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any other powers, preferences and relative, participating, optional, or other special rights, and qualifications, limitations or restrictions thereof, as shall not be inconsistent with the provisions of this Article FOURTH or the limitations provided by law.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Common Stock</font>. The designations and the powers, preferences and rights, and the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">qualifications, limitations or restrictions thereof of the Common Stock are as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subject to the rights of the Preferred stockholders, the holders of the Common Stock shall be entitled to receive such dividends as may be declared thereon by the Board of Directors of the Corporation in its discretion, from time to time, out of any funds or assets of the Corporation lawfully available for the payment of such dividends.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the event of any liquidation, dissolution or winding up of the Corporation, or any reduction of its capital, resulting in a distribution of its assets to its stockholders, whether voluntary or involuntary, then, after there shall have been paid or set apart for the holders of the Preferred Stock the full preferential amounts to which they are entitled, the holders of the Common Stock shall be entitled to receive as a class, pro rata, the remaining assets of the Corporation available for distribution to its stockholders.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For any and all purposes of this Certificate of Incorporation, neither the merger or consolidation of the Corporation into or with any other corporation, nor the merger or consolidation of any other corporation into or with the Corporation, nor a sale, transfer or lease of all or substantially all of the assets of the Corporation, or any other transaction or series of transactions having the effect of a reorganization shall be deemed to be a liquidation, dissolution or winding-up of the Corporation.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Except as otherwise expressly provided by, law or in a resolution of the Board of Directors providing voting rights to the holders of the Preferred Stock, the holders of the Common Stock shall possess exclusive voting power for the election of directors and for all other purposes and each holder thereof shall be entitled to one vote for each share thereof.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Corporation is hereby reducing the number of shares of Common Stock </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">issued and outstanding by means of a reverse stock split. Effective at 9:00 a.m. (the &#8220;Effective </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Time&#8221;) on August 31, 2006 (the &#8220;Effective Date&#8221;), each ten (10) shares of authorized Common </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock issued and outstanding or held in the treasury of the Corporation immediately prior to the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective Time shall automatically be reclassified and changed into one (1) validly issued, fully </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">paid and nonassessable share of Common Stock (a &#8220;New Share&#8221;). Each holder of record of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">shares of Common Stock so reclassified and changed shall at the Effective Time automatically </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">become the record owner of the number of New Shares as shall result from such reclassification </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and change.&#160;&#160;Each such record holder shall be entitled to receive, upon the surrender of the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">certificate or certificates representing the shares of Common Stock so reclassified and changed at the office of the transfer agent of the Corporation in such form and accompanied by such documents, if any, as may be prescribed by the transfer agent of the Corporation, a new certificate or certificates representing the number of New Shares of which he or she is the record owner after giving effect to the provisions of this Article FOURTH. The Corporation shall not issue fractional New Shares. Stockholders entitled to receive fractional New Shares shall, in lieu thereof, be rounded up to the next whole share of Common Stock held by such holder immediately prior to the Effective Time which have not been classified into a whole New Share.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-5-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FIFTH: Whenever a compromise or arrangement is proposed between this corporation and its creditors or any class of them and/or between this corporation and its stockholders or any class of them, any Court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of this corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed for this corporation under the provisions of Section 291 of Title 8 of the Delaware Code or on the application of trustees in dissolution or of any receiver or receivers appointed for this corporation under the provisions of Section 279 of Title 8 of the Delaware Code, order a meeting of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this corporation, as the case may be, to be summoned in such a manner as the Court directs. If a majority in number representing three-fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of this corporation as a consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if made, be binding upon all of the creditors or class of creditors, and/or on all the stockholders or class of stockholders, of this corporation, as the case may be, and also on this corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIXTH: The corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that he is or was a director, officer, employee, or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceedings, had no reasonable cause to believe his conduct was unlawful. The termination of any action, upon a plea of nolo contendere or equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his conduct was lawful.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SEVENTH: The Board of Directors shall have the power to make, alter or repeal the By-laws.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EIGHTH: The corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation in the manner now or hereafter prescribed by law and all rights conferred on officers, directors and stockholders herein are granted subject to this reservation.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-6-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NINTH: The personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director is hereby eliminated, provided that this Article shall not eliminate or limit the liability of a director (i) for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders; (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) under section 174 of Title 8 of the Delaware Code, or (iv) for any transaction from which the director derived an improper personal benefit. This article shall not eliminate or limit the liability of a director for any act or omission occurring prior to the date this Article first became effective.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TENTH: The Series B Convertible Redeemable Preferred Stock, shall be designated the following relative rights, preferences and limitations as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section <font style="DISPLAY: inline; FONT-SIZE: 10pt">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Designation and Amount; Rank</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There is hereby established a series of preferred stock which is designated &#8220;Series B Convertible Redeemable Preferred Stock&#8221; (referred to herein as &#8220;Series B Convertible Redeemable Preferred Stock&#8221;). The number of shares which will constitute such series shall be Eight Hundred Twenty-Five Thousand (825,000). The Series B Convertible Redeemable Preferred Stock shall rank pari passu with the Common Stock with respect to the payment of dividends and to the distribution of assets upon liquidation, dissolution or winding up.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Dividends</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">So long as any shares of the Series B Convertible Redeemable Preferred Stock are outstanding, no dividend shall be declared or paid or set aside for payment or other distribution declared or made upon the Common Stock or upon any other stock ranking junior to, or on a parity with, the Series B Convertible Redeemable Preferred Stock as to dividends or upon liquidation, dissolution or winding up, unless, in the case of Preferred Stock, the same dividend is declared, paid or set aside for payment on all outstanding shares of the Series B Convertible Redeemable Preferred Stock or in the case of Common Stock, ten times such dividend per share is declared, paid or set aside for payment on each outstanding share of the Series B Preferred Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section 3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">General, Class and Series Voting Rights</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Except as otherwise provided by law, each share of the Series B Convertible Redeemable Preferred Stock shall have the same voting rights as ten (10) shares of Common Stock and the holders of the Series B Convertible Redeemable Preferred Stock and the Common Stock shall vote together as one class on all matters.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The foregoing voting provisions shall not apply if, at or prior to the time when the act with respect to which such vote would otherwise be required shall be effected, all outstanding shares of Series B Convertible Redeemable Preferred Stock shall have been converted into </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Common Stock or shall have been redeemed or sufficient funds shall have been deposited in trust to effect such redemption.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-7-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section 4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Redemption</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(A)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The shares of Series B Convertible Redeemable Preferred Stock are not redeemable prior to March 31, 2000. At any time on or after such date through June 30, 2000, the shares of Series B Convertible Redeemable Preferred Stock are redeemable, in whole or in part, at the option of the &#8220;Special Director&#8221; of the corporation, at the redemption price per share of $.10, if the &#8220;Trigger Conditions&#8221; have not been met.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(B)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For purposes of this paragraph, the &#8220;Trigger Condition&#8221; shall mean that:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;the closing bid prices of the Common Stock of the corporation as reported by Nasdaq (or otherwise as set forth below) is greater than $2.00 per share during a period of any ten (10) consecutive trading days <font style="DISPLAY: inline; TEXT-DECORATION: underline">and</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 144pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;either</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 144pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;&#160;the corporation&#8217;s net revenues for any fiscal quarter through the fiscal quarter ended March 31, 2000 are $1 million or more (as computed by the corporation&#8217;s regular independent public accountants); or</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 144pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)&#160;the corporation has received net receipts of not less than $2.5 million from the sale of its Common Stock from the date hereof through March 31, 2000.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the purpose of any computation under the foregoing paragraph, the closing price per share of Common Stock on any date shall be the reported last sale price, regular way, or, in case no such reported sale takes place on such day, the average of the reported closing bid and asked prices, regular way, in either case as reported on the New York Stock Exchange Composite Tape or, if the Common Stock is not listed or admitted to trading on the New York Stock Exchange at such time, on the principal national securities exchange on which the Common Stock is listed or admitted to trading, or, if not listed or admitted to trading on any national securities exchange, on the Nasdaq National Market or, if the Common Stock is not quoted on the Nasdaq National Market, the average of the closing bid prices on such day in the over-the-counter market as reported by Nasdaq or, if bid prices for the Common Stock on each such day shall not have been reported through Nasdaq, the average of the bid prices for such date as furnished by any New York Stock Exchange member firm regularly making a market in the Common Stock selected from time to time by the Board of Directors of the corporation for such purpose or, if no such quotations are available, the fair market value of the Common Stock as determined by a New York Stock</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-8-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exchange member firm regularly making a market in the Common Stock selected from time to time by the Board of Directors of the corporation for such purpose.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(C)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For purposes of this paragraph, the &#8220;Special Director&#8221; mean James Fyfe or his successor as director of the corporation if such successor has been approved by Fyfe. So long as any shares of the Class B Preferred Stock are outstanding, through June 30, 2000, the corporation shall nominate to the Board of Directors Fyfe or, if Fyfe so determines, Fyfe&#8217;s designee.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(D)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event the corporation shall elect to redeem the shares of Series B Convertible Redeemable Preferred Stock following the Trigger Condition, the corporation shall give notice to the holders of record of shares of the Series B Convertible Redeemable Preferred Stock being so redeemed, not less than 30 nor more than 60 days prior to such redemption, by first class mail, postage prepaid, at their addresses as shown on the stock registry books of the corporation, that said shares are being redeemed, provided that without limiting the obligation of the corporation hereunder to give the notice provided in this Section 5(D), the failure of the corporation to give such notice shall not invalidate any corporate action by the corporation. Each such notice shall state: (i) the redemption date; (ii) that all of the shares of Series B Convertible Redeemable Preferred Stock are to be redeemed; (iii) that the redemption price is $.10 per share; (iv) the place or places where certificates for such shares are to be surrendered for payment of the redemption price; and (v) that such holder does not have the right to convert such shares into Common Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(E)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notice having been mailed as aforesaid, from and after the applicable redemption date (unless default shall be made by the corporation in providing money for the payment of the redemption price), said shares shall no longer be deemed to be outstanding, and all rights of the holders thereof as stockholders of the corporation (except the right to receive from the corporation the redemption price) shall cease. Upon surrender of the certificates for any shares so redeemed (properly endorsed or assigned for transfer, if the Board of Directors of the corporation shall so require and the notice shall so state), such shares shall be redeemed by the corporation at the redemption price aforesaid.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(F)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any shares of Series B Convertible Redeemable Preferred Stock which shall at any time have been redeemed shall, after such redemption, have the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such shares are once more designated as part of a particular series by the Board of Directors of the corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section 5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Conversion</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(A)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The holder of any share of Series B Convertible Redeemable Preferred Stock shall have the right, at such holder&#8217;s option (but not if such share is called for redemption), exercisable on or after September 30, 2000, to convert such share into ten (10) fully paid and non-assessable shares of Common Stock (the &#8220;Conversion Rate&#8221;). The Conversion Rate shall be subject to adjustment as set forth below.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-9-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(B)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In order to exercise the conversion privilege, the holder of shares of Series B Convertible Redeemable Preferred Stock shall surrender the certificates representing such shares, accompanied by transfer instruments satisfactory to the corporation and sufficient to transfer the Series B Convertible Redeemable Preferred Stock being converted to the corporation free of any adverse interest, at any of the offices or agencies maintained for such purpose by the corporation (&#8220;Conversion Agent&#8221;) and shall give written notice to the corporation at such Conversion Agent that the holder elects to convert such shares. Such notice shall also state the names, together with addresses, in which the certificates for shares of Common Stock which shall be issuable on such conversion shall be issued. As promptly as practicable after the surrender of such shares of Series B Convertible Redeemable Preferred Stock as aforesaid, the corporation shall issue and shall deliver at such Conversion Agent to such holder, or on his written order, a certificate for the number of full shares of Common Stock issuable upon the conversion of such shares in accordance with the provisions hereof. Balance certificates will be issued for the remaining shares of Series B Convertible Redeemable Preferred Stock in any case in which fewer than all of the shares of Series B Convertible Redeemable Preferred Stock represented by a certificate are converted. Each conversion shall be deemed to have been effected immediately prior to the close of business on the date on which shares of Series B Convertible Redeemable Preferred Stock shall have been so surrendered and such notice received by the corporation as aforesaid, and the persons in whose names any certificates for shares of Common Stock shall be issuable upon such conversion shall be deemed to have become the holders of record of the Common Stock represented thereby at such time, unless the stock transfer books of the corporation shall be closed on the date on which shares of Series B Convertible Redeemable Preferred Stock are so surrendered for conversion, in which event such conversion shall be deemed to have been effected immediately prior to the close of business on the next succeeding day on which such stock transfer books are open, and such persons shall be deemed to have become such holders of record of the Common Stock at the close of business on such later day. In either circumstance, such conversion shall be at the Conversion Rate in effect on the date upon which such share shall have been surrendered and such notice received by the corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(C)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the case of any share of Series B Convertible Redeemable Preferred Stock which is converted after any record date with respect to the payment of a dividend on the Series B Convertible Redeemable Preferred Stock and on or prior to the Dividend Payment Date related to such record date, the dividend due on such Dividend Payment Date shall be payable on such Dividend Payment Date to the holder of record of such share as of such preceding record date notwithstanding such conversion.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-10-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(D)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No fractional shares or scrip representing fractions of shares of Common Stock shall be issued upon conversion of any shares of Series B Preferred Stock. Instead of any fractional interest in a share of Common Stock which would otherwise be deliverable upon the conversion of a share of Series B Convertible Redeemable Preferred Stock, the corporation shall pay to the holder of such share of Series B Convertible Redeemable Preferred Stock an amount in cash (computed to the nearest cent, with one-half cent being rounded upward) equal to such fraction multiplied by the reported closing price (as defined above) of the Common Stock at the close of business on the day on which such share or shares of Series B Convertible Redeemable Preferred Stock are surrendered for conversion in the manner set forth above, or if such date is not a trading date, on the next succeeding trading date. If more than one certificate representing shares of Series B Convertible Redeemable Preferred Stock shall be surrendered for conversion at one time by the same holder, the number of full shares issuable upon conversion thereof shall be computed on the basis of the aggregate number of shares of Series B Convertible Redeemable Preferred Stock represented by such certificates, or the specified portions thereof to be converted, so surrendered.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(E)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Conversion Rate shall be adjusted from time to time as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;In case outstanding shares of Common Stock shall be subdivided into a greater number of shares of Common Stock and the Series B Convertible Redeemable Preferred Stock is not similarly subdivided, the Conversion Rate in effect at the opening of business on the day following the day upon which such subdivision becomes effective shall be proportionately increased, and, conversely, in case outstanding shares of Common Stock shall each be combined into a smaller number of shares of Common Stock and the Series B Convertible Redeemable Preferred Stock is not similarly subdivided, the Conversion Rate in effect at the opening of business on the day following the day upon which such combination becomes effective shall be proportionately decreased, such reduction or increase, as the case may be, to become effective immediately after the opening of business on the day following the day upon which such subdivision or combination becomes effective.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;Whenever the Conversion Rate is adjusted as herein provided, (x) the corporation shall promptly file with any Conversion Agent a certificate of a firm of independent public accountants setting forth the Conversion Rate after such adjustment and setting forth a brief statement of the facts requiring such adjustment, and the manner of computing the same, which certificate shall be conclusive evidence of the correctness of such adjustment, and (y) a notice stating that the Conversion Rate has been adjusted and setting forth the adjusted Conversion Rate shall forthwith be given by the corporation to any Conversion Agent and mailed by the corporation to each holder of shares of Series B Convertible Redeemable Preferred Stock at their last address as the same appears on the books of the corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(F)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In case of any consolidation of the corporation with, or merger of the corporation into, any other entity (other than a merger or consolidation in which the corporation is the continuing corporation) or any sale or conveyance to another corporation of the property of the corporation as an entirety or substantially as an entirety, or in the case of a statutory exchange of securities with another corporation, or any reclassification of shares, the Conversion Rate shall not be adjusted but each holder of a share of Series B Convertible Redeemable Preferred Stock then outstanding shall have the right thereafter to convert such share only into the kind and amount of securities, cash and other property which such holder would have owned or have been entitled to receive immediately after such consolidation, merger, sale, conveyance, exchange or reclassification had such share of Series B Convertible Redeemable Preferred Stock been converted immediately prior to such consolidation, merger, sale, conveyance, exchange or reclassification. Provision shall be made in any such consolidation, merger, sale, conveyance, exchange or reclassification for adjustments in the Conversion Rate which shall be as nearly equivalent as may be practicable to the adjustments provided for in Section (E). The above provisions shall similarly apply to successive consolidations, mergers, sales, conveyances, exchange or reclassification.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-11-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 81pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For purposes of this Section 5, &#8220;Common Stock&#8221; includes any stock of any class of the corporation which has no preference in respect of dividends or of amounts payable in the event of any voluntary or involuntary liquidation, dissolution or winding up of the corporation and which is not subject to redemption by the corporation. However, subject to the provisions of paragraph (F) above, shares issuable on conversion of shares of Series B Convertible Redeemable Preferred Stock shall include only shares of the class designated as Common Stock of the corporation on the date of the initial issuance of Series B Convertible Redeemable Preferred Stock by the corporation, or shares of any class or classes resulting from any reclassification or reclassifications thereof and which have no preference in respect of dividends or of amounts payable in the event of any voluntary or involuntary liquidation, dissolution or winding up of the corporation and which are not subject to redemption by the corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In case:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the corporation shall declare a stocks split, stock dividend (or any other distribution) on its Common Stock that would cause an adjustment to the Conversion Rate of the Series B Convertible Redeemable Preferred Stock pursuant to the terms of subparagraph (i) of Paragraph (E) above; or</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;of any reclassification of the Common Stock of the corporation (other than a subdivision or combination of its outstanding shares of Common Stock), or of any consolidation, merger or share exchange to which the corporation is a party and for which approval of any stockholders of the corporation is required, or of the sale or conveyance, of the property of the corporation as an entirety or substantially as an entirety; or</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;of the voluntary or involuntary dissolution, liquidation or winding up of the corporation;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">then the corporation shall cause to be filed with any Conversion Agent, and shall cause to be mailed to all holders of shares of Series B Convertible Redeemable Preferred Stock at each such holder&#8217;s last address as the same appears on the books of the corporation, at least 20 days (or 10 days in any case specified in clause (i) above) prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, rights or warrants, or, if a record is not to be taken, the date as of which the holders of Common Stock of record to be entitled to such dividend, distribution, rights or warrants are to be determined, or (y) the date on which such reclassification, consolidation, merger, share exchange, sale, conveyance, dissolution, liquidation or winding up is expected to become effective, and the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, share exchange, sale, conveyance, dissolution, liquidation or winding up. Neither the failure to give such notice nor any defect therein shall affect the legality or validity of the proceedings described in clauses (i) through (iii) above.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-12-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The corporation will pay any and all documentary stamp or similar issue or transfer taxes payable in respect of the issue or delivery of shares of Common Stock on conversions of shares of Series B Convertible Redeemable Preferred Stock pursuant hereto; provided, however, that the corporation shall not be required to pay any tax which may be payable in respect of any transfer involved in the issue or delivery of shares of Common Stock in a name other than that of the holder of the shares of Series B Convertible Redeemable Preferred Stock to be converted and no such issue or delivery shall be made unless and until the person requesting such issue or delivery has paid to the corporation the amount of any such tax or has established, to the satisfaction of the corporation, that such tax has been paid.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The corporation covenants that all shares of Common Stock which may be delivered upon conversions of shares of Series B Convertible Redeemable Preferred Stock will upon delivery be duly and validly issued and fully paid and non-assessable, free of all liens and charges and not subject to any pre-emptive rights. The corporation further covenants that, if necessary, it shall reduce the par value of the Common Stock so that all shares of Common Stock delivered upon conversion of shares of Series B Convertible Redeemable Preferred Stock are fully paid and non-assessable.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The corporation covenants that it will at all times reserve and keep available, free from pre-emptive rights, out of its authorized but unissued shares of Common Stock or its issued shares of Common; Stock held in its treasury, or both, for the purpose of effecting conversions of shares of Series B Preferred Stock, the full number of shares of Common Stock deliverable upon the conversion of all outstanding shares of Series B Convertible Redeemable Preferred Stock not theretofore converted. For purposes of this reservation of Common Stock, the number of shares of Common Stock which shall be deliverable upon the conversion of all outstanding shares of Series B Convertible Redeemable Preferred Stock shall be computed as if at the time of computation all outstanding shares of Series B Convertible Redeemable Preferred Stock were held by a single holder. The issuance of shares of Common Stock upon conversion of shares of Series B Convertible Redeemable Preferred Stock is authorized in all respects.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section 6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Liquidation</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the event of any voluntary or involuntary dissolution, liquidation or winding up of the corporation (for the purposes of this Section 6, a &#8220;Liquidation&#8221;), after any distribution of assets is made to the holders of any other class or series of stock that ranks prior to the Series B Convertible Redeemable Preferred Stock in respect of distributions upon the Liquidation of the corporation, the holder of each share of Series B Convertible Redeemable Preferred Stock then outstanding shall be entitled to be paid out of the assets of the corporation available for distribution to its stockholders, an amount on a pari passu basis equal to ten times the amount per share distributed to the holders of the Common Stock.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-13-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The voluntary sale, conveyance, lease, exchange or transfer of the property of the corporation as an entirety or substantially as an entirety, or the merger or consolidation of the corporation into or with any other corporation, or the merger of any other corporation into the corporation, or any purchase or redemption of some or all of the shares of any class or series of stock of the corporation, shall not be deemed to be a Liquidation of the corporation for the purposes of the Section 6 (unless in connection therewith the Liquidation of the corporation is specifically approved).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The holder of any shares of Series B Convertible Redeemable Preferred Stock shall not be entitled to receive any payment owed for such shares under this Section 6 until such holder shall cause to be delivered to the corporation (i) the certificate or certificates representing such shares of Series B Convertible Redeemable Preferred Stock and (ii) transfer instrument or instruments satisfactory to the corporation and sufficient to transfer such shares of Series B Convertible Redeemable Preferred Stock to the corporation free of any adverse interest. As in the case of the redemption price, no interest shall accrue on any payment upon Liquidation after the due date thereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">After payment of the full amount of the liquidating distribution to which they are entitled, the holders of shares of the Series B Convertible Redeemable Preferred Stock will not be entitled to any further participation in any distribution of assets by the corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section 7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Payments</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The corporation may provide funds for any payment of the redemption price for any shares of Series B Convertible Redeemable Preferred Stock or any amount distributable with respect to any Series B Convertible Redeemable Preferred Stock under Section 6 hereof by depositing such funds with a bank or trust company selected by the corporation having a net worth of at least $50,000,000 and organized under the laws of the United States or any state thereof, in trust for the benefit of the holder of such shares of Series B Convertible Redeemable Preferred Stock under arrangements providing irrevocably for payment upon satisfaction of any conditions to such payment by the holder of such shares of Series B Convertible Redeemable Preferred Stock which shall reasonably be required by the corporation. The corporation shall be entitled to make any deposit of funds contemplated by this section 7 under arrangements designated to permit such funds to generate interest or other income for the corporation, and the corporation shall be entitled to receive all interest and other income earned by any funds while they shall be deposited as contemplated by this section 7, provided that the corporation shall maintain on deposit funds sufficient to satisfy all payments which the deposit arrangement shall have been established to satisfy if the conditions precedent to the disbursement of any funds deposited by the corporation pursuant to this Section 7 shall not have been satisfied within two years after the establishment of the trust for such funds, then (i) such funds shall be returned to the corporation upon its request; (ii) after such return, such funds shall be free of any trust which shall have been impressed upon them; (iii) the person entitled to the payment for which been originally intended shall have the right to look only to the corporation for such payment, subject to applicable escheat laws; and (iv) the trustee which shall have held such funds shall be relieved of any responsibility for such of such funds to the corporation.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-14-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any payment which may be owed for the payment of the redemption price for any shares of Series B Convertible Redeemable Preferred Stock pursuant to Section 4 or the payment of any amount distributable with respect to the shares of Series B Convertible Redeemable Preferred Stock under Section 6 shall be deemed to have been &#8220;paid or properly provided for&#8221; upon the earlier to occur of: (i) the date upon which funds sufficient to make such payment shall be deposited in a manner contemplated by the preceding paragraph or (ii) the date upon which a check payable to the person entitled to receive such payment shall be delivered to such person or mailed to such person at the address of such person then appearing on the books of the corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section 8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Status of Reacquired Shares</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Shares of Series B Convertible Redeemable Preferred Stock issued and reacquired by the corporation shall have the status of authorized and unissued shares of Preferred Stock, undesignated as to series, subject to later issuance.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section 9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Preemptive Rights</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Holders of shares of Series B Convertible Redeemable Preferred Stock are not entitled to any preemptive or subscription rights in respect of any securities of the corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section <font style="DISPLAY: inline; FONT-SIZE: 10pt">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Legal Holidays</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In any case where any Dividend Payment Date, redemption date or the last date on which a holder of Series B Convertible Redeemable Preferred Stock has the right to convert such holder&#8217;s shares of Series B Convertible Redeemable Preferred Stock shall not be a Business Day (as defined below), then (notwithstanding any other provision of this Certificate of Designation of the Series B Preferred Stock) payment of a dividend due or a redemption price or conversion of the shares of Series B Convertible Redeemable Preferred Stock need not be made on such date, but may be made on the next succeeding Business Day with the same force and effect as if made on the Dividend Payment Date or redemption date or the last day for conversion, <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font> that, for purposes of computing such payment, no interest shall accrue for the period from and after such Dividend Payment Date or redemption date, as the case may be. As used in this Section 10, &#8220;Business Day&#8221; means each Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which banking institutions in the City of New York or the State of New Jersey are authorized or obligated by law or executive order to close.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-15-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">State of Delaware</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Secretary of State</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Division of Corporations</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Delivered 11:09 AM 08/08/2007</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">FILED 11:08 AM 08/08/2007</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">SRV 070900970 - 0899444 FILE</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATE OF AMENDMENT</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OF</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OF</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEOSTEM, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Section 242 of the General Corporation Law of the State of Delaware, NeoStem, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;Corporation&#8221;), does hereby certify as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;The name of the Corporation is NeoStem, Inc. The date of filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was September 18, 1980, under the name of Fidelity Medical Services, Inc. The name of the Corporation was changed to Corniche Group Incorporated by filing a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of Delaware on September 28, 1995. The name of the Corporation was changed to Phase III Medical Inc. by filing a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of Delaware on July 24, 2003. The name of the Corporation was changed to NeoStem, Inc. by filing an Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware on August 29, 2006.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;The Board of Directors of the Corporation has duly adopted a resolution pursuant to Section 242 of the General Corporation Law of the State of Delaware setting forth a proposed amendment to the Amended and Restated Certificate of Incorporation of the Corporation and declaring said amendment to be advisable. The requisite stockholders of the Corporation have duly approved said proposed amendment in accordance with Section 242 of the General Corporation Law of the State of Delaware. The amendment amends the Amended and Restated Certificate of Incorporation of the Corporation as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Article FOURTH is hereby amended by adding a Section E which reads as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;1. Effective upon the filing of this Certificate of Amendment of the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the &#8220;Effective Time&#8221;), the shares of Common Stock issued and outstanding immediately prior to the Effective Time and the shares of Common Stock issued and held in the treasury of the Corporation immediately prior to the Effective Time are reclassified into a smaller number of shares such that each ten (10) shares of issued Common Stock immediately prior to the Effective Time is reclassified into one (1) share of Common Stock. Notwithstanding the immediately preceding sentence, no fractional shares shall be issued and, in lieu thereof, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the reclassification shall be entitled to be rounded up to the next whole share of Common Stock.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic"><font style="FONT-STYLE: normal">2</font>.</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>Each stock certificate that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been reclassified (as well as the right to receive a whole share in lieu of a fractional share of Common Stock), provided, however, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been reclassified (including the right to receive a whole share in lieu of a fractional share of Common Stock).&#8221;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3. This Certificate of Amendment shall be effective August 9, 2007 at 10:00 a.m.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">IN WITNESS WHEREOF, </font>the Corporation has caused this Certificate of Amendment to be signed by its President on this 8th day of August, 2007:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:&#160;&#160;</font></div>
</td>
<td valign="top" width="22%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;Robin L. Smith</font></td>
<td valign="top" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="22%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name: Robin L. Smith</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="22%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title: President</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">State of Delaware</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Secretary of State</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Division of Corporations</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Delivered 05:19 PM 04/15/2009</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">FILED 05:05 PM 04/15/2009</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">SRV 090366790 - 0899444 FILE</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CERTIFICATE OF DESIGNATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">of</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SERIES D CONVERTIBLE REDEEMABLE PREFERRED STOCK</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">of</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEOSTEM, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Pursuant to Section 151(g) of the</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Delaware General Corporation Law)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<hr style="COLOR: black" align="center" noshade size="1" width="30%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It is hereby certified that:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;&#160;&#160;The name of the corporation is NeoStem, Inc. (hereinafter called the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Corporation</font>&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;&#160;&#160;&#160;The Certificate of Incorporation of the Corporation, as amended (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Certificate of Incorpo</font>r<font style="DISPLAY: inline; TEXT-DECORATION: underline">ation</font>&#8221;) authorizes the issuance of 5,000,000 shares of Preferred Stock, par value $.01 per share, and expressly vests in the Board of Directors of the Corporation the authority to issue any or all of said shares in one or more series and by resolution to fix the designation and number of shares of the class and series acted upon, the full or limited voting powers or the denial of voting powers, and the relative rights, preferences and limitations and other distinguishing characteristics of each such class and series to be issued.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;&#160;&#160;&#160;Pursuant to such authority, the following resolutions were duly adopted by the Board of Directors of the Corporation as required by Subsection 151(g) of the Delaware General Corporation Law on March 13, 2009 and March 29, 2009 creating a series of Series D Convertible Redeemable Preferred Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">RESOLVED, that pursuant to the authority granted to and vested in the Board of Directors of this Corporation in accordance with the provisions of the Certificate of Incorporation, the Board of Directors hereby creates a series of Preferred Stock, par value $.01 per share, of the Corporation and hereby states the designation and number of shares, and fixes the relative rights, preferences, and limitations thereof (in addition to the provisions set forth in the Certificate of Incorporation, which are applicable to the Preferred Stock of all series) as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ARTICLE THIRTEENTH</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SERIES D CONVERTIBLE REDEEMABLE PREFERRED STOCK,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PAR VALUE $.01 PER SHARE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Section 1. Designation and Amount; Rank</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There is hereby established a series of preferred stock which is designated &#8220;Series D Convertible Redeemable Preferred Stock&#8221; (referred to herein as &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Series D Preferred Stock</font>&#8221;). The number of shares which will constitute such series shall be one million six hundred thousand (1,600,000). The Series D Preferred Stock shall rank senior to all of the Corporation&#8217;s capital stock with respect to the payment of dividends and to the distribution of assets upon liquidation, dissolution or winding up.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Section <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2. </font>Dividends.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">From and after the date of the issuance of any shares of Series D Preferred Stock, dividends at the rate per annum of $1.25 per share shall accrue on such shares of Series D Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series D Preferred Stock) (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Accruing Dividends</font>&#8221;). Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative; provided however, that except as set forth in the following sentence of this Section 2 or Section 6,<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic"> </font>such Accruing Dividends shall be payable in cash on April 9th of each year beginning on April 9, 2010 provided that such shares of Series D Preferred Stock remain issued and outstanding on each such date. The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Certificate of Incorporation) the holders of the Series D Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series D Preferred Stock in an amount at least equal to the greater of (i) the amount of the aggregate Accruing Dividends then accrued on such share of Series D Preferred Stock and not previously paid and (ii) (A) in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Series D Preferred Stock as would equal the product of (1) the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (2) the number of shares of Common Stock issuable upon conversion of a share of Series D Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (B) in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Series D Preferred Stock determined by (1) dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (2) multiplying such fraction by an amount equal to the Series D Original Issue Price (as defined below); provided that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders of Series D Preferred Stock pursuant to this Section 2 shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest Series D Preferred Stock dividend. The &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Series D Original Issue Price</font>&#8221; shall mean $32.50 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series D Preferred Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Section 3. General, Class and Series Voting Rights.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Except as otherwise provided by law, each share of the Series D Preferred Stock shall not have any voting rights.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Section 4. Redemption.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(A)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If by October 31, 2009 the affirmative vote of the number of holders of the Corporation&#8217;s stock required pursuant to the Amended and Restated By-Laws of the Corporation and subject to the rules of the NYSE Amex to convert the shares of Series D Preferred Stock into Common Stock pursuant to Section 5(A) has not been achieved, the Company shall automatically redeem all shares of Series D Preferred Stock at the redemption price per share of $12.50 plus the Accruing Dividends as of such date.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(B)&#160;&#160;&#160;In the event of a redemption of the shares of Series D Preferred Stock, the Corporation shall give notice to the holders of record of shares of the Series D Preferred Stock being so redeemed by first class mail, postage prepaid, at their addresses as shown on the stock registry books of the Corporation, that said shares have been redeemed, provided that without limiting the obligation of the Corporation hereunder to give the notice provided in this Section 4(B), the failure of the Corporation to give such notice shall not invalidate any corporate action by the Corporation. Each such notice shall state: (i) the redemption date; (ii) that all of the shares of Series D Preferred Stock have been redeemed; (iii) that the redemption price is $12.50 plus the Accruing Dividends as of such date per share; and (iv) the place or places where certificates for such shares are to be surrendered for payment of the redemption price.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(C)&#160;&#160;&#160;Notice having been mailed as aforesaid, from and after the redemption date, said shares shall no longer be deemed to be outstanding, and all rights of the holders thereof as stockholders of the Corporation (except the right to receive from the Corporation the redemption price) shall cease. Upon surrender of the certificates for any shares so redeemed (properly endorsed or assigned for transfer, if the Board of Directors of the Corporation shall so require and the notice shall so state), such shares shall be redeemed by the Corporation at the redemption price aforesaid.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(D)&#160;&#160;&#160;Any shares of Series D Preferred Stock which shall at any time have been redeemed shall, after such redemption, have the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such shares are once more designated as part of a particular series by the Board of Directors of the Corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Section 5. Conversion.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(A)&#160;&#160;&#160;Upon the affirmative vote of the number of holders of the Corporation&#8217;s stock required pursuant to the Amended and Restated By-Laws of the Corporation and subject to the rules of the NYSE Amex (such date, the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Conversion Date</font>&#8221;), each share of Series D Preferred Stock shall automatically convert into such number of fully paid and nonassessable shares of Common Stock as is determined by dividing (i) the Series D Original Issue Price by (ii) $1.25 (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Conversion Rate</font>&#8221;). The Conversion Rate shall be subject to adjustment as provided below.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(B)&#160;&#160;&#160;&#160;Each holder of shares of Series D Preferred Stock shall surrender the certificates representing such shares, accompanied by transfer instruments satisfactory to the Corporation and sufficient to transfer the Series D Preferred Stock being converted to the Corporation free of any adverse interest, at any of the offices or agencies maintained for such purpose by the Corporation (&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Conversion Agent</font>&#8221;), together with a written notice to the Corporation at such Conversion Agent stating the names, together with addresses, in which the certificates for shares of Common Stock which shall be issuable on such conversion shall be issued. As promptly as practicable after the surrender of such shares of Series D Preferred Stock as aforesaid, the Corporation shall issue and shall deliver at such Conversion Agent to such holder a certificate for the number of full shares of Common Stock issuable upon the conversion of such shares in accordance with the provisions hereof. Each conversion shall be deemed to have been effected immediately prior to the close of business on the Conversion Date, and the persons in whose names any certificates for shares of Common Stock shall be issuable upon such conversion shall be deemed to have become the holders of record of the Common Stock represented thereby at such time. Any such conversion shall be at the Conversion Rate in effect on the Conversion Date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(C)&#160;&#160;&#160;&#160;In the case of any share of Series D Preferred Stock which is converted after any record date with respect to the payment of a dividend on the Series D Preferred Stock and on or prior to the Dividend Payment Date related to such record date, the dividend due on such Dividend Payment Date shall be payable on such Dividend Payment Date to the holder of record of such share as of such preceding record date notwithstanding such conversion.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-3-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(D) No fractional shares or scrip representing fractions of shares of Common Stock shall be issued upon conversion of any shares of Series D Preferred Stock. Instead of any fractional interest in a share of Common Stock which would otherwise be deliverable upon the conversion of a share of Series D Preferred Stock, the Corporation shall round the number of shares of Common Stock down to the nearest whole share. If more than one certificate representing shares of Series D Preferred Stock shall be surrendered for conversion at one time by the same holder, the number of full shares issuable upon conversion thereof shall be computed on the basis of the aggregate number of shares of Series D Preferred Stock represented by such certificates, or the specified portions thereof to be converted, so surrendered.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(E) The Conversion Rate shall be adjusted from time to time as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;In case outstanding shares of Common Stock shall be subdivided into a greater number of shares of Common Stock and the Series D Preferred Stock is not similarly subdivided, the Conversion Rate in effect at the opening of business on the day following the day upon which such subdivision becomes effective shall be proportionately increased, and, conversely, in case outstanding shares of Common Stock shall each be combined into a smaller number of shares of Common Stock and the Series D Preferred Stock is not similarly subdivided, the Conversion Rate in effect at the opening of business on the day following the day upon which such combination becomes effective shall be proportionately decreased, such reduction or increase, as the case may be, to become effective immediately after the opening of business on the day following the day upon which such subdivision or combination becomes effective.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)&#160;&#160;Whenever the Conversion Rate is adjusted as herein provided, (x) the Corporation shall promptly file with any Conversion Agent a certificate of a firm of independent public accountants setting forth the Conversion Rate after such adjustment and setting forth a brief statement of the facts requiring such adjustment, and the manner of computing the same, which certificate shall be conclusive evidence of the correctness of such adjustment, and (y) a notice stating that the Conversion Rate has been adjusted and setting forth the adjusted Conversion Rate shall forthwith be given by the Corporation to any Conversion Agent and mailed by the Corporation to each holder of shares of Series D Preferred Stock at their last address as the same appears on the books of the Corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(F) In case of any consolidation of the Corporation with, or merger of the Corporation into, any other entity (other than a merger or consolidation in which the Corporation is the continuing Corporation) or any sale or conveyance to another Corporation of the property of the Corporation as an entirety or substantially as an entirety, or in the case of a statutory exchange of securities with another Corporation, or any reclassification of shares, the Conversion Rate shall not be adjusted but each holder of a share of Series D Preferred Stock then outstanding shall have the right thereafter to convert such share only into the kind and amount of securities, cash and other property which such holder would have owned or have been entitled to receive immediately after such consolidation, merger, sale, conveyance, exchange or reclassification had such share of Series D Preferred Stock been converted immediately prior to such consolidation, merger, sale, conveyance, exchange or reclassification. Provision shall be made in any such consolidation, merger, sale, conveyance, exchange or reclassification for adjustments in the Conversion Rate which shall be as nearly equivalent as may be practicable to the adjustments provided for in Section (E). The above provisions shall similarly apply to successive consolidations, mergers, sales, conveyances, exchange or reclassification.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For purposes of this Section 5, &#8220;Common Stock&#8221; includes any stock of any class of the Corporation which has no preference in respect of dividends or of amounts payable in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation and which is not subject to redemption by the Corporation. However, subject to the provisions of paragraph (F) above, shares issuable on conversion of shares of Series D Preferred Stock shall include only shares of the class designated as Common Stock of the Corporation on the date of the initial issuance of Series D Preferred Stock by the Corporation, or shares of any class or classes resulting from any reclassification or reclassifications thereof and which have no preference in respect of dividends or of amounts payable in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation and which are not subject to redemption by the Corporation.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-4-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In case:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;&#160;&#160;&#160;&#160;the Corporation shall declare a stocks split, stock dividend (or any other distribution) on its Common Stock that would cause an adjustment to the Conversion Rate of the Series D Preferred Stock pursuant to the terms of subparagraph (i) of Paragraph (E) above; or</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)&#160;&#160;&#160;&#160;of any reclassification of the Common Stock of the Corporation (other than a subdivision or combination of its outstanding shares of Common Stock), or of any consolidation, merger or share exchange to which the Corporation is a party and for which approval of any stockholders of the Corporation is required, or of the sale or conveyance, of the property of the Corporation as an entirety or substantially as an entirety; or</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)&#160;&#160;&#160;of the voluntary or involuntary dissolution, liquidation or winding up of the Corporation;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">then the Corporation shall cause to be filed with any Conversion Agent, and shall cause to be mailed to all holders of shares of Series D Preferred Stock at each such holder&#8217;s last address as the same appears on the books of the Corporation, at least 20 days (or 10 days in any case specified in clause (i) above) prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, rights or warrants, or, if a record is not to be taken, the date as of which the holders of Common Stock of record to be entitled to such dividend, distribution, rights or warrants are to be determined, or (y) the date on which such reclassification, consolidation, merger, share exchange, sale, conveyance, dissolution, liquidation or winding up is expected to become effective, and the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, share exchange, safe, conveyance, dissolution, liquidation or winding up. Neither the failure to give such notice nor any defect therein shall affect the legality or validity of the proceedings described in clauses (i) through (iii) above.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Corporation will pay any and all documentary stamp or similar issue or transfer taxes payable in respect of the issue or delivery of shares of Common Stock on conversions of shares of Series D Preferred Stock pursuant hereto; provided, however, that the Corporation shall not be required to pay any tax which may be payable in respect of any transfer involved in the issue or delivery of shares of Common Stock in a name other than that of the holder of the shares of Series D Preferred Stock to be converted and no such issue or delivery shall be made unless and until the person requesting such issue or delivery has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Corporation covenants that all shares of Common Stock which may be delivered upon conversions of shares of Series D Preferred Stock will upon delivery be duly and validly issued and fully paid and non-assessable, free of all liens and charges and not subject to any pre-emptive rights. The Corporation further covenants that, if necessary, it shall reduce the par value of the Common Stock so that all shares of Common Stock delivered upon conversion of shares of Series D Preferred Stock are fully paid and non-assessable.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-5-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Corporation covenants that it will at all times reserve and keep available, free from pre-emptive rights, out of its authorized but unissued shares of Common Stock or its issued shares of Common; Stock held in its treasury, or both, for the purpose of effecting conversions of shares of Series D Preferred Stock, the full number of shares of Common Stock deliverable upon the conversion of all outstanding shares of Series D Preferred Stock not theretofore converted. For purposes of this reservation of Common Stock, the number of shares of Common Stock which shall be deliverable upon the conversion of all outstanding shares of Series D Preferred Stock shall be computed as if at the time of computation all outstanding shares of Series D Preferred Stock were held by a single holder. The issuance of shares of Common Stock upon conversion of shares of Series D Preferred Stock is authorized in all respects.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Section 6. Liquidation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the event of any voluntary or involuntary dissolution, liquidation or winding up of the Corporation (for the purposes of this Section 6, a &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Liquidation</font>&#8221;), prior to any distribution of assets to the holders of the Series B Preferred Stock and any other class or series of stock of the Corporation, the holder of each share of Series D Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders an amount per share equal to $12.50 plus the Accruing Dividends (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Series D Preference</font>&#8221;). Following the payment of the Series D Preference and the payment of any distributions required to be made to the holders of the Series B Preferred Stock in respect of distributions upon the Liquidation of the Corporation, the holder of each share of Series D Preferred Stock then outstanding shall be entitled to be paid out of the remaining assets of the Corporation available for distribution an amount on a pari passu basis equal to ten (10) times the amount per share distributed to the holders of the Common Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The voluntary sale, conveyance, lease, exchange or transfer of the property of the Corporation as an entirety or substantially as an entirety, or the merger or consolidation of the Corporation into or with any other Corporation, or the merger of any other Corporation into the Corporation, or any purchase or redemption of some or all of the shares of any class or series of stock of the Corporation, shall not be deemed to be a Liquidation of the Corporation for the purposes of the Section 6 (unless in connection therewith the Liquidation of the Corporation is specifically approved).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The holder of any shares of Series D Preferred Stock shall not be entitled to receive any payment owed for such shares under this Section 6 until such holder shall cause to be delivered to the Corporation (i) the certificate or certificates representing such shares of Series D Preferred Stock and (ii) transfer instrument or instruments satisfactory to the Corporation and sufficient to transfer such shares of Series D Preferred Stock to the Corporation free of any adverse interest. As in the case of the redemption price, no interest shall accrue on any payment upon Liquidation after the due date thereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">After payment of the full amount of the liquidating distribution to which they are entitled, the holders of shares of the Series D Preferred Stock will not be entitled to any further participation in any distribution of assets by the Corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Section 7. Status of Reacquired Shares.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Shares of Series D Preferred Stock issued and reacquired by the Corporation shall have the status of authorized and unissued shares of Preferred Stock, undesignated as to series, subject to later issuance.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-6-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Section 8. Preemptive Rights.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Holders of shares of Series D Preferred Stock are not entitled to any preemptive or subscription rights in respect of any securities of the Corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Section 9. Legal Holidays.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In any case where any Dividend Payment Date, redemption dale or the last date on which a holder of Series D Preferred Stock has the right to convert such holder&#8217;s shares of Series D Preferred Stock shall not be a Business Day (as defined below), then (notwithstanding any other provision of this Certificate of Designation of the Series D Preferred Stock) payment of a dividend due or a redemption price or conversion of the shares of Series D Preferred Stock need not be made on such date, but may be made on the next succeeding Business Day with the same force and effect as if made on the Dividend Payment Date or the last day for conversion, provided that, for purposes of computing such payment, no interest shall accrue for the period from and after such Dividend Payment Date or redemption date, as the case may be. As used in this Section 9, &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Business Day&#8221;</font> means each Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which banking institutions in the City of New York or the State of New Jersey are authorized or obligated by law or executive order to close.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FURTHER RESOLVED, that the statements contained in the foregoing resolutions creating and designating the said Series D issue of Preferred Stock and fixing the number, voting rights, powers, preferences and relative, optional, participating, and other special rights and the qualifications, limitations, restrictions, and other distinguishing characteristics thereof shall, upon the effective date of said series, be deemed to be included in and be a part of the Certificate of incorporation of the Corporation pursuant to the provisions of Sections 104 and 151 of the General Corporation Law of the State of Delaware.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FURTHER RESOLVED, that the effective time and date of the series herein certified shall be April 9, 2009.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">IN WITNESS WHEREOF, NEOSTEM, INC. has caused this certificate to be signed by its President, this <font style="DISPLAY: inline; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="FONT-STYLE: normal">9th</font> </font>day of April 2009.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEOSTEM, INC.</font></div>
</td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="55%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ <font style="DISPLAY: inline; FONT-SIZE: 10pt">Robin Smith</font></font></div>
</td>
<td valign="top" width="15%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="27%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name: Robin Smith</font></div>
</td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="27%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title: Chief Executive Officer</font></div>
</td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-7-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">State of Delaware</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Secretary of State</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Division of Corporations</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Delivered 08:01 AM 10/30/2009</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">FILED 08:01 AM 10/30/2009</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">SRV 090977299 - 0899444 FILE</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CERTIFICATE OF AMENDMENT</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">OF</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">OF</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEOSTEM, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Section 242 of the General Corporation Law of the State of Delaware, NeoStem, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;Corporation&#8221;), does hereby certify as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;&#160;&#160;The name of the Corporation is NeoStem, Inc. The date of filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was September 18, 1980, under the name of Fidelity Medical Services, Inc. The name of the Corporation was changed to Corniche Group Incorporated by filing a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware on September 28, 1995. The name of the Corporation was changed to Phase III Medical Inc. by filing a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware on July 24, 2003. The name of the Corporation was changed to NeoStem, Inc. by filing an Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on August 29, 2006.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;&#160;&#160;&#160;The Board of Directors of the Corporation has duly adopted a resolution pursuant to Section 242 of the General Corporation Law of the State of Delaware setting forth a proposed amendment to the Amended and Restated Certificate of Incorporation of the Corporation and declaring said amendment to be advisable. The requisite stockholders of the Corporation have duly approved said proposed amendment in accordance with Section 242 of the General Corporation Law of the State of Delaware. The amendment amends the Amended and Restated Certificate of Incorporation of the Corporation as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section A of Article FOURTH is hereby deleted in its entirety and the following language is hereby inserted in its stead.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;A. The total number of shares of stock which the Corporation shall have authority to issue is 520,000,000 shares, of which 500,000,000 shares are designated as common stock, having a par value of $0.001 per share (&#8220;Common Stock&#8221;) and 20,000,000 share are designated as preferred stock, $0.01 par value per share (&#8220;Preferred Stock&#8221;).&#8221;</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">IN WITNESS WHEREOF</font>, the Corporation has caused this Certificate of Amendment to be signed by its Chief Executive Officer on this 29<font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font></font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">&#160;</font>day of October, 2009</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEOSTEM, INC.</font></div>
</td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ Robin L. Smith</font></font></div>
</td>
<td valign="top" width="20%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="27%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name: Robin L. Smith</font></div>
</td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="27%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title: Chief Executive Officer</font></div>
</td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-STYLE: italic"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">State </font><font style="DISPLAY: inline; FONT-STYLE: italic">of</font><font style="DISPLAY: inline; FONT-STYLE: italic"> Delaware</font></font></font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Secretary of State</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Division of Corporations</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Delivered 08:01 AM 10/30/2009</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">FILED 08:02 AM 10/30/2009</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">SRV 090977300 - 0899444 FILE</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CERTIFICATE OF AMENDMENT</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">OF</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">OF</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEOSTEM, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Section 242 of the General Corporation Law of the State of Delaware, NeoStem, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;Corporation&#8221;), does hereby certify as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;&#160;&#160;The name of the Corporation is NeoStem, Inc. The date of filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was September 18, 1980, under the name of Fidelity Medical Services, Inc. The name of the Corporation was changed to Corniche Group Incorporated by filing a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware on September 28, 1995. The name of the Corporation was changed to Phase III Medical Inc. by filing a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware on July 24, 2003. The name of the Corporation was changed to NeoStem, Inc. by filing an Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on August 29, 2006.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;&#160;&#160;&#160;The Board of Directors of the Corporation has duly adopted a resolution pursuant to Section 242 of the General Corporation Law of the State of Delaware setting forth a proposed amendment to the Amended and Restated Certificate of Incorporation of the Corporation and declaring said amendment to be advisable. The requisite stockholders of the Corporation have duly approved said proposed amendment in accordance with Section 242 of the General Corporation Law of the State of Delaware. The amendment amends the Amended and Restated Certificate of Incorporation of the Corporation as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following text is hereby added to the Corporation&#8217;s Amended and Restated Certificate of Incorporation as Article ELEVENTH:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;ELEVENTH: For the management of the business and for the conduct of the affairs of the Corporation, and for further definition, limitation and regulation of the powers of the Corporation and its Directors and stockholders:</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;A. The number of Directors constituting the Corporations&#8217; Board of Directors shall be determined by the Board of Directors, from time to time. The Directors constituting the Corporation&#8217;s Board of Directors, other than those who may be elected by the holders of any classes or series of stock having a preference over the Common Stock as to dividends or upon liquidation, shall be classified, with respect to the time for which they severally hold office, into three classes, as nearly equal in number as possible, as shall be determined by the Board of Directors consistent with the terms of this Article ELEVENTH. The Board shall have the authority to assign members of the board already in office to such classes at the time the amendment becomes effective. One class shall be assigned a term expiring at the annual meeting of stockholders to be held in 2010, another class shall be assigned a term expiring at the annual meeting of stockholders to be held in 2011, and another class shall be assigned a term expiring at the annual meeting of stockholders to be held in 2012, with each class to hold office until its successor is elected and qualified. At each annual meeting of the stockholders of the Corporation commencing with the election in 2010, the successors of the class of Directors whose term expires at that meeting shall be elected to hold office for a term expiring at the annual meeting of stockholders held in the third year following the year of their election.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;B. Except as otherwise fixed by or pursuant to provisions hereof relating to the rights of the holders of any class or series of stock having a preference over Common Stock as to dividends or upon liquidation to elect additional Directors under specified circumstances, newly created directorships resulting from any increase in the number of Directors and any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other cause shall be filled by the affirmative vote of a majority of the remaining Directors then in office, even though less than a quorum of the Board of Directors, or by a sole remaining Director. Any Director appointed by the Board of Directors in accordance with the preceding sentence shall hold office and shall be elected for the remainder of the full term of the class of Directors in which the new directorship was created or the vacancy occurred and until such Director&#8217;s successor shall have been elected and qualified.&#8221;</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">IN WITNESS WHEREOF</font>, the Corporation has caused this Certificate of Amendment to be signed by its Chief Executive Officer on this <font style="DISPLAY: inline; FONT-SIZE: 10pt">29<font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font></font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>day of October, 2009.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEOSTEM, INC.</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="22%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;Robin L. Smith</font></td>
<td valign="top" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="22%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name: Robin L. Smith</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" nowrap valign="top" width="22%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title: Chief Executive Officer</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-3-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-STYLE: italic"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">State </font><font style="DISPLAY: inline; FONT-STYLE: italic">of</font><font style="DISPLAY: inline; FONT-STYLE: italic"> Delaware</font></font></font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Secretary of State</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Division of Corporations</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Delivered 08:01 AM 10/30/2009</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">FILED 08:03 AM 10/30/2009</font></font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">SRV 090977301 &#8211; 0899444 FILE</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATE OF DESIGNATIONS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SERIES C CONVERTIBLE PREFERRED STOCK</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEOSTEM, INC.</font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Section 151(g) of the</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">General Corporation Law of the State of Delaware</font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">NEOSTEM, INC., </font>a corporation organized and existing under the laws of the State of Delaware (the &#8220;Corporation&#8221;), does hereby certify that, pursuant to the authority conferred on the Board of Directors of the Corporation by the Certificate of Incorporation, as amended and restated to date (the &#8220;Certificate of Incorporation&#8221;), of the Corporation and in accordance with Section 151(g) of the General Corporation Law of the State of Delaware, the Board of Directors of the Corporation adopted the following resolution establishing a series of 8,177,512 shares of Preferred Stock of the Corporation designated as &#8220;Series C Convertible Preferred Stock:&#8221;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">RESOLVED, </font>that pursuant to the authority conferred on the Board of Directors of this Corporation by the Certificate of Incorporation, a series of Preferred Stock, par value $0.01 per share, of the Corporation is hereby established and created, and that the designation and number of shares thereof and the voting and other powers, preferences and relative, participating, optional or other rights of the shares of such series and the qualifications, limitations and restrictions thereof are as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Designation and Amount. </font>The shares of such series created hereby shall be designated as Series C Convertible Preferred Stock (the &#8220;Series C Preferred Stock&#8221;) and the authorized number of shares constituting such series shall be 8,177,512. The agreed stated value of each of the Series C Preferred Stock shall be $1.00 per share (the &#8220;Agreed Stated Value&#8221;). The Series C Preferred Stock shall, with respect to dividend rights, have the entitlements set forth herein and shall, with respect to rights on liquidation, dissolution and winding up of the affairs of the Corporation, rank senior to all classes of Common Stock of the Corporation and, subject to the rights of any series of Preferred Stock outstanding or that may from time to time come into existence providing that the Series C Preferred Stock shall rank junior or senior thereto, other equity securities of the Corporation. Such number of shares may be decreased by resolution of the Board of Directors of the Corporation; provided, however, that no decrease shall reduce the number of shares of Series C Preferred Stock to less than the number of shares then issued and outstanding.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.</font>&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Dividends and Distributions.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160; <font style="DISPLAY: inline; FONT-STYLE: italic">Amount. </font>The holders of shares of Series C Preferred Stock shall be entitled to receive an annual dividend of 5% of the Agreed Stated Value (the &#8220;Annual Dividend&#8221;), payable annually on the first day of January (the &#8220;Annual Dividend Payment Date&#8221;). Payment of the Annual Dividend may be either in cash or in kind as determined by the Board of Director. In the event that the Annual Dividend Payment Date shall fall due on a Saturday, Sunday or legal holiday in the State of Delaware, the dividend due on such date shall be paid on the next day thereafter that is not a Saturday, Sunday or legal holiday in the State of Delaware. The Annual Dividend shall be cumulative and shall begin to accrue on outstanding shares of Series C Preferred Stock from and after&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>, 2009 (the &#8220;Series C Issuance Date&#8221;) on a daily basis computed on the basis of a 365-day year and compounded annually whether or not the Corporation shall have assets legally available therefore.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Limitation on Other Dividends. </font>So long as any shares of Series C Preferred Stock shall be outstanding, no dividend shall be declared or paid or set apart for payment on any Junior Stock, unless there shall also have been declared and paid or set apart for payment on the shares of Series C Preferred Stock, all accrued and unpaid Annual Dividends. In the event that full cumulative dividends on the shares of Series C Preferred Stock have not been declared and paid or set apart for payment when due, the Corporation shall not declare or pay or set apart for payment any dividends or make any other distributions on or make payment on account of the purchase, redemption or other retirement of any Junior Stock, until full cumulative dividends on the shares of Series C Preferred Stock shall have been paid or declared and set apart for payment; provided, however, that the foregoing shall not apply to (i) any dividend payable solely in shares of any class or series of Junior Stock or (ii) the purchase, redemption or conversion of shares of any Junior Stock, in exchange solely for shares of Junior Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Timing. </font>Accrued but unpaid Annual Dividends shall cumulate as of each Annual Dividend Payment Date on which they first become payable whether or not the Corporation shall have assets legally available for the payment thereof, and shall be payable as provided in this Section 2.1 and/or as further provided herein.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Waiver. </font>To the fullest extent permitted by law and notwithstanding anything contained herein to the contrary, the holders of the outstanding shares of Series C Preferred Stock may waive any Annual Dividend that such holders shall be entitled to receive under this Section 2 by the affirmative vote or written consent of the holders of at least a majority of the shares of Series C Preferred Stock then outstanding.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Form of Payment. </font>Dividends shall be payable at the option of the Corporation either in cash or in kind in shares of Series C Preferred Stock or in kind in shares of Common Stock. Any payment in shares of Series C Preferred Stock shall be based on the Agreed Stated Value. Any payment in kind in shares of Common Stock shall be made at the Market Value on the dividend payment date. &#8220;Market Value,&#8221; on a given date, shall mean the average of the closing sales price of a share of the Company&#8217;s Common Stock on the American Stock Exchange, or on its principal securities exchange or trading market if other than the American Stock Exchange, on each trading day (excluding each day on which there is no closing price) for a period of ten (10) consecutive trading days (excluding each day on which there is no closing price) immediately prior to such date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(f)&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Junior Stock. </font>&#8220;Junior Stock&#8221; shall mean (i) the Corporation&#8217;s common stock (&#8220;Common Stock&#8221;), and (ii) each other class or series of the Corporation&#8217;s capital stock, whether common, preferred or otherwise, the terms of which do not provide that shares of such class or series shall rank senior to or on a parity with shares of the Series C Preferred Stock as to distributions of dividends and distributions upon the liquidation, winding-up and dissolution of the Corporation.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3. </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Liquidation Preference.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;In the event of a (i) liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, (ii) a sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation of all or substantially all the assets of the Corporation for cash or (iii) voluntary or involuntary bankruptcy of the Corporation (subparagraphs (i), (ii) and (iii) being collectively referred to as a &#8220;Liquidation Event&#8221;), after payment or provision for payment of debts and other liabilities of the Corporation, the holders of the Series C Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, whether such assets are capital, surplus, or earnings, before and in preference to any payment or declaration and setting apart for payment of any amount shall be made in respect of any Junior Stock, an amount equal to $1.125 per share plus an amount equal to all accrued dividends unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon. In the case of property or in the event that any such securities are restricted, the value of such property or securities shall be determined by agreement between the Corporation and the holders of a majority of the shares of Series C Preferred Stock then outstanding. If upon any Liquidation Event, whether voluntary or involuntary, the assets to be distributed to the holders of the Series C Preferred Stock shall be insufficient to permit the payment to such stockholders of the full preferential amounts aforesaid, then all of the assets of the Corporation to be distributed shall be so distributed ratably to the holders of the Series C Preferred Stock on the basis of the number of shares of Series C Preferred Stock held. All shares of Series C Preferred Stock shall rank as to payment upon the occurrence of any Liquidation Event senior to the Common Stock as provided herein and, unless the terms of such other series shall provide otherwise, senior to all other series of the Corporation&#8217;s preferred stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;The holder of any shares of Series C Preferred Stock shall not be entitled to receive any payment owed for such shares under this Section 3 until such holder shall cause to be delivered to the Corporation (i) the certificate or certificates representing such shares of Series C Preferred Stock (or a lost stock affidavit and indemnity agreement in form reasonably acceptable to the Corporation with respect to such shares) and (ii) transfer instrument or instruments satisfactory to the Corporation and sufficient to transfer such shares of Series C Preferred Stock to the Corporation free of any adverse interest. No interest shall accrue on any payment upon a Liquidation Event after the due date thereof. After payment of the full amount of the liquidating distribution to which they are entitled, the holders of shares of the Series C Preferred Stock will not be entitled to any further participation in any distribution of assets by the Corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;Upon the completion of the distribution required by subparagraph (a) of this Section 3 and subject to any other distribution that may be required with respect to any series of Preferred Stock that may from time to time come into existence, the remaining assets of the Corporation available for distribution to stockholders shall be distributed among the holders of the Common Stock, pro rata based on the number of shares held by each such holder.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-3-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: normal">4.</font> Conversion </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Rights.</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Conversion, Per Share Conversion Price. </font>Each share of the Series C Preferred Stock shall be convertible, at the option of the holder thereof upon exercise in accordance with Section 4(b), without the payment of additional consideration, into such number of fully paid and nonassessable shares of the Corporation&#8217;s Common Stock equal to the quotient obtained by dividing the Agreed Stated Value plus all accrued dividends unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon, by $0.90 (the &#8220;Conversion Price&#8221;) (as such amount may be adjusted from time to time pursuant to this Certificate of Designations, the &#8220;Per Share Conversion Price&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Conversion Procedures. </font>The optional conversion of shares of Series C Preferred Stock in accordance with Section 4(a) may be effected by a holder of record thereof by making written demand for such conversion (a &#8220;Conversion Demand&#8221;) upon the Corporation at its principal executive offices setting forth therein: (i) the number of shares to be converted; (ii) the certificate or certificates representing such shares; and (iii) the proposed date of such conversion, which shall be a business day not less than five (5) nor more than thirty (30) days after the date of such Conversion Demand (the &#8220;Conversion Date&#8221;). Within five days of receipt of the Conversion Demand, the Corporation shall give written notice (a &#8220;Conversion Notice&#8221;) to such holder setting forth therein: (i) the address of the place or places at which the certificate or certificates representing the shares so to be converted are to be surrendered; and (ii) whether the certificate or certificates to be surrendered are required to be indorsed for transfer or accompanied by a duly executed stock power or other appropriate instrument of assignment and, if so, the form of such endorsement or power or other instrument of assignment, including a medallion seal. The Conversion Notice shall be sent by first class mail, postage prepaid, to such holder at such holder&#8217;s address as may be set forth in the Conversion Demand. On or before the Conversion Date, the holder of Series C Preferred Stock to be converted shall surrender the certificate or certificates representing such shares, duly indorsed for transfer accompanied by a duly executed stock power or other instrument of assignment, including a medallion seal if the Conversion Notice so provides, to the Corporation at any place set forth in such notice or, if no such place is so set forth, at the principal executive offices of the Corporation. As soon as practicable after the Conversion Date and the surrender of the certificate or certificates representing such shares, the Corporation shall issue and deliver to such holder, or its nominee, a certificate or certificates for the number of whole shares of Common Stock issuable upon such conversion in accordance with the provisions hereof. Upon surrender of certificates of Series C Preferred Stock to be converted in part, the Corporation shall issue a balance certificate representing the number of full shares of Series C Preferred Stock not so converted.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Effect of Conversion. </font>All outstanding shares of Series C Preferred Stock to be converted pursuant to the Conversion Notice shall, on the Conversion Date, be converted into Common Stock for all purposes, notwithstanding the failure of the holder thereof to surrender any certificate representing such shares on or prior to such date. On and after the Conversion Date, (i) no such share of Series C Preferred Stock shall be deemed to be outstanding or be transferable on the books of the Corporation or the stock transfer agent, if any, for the Series C Preferred Stock, and (ii) the holder of such shares, as such, shall not be entitled to receive any dividends or other distributions (other than any accrued dividends unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon), to receive notices or to vote such shares or to exercise or to enjoy any other powers, preferences or rights in respect thereof, other than the right, upon surrender of the certificate or certificates representing such shares, to receive a certificate or certificates for the number of shares of Common Stock into which such shares shall have been converted. On the Conversion Date, all such shares of Series C Preferred Stock shall be retired and canceled and shall not be reissued.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-4-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d) <font style="DISPLAY: inline; FONT-STYLE: italic">Adjustments to Conversion Price.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(A) The Conversion Price shall be adjusted from time to time as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;&#160;&#160;&#160;&#160;In case the Corporation shall pay or make a dividend or other distribution on any class of capital stock of the Corporation in Common Stock, the Conversion Price in effect at the opening of business on the day following the date fixed for the determination of stockholders entitled to receive such dividend or other distribution shall be reduced by multiplying such Conversion Price by a fraction of which the numerator shall be the number of shares of Common Stock outstanding immediately prior to any Common Stock dividend or distribution and the denominator shall be the sum of such number of shares of Common Stock outstanding immediately prior to any Common Stock dividend or distribution plus the total number of shares constituting such Common Stock dividend or other distribution, such reduction to become effective immediately after the opening of business on the day following the date fixed for such determination. For the purposes of this subparagraph (i), the number of shares of Common Stock at any time outstanding shall not include shares held in the treasury of the Corporation. The Corporation will not pay any dividend or make any distribution on shares of Common Stock held in the treasury of the Corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)&#160;&#160;In case outstanding shares of Common Stock shall be subdivided into a greater number of shares of Common Stock and the Series C Preferred Stock is not similarly subdivided, the Conversion Price in effect at the opening of business on the day following the day upon which such subdivision becomes effective shall be proportionately reduced, and, conversely, in case outstanding shares of Common Stock shall each be combined into a smaller number of shares of Common Stock and the Series C Preferred Stock is not similarly combined, the Conversion Price in effect at the opening of business on the day following the day upon which such combination becomes effective shall be proportionately increased, such reduction or increase, as the case may be, to become effective immediately after the opening of business on the day following the day upon which such subdivision or combination becomes effective.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)&#160;No adjustment in the Conversion Price shall be required unless such adjustment would require an increase or decrease of at least 1% of such price; provided, however, that any adjustments which by reason of this subparagraph (iii) are not required to be made shall be carried forward and taken into account in any subsequent adjustment.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-5-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iv)&#160;&#160;Whenever the Conversion Price is adjusted as herein provided, (x) the Corporation shall promptly file with any Conversion Agent a certificate of a firm of independent public accountants setting forth the Conversion Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment, and the manner of computing the same, which certificate shall be conclusive evidence of the correctness of such adjustment, and (y) a notice stating that the Conversion Price has been adjusted and setting forth the adjusted Conversion Price shall forthwith be given by the Corporation to any Conversion Agent and mailed by the Corporation to each holder of shares of Series C Preferred Stock at their last address as the same appears on the books of the Corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(B) In case of any consolidation of the Corporation with, or merger of the Corporation into, any other entity (other than a merger or consolidation in which the Corporation is the continuing corporation) or any sale or conveyance to another corporation of the property of the Corporation as an entirety or substantially as an entirety, or in the case of a statutory exchange of securities with another corporation, or any reclassification of shares, the Conversion Price shall not be adjusted but each holder of a share of Series C Preferred Stock then outstanding shall have the right thereafter to convert such share only into the kind and amount of securities, cash and other property which such holder would have owned or have been entitled to receive immediately after such consolidation, merger, sale, conveyance, exchange or reclassification had such share of Series C Preferred Stock been converted immediately prior to such consolidation, merger, sale, conveyance, exchange or reclassification. Provision shall be made in any such consolidation, merger, sale, conveyance, exchange or reclassification for adjustments in the Conversion Price which shall be as nearly equivalent as may be practicable to the adjustments provided for in Section (A). The above provisions shall similarly apply to successive consolidations, mergers, sales, conveyances, exchange or reclassification.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For purposes of this Section 4, &#8220;Common Stock&#8221; includes any stock of any class of the Corporation which has no preference in respect of dividends or of amounts payable in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation and which is not subject to redemption by the Corporation. However, subject to the provisions of paragraph (B) above, shares issuable on conversion of shares of Series C Preferred Stock shall include only shares of the class designated as Common Stock of the Corporation on the date of the initial issuance of Series C Preferred Stock by the Corporation, or shares of any class or classes resulting from any reclassification or reclassifications thereof and which have no preference in respect of dividends or of amounts payable in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation and which are not subject to redemption by the Corporation</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In case;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;&#160;&#160;&#160;&#160;the Corporation shall declare a stock split, stock dividend (or any other distribution) on its Common Stock that would cause an adjustment to the Conversion Price of the Series C Preferred Stock pursuant to the terms of subparagraph (i) of Paragraph (A) above; or</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)&#160;&#160;the Corporation shall authorize the granting to the holders of its Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any other rights; or</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-6-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)&#160;&#160;of any reclassification of the Common Stock of the Corporation (other than a subdivision or combination of its outstanding shares of Common Stock), or of any consolidation, merger or share exchange to which the Corporation is a party and for which approval of any stockholders of the Corporation is required, or of the sale or conveyance, of the property of the Corporation as an entirety or substantially as an entirety; or</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iv)&#160;&#160;of the voluntary or involuntary dissolution, liquidation or winding up of the Corporation;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">then the Corporation shall cause to be filed with any Conversion Agent, and shall cause to be mailed to all holders of shares of Series C Preferred Stock at each such holder&#8217;s last address as the same appears on the books of the Corporation, at least 20 days (or 10 days in any case specified in clause (i) or (ii) above) prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, rights or warrants, or, if a record is not to be taken, the date as of which the holders of Common Stock of record to be entitled to such dividend, distribution, rights or warrants are to be determined, or (y) the date on which such reclassification, consolidation, merger, share exchange, sale, conveyance, dissolution, liquidation or winding up is expected to become effective, and the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, share exchange, sale, conveyance, dissolution, liquidation or winding up. Neither the failure to give such notice nor any defect therein shall affect the legality or validity of the proceedings described in clauses (i) through (iv) above.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(C) All shares of Series C Preferred Stock converted as herein provided shall no longer be deemed to be outstanding and all rights with respect to such shares, including the rights, if any, to receive notices, to vote and to further accrual of dividends, if any, shall immediately cease and terminate upon such conversion (except only the right of the holder, thereof to receive shares of the Common Stock and cash in lieu of actual shares in exchange therefor pursuant to the term hereof).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5. <font style="FONT-WEIGHT: bold">Mandatory Conversion.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a) <font style="DISPLAY: inline; FONT-STYLE: italic">Trigger Events. </font>Beginning any time after the Series C Issuance Date, if the closing price of the sale of shares of Common Stock on the NYSE Amex (or the Corporation&#8217;s principal securities exchange, if other than the NYSE Amex) exceed $2.50 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock), for a period of twenty (20) out of thirty (30) consecutive trading days, and if the dollar value of the trading volume of the Common Stock for each day during such twenty (20) out of thirty (30) consecutive trading days equals or exceeds $250,000, the Corporation may require the holders of Series C Preferred Stock to convert the Preferred Stock to Common Stock, on ten (10) days notice (the &#8220;Mandatory Conversion Time&#8221;), based on the Conversion Price.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-7-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b) <font style="DISPLAY: inline; FONT-STYLE: italic">Procedural Requirements. </font>All holders of record of shares of Series C Preferred Stock shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Series C Preferred Stock pursuant to this Section 5. Upon receipt of such notice, each holder of shares of Series C Preferred Stock shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, including medallion seal, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Series C Preferred Stock converted pursuant to Section 5, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender the certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of their certificate or certificates (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this Section 5(b). As soon as practicable after the Mandatory Conversion Time and the surrender of the certificate or certificates (or lost certificate affidavit and agreement) for Series C Preferred Stock, the Corporation shall issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof, together with cash as provided in Section 11 in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the shares of Series C Preferred Stock converted. Such converted Series C Preferred Stock shall be retired and canceled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Series C Preferred Stock accordingly.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6. <font style="FONT-WEIGHT: bold">Redemption.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Optional Redemption. </font>Prior to the seventh anniversary of the Series C Issuance Date, the Corporation may at any time it may lawfully do so, at the option of the Board of Directors and after giving the holders of shares Series C Preferred Stock written notice of Directors and after giving the holders of shares of Series C Preferred Stock written notice thereof containing the redemption date (which date shall not be less than 20 days from the date of such notice) (the &#8220;Redemption Date&#8221;) and offering the holders of the shares of Series C Preferred Stock at least such 20 days to convert all such shares into shares of Common Stock pursuant to Section 4, redeem in whole, but not in part, all the shares of Series C Preferred Stock then outstanding by paying in cash, for each share, an amount equal to the sum of (i) the Original Series C Issue Price and (ii) all accrued but unpaid Annual Dividends on such share (such sum, as adjusted for any stock splits, dividends combinations, subdivisions, recapitalizations, reclassifications or the like, the &#8220;Optional Redemption Price&#8221;).</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-8-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Mandatory Redemption. </font>At any time following the seventh anniversary of the Series C Issuance Date, within sixty (60) days after the receipt by the Corporation of the written request of the holders of not less than a majority of the shares of Series C Preferred Stock then outstanding, the Corporation shall redeem all of the shares of Series C Preferred Stock (or, if less, the maximum amount it may lawfully redeem) by paying in cash, for each share, an amount equal to the sum of (i) the Original Series C Issue Price, and (ii) all accrued but unpaid Annual Dividends on such share (such sum, as adjusted for any stock splits, dividends combinations, subdivisions, recapitalizations, reclassifications or the like, the &#8220;Mandatory Redemption Price&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.&#160;&#160;<font style="FONT-WEIGHT: bold">Voting Rights</font>. Holders of shares of Series C Preferred Stock shall not be entitled to vote, as a separate class or otherwise on any matter, and their consent shall not be required for any corporate action, except as otherwise required by law or as expressly provided in this Certificate of Designations or the Certificate of Incorporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.&#160;&#160;<font style="FONT-WEIGHT: bold">Amendments</font>. For so long as any shares of Series C Preferred Stock remain outstanding, consent of the holders of at least a majority of the then outstanding shares of the Series C Preferred Stock voting together as a class shall be required for any amendment to this Certificate of Designations or any waivers of the rights of the holders of shares of Series C Preferred Stock or under any other agreement to which all of the holders of shares of Series C Preferred Stock are a party.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.&#160;&#160;<font style="FONT-WEIGHT: bold">Restrictions on Transfer</font>. Each certificate representing shares of Series C Preferred Stock and each certificate representing shares of Common Stock issuable upon conversion of any shares of Series C Preferred Stock shall be stamped or otherwise imprinted with a legend in substantially the following form:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;THE SHARES REPRESENTED BY THIS CERTIFICATE AND ANY SHARES ACQUIRED UPON THE CONVERSION OF THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND MAY NOT BE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SUCH ACT, EXCEPT UNDER CIRCUMSTANCES WHERE NEITHER SUCH REGISTRATION NOR SUCH AN EXEMPTION IS REQUIRED BY LAW.&#8221;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.&#160;&#160;<font style="FONT-WEIGHT: bold">Reservation of Shares</font>. The Corporation shall at all times reserve and keep available, out of its authorized and un-issued shares of Common Stock, solely for the purpose of effecting the conversion of the Series C Preferred Stock, including shares of Series C Preferred Stock issued as payment of dividends, such number of shares of its Common Stock as shall be sufficient to effect the conversion of all shares of Series C Preferred Stock from time to time outstanding.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-9-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11.&#160;&#160;<font style="FONT-WEIGHT: bold">Fractional Shares</font>. No fractional shares of Common Stock shall be issued upon conversion of the Series C Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board of Directors of the Corporation, or it may round to the nearest number of whole shares, in the Board&#8217;s sole discretion. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Series C Preferred Stock the holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Severability of Provisions. </font>Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof. If a court of competent jurisdiction should determine that a provision hereof would be valid or enforceable if a period of time were extended or shortened or a particular percentage were increased or decreased, then such court may make such change as shall be necessary to render the provision in question effective and valid under applicable law.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13.&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Status of Reacquired Shares. </font>Shares of Series C Preferred Stock issued and reacquired by the Corporation (including, without limitation, shares of Series C Preferred Stock which have been converted into Common Stock) shall have the status of authorized and unissued shares of Preferred Stock, undesignated as to series, subject to later issuance.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14.&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Preemptive Rights. </font>Holders of shares of Series C Preferred Stock are not entitled to any preemptive or subscription rights in respect to any securities of the Corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">FURTHER RESOLVED, </font>that the statements contained in the foregoing resolutions creating and designating the said Series C issue of Preferred Stock and fixing the number, voting tights, powers, preferences and relative, optional, participating, and other special rights and the qualifications, limitations, restrictions, and other distinguishing characteristics thereof shall, upon the effective date of said series, be deemed to be included in and be a part of the Certificate of Incorporation of the Corporation pursuant to the provisions of Sections 104 and 151 of the General Corporation Law of the State of Delaware.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-10-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">IN WITNESS WHEREOF, </font>NeoStem Inc. has caused this Certificate to be signed on its behalf by its Chief Executive Officer, this 29<font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font></font> day of&#160;&#160;October, 2009.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEOSTEM, INC.</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="22%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;Robin L. Smith</font></td>
<td valign="top" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="22%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name: Robin L. Smith</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" nowrap valign="top" width="22%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title: Chief Executive Officer</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-11-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">State of Delaware</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Secretary of State</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Division of Corporations</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Delivered 02:26 PM 12/09/2009</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">FILED 02:24 PM 12/09/2009</font></div>
</td>
</tr><tr>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">SRV 091083008 - 0899444 FILE</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">STATE OF DELAWARE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">CERTIFICATE OF CORRECTION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Neostem, Inc.,&#160;a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DOES HEREBY CERTIFY:</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.</font></div>
</td>
<td align="left" colspan="2" valign="top" width="27%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The name of the corporation is</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Neostem, Inc.</font></font></td>
</tr><tr>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-FAMILY: times new roman">2.</font></div>
</td>
<td colspan="2" valign="top" width="27%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">That a Certificate of</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Designation </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">of </font><font style="DISPLAY: inline">Series C Convertib</font>l<font style="DISPLAY: inline">e </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Preferred </font><font style="DISPLAY: inline">Stock</font></font></td>
</tr><tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="27%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;(Title of Certificate Being Corrected)</font></td>
</tr><tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="93%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">was filed by the Secretary of State of Delaware on </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">October </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman">30, 2009 </font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">and that said Certificate requires correction as permitted </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman">by </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">Section 103 of the General Corporation Law of the State of Delaware.</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.</font></div>
</td>
<td align="left" colspan="2" valign="top" width="93%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The inaccuracy or defect of said Certificate is: (must <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">be </font>specific)</font></div>
</td>
</tr><tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="93%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">in Article </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman">2 </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">Dividends and Distributio</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">ns section </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman">(a) </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">Amount on </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman">page 2 </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">there is </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman">a date </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">missing in the </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman">paragraph.</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.</font></div>
</td>
<td align="left" colspan="2" valign="top" width="93%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Article 2(<font style="DISPLAY: inline">a) </font>of the Certificate is corrected to read as follows:</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="93%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Please see Rider 1 attached hereto.</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="93%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="93%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-WEIGHT: bold">IN WITNESS WHEREOF</font>, said corporation has caused this Certificate of Correction this 12 day of <font style="DISPLAY: inline">November,</font> A.D. <font style="DISPLAY: inline">2009</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td align="left" valign="top" width="40%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ Catherine M. Vaczy</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="40%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Authorized Officer</font></div>
</td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:</font></div>
</td>
<td valign="top" width="40%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Catherine M. Vaczy</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="40%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Print or Type</font></div>
</td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
</td>
<td align="left" valign="top" width="40%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vice President and General Counsel</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Rider 1 to Certificate of Correction.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Article 2. Dividends and Distributions</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a) <font style="DISPLAY: inline; FONT-STYLE: italic">Amount. </font>The holders of shares of Series C Preferred Stock shall be entitled to receive an annual dividend of 5% of the Agreed Stated Value (the &#8220;Annual Dividend&#8221;), payable annually on the first day of January (the &#8220;Annual Dividend Payment Date&#8221;). Payment of the Annual Dividend may be either in cash or in kind as determined by the Board of Director. In the event that the Annual Dividend Payment Date shall fall due on a Saturday, Sunday or legal holiday in the State of Delaware, the dividend due on such date shall be paid on the next day thereafter that is not a Saturday, Sunday or legal holiday in the State of Delaware. The Annual Dividend shall be cumulative and shall <font style="FONT-STYLE: normal">begin </font><font style="DISPLAY: inline; FONT-STYLE: italic"><font style="FONT-STYLE: normal">to</font> </font>accrue on outstanding shares of Series C Preferred Stock from and after October 30, 2009 (the &#8220;Series C Issuance Date&#8221;) on a daily basis computed on the basis of a 365-day year and compounded annually whether or not the Corporation shall have assets legally available therefore.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">State of Delaware</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Secretary of State</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Division of Corporations</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Delivered 10:30 AM 11/18/2010</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">FILED 10:30 AM 11/18/2010</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">SRV 101100631 - 0899444 FILE</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CERTIFICATE OF ELIMINATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">OF THE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SERIES C CONVERTIBLE PREFERRED STOCK</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">OF</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEOSTEM, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware, it is hereby certified that:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;&#160;&#160;&#160;The name of the corporation is NeoStem, Inc. (hereinafter referred to as the&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Corporation&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;&#160;&#160;&#160;&#160;The designation of the series of shares of stock of the Corporation to which this certificate relates is &#8220;Series C Convertible Preferred Stock.&#8221;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;&#160;&#160;&#160;&#160;Pursuant to Section 151 of the General Corporation Law of the State of Delaware and authority granted in the certificate of incorporation of the Corporation (the &#8220;Certificate of Incorporation&#8221;), the Board of Directors of the Corporation previously designated 8,177,512 shares of preferred stock as Series C Convertible Preferred Stock, par value $0.01 per share (the &#8220;Series C Convertible Preferred Stock&#8221;), and established the voting powers, designations, preferences, and the relative, participating, optional, or other rights, and the qualifications, limitations, and restrictions of such series as set forth in the Certificate of Designations of Series C Convertible Preferred Stock of NeoStem, Inc. (the &#8220;Series C Certificate of Designations&#8221;), with respect to such Series C Convertible Preferred Stock, which Series C Certificate of Designations has been heretofore filed with the Secretary of State of the State of Delaware. None of the authorized shares of Series C Convertible Preferred Stock are outstanding and none will be issued subject to the Series C Certificate of Designations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.&#160;&#160;&#160;&#160;&#160;&#160;The Board of Directors of the Corporation has duly adopted the following </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">resolutions, which resolutions remain in full force and effect as of the date hereof:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">RESOLVED</font>, that none of the authorized shares of Series C Convertible Preferred Stock are outstanding, and that none will be issued subject to the Series C Certificate of Designations, and</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">FURTHER RESOLVED</font>, that pursuant to the authority conferred on the Board of Directors by the provisions of Section 151 of the General Corporation Law of the State of Delaware, the Board of Directors hereby eliminates the Series C Convertible Preferred Stock, and</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">FURTHER RESOLVED</font><font style="FONT-WEIGHT: bold">,</font> that the appropriate officers of the Corporation, or any one or more of them, are hereby authorized, in the name and on behalf of the Corporation, pursuant to Section 151(g) of the General Corporation Law of the State of Delaware, to execute and file a Certificate of Elimination of the Series C Convertible Preferred Stock of NeoStem, Inc. with the Secretary of State of the State of Delaware, which shall have the effect when filed with the Secretary of State of the State of Delaware of eliminating from the Certificate of Incorporation all matters set forth in the Series C Certificate of Designations with respect to such Series C Convertible Preferred Stock, and</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">FURTHER RESOLVED</font><font style="FONT-WEIGHT: bold">,</font> that in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware, the Certificate of Incorporation is hereby amended to eliminate all references to the Series C Convertible Preferred Stock, and the shares that were designated to such series hereby are returned to the status of authorized but unissued shares of the preferred stock of the Corporation, without designation as to series.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Signed on November 18, 2010</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEOSTEM, INC.</font></div>
</td>
</tr><tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="37%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="60%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td align="left" valign="top" width="37%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ <font style="DISPLAY: inline; FONT-SIZE: 10pt">Robin Smith</font></font></div>
</td>
</tr><tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name: Robin Smith</font></div>
</td>
</tr><tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title: CEO</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">State of Delaware</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Secretary of State</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Division of Corporations</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Delivered 10:30 AM 11/18/2010</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">FILED 10:31 AM 11/18/2010</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">SRV 101100633 - 0899444 FILE</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATE OF ELIMINATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OF THE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SERIES D CONVERTIBLE REDEEMABLE PREFERRED STOCK</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OF</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEOSTEM, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware, it is hereby certified that:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;The<font style="DISPLAY: inline; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">&#160;</font>name of the corporation is NeoStem, Inc. (hereinafter sometimes referred to as the &#8220;Corporation&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;&#160;The designation of the series of shares of stock of the Corporation to which this certificate relates is &#8220;Series D Convertible Redeemable Preferred Stock.&#8221;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;&#160;Pursuant to Section 151 of the General Corporation Law of the Stale of Delaware and authority granted in the certificate of incorporation of the Corporation (the &#8220;Certificate of Incorporation&#8221;), the Board of Directors of the Corporation previously designated 1,600,000 shares of preferred stock as Series D Convertible Redeemable Preferred Stock, par value $0.01 per share (the &#8220;Series D Convertible Redeemable Preferred Stock&#8221;), and established the voting powers, designations, preferences, and the relative, participating, optional, or other rights, and the qualifications, limitations, and restrictions of such series as set forth in the Certificate of Designation of Series D Convertible Redeemable Preferred Stock of NeoStem, Inc. (the &#8220;Series D Certificate of Designations&#8221;), with respect to such Series D Convertible Redeemable Preferred Stock, which Series D Certificate of Designations has been heretofore filed with the Secretary of State of the State of Delaware. None of the authorized shares of Series D Convertible Redeemable Preferred Stock are outstanding and none will be issued subject to the Series D Certificate of Designations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.&#160;&#160;&#160;The Board of Directors of the Corporation has duly adopted the following resolutions, which resolutions remain in full&#160;force and effect as of the date hereof:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">RESOLVED</font><font style="FONT-WEIGHT: bold">,</font> that none of the authorized shares of Series D Convertible Redeemable Preferred Stock are outstanding, and that none will be issued subject to the Series D Certificate of Designations, and</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">FURTHER RESOLVED</font><font style="FONT-WEIGHT: bold">,</font> that pursuant to the authority conferred on the Board of Directors by the provisions of Section 151 of the General Corporation Law of the State of Delaware, the Board of Directors hereby eliminates the Series D Convertible Redeemable Preferred Stock, and</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">FURTHER RESOLVED</font><font style="FONT-WEIGHT: bold">,</font> that the appropriate officers of the Corporation, or any one or more of them, are hereby authorized, in the name and on behalf of the Corporation, pursuant to Section 151(g) of the General Corporation Law of the State of Delaware, to execute and file a Certificate of Elimination of the Series D Convertible Redeemable Preferred Stock of NeoStem, Inc. with the Secretary of State of the State of Delaware, which shall have the effect when filed with the Secretary of State of the State of Delaware of eliminating from the Certificate of Incorporation all matters set forth in the Series D Certificate of Designations with respect to such Series D Convertible Redeemable Preferred Stock, and</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">FURTHER RESOLVED</font><font style="FONT-WEIGHT: bold">,</font> that in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware, the Certificate of Incorporation is hereby amended to eliminate all references to the Series D Convertible Redeemable Preferred Stock, and the shares that were designated to such series hereby are returned to the status of authorized but unissued shares of the preferred stock of the Corporation, without designation as to series.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Signed on November 18, 2010</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEOSTEM, INC.</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="55%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="37%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ Robin Smith</font></div>
</td>
<td valign="top" width="5%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name: Robin Smith</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title: CEO</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">State of Delaware</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Secretary of State</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Division of Corporations</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Delivered 10:30 AM 11/18/2010</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">FILED 10:31 AM 11/18/2010</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">SRV 101100633 - 0899444 FILE</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATE OF DESIGNATIONS OF THE POWERS, PREFERENCES </font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AND RELATIVE, PARTICIPATING, OPTIONAL AND OTHER </font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SPECIAL RIGHTS OF PREFERRED STOCK AND QUALIFICATIONS, </font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LIMITATIONS AND RESTRICTIONS THEREOF</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SERIES E 7% SENIOR CONVERTIBLE PREFERRED STOCK</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">for</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEOSTEM, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">NEOSTEM, INC</font><font style="FONT-WEIGHT: bold">.,</font> a Delaware corporation (the &#8220;Corporation&#8221;), pursuant to the provisions of Section 151 of the General Corporation Law of the State of Delaware, does hereby make this Certificate of Designations and does hereby state and certify that pursuant to the authority expressly vested in the Board of Directors of the Corporation by the Certificate of Incorporation of the Corporation, the Board of Directors duly adopted the following resolutions, which resolutions remain in full force and effect as of the date hereof:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">RESOLVED</font><font style="FONT-WEIGHT: bold">,</font> that, pursuant to Article Fourth of the Certificate of incorporation of the Corporation, the Board of Directors hereby authorizes the issuance of, and fixes the designation and preferences and relative, participating, optional and other special rights, and qualifications, limitations and restrictions, of a series of Preferred Stock consisting of 10,582,011 shares, par value $0.01 per share, to be designated &#8220;Series E 7% Senior Convertible Preferred Stock&#8221; (the &#8220;Preferred Shares&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">RESOLVED</font><font style="FONT-WEIGHT: bold">,</font> that each of the Preferred Shares shall rank equally in all respects and shall be subject to the following terms and provisions:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">1. <font style="TEXT-DECORATION: underline">Certain Defined Terms</font></font><font style="FONT-WEIGHT: bold">.</font>&#160;&#160;For purposes of this Certificate of Designations, the following terms shall have the following meanings:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#8220;Bloomberg&#8221; means Bloomberg Financial Markets.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#8220;Business Day&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in the City of New York are authorized or required by law to remain closed.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#8220;Common Stock&#8221; means the common stock, par value $0,001 per share, of the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#8220;Common Shares&#8221; means fully paid, validly issued and non-assessable shares of Common Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)&#160;&#160;&#8220;Dollar Volume Limitation&#8221; means fifteen percent (15%) of the aggregate dollar trading volume of the Common Stock on the NYSE Amex Equities (or other applicable Trading Market) over the twenty-two (22) consecutive Trading Day period ending on the Trading Day immediately preceding the date of the Mandatory Redemption Notice (as defined below) or Optional Redemption Notice (as defined below), as applicable. For the purposes of this section the term &#8220;dollar trading volume&#8221; for any Trading Day shall be determined by multiplying the Daily VWAP by the volume as reported on Bloomberg for such Trading Day.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(f) &#8220;Daily VWAP&#8221; means, for any date, (i) the daily volume weighted average price of the Common Stock for such date on the NYSE Amex Equities as reported by Bloomberg (based on a Trading Day from 9:30 a.m. New York City Time to 3:59 p.m. New York City Time); (ii) if the Common Stock is not then listed on the NYSE Amex Equities, the daily volume weighted average price of the Common Stock for such date on such other Trading Market where the Common Stock is then listed as reported by Bloomberg (based on a Trading Day from 9:30 a.m. New York City Time to 3:59 p.m. New York City Time); (iii) if the foregoing do not apply, the volume weighted average price of the Common Stock in the over-the-counter market on the electronic bulletin board for the Common Stock as reported by Bloomberg, or, if no volume weighted average price is reported for such security by Bloomberg, the highest bid as reported on the &#8220;pink sheets&#8221; by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.) at the close of trading; or (iv) in all other cases, the fair market value of a share of Common Stock as determined by an<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>independent appraiser selected in good faith by the Required Holders and reasonably acceptable to the Corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(g) &#8220;Equity Conditions&#8221; means each of the following: (i) on each day during the Equity Conditions Measuring Period, all Common Shares to be issued on the applicable Mandatory Redemption Date (or such other date on or event for which the Equity Conditions are required to be satisfied) shall be eligible for resale by the Holder without restriction and without need for additional registration under any applicable federal or state securities laws, and the Corporation shall have no knowledge of any fact that would cause any Common Shares not to be so eligible for resale by the Holder without restriction and without need for additional registration under any applicable federal or state securities laws; (ii) on each day during the Equity Conditions Measuring Period, the Common Shares arc designated for listing on a Trading Market and shall not have been suspended from trading on such Trading Market nor shall delisting or suspension by such exchange or market have been threatened or pending in writing by such exchange nor shall there be any Securities and Exchange Commission (&#8220;SEC&#8221;) or judicial stop trade order or trading suspension stop order; (iii) any Common Shares to be issued in connection with the applicable Mandatory Redemption Date (or such other date on or event for which the Equity Conditions are required to be satisfied) may be issued in full without violating the rules or regulations of the Trading Market or any applicable laws; <font style="DISPLAY: inline; FONT-STYLE: italic"><font style="FONT-STYLE: normal">(iv)</font> </font>on each day during the Equity Conditions Measuring Period, there shall not have occurred and be continuing, unless waived by the Holder, either (A) a Trigger Event (as defined below) or (B) an event that with the passage of time or giving of notice would constitute a Trigger Event; (v) on each day during the Equity Conditions Measuring Period, the Corporation has not provided any Holder with any non-public information in breach of Section 3.8 of the Purchase Agreement; (vi) on each day during the Equity Conditions Measuring Period, neither the Registration Statement (as defined in the Purchase Agreement) nor the Prospectus (as defined in the Purchase Agreement) nor any Prospectus Supplements (as defined in the Purchase Agreement) contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading and such Registration Statement, such Prospectus and such Prospectus Supplements comply with all applicable securities laws as to form and substance (unless all Common Shares issuable on the applicable Mandatory Redemption Date (or such other date requiring payment in Common Shares) may be resold by the Holder pursuant to Rule 144 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) without volume limitations or any public information requirements or such other exemption from registration that would permit the Holder to resell such Common Shares without restriction and without need for additional registration under any securities laws); (vii) the Corporation&#8217;s transfer agent for the Common Shares is participating in the Depository Trust Company (&#8220;DTC&#8221;) Fast Automated Securities Transfer Program; and (ix) all Common Shares to be issued in connection with the applicable Mandatory Redemption Date (or such other date on or event for which the Equity Conditions are required to be satisfied) are duly authorized and will be validly issued, fully paid and non-assessable upon issuance, free and clear of all liens, claims or encumbrances, and the issuance thereof will not require any further approvals of the Corporation&#8217;s Board of Directors or stockholders. All references to the &#8220;Registration Statement&#8221; or &#8220;Prospectus&#8221; shall include any amendments or supplements thereto, as filed from time to time, including, without limitation, any Exchange Act (as defined below) filings incorporated by reference.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(h)&#160;&#160;&#8220;Equity Conditions Measuring Period&#8221; means the period beginning twenty (20) Trading Days prior to the applicable Mandatory Redemption Date (or such other date on or event for which the Equity Conditions are required to be satisfied) and ending on and including such Mandatory Redemption Date. For the avoidance of doubt, the Equity Conditions Measuring Period for each Mandatory Redemption Date shall include the Stock Payment Pricing Period and such Mandatory Redemption Date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;&#160;&#160;&#160;&#8220;Equity Line&#8221; means (i) the Common Stock Purchase Agreement, dated May 19, 2010, by and between the Corporation and Commerce Court Small Cap Value Fund, Ltd. and the transactions contemplated thereby and/or (ii) any other similar agreement, contract, arrangement or understanding commonly known as an &#8220;equity line&#8221; between the Corporation and any person.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(j) &#8220;Excluded Securities&#8221; means (a) Common Shares or Common Stock Equivalents issued pursuant to a stock option plan that has been approved by the Board of Directors and stockholders of the Corporation, pursuant to which the Corporation&#8217;s securities may be issued only to a person eligible for award under such plan, (b) Common Shares or Common Stock Equivalents issued to employees or consultants (including in connection with investor relations activities) for compensatory purposes, (c) Common Shares or Common Stock Equivalents issued upon the exercise or conversion of Common Stock Equivalents outstanding on the date hereof, (d) Common Shares or Common Stock Equivalents issued to investors in the common stock and warrant offering contemplated by Section 4.2(i) of the Purchase Agreement, (e) Common Shares or Common Stock Equivalents issued in the pending transaction with Progenitor Cell Therapy, LLC (&#8220;Progenitor&#8221;) as currently contemplated by that certain Agreement and Plan of Merger, dated September 23, 2010, by and among the Corporation, NBS Acquisition Company LLC and Progenitor (the &#8220;Merger Agreement&#8221;), (f) Common Shares or Common Stock Equivalents issued in the transactions contemplated by the Purchase Agreement, including pursuant to the Certificate of Designations or the Warrants, and (g) Common Shares or Common Stock Equivalents issued or deemed to be issued in connection with any acquisition by the Corporation, whether through a merger, an acquisition of stock or an acquisition of assets, or a license, of any business, product, assets or technologies, or any strategic partnership, strategic investment or joint venture involving any technology or product, or any other transaction the primary purpose of which is not to raise capital; provided however, that the number of Common Shares which may be issued pursuant to this clause (g) in any transaction, or series of related transactions, shall not exceed 33% of the number of Common Shares outstanding immediately prior to any such transaction.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(k) &#8220;Holder&#8221; means each holder of the Preferred Shares.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(l) &#8220;Initial Issuance Date&#8221; means November 19, 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(m) <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8220;</font>Mandatory Redemption Shares&#8221; means, with respect to (a) any Mandatory Redemption Date (other than the Maturity Date) an amount equal to l/27<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> of the Preferred Shares initially issued pursuant to the Purchase Agreement (regardless of whether any Holder has converted any shares of Preferred Stock pursuant to Section 7 or the Corporation has optionally redeemed any shares of Preferred Stock pursuant to Section 8) and (b) the Maturity Date, all outstanding Preferred Shares.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(n) &#8220;Mandatory Redemption Date&#8221; means March 19, 2011, and the 19th day of each calendar month thereafter (or the next Trading Day thereafter) and ending on and including the Maturity Date. Notwithstanding anything contained herein to the contrary and for all purposes hereunder, the Maturity Date shall be deemed to be a Mandatory Redemption Date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(o) &#8220;Maturity Date&#8221; means May 20, 2013.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(p) &#8220;Purchase Agreement&#8221; means the Securities Purchase Agreement, of even date herewith, by and among the Corporation and the initial purchasers of Preferred Shares </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">thereunder.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(q) &#8220;Required Holders&#8221; means the Holders of Preferred Shares representing at least a majority of the aggregate Preferred Shares then outstanding.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(r) &#8220;Stock Payment Price&#8221; means, with respect to any date when any amount hereunder is due and payable, that price which shall be computed as 92% of the arithmetic average of the five lowest Daily VWAPs of the Common Shares during the Stock Payment Pricing Period. All such determinations will be appropriately adjusted for any stock split, stock dividend, stock combination or other similar transaction.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(s) &#8220;Stock Payment Pricing Period&#8221; means, with respect to any Mandatory Redemption Date or any other date when any amount hereunder is due and payable, the twenty (20) Trading Days immediately prior to such date. For the avoidance of doubt, the Stock Payment Pricing Period does not include the Mandatory Redemption Date or such other date when any amount hereunder is due and payable.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(t) &#8220;Subsidiaries&#8221; shall have the meaning as set forth in the Purchase Agreement.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(u) &#8220;Trading Day&#8221; means 9:30AM to 3:59PM on any day on which the Common Shares are traded on a Trading Market, or, if the Common Shares are not so traded, a Business Day.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(v) &#8220;Trading Market&#8221; means the NYSE Amex Equities, the New York Stock Exchange or the NASDAQ Global Select Market, the NASDAQ Global Market or the NASDAQ Capital Market.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(w) <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8220;</font>Tax&#8221; means any tax, levy, impost, duty or other charge or withholding of a similar nature (including any related penalty or interest).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(x) &#8220;Tax Deduction&#8221; means a deduction or withholding for or on account of Tax from a payment under this Certificate of Designations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(y) &#8220;Transfer Agent&#8221; means Continental Stock Transfer or such other person designated by the Corporation as the transfer agent for the Common Shares.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(z)</font> </font>&#8220;Warrants&#8221; shall have the meaning as set forth in the Purchase Agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">2. <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Designation</font></font>. There is hereby created out of the authorized and unissued shares of preferred stock of the Corporation a series of preferred stock designated as the &#8220;Series E 7% Senior Convertible Preferred Stock&#8221; (the &#8220;Preferred Stock&#8221;). The number of shares constituting such series shall be 10,582,011.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">3.&#160;&#160;&#160;&#160;<font style="TEXT-DECORATION: underline">Cumulative Dividends</font></font>. The Holders of the Preferred Shares shall be entitled to receive dividends payable in cash (or, at the Corporation&#8217;s option in Common Shares pursuant to Section 6) on the Liquidation Preference (as defined below) of such Preferred Share at the per share rate of seven percent (7%) per annum, which shall be cumulative. Dividends on the Preferred Shares shall commence accruing on the Initial Issuance Date and shall be computed on the basis of a 360-day year of twelve 30-day months. Dividends shall be payable in arrears on each Mandatory Redemption Date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">4.&#160;&#160;&#160;&#160;<font style="TEXT-DECORATION: underline">Liquidation Preference</font></font>. In the event of any liquidation, dissolution or winding up of the Corporation, either voluntary or involuntary (a &#8220;Liquidation Event&#8221;), the Holders of the Preferred Shares shall be entitled to receive, out of the assets of the Corporation available for distribution to stockholders (&#8220;Liquidation Funds&#8221;), prior and in preference to any distribution of any assets of the Corporation to the holders of any other class or series of equity securities, the amount of one dollar ($1.00) per share plus all accrued but unpaid dividends (the &#8220;Liquidation Preference&#8221;). After payment of the full amount of the Liquidation Preference, in the case of a Liquidation Event, the Holders will not be entitled to any further participation in any distribution of assets of the Corporation; provided that the foregoing shall not affect any rights which Holders may have with respect to any requirement that the Corporation repurchase the Preferred Shares or for any right to monetary damages. All the preferential amounts to be paid to the Holders of the Preferred Shares under this Section 4 shall be paid or set apart for payment before the payment or setting apart for payment of any amount for, or the distribution of any Liquidation Funds of the Corporation to the holders of shares of other classes or series of preferred stock of the Corporation junior in rank to the Preferred Shares in connection with a Liquidation Event. A Change of Control (as defined below) shall not, <font style="DISPLAY: inline; FONT-STYLE: italic">ipso facto<font style="FONT-STYLE: normal">,</font> </font>be deemed a Liquidation Event.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">5.</font>&#160;&#160;&#160;&#160;<font style="TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Issuance of</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">Preferred </font>Shares</font></font>.&#160;&#160;The Preferred Shares shall be issued by the Corporation pursuant to the Purchase Agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.</font>&#160;&#160;&#160;&#160;&#160;<font style="TEXT-DECORATION: underline">Mandatory <font style="DISPLAY: inline; FONT-WEIGHT: bold">Monthly</font> Redemption</font><font style="FONT-WEIGHT: normal">.</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">General. </font>On each applicable Mandatory Redemption Date, the Corporation shall redeem the Mandatory Redemption Shares at an aggregate redemption price equal to the sum of (x) the product of (A) the Liquidation Preference and (B) the number of Mandatory Redemption Shares required to be redeemed on such Mandatory Redemption Date plus (y) any and all accrued but unpaid dividends on all of the outstanding Preferred Shares (the &#8220;Mandatory Redemption Price&#8221;). Subject to Section 6(g), the Mandatory Redemption Price shall be payable, at the Corporation&#8217;s option, in cash or Common Shares or any combination of cash and Common Shares, subject to the provisions of this Section 6; provided, however, that no portion of the Mandatory Redemption Price may be paid in Common Shares unless the Equity Conditions are satisfied or waived by the Required Holders in writing prior to delivery of the applicable Mandatory Redemption Notice (as defined below); provided, further, however, that the portion of the applicable Mandatory Redemption Price that the Corporation elects to pay in Common Shares (if any) shall not exceed the Dollar Volume Limitation (unless waived by the Required Holders in writing).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Mandatory Redemption Notice. </font>On a date not less than twenty-two (22) Trading Days, but in no event more than twenty-five (25) Trading Days, prior to each Mandatory Redemption Date (the &#8220;Mandatory Redemption Notice Date&#8221;), the Corporation shall deliver a written notice (a &#8220;Mandatory Redemption Notice&#8221;) to the Holders, which shall either: (i) confirm that the entire applicable Mandatory Redemption Price shall be paid in cash; or (ii) (A) state that the Corporation elects to pay all or a portion of the Mandatory Redemption Price in Common Shares, (B) specify the portion that the Corporation elects to pay in cash (expressed in dollars) (such amount, the &#8220;Cash Payment Amount&#8221;) and the portion that the Corporation elects to pay in Common Shares (expressed in dollars) (such portion a &#8220;Stock Payment Amount&#8221;), which amounts when added together must equal the applicable Mandatory Redemption Price, (C) certify that the Equity Conditions are then satisfied (or waived by the Required Holders), (D) state the Dollar Volume Limitation (expressed in dollars) and certify that the Stock Payment Amount does not exceed such Dollar Volume Limitation and (E) certify that the Maximum Share Amount (as defined below) has not been exceeded. If (x) the Corporation does not timely deliver a Mandatory Redemption Notice in accordance with this Section 6(b) or (y) the Equity Conditions are not satisfied (unless waived by the Required Holders), then the Corporation shall be deemed to have delivered, a Mandatory Redemption Notice electing to pay the entire Mandatory Redemption Price in cash. Any Cash Payment Amount shall be paid in accordance with Section 6(c) and any Stock Payment Amount shall be paid in accordance with Section 6(d).</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each Mandatory Redemption Notice, whether actually given or deemed given, shall be irrevocable.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Mechanics of Cash Payment. </font>On each Mandatory Redemption Date, to the extent that the Corporation elects to pay all or any portion of the Mandatory Redemption Price in cash, then the Corporation shall pay all or such portion of the Mandatory Redemption Price, as applicable, by wire transfer of immediately available funds in accordance with the wire instructions of each Holder provided to the Corporation in writing. If the Corporation fails to pay such portion of the Mandatory Redemption Price (&#8220;Cash Payment Failure&#8221;) to be paid in cash on the applicable Mandatory Redemption Date (the &#8220;Applicable Cash Payment&#8221;), then the Corporation shall pay damages to the Holder for each day after such Mandatory Redemption Date in an amount in equal to two percent (2%) of such Applicable Cash Payment, but in no event in excess of twenty-four percent (24%) (&#8220;Cash Payment Liquidated Damages&#8221;). Notwithstanding the foregoing, the Corporation shall only be liable for Cash Payment Liquidated Damages to the extent that there is more than one (1) Cash Payment Failure in any twelve (12) month period. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&#8217;s failure to timely pay any Applicable Cash Payment as required pursuant to the terms hereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Mechanics of Stock Payment.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 54pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;&#160;&#160;&#160;To the extent that the Corporation elects (or is required pursuant to Section 6(g)) to pay all or any portion of the applicable Mandatory Redemption Price in Common Shares, the applicable Stock Payment Amount shall be paid as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(A) twenty-one (21) Trading Days prior to the applicable Mandatory Redemption Date (the &#8220;First Advance Date&#8221;), the Corporation shall deliver to the Holders a number of Common Shares determined by dividing (x) the Stock Payment Amount for such Mandatory Redemption Date by (y) ninety-two percent (92%) of the Daily VWAP on the Trading Day immediately preceding such Advance Date (the &#8220;First Advance Shares&#8221;);</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(B) eleven (11) Trading Days prior to the applicable Mandatory Redemption Date (the &#8220;Second Advance Date&#8221; and together with the First Advance Date, the &#8220;Advance Dates&#8221; and each, an &#8220;Advance Date&#8221;), the Corporation shall deliver to the Holders a number of Common Shares equal to the positive difference (if any) between (x) the quotient of (1) the Stock Payment Amount and (2) ninety-two percent (92%) of the average of the five lowest Daily VWAPs during the first (10) ten Trading Days of the applicable Stock Payment Pricing Period and (y) the number of First Advance Shares delivered to the Holders pursuant to 6(d)(i)(B) in connection with such Mandatory Redemption Date (the &#8220;Second Advance Shares&#8221; and together with the First Advance Shares, the &#8220;Advance Shares&#8221;). For the avoidance of doubt, to the extent that the difference between clauses (x) and (y) is a negative number the Corporation shall not be required to deliver any Common Shares to the Holders pursuant to this Section&#160;6(d)(i)(B); and</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(C) not later than three (3) Trading Days after the applicable Mandatory Redemption Date, the Corporation shall deliver an additional number of Common Shares (the &#8220;True-Up Shares&#8221;), if any, to the Holders equal to the positive difference between (a) the Stock Payment Amount divided by the Stock Payment Price for such Mandatory Redemption Date and (b) the Advance Shares; provided; however, that if clause (b) exceeds clause (a), then each Holder shall return its pro rata portion of such excess number of Common Shares to the Corporation, and such excess shares shall immediately be deemed cancelled effective as of the applicable Mandatory Redemption Date, For the avoidance of doubt, no Holder shall have any liability to the Corporation to the extent that any Advance Shares that are returned to the Corporation pursuant to the immediately preceding sentence decrease in value following the applicable Advance Date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 54pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)&#160; &#160;Notwithstanding any other provision of this Section 6(d), to the extent that the Corporation elects to pay all or any portion of the applicable Mandatory Redemption Price in Common Shares:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(A) to the extent that the aggregate number of Advance Shares or True-Up Shares to be delivered to a Holder pursuant to this Section 6(d) in respect of any individual Stock Payment Amount would cause such Holder to exceed the Beneficial Ownership Limitation (as defined below), then, (I) the Holder shall provide written notice to the Corporation that such delivery of all or a portion of the Advance Shares or True-Up Shares would cause such Holder to exceed the Beneficial Ownership Limitation, and (II) in addition to delivery of the number of Advance Shares or True-Up Shares that would not cause such Holder to exceed the Beneficial Ownership Limitation, the Corporation shall pay to such Holder in lieu of such number of Advance Shares or True-Up Shares that would cause such Holder to exceed the Beneficial Ownership Limitation (such excess number of shares, the &#8220;Excess Shares&#8221;), not more than the later of three (3) Trading Days after the Mandatory Redemption Date or ten (10) Trading Days after the date of such Holder&#8217;s written notice, an amount in cash equal to the portion of the Stock Payment Amount that would otherwise be payable in respect of the Excess Shares;</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(B)&#160;to the extent that such Stock Payment Amount, when aggregated with any Common Shares already issued in respect of all of the Preferred Stock, would cause the Maximum Share Amount to be exceeded, then that portion of such Stock Payment Amount that would not exceed the Maximum Share Amount shall be delivered to the Holders hereunder in Common Shares as provided above, ratably based on the Holders&#8217; relative ownership of the outstanding Preferred Shares, and the Corporation shall pay to the Holders, not more than three (3) Trading Days after the Mandatory Redemption Date, an amount in cash equal to the Stock Replacement Payment in lieu of any portion of such Stock Payment Amount that would cause the Maximum Share Amount to be exceeded;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(C)&#160;if the Equity Conditions are neither (x) satisfied nor (y) waived <font style="DISPLAY: inline; FONT-STYLE: italic"><font style="FONT-STYLE: normal">in</font> </font>accordance with the terms hereof, as applicable, on the Trading Day immediately preceding the First Advance Date and/or on the First Advance Date, or if the Daily VWAP cannot be determined on the Trading Day immediately preceding the First Advance Date, or if the Corporation fails to deliver the First Advance Shares to the Holders on the First Advance Date, then the Holder may, at its option upon written notice to the Corporation, require the Corporation to pay to such Holder, not later than three (3) Trading Days after the Mandatory Redemption Date, an amount of cash equal to the Stock Replacement Payment in lieu of such Stock Payment Amount; or</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(D) if subsequent to the delivery of the First Advance Shares (A) the Equity Conditions are neither (x) satisfied nor (y) waived in accordance with the terms hereof, as applicable, on any day of the Stock Payment Pricing Period or (B) if the Daily VWAP cannot be determined on any day of the Stock Payment Pricing Period, then each Holder may, at its option, elect in a written notice to the Corporation to redeliver ail or any portion of the Advance Shares to the Corporation and the Corporation shall pay to such Holder, not later than three (3) Trading Days after the Mandatory Redemption Date, an amount of cash equal to the Stock Replacement Payment in lieu of such portion of the Stock Payment Amount for which such Holder has elected in writing to redeliver Advance Shares to the Corporation. For the avoidance of doubt, to the extent this Section 6(d)(ii)(D) applies, then by the third (3<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">rd</font>) Trading Day after the Mandatory Redemption Date the Corporation must pay to the Holder an amount of cash and Advance Shares equal in value to at least the product of (x) a fraction the numerator of which is the average Daily VWAP of the Common Shares for the applicable Stock Payment Pricing Period and the denominator of which is the Stock Payment Price for such Stock Payment Pricing Period and (y) the entire Stock Payment Amount.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The &#8220;Stock Replacement Payment&#8221; shall be determined according to the following formula:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SRP = (X/Y) * S</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the purposes of the foregoing formula:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SRP = Stock Replacement Payment</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">X = the average Daily VWAP of the Common Shares for the applicable Stock Payment Pricing Period</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Y = the Stock Payment Price for the applicable Stock Payment Pricing Period</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">S = the Stock Payment Amount (or, (A) in the case that either or both of Maximum Share Amount and/or Beneficial Ownership Limitation is exceeded as provided above, only that portion of such Stock Payment Amount that would exceed the Maximum Share Amount and/or Beneficial Ownership Limitation, as applicable, and/or (B) in the case of Section 6(d)(ii)(D) that portion of the Stock Payment Amount for which the Holder has elected in its written notice to redeliver Advance Shares to the Corporation).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii) Any Common Shares required to be delivered by the Corporation to a Holder under this Section 6 shall be credited to such Holder&#8217;s or its designee&#8217;s balance account with DTC through its Deposit/Withdrawal at Custodian system (&#8220;DWAC&#8221;). In addition, the provisions of Section 7(c) and Section 7(g) shall apply to the delivery of Common Shares under this Section 6 <font style="DISPLAY: inline; FONT-STYLE: italic">mutatis mutandis </font>as if each date when Common Shares are required to be delivered under this Section <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: normal">6</font> </font>was a Share Delivery Date. Notwithstanding the foregoing, the Corporation shall only be liable for Stock Payment Liquidated Damages (as defined below) with respect to any Advance Date or Mandatory Redemption Date to the extent that the Corporation fails to deliver Common Shares when due more than once (I) in any twelve month period.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e) Each mandatory redemption pursuant to this Section 6 (and the related payment of the Mandatory Redemption Price) shall be made pro rata among the Holders based on each Holder&#8217;s relative percentage ownership of the outstanding Preferred Shares.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(f) Notwithstanding the delivery of a Mandatory Redemption Notice or any provision of this Section <font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-WEIGHT: normal">6</font> </font>to the contrary, the Holder may deliver a Conversion Notice with respect to all or any portion of the specific Mandatory Redemption Shares to be redeemed on the applicable Mandatory Redemption Date at any time prior to such Mandatory Redemption Date. Any Advance Shares delivered to such Holder in connection with such Mandatory Redemption Date shall count towards the number of Common Shares that Corporation shall be obligated to deliver on the applicable Share Delivery Date (as defined below), and to the extent that the Advance Shares exceeds the number of Common Shares that the Corporation would be required to deliver on the applicable Share Delivery Date, the Holder shall return such excess to the Corporation.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(g) Each and every time that the Corporation sells any Common Shares pursuant to any Equity Line, the Corporation shall immediately deliver a written notice to each Holder (an &#8220;Equity Line Draw Notice&#8221;), which Equity Line Draw Notice shall state the aggregate purchase price for such Common Shares (the &#8220;Equity Line Aggregate Purchase Price&#8221;), Each Holder may, at its option, by delivering a written notice to the Corporation, require the Corporation to pay the Mandatory Redemption Price (or the appropriate portion thereof) on the next succeeding Mandatory Redemption Date (or to the extent that the date of such Equity Line Draw notice is subsequent to the date of the Mandatory Redemption Notice for such Mandatory Redemption Date, then the next succeeding Mandatory Redemption Date) in Common Shares in an amount equal to its &#8220;pro rata portion&#8221; of the Equity Line Aggregate Purchase Price. To the extent that the Equity Line Aggregate Purchase Price exceeds the aggregate amount of the entire Mandatory Redemption Price for such Mandatory Redemption Date, then on each succeeding Mandatory Redemption Date the Holder may, at its option, by delivering a written notice to the Corporation, require the Corporation to pay its &#8220;pro rata portion&#8221; of the applicable Mandatory Redemption Price in Common Shares until the Corporation has made aggregate payments in Common Shares equal to its &#8220;pro rata portion&#8221; of the entire Equity Line Aggregate Purchase Price. Notwithstanding anything contained in this Section 6(g) to the contrary, all payments of Mandatory Redemption Price made in Common Shares shall be subject to Section 6(d) and upon the occurrence of any of the events described in Sections 6(d)(ii)(A) &#8211; (D) the Corporation shall make the appropriate Stock Replacement Payment as required by Section 6(d)(ii). For purposes of this Section 6(g), &#8220;pro rata portion&#8221; means, with respect to each Holder, the number of Preferred Shares then held by such Holder divided by the aggregate number of outstanding Preferred Shares.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">7. <font style="TEXT-DECORATION: underline">Optional Conversion <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">by </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">the</font> Holders</font></font>. Each Holder shall have the right at any time and from time to time, at the option of such Holder, to convert all or any portion of the Preferred Shares held by such Holder, for such number of Common Shares, free and clear of any liens, claims or encumbrances, as is determined by dividing <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">(i)</font> </font>the Liquidation Preference times the number of Preferred Shares being converted, by (ii) the Conversion Price (as defined below) in effect on the Conversion Date (as defined below). Immediately following such conversion, the persons entitled to receive the Common Shares upon the conversion of Preferred Shares shall be treated for all purposes as having become the owners of such Common Shares, subject to the rights provided herein to Holders. The term &#8220;Conversion Price&#8221; means $2.0004, subject to adjustment as provided herein.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a) <font style="DISPLAY: inline; FONT-STYLE: italic">Delivery of Conversion Notice. </font>To convert Preferred Shares into Common Shares on any date (a &#8220;Conversion Date&#8221;), the Holder shall give written notice (a &#8220;Conversion Notice&#8221;) to the Corporation in the form of page 1 of Exhibit A hereto (which Conversion Notice will be given by facsimile transmission, e-mail or other electronic means no later than 11:59 p.m. New York City Time on such date, and sent via overnight delivery no later than one (1) Trading Day (as defined below) after such date) stating that such Holder elects to convert the same and shall state therein the number of Preferred Shares to be converted and the name or names in which such Holder wishes the certificate or certificates for Common Shams to be issued.&#160;&#160;If required by Section 14, as soon as possible after delivery of the Conversion Notice, such Holder shall surrender the certificate or certificates representing the Preferred Shares being converted, duly endorsed, at the office of the Corporation.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(b)&#160;<font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-STYLE: italic">Mechanics of Conversion. </font>The Corporation shall, promptly upon receipt of a Conversion Notice (but in any event not less than one (1) Trading Day after receipt of such Conversion Notice), <font style="DISPLAY: inline; FONT-WEIGHT: normal">(I) </font>send, via facsimile, e-mail or other electronic means a confirmation of receipt <font style="DISPLAY: inline; FONT-WEIGHT: normal">of </font>such Conversion Notice to such Holder and the Transfer Agent (as defined below), which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein and (II) on or before the third (3rd) Trading Day following the date of receipt by the Corporation of such Conversion Notice (the &#8220;Share Delivery Date&#8221;), credit such aggregate number of Common Shares to which the Holder shall be entitled to such Holder&#8217;s or its designee&#8217;s balance account with DTC via DWAC. If the number of Preferred Shares represented by the Preferred Stock certificate(s) delivered to the Corporation in connection with a Conversion Notice, to the extent required by Section 14 or to the extent otherwise requested by the Holder, is greater than the number of Preferred Shares being converted, then the Corporation shall, as soon as practicable and in no event later than three (3) Business Days after receipt of such Preferred Stock certificate(s) (the &#8220;Preferred Stock Delivery Date&#8221;) and at its own expense, issue and deliver to the Holder a new Preferred Stock certificate representing the number of Preferred Shares not converted. The person or persons entitled to receive the Common Shares issuable upon a conversion of Preferred Shares shall be treated for all purposes as the record holder or holders of such Common Shares on the Conversion Date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold">The Corporation&#8217;s obligation to </font>issue <font style="DISPLAY: inline; FONT-WEIGHT: bold">Common Shares upon conversion of </font>Preferred Shares shall, <font style="DISPLAY: inline; FONT-WEIGHT: bold">except as </font>set <font style="DISPLAY: inline; FONT-WEIGHT: bold">forth </font>below, <font style="DISPLAY: inline; FONT-WEIGHT: bold">be </font>absolute, <font style="DISPLAY: inline; FONT-WEIGHT: bold">is independent of any covenant of any </font>Holder, and shall <font style="DISPLAY: inline; FONT-WEIGHT: bold">not </font>be subject <font style="DISPLAY: inline; FONT-WEIGHT: bold">to: (i) </font>any <font style="DISPLAY: inline; FONT-WEIGHT: bold">offset or defense; or (ii) any </font>claims <font style="DISPLAY: inline; FONT-WEIGHT: bold">against the Holders </font>of <font style="DISPLAY: inline; FONT-WEIGHT: bold">Preferred Shares whether pursuant to this Certificate, the Purchase Agreement, the Warrant or otherwise, including, without limitation, any claims arising </font>out <font style="DISPLAY: inline; FONT-WEIGHT: bold">of any </font>selling <font style="DISPLAY: inline; FONT-WEIGHT: bold">or short-selling activity </font>by <font style="DISPLAY: inline; FONT-WEIGHT: bold">Holders.</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="FONT-WEIGHT: bold"><font style="FONT-WEIGHT: normal"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">(c)&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-STYLE: italic">Corporation&#8217;s Failure to Timely Convert. </font>If within three (3) Trading Days after the Corporation&#8217;s receipt of the facsimile copy of a Conversion Notice the Corporation shall fail to credit a Holder<font style="DISPLAY: inline; FONT-WEIGHT: normal">&#8217;s </font>balance account with DTC for the number of shares of Common Stock to which such Holder is entitled upon such Holder&#8217;s conversion of Preferred Shares, then in addition to all other available remedies which such Holder may pursue hereunder and under the Purchase Agreement (including indemnification pursuant to Article 5 thereof), the Corporation shall pay additional damages to such Holder for each day after the Share Delivery Date that such conversion is not timely effected in an amount equal to two percent (2.0%) of the product of (I) the sum of the number <font style="DISPLAY: inline; FONT-WEIGHT: normal">of </font>Common Shares not issued to the Holder on or prior <font style="DISPLAY: inline; FONT-WEIGHT: normal">to </font>the Share Delivery Date and to which such Holder is entitled pursuant to the applicable Conversion Notice and the terms of this Certificate of Designations, and (II) the Closing Sale Price (as defined below) of the Common Stock on the Share Delivery Date, but in no event in excess <font style="DISPLAY: inline; FONT-WEIGHT: normal">of </font>twenty- four percent (24.0%) (&#8220;Stock Payment Liquidated Damages&#8221;). In addition to the foregoing, if on the Share Delivery Date, the Corporation shall fail to credit such Holder&#8217;s balance account with DTC for the number <font style="DISPLAY: inline; FONT-WEIGHT: normal">of </font>Common Shares to which such Holder is entitled upon such Holder&#8217;s conversion of Preferred Shares, and if on or after such Trading Day the Holder purchases (in an open market transaction or otherwise) Common Shares to deliver in satisfaction of a sale by the Holder of the Common Shares issuable upon such conversion that the Holder anticipated receiving from the Corporation (a &#8220;Buy-In&#8221;), then the Corporation shall, within three (3) Trading Days after the Holder&#8217;s request and in the Holder&#8217;s discretion, either (i) pay cash to the Holder in an amount equal to the Holder&#8217;s total purchase price (including brokerage commissions and out-of-pocket expenses, if any) for the Common Shares so purchased (the &#8220;Buy-In Price&#8221;), at which point the Corporation&#8217;s obligation to deliver such certificate (and to issue such Common Shares) shall terminate, or (it) promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Common Shares and pay cash to the Holder in an amount equal to the difference between (if any) of the Buy-In Price and the product of (A) such number of Common Shares, times (B) the Closing Sale Price on the Conversion Date. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance ane/or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver certificates representing Common Shares upon conversion of the Preferred Shares as required pursuant to the terms hereof.</font></font></font></div>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The terms &#8220;Closing Sale Price&#8221; means the last closing trade price for the Common Shares on the NYSE Amex Equities, as reported by Bloomberg, or, if the NYSE Amex Equities begins to operate on an extended hours basis and does not designate the closing trade price then the last trade price, respectively, of such security prior to 3:59 p.m., New York City Time, as reported by Bloomberg, or, if the foregoing do not apply, the last trade price, respectively, of the Common Shares in the over-the-counter market on the electronic bulletin board for the Common Shares as reported by Bloomberg, or, if no last trade price is reported for such security by Bloomberg, the highest bid price as reported on the &#8220;pink sheets&#8221; by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.) at the close of trading. If the Closing Sale Price cannot be calculated for the Common Shares on a particular date on any of the foregoing bases, the Closing Sale Price of the Common Shares on such date shall be the fair market value as mutually determined by the Corporation and the Holder. All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d) <font style="DISPLAY: inline; FONT-STYLE: italic">Adjustments to the Conversion Price.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Adjustments for Stock Splits and Combinations. </font>If the Corporation shall at any time or from time to time after the Closing Date effect a stock split of the outstanding Common Stock, the applicable Conversion Price in effect immediately prior to the stock split shall be proportionately decreased. If the Corporation shall at any time or from time to time after the Closing Date, combine the outstanding shares of Common Stock, the applicable Conversion Price in effect immediately prior to the combination shall be proportionately increased. Any adjustments under this Section 7(d)(i) shall be effective at the close of business on the date the stock split or combination occurs.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Adjustments for Certain Dividends and Distributions. </font>If the Corporation shall at any time or from time to time on or after the Initial Issuance Date make or issue or set a record date for the determination of holders of Common Stock entitled to receive a dividend or other distribution payable in Common Shares then, and in each event, the applicable Conversion Price in effect immediately prior to such event shall be decreased as of the time of such issuance or, in the event such record date shall have been fixed, as of the close of business on such record date, by multiplying the applicable Conversion Price then in effect by a fraction:</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 117pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(A)&#160;&#160;the numerator of which shall be the total number of Common Shares issued and outstanding immediately prior to the time of such issuance or the close of business on such record date; and</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 117pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(B)&#160;&#160;&#160;the denominator of which shall be the total number of Common Shares issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of Common Shares issuable in payment of such dividend or distribution.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Adjustment for Other Dividends and Distributions. </font>If the Corporation shall at any time or from time to time on or after the Initial Issuance Date make or issue or set a record date for the determination of holders of Common Stock entitled to receive a dividend or other distribution payable in securities or property other than Common Shares, then, and in each event, an appropriate revision to the applicable Conversion price shall be made and provision shall be made (by adjustments of the Conversion Price or otherwise) so that the Holders of Preferred Shares shall receive upon conversions thereof, in addition to the number of Common Shares receivable thereon, the number of securities of the Corporation or other issuer (as applicable) or other property that they would have received had the Preferred Shares been converted into Common Shares on the date of such event.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iv)&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Adjustments for Issuance of Additional Shares of Common Stock. </font>In the event the Corporation shall issue or sell any Common Shares (otherwise than as provided in the foregoing subsections (i) through (iii) of this Section 7 or upon the exercise or conversion of Common Stock Equivalents (as defined below) that were outstanding on or prior to the Initial Issuance Date (for the avoidance of doubt, this Section&#160;7(d)(iv) shall apply to the issuance and sale of Common Shares under the Equity Line) (the &#8220;Additional Shares&#8221;), at a price per share less than the Conversion Price, or without consideration, the Conversion Price then in effect upon each such issuance shall be adjusted to that price (rounded to the nearest cent) determined by multiplying the Conversion Price by a fraction:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 117pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(A)&#160;the numerator of which shall be equal to the sum of (A) the number of Common Shares outstanding immediately prior to the issuance of such Additional Shares plus (B) the number of Common Shares (rounded to the nearest whole share) which the aggregate consideration for the total number of such Additional Shares so issued would purchase at a price per share equal to the men Conversion Price, and</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 117pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(B) the denominator of which shall be equal to the number of Common Shares outstanding immediately after the issuance of such Additional Shares.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No adjustment shall be made under this Section 7(d)(iv) upon the issuance of any Additional Shares which are issued pursuant to the exercise, conversion or exchange rights under any Common Stock Equivalents (as defined below), if any such adjustment shall previously have been made upon the issuance of such Common Stock Equivalents (or upon the issuance of any warrant or other rights therefore) pursuant to Section 7(d)(v).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(v)&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Issuance of Common Stock Equivalents. </font>In the event the Corporation shall issue or sell any Common Stock Equivalents (other than the Preferred Shares and the Warrants) and the price per share for which Additional Shares may be issued pursuant to any such Common Stock Equivalent shall be less than the applicable Conversion Price then in effect, or if, after any such issuance of Common Stock Equivalents, the price per share for which Additional Shares of Common Stock may be issued thereafter is amended or adjusted, and such price as so amended shall be less than the applicable Conversion Price in effect at the time of such amendment or adjustment, then the applicable Conversion Price upon each such issuance or amendment shall be adjusted as provided in Section 7(d)(iv). For purposes of the foregoing, in the case of the sale of issuance of any Common Stock Equivalents or in that case that any Common Stock Equivalents are amended and adjusted as provided in this Section 7(d)(v), the maximum number of Additional Shares issuable upon conversion, exchange or exercise of such Common Stock Equivalent shall be deemed to be outstanding at the time of such sale or issuance or amendment or adjustment, as the case may be, and no further adjustment shall be made to the Conversion Price upon the actual issuance of Additional Shares pursuant to the exercise, conversion or exchange of such Common Stock Equivalents. The term &#8220;Common Stock Equivalent&#8221; means any rights, warrants or options to purchase or other securities convertible into or exchangeable or exercisable for, directly or indirectly, any (1) Common Shares or (2) securities convertible into or exchangeable or exercisable for, directly or indirectly, Common Shares or Common Stock Equivalents.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(vi)&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Certain Issues Excepted. </font>There shall be no adjustment to the Conversion Price pursuant to Section 7(d)(iv) or Section 7(d)(v) with respect to the sale or issuance of Excluded Securities.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(vii)&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-STYLE: italic">Calculation of Consideration Received. </font>In case any Common Stock Equivalents are issued in connection with the issue or sale of other securities of the Corporation, together comprising one integrated transaction in which no specific consideration is allocated to such Common Stock Equivalents by the parties thereto, the Common Stock Equivalents will be deemed to have been issued for a consideration of $.01.&#160;&#160;If any Common Shares or Common Stock Equivalents arc issued or sold or deemed to have been issued or sold for cash, the consideration received therefor will be deemed to be the net amount received by the Corporation therefor. <font style="DISPLAY: inline; FONT-WEIGHT: normal">If </font>any Common Stock or Common Stock Equivalents arc issued or sold for a consideration other than cash, the amount of the consideration other than <font style="DISPLAY: inline; FONT-WEIGHT: normal">cash </font>received by the Corporation will be the fair market value of such consideration. <font style="DISPLAY: inline; FONT-WEIGHT: normal">If </font>any Common Stock or Common Stock Equivalents are issued to the owners of the non surviving entity in connection with any merger in which the Corporation is the surviving entity, the amount of consideration therefor will be deemed to be the fair market value of such portion of the net assets and business of the non surviving entity as is attributable to such Common Stock or Common Stock Equivalents, as the case may be. The fair market value of any consideration other than cash or securities will be determined jointly by the Corporation and the Holders of the Preferred Shares. If such parties are unable to reach agreement within 10 days after the occurrence of an event requiring valuation (the &#8220;Valuation Event&#8221;), the fair market value of such consideration will be determined within five (5) Business Days after the tenth (10th) day following the Valuation Event by an independent, reputable appraiser jointly selected by the Corporation and the Required Holders. The determination of such appraiser shall be deemed binding upon all parries absent manifest error or fraud and the fees and expenses of such appraiser shall be borne by the Corporation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(e)&#160;<font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-STYLE: italic">Notice of Record Date. </font>In the event <font style="DISPLAY: inline; FONT-WEIGHT: normal">of </font>any taking by the Corporation of a record date of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend or other distribution, any security or right convertible into <font style="DISPLAY: inline; FONT-WEIGHT: normal">or </font>entitling the holder thereof to receive additional Common Shares, or any right to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other securities or property, <font style="DISPLAY: inline; FONT-WEIGHT: normal">or </font>to receive any other right, the Corporation shall deliver to each Holder at least twenty (20) days prior to the date specified therein, <font style="DISPLAY: inline; FONT-WEIGHT: normal">a </font>notice specifying the date on which any such record is to be taken for the purpose of such dividend, distribution, security or right and the amount and character of such dividend, distribution, security or right.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(f)&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-STYLE: italic">Reservation of Stock Issuable Upon Conversion. </font>The Corporation shall at all times reserve and keep available out of its authorized but unissued Common Stock, solely for the purposes of effecting the conversion and/or redemption of the Preferred Shares, <font style="DISPLAY: inline; FONT-WEIGHT: normal">an </font>amount of Common Shares equal to 200% of the number of shares issuable upon conversion of the Preferred Shares at the current Conversion Price (the &#8220;Required Reserve Amount&#8221;). If at any time while any of the Preferred Shares remain outstanding the Corporation does not have a sufficient number of authorized and unreserved Common Shares to satisfy its obligation to reserve for issuance upon conversion and/or redemption of the Preferred Shares at least <font style="DISPLAY: inline; FONT-WEIGHT: normal">a </font>number of Common Shares equal to the Required Reserve Amount (an &#8220;Authorized Share Failure&#8221;), then the Corporation shall promptly take all action necessary to increase the Corporation&#8217;s authorized Common Shares to an amount sufficient to allow the Corporation to reserve the Required Reserve Amount for the Preferred Shares then outstanding. Without limiting the generality of the foregoing sentence, as soon as practicable after the date <font style="DISPLAY: inline; FONT-WEIGHT: normal">of </font>the occurrence of an Authorized Share Failure, but in no event later than sixty (60) days (or the lesser of (i) ninety (90) days if the proxy statement is reviewed by the staff of the SEC or (ii) ten (10) days after the staff of the SEC indicates that it has no further comments to such proxy statement) after the occurrence of such Authorized Share Failure (the &#8220;Meeting Outside Date&#8221;), the Corporation shall hold a meeting of its stockholders for the approval of an increase in the number of authorized Shares of Common Stock. In connection with such meeting, the Corporation shall provide each stockholder with a proxy statement and shall use its reasonable best efforts to solicit its stockholders<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8217;</font> approval of such increase in authorized Common Shares and to cause its Board of Directors to recommend to the stockholders that they approve such proposal. Notwithstanding the foregoing, if at such time of an Authorized Share Failure, the Corporation is able to obtain the written consent of a majority of the shares of its issued and outstanding Common Stock to approve the increase in the number of authorized shares of Common Stock, the Corporation shall satisfy this obligation by obtaining such consent and submitting for filing with the SEC an Information Statement on Schedule 14C.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(g)&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Fractional Shares. </font>No fractional shares shall be issued upon the conversion of any Preferred Shares. All Common Shares (including fractions thereof) issuable upon conversion of more than one Preferred Share by a Holder thereof and all Preferred Shares issuable upon the purchase thereof shall be aggregated for purposes of determining whether the conversion and/or purchase would result in the issuance of any fractional share. If, after the aforementioned aggregation, the conversion and/or purchase would result in the issuance of a fraction of a share of Common Stock, the Corporation shall, in lieu of issuing any fractional share, either round up the number of shares to the next highest whole number or, at the Corporation&#8217;s option, pay the Holder otherwise entitled to such fraction a sum in cash equal to the fair market value of such fraction on the Conversion Date (as determined in good faith by the Board of Directors of the Corporation).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(h)&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Reorganization, Merger or Going Private. </font>In case of any reorganization or any reclassification of the capital stock of the Corporation or any consolidation or merger of the Corporation with or into any other corporation or corporations or a sale or transfer of all or substantially all of the assets of the Corporation to any other person or a &#8220;going private&#8221; transaction under Rule 13e-3 promulgated pursuant to the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), as amended, then, as part of such reorganization, consolidation, merger, or transfer if the holders of Common Shares receive any publicly traded securities as part or all of the consideration for such reorganization, reclassification, consolidation, merger or sale, then it shall be a condition precedent of any such event or transaction that provision shall be made such that each Preferred Share shall thereafter be convertible into such new securities at a conversion price and pricing formula which places the Holders of Preferred Shares in an economically equivalent position as they would have been if not for such event. The Corporation shall give each holder written notice at least ten (10) Trading Days prior to the consummation of any such reorganization, reclassification, consolidation, merger or sale. Notwithstanding anything contained herein to the contrary, nothing contained in this Section 7(h) shall be deemed to limit the Holder&#8217;s right to require the Corporation to repurchase the Preferred Shares in accordance with Section 9.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Certificate for Conversion Price Adjustment. </font>The Corporation shall promptly furnish or cause to be furnished to each Holder a certificate prepared by the Corporation setting forth any adjustments or readjustments of the Conversion Price pursuant to this Section 7.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">17</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(j) <font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-STYLE: italic">Failure to Redeliver. </font>If a Holder fails to re-deliver shares of Common Stock to the Corporation within ten (10) Trading Days of being required to do so pursuant to Section <font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font>(d<font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)(i</font>)(C) in connection with a Mandatory Redemption or Section <font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8</font><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font>in connection with an optional redemption by the Corporation, then, unless such Common Shares have been cancelled by the Corporation, the Corporation may, at its option, redeem a number of Preferred Share having a Liquidation Preference equal in value to the product of (x) such number of Common Shares and (y) the Stock Payment Price for such Mandatory Redemption Date or Optional Redemption Date, as the case may be, in lieu of requiring such Holder to return such Common Shares.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(k) <font style="DISPLAY: inline; FONT-STYLE: italic">Cash Settlement. </font>Notwithstanding anything contained herein to the contrary, to the extent that the effectiveness of the Registration Statement or the ability to use the Prospectus has lapsed or such Registration Statement or Prospectus is unavailable for the issuance of Common Shares pursuant to this Section 7, then, unless such Common Shares may be resold by the Holder pursuant to Rule 144 under the Securities Act without volume limitations or any public information requirements or such other exemption from registration that would permit the Holder to resell such Common Shares without restriction and without need for additional registration under any securities laws, at the option of the Holder, any conversion of Preferred Shares into Common Shares shall be &#8220;cash settled&#8221; and the Corporation shall pay to such Holder an amount in cash equal to the sum of (x) the Liquidation Preference for each Preferred Share being converted and (y) the Conversion Premium. The &#8220;Conversion Premium&#8221; means the product of (v) the difference between (A) the Daily VWAP on the Conversion Date and (B) the Conversion Price in effect on such Conversion Date and (w) the quotient of (I) the Liquidation Preference times the number of Preferred Shares being converted and (II) the Conversion Price in effect on such Conversion Date, no later than three (3) Trading Days after the date of the applicable Conversion Notice.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8. </font>Optional Redemption by the </font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-WEIGHT: bold">Corporation</font>. </font>The Corporation may, at its option, redeem the Preferred Stock, at any time and from time to time, in whole or in part (but not less than 1,000,000 Preferred Shares at any one time) for an amount equal to (a) the Liquidation Preference per Preferred Share plus any accrued and unpaid dividends through the Optional Redemption Date (as defined below) (the &#8220;Base Redemption Price&#8221;) plus (b) (i) if such prepayment occurs on or before the twelve (12) month anniversary of the Initial Issuance Date, an amount equal to 15% of the Base Redemption Price or (ii) if such prepayment occurs at any time after the twelve (12) month anniversary of the Initial Issuance Date, an amount equal to 10% of the Base Redemption Price (the additional amount under clause (b) being referred to as the &#8220;Additional Redemption Price&#8221;). The Base Redemption Price shall be paid in cash and the Additional Redemption Price shall be paid in cash or, at the Corporation&#8217;s option and provided (w) the Equity Conditions are satisfied (unless waived by the Required Holders), (x) the portion of the Additional Redemption Price to be paid in Common Shares does not exceed the Dollar Volume Limitation (unless waived by the Required Holders), (y) the Maximum Share Amount is not exceeded and (z) the Daily VWAP is available on the Trading Day immediately preceding the First Optional Redemption Advance Date (as defined below) and on each day of the Stock Payment Pricing Period, in Common Shares. The Corporation shall deliver written notice of optional redemption (an &#8220;Optional Redemption Notice&#8221;) to the Holders thirty (30) Trading Days prior to the date set by the Corporation for such optional redemption (the &#8220;Optional Redemption Date&#8221;), which Optional Redemption Date may not be a Mandatory Redemption Date or any day of a Stock Payment Pricing Period with respect to any Mandatory Redemption Date. For the avoidance of doubt, each Holder may submit a Conversion Notice for the specific Optional Redemption Shares (as defined below) to be redeemed on such Optional Redemption Date at any time prior to the Optional Redemption Date notwithstanding the delivery of an Optional Redemption Notice by the Corporation. Such Optional Redemption Notice shall specify the number of preferred shares to be redeemed (the &#8220;Optional Redemption Shares&#8221;) and what portion of the Additional Redemption Price will be paid in Common Shares (expressed in dollars), what portion of the Additional Redemption Price will be paid in cash (expressed in dollars) and (A) certify that the Equity Conditions are satisfied, (B) state the Dollar Volume Limitation (expressed in dollars) and certify that the portion of the Additional Redemption Price to be paid in Common Shares does not exceeded such Dollar Volume Limitation and (C) certify that the Maximum Share Amount has not been exceeded. Such Optional Redemption Notice shall be irrevocable. To the extent that any portion of the Additional Redemption Price will be paid in Common Shares, twenty-one (21) Trading Days prior to the Optional Redemption Date (the &#8220;First Optional Redemption Advance Date&#8221;), the Corporation shall advance to the Holder a number of Common Shares determined by dividing (x) that portion of the Additional Redemption Price to be paid in Common Shares by (y) 92% of the Daily VWAP on the Trading Day immediately preceding the First Optional Redemption Advance Date (the &#8220;First Optional Redemption Advance Shares&#8221;). In addition, eleven (11) Trading Days prior to the applicable Optional Redemption Date (the &#8220;Second Optional Redemption Advance Date&#8221; and together with the First Optional Redemption Advance Date, the &#8220;Optional Redemption Advance Dates&#8221; and each, an &#8220;Optional Redemption Advance Date&#8221;), the Corporation shall advance to the Holders and an additional number of Common Shares equal to the positive difference (if any) between (x) the quotient of (1) the portion of the Additional Redemption Price to be paid in Common Shares and (2) the average of the five lowest Daily VWAPs during the first ten (10) Trading Days of the applicable Stock Payment Pricing Period and (y) the number of First Optional Redemption Advance Shares delivered to the Holders pursuant to <font style="FONT-WEIGHT: normal">the immediately preceding sentence in connection with such Optional Redemption Date (the &#8220;Second Optional Redemption Advance Shares&#8221; and together with the First Optional Redemption Advance Shares, the &#8220;Optional Redemption Advance Shares&#8221;). Not later than three (3) Trading Days after the Optional Redemption Date, the Corporation shall deliver an additional number of Common Shares, if any, to the Holder equal to the positive difference between </font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-WEIGHT: normal">(I)</font> </font>that portion of the Additional Redemption Price to be paid in Common Shares divided by the Stock Payment Price and (2) the Optional Redemption Advance Shares. If clause (2) of the immediately preceding sentence exceeds clause (1) of the immediately preceding sentence, then each Holder shall return to the Corporation its pro rata portion of such excess number of Common Shares. For the avoidance of doubt, no Holder shall have any liability to the Corporation to the extent that any Optional Redemption Advance Shares that are returned to the Corporation pursuant to the immediately preceding sentence decrease in value following the applicable Optional Redemption Advance Date. The provisions of Section 6(d)(ii), Section 6(d)(iii), Section 6(e) and Section 6(f) shall apply to this Section 8 mutatis mutandis.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">19</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">9. Mandatory Repurchase</font>. Each Holder shall have the unilateral option and right to compel the Corporation to repurchase for cash any or all of such Holder&#8217;s Preferred Shares within three (3) days of a written notice requiring such repurchase (provided that no such written notice shall be required for <font style="FONT-WEIGHT: normal">clauses <font style="DISPLAY: inline; FONT-WEIGHT: normal">(v) </font>and</font> (vi) and such demand for repurchase shall be deemed automatically made upon the occurrence of any of the events set forth in such clauses (v) and (vi)) , at a price per Preferred Share equal to the sum of (a) the Liquidation Preference plus (b) any and all accrued and unpaid dividends on the Preferred Shares (the sum of (a) and (b), the &#8220;Base Mandatory Repurchase Price&#8221;) plus (c) (i) if such demand for repurchase occurs on or before the twelve (12) month anniversary of the Initial Issuance Date, an amount equal to <font style="FONT-STYLE: normal">15% of <font style="DISPLAY: inline; FONT-STYLE: normal">the </font>Base Mandatory</font> Repurchase Price, or (ii) if such demand for repurchase occurs at any time after the twelve (12) month anniversary of the Initial Issuance Date, an amount equal to 10% of the Base Mandatory Repurchase Price, if any of the following events shall have occurred or are continuing:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;&#160;&#160;&#160;A Change in Control Transaction (as defined below);</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)&#160;&#160;&#160;A &#8220;going private&#8221; transaction under Rule 13e-3 promulgated pursuant to the Exchange Act;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)&#160;&#160;A tender offer by the Corporation under Rule 13e-4 promulgated pursuant to the Exchange Act;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iv)&#160;&#160;the suspension from trading or the failure of the Common Shares to be listed on a Trading Market for a period of five (5) consecutive Trading Days or for more than an aggregate of ten (10) trading days in any 365-day period;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(v)&#160;&#160;the entry by a court having jurisdiction in the premises of (i) a decree or order for relief in respect of the Corporation or any Subsidiary of a voluntary case or proceeding under any applicable federal or state bankruptcy, insolvency, reorganization or other similar law or (ii) a decree or order adjudging the Corporation or any Subsidiary as bankrupt or insolvent, or approving as properly filed a petition seeking reorganization, arrangement, adjustment or composition of or in respect of the Corporation or any Subsidiary under any applicable federal or state law or (iii) appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Corporation or any Subsidiary or of any substantial part of its property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree or order for relief or any such other decree or order unstayed and in effect for a period of 60 consecutive days;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(vi)&#160;&#160;the commencement by <font style="FONT-STYLE: normal">the Corporation or any Subsidiary of a voluntary case or proceeding under any applicable federal or state bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or insolvent, or the consent by it to the entry of a decree or order for relief in respect of the Corporation or any Subsidiary in an involuntary case or proceeding under any applicable federal or state bankruptcy, insolvency, reorganization or other similar law or to the commencement <font style="DISPLAY: inline; FONT-STYLE: normal">of</font><font style="DISPLAY: inline; FONT-STYLE: normal">&#160;</font>any bankruptcy or insolvency case or proceeding against it, or the filing by it of a petition or answer or consent seeking reorganization or relief under any applicable federal or state law, or the consent by it to the filing of such petition or to the appointment of or taking possession by a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Corporation or any Subsidiary or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors, or the admission by it in writing of its inability to pay its debts generally as they become</font> due, or the taking of corporate action by the Corporation or any Subsidiary in furtherance of any such action;</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(vii) following an Authorized Share Failure, the Corporation fails to receive stockholder approval or the written consent of a majority of the issued and outstanding Common Shares to approve the required increase in the number of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Common Shares within five (5) days after the Meeting Outside Date; or</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(viii) the Corporation&#8217;s failure to deliver Common Shares on any Share Delivery Date, Advance Date, Mandatory Redemption Date or Optional Redemption Date, if such failure continues for two (2) Trading Days after the date that delivery of such Common Shares is due;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ix) the Corporation&#8217;s failure to pay any amounts when and as due </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pursuant to this Certificate of Designations or any other Transaction Document, if such failure continues for two (2) Trading Days after the date that such payment is due;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(x)&#160;&#160;&#160;the Corporation breaches any covenants and agreements contained in Section 13 of this Certificate of Designations, Section 3.10 of the Purchase Agreement, Section 3.11, Section 3.12 of the Purchase Agreement and/or Section 3.14 of the Purchase Agreement;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(xi)&#160;&#160;the Corporation or any of its Subsidiaries shall (A) default in any payment of any amount or amounts of principal of or interest on any Indebtedness (as defined the Purchase Agreement) the aggregate principal amount of which Indebtedness is in excess of&#160;<font style="FONT-WEIGHT: bold"><font style="FONT-WEIGHT: normal">$1,000,000</font></font> or (B) default in the observance or performance of any other agreement or condition relating to any such Indebtedness or contained in any instrument or agreement evidencing, securing or relating thereto, or any other event shall occur or condition exist, as a result of which default or other event or condition the holder or holders or beneficiary or beneficiaries of such Indebtedness or a trustee on their behalf have declared such Indebtedness to be due prior to its stated maturity;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(xii)&#160;the effectiveness of the Registration Statement or the ability to use the Prospectus lapses for any reason (including, without limitation, the issuance of a stop order) or such Registration Statement or Prospectus is unavailable for the issuance of Common Shares hereunder, and such lapse or unavailability continues for a period of ten (10) consecutive days or for more than an aggregate of twenty (20) days in any 365-day period;</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">21</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(xiii)&#160;&#160;&#160;the&#160;&#160;Corporation&#160;&#160;breaches&#160;&#160;any representation,&#160;&#160;warranty, covenant or other term or condition of any this Certificate of Designations, the Purchase Agreement or the Warrant, except to the extent that such breach, or the event that gave rise to such breach, would not have a Material Adverse Effect (as defined in the Purchase Agreement), and except in the case of a breach of a covenant which is curable, only if such breach remains uncured for a period of at least ten (10) calendar days (the events described in clauses (v), (vi), (viii), (ix), (x), (xi), (xii) and this (xiii) of this Section 9, collectively, the &#8220;Trigger Events&#8221; and each a &#8220;Trigger Event&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A &#8220;Change in Control Transaction&#8221; will be deemed to exist if (i) there occurs any consolidation or merger of the Corporation with or into any other corporation or other entity or person (whether or not the Corporation is the surviving corporation), or any other corporate reorganization or transaction or series of related transactions in which in excess of 50% of the Corporation&#8217;s voting power is transferred through a merger, consolidation, tender offer or similar transaction, (ii) any person (as defined in Section 13(d) of the Exchange Act), together with its affiliates and associates (as such terms are defined in Rule 405 under the Securities Act), beneficially owns or is deemed to beneficially own (as described in Rule 13d-3 under the Exchange Act without regard to the 60-day exercise period) in excess of 50% of the Corporation&#8217;s voting power (provided, however, that if any person is immediately prior to he Initial Issuance Date a Beneficial Owner of 40% or more of the Corporation&#8217;s Common Stock, it shall not be deemed to be a Change of Control Transaction if such person increases its Beneficial Ownership percentage by not more than 10 percentage points), (iii) there is a replacement of more than one-half of the members of the Corporation&#8217;s Board of Directors which is not approved by those individuals who are members of the Corporation&#8217;s Board of Directors on the date thereof, in one or a series of related transactions or (iv) a sale or transfer of all or substantially all of the assets of the Corporation, determined on a consolidated basis; provided, however that a Change in Control Transaction will not be deemed to have occurred pursuant to clause (iv) if such sale or transfer is the sale or transfer of not more than one business segment during the period from the Initial Issuance Date through the Maturity Date and the Corporation remains a publicly traded corporation and if, on the effective date of the sale or transfer described therein, the Corporation deposits funds in the Escrow Account (as defined in the Purchase Agreement) such that the balance in the Escrow Account after such deposit is the lesser of $5 million or 100% of the aggregate Liquidation Preference of the outstanding Preferred Shares.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">10.&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Voting Rights</font></font><font style="FONT-WEIGHT: bold">.</font> Except as otherwise set forth herein, the Preferred Shares shall not have any voting rights.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">11.&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Rank</font></font><font style="FONT-WEIGHT: bold">.</font> All shares of Common Stock shall be of junior rank to all Preferred Shares with respect to the preferences as to dividends, distributions and payments upon a Liquidation Event. The rights of the shares of Common Stock shall be subject to the preferences and relative rights of the Preferred Shares. Without the prior express written consent of the Required Holders, the Corporation shall not hereafter authorize or issue additional or other capital stock that is of senior or pari-passu rank to the Preferred Shares in respect of the preferences as to dividends and other distributions, amortization and redemption payments and payments upon Liquidation Event. The Corporation shall be permitted to issue preferred stock that is junior in rank to the Preferred Shares in respect of the preferences as to dividends and other distributions, amortization and redemption payments and payments upon Liquidation Event, provided, that the maturity date (or any other date requiring redemption, repayment or any other payment, including, without limitation, dividends in respect of any such preferred shares) of any such junior preferred shares is not on or before ninety-one (91) days after the Maturity Date. In the event of the merger or consolidation of the Corporation with or into another corporation, the Preferred Shares shall maintain their relative powers, designations and preferences provided for herein (except that the Preferred Shares may not be pari passu with, or junior to, any capital stock of the successor entity) and no merger shall have a result inconsistent therewith.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">22</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">12.&#160;&#160;<font style="TEXT-DECORATION: underline">Participation</font></font><font style="FONT-WEIGHT: bold">.</font> The Holders of the <font style="FONT-STYLE: normal">Preferred Shares shall be entitled t<font style="DISPLAY: inline; FONT-STYLE: normal">o </font>such dividends paid and distributions made to the holders of Common Stock to the same extent as if such Holders of the Preferred Shares had converted the Preferred Shares into Common Shares (without regard to any limitations on conversion herein or elsewhere) and had held such Common Shares <font style="DISPLAY: inline; FONT-STYLE: normal">on </font>the record date for such dividends and distributions. Payments under the preceding sentence shall be made concurrently with</font> the dividend or distribution to the holders of Common Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">13.&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Vote to </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Change </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">the Terms of </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">or </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Issue Preferred Shares</font></font><font style="FONT-WEIGHT: bold">.</font> In addition to any other rights provided by law, except where the vote or written consent of the Holders of a greater number of shares is required by law or by another provision of the Certificate of Incorporation, the affirmative vote at a meeting duly called for such purpose or the written consent without a meeting of the Required Holders, voting together as a single class, shall be required before the Corporation may: (a) amend or repeal any provision of, or add any provision to, this Certificate of Designations, the Certificate of Incorporation or bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Preferred Shares, regardless of whether any such action shall be by means of amendment to the Certificate of Incorporation or&#160;by merger, consolidation or otherwise; (b) increase or decrease (other than by conversion) the authorized number of shares of Preferred Shares (for the avoidance of doubt, the Corporation may increase or decrease the number of authorized shares of undesignated &#8220;blank check&#8221; preferred stock); (c) create or authorize (by reclassification or otherwise) any new class or series of shares that has a&#160;&#160;preference over or is on a parity with the Preferred Shares with respect to dividends or the distribution of assets on a Liquidation Event; (d) purchase, repurchase or redeem any Common Shares or other shares of capital stock of the Corporation; (e) pay dividends or make any other distribution on the Common Stock or any other capital stock of the Corporation or (f) whether or not prohibited by the terms of the Preferred Shares, circumvent a right of the Preferred Shares.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">23</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">14.</font>&#160;&#160;<font style="TEXT-DECORATION: underline">Book-Entry</font></font><font style="FONT-WEIGHT: bold">.</font> Notwithstanding anything to the contrary set forth herein, upon conversion or redemption of Preferred Shares in accordance with the terms hereof, the Holder thereof shall not be required to physically surrender the certificate representing the Preferred Shares to the Corporation unless (A) the full or remaining number of Preferred Shares represented by the certificate are being converted or redeemed or (B) such Holder has provided the Corporation with prior written notice requesting reissuance of Preferred Shares upon physical surrender of any Preferred Shares. Each Holder and the Corporation shall maintain records showing the number of Preferred Shares so converted or redeemed and the dates of such conversions or redemptions. Notwithstanding the foregoing, if Preferred Shares represented by a certificate are converted or redeemed as aforesaid, a Holder may not transfer the certificate representing the Preferred Shares unless such Holder first physically surrenders the certificate representing the Preferred Shares to the Corporation, whereupon the Corporation will forthwith issue and deliver upon the order of such Holder a new certificate of like tenor, registered as such Holder may request, representing in the aggregate the remaining number of Preferred Shares represented by such certificate. A Holder and any assignee, by acceptance of a certificate, acknowledges and agrees that, by reason of the provisions of this paragraph, following conversion or redemption of any Preferred Shares, the number of Preferred Shares represented by such certificate will be less than the number of Preferred Shares stated on the face thereof. Each certificate for Preferred Shares shall bear the following legend:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ANY TRANSFEREE OF THIS CERTIFICATE SHOULD CAREFULLY REVIEW THE TERMS OF THE CORPORATION&#8217;S CERTIFICATE OF DESIGNATIONS RELATING TO THE PREFERRED SHARES REPRESENTED BY THIS CERTIFICATE. THE NUMBER OF PREFERRED SHARES REPRESENTED BY THIS CERTIFICATE MAY BE LESS THAN THE NUMBER OF PREFERRED SHARES STATED ON THE FACE HEREOF PURSUANT TO THE CERTIFICATE OF DESIGNATIONS RELATING TO THE PREFERRED SHARES REPRESENTED BY THIS CERTIFICATE.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15. <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Taxes</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;Any and all payments made by the Corporation hereunder, including any amounts received on a conversion or redemption of the Preferred Shares and any amounts on account of dividends or deemed dividends, must be made by it without any Tax Deduction, <font style="FONT-STYLE: normal">unless a Tax Deduction is required by law. If the Corporation is aware that it must make a Tax Deduction (or that there is a change <font style="DISPLAY: inline; FONT-STYLE: normal">in </font>the rate or the basis of a Tax Deduction) in respect of any payment to any Holder, it must notify such Holders</font> promptly.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;If a Tax Deduction for Taxes other than Excluded Taxes (as defined below) is required to be made by the Corporation with respect to any payment to any Holder, the amount of the payment made by the Corporation will be increased to an amount which (after making the Tax Deduction, including any Tax Deduction applicable to additional sums payable pursuant to this Section 15(b)) results in the receipt by such Holder of an amount equal to the payment which would have been due if no Tax Deduction had been required. If the Corporation is required to make a Tax Deduction, it must make any payment required in connection with that Tax Deduction within the time allowed by law. As soon as practicable after making a Tax Deduction or a payment required in connection with a Tax Deduction, the Corporation must deliver to the Holder any official receipt or form, if any, provided by or required by the taxing authority to whom the Tax Deduction was paid, &#8220;Excluded Taxes&#8221; means (a) Taxes imposed on or measured by the Holder&#8217;s net income (however denominated), and franchise Taxes imposed on the Holder (in lieu of net income Taxes), by the jurisdiction (or any political subdivision thereof) under the taws of which such Holder is a citizen or resident, under the laws of which such Holder is organized, in which the Holder&#8217;s principal office is located, or in which the Holder is otherwise doing business, (b) any branch profits Taxes imposed by the United States of America or any similar Tax imposed by any other jurisdiction in which the Corporation is located, (c) in the case of a non-US Holder, any withholding Tax that is imposed on amounts payable to such non-US Holder at the time such non-US Holder becomes a Holder (or at such time that such Holder changes its citizenship, residence, place of organization, principal office, or location where doing business) or is attributable to such non-US Holder&#8217;s failure or inability to comply with any applicable documentation requirements or to provide any documents or certifications that are reasonably requested by the Corporation, and (d) in the case of any Holder, any withholding Tax (including any backup withholding tax) that is imposed on amounts payable to such Holder that is attributable to such Holder&#8217;s failure or inability to comply with any applicable documentation requirements or to provide any documents or certifications that arc reasonably requested by the Corporation.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;In addition, the Corporation agrees to pay in accordance with applicable law any present or future stamp or documentary taxes or any other excise or property taxes, charges or similar levies that arise from any payment made hereunder or in connection with the execution, delivery, registration or performance of, or otherwise with respect to, the Preferred Shares other than income taxes (&#8220;Other Taxes&#8221;). As soon as practicable after making a payment of Other Taxes, the Corporation must deliver to such Holder any official receipt or form, if any, provided by or required by the taxing authority to whom such Other Taxes were paid.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;The obligations of the Corporation under this Section 15 shall survive the Maturity Date of the Preferred Shares and the payment for the Preferred Shares and all other amounts payable hereunder.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold">16. <font style="TEXT-DECORATION: underline">Issuance </font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Limitations</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">.</font></font> The total number of Common Shares issued or issuable hereunder shall not (when aggregated with any Common Shares already issued in respect of all of the Preferred Shares) exceed the maximum number of Common Shares which the Corporation can so issue pursuant to any rule or regulation of the NYSE Amex Equities (or any other Trading Market on which the Common Shares trade) (the &#8220;Maximum Share Amount&#8221;), subject to equitable adjustments from time to time for stock splits, stock dividends, combinations, capital reorganizations and similar events relating to the Common Shares occurring after the Initial Issuance Date. For the avoidance of doubt, each and every provision of this Certificate of Designations shall remain in full force and effect and the Corporation shall be required to perform its obligations in accordance with the terms hereof notwithstanding the fact that the number of Common Shares issued hereunder may exceed the Maximum Share Amount. Notwithstanding any other provision hereof, no shares of Common Stock in excess of 4,962,000 shares shall be issued by the Corporation hereunder, whether by reason of conversion, redemption or otherwise, and no voting rights may be exercised, until after approval of the shareholders of the Corporation as contemplated by Section 3.14 of the Purchase Agreement.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">25</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold"><font style="FONT-WEIGHT: normal"><font style="FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold">17. </font><font style="TEXT-DECORATION: underline">Ownership <font style="DISPLAY: inline; FONT-WEIGHT: bold">Cap</font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font></font> Notwithstanding anything to the contrary set forth herein, at no time may the Corporation issue to a Holder, Common Shares if the number of Common Shares to be issued pursuant to such issuance would exceed, when aggregated with all other Common Shares beneficially owned by such Holder at such time (as determined in accordance with Section 13(d) of the Exchange Act and the rules thereunder, including without limitation, Common Shares that would be aggregated with the Holder&#8217;s beneficial ownership for purpose of determining a group under Section 13(d) of the Exchange Act), the number of Common Shares that would result in the Holder beneficially owning (as determined in accordance with Section 13(d) of the Exchange Act and the rules thereunder, including without limitation, Common Shares that would be aggregated with the Holder&#8217;s beneficial ownership for purpose of determining a group under Section 13(d) of the Exchange Act) more than 4.9% (the &#8220;Beneficial Ownership Limitation&#8221;) of the then issued and outstanding Common Shares. Each Holder shall have the right (with respect to itself only) to waive the provisions of this Section <font style="DISPLAY: inline; FONT-WEIGHT: normal">17 </font>upon not less than sixty-five (65) days&#8217; prior notice to the Corporation. Notwithstanding the foregoing, the Holder shall have the right to: (A) at any time and from time to time immediately reduce the Beneficial Ownership Limitation and (B) (subject to waiver) at any time and from time to time, increase the Beneficial Ownership Limitation immediately in the event of the announcement as pending or planned, <font style="DISPLAY: inline; FONT-WEIGHT: normal">of </font>a Change in Control Transaction.</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold">18. <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Notices.</font></font> The Corporation shall distribute to the Holders of Preferred Shares copies of all notices, materials, annual and quarterly reports, proxy statements, information statements and any other documents distributed generally to the holders of shares of Common Stock of the Corporation, at such times and by such method as such documents are distributed to such holders of such Common Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold"><font style="FONT-WEIGHT: normal"><font style="FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold">19. </font></font><font style="DISPLAY: inline; FONT-WEIGHT: normal"><font style="FONT-WEIGHT: bold; TEXT-DECORATION: underline">Replacement Certificates</font><font style="FONT-WEIGHT: bold">.</font> The </font>certificate(s) representing <font style="DISPLAY: inline; FONT-WEIGHT: normal">the </font>Preferred Shares held by any Holder may be exchanged by such Holder at any time and from time to time for certificates with different denominations representing an equal aggregate number of Preferred Shares, as reasonably requested by such Holder, upon surrendering the same. No service charge will be made for such registration or transfer or exchange.</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold">20. </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Attorneys&#8217; Fees</font></font><font style="FONT-WEIGHT: bold">.</font> In connection with enforcement by a Holder <font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-WEIGHT: normal">of</font> </font>any obligation of the Corporation hereunder, the prevailing party shall be entitled to recovery <font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-WEIGHT: normal">of</font> </font>reasonable attorneys&#8217; fees and expenses incurred.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">21. </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">No</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="TEXT-DECORATION: underline">&#160;Reissuance</font>. </font>No Preferred Shares acquired by the Corporation by reason of redemption, purchase, conversion or otherwise shall be reissued. Preferred Shares issued and reacquired by the Corporation, whether upon redemption, conversion <font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-WEIGHT: normal">or</font> </font>otherwise, shall have the status of authorized and unissued undesignated shares of &#8220;blank check&#8221; preferred stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-WEIGHT: bold">22.&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Severability of Provisions</font></font><font style="FONT-WEIGHT: bold">.</font> If any right, preference or limitation of the Preferred Shares set forth in this Certificate of Designations (as this Certificate <font style="DISPLAY: inline; FONT-WEIGHT: normal">of </font>Designations may be amended from time to time) is invalid, unlawful or incapable of being enforced by reason of any rule or law or public policy, all other rights, preferences and limitations set forth in this Certificate of Designations, which can be given effect without the invalid, unlawful or unenforceable right, preference or limitation shall nevertheless remain in full force and effect, and no right, preference or limitation herein set forth <font style="DISPLAY: inline; FONT-WEIGHT: normal">be </font>deemed dependent upon any such other right, preference or limitation unless so expressed herein.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">26</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold"><font style="FONT-WEIGHT: normal"><font style="FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold">23. </font></font><font style="DISPLAY: inline; FONT-WEIGHT: normal"><font style="FONT-WEIGHT: bold; TEXT-DECORATION: underline">Limitations</font><font style="FONT-WEIGHT: bold">.</font> </font>Except as may otherwise <font style="DISPLAY: inline; FONT-WEIGHT: normal">be </font>required <font style="DISPLAY: inline; FONT-WEIGHT: normal">by </font>law and as are set forth in the Purchase Agreement, the Preferred Shares shall not have any powers, preference or relative participating, optional or other special rights other than those specifically <font style="DISPLAY: inline; FONT-WEIGHT: normal">set </font>forth in this Certificate of Designation (as may be amended from time to time) or otherwise <font style="DISPLAY: inline; FONT-WEIGHT: normal">in </font>the Certificate of Incorporation of the Corporation.</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">24. </font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="TEXT-DECORATION: underline">Payments</font>. </font>Any payments required to be made to the Holders in cash hereunder, shall be made by wire transfer of immediately available funds.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Signed on November 18, 2010</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="49%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEOSTEM, INC.</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ Robin Smith</font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="46%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name: Robin Smith</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="46%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title: CEO</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">27</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EXHIBIT A</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(To be Executed by Holder</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">in order to Convert Preferred Shares)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CONVERSION NOTICE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FOR</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">SERIES E </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">7% </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">SENIOR CONVERTIBLE PREFERRED STOCK</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The undersigned, as a holder (&#8220;Holder&#8221;) of shares of Series E 7% Senior Convertible Preferred Stock (&#8220;Preferred Shares&#8221;) of Neostem, Inc. (the &#8220;Corporation&#8221;), hereby irrevocably elects to convert <font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> Preferred Shares for shares (&#8220;Common Shares&#8221;) of common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;), of the Corporation according to the terms and conditions of the Certificate of Designations for the Preferred Shares as of the date written below. The undersigned hereby requests the Common Shares to be issued to the undersigned pursuant to this Conversion Notice be issued in the name of, and delivered via DWAC to, the undersigned or its designee as indicated below. No fee will be charged to the Holder of Preferred Shares for any conversion. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the Certificate of Designations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="15%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Conversion Date:</font></div>
</td>
<td valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="60%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td colspan="3" valign="top" width="100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" colspan="3" valign="top" width="100%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Conversion Information:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; NAME OF HOLDER:</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="26%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
</tr><tr>
<td valign="top" width="26%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Print Name</font></div>
</td>
</tr><tr>
<td valign="top" width="26%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Print Title:</font></div>
</td>
</tr><tr>
<td valign="top" width="26%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="74%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="26%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="74%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Print Address of Holder:</font></div>
</td>
</tr><tr>
<td valign="top" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="74%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="74%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="26%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="74%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" nowrap valign="top" width="11%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DWAC&#160;Instructions:&#160;&#160;</font></div>
</td>
<td valign="top" width="63%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="74%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="74%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">If Common Shares are to be issued to a person other than Holder,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Holder&#8217;s signature must be guaranteed below:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURE GUARANTEED BY:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THE COMPUTATION OF NUMBER OF COMMON SHARES TO BE RECEIVED IS SET FORTH ON PAGE 2 OF THE CONVERSION NOTICE.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page&#160;1 of Conversion Notice</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page 2 to Conversion Notice dated&#160;&#160;&#160;&#160;<font style="TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>
</td>
<td align="left" nowrap valign="top" width="5%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;for:</font></div>
</td>
<td valign="top" width="43%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="right" valign="top" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-WEIGHT: bold">(Conversion <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="43%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Name </font>of Holder)</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline">COMPUTATION OF NUMBER OF COMMON SHARES TO BE RECEIVED</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Number of Preferred Shares converted:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;<font style="TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;</font>&#160;shares</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number of Preferred Shares converted x Liquidation Preference</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total dollar amount converted</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Conversion Price</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="white">
<td align="left" valign="top" width="21%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number of Common Shares</font></div>
</td>
<td valign="top" width="6%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">=</font></div>
</td>
<td valign="top" width="36%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline">Total dollar amount converted</font></div>
</td>
<td valign="top" width="6%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">=</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="21%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="36%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Conversion Price</font></div>
</td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="86%">
<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number of Common Shares =</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="86%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Please issue and deliver&#160;&#160;<font style="TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;</font>&#160;certificate(s) for Common Shares in the following amount(s):</font></div>
</td>
</tr><tr>
<td valign="top" width="86%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="86%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="86%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="86%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="86%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="86%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">29</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">&#160;</div>
</div>

<br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>v236875_ex3-2.htm
<DESCRIPTION>EXHIBIT 3.2
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATE OF AMENDMENT</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TO THE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OF</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEOSTEM, INC.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Section 242 of the</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">General Corporation Law of the State of Delaware</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NeoStem, Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the &#8220;Corporation&#8221;), does hereby certify that:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 108pt"></font>1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Amended and Restated Certificate of Incorporation of the Corporation is hereby amended by deleting ARTICLE ELEVENTH thereof and inserting the following in lieu thereof:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 72pt"></font>&#8220;ELEVENTH:&#160;&#160;For the management of the business and for the conduct of the affairs of the Corporation, and for further definition, limitation and regulation of the powers of the Corporation and its Directors and stockholders:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The number of Directors constituting the Corporation&#8217;s Board of Directors shall be determined by the Board of Directors, from time to time.&#160;&#160;The term of office of all Directors shall expire at the 2011 annual meeting of stockholders of the Corporation.&#160;&#160;Commencing with the 2011 annual meeting of stockholders, the Directors constituting the Corporation&#8217;s Board of Directors shall not be classified and, other than those who may be elected by the holders of any classes or series of stock having a preference over the Common Stock as to dividends or upon liquidation, shall be elected annually at each annual meeting of stockholders of the Corporation, to hold office for a term expiring at the next annual meeting of stockholders, with each director to hold office until his or her successor shall have been duly elected and qualified.&#160;&#160;Any Director, other than those who may be elected by the holders of any classes or series of stock having a preference over the Common Stock as to dividends or upon liquidation, may be removed from office at any time, with or without cause by the affirmative vote of at least a majority of the voting power of then outstanding capital stock entitled to vote on the matter, voting together as a single class.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as otherwise fixed by or pursuant to provisions hereof relating to the rights of the holders of any class or series of stock having a preference over Common Stock as to dividends or upon liquidation to elect additional Directors under specified circumstances, newly created directorships resulting from any increase in the number of Directors and any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other cause shall be filled by the affirmative vote of a majority of the remaining Directors then in office, even though less than a quorum of the Board of Directors, or by a sole remaining Director. Any Director appointed by the Board of Directors in accordance with the preceding sentence shall hold office and shall be elected for the remainder of the full term of the class of Directors in which the new directorship was created or the vacancy occurred and until such Director&#8217;s successor shall have been elected and qualified.&#8221;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div>&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 108pt"></font>2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;T<a name="QuickMark"><!--EFPlaceholder--></a>he foregoing amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[Signature Page Follows]</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">IN WITNESS WHEREOF, we have set our hands on this 14<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> day of October, 2011.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font></font>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEOSTEM, INC.</font></font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;Robin L. Smith, M.D.</font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:&#160;&#160;Robin L. Smith, M.D.</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Title:&#160;&#160;Chief Executive Officer</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-3-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>4
<FILENAME>v236875_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<html>
<head>
    <title></title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
&#160;<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WARRANT AGREEMENT</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SERIES NA WARRANTS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">THIS WARRANT AGREEMENT</font> (this &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Agreement</font>&#8221;), dated as of July 22, 2011, is entered into by and between NeoStem, Inc., a Delaware corporation ("<font style="DISPLAY: inline; TEXT-DECORATION: underline">NeoStem</font>" or the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Company</font>&#8221;), and Continental Stock Transfer &amp; Trust Company, a New York corporation (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant Agent</font>&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">WHEREAS,</font> on July 22, 2011 in connection with a registered offering of units (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Units</font>&#8221;) consisting of common stock and warrants, with each Unit consisting of one share of common stock and a warrant to purchase 0.75 shares of common stock, the Company agreed to issue warrants to purchase ten million three hundred twelve thousand five hundred (10,312,500) shares of the Company's common stock, par value $0.001 per share, (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Common Stock</font>") exercisable over a five-year period at an exercise price of $1.45 per share (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrants</font>&#8221;);</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">WHEREAS</font>, the Company filed with the Securities and Exchange Commission (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Commission</font>&#8221;), a Registration Statement on Form S-3, Registration No. 333-173855 (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Registration Statement</font>&#8221;), for the registration, under the Securities Act of 1933, as amended (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Act</font>&#8221;) of, among other securities, the Warrants and the shares of Common Stock issuable upon exercise of the Warrants (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant Shares</font>"), and such Registration Statement was declared effective on June 13, 2011; and</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">WHEREAS,</font> the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, transfer, exchange and exercise of the Warrants; and</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">WHEREAS,</font> the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NOW, THEREFORE,</font> in consideration of the mutual agreements herein contained, the parties hereto agree as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Appointment of Warrant Agent</font>.&#160;&#160;The Company hereby appoints the Warrant Agent to act as agent for the Company for the Warrants, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this Agreement.&#160;&#160;The Warrant Agent shall have the powers and authority granted to and conferred upon it hereunder and in the Warrant Certificates (as hereinafter defined), and such further powers and authority as the Company may hereafter grant to or confer upon it.&#160;&#160;Notwithstanding anything to the contrary herein, all of the terms and provisions contained in the Warrant Certificates are subject to and governed by the terms and provisions of this Agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160;<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page2"><!--EFPlaceholder--></a>2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrants</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Form of Warrant</font>.&#160;&#160;Each Warrant shall be issued in registered form only, shall be in substantially the form of <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A</font> hereto, the provisions of which are incorporated herein, and shall be signed by, or bear the facsimile signature of, the Chairman of the Board, the Chief Executive Officer, the Chief Financial Officer, the Secretary or any vice president of the Company and shall bear a facsimile of the Company&#8217;s seal. In the event the person whose facsimile signature has been placed upon any Warrant shall have ceased to serve in the capacity in which such person signed the Warrant before such Warrant is issued, it may be issued with the same effect as if he or she had not ceased to be such at the date of issuance.&#160;&#160;All of the Warrants may be represented by one or more book-entry certificates (each a &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Book-Entry Warrant Certificate</font>&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Effect of Countersignature</font>.&#160;&#160;Unless and until countersigned by the Warrant Agent pursuant to this Warrant Agreement, a Warrant shall be invalid and of no effect and may not be exercised by the holder thereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Registration</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.3.1.&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant Register</font>.&#160;&#160;The Warrant Agent shall maintain books (&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant Register</font>&#8221;), for the registration of original issuance and the registration of transfer of the Warrants.&#160;&#160;Upon the initial issuance of the Warrants, the Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise in accordance with instructions delivered to the Warrant Agent by the Company.&#160;&#160;Except as provided in this <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2.3.1</font>, all of the Warrants shall initially be represented by one or more physical or Book-Entry Warrant Certificates deposited with the Depository Trust Company (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Depository</font>&#8221;) and registered in the name of Cede &amp; Co., a nominee of the Depository. Ownership of beneficial interests in the Book-Entry Warrant Certificates shall be shown on, and the transfer of such ownership shall be effected through, records maintained (i) by the Depository or its nominee for each Book-Entry Warrant Certificate; (ii) by institutions that have accounts with the Depository (such institution, with respect to a Warrant in its account, a &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Participant</font>&#8221;); or (iii) directly on the book-entry records of the Warrant Agent with respect only to owners of beneficial interests that represent such direct registration.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If the Depository subsequently ceases to make its book-entry settlement system available for the Warrants, the Company may instruct the Warrant Agent regarding making other arrangements for book-entry settlement within ten (10) days after the Depository ceases to make its book-entry settlement available.&#160;&#160;In the event that the Company does not make alternative arrangements for book-entry settlement within ten (10) days, or the Warrants are not eligible for, or it is no longer necessary to have the Warrants available in, book-entry form, the Warrant Agent shall provide written instructions to the Depository to deliver to the Warrant Agent for cancellation each Book-Entry Warrant Certificate, and the Company shall instruct the Warrant Agent to deliver to the Depository definitive Warrant Certificates in physical form evidencing such Warrants.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At the request of any initial purchaser or beneficial owner of Warrants, the Warrant Agent shall deliver to such purchaser or beneficial owner definitive Warrant Certificates in physical form, registered in the name of such purchaser, evidencing the Warrants purchased by such initial purchaser.&#160;&#160;The Warrant Certificates shall represent the number of outstanding Warrants from time to time endorsed thereon and that the number of outstanding Warrants represented thereby may from time to time be reduced or increased, as appropriate, to reflect exchanges, redemptions, exercises and other similar transactions.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page3"><!--EFPlaceholder--></a>All definitive Warrant Certificates shall be in substantially the form annexed hereto as <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A</font>.&#160;&#160;No Warrant Certificate shall be valid for any purpose, and no Warrant evidenced thereby shall be exercisable, until the Warrant has been countersigned by the Warrant Agent by manual or facsimile signature.&#160;&#160;Such signature by the Warrant Agent upon the Warrant executed by the Company shall be conclusive evidence, and the only evidence, that the Warrant so countersigned has been duly issued hereunder.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.3.2.&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Beneficial Owner; Registered Holder</font>.&#160;&#160;The term &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">beneficial owner</font>&#8221; shall mean any person in whose name ownership of a beneficial interest in the Warrants evidenced by a Book-Entry Warrant Certificate is recorded in the records maintained by the Depository or its nominee.&#160;&#160;Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and treat the person in whose name such Warrant shall be registered upon the Warrant Register (&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">registered holder</font>&#8221;), as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other writing on the Warrant Certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.&#160;&#160;Any reference herein to the term holder or registered holder shall include a beneficial owner who has received definitive Warrant Certificates registered in its name.&#160;&#160;The term "Holder," when used with respect to any Warrant, shall mean any person in whose name at the time such Warrant shall be registered upon the books to be maintained by the Warrant Agent for that purpose.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Uncertificated Warrants</font>.&#160;&#160;Notwithstanding the foregoing and anything else herein to the contrary, the Warrants may be issued in uncertificated form.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Terms and Exercise of Warrants</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise Price</font>.&#160;&#160;For purposes of this Agreement, "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise Price</font>" shall mean the initial exercise price for each Warrant as set forth in the Warrant, subject to adjustment as provided in the Warrant and herein.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Duration of Warrants</font>.&#160;&#160;A Warrant may be exercised only during the period (&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise Period</font>&#8221;) specified in the Warrant.&#160;&#160;Each Warrant not exercised on or before the expiration date, as set forth in the Warrant (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Expiration Date</font>"), shall become void, and all rights thereunder and all rights in respect thereof under this Agreement shall cease at the close of business on the Expiration Date.&#160;&#160;The Company, in its sole discretion, may extend the duration of the Warrants by delaying the Expiration Date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise of Warrants</font>.&#160;&#160;Warrants may be exercised, at the option of the Holder, in whole or in part, at any time or from time to time during the Exercise Period, by complying with the Warrant Agent's procedures relating to the exercise of such Warrant.&#160;&#160;In addition, the Holder shall deliver to the then designated office of the Warrant Agent (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant Agent Office</font>") (i) the Exercise Form substantially in the form attached to the Warrant duly executed by such Holder or its duly authorized agent or attorney (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise Form</font>&#8221;) (with a copy to the Company) and (ii) payment of the aggregate Exercise Price.&#160;&#160;In case an exercise of Warrants is in part only, the Warrant Agent shall make an appropriate adjustment to the account of the Holder to reflect a number of Warrants for the number of shares of Common Stock equal (without giving effect to any adjustment thereof) to the number of such shares called for by such Holder's Warrants prior to such exercise, minus the number of shares designated by the Holder upon such exercise.<a name="Page4"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-3-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.3.1&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Payment</font>.&#160;&#160;The Holder shall pay the Exercise Price by wire transfer of immediately available funds or good cashier&#8217;s check drawn on a United States bank and in accordance with the procedures in the Warrant and this Agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Warrant Agent shall deposit all funds received by it in payment of the Exercise Price in the account of the Company maintained with the Warrant Agent for such purpose and shall advise the Company at the end of each day on which funds for the exercise of the Warrants are received of the amount so deposited to its account.&#160;&#160;The Warrant Agent shall promptly confirm such telephonic advice to the Company in writing.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.3.2&#160;&#160; &#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Procedures and Validity.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 144pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any exercise of a Warrant pursuant to the terms of this Agreement shall be irrevocable and shall constitute a binding agreement between the Holder and the Company, enforceable in accordance with its terms.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 144pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Warrant Agent shall:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 144pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;examine all Exercise Forms and all other documents delivered to it by or on behalf of Holders as contemplated hereunder to ascertain whether or not, on their face, such Exercise Forms and any such other documents have been executed and completed in accordance with their terms and the terms hereof;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 144pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;where an Exercise Form or other document appears on its face to have been improperly completed or executed or some other irregularity in connection with the exercise of the Warrants exists, the Warrant Agent shall endeavor to inform the appropriate parties (including the person submitting such instrument) of the need for fulfillment of all requirements, specifying those requirements which appear to be unfulfilled;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 144pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;inform the Company of and cooperate with and assist the Company in resolving any reconciliation problems between the Exercise Forms received and the crediting of Warrant Shares to the respective Holders&#8217; accounts; and</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 144pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;advise the Company no later than two (2) business days after receipt of an Exercise Form, of (i) the receipt of such Exercise Form and the number of Warrants exercised in accordance with the terms and conditions of this Agreement, (ii) the percentage of the then outstanding Warrants represented by such exercise and (iii) such other information as the Company shall reasonably require.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-4-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 144pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page5"><!--EFPlaceholder--></a>(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All questions as to the validity, form and sufficiency (including time of receipt) of an exercised Warrant and any Exercise Form will be determined by the Company in its sole discretion, which determination shall be final and binding.&#160;&#160;The Company reserves the right to reject any and all Exercise Forms not in proper form or for which any corresponding agreement by the Company to exchange would, in the opinion of the Company, be unlawful.&#160;&#160;Such determination by the Company shall be final and binding on the Holders, absent manifest error.&#160;&#160;Moreover, the Company reserves the absolute right to waive any of the conditions to the exercise of Warrants or defects in the exercise thereof with regard to any particular exercise of Warrants.&#160;&#160;Neither the Company nor the Warrant Agent shall be under any duty to give notice to the Holders of the Warrants of any irregularities in any exercise of Warrants or any Exercise Form, nor shall it incur any liability for the failure to give such notice.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.3.3&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Issuance of Certificates</font>.&#160;&#160;Certificates for shares purchased hereunder shall be transmitted by the transfer agent for the Company's Common Stock (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Transfer Agent</font>") to the Holder by making available for credit to the account of the Holder's prime broker with The Depository Trust Company through its Deposit or Withdrawal at Custodian system ("<font style="DISPLAY: inline; TEXT-DECORATION: underline">DWAC</font>") if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, if permitted, and otherwise by physical delivery to the address specified by the Holder in the Exercise Form by the date that is three (3) Trading Days after the latest of (A) the delivery to the Company of the Exercise Form, (B) surrender of the Warrant (if required) and (C) payment of the aggregate Exercise Price as set forth above (including by cashless exercise, if permitted) (such date, the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant Share Delivery Date</font>").&#160;&#160;&#160;The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) of the Warrant Certificate, prior to the issuance of such shares, having been paid.&#160;&#160;Notwithstanding the foregoing, the Company shall not be obligated to deliver any securities pursuant to the exercise of a Warrant unless (a) a registration statement under the Securities Act of 1933 (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Securities Act</font>") with respect to the Common Stock issuable upon exercise of such Warrants is effective and a current prospectus relating to the shares of Common Stock issuable upon exercise of the Warrants is available for delivery to the Holders or (b) in the opinion of counsel to the Company, the exercise of the Warrants is exempt from the registration requirements of the Securities Act and such securities are qualified for sale or exempt from qualification under applicable securities laws of the states or other jurisdictions in which the registered holder resides.&#160;&#160;Warrants may not be exercised by, or securities issued to, any Holder in any state in which such exercise or issuance would be unlawful.&#160;&#160;In the event that a registration statement under the Securities Act with respect to the Common Stock underlying the Warrants is not effective or a current prospectus is not available, or because such exercise would be unlawful with respect to a Holder in any state, the registered holder shall not be entitled to exercise such Warrants and such Warrants may have no value and expire worthless.&#160;&#160;In no event will the Company be required to &#8220;net cash settle&#8221; the warrant exercise.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.3.4&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Valid Issuance</font>.&#160;&#160;All shares of Common Stock issued upon the proper exercise of a Warrant in conformity with this Agreement shall be validly issued, fully paid and nonassessable.<a name="Page6"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-5-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Adjustments</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Adjustments Generally</font>.&#160;&#160;The Exercise Price, the number of shares of Common Stock issuable upon exercise of the Warrants and the number of Warrants outstanding are subject to adjustment from time to time upon the occurrence of certain events in accordance with the provisions of the Warrant Certificate.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Notices of Changes in Warrant</font>.&#160;&#160;Upon every adjustment of the Exercise Price, the number of shares of Common Stock issuable upon exercise of the Warrants and the number of Warrants outstanding, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based.&#160;&#160;Upon the occurrence of any event specified in the Warrant Certificate then, in any such event, the Company shall give written notice to each Holder, at the last address set forth for such Holder in the Warrant Register, of the record date or the effective date of the event.&#160;&#160;Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Fractional Shares</font>.&#160;&#160;Notwithstanding any provision contained in this Agreement to the contrary, the Company shall not issue fractional shares upon exercise of Warrants.&#160;&#160;If, by reason of any adjustment made pursuant to this <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 4</font>, the Holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company shall, upon such exercise, round up or down to the nearest whole number the number of shares of Common Stock to be issued to the Holder.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Form of Warrant</font>.&#160;&#160;The form of Warrant need not be changed because of any adjustment pursuant to this <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 4</font>.&#160;&#160;However, the Company may, at any time, in its sole discretion, make any change in the form of Warrant that the Company may deem appropriate and that does not affect the substance thereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Transfer and Exchange of Warrants</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exchange and Transfer</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1&#160;&#160;&#160;&#160;&#160;&#160;The Warrant Agent shall keep, at the Warrant Agent Office, books in which, subject to such reasonable regulations as it may prescribe, it shall register Warrants and exchanges and transfers of outstanding Warrants upon request to exchange or transfer such Warrants, provided, that the Warrant Agent shall have received a written instruction of transfer or exchange&#160;in form satisfactory to the Warrant Agent, duly executed by the Holder thereof or by&#160;&#160;his duly authorized&#160;agent or attorney,&#160; providing all information required to be delivered hereunder,&#160; such signature to be guaranteed by an eligible guarantor institution to the extent required by the Warrant Agent or the Depository.&#160;&#160;Upon any such registration of transfer, a Warrant Statement shall be issued to the transferee.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-6-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page7"><!--EFPlaceholder--></a>5.1.2&#160;&#160;&#160;&#160;&#160;&#160;No service charge shall be made for any exchange or registration of transfer of Warrants; however, the Warrant Agent and/or the Company may require payment of a sum sufficient to cover any stamp or other tax or other charge that may be imposed in connection with any such exchange or registration of transfer.&#160;&#160;Neither the Warrant Agent nor the Company shall be required to pay any stamp or other tax or other charge required to be paid in connection with such transfer, and neither the Warrant Agent nor the Company shall be required to issue or deliver any Warrant Share until it has been established to the Company's and the Warrant Agent's satisfaction that such tax or other charge has been paid or that no such tax or other charge is due.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.3&#160;&#160;&#160;&#160;&#160;&#160;The Warrant Agent shall not effect any exchange or registration of transfer which will result in the issuance of a Warrant evidencing a fraction of a Warrant or a number of full Warrants and a fraction of a Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.4&#160;&#160;&#160;&#160;&#160;&#160;All Warrants credited to a Holder's or transferee's &#160;account&#160;upon any exchange or transfer of Warrants&#160;in accordance with the provisions of this Agreement shall be the valid obligations of the Company evidencing the same obligations, and entitled to the same benefits under this Agreement, as the Warrants&#160;that were so exchanged or transferred.&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Treatment of Holders of Warrants</font>.&#160;&#160;Each Holder of Warrants, by accepting the same, consents and agrees with the Company, the Warrant Agent and every subsequent Holder of such Warrants that until the transfer of such Warrants is registered on the books of such Warrant Agent, the Company and the Warrant Agent may treat the registered Holder of such Warrants as the absolute owner thereof for any purpose and as the person entitled to exercise the rights represented by the Warrants evidenced thereby, any notice to the contrary notwithstanding.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Cancellation of Warrant</font><font style="DISPLAY: inline; TEXT-DECORATION: underline"> Certificates</font>.&#160;&#160;Any Warrant Certificate surrender to the Warrant Agent for transfer, exchange or exercise of the Warrants evidenced thereby shall be promptly canceled by the Warrant Agent and shall not be reissued.&#160;&#160;Promptly following the Expiration Date or at such earlier time that there are no longer outstanding any Warrants, the Global Warrant shall be cancelled or destroyed and the Warrant Agent shall deliver a certificate of such cancellation or destruction to the Company.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Other Provisions Relating to Rights of Holders of Warrants</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Rights as Stockholder</font>.&#160;&#160;No Warrant shall, and nothing contained in this Agreement, in the Warrant or in the Warrant Statement shall be construed to, entitle the Holder or any beneficial owner thereof to any of the rights of a holder or beneficial owner of Warrant Shares, including, without limitation, the right to vote or to consent or to receive notice as a stockholder in respect of any meeting of stockholders for the election of directors of the Company or any other matter, to receive dividends on Warrant Shares or any rights whatsoever as stockholders of the Company, until such Warrant is duly exercised in accordance with this Agreement and such Holder is issued the Warrant Shares to which it is entitled in connection therewith.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Reservation of Common Stock</font>.&#160;&#160;The Company shall at all times reserve and keep available a number of its authorized but unissued shares of Common Stock that will be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.<a name="Page8"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-7-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Registration of Common Stock</font>.&#160;&#160;The Company included the shares of Common Stock underlying the Warrants in the registration statement on Form S-3 that was filed with the Securities and Exchange Commission in connection with the registered offering of the Units (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Registration Statement</font>").&#160;&#160;The Company will use its commercially reasonable efforts to maintain the effectiveness of such Registration Statement or file and maintain the effectiveness of another registration statement covering the shares of Common Stock issuable upon exercise of the Warrants at any time that both (a) the Warrants are exercisable and (b) the Exercise Price of the Warrants is less than the price at which the Common Stock is trading on the NYSE Amex (or if the Common Stock is no longer trading on the NYSE Amex, such other stock exchange on which the shares of Common Stock trades).&#160;&#160;In no event will any Holder of a Warrant be entitled to receive a &#8220;net cash settlement&#8221; in lieu of physical settlement in shares of Common Stock, regardless of whether the Company complies with this <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 6.3</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Limitation on Monetary Damages</font>. In no event shall the Holder of a Warrant be entitled to receive monetary damages for failure to settle any Warrant exercise if the Common Stock issuable upon exercise of the Warrants has not been registered with the SEC pursuant to an effective registration statement or if a current prospectus is not available for delivery by the Warrant Agent, provided the Company has fulfilled its obligations under <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 6.3</font> to use its commercially reasonable efforts to effect the registration under the Securities Act of the Common Stock issuable upon exercise of the Warrants.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Concerning the Warrant Agent and Other Matters</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Payment of Taxes</font>.&#160;&#160;The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Warrant Agent in respect of the issuance or delivery of shares of Common Stock upon the exercise of Warrants, but the Company shall not be obligated to pay any transfer taxes in respect of the Warrants or such shares.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Resignation, Consolidation, or Merger of Warrant Agent</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.2.1&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Appointment of Successor Warrant Agent</font>.&#160;&#160;The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged from all further duties and liabilities hereunder after giving sixty (60) days&#8217; notice in writing to the Company.&#160;&#160;If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor Warrant Agent in place of the Warrant Agent.&#160;&#160;If the Company shall fail to make such appointment within a period of 30 days after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by any Holder of a Warrant, then the Holder of any Warrant may apply to the Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company&#8217;s cost.&#160;&#160;Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing under the laws of the State of New York, in good standing and having its principal office in the Borough of Manhattan, City and State of New York, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state authority.&#160;&#160;After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.<a name="Page9"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-8-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.2.2&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Notice of Successor Warrant Agent</font>.&#160;&#160;In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to the predecessor Warrant Agent and the transfer agent for the Common Stock not later than the effective date of any such appointment.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.2.3&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Merger or Consolidation of Warrant Agent</font>.&#160;&#160;Any corporation into which the Warrant Agent may be merged or with which it may be consolidated or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant Agent under this Agreement without any further act.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.3&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Fees and Expenses of Warrant Agent</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.3.1&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Remuneration</font>.&#160;&#160;The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent hereunder and will reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its duties hereunder.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.3.2&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Further Assurances</font>.&#160;&#160;The Company agrees to perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required by the Warrant Agent for the carrying out or performing of the provisions of this Agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.4&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Liability of Warrant Agent</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.4.1&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Reliance on Company Statement</font>.&#160;&#160;Whenever in the performance of its duties under this Agreement the Warrant Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a statement signed by the General Counsel, President or Chairman of the Board of the Company and delivered to the Warrant Agent.&#160;&#160;The Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions of this Agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.4.2&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Indemnity</font>.&#160;&#160;The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith.&#160;&#160;The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement, except as a result of the Warrant Agent&#8217;s gross negligence, willful misconduct or bad faith.<a name="Page10"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-9-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.4.3&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exclusions</font>.&#160;&#160;The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the validity or execution of any Warrant (except its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant; nor shall it be responsible to make any adjustments required under the provisions of <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 4</font> hereof or responsible for the manner, method or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant to this Agreement or any Warrant or as to whether any shares of Common Stock will when issued be valid and fully paid and nonassessable.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 54pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.5&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Acceptance of Agency</font>.&#160;&#160;The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon the terms and conditions herein set forth and, among other things, shall account promptly to the Company with respect to Warrants exercised and concurrently account for, and pay to the Company, all moneys received by the Warrant Agent for the purchase of shares of Common Stock through the exercise of Warrants.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Definitions</font>.&#160;&#160;For purposes of this Agreement, the following terms shall have the following meanings:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; TEXT-DECORATION: underline">Affiliate</font>" means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; TEXT-DECORATION: underline">Black Scholes Value</font>" means the value of this Warrant based on the Black and Scholes Option Pricing Model using (i) a price per share of Common Stock equal to the Weighted Average Price of the Common Stock for the Trading Day immediately preceding the date of consummation of the applicable Change of Control, (ii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant as of the date of consummation of the applicable Fundamental <a name="SelTemp"><!--EFPlaceholder--></a>Transaction and (iii) an expected volatility equal to the greater of 60% and the 100-day volatility determined as of the Trading Day next following the date of the public announcement of the applicable Fundamental Transaction.&#160;&#160;Information concerning Company Common Stock activity can be obtained from either Nasdaq Data on Demand or Bloomberg LP.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; TEXT-DECORATION: underline">Change of Control</font>" means any Fundamental Transaction other than (A) any reorganization, recapitalization or reclassification of the Common Stock, in which holders of the Company's voting power immediately prior to such reorganization, recapitalization or reclassification continue after such reorganization, recapitalization or reclassification to hold publicly traded securities and, directly or indirectly, the voting power of the surviving entity or entities necessary to elect a majority of the members of the board of directors (or their equivalent if other than a Company) of such entity or entities, or (B) pursuant to a migratory merger effected solely for the purpose of changing the jurisdiction of incorporation of the Company.<a name="Page11"><!--EFPlaceholder--></a></font></div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-10-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; TEXT-DECORATION: underline">Common Stock</font>" means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">e)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;"<font style="DISPLAY: inline; TEXT-DECORATION: underline">Common Stock Equivalents</font>" means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">f)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;"<font style="DISPLAY: inline; TEXT-DECORATION: underline">Eligible Market</font>" means The New York Stock Exchange, Inc., The NYSE Amex, The NASDAQ Global Select Market, The NASDAQ Global Market or The NASDAQ Capital Market.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">g)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;"<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exchange Act</font>" means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">h)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;"<font style="DISPLAY: inline; TEXT-DECORATION: underline">Parent Entity</font>" of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">i)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;"<font style="DISPLAY: inline; TEXT-DECORATION: underline">Person</font>" means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">j)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;"<font style="DISPLAY: inline; TEXT-DECORATION: underline">Securities Act</font>" means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">k)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;"<font style="DISPLAY: inline; TEXT-DECORATION: underline">Subsidiary</font>" means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">l)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;"<font style="DISPLAY: inline; TEXT-DECORATION: underline">Successor Entity</font>" means the Person (or, if so elected by the Holder, the Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been entered into.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Trading Day</font>" means a day on which the principal Trading Market is open for trading.&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; TEXT-DECORATION: underline">Trading Marke</font>t" means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question:&#160;&#160;the NYSE AMEX, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or the OTC Bulletin Board (or any successors to any of the foregoing).<a name="Page12"><!--EFPlaceholder--></a></font></div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-11-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; TEXT-DECORATION: underline">VWAP</font>" means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. or Nasdaq Data on Demand (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&#160; if the OTC Bulletin Board is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board, (c) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and if prices for the Common Stock are then reported in the "Pink Sheets" published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&#160;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Miscellaneous Provisions</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.1&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Successors</font>.&#160;&#160;All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit of their respective successors and assigns.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.2&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Notices</font>.&#160;&#160;Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the holder of any Warrant to or on the Company shall be delivered by hand or sent by registered or certified mail or overnight courier service, addressed (until another address is filed in writing by the Company with the Warrant Agent) as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NeoStem, Inc.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">420 Lexington Avenue, Suite 450</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">New York, New York 10170</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attention:&#160;&#160;General Counsel</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any notice, statement or demand authorized by this Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall be delivered by hand or sent by registered or certified mail or overnight courier service, addressed (until another address is filed in writing by the Company with the Warrant Agent) as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-12-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page13"><!--EFPlaceholder--></a>Continental Stock Transfer &amp; Trust Company</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">17 Battery Place</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">New York, New York 10004</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attn:&#160;&#160;&#160;Compliance Department</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">with a copy in each case to:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 126pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Lowenstein Sandler PC</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 126pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">65 Livingston Avenue</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 126pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Roseland, NJ 07068</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 126pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Telephone: 973-597-2564</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 126pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Facsimile:&#160;&#160;973-597-2565</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 126pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attention: Alan Wovsaniker, Esq.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any notice, sent pursuant to this Agreement shall be effective, if delivered by hand, upon receipt thereof by the party to whom it is addressed, if sent by overnight courier, on the next business day of the delivery to the courier, and if sent by registered or certified mail on the third day after registration or certification thereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.3&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Notices to Holders of Warrants</font>.&#160;&#160;Any notice to Holders of Warrants which by any provisions of this Warrant Agreement is required or permitted to be given shall be given by first class mail prepaid at such Holder's address as it appears on the books of the Warrant Agent.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.4&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Applicable Law</font>.&#160;&#160;The validity, interpretation and performance of this Agreement and of the Warrants shall be governed in all respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction.&#160;&#160;The Company hereby agrees that any action, proceeding or claim against it arising out of or relating in any way to this Agreement shall be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive.&#160;&#160;The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum.&#160;&#160;Any such process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 8.2</font> hereof.&#160;&#160;Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.5&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Persons Having Rights under this Agreement</font>.&#160;&#160;Nothing in this Agreement expressed and nothing that may be implied from any of the provisions hereof is intended, or shall be construed, to confer upon, or give to, any person or corporation other than the parties hereto and the registered holders of the Warrants, any right, remedy, or claim under or by reason of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof.&#160;&#160;All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors and assigns and of the registered holders of the Warrants.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-13-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page14"><!--EFPlaceholder--></a>9.6&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Examination of the Warrant Agreement</font>.&#160;&#160;A copy of this Agreement shall be available at all reasonable times at the office of the Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the Holder of any Warrant.&#160;&#160;The Warrant Agent may require any such Holder to submit his, her or its Warrant Statements for inspection by it.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.7&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Counterparts</font>.&#160;&#160;This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.8&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Effect of Headings</font>.&#160;&#160;The section headings herein are for convenience only and are not part of this Agreement and shall not affect the interpretation thereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.9&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Amendments</font>.&#160;&#160;This Agreement may be amended by the parties hereto without the consent of any Holder for the purpose of curing any ambiguity, or curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable and that the parties deem shall not adversely affect the interest of the Holders.&#160;&#160;Except for modifications, adjustments or amendments in accordance with the terms of the Warrant Certificate or this Agreement, all other modifications or amendments, including any amendment to increase the Exercise Price or shorten the Exercise Period, shall require the written consent of the registered holders of a majority of the then outstanding Warrants.&#160;&#160;The Warrant Agent may request from either the Company or the Holders an opinion of counsel with respect to the validity of any amendment as a condition to its execution of any amendment.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.10&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Severability</font>.&#160;&#160;Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[Signature page follows]</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-14-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">IN WITNESS WHEREOF,</font> this Warrant Agreement has been duly executed by the parties hereto as of the day and year first above written.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="50%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEOSTEM, INC.</font></div>
</td>
</tr><tr>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="46%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td align="left" valign="top" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/ Robin L. Smith</font></font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Robin L. Smith</font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer</font></td>
</tr><tr>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="46%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CONTINENTAL STOCK TRANSFER &amp; TRUST COMPANY</font></div>
</td>
</tr><tr>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="46%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td align="left" valign="top" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/ Leslie A. DeLuca</font></font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Leslie A. DeLuca</font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vice President</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-15-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT A</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FORM OF WARRANT CERTIFICATE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-16-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div><br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[FORM OF WARRANT CERTIFICATE FOR SERIES NA WARRANTS]</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXERCISABLE ONLY IF AUTHENTICATED BY THE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WARRANT AGENT AS PROVIDED HEREIN</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">VOID AFTER THE CLOSE OF BUSINESS ON JULY 18, 2016</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEOSTEM, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;Warrant Certificate representing</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Warrants to purchase _______ shares of common stock, par value $0.001 per share</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">as described herein</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Warrant No. _______&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cusip No. 640650 164</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font>

<div>
<hr style="COLOR: black" align="center" noshade size="1" width="50%">
</div>

<div>&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED, OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each Series NA Warrant (each a "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant</font>") represented hereby, entitles the holder to purchase one share (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant Share</font>") of common stock, $.001 par value (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Common Stock</font>") of NeoStem, Inc., a Delaware corporation, (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Company</font>") for the benefit of certain Holders (as defined in the Warrant Agreement) of such Warrants on the following terms.&#160;&#160;This&#160;&#160;Warrant Certificate represents the number of outstanding Warrants from time to time endorsed hereon and the number of outstanding Warrants represented hereby may from time to time be reduced or increased, as appropriate to reflect exchanges, exercises and other similar transactions.&#160;&#160;This&#160;&#160;Warrant Certificate is issued under and in accordance with the Warrant Agreement (as hereinafter defined), and is subject to the terms and provisions contained therein, all of which terms and provisions the Holders consent to by acceptance of their book-entry interests in the Warrant Certificate or their receipt of this Warrant Certificate.&#160;&#160;Copies of the Warrant Agreement are on file at the Company's headquarters.&#160;&#160;In the event of any conflict or inconsistency between this Warrant Certificate and the Warrant Agreement, the Warrant Agreement shall control.&#160;&#160;Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Warrant Agreement dated as of July 22, 2011 by and between the Company and Continental Stock Transfer &amp; Trust Company (as such agreement may be amended from time to time, the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant Agreement</font>").</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise Period</font>.&#160;&#160;The Warrants shall vest in full and become exercisable on July 22, 2011 (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Initial Exercise Date</font>") and, notwithstanding anything to the contrary contained herein, shall expire at 5:00 p.m. (Eastern Time) on July 18, 2016 (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Termination Date</font>").<a name="Page2"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 1</font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Definitions</font>.&#160;&#160;For purposes of this Warrant, capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Warrant Agreement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 81pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2</font>.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise</font>.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the then designated office of the Warrant Agent (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) (i) a duly executed facsimile copy of the Exercise Form substantially in the form attached hereto (with a copy to the Company) and (ii) within three (3) Trading Days following the delivery of the Exercise Form, payment of the aggregate Exercise Price for the shares specified in the applicable Exercise Form.&#160;&#160;The Holder shall deliver the aggregate Exercise Price by wire transfer of immediately available funds or good cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Exercise Form.&#160;&#160;Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.&#160;&#160;The Warrant Agent and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Exercise Form within one (1) Business Day of receipt of such notice.&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise Price</font>.&#160;&#160;The exercise price per share of the Common Stock under this Warrant shall be $1.45, subject to adjustment hereunder (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise Price</font>").</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Cashless Exercise</font>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder and all of the Warrant Shares are not then registered for resale by Holder into the market at market prices from time to time on an effective registration statement for use on a continuous basis (or the prospectus contained therein is not available for use), then this Warrant may also be exercised, in whole or in part, at such time by means of a "cashless exercise" in which the Holder shall be entitled to receive a certificate for the number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(A) = the VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a "cashless exercise," as set forth in the applicable Exercise Form;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</font></div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><a name="Page3"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In no event may this warrant be net cash settled.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Mechanics of Exercise</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Delivery of Certificates Upon Exercise</font>.&#160;&#160;Certificates for shares purchased hereunder shall be transmitted by the transfer agent for the Company's Common Stock (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Transfer Agent</font>") to the Holder by crediting the account of the Holder's prime broker with The Depository Trust Company through its Deposit or Withdrawal at Custodian system ("<font style="DISPLAY: inline; TEXT-DECORATION: underline">DWAC</font>") if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery to the address specified by the Holder in the Exercise Form by the date that is three (3) Trading Days after the latest of (A) the delivery to the Company of the Exercise Form, (B) surrender of this Warrant (if required) and (C) payment of the aggregate Exercise Price as set forth above (including by cashless exercise, if permitted) (such date, the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant Share Delivery Date</font>").&#160;&#160;&#160;The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance of such shares, having been paid.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intentionally Omitted.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">iii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Rescission Rights</font>.&#160;&#160;If the Company fails to cause the Transfer Agent to transmit to the Holder a certificate or the certificates representing the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-3-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page4"><!--EFPlaceholder--></a>iv.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Compensation for Buy-In on Failure to Timely Deliver Certificates Upon Exercise</font>.&#160;&#160;In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder a certificate or the certificates representing the Warrant Shares (or to credit Holder's broker's DWAC account) pursuant to an exercise on or before the second Trading Day following the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder's brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Buy-In</font>"), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder's total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.&#160;&#160;For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.&#160;&#160;Nothing herein shall limit a Holder's right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company's failure to timely deliver certificates representing shares of Common Stock or credit the Holder's broker's DWAC account upon exercise of the Warrant as required pursuant to the terms hereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">v.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Fractional Shares or Scrip</font>.&#160;&#160;No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.&#160;&#160;As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">vi.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Charges, Taxes and Expenses</font>.&#160;&#160;Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">however</font>, that in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; <a name="Page5"><!--EFPlaceholder--></a></font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-4-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">vii.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Closing of Books</font>.&#160;&#160;The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Holder's Exercise Limitations</font>.&#160;&#160;The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Exercise Form, the Holder (together with the Holder's Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder's Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&#160; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other&#160;&#160;Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates.&#160; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.&#160;&#160;&#160;To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Exercise Form shall be deemed to be the Holder's determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.&#160;&#160;&#160;In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.&#160;&#160;For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company's most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&#160; Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&#160; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported.&#160;&#160;The "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Beneficial Ownership Limitation</font>" shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant.&#160;&#160;The Holder, upon not less than 61 days' prior notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply.&#160;&#160;Any such increase or decrease will not be effective until the 61<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">st</font> day after such notice is delivered to the Company.&#160;&#160;The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.<a name="Page6"><!--EFPlaceholder--></a></font></div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-5-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 81pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 3</font>.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Certain Adjustments</font>.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Stock Dividends and Splits</font>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant, and which shall not include any shares of Common Stock issued in connection with dividend payments in respect of the Company&#8217;s Series E 7% Senior Convertible Preferred Stock), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged.&#160;&#160;Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Subsequent Rights Offerings</font>.&#160;&#160;If the Company, at any time while the Warrant is outstanding, shall issue rights, options or warrants to all holders of Common Stock (and not to the Holder) entitling them to subscribe for or purchase shares of Common Stock at a price per share less than the VWAP on the record date mentioned below, then the Exercise Price shall be multiplied by a fraction, of which the denominator shall be the number of shares of the Common Stock outstanding on the date of issuance of such rights, options or warrants plus the number of additional shares of Common Stock offered for subscription or purchase, and of which the numerator shall be the number of shares of the Common Stock outstanding on the date of issuance of such rights, options or warrants plus the number of shares which the aggregate offering price of the total number of shares so offered (assuming receipt by the Company in full of all consideration payable upon exercise of such rights, options or warrants) would purchase at such VWAP.&#160;&#160;Such adjustment shall be made whenever such rights, options or warrants are issued, and shall become effective immediately after the record date for the determination of stockholders entitled to receive such rights, options or warrants.&#160;<a name="Page7"><!--EFPlaceholder--></a></font></div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-6-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Pro Rata Distributions</font>.&#160;&#160;If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Common Stock (and not to the Holder) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe for or purchase any security, then in each such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned above, and of which the numerator shall be such VWAP on such record date less the then per share fair market value at such record date of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share of the Common Stock as determined by the Board of Directors of the Company in good faith.&#160;&#160;In either case the adjustments shall be described in a statement provided to the Holder of the portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Common Stock.&#160;&#160;Such adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned above.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Fundamental Transaction</font>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (each a "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Fundamental Transaction</font>"), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring Company or of the Company, if it is the surviving Company, and any additional consideration (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Alternate Consideration</font>") receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).&#160;&#160;For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.&#160;&#160;If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.&#160;&#160;Notwithstanding the foregoing, in the event of a Change of Control other than one in which a Successor Entity that is a publicly traded Company whose stock is quoted or listed for trading on an Eligible Market assumes this Warrant such that the Warrant shall be exercisable for the publicly traded common stock of such Successor Entity, at the request of the Holder delivered before the 90th day after such Change of Control (such a request, a "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Black Scholes Exercise</font>"), the Company (or the Successor Entity) shall purchase this Warrant from the Holder by paying to the Holder, within five business days after such request (or, if later, on the effective date of the Fundamental Transaction), cash in an amount equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the date of such Change of Control.&#160;<a name="Page8"><!--EFPlaceholder--></a></font></div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-7-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Calculations</font>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">f)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Notice to Holder</font>.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Adjustment to Exercise Price</font>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-8-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page9"><!--EFPlaceholder--></a>ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Notice to Allow Exercise by Holder</font>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice.&#160;&#160;To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.&#160;&#160;The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 81pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 4</font>.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Transfer of Warrant</font>.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Transferability</font>.&#160;&#160;This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon delivery at the principal office of the Company or its designated agent, of a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.&#160;&#160;Upon such delivery and, if required, such payment, the Company shall instruct the Warrant Agent to record the Holder's transfer of its interest in the Warrant to be duly noted on its record in the denomination or denominations specified in such instrument of assignment.&#160;&#160;The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intentionally Omitted.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant Register</font>. The Company shall register this Warrant, upon records to be maintained by the Company or the Warrant Agent for that purpose (the "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant Register</font>"), in the name of the record Holder hereof from time to time.&#160;&#160;The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; <a name="Page10"><!--EFPlaceholder--></a></font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-9-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 81pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 5</font>.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Miscellaneous</font>.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Rights as Stockholder Until Exercise</font>.&#160;&#160;This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;Intentionally Omitted.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Saturdays, Sundays, Holidays, etc</font>.&#160;&#160;If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Authorized Shares</font>.&#160;&#160;The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.&#160;&#160;The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant.&#160;&#160;The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.&#160;&#160;The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.&#160;&#160;Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.<a name="Page11"><!--EFPlaceholder--></a></font></div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-10-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Jurisdiction</font>. This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Restrictions</font>.&#160;&#160;The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions upon resale imposed by state and federal securities laws.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Nonwaiver and Expenses</font>.&#160;&#160;No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder's rights, powers or remedies.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Notices</font>.&#160;&#160;Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the information provided by the Holder to the Company in writing.&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Limitation of Liability</font>.&#160;&#160;No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Remedies</font>.&#160;&#160;The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant.&#160;&#160;The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">k)&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Successors and Assigns</font>.&#160;&#160;Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.&#160;&#160;The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Amendment</font>.&#160;&#160;This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holders of a majority in interest of the Warrants.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Severability</font>.&#160;&#160;Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.<a name="Page12"><!--EFPlaceholder--></a></font></div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-11-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Headings</font>.&#160;&#160;The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 6</font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Validity</font>.&#160;&#160;This Warrant Certificate shall not be valid or obligatory for any purpose until authenticated by the Warrant Agent.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-12-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant Certificate to be executed by its duly authorized officer, this ___ day of ____________, 20__.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEOSTEM, INC.</font></div>
</td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="50%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Robin L. Smith</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chairman &amp; Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[Certificate of Authentication]</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[This is a Warrant Certificate for the NA Warrants referred to in the within-mentioned Warrant Agreement.]</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CONTINENTAL STOCK TRANSFER</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&amp; TRUST COMPANY, As Warrant Agent</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="50%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="95%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160; </font></td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="95%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Authorized Signature</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-13-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160;<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[TO BE ATTACHED TO GLOBAL WARRANT CERTIFICATE]</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SCHEDULE OF INCREASES OR DECREASES IN GLOBAL WARRANT CERTIFICATE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NA WARRANTS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following increases or decreases in this Global Warrant have been made:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="10%" style="BORDER-TOP: black 1pt solid; MARGIN-LEFT: 0pt; BORDER-LEFT: black 1pt solid; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
</td>
<td valign="top" width="23%" style="BORDER-RIGHT: black 1pt solid; BORDER-TOP: black 1pt solid; MARGIN-LEFT: 0pt; BORDER-LEFT: black 1pt solid; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amount of decrease in the number of Warrants represented by this Global Warrant</font></div>
</td>
<td valign="top" width="22%" style="BORDER-TOP: black 1pt solid; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amount of increase in number of Warrants represented by this Global Warrant</font></div>
</td>
<td valign="top" width="23%" style="BORDER-RIGHT: black 1pt solid; BORDER-TOP: black 1pt solid; MARGIN-LEFT: 0pt; BORDER-LEFT: black 1pt solid; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number of Warrants represented by this Global Security following such decrease or increase</font></div>
</td>
<td valign="top" width="22%" style="BORDER-RIGHT: black 1pt solid; BORDER-TOP: black 1pt solid; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Signature of authorized officer of the Depositary</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-14-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160;<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FORM OF EXERCISE FORM</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To Be Executed by the Holder in Order to Exercise NA Warrant</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The undersigned hereby irrevocably elects to exercise the right, represented by the book-entry Warrant(s), to purchase ____________ shares of the Common Stock of NeoStem, Inc. (the "Warrant Shares") and the undersigned herewith makes payment of the full purchase price for such shares at the price per share provided for in such Warrant in accordance with the terms of the Warrant Agreement.&#160;&#160;Such payment takes the form of $__________ in lawful money of the United States.</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The undersigned hereby requests that certificates for the Warrant Shares purchased hereby be issued in the name of:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 252pt"></font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(please print or type name and address)</font></div>
</td>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(please insert social security or other identifying number)</font></div>
</td>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">and be delivered as follows:</font></div>
</td>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(please print or type name and address)</font></div>
</td>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(please insert social security or other identifying number)</font></div>
</td>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and if such number of shares of Common Stock shall not be all the shares evidenced by this Warrant Certificate, that a new Warrant for the balance of such shares be registered in the name of, and delivered to, Holder.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div align="right">
<table cellpadding="0" cellspacing="0" width="50%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="100%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="100%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Signature of Holder</font></div>
</td>
</tr><tr>
<td valign="top" width="100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="100%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SIGNATURE GUARANTEE:</font></div>
</td>
</tr><tr>
<td valign="top" width="100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="100%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This Warrant may be exercised by delivering the Exercise Form to Continental Stock Transfer &amp; Trust Company at the following addresses:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By mail at&#160;&#160;&#160;&#160;&#160;&#160;&#160;Continental Stock Transfer &amp; Trust Company</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; 17 Battery Place</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; New York, New York 10004</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; Attn:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[_______________]</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-15-</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160;<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[FORM OF ASSIGNMENT]</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(TO BE EXECUTED TO TRANSFER THE WARRANT)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For value received, ______________________________ hereby sells, assigns and transfers unto the Assignee(s) named below the rights represented by such number of NA Warrants listed opposite the respective name(s) of the Assignee(s) named below and all other rights of the Holder with respect to such Warrants, and does hereby irrevocably constitute and appoint _____________________________ attorney, to transfer said Warrant on the books of the Depositary and/or the Warrant Agent with respect to the number of Warrants set forth below, with full power of substitution:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="31%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name(s) of</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Assignee(s)</font></font></div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="32%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Address</font></font></div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="32%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">No. of Warrants</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dated: _____________</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 99pt" align="left">
<table cellpadding="0" cellspacing="0" width="50%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="100%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
</tr><tr>
<td valign="top" width="100%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Signature</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="100%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Signed exactly as name appears in the</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="100%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">records of the Depositary)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Signature Guarantee:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_____________________________________</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>v236875_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 31.1</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I, Robin Smith, M.D., certify that:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of NeoStem, Inc.;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by&#160;&#160;this report based on such evaluation; and</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date: November 10, 2011</font></div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/ Robin Smith, M.D.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name: Robin Smith, M.D.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Title: Chief Executive Officer of NeoStem, Inc.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A signed original of this written statement required by Section 302 has been provided to NeoStem, Inc. and will be retained by NeoStem, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>v236875_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 31.2</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I, Larry A. May, certify that:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of NeoStem, Inc.;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by&#160;&#160;this report based on such evaluation; and</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date: November 10, 2011</font></font></div>

<br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/ Larry A. May</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name: Larry A. May</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Title: Chief Financial Officer of NeoStem, Inc.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A signed original of this written statement required by Section 302 has been provided to NeoStem, Inc. and will be retained by NeoStem, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>v236875_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 32.1</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION PURSUANT TO</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18 U.S.C. SECTION 1350,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AS ADOPTED PURSUANT TO</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the Quarterly Report of NeoStem, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September 30, 2011 filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Robin Smith, M.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date: November 10, 2011</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ Robin Smith, M.D.</font></div>
</td>
</tr><tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Robin Smith, M.D.</font></div>
</td>
</tr><tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A signed original of this written statement required by Section 906 has been provided to NeoStem, Inc. and will be retained by NeoStem, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>v236875_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 32.2</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION PURSUANT TO</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18 U.S.C. SECTION 1350,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AS ADOPTED PURSUANT TO</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the Quarterly Report of NeoStem, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September 30, 2011 filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Larry A. May, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)&#160;&#160;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended ; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)&#160;&#160;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date: November 10, 2011</font></font></div>

<br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ Larry A. May</font></div>
</td>
</tr><tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Larry A. May</font></div>
</td>
</tr><tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A signed original of this written statement required by Section 906 has been provided to NeoStem, Inc. and will be retained by NeoStem, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex3-1pg1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-1pg1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`?0!]`P$1``(1`0,1`?_$`'(```("`P$``P``````
M``````@)``<%!@H$`0(#`0$`````````````````````$``!!`,``00"`0,"
M!04````%`P0&!P$""`D`$Q05$A81(A<8(PHA,B0E)C,G&2D:$0$`````````
M````````````_]H`#`,!``(1`Q$`/P#OX]!/03T$]`I/J_S1\8\R6,]YZBY&
M?=9]=:ID$1O)W(D)+7A<&YD?N@DN'E"<737C->N&FSG51WJ;?LW#9MINKE';
M\<:[`K2=^1?RR]`S1:N(N5Y%\:Q+;1XIFIQXJ9>37OMHCHS4+,E3](<_@BD`
MJ]?9HCHW=LY/JS<-72^4\J84QIC(:20X%\A5S,R;^]NG?+K;8@:7;N5Y!(NF
M^5?&141-H#)+BLGQ\$I;-[6H"^*)US_TY$<*0*I**/=UD7&44<A0=J^('D(Q
M:TP1EFG&)Z;*J_<$][<\\'8"MN.@_P`5K]:8FK1[0Y$EHYV$;-_Y5V551PGG
M3&BFVGXYR&V5)XCZP>U_,VO+!L(R+%S\>;(:>/[SV]#*&"Y0=JJY+-I&K.>>
MR,%4=#@CI-5/15HY>8;**?A[7Y:;Y"YB-0>5_FQ\Y*0OO[R.UP'9[$26@3LO
ME.E/(M5A#1%8DWRN=M[DP[+[7AD<UCX?5?&[F/C\-MM/D.,(KO=6^`O6GO-5
MUU!1Q`WU'R'!>H:<`*(-I1T_XI+`<=!L:_PALOJ4)7;RM,-@W150#V+%BX>.
ME'[;95MLBHV^-NIKC.0=9R1W=R)W9#7DZY.OJ!W*'$[H(2,?'R"S.7P]VXUS
ML@SFL$.-Q4TA[I;\=L)ZD6#;WOPVRGG?&,Y]`6WH)Z">@GH)Z">@I?H/HFDN
M4ZDEU[=$63&JGJ:#-$7<EF<I=*(#V?RG"3)@Q:MVR3DB7,%7RZ;=FQ9HN'CQ
MPIJFBEOOMC7(<P=R]<]K>3D[&8H'UO[B#CJT4<&:2I"A$F./)?W?7SW?\AUC
M2$J\>,X_P[RB>%M'.V\M/.F/O;YU:ZJD,ND$M0O:H>3.8N.@QZLR.@N)/1;<
M9)YYQ5P[(W<<R)2?ZJD`9?OONB6R6+678+E71ZBIN0F<M@43*?EMHU`O]-D]
M-POJGK&F,CHJU35(,(9R_P`_4W6]AV/%8CQM!1+>OK=+5F7D0PI#VW:L\K]Q
M!4C@^3PQ8-+_`*ZO='6JJRKD<;(HHN5M`HBSIWS]=7CYVZZC<;&I692-^U#3
MO943Z4>.^S']:LT;RJ:HNM*W?8M5Q8T=P#S!GN3PB4BAS1L]!(LS+=-%!TII
MZ#T1.R[,">/ZZ^G(',H,TM[@SI^W9%:E6/8!3E77)/.4*1FI5R\Y*ZV5%PN.
MA8?<LOHM-$PS(@F[$46):!%M-WS!TX4=`REQ37*%$<@V5T58-20V[H_#8=:_
M7K_]BBT3GI!DT3C,EL;2*5BO(&C]A'Q,8B"VP`&DSW;H:M-/RV_J77VW`+X_
M%I_3K_A0:]D$DY,D':S\]&PD"YSM66G8[S]-AU!&+G!Q61U5T,:MNH[<B(2+
M5@H&,$`$4A66#_'OIXU2(*;:!KPB[*^ZA&UQ;<\YSF5X[3BJC-B5OT]S%`;(
MYM[;%U]&S4=B#Z:QV-@3^ANPHHB;=L7>=89.RCMVR79;YB:C5SIKL`JW9P3%
M+`T1[5YEMRQ);8$6(/"3;NCC6&`*[[ZJU5BCES^J=>\M1\#$(1VR#;DTTMY,
M*=1N)6/AJC\?8:54]W54"GXE\Q,TB<TKOFCR8$*R&'+3R^:\R^06J%/J>.^K
M<#,Y:ZP\^1,8':T-TVW<L'B9F%%TAZC0@CLUP@U6W:H.0Z+O03T$]!/04OT3
MT'4?*=)61T1>\N9P6I:HC;F4S.3/$G#G#-@BHBU;-63%HFL]*&#!)T@R8LT-
M-W#QZX213UVWWUQD.7P0&O;RQ7M".E>EH0"!0($"1MCBSBNV&[,_2_*U,'V;
MW4+Y`_(&%P\2CT\NZ>1Y)PO7-<KN,))I8W44W09H%"B`'?6KZG(PY`1$)?9.
MCJ[Z<G+2/N.I;1EF=>UO(9.)`0?;038'8>\>9(TM1LF?KEQD)<-TQ[HB/QJC
M#&(5BHR>O0Q/*\V"5%(N@J%Z8JM:%&.36K&?V1`ZX,:E:DLP1M/`4^Y7N2C*
ML>C#-WW;()I^DY;FI1(S!"3:3F/O1Q!P_;*H[(!DJ]82XC:7D3H[DH.AT+RK
MT[.BL@^_BIK8%!N=KUM.,%(YUBS<6E8S$O!YS&Y),6C8_N&A;>4NPYPP4T<L
M&VF===PS-@<U1,-9ELV5U7=W.G.@RU0U-PNU328,*VJ21/:T;1MY6M<N)#T/
M8XNGI=/6<4!DMM\-ZLTS@.[3PJJDDFW8^@(F#P:M)9H:=QZY>@9WM>3_`'DL
M:7P]YR3J6P1,6`.!3`F+GE#U.^J\O$A@*"(+Z+E'!$FPU=LV^^$U-T&B845'
M+>@-A2&=U+17;FUWCE&,='R>DJZLCF#II(3#AL>="+.`,J9D-%UQ,I562JNJ
MC)WM&9*7?KMU]%DVC+7*;/8*CLCA^_C=*RQY5)6)](+E.8)CS%3%PP":2N'V
MUSI6TZAJ4>F8ZDJ"O>:RBH!4J,H,]!KLJXFH&5)#T&37=PIHTW35`T^4NB>%
M*%HB7!8BXDU*K4)%(^ZM:C++C=JL;DJ,`##P^MV&!M7SA(Y8R-2_F%8:C7H?
M5[%]]5LN4'/X;JJ8`+("K;UY3'HWH.4M3<5Z9Y$Z#N^C;"L"A7=8P%W&@`$[
M#Y52;MMB9&(O7G2/-*?*]HI2&4A;$(D#[*0#LZ!<BGV=<(!J,KJ6ANY`IQ%2
M%T_/)5T+#7TP.59%Y`X"\4>36(-/Q./[)KM9VKD]0/<,/CCM%\W-**-9<$T=
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M4/QN*33R"`XQ,DJ1K?>`U[8K%S5_=\'D%PXN&)U39O,):/HN7(-9H8:2@%E<
M=JDY=#@^=0Q'$PVL_)!)G<ANF:6#:82M8)O'(ZUN6N@%=WK?M0&I@ON&D=YD
M87#H`.BE;'B,42>:UP(9C<&6:[$I*LD='[1@T"[KEGUE27J6M$N7)GSC+>90
M=7$V\\I]XC8*!]U'N>)IJ[E9RE)W6DTC\%J1']AE`0`-=/1A%`T>"X9?DDR;
M+;X"Z"XZNJY',[.NX-&9*RJF`R(:Z*6_^O$HG";$M221B0SI&:3PTU+;$)-%
M@S&*QU%PV^UD4F4T6U;-UWF[O"H!393>I6E4=J9D;+/+]46K5SN/S9X['1_E
M5<VQM">Q4+8\OA53/IU(IG7ZIFKG3)`V<,"8^7..,HN7++.VJ6=0-_HD9R]K
MSH(TG;6+PU]R`M*"E7V7!8P4;O\`F#%+H/(QO8L'>Q@,Q5C*PV!-D6SB.L,_
M$/[/=8[A%ZB[U24#0&_=TQB$HI.53_GN\ZD@W0S]5F$L.?Z<\'XF3)FI'D;6
MD$MU:K))F6TC*I.X.C@T:('%G(A@0?M11K?!!9==L%R=`D:)Z+EU-0L[!]9.
M]/RA:,UM9T;-*Q:VJZG9:(RXQ,G<)D`+9:3Q)Q64(C#W]N'$T4A[I8H-'/$7
M";APA@$]VC;T(L*YXSXF[)L2/1:DM+(F1>6LJTJJOZ_%>3.-1=@ZE3KD]C)8
MK(X=$JAO@S-&Z;&8"MV@EI9HMLJH)=C$'CACD#CLV:B+;OJ!<SA^58_5IJ^`
MT6Z0L>9FYRE&+IHVF*>BND8A'1Z9*LVDIC%265"I(@.B\-8*&%]B3C4AHKKH
M-8D<*`$?3%:TIV73-Y2>Q\,;J?CZWA(?MMA0)A9?/1//\-.FA5)^1CF1/*R4
M;%7?SK*8D>4=MF2#EVND!D<-74?)(A??`XO#;V!:4V!VGP1UO,@,R[!XIVCP
MW-EA7C5P(ZIY<E8UB4Y]ZKB2K7=5N2'S6'OVC8JHDLYWT(Z:*NMTW+S=!('?
M>@4KYH.K;$YGXS)17GQZCKUSUG.X9R-R<,3(9'F%;>NTJG&=9.'7TT4V:.:]
MBRY`VFZWQJW;NF:'N;X_/778%V\;<_-:+K.!U;41]R)=;"YEQWS58[WV&AN,
M5%69U1_Y`>YQJAQRJ.$V/U'TD_4"1X@[S["VVL,4VRHR473V#Z+SJ(Q<'8/!
MW;?'[V!9O&+%QE-<VVO<4MD/.MQ26MM&CKF2M>&+3KV.N8?%['5*(LE9GAUM
M&)PSD2B4DU6*9UW63"P`/--8R*B;=OY@P?VE1^P.#QKF2-=,](RF;,>B)U#G
M)`#&[>NFW>C"9_4Y1\7*%EF=>B]T,#=06A.3Z,7A4R.79`%O5MP2;G[FOQTW
M_P`IM7^.MK=*R>NI)O1%(2>VDK>1(SF:%9^Q#4"6?/$2X8U,"DE,LT7)(%N@
M(27:MG;;35HP]`=GC,O+A6_X=.=J2YGIKCGK:RCT3L^Q:7@F("ZTN!+GJ4`R
M[!6O38P0Q92:`#5PV!SG+44-3%F'+Q5'397.2*X$Q=%E58"L(-$1`\A>/0S:
M8&;KIZH*_C\X,7)'STX<NA'\G:\D6$Z+YSR/'^Z*4L23J#FPO5ZZ?Y;ID7;A
MT^!<??"DGY@?U?=_:E><JW_&Y+'U`<&Y$/:PZ6QFF964--G,K;$E[E/,B]]R
MNWZ_#(BB5K+L]BX&2@6F@X*H-+/V2X%#1%8UJ+!UF4D='=D.*;`RR+R^M:9-
ME,]14)!)&8G!U^:-Y(\LV%/U[B6@CIJ@@(2G(TBA"]6K9)OHCAMILV#/XJHQ
MW?>M>"\XG!7QOU;2W6D;Z'?7;7METTMTK8_3<E'%V</KV*V&)B$[!P_G3>/;
MO&<G239Y%.<MV0YZY60=*M@5'WQW6ASWF2X\?UKW_P!2SU&`RDS.>BI@:Q?S
MVB^;QC.$S";8HN,QF+LF3Z'2-B@P1G-LDV4N.QKX(U$GH5478HI`4?4E55G<
MM1<*Q;9XP*4N<J^(3[HH><*Q."&A40A=AC7IB7PA1V/8&0UNN)>=,OQPX#@,
M[#I1UY\;=`D@,3P!H1^(=-4I<-L4=38*F!O7EWXAC1;L>VB\EESZQ>3:LCY$
M!#>@#E5,EA"-@7G2AZ3;126@&;\(,?G9`%DKA7XA9VT0"H"L+B/*O0==5W7/
M67^2G>D=$V'=NL4F!4'(;SMYJ;5=S[L&IY=&8$'%@*CI:ZXP%9%()'MD4&(>
MP@(MTANHEDCH^!?O5Q%KR7;E$>1'FTCL2JWD?$(NF,%X2+RBPM[PW=32H+&+
MSHQ0:/;#]3C[BBY"B1B."7FV-PD=DHS^C509_&@=@G[]#/T+^Z/[&+_M[^H?
MOW[=\C'TOZ9]-^Q?L?ROX_'ZOZ/_`*KW/X_CVO\`CZ#EV\C-@R6_/+,I%H4L
M^_\`KEY:`QVKW+!JW(*BN^O)Y.(_SQ2\I3&$%&[%YFI*\,8E*+G&^GP7++?.
M5D]_XQZ`[4>7-;F;7?3U96)4E;3SG$]2_.%`QZY83%^EXRK4//-11R2C"UDT
MH4F$5($/VNSK+7-_FJX:.DR45CQ;.[K#5OC8!ZNB$WKR_5%G5A8-R=1=)-ID
M\4E0IYT*6K"=7(Z(Q[#B+73).?I!`"T$$UK#^G?[OQ"HX9&=WXAQ'"TT(ND]
MV2#;?*X>.ZNS5;I\?O2-67/6@T&7YTNR&<U]`U73@@]#T3HXI3T=MV-U96(4
M_F2/620_>0B8[*\*O$!FT88F'VCU@U4RFT#0J,@Y6V/+IP!`7Q./J1[@KAJ8
MV7)(O&12>8:]M2<1H+&F$T9NW1K+=_*7@+HMJZ>$&3-RHH_PXV4>JJ+.=$`,
M?R,>++ANT7CNU,6MMPS?]@RQ,H-M:MMH]JUG%GHJ#I(C+3=/FT5H_+)ZTVA3
M8B[."$Q,A=)B$LD"*[%KE#T&GQ/F?RLW:%!*!O+W63J&-!K^.EB\`YC?!)3L
M)+CC6P@J\0=V.Q.-9\+1.-%=EGCS3"B@M'3*2*FSS9<"/JSPR\JBCQFQ.GMI
M+W);<CT>?92GIAWO-(6"R3$,P9)&OZF(N",0C*3L>-:_D\>8+G-G#?5SN1W=
M;*+[A4CSPURJD"SL[X]>W;XY8&JO199.FYD6D5X4KHY`LV+$8%%BS,QC\K"1
MAR/$MF3AHX(EVZ+39QLT2;.E\N=`Q\Z\9G>_3D!&TSV!Y&6)^HT561.3MZ:H
M@)$9M.#"!%Z9W^Q,24V?C`L8,.;LGH?3<014%[C$-,;*XRKON!B5KX_N08!R
M_>_-%$1Z([,+QK*:5Q:<V>D6LPG,[S-(&ZBZ*UAR@>Y:ER`L7'CR*0T0V48B
M0PG9%F*:L66J".@<^O.-I.9?XV^371HR0;S#CFT9M1;?2*D56\NBUE02`JR:
M(1^;MDA%P22QHK6N8V8=RF/BEG6KT.,V7>)(--%F*(&%U7T_9?6/0QZF:XK<
M'*HARQ9(JHIA.@L-M$%.&UOVK0[DGL($VPC)0<)2HCI07)7E;ZZ-FA-ZP,D1
M)W.^NJ39=@!K<6\.TBRH>%RB,@2M+Q$MFEYSL[K>S-O@WN(J"9#[CKN^+3-?
M5LICFU;*?HM%9OL6)DGKE%)<8X>.6O\`J[@)EV#*+D*=[PD'O#Y?37+73H>N
M;57;.P:L-&\C>4")"(WT;4S$RQ6V!ZYKV=6+I.<CUL;_`%Z`@5KJDI_"*&X+
MATZ.MQ3P.N/&UI+#^W837NYGX&7$IPU>902-/[6?"6AG<A]Y\O6)K\G#5V^I
M'+CV,ND]D\?Z.,Y]`0/CV%E.B>_;YO,@`-CVUL>87IZ;/WJP(JQ^RJ[QQ\Q.
M>9JU&E#(;;4$BD+MF\&:[#?7\D2GPB*3Q79REHCD"3J:75M)?,QT91<FJEB4
MC=P")A,8U;)50DTM.56'!VT*CQ1Z`.N0`.0MJQI).K'X0"2%$$,"B!E9LUU>
M-W"Y#<"8Z$JJSHW=$W+V5I<\\#CH9S%*N7K@I*F+#MZ9-W7+EX&[OEU-W_&H
M3)V(\P2L"4.0&B3Q%*,LI,+;8T=.M78S=10`@N>L;FY$Y?YKB\SE(&-]2]7=
M.W'<=X6E+'A,7$=+&MX"M^QT^_7IT`2`HE)I#E&8)R4W%FA8QB++D4DE4TTU
M4PO3QG1NOBGE9\F9ZNM6KJ/<_P!=T'S$W^\8&M)Q$"HLW8#201Q(F8_-N^BI
MUM5@LGIL-U;,%=LHJYT6<[N%\AIWF(ZWO#G:IKZD'.P\D\[+E%[4KSS2Q:.1
MUW)C5(55+6L9D>EH.HRYCY0@XA,L>(R!H^)M&^S%P4318JKJZM\HZ@('C+[(
ML/Q[-(7SQT<4MOJ:P;:DAAN%7F-JZ$^A896\.9+M$CKBMY^3'A(E5P>3/!L:
M0&+DQ+E`NHY]C1U[#O1N'7E&CX^5QP!*1.'F!4E""CXS!!B[%O\``\RQ0(L\
M/AA!%N_'/,-G.ONH+IIK([_SIOKKMC.,`*74-DW%$H[9*L<C+2$5=`JO=V3,
M+\-R@?MIL/!IFBDNAD0AL><KS5L<91L-[JA=QA@BGEVFFRWV7_-RS!`=T6SU
M1SI`D6MS=LV(RT8Q6'6'>R4QC$"J72L)Q(GC&XX5#ZZL`$/PJPJ:M&9/>,NL
MD9`]:O56N<J$%-]G*:8-S\5W.]<U349.>QRPI7:LRE;I6&R&3GY;+),`!BH2
M7*[#HA`\R-^NU<`FS@LJZ<&V[=HK)'2V7JR:?Y)H(@A>%QMC4T%\G\&.)Z5$
M*H'O^X9Q$C0QG8#N-"JOGYJXID0;%%H@^5=3-E)HQJ.T)MV;]AD/_*C@GLEN
MFXP2!E;?EZ6,K+K?HJ/M;#B///3]*\3R"Z(37\2DG1IR(6]R'((9-*L^J"Y5
M5E<9&RR$@FHG25B0[U1NH.64)-4GCP>\:@:'(O,DS<U<V<WLM*`E=)6E>%AU
M%S"]U&Q<)%:\L"Z;%L6N1MW"P6ZN)5(0L2E;%OB-O72X0'JV12<MG)%!1U@%
MC<!1ES?4.\C-0LF,:CP6^ZVM>:AY>.L5]*XOT&WMR1V&$KGHJK5H,_*Q6(P>
M%R83(8IGZ%VB0V:`@SK#9LGECKZ!6<2EA'7M"_[@=?(V:*QCD'S9`A&D3.87
M2L1#Q"]PQ65J.6.'6I/9\XZ#<!GJ`'+O<=ABDJQPOHOG9+<#)_VX4LE,G%\K
MDY'(S9TA)J=\NTND;HH3=NU#LJ(^0GEY=_)"NJJN4GIUVJ_7VW=;ZY6S[V_]
M7\;[8R&?BT[$<_=WAS@9].S8HG>I<_-GZ)B1QV)<P`B#22V-;M"*0PXY'"=)
MF3$2:*.9D<*G%TWKA'.B+95%(8D.#K:]`BSH(I)^HO(U`*SK5:,QT52"+./O
M;8-,V9V0C9"'D,:M&U@-2.8W(G+F+DEA`02Q*.#S%LKDJ);MV'YHY(K)`J>@
M/)55G$?D1\LB7]D;"M"T>@;QI)]':SIF/#$5B[R,![F_;)44)/2*;)8B\'K-
MW&K9BB]+%,ZK.TVZS)-<CZ!F+#SE\C'I(W-R?FNRV%H5U@M%W!0U*^)!9&)/
MRF4D)8`ATOLCJ"!FR(UPY%Z)/MF+='139!/#E/3;&FOH%6]R];^-J][M;=)*
M<H6V>MD%#AC6:CV=I43!(59@@":U?Q7-I6?S%9E^RV0BF;];ZYR,PVTT75<#
M,/';--NWW]!G'WG?ZYD#UDBJV@W/T(38/4XR\@%$M[H:/GH(1A(I&R,F(7PY
M%/<-##+1N.5',&>_M$$%GZ;9#;13`8>4>8"T^@Z5D?./;'/L9M^JK?!:"9?'
M8:K97+MESZLLN&1!H[9YB,^MXT2WG"0EUE\V9,@X!T/15;?89;O=LHA>L:Z_
M\2SEDXD@3DBYA=AMX_+8E&+!LJ[^2K.F52$)1'=XI)RE.H]==KR7,:]QDI[&
MKQH%;LB:2.NJR2J>-DL!?4-\W/*G/4%:5ESYR!T5(8G!'A,K-MF<BH`CJ-<3
M`^Y/FIZ5ET,N6Q(J8_:949>.21I^3&BDG[C751TGC?.$@H/Q;SNL^W.AO-B6
MKX3NT!W390XP.D,UCA^+&]6#:#UR1&!S>!1<>Z>N(`>).UE4DG*R"JKG3353
MX.Z:Q`&U>'NZR4\YI95G,!A\1.*UVR71T)"`8&.%JXL(H8D<`=P``&>N'44B
MH!CLJ#P$)(,'XEP,W1U;X9_$WW`YNJYAO">?[.*,Y&YBAM[%BH2,FF#L4S*-
M9(79+M16XE0P]8MMR*:VV5--=-E%_P"-,[))*J:ZI[`BGPK0YK!;]NI=N%LK
M3,N$2C07#YSM*LD.7JT2E0HS3=2FLR'44@]<2^#[:.L;CQ^P!BY$*("'JJ*K
MAJS!2B%SVFVOHF=0FI9,P9\%0-$H0U3'Y7>I1KS'2&K`.BOY,LIZX&5[+"0I
M/\==<Y0=[[;?DMC134#@\!`.&5`9J6!O;*!E"=,'_,_RP23W%E13@K+(1V/S
M):1([C9=-P*%B=*^;M2"F%'>^$OG)IX4WWT4QJ!I<A\WQ_HOG_IWF2QPSD%:
M,%FB+L-.97#58T7,1NTC<]NN!V*9CL8M.2(D5;&:6F:^\T5):N"#5_LR)I*I
MH:-4@(AMRMW\LPFE&&.G),-K:616)LH39=;N8Z!:4XR:)Y'3>+Y2DFA^]YP:
M)_6).PSA*0"FXY`ALT5=JZM_]4"^Y-XDJCE1&5'`0L,;M*>2`X<F=E_1-QQT
MHB7T!-D8\W=*+DC.D9&M8RTV;M73Y[E%SNX5U4QEPIC(<.WD!KDE5WELZM<H
MD@]<M#,HB5A%9,*'PT:V;('CLD$B9*69$#!M,XI'!\T".3*LE:1YJ_\`Y;[M
MGB*V[9P5"FPLVJ>M7^VT[08W/`HTN3B4+A1"Q1-6.'1)VF.*2BP?JZE`2=TL
M"5*H;-QSE\_66=M544]7#C5GLDV#'"FH^S&\=CM1@BUJNWLJ*/H%32TI7M*=
MCI3MH%0+`GPZ*0FJK(/A)2RP@0'[`O=;I;BU4%47"VSQ9(&&"_&)Y++!APB0
M1CFLTAB0:X>RH%80?FV*N4)(Q2%*!I1&U+&-P.T6;)Z.:L/D,2@H:JH^8+ID
MT7VBZ^J@5;>7!O8U(`E"UNTA:XC)!HU+3N<QZ$P,_7PURR59;,&JC2C71VOV
M@&+#&C--9W*B@8+C5T\U19;;(*+;@(8BT:/C#](I80U"Y7!:+HHB0,=O%*)1
M"OQ+S1/8.,T'P"IGX;]R$()Y77PQ)9'I.7BJ;QG\_5QG`>H&>CKM@X5$V$R+
MEHNR2B,09/'5>S,?8<4G3END,K-T;)`@LSW/@Y9(=VI1%$&5(9;;K(M&C?+9
M)LJ#]?\`:Y54H!%=RVBE'XT$"R^\%(L"2"MV"B^@6$9=Q((W4*-Y1*"2K+8#
M&VJFK`EEL_9*[[K[_+U?:O5P;W>/C_F#&U!%W<82B#4/,V@I7]G&8'2$6VF+
M@`&):1Z.IN`C]U%1HV7D=A[4R0)Q\XZ9,!B.&:6=-W+9P%4K<&=9]!6D\DG5
M5^-Y/2@*P1KJNJ>/!73*3`81'547CQN=DM)3ZOX3/BD^+:[;Y*/`PY\.8ZHH
M8;?PFJDN'UY[=J5UY,[PC\B_1B<+D4+GC6BYD";D!LQ&?I;^%E+0H1Z%&2-8
M,M`Z[%JAE0*[H9KNH_;%VK+=%(?NAZ#GL&A:9(7G--\V'+DXW$O`I6)W0MK!
MEMGSQK8?4%N>2Q7W1N5\;I9&UI6&C1/&N<Y45=;H[?P[TU2V`U*P;M^=O*5W
M)5[@!JX$U?Y#J5ZTB8)9YALR.5AY.^<)%RQ8[3ZX6#R-0B3'H8W&%GJ>ZC9I
M^22;TFKLJQ2WW!F')9ICP/0\WGETTI+(78%GS^.1]I6T5@<*:2Z>6J]C\NE:
M=?5U(61P5#G5>-6S9\G%TY":9-8_IHL*U?;M]1^50MKM2?\`4L9/T]T51T-L
M.X>8<T#=S2^*LK.=PJ+38:3D+"#2"M)^$4?2,(N_>CFPXP'?O@Q%^]`LGRQ!
MBQ?.D$4]P/:A5'PB`!:YE-A![!L>M!8V-SEVVF",TDK-75-;]=VG)C89'B9*
M5OX\@CN](N1(G)9YJL[T9M]%,(I@CSLN)Q3G'S;\(]72N),3\)Z(!D.83QPU
M"6IH-7%@']$V<"GS:3.=7:$7E1&=AH5'6;W1%JXU;%7"*CO?55J@D![^26_)
M'3L6KP=10>@[)Z</3^$J!Z3MP*Y-E)Q2_P!XLSM,DQ(B':#FL!,4#JK%MI27
MUV`-]QRC)3&SIVAC`*%J3S(WES;95FD^G>6+'M6IK*'1:15HCQ?SL)$/*G1!
M)M8H18DXS+Y>#L.S838!YZY*L#KG;WQ235SLLV007RW'`?D&_P!P#X^#[R6Q
M^Q'=_P!"SB#FB8*20:R^>K*D15JX$D7XUT\:GJ.$W#`R0K*H_;;1P@7WTWTV
MQG'\YU4QH&R0_P`[/!%C2YQ#:X(W?-7NP@:=CY)C1,_`!9R++DF(4:K`WDX'
MQ164NW)DAHU^(V2V>)JXW_-+733;;`&QR_<7+7:]-Q[HJD0T8ED&FK^0(:OS
M<&'"9(U.@CCX-(!TF#DV'V8PT@39[[[Z+X_)9)1-?7.Z2J>^P:YY`[8K?E_@
MWJ"TI9#(C(89!*8FJC&MC4=&E(G-Y.=9K!(37[R+*L73`NC/)Z:8#/AX;+9=
M*O?QPFIOMC78%R^-&C+:X_\`%Q6+RM@8D@Z8QR;VA+H`B-&UC+YFR2:(#04;
M%2J?%Q3.(_,;,7QM0L>=(.<*K(8_!@AMNR;@.UKV'VET.&@]M1!.W2]SI#7%
M'0F"TGTQ#(;3E`=INK6L&2AWEQCHM-Q\:M^*QZBY+'"BQ-R%FP`D#"9]AEA8
MHK[H.`KWR%4Z9Z)`<<SL?9<"Z))#I(@.0F%:DP4'GAZ"C6962(0V6#7\C`).
MRL:<XD8P:^=MGZP#?#CV_P"=-]=07)V/%+G@W2W5%S@:TV;10_S?(Z5KR6Z0
M$>Q&E[GNAO&*GIY.'R(:3B\N:6/M9EIO4BA1-0DH?%DO@-?C.1C;"X)BC;J.
M"NL;FN90P<S1,[\TO,_AU:&-B9#=IK4U3>-7K/B,@03=:YPLAMM,+I;/=RV^
MV02IC&A#1MC*>^N0:IYG*I2K#LWD?JM9?>+5)U97\Z\6'5%C-6@W?>M$;G)(
MS;CZY'!!XNT^DTJ3HYBF4V(953]K9)!+55-11/50#!E?11?JBF>5*'>.JVA%
MRW,.N)U=THMRL1MEQ*D;-XAU!C+S9JUR^E$2'*2,5=S]C@6L\>MF:8+5=_IG
M.=FGYAH4!KFBAP"=C>RW\N&S:OJLWEL]BO/3B:P3E[J2HW*C4,TN>IZ<Y\T:
MK66(,OC+%J^CC_<^9C)QTDCC*K=^R(E`_4=:,'I:7@>@&O,#?DB=1EA+)_-*
MQ'Q7?6TN@?'V\?Q..R2W;'%QB'Y45N"A39(#*"<66)R"41P8BY:JY06.*-M`
M)SRM\:M>]N-)+"H?N*?SX'\.Q:>/Z89%&Z9M!FJGJ^#;.C8<`Z>.P;]58:X<
MN,-TGZ;9QKNGOIHNF`R<GL>?O,IRU6%@=)Q:6`.GZ$44IR\58#8<WI:P@\]C
M>&#LLNB?JV4QX^ZJ>UE$&DJ$,]W2P]1%WA+/YJH.=?0+."\>T)XA/*;%0<PD
M\[M3D?J^K#Y&M`UZV7()$E3\\82@!`)W&'Y:6NTXO.H8U962T=#M"+C#]DD>
M>IJ).=]4W>X&-T]YH?#KSO)9S"Y+%=+(F63\MKV;Q"#Q6)'-G[Z/OI"$D`29
MC7TH:-A,8;LLE/R5/(,P[<<NHGLHFFYPFH"5.T>PN-ND^?[K&\)9C4.OXG'-
MY#=X2+6&?LRW?_:I-J!VDD;_`$UH]C@[>+/R215]+DVY+<N.UP/3VT7]MF@#
MX/\`;L5@QH'F*UZ&C\I"2.$1B8499\&28ETC<A'!.A>/.=[@**35]A)%3>0%
MYC(BCG3&F-FB;+=!-#;.--\8#'>258OY!^S^=O&W$6&Q*AJXF[6YNM)HR5:+
M-$I_#@XN2P6GW*#E;;"FL9@\JS*WZN6;QLD>>1=OA1!QNKN@!X]13.H_O8Y1
MTJ(QV-\W\Y1J.7ATWH0UUVBVH(`X39\Z4.19ZH/4B;BP9N.P;5#X177>CXVB
MSV05T+(ZJ@!=%N.9.@IO/#\JKMIR#.8[&!'0$KM+EJU9-"F,+3IDP]U:QF]X
MD?A<12A-@0N#S%XR2+K`WL9F,<+E=PA-R@CG5L%S@KBZ0JBNIQTBF;JV+5T/
MF8VXR=+V;!0@[I^[*>G%C,HH;MVPS+*=0X=4A5]$WF[J"@%0[MXVT:,Q)9PF
MLIN.'AA/,OU<$H^/#C#O=F3#\BPM_P!O3B.Y6<;+RJSACDE4G"U2[M$T\-G+
MBR.H9*E(4$]U-E-DH`OC5!;\\8P%*?\`Q46!_P#GD_P@^Q>_Y1_VC_R-_8OQ
M=?L7^8?[]_E-^/V?Q?O?M?[J?]D^9_'R_C?T_P#)_I^@<)WMQ_!N]N0KUY-L
M!?ZX/;T*="!,BT0^0YADW%N6T@KZ=,D<;I;+/(9-A+`EHGC?3WOC93SG&N^?
M0<L%#R>6797TYJR]F@W7H@!.7_&G849D)/6+"4.T@=;%:,&F#4O)_$1#UOY5
M^:0H08,D.=<BVUM18$Z]A\JZ]A0&/4S5?50(3+SM$PY]-F])F6W0]>)2RJS/
M&?T-A2`7(&_0/&%;5-J@?0?M[QBHH<XD#],BE#H]9!IT4%[*Z-6C`<'AO2TF
M_/X&A3?-E7BG-4678%(V13CB#3J09N`C%9C)`,)G,?OR8]%3H5#7VTP/V:O&
MMX6U5E)A7579RHW:J"-'#4&E\]R(QSA.AG)]E8P$KZ4,]S7&A@R14>/DXHW'
M?:R7EN3FU'I$4[L&C=?=UCNC=XO]S!T4=D=G"P<FOD%8=N5GT!XR.N$O(]R;
M`#5N4S;)$+$^Q:>3E.HMKB-$3FB#,L&':--\NY0'-%4]X6Z=>XS$+/"(I99H
MP(M]=0M7RHD(9Y)>&J,B',%;SKHV.]26;7NT>Z.I&/BS!3EN`AYG&'=M6/H;
M)D@IB"V'^IZD(S@5G9J]RNX?-GNNFK5=#<*J\>7!--Q/QL2XGUSXUV4VLAA9
M=RSMQ!I%3,'-])W!&]K)2F4)=NV9I=G(&$CD;1BQ0>1]Z9RQSECNVU4<C-D,
MJ@+(#Q#-S42\EGD?[!Y%-3WH/K<%8<>JCC.HFNSR70F`%DX!&:<0:F0)T84C
M-AI9C3=60[#';=!L-4>JKIK:YU8-@H0%3T0\4W.WC\7JN4VNT\N(BBW@9#BX
M!:.7L)DJ5\&),K@WTQ$"`2QR:\#YU7D[P=&<M%6Y(B]8I#F.-L;J[-P<1R33
M9OQA<I9GMAMIO>'?W6,O<HM(9*Y,C(IG9U]6*4*%(Q'9<;B[)X%')@&"J3^Q
M):T;KCPXD6\=:[*L1[-+(:)T8*NF@@M94E%;<@<(O:QK*$77;G4O25:.MN;I
MYUQ(C\6D45;Q:7'*\FH$H1@XB&ZQN.031U!R:@)84H)D2144Y15`A2\)EZY"
M,<VP:JI7/ZTC+X3U-UA4:UFQQ[K!)!.4MI+5O(E=JGOI`L@K!"TAA.5%`CHH
MV0:!6+9DE[H\NBQP`95S`GC<FOU?U'/+26@=5Q=U<72L_M"BC%&R_<V=E<,L
M=KR+L)+D%)!=LR9V]#`(L<B);ZQ<+%H^(CXAN\+R4J_5`>8-6\W\D/E##U--
ML8:PWDNXX1WYY#<,W(^0`M>D$0;</POP./D@=3<8:;<J5ZS4?2[&-EQSZ4JG
M=_926<)[8#KS]!/0<X_F-XZD]<SI_P"3V@:S)6ZB.JI[3_D4Y<C*SQF:ZJY3
M1W9JCII"<#63E1KT/S8NA@[&3&/:(-D!R7QG*&S/1-<#N\=7:8V[('!HC+;/
MC-I;S4(3EG+U_`EMM0W5%'"=$<H$BWN8T;Q_IZK$=LB[+B?]#EJ1:[%FR.C!
MWN@P#9BH")\J=`"G,Y!!"_-M\6[K(ZM.%XV"?,>5>KYF.<L2S1@07;[.HA!^
MCGNSQRT*)^WJPG!!TR56QK(6:204UV9:<;9.PG!4"U6[)ZQZ!LH];<>JR93A
M&([T)4XJ=)3&06;)K:KT!J:YXBU+L5-1U=&?AOI&ZDJ8UJVT?J8=KHA[:5[?
M(1P$,A_7H[23TG*Y.3K.MNQ6X=@2KP\=C1_6`':NZ]`B4%A]!7<`L$>^#NBJ
MB&L`D+IENX:/!JRR8O4!$D_C#Z"X(L>7=1^)"S5$(K8)=[8%Q<D3MRZF%6V8
MGH/<E$E(R.0>-571HJIKA%N88.6DJ3PZ467=2+^4!V@6I2W^X`Y.7&.0G<(6
M4>/ZU@:RHPZ&N5!\:JLJ::93U=L(3<<>#Y"NB>$U-5LA3C4!)&R6W^L/TVT4
M_$-!F?EDZ0[0F6]'^**@Y>Y'/%7+.0]J7A`U1<`A+9)=PU3*PZF)02BLI+MR
M>R"FS$S*L@QBV&R^&;(RLGEKD/3S1Q'0WC[MHQ;$]E]A]Z>3^WQB:3P>I(MY
ME-'&7*R7UYXVL;RFR@$3!H.<-MIM*<CAHL9LLT!M&.CG84Y`F*)ML,IUO(EK
M//5O9G0S$^E2MKG$9P]#B^7GTT"XF]<4!S]6A:)K2>5125M0BVTBG+WZ)*4G
MF6NNBR^K'0.$`K[FMU*!4VWV25BW4-FVM/C`[FR`-&H$4&L";YD)68UI'73M
MFZ,CFD4J)H%0>2"4YU5W'CPBY/*.76J;?<+(Y\ID;SQ7!G$CDJ4BGDO.&;9O
MFTBJN[!*:66;8L_VJ4;Z/W:R,<B8<:);#@X_"F&X<"-:-L9SA'938.>_R3]T
M6K9UG45!^;8T-L6;VG)TAWC?IMTB[?M[;MI+#T:>\A71D1>I*MF/&O,+978C
M7^[YBX1D<H;YD6-<LAHUQ@'4>./A*$>/3F6/TA'31&=SPV;-VC?UR2);=[,+
MOON>+)D[&LR4E%]-7S]R4):ZMF7R,J+H#&K9)11533=7<#Q]!/03T',MV]P=
M.N%9E.^K.,*LG%M<E6=,V=F]?<,4RIN.M&L;28*^X.[D\?GQ/Q_2+YB*^WOF
MXZRPFQD3/"B>Z6Z"BB:`$ERKY&J2Z=YX!13J&?5_<U*7NF7K$!U''@Z41JF;
M.Y`T(JH4MTS#F9=T7Y!ZF&Q_7"1`68V81\F1UT6CY+Y#A$<W#;SU8/>:9F;;
M6)<<TH]*PXN`JD#Y%(C'JD,R2PH"`&GDJT@78,MLN$3-K'[EJ'Y[E&.S]\BF
M$E"3[7YRFI13X6P"S3O,$RVZ;_4Z]=GN<.?*;A5H<G<W![5LIP/M2QYQ.&F;
MHO7N\M6KS[N)]B:7I:K]N*;H'5EA"HYD9++-L9?X;(@4W#T*)7?`[=NJE[-/
M\PUVSOVZ*XJ#>G7FY&I+&@=*64;@!2S#5%7"PG%40)G,9;%"V$-8.B"2<B<)
MN=G.JJVJ30*7D]CU_;=:P6>=%*QN>$&'5HGC,_(K4X2"#IK"KK+E6]?P^4V6
MM&^C4!E?0*U1$M%K#'ZCE-LL$EK)HX00R1499#T<[&-+I/V%3$;NCH6,QVL^
MT[1Y,FE#4S75(<3@XNM7<0&3>36"YD<`(6'=<BKO]/:-D@QEA)PQ,ZF:9YW3
MTVRF[U"DI_9<C(T#T/6U%U["8G:/$]GM[*ZVY4I^8$38?O\`XOF+%VZUM&)W
MUA`1>\G/*UB3?DVZ[4QL35G,;7`D?FM739-P$IJ.N1];\HR&RVUFB.L:*C(B
M'<G]"TC;L7O"Y_(/S-.G)PO(ZI;#)H`C%GC*F:A=0VA$S9@`>C!R&C4PD8W=
M).'CH&4T]5L'XGC$VZZ[+L6!PN2J`F\2CH`<ZVQ3O,%5[$EWX2B*&8;"T)+,
M9G-S2J;R4&=6KB36#)O9UU1R@U&LD`5CW/Y*K+L^U8SS5"*)D]I3NQ!^SFG?
M&\,2RE;EM(.7VKB)=%^0P\/>;M.8>-AR>1[M2OB.S64R))WC,BV8,/>&Y!J7
MCL\=JW+*TWZ)Z)F[;H3R`="-F+GH+H%RQU;#`XQMJBJ&HRC`RB*6E?4/7VB2
M34<.:I-LO\MM'+G37\6[=J#2/03T$]!/03T"->O_``Q1Z86-->I.`+!!<9=7
M3]@N-N`>M!Q$]Y1ZSC[TBF3,1+J+GPFV<1:2??K85PJ>8-DBNF[E5=75VMG3
M;0%9">[+^X",O:.[/JI_Q"`()OHSB+V^.G73_A]N$$^W2".!M+7^#"R:\>-P
M<@;$,)-XR=:2V+#$7:37<./TSA+4#EBUUUJRB@NQZE+6)R[62>Q-D$5CX5CW
M=X[I8(F0PHU2Q7%O\\DY+.>711[1PVQOEB1K?5GERCC<.LHJWVR'EK*7J;U4
M/YTY[AX*U:B0K]M6[2)<(];<Y]`U3"(;^[Y:V"(0JJZYOSC;0MK/0*;H6]=D
M#TG<!?L\MV&VSC;9?8+!BM"U1-:N\@%0*U=UK4G//:SD>Z`TPIR-8<;E7/UE
MCJOC==R2T(%)(T5E@4F@<-0H!)A.NB;)0<='+;_SNFHG^(?,#PVIN[CEDTUQ
MCY%+@L9CS/#.=I&?EL2I.CJOG9RM%WXD5?YF2WY9$#W*6I/FIE,<X(HM7RK<
M*U_#=CJGCVU`JX3.HGEW2S*76GRQSW<O/E4DZ9JJ1P25QKO_`,C(FO7CR,@S
MD=!PBGZX`5F#*'U8SJRSJC&9DS9ND$,Z-<+K*:Z!CK$[>H+Q_M)5)!HL50LZ
MGK7#(MU=Y(YM)9OU9=ZS15G\1I`.4H>]D/6<\%>TW]T;'7K2KXRU<803:((_
M(TQD!GI^->33R3S'2R:8#V?S+"-=/8%^1OON$`U^@4P1510=(M.`.%0Z32KN
M:&4A#)9TQ*BWS)"_&.==53#A?3'X`_[A;QN<P>/J+GV-*QDJ<LVPG6QFZ>B+
M.+*3F_;PE#E?9\1D-D6*23P2?Y>DU-W.H]KJU%MUU-]TFVBF^^^X'MZ">@GH
M)Z">@GH)Z#2K'_MS^B2O^[OZ5_;+Z5[^\?W'^B_1/UWV_P#N'[7^S?\`C_TO
MM?\`K?,_T/Q_YO\`AZ#C"Z&T\#F]O&-/&0OWTUZKV46P?<>`QI8;_9'/S7G]
M<B9L'H[F%P)PA\[^=6JZ6F6/N_SMC3V?05R?BG<&LL'.9O?<`664?Q#1F'\P
MO(WA[;7*TDF'J7ZLX>22KNVG?11"=J+:[?3HE!35;0/OI\17971O[@:S9*5Y
MHV!,T2KWP6$B2<D+:/B"0OS.A$WKK5XKA9SH'K\Q((.,T6W_`)SA`2^=L$\9
M_A%7?3&-LA^H8?=Q"N[$US+_``*Q(.F[A62RIRN>L[#:O=]B;_ZS35#R5VG6
M%,C%$76N<XV:*.WRN=L8QJFIJWSN&9_7>IQD5*K7?<7E\FU.['R>\Y'>%[FW
MQB5=7B/YIC\/FTE,\.=66_;KELWU_#.5R[!(JL!RWPJDEG"NV0:]XGO_`,[?
M[ZT_PY_M7_E_]EM]U_E7^T_YO?NOY;_<>Y_D?_Y[^U?*_+YOZS_TWY_Q_']'
/X>@Z8O03T$]!/03T'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>nbs-20110930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- EDGAR Online I-Metrix Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.12.8 -->
<!-- Round: 40cd2c42-57e3-45c8-9ccf-d40a656c8aa1 -->
<!-- Creation date: 2011-11-09T02:07:40Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:nbs="http://www.neostem.com/20110930" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="nbs-20110930.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE6286----1110-Q0012_STD_0_20111108_0" unitRef="shares" decimals="INF">107324573</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE6286----1110-Q0012_STD_0_20100930_0" unitRef="iso4217_USD" decimals="0">4066693</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">5625734</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">621105</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">5001635</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">31517651</us-gaap:LiabilitiesCurrent>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="shares" decimals="INF">10582011</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">3066851</us-gaap:DeferredRevenueCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">-124116505</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">5863031</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">1808695</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">1427827</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">8944803</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:Assets contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">168214682</us-gaap:Assets>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">180808</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccruedIncomeTaxesCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">589230</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">100361</us-gaap:CommonStockValue>
  <us-gaap:InventoryNet contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">20582284</us-gaap:InventoryNet>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="shares" decimals="INF">7838527</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:MinorityInterest contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">26881066</us-gaap:MinorityInterest>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:SecuredLongTermDebt contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">3487175</us-gaap:SecuredLongTermDebt>
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">30778935</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">10743</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="shares" decimals="INF">100361443</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="shares" decimals="INF">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:AssetsCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">45098607</us-gaap:AssetsCurrent>
  <us-gaap:DeferredTaxLiabilitiesCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">338054</us-gaap:DeferredTaxLiabilitiesCurrent>
  <us-gaap:Goodwill contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">32586656</us-gaap:Goodwill>
  <us-gaap:DueToRelatedPartiesNoncurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">20534147</us-gaap:DueToRelatedPartiesNoncurrent>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="shares" decimals="INF">7838527</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="shares" decimals="INF">10000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">11713338</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">910318</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD_per_shares" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">192575872</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">437443</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">5655744</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:OtherIntangibleAssetsNet contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="INF">4870549</us-gaap:OtherIntangibleAssetsNet>
  <us-gaap:TemporaryEquityLiquidationPreferencePerShare contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD_per_shares" decimals="2">1.00</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
  <us-gaap:SecuredDebtCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">187935</us-gaap:SecuredDebtCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">168214682</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="shares" decimals="INF">10000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">100</us-gaap:PreferredStockValue>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="shares" decimals="INF">1</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:LoansPayableToBankCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">7810000</us-gaap:LoansPayableToBankCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">73561463</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="shares" decimals="INF">100361443</us-gaap:CommonStockSharesIssued>
  <us-gaap:TemporaryEquityCarryingAmount contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">5475567</us-gaap:TemporaryEquityCarryingAmount>
  <us-gaap:ShortTermInvestments contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">555</us-gaap:ShortTermInvestments>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD_per_shares" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">49571589</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="INF">5475567</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:NotesPayableCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">3766272</us-gaap:NotesPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">9896278</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">100442529</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">30461547</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <nbs:PreferredStockSharesDesignated contextRef="eol_PE6286----1110-Q0012_STD_0_20110930_0" unitRef="shares" decimals="INF">825000</nbs:PreferredStockSharesDesignated>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE6286----1110-Q0012_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">7159369</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">2867188</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">2779066</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">32844612</us-gaap:LiabilitiesCurrent>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="shares" decimals="INF">10582011</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">1708280</us-gaap:DeferredRevenueCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">-95320620</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">2772019</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">993711</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">3381369</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">5871474</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:Assets contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">143024749</us-gaap:Assets>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">282518</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccruedIncomeTaxesCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">1242911</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">63813</us-gaap:CommonStockValue>
  <us-gaap:InventoryNet contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">21023388</us-gaap:InventoryNet>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="shares" decimals="INF">10582011</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:MinorityInterest contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">37827738</us-gaap:MinorityInterest>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">17160243</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">45489</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="shares" decimals="INF">64221130</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="shares" decimals="INF">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:AssetsCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">46882845</us-gaap:AssetsCurrent>
  <us-gaap:DeferredTaxLiabilitiesCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">232075</us-gaap:DeferredTaxLiabilitiesCurrent>
  <us-gaap:Goodwill contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">27002044</us-gaap:Goodwill>
  <us-gaap:DueToRelatedPartiesNoncurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">8301361</us-gaap:DueToRelatedPartiesNoncurrent>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="shares" decimals="INF">10582011</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="shares" decimals="INF">10000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">15612391</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">2571367</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD_per_shares" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">141137522</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">210977</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">5959508</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:OtherIntangibleAssetsNet contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="INF">4807834</us-gaap:OtherIntangibleAssetsNet>
  <us-gaap:TemporaryEquityLiquidationPreferencePerShare contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD_per_shares" decimals="2">1.00</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">143024749</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="shares" decimals="INF">10000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">100</us-gaap:PreferredStockValue>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="shares" decimals="INF">1</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:LoansPayableToBankCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">3034000</us-gaap:LoansPayableToBankCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">48659881</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="shares" decimals="INF">64221130</us-gaap:CommonStockSharesIssued>
  <us-gaap:TemporaryEquityCarryingAmount contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">6532275</us-gaap:TemporaryEquityCarryingAmount>
  <us-gaap:ShortTermInvestments contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">512</us-gaap:ShortTermInvestments>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD_per_shares" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">36998241</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="INF">6532275</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:NotesPayableCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">9568398</us-gaap:NotesPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">14286929</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">86487619</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">24466597</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <nbs:PreferredStockSharesDesignated contextRef="eol_PE6286----1110-Q0012_STD_0_20101231_0" unitRef="shares" decimals="INF">825000</nbs:PreferredStockSharesDesignated>
  <us-gaap:GrossProfit contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">16700720</us-gaap:GrossProfit>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">566775</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">4085743</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">2452015</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-11019055</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:PaymentsToAcquireInvestments contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">2424132</us-gaap:PaymentsToAcquireInvestments>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">31326</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-1278573</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">1784325</us-gaap:IncomeTaxesPaid>
  <us-gaap:Revenues contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">51716260</us-gaap:Revenues>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-3175708</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:GainLossOnInvestments contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-7215</us-gaap:GainLossOnInvestments>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="INF">153469</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">13138948</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">7399842</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-11849103</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="INF">13720048</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:InterestExpense contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">25380</us-gaap:InterestExpense>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-182417</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">16311</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:NetIncomeLoss contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-17126025</us-gaap:NetIncomeLoss>
  <us-gaap:ProceedsFromNotesPayable contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">13256799</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">5946</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">5113487</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostOfRevenue contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">35015540</us-gaap:CostOfRevenue>
  <us-gaap:RepaymentsOfBankDebt contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">2203650</us-gaap:RepaymentsOfBankDebt>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-17279494</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">12510648</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">2556994</us-gaap:DepreciationAndAmortization>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-11855049</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestPaidCapitalized contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="INF">307200</us-gaap:InterestPaidCapitalized>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">23442282</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">1191179</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-3092676</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">461743</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">108754</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:InterestPaid contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">219376</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">1405838</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:OperatingExpenses contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">28555769</us-gaap:OperatingExpenses>
  <us-gaap:PaymentsOfDividends contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">222924</us-gaap:PaymentsOfDividends>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-392040</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">10993333</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:RepaymentsOfNotesPayable contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">16644465</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">128225</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:ProfitLoss contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-13040282</us-gaap:ProfitLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.36</us-gaap:EarningsPerShareBasicAndDiluted>
  <nbs:SupplementalPropertyAndEquipmentNet contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">348488</nbs:SupplementalPropertyAndEquipmentNet>
  <nbs:ProceedsFromStockOptionAndWarrantExcercises contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">3101850</nbs:ProceedsFromStockOptionAndWarrantExcercises>
  <nbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">1175902</nbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
  <nbs:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="shares" decimals="0">48599359</nbs:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <nbs:SupplementalDeferredFinancingCosts contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">75466</nbs:SupplementalDeferredFinancingCosts>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE6286----1110-Q0012_STD_273_20100930_0_455296x446364" unitRef="iso4217_USD" decimals="0">-1463710</us-gaap:IncreaseDecreaseInRestrictedCash>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">NBS</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">NEOSTEM, INC.</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">2011</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">2011-09-30</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">0000320017</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:GrossProfit contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">14221030</us-gaap:GrossProfit>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">644414</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:CashAcquiredFromAcquisition contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">227942</us-gaap:CashAcquiredFromAcquisition>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Note 9
&amp;#x2013; Shareholders&amp;#x2019; Equity&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Common Stock:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
authorized common stock of the Company is 500 million shares, par
value $0.001 per share.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
March 3, 2011, the Company consummated a private placement pursuant
to which five persons and entities acquired an aggregate of
2,343,750 shares of Common Stock for an aggregate consideration of
$3,000,000 (purchase price $1.28 per share). The investors included
Steven S. Myers (one of the Company&amp;#x2019;s directors) (who
purchased 390,625 shares) and Dr. Andrew L. Pecora (the Chief
Medical Officer of the Company&amp;#x2019;s subsidiary PCT, who is also
now the Chief Medical Officer of NeoStem, and the Chief Scientific
Officer of Amorcyte) (who purchased 78,125 shares). On April 5,
2011, the Company consummated a private placement pursuant to which
nine persons and entities acquired an aggregate of 1,244,375 shares
of Common Stock for an aggregate consideration of approximately
$1,592,800 (purchase price $1.28 per share).&amp;#xA0;&amp;#xA0;On June 13,
2011 the Company consummated a private placement pursuant to which
one entity acquired 781,250 shares of Common Stock for an aggregate
consideration of $1,000,000 (purchase price $1.28 per
share).&amp;#xA0;&amp;#xA0;On July 6, 2011, three then key Amorcyte
stockholders (including a fund managed by a then Amorcyte director)
invested an aggregate of $728,000 in a private placement of 568,750
shares of Common Stock (purchase price $1.28 per
share).&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
July 22, 2011, the Company completed an underwritten offering of
13,750,000 units at a purchase price of $1.20 per unit, with each
unit consisting of one share of Common Stock and a five year
warrant to purchase 0.75 of a share of Common Stock at an exercise
price of $1.45 per share (the
&amp;#x201C;Offering&amp;#x201D;).&amp;#xA0;&amp;#xA0;The Company sold securities in
the Offering under the Company&amp;#x2019;s previously filed shelf
registration statement on Form S-3 (333-173855), which was declared
effective by the Securities and Exchange Commission on June 13,
2011.&amp;#xA0;&amp;#xA0;Lazard Capital Markets LLC (&amp;#x201C;Lazard&amp;#x201D;)
and JMP Securities LLC (&amp;#x201C;JMP&amp;#x201D;) acted as representatives
of the underwriters named in an Underwriting Agreement, dated as of
July 19, 2011, by and among the Company, Lazard, JMP and such
underwriters.&amp;#xA0;&amp;#xA0;The Company received gross proceeds of
$16,500,000, prior to deducting underwriting discounts and offering
expenses payable by the Company, for net proceeds of approximately
$14,667,000.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
September 28, 2011, the Company entered into a Common Stock
Purchase Agreement (the &amp;#x201C;Purchase Agreement&amp;#x201D;) with
Aspire Capital Fund, LLC, an Illinois limited liability company
(&amp;#x201C;Aspire Capital&amp;#x201D;), which provides that, subject to
certain terms and conditions, Aspire Capital is committed to
purchase up to an aggregate of $20.0 million worth of shares of the
Company&amp;#x2019;s common stock over the 24-month term of the Purchase
Agreement. At the Company&amp;#x2019;s discretion, it may present Aspire
Capital with purchase notices under the Purchase Agreement from
time to time, to purchase the Company&amp;#x2019;s Common Stock,
provided certain price and other requirements are met.&amp;#xA0;The
purchase price for the shares of stock will be based upon one of
two formulas set forth in the Purchase Agreement depending on the
type of purchase notice we submit to Aspire Capital from time to
time, and will be based on market prices of the Company&apos;s common
stock (in the case of regular purchases) or a discount of 5%
applied to volume weighted average prices (in the case of VWAP
purchases), in each case as determined by parameters defined in the
agreement.&amp;#xA0;&amp;#xA0;&amp;#xA0;The Company and Aspire Capital shall
not effect any sales under the Purchase Agreement on any date where
the closing sales price is less than 75% of the closing sales price
on the business day immediately preceding the date of the Purchase
Agreement. The Company&amp;#x2019;s net proceeds will depend on the
purchase price and the frequency of the Company&amp;#x2019;s sales of
shares to Aspire Capital; provided, however, that the maximum
aggregate proceeds from sales of&amp;#xA0;&amp;#xA0;shares is $20.0
million, and the maximum number of shares that may be sold may not
exceed 18,747,906 shares unless shareholder approval is
obtained.&amp;#xA0;&amp;#xA0;The Company&amp;#x2019;s delivery of purchase
notices will be made subject to market conditions, in light of the
Company&amp;#x2019;s capital needs from time to time and under the
limitations contained in the Purchase Agreement. As consideration
for entering into the Purchase Agreement, effective September 30,
2011, we issued 990,099 shares of our Common Stock to Aspire
Capital (the &amp;#x201C;Commitment Shares&amp;#x201D;). The issuance of
shares of common stock to Aspire Capital pursuant to the Purchase
Agreement, including the Commitment Shares, and the sale of those
shares from time to time by Aspire Capital to the public, are
covered by an effective shelf registration statement on Form
S-3.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Warrants:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company has issued common stock purchase warrants from time to time
to investors in private placements and public offerings, and to
certain vendors, underwriters, placement agents and consultants of
the Company. A total of &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;35,208,817&lt;/font&gt;
shares of common stock are reserved for issuance upon exercise of
outstanding warrants as of September 30, 2011 at prices ranging
from $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;0.50&lt;/font&gt; to
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;7.00&lt;/font&gt; and
expiring through January 2018.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During
the three and nine months ended September 30, 2011 and 2010, the
Company issued warrants for services as follows ($ in thousands,
except share data):&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="85%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="28%" colspan="6" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Three Months Ended September 30,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="28%" colspan="6" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Nine
Months Ended September 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="40%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Number
of Common Stock Purchase Warrants Issued&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;25,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;370,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;627,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Value
of Common Stock Purchase Warrants Issued&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;32.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;289.5&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;772.2&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
weighted average estimated fair value of warrants issued for
services in the three and nine months ended September 30, 2011 was
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;0&lt;/font&gt; and
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;0.78&lt;/font&gt;,
respectively. The fair value of warrants at the date of grant was
estimated using the Black-Scholes option pricing model. The
expected volatility is based upon historical volatility of the
Company&amp;#x2019;s stock. The expected term is based upon the
contractual term of the warrants.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
range of assumptions used in calculating the fair values of
warrants issued for services during the three and nine months ended
September 30, 2011 and 2010, respectively, were as
follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;
&lt;div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="75%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="34%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="32%" colspan="3"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Three
Months Ended September 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="32%" colspan="3"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
Nine Months Ended September 30,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="34%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="34%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Expected term (in years)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;to
5&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
3 &lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;to
5&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
4&amp;#xA0;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;to
5&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="34%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="34%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
Expected volatility&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;81%
- 83%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;91%
- 96%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;80%
- 86%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;91%
- 99%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="34%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="34%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Expected dividend yield&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="34%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="34%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Risk-free interest rate&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0.42%
- 1.53%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.27%
- 1.60%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0.42%
- 2.24%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.27%
- 2.04%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="bottom" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Activity
related to warrants outstanding was as follows:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: center"&gt;
&lt;table style="TEXT-ALIGN: center; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="75%"&gt;
&lt;tr style="TEXT-ALIGN: center"&gt;
&lt;td valign="bottom" width="40%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="40%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="40%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Remaining&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="40%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Number
of&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Contractual&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Shares&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Exercise Price&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Term
(years)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Intrinsic
Value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Balance at December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;21,843,507&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.62&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
Granted&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;13,812,939&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;*&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.23&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
Exercised&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
Expired&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(447,629&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;6.18&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
Cancelled&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Balance at September 30, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;35,208,817&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.41&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,600&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Warrants Exercisable at September 30, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;33,933,317&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.29&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="84%" colspan="16" nowrap="nowrap" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
* Includes 3 million warrants issued pursuant to the PCT Merger
Agreement - See Note 4, and 10,312,500 warrants issued in
the&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
July 22,&lt;/font&gt;&lt;/font&gt; &lt;font size="2"&gt;2011 offering&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;
&lt;div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company&amp;#x2019;s results include share-based compensation expense of
approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;5,600&lt;/font&gt; and a
benefit of $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;147,300&lt;/font&gt; for
the three months ended September 30, 2011 and 2010, respectively,
and an expense of approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;247,500&lt;/font&gt; and
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;417,300&lt;/font&gt; for
the nine months ended September 30, 2011 and 2010,
respectively.&amp;#xA0;&amp;#xA0;The total fair value of shares vested for
warrants issued for services during the three and nine months ended
September 30, 2011 was approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;60,100&lt;/font&gt; and
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;235,800&lt;/font&gt;,
respectively.&amp;#xA0;&amp;#xA0;As of September 30, 2011, there was
approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;93,300&lt;/font&gt; of
total unrecognized service cost related to unvested warrants of
which approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;49,500&lt;/font&gt; is
related to warrants that vest over a weighted average life of
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;0.25&lt;/font&gt; years.
The remaining balance of unrecognized service cost of $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;43,800&lt;/font&gt; is
related to warrants that vest based on the accomplishment of
business milestones as to which expense begins to be recognized
when such milestones become probable of being
achieved.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Options:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
&lt;!--EFPlaceholder--&gt;At the 2011 Annual Meeting of Shareholders of
the Company held on October 14, 2011, the shareholders approved an
amendment to increase the number of shares of common stock
authorized for issuance under the 2009 Equity Compensation Plan
(the &amp;#x201C;2009 Equity Plan&amp;#x201D;) from 17,750,000 to
23,750,000.&amp;#xA0;&amp;#xA0;Effective October 14, 2011, concurrent with
shareholder approval to increase the number of shares of common
stock authorized for issuance under the 2009 Equity Plan by
6,000,000, the Company&amp;#x2019;s Board of Directors authorized a
decrease in the shares available for issuance under the Non-U.S,
Equity Plan from 8,700,000 to 5,700,000.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company&amp;#x2019;s results include share-based compensation expense of
approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;831,400&lt;/font&gt; and
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;2,453,100&lt;/font&gt;
for the three months ended September 30, 2011 and 2010,
respectively, and approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;5,631,400&lt;/font&gt;
and $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;5,982,500&lt;/font&gt;
for the nine months ended September 30, 2011 and 2010,
respectively. Options vesting on the accomplishment of business
milestones will not be recognized for compensation purposes until
such milestones are deemed probable of accomplishment. At September
30, 2011 there were options to purchase &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;654,928&lt;/font&gt;
shares outstanding that will vest upon the accomplishment of
business milestones and will be accounted for as an operating
expense when such business milestones are deemed probable of
accomplishment.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
April 4, 2011, the Company entered into an amendment of its May 26,
2006 employment agreement with Dr. Robin L. Smith, pursuant to
which, as previously amended (the &amp;#x201C;Agreement&amp;#x201D;), Dr.
Smith serves as Chairman of the Board and Chief Executive Officer
of the Company. Pursuant to the amendment, (i) the term of the
Agreement was extended from December 31, 2011 to December 31, 2012;
(ii) Dr. Smith will receive cash bonuses on October 1, 2011 and
2012 in the minimum amount of 110% of the prior year&amp;#x2019;s bonus;
(iii) a failure to renew the Agreement at the end of the term
regardless of reason shall be treated as a termination by the
Company without cause; (iv) the Company shall pay Dr. Smith her
base salary and COBRA premiums (a) for one year in the event of a
termination of the agreement by Dr. Smith for other than good
reason and (b) during any period during which she is bound by
non-competition, non-solicitation or similar covenants with the
Company (such payments shall not be made during the time Dr. Smith
is also receiving payments under (iii) or (iv)(a)); (v) Dr. Smith
was granted an option to purchase 1,500,000 shares of Common Stock
at a per share exercise price equal to the closing price of the
Common Stock on the date of the amendment, vesting as to 500,000
shares on each of the date of grant, December 31, 2011 and December
31, 2012; (vi) all other unvested options held by Dr. Smith were
immediately vested; (vii) any vested options previously or
hereafter granted to Dr. Smith during the remainder of the term
shall remain exercisable following termination of employment for
the full option term until the expiration date; (viii) the Company
agreed that, with the exception of the period of time during which
Dr. Smith is a Company affiliate and for 90 days thereafter (during
which time any shares owned by or issued to Dr. Smith will bear the
Company&amp;#x2019;s standard affiliate legend), the Company will not
place legends on shares on Common Stock owned by Dr. Smith
restricting the transfer of such shares so long as such shares are
sold under an effective registration statement, pursuant to Rule
144 or are eligible for sale under Rule 144 without volume
limitations; and (ix) if Dr. Smith ceases to be employed by the
Company and for so long as she continues to own shares of Common
Stock the sale of which would require that the current public
information requirement of Rule 144 be met, the Company will use
its reasonable best efforts to timely meet those requirements or
obtain appropriate extensions or otherwise make available such
information as is required. Except as set forth in the amendment,
the Agreement remains unchanged.&amp;#xA0;&amp;#xA0;Pursuant to the
modification on April 4, 2011 of Dr. Smith&amp;#x2019;s stock options,
the Company recognized $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;723,000&lt;/font&gt; of
incremental compensation cost during the nine months ended
September 30, 2011.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
weighted average estimated fair value of stock options granted in
the three and nine months ended September 30, 2011 was
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;0.50&lt;/font&gt;
and $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;1.10&lt;/font&gt;,
respectively. The fair value of options at the date of grant was
estimated using the Black-Scholes option pricing model. The
expected volatility is based upon historical volatility of the
Company&amp;#x2019;s stock. The expected term is based upon observation
of actual time elapsed between date of grant and exercise of
options for all employees.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
range of assumptions used in calculating the fair values of options
granted during the three and nine months ended September 30, 2011
and 2010, respectively, were as follows:&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="34%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="32%" colspan="3"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Three Months Ended September 30,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="32%" colspan="3"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Nine Months Ended September 30,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="34%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="34%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Expected term (in years)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;to
6&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2
to 10&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1
to 10&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2
to 10&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="34%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="34%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
Expected volatility&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;76%
- 84%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;91%
- 99%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;75%
- 85%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;91%
- 122%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="34%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="34%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Expected dividend yield&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="34%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="34%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Risk-free interest rate&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0.13%
- 1.82%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0.42%
- 3.00%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0.13%
- 3.45%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="2%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0.42%
- 3.58%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="center"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="59%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Activity
related to stock options outstanding under the U.S. Equity Plans
was as follows:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="75%"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="40%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="40%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="40%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Remaining&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="40%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Number
of&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Contractual&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Aggregate&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="40%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Shares&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Exercise
Price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Term
(years)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Intrinsic Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Balance
at December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;9,932,214&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.87&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Granted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;7,544,600&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.54&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Exercised&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(5,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.42&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Expired&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(2,071,919&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.74&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Balance
at September 30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;15,399,895&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.73&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;7.5&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Options
Exercisable at September 30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8,812,002&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.84&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;6.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Activity
related to stock options outstanding under the Non U.S. Equity Plan
was as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="75%"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="40%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="40%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="40%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Remaining&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="40%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Number
of&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Contractual&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Aggregate&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="40%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Shares&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Exercise
Price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Term
(years)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="14%" colspan="3" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Intrinsic Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Balance
at December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,100,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.02&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Granted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;650,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.74&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Exercised&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Expired&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(1,400,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.02&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Balance
at September 30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,350,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.94&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Options
Exercisable at September 30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;950,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.07&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8.3&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
total fair value of shares vested during the three and nine months
ended September 30, 2011 was approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;1,169,300&lt;/font&gt;
and $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;3,973,800&lt;/font&gt;,
respectively.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
number of remaining shares authorized to be issued under the
various equity plans at September 30, 2011 are as
follows:&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="70%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Non
US Equity&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;US
Equity Plan&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Plan&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Shares
Authorized for Issuance under 2003 Equity Plan&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,500,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Shares
Authorized for Issuance under 2009 Equity Plan&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;17,750,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Shares
Authorized for Issuance under Non US Equity Plan&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8,700,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;20,250,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8,700,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
Options - US Equity Plan&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(15,399,895&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Exercised
Options&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(97,500&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
Options - Non US Equity Plan&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(2,350,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Restricted
stock or equity grants issued under Equity Plans&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(2,479,085&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(885,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
common shares remaining to be issued under the Equity
Plans&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,273,520&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5,465,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As
of September 30, 2011, there was approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;6,515,400&lt;/font&gt; of
total unrecognized compensation costs related to unvested stock
option awards of which approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;5,776,100&lt;/font&gt; is
related to stock options that vest over a weighted average life of
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;1.9&lt;/font&gt; years.
The remaining balance of unrecognized compensation costs of
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;739,300&lt;/font&gt; is
related to stock options that vest based on the accomplishment of
business milestones which expense begins to be recognized when such
milestones become probable of being achieved.&amp;#xA0;&amp;#xA0;Effective
October 14, 2011, concurrent with shareholder approval to increase
the number of shares of common stock authorized for issuance under
the 2009 Equity Plan by 6,000,000, the Company&amp;#x2019;s Board of
Directors authorized a decrease in the shares available for
issuance under the Non-U.S, Equity Plan from 8,700,000 to
5,700,000.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Changes in Stockholders Equity:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
changes in Stockholders Equity for the nine months ended September
30, 2011 were as follows:&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" colspan="6" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
Series B Convertible&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" align="right"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="6" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
Preferred Stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
Common Stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
Shares&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
Amount&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
Shares&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
Amount&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
Additional Paid&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;in
Capital&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
Accumulated&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;Other&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;Comprehensive&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;Income&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
Deficit&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
Non-&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;Controlling&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
Interest in&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;Subsidiary&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
Total&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="28%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
Balance at January 1, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;10,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;100&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;64,221,130&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;63,813&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;141,137,522&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;2,779,066&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(95,320,620&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;37,827,738&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;86,487,619&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="28%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Exercise
of stock options&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;5,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;5&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;7,095&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;7,100&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="28%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Share-based
compensation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;2,394,530&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;2,395&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;8,162,419&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;8,164,814&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="28%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Proceeds
from issuance of common stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;19,678,224&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;19,678&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;21,148,004&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;21,167,682&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="28%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Shares
issued for charitable contribution&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;408&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;606,955&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;607,363&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="28%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Repayment
of Series E Preferred Principal and Dividends&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;3,462,559&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;3,462&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;3,404,477&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(508,070&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;2,899,869&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="28%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Foreign
currency translation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;2,222,569&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(9,652&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;2,212,917&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="28%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Net
income attributable to non-controlling interest&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;559,079&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;559,079&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="28%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Dividends
to related party&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(11,726,099&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(11,726,099&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="28%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Technology
contributed to Athelos by Non-Controlling Interest&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;920,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;230,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;1,150,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="28%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Net
loss attributable to NeoStem, Inc.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(28,287,815&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="5%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(28,287,815&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="28%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Shares
issued in PCT Merger&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;10,600,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;10,600&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;17,189,400&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;17,200,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="28%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"&gt;
Balance at September 30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;10,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;100&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;100,361,443&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;100,361&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;192,575,872&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;5,001,635&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(124,116,505&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;26,881,066&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;100,442,529&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">559079</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-3127902</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:PaymentsToAcquireInvestments contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">27</us-gaap:PaymentsToAcquireInvestments>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">1721419</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">2489064</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">1463100</us-gaap:IncomeTaxesPaid>
  <us-gaap:Revenues contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">55857980</us-gaap:Revenues>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Note 13
&amp;#x2013; Commitments and Contingencies&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Company leases office and laboratory facilities and certain
equipment under certain noncancelable operating leases that expire
from time to time through 2015.&amp;#xA0;&amp;#xA0;A summary of future
minimum rental payments required under operating leases that have
initial or remaining terms in excess of one year as of September
30, 2011 are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;
Lease Commitments:&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;div style="TEXT-ALIGN: center" align="left"&gt;
&lt;table cellpadding="0" cellspacing="0" width="30%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr style="TEXT-ALIGN: center;"&gt;
&lt;td valign="bottom" width="60%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Years
ended&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" colspan="2" nowrap="nowrap" valign="bottom" width="37%" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Operating
Leases&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="35%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;383.8&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="35%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1259.1&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="35%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;898.3&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="35%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;629.5&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="2%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="35%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;587.0&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="60%" style="PADDING-BOTTOM: 2px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="35%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;857.2&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="60%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Total
minimum lease payments&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="2%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="35%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;4,614.9&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Expense
incurred under operating leases was approximately $535,300 and
$1,672,600 for the three and nine months ended September 30, 2011,
respectively, and $522,800 and $1,139,400 for the three and nine
months ended September 30, 2010, respectively.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;
Contingencies:&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Under
license agreements with third parties the Company is typically
required to pay maintenance fees, make milestone payments and/or
pay other fees and expenses and pay royalties upon
commercialization of products.&amp;#xA0; The Company also sponsors
research at various academic institutions, which research
agreements generally provide us with an option to license new
technology discovered during the course of the sponsored
research.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In
connection with the issuance to investors and service providers of
many of the shares of the Company&amp;#x2019;s common stock and warrants
to purchase common stock previously disclosed and described herein,
the Company granted the holders registration rights providing for
the registration of such shares of common stock and shares of
common stock underlying warrants on a registration statement to be
filed with the Securities and Exchange Commission
(&amp;#x201C;SEC&amp;#x201D;) so as to permit the resale of those shares.
Certain of the registration rights agreements provided for
penalties for failure to file or failure to obtain an effective
registration statement. With respect to satisfying its obligations
to the holders of these registration rights, the Company has been
in various situations. The Company had previously filed a
registration statement as required for some of the holders, and in
May 2011 filed a registration statement for all of the holders
(except for holders whose shares of Common Stock were currently
salable under Rule 144 of the Securities Act or who waived certain
rights); such registration statement was declared effective by the
SEC on September 30, 2011. The Company has certain obligations to
maintain the effectiveness of this registration
statement.&amp;#xA0;&amp;#xA0;Certain holders who had outstanding
registration rights had previously waived their registration rights
or were subject to lock-up agreements. No holder has yet asserted
any claim against the Company with respect to a failure to satisfy
any registration obligations. Were someone to assert a claim
against the Company for breach of registration obligations, the
Company believes it has several defenses that would result in
relieving it from some or any liability, although no assurances can
be given. The Company also notes that damage claims may be limited,
as (i) most shares of Common Stock as to which registration rights
attached are either now registered or currently salable under Rule
144 of the Securities Act or are otherwise currently subject to
other restrictions on sale and (ii) the shares of Common Stock
underlying warrants with registration rights are now registered,
and during much of the relevant periods the warrants with
registration rights generally have been out of the money, were
subject to lock-up agreements and/or the underlying shares of
Common Stock were otherwise subject to restrictions on resale.
Accordingly, were holders to assert claims against the Company
based on breach of the Company&amp;#x2019;s obligation to register, the
Company believes that the Company&amp;#x2019;s maximum exposure would
not be material.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Xiangbei Welman Pharmaceutical Co., Ltd. v Suzhou Erye
Pharmaceutical Co., Ltd. and Hunan Weichu Pharmacy Co.,
Ltd.&lt;/font&gt;&amp;#xA0;&amp;#xA0;involves a patent infringement dispute with
respect to a particular antibiotics complex manufactured by Erye
(the &amp;#x201C;Product&amp;#x201D;). The Changsha Intermediate
People&amp;#x2019;s Court in Hunan Province, PRC in the foregoing case
rendered a judgment on May 13, 2010 against Erye as follows: (i)
awarding plaintiff Xiangbei Welman damages and costs of
approximately 5 million RMB (approximately $778,500) against Erye
which was fully accrued for at September 30, 2011; and (ii)
enjoining Erye from manufacturing, marketing and selling the
Product. On March 21, 2011, Changsha Intermediate Court issued a
civil decision suspending the execution of the Preliminary
Injunction. Therefore, Erye is currently free to produce, sell or
offer to sell the product.&amp;#xA0;&amp;#xA0;Following the filing of the
patent infringement dispute, in 2009 Xiangbei Welman brought a
copyright infringement lawsuit against Erye claiming the package
inserts with respect to the Product infringed upon their copyright
and Erye was enjoined from copying and using the package inserts on
the Product and selling the Product with the package inserts and
Xiangbei Welman was awarded 50,000 RMB, or approximately
$7,800.&amp;#xA0; &amp;#xA0;In July 2011, a new copyright infringement
lawsuit was brought by Xiangbei Welman against Erye claiming that
Erye was not complying with the earlier judgment enjoining them
from copying and using the package inserts for the Product. The
Changsha Intermediate Court was applied to for property
preservation and it issued a civil decision freezing Erye&amp;#x2019;s
bank deposits of up to 50 million RMB, or approximately $7.8
million, or sealing up or detaining Erye&amp;#x2019;s other properties
of equal value. Currently this case is pending.&amp;#xA0;&amp;#xA0;As of
September 30, 2011, approximately 13,744,700 RMB (approximately
$2,140,000) of cash had been frozen in six bank accounts, and is
classified in Other Assets.&amp;#xA0;&amp;#xA0;Erye is working with their
counsel to respond.&amp;#xA0;&amp;#xA0;Erye has contended that jurisdiction
is not proper.&amp;#xA0;&amp;#xA0;A similar action was recently instituted
by Welman against Erye in the Guangzhou Intermediate Court to (i)
enjoin Erye from copying and using the package inserts from the
Product and selling the drugs with the aforesaid package inserts
and; (ii) award Welman economic losses of approximately 2,000,000
RMB (approximately $312,400) against Erye and the case is being
reviewed by the Court. Welman made an application for preliminary
injunction to prohibit Erye from copying and using the package
inserts from the Product and selling the drugs with the aforesaid
package inserts and Welman&apos;s application was denied by the Court on
September 6, 2011.&amp;#xA0;&amp;#xA0;Welman subsequently obtained a
preliminary injunction from a lower court Guangzhou Haizhu District
People&amp;#x2019;s Court in Guangzhou Province, PRC (the &amp;#x201C;Haizhu
District Court&amp;#x201D;)&amp;#xA0;on September 14, 2011.&amp;#xA0;&amp;#xA0;But
on October 28, 2011, upon the appeal by Erye, the Haizhu District
Court issued a decision withdrawing the preliminary
injunction.&amp;#xA0; The Company cannot reasonably assess the
possibility of additional exposure above the amounts previously
accrued as of September 30, 2011.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Chinese regulatory approvals&lt;/font&gt; &amp;#x2013; The Company has
determined that it did not obtain all Chinese regulatory approvals
(and associated registrations) required to reflect the legal title
of its interest in Erye as being held by the proper entity within
our group which is its current beneficial owner as that term is
used under U.S. law.&amp;#xA0; The Company believes it has now
determined what governmental approvals (and associated
registrations) will need to be issued by the Suzhou Municipal
Bureau of Foreign Investment and Commerce and the Suzhou
Administration for Industry and Commerce to remediate these
deficiencies and the Company has had counsel in China prepare these
filings.&amp;#xA0; The Company&amp;#x2019;s management believes these
regulatory deficiencies can be remediated within a reasonable
period of time and should not delay a possible divestiture of the
Company&amp;#x2019;s interests in Erye that is currently under
evaluation.&amp;#xA0; However, the Company requires the cooperation of
the officers of Erye, as to which no assurance can be given, and we
could be compelled to seek to replace those officers or&amp;#xA0;to
commence legal action to obtain the required consents or otherwise
move forward with requisite filings.&amp;#xA0; In addition, even if the
filings are made, no assurance can be given that any unremediated
regulatory deficiencies would not have an adverse effect on the
operating results and liquidity of Erye and the Company and will
not impede or delay efforts to divest the Company&amp;#x2019;s interest
in Erye.&amp;#xA0; In addition, the remediation process is expected to
trigger certain tax liabilities and penalties, however the ultimate
liability will be based on future discussions with the relevant
Chinese authorities.&amp;#xA0;&amp;#xA0;The Company cannot reasonably
assess the exposure as of September 30, 2011.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Amorcyte line of credit &amp;#x2013;&lt;/font&gt; On May&amp;#xA0;19, 2006, PCT
entered into a line of credit agreement with Amorcyte Inc.
(&amp;#x201C;Amorcyte&amp;#x201D;), an entity which was spun out of PCT in
2006, whereby PCT agreed to loan Amorcyte up to $500,000 at an
annual interest rate of 5%.&amp;#xA0; The line of credit agreement was
a condition to Amorcyte closing a Series A Preferred Stock
Financing completed during 2006.&amp;#xA0; The Company has not loaned
any amount to Amorcyte under this agreement through September 30,
2011.&amp;#xA0;&amp;#xA0;The line of credit agreement expires on the
earlier of (i)&amp;#xA0;the date on which the Company declares the
outstanding principal and accrued interest due and payable based on
an event of default as defined within the agreement, or
(ii)&amp;#xA0;the date of closing of the first debt or equity financing
of Amorcyte following the initial borrowing of the principal. These
events have not occurred to date.&amp;#xA0;&amp;#xA0;On October 17, 2011,
the Company acquired Amorcyte pursuant to the Amorcyte Agreement
and Plan of Merger, and this line of credit was
cancelled.&amp;#xA0;&amp;#xA0;&amp;#xA0; (See Note 14).&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Note 11
&amp;#x2013; Segment Information&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company&amp;#x2019;s financial information broken down by reportable
segment was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="28%" colspan="6" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Three
Months Ended September 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="28%" colspan="6" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Nine Months Ended September 30,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="40%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Revenues&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Pharmaceutical Manufacturing - China&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;15,513.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;16,384.5&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;49,806.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;51,528.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Cell Therapy - United States&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,177.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;61.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5,837.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;157.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Regenerative Medicine - China&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;66.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;30.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;215.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;30.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;17,756.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;16,475.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;55,858.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;51,716.3&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="40%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Loss from operations&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Pharmaceutical Manufacturing - China&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;717.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,552.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,480.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;9,302.3&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Cell Therapy - United States&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(2,996.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(2,304.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(9,957.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(6,917.2&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Regenerative Medicine - China&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(681.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(321.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(1,847.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(1,058.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
Corporate office&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(4,420.3&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(5,669.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(17,049.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(13,181.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(7,380.3&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(5,743.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(25,374.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(11,855.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="40%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="40%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Total assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;September
30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Pharmaceutical Manufacturing - China&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;124,045.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;125,458.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Cell Therapy - United States&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;28,445.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,101.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Regenerative Medicine - China&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,640.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4,949.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
Corporate office&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;13,084.3&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;11,514.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;168,214.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;143,024.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:RepaymentsOfSecuredDebt contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">109492</us-gaap:RepaymentsOfSecuredDebt>
  <us-gaap:PreferredStockTextBlock contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Note 8
&amp;#x2013; Preferred Stock&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Convertible
Redeemable Series E 7% Preferred Stock&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;On
November 19, 2010, the Company sold 10,582,011 Preferred Offering
Units consisting of (i) one share (&amp;#x201C;Preferred Share&amp;#x201D;)
of Series E 7% Senior Convertible Preferred Stock, par value $0.01
per share, of the Company, (ii) a warrant to purchase 0.25 of a
share of Common Stock (consisting of at issuance an aggregate of
1,322,486 warrants, adjusted to an aggregate of 1,452,925 as of
September 30, 2011); and (iii) 0.0155 of a share of Common Stock
(an aggregate of 164,418 shares). Each Preferred Offering Unit was
priced at $0.945 and total gross and net proceeds received by the
Company were $10,000,000 and $8,876,700, respectively.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In
the event of any liquidation, dissolution or winding up of the
Company, either voluntary or involuntary, the holders of the
Preferred Shares are entitled to receive, out of the assets of the
Company available for distribution to shareholders, prior and in
preference to any distribution of any assets of the Company to the
holders of any other class or series of equity securities, the
amount of $1.00 per share plus all accrued but unpaid
dividends.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Dividends
on the Preferred Shares accrue at a rate of 7% per annum and are
payable monthly in arrears.&amp;#xA0;&amp;#xA0;The Company is required to
redeem 1/27 of the Preferred Shares monthly.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Monthly
dividend and principal payments began on March 21, 2011 and
continue on the 19th of each month thereafter with the final
payment due on May 20, 2013. Payments can be made in cash or, upon
notification to the holders, in shares of Company common stock,
provided certain conditions are satisfied or holders of Preferred
Shares agree to waive the conditions for that payment period. If
the conditions are not satisfied, the Company must make payments in
cash. Payments which are made in stock will be made in shares which
are freely tradable. The price of the shares will be calculated
based on 92% of the average of the lowest 5 days&amp;#x2019; volume
weighted average prices of the 20 trading days prior to the payment
date, and the shares are delivered in tranches beginning in advance
of the applicable payment date.&amp;#xA0;&amp;#xA0;As of September 30,
2011, the Company had issued 3,462,559 shares of Company common
stock in payment of monthly dividends and principal, including
required advanced payments.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Company may pre-pay the outstanding balance of the Preferred Shares
in full or in part (in increments of no less than $1,000,000) at
115% of the then outstanding balance, reducing to 110% after
November 19, 2011, with notice of not less than thirty days and
adequate opportunity to convert. If the Company chooses to pre-pay,
the outstanding balance must be paid in cash and the premium may be
paid in cash or shares of Company common stock.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Upon
issuance, the Preferred Shares were convertible at an initial
conversion price of $2.0004. The conversion price is subject to
certain weighted average adjustments upon the occurrence of
specific events, including stock dividends, stock splits,
combinations and reclassifications of the Company&amp;#x2019;s common
stock and if (with certain exceptions) the Company issues or sells
any additional shares of common stock or common stock equivalents
at a price per share less than the conversion price then in effect,
or without consideration.&amp;#xA0;&amp;#xA0;As of September 30, 2011, the
conversion price had been adjusted to $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;1.67&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;An
aggregate of $2,500,000 of the proceeds from the Preferred Offering
was placed in escrow for a maximum of 2.5 years as security for the
Company&amp;#x2019;s obligations relative to the Preferred Shares, and
is included in other assets.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
characteristics of the Series E Preferred Stock: cumulative
dividends, mandatory redemption, no voting rights, and callable by
the Company, require that this instrument be treated as mezzanine
equity. The Company bifurcated the fair value of the embedded
conversion options and redemption options from the preferred stock
since the conversion options and certain redemption options were
determined to not be clearly and closely related to the Series E
Preferred Stock. The Company recorded the fair value of the
embedded conversion and redemption options as long-term derivative
liabilities as the conversion price is not fixed and the forced
redemption option contains substantial premiums over the stated
dividend rate for the preferred stock. The Company also recorded
the fair value of the warrants as a long-term derivative liability
as the number of warrant shares and exercise price of the warrants
is not fixed. The Series E Preferred Stock was discounted by the
fair value of the derivatives liabilities. The fair value of the
preferred stock (net of issuance costs and discounts), the embedded
derivatives, and warrant derivative were approximately
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;5,475,600&lt;/font&gt;,
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;783,400&lt;/font&gt; and
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;126,900&lt;/font&gt;,
respectively, as of September 30, 2011.&amp;#xA0;&amp;#xA0;The Company will
report changes in the fair value of the embedded derivatives and
warrant derivative in earnings within other income (expense), net.
The discount and issuance costs on the preferred stock will be
amortized through May 20, 2013 using the effective interest method
and will be reflected within interest expense. For the nine months
ended September 30, 2011, the Company recorded a decrease in the
fair value of the embedded derivatives of approximately
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;1,498,400&lt;/font&gt;
and a decrease in the warrant derivative of approximately
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;148,400&lt;/font&gt;.&amp;#xA0;&amp;#xA0;For
the three months ended September 30, 2011, the Company recorded a
decrease in the fair value of the embedded derivatives of
approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;1,150,300&lt;/font&gt;
and a decrease in the warrant derivative of approximately
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;213,000&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:PreferredStockTextBlock>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Note 7
&amp;#x2013; Bank Loans, Notes Payable and Mortgages
Payable&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Bank
Loans&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In
November 2010, Erye obtained a bank loan of approximately
$3,124,000 from the CITIC Bank International with a variable
interest rate that is currently 6.06% and is due in November
2011.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In
May 2011, Erye obtained a bank loan of approximately $3,124,000
from Commercial Bank of China with a variable interest rate that is
currently 7.02% and is due in November 2011.&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In
July 2011, Erye obtained a bank loan of approximately $1,562,000
from the &lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
Agricultural Bank of China&lt;/font&gt;&lt;/font&gt; with a variable interest
rate that is currently&amp;#xA0;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;6.56&lt;/font&gt;%
and is due in May 2012.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Notes
Payable&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Erye
has approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;3,571,000&lt;/font&gt; of
notes payable outstanding as of September 30, 2011. Notes are
payable to the banks who issue bank notes to Erye&amp;#x2019;s
creditors. Notes payable are interest free and usually mature after
a three to six month period. In order to issue notes payable on
behalf of Erye, the banks require collateral, such as cash deposits
which are approximately 30% - 50% of notes to be issued, or
properties owned by Erye. Restricted cash pledged as collateral for
the balance of notes payable at September 30, 2011 and December 31,
2010, amounted to approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;1,428,000&lt;/font&gt;
and $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;3,381,400&lt;/font&gt;,
respectively.&amp;#xA0; At September 30, 2011 and December 31, 2010,
the restricted cash amounted to &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;40&lt;/font&gt;% and
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;35.8&lt;/font&gt;%,
respectively, of the notes payable Erye issued, and the remainder
of the notes payable is collateralized by pledging the land use
right Erye owns, which amounted to approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;4,870,500&lt;/font&gt;
and $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;4,807,800&lt;/font&gt; at
September 30, 2011 and December 31, 2010,
respectively.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Company has financed certain insurance policies and has notes
payable at September 30, 2011 of approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;38,700&lt;/font&gt;
related to these policies. These notes require monthly payments and
mature in less than one year.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Mortgages
Payable&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;On
October 31, 2007, PCT issued a note to borrow $3,120,000 (the
&amp;#x201C;Note&amp;#x201D;) in connection with its $3,818,500 purchase of
condominium units in an existing building in Allendale, New Jersey
(the &amp;#x201C;Property&amp;#x201D;) that PCT uses as a laboratory and stem
cell processing facility. The Note is payable in 239 consecutive
monthly payments of principal and interest, based on a 20 year
amortization schedule; and one final payment of all outstanding
principal plus accrued interest then due. The current monthly
installment is $20,766, which includes interest at an initial rate
of 5.00%; the interest rate and monthly installments payments are
subject to adjustment on October 1, 2017. On that date, upon prior
written notice, the lender has the option to declare the entire
outstanding principal balance, together with all outstanding
interest, due and payable in full. The Note is secured by
substantially all of the assets of PCT, including a first mortgage
on the Property and assignment of an amount approximately equal to
eighteen months debt service held in escrow. The Note matures on
October 1, 2027 if not called by the lender on October 1, 2017. The
note is subject to certain debt service coverage and total debt to
tangible net worth financial covenant ratios measured
semi-annually. The next measurement date for compliance with
financial covenants is December 31, 2011. PCT was not in compliance
with such covenants at the measurement date of June 30, 2011, and
obtained a covenant waiver letter from the lender for all periods
through June 30, 2011. The outstanding balance was approximately
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;2,736,100&lt;/font&gt; at
September 30, 2011 of which $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;112,700&lt;/font&gt; is
payable within twelve months. On December 6, 2010&amp;#xA0; PCT
Allendale, a wholly-owned subsidiary of PCT, entered into a note
for a second mortgage in the amount of $1 million on the Allendale
Property with TD Bank, N.A.&amp;#xA0; This loan is guaranteed by PCT,
DomaniCell (a wholly-owned subsidiary of PCT, now known as NeoStem
Family Storage, LLC), Northern New Jersey Cancer Associates
(&amp;#x201C;NNJCA&amp;#x201D;) and certain partners of NNJCA and is subject
to a financial covenant starting December 31, 2011. The loan is for
124 months at a fixed rate of 6% for the first 64 months. The loan
is callable for a certain period prior to the interest reset
date.&amp;#xA0;&amp;#xA0; The initial four months was interest only.&amp;#xA0;
The outstanding balance as of September 30, 2011 is $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;939,000&lt;/font&gt; of
which $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;75,200&lt;/font&gt; is
payable within twelve months.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-17522431</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="INF">508070</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">21167682</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">8164814</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-26821108</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:InterestExpense contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">3168118</us-gaap:InterestExpense>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-678211</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Note 14
&amp;#x2013; Subsequent Events&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;
The Amorcyte Merger&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;On
October 17, 2011 (the &amp;#x201C;Closing Date&amp;#x201D;), Amo Acquisition
Company I, Inc. (&amp;#x201C;Subco&amp;#x201D;), a newly-formed wholly-owned
subsidiary of NeoStem, Inc. (&amp;#x201C;NeoStem&amp;#x201D; or the
&amp;#x201C;Company&amp;#x201D;), merged (the &amp;#x201C;Amorcyte Merger&amp;#x201D;)
with and into Amorcyte, Inc., a Delaware corporation
(&amp;#x201C;Amorcyte&amp;#x201D;), in accordance with the terms of the
Agreement and Plan of Merger, dated as of July 13, 2011 (the
&amp;#x201C;Amorcyte Merger Agreement&amp;#x201D;), among NeoStem, Amorcyte,
Subco, and Amo Acquisition Company II, LLC (&amp;#x201C;Subco
II&amp;#x201D;).&amp;#xA0;&amp;#xA0;As a result of the consummation of the
Amorcyte Merger, Amorcyte is now a wholly-owned subsidiary of
NeoStem.&amp;#xA0;&amp;#xA0;Amorcyte is a development stage cell therapy
company focusing on novel treatments for cardiovascular disease.
Amorcyte&amp;#x2019;s lead product candidate, AMR-001, is entering a
Phase 2 study for the treatment of acute myocardial infarction
(AMI). We are currently recruiting trial sites in connection with
the launch of this Phase 2 clinical trial which is expected to
start enrolling patients by the end of first quarter of
2012.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Pursuant
to the terms of the Amorcyte Merger Agreement, all of the shares of
Amorcyte common stock and Amorcyte Series A Preferred Stock and all
options and warrants to acquire equity of Amorcyte, issued and
outstanding immediately prior to the effective time of the Amorcyte
Merger (the &amp;#x201C;Effective Time&amp;#x201D;), were by virtue of the
Amorcyte Merger cancelled and converted into the right to receive,
in the aggregate:&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="top" width="7%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="7%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(i)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="76%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;5,843,483
shares of NeoStem Common Stock (reflecting certain adjustments
taken at the closing, and subject to further adjustment following
the closing in accordance with the Amorcyte Merger Agreement) (the
&amp;#x201C;Base Stock Consideration&amp;#x201D;);&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="top" width="7%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="7%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(ii)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="76%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;the
right to receive 4,092,768 shares of NeoStem Common Stock (the
&amp;#x201C;Contingent Shares&amp;#x201D;, and together with the Base Stock
Consideration, the &amp;#x201C;Stock Consideration&amp;#x201D;), which
Contingent Shares will be issued only if certain specified business
milestones (described below) are accomplished;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="top" width="7%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="7%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(iii)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="76%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;warrants
to purchase&amp;#xA0;1,881,008 shares of NeoStem Common Stock
exercisable over a seven (7) year period at an exercise price of
$1.466 per share (the &amp;#x201C;Warrants&amp;#x201D;) (such Warrants are
redeemable in certain circumstances, and transfer of any shares of
NeoStem Common Stock issued upon exercise of the Warrants will be
restricted until one year after the Closing Date); and&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="top" width="7%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="7%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(iv)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="76%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;earn
out payments equal to 10% of the net sales of Amorcyte&amp;#x2019;s lead
product candidate AMR-001 (in the event of and following the date
of first commercial sale of AMR-001), provided that in the event
NeoStem sublicenses AMR-001, the applicable earn out payment will
be equal to 30% of any sublicensing fees, and provided further that
NeoStem will be entitled to recover direct out-of-pocket clinical
development costs not previously paid or reimbursed and any costs,
expenses, liabilities and settlement amounts arising out of claims
of patent infringement or otherwise challenging Amorcyte&amp;#x2019;s
right to use intellectual property, by reducing any earn out
payments due by 50% until such costs have been recouped in full
(the &amp;#x201C;Earn Out Payments&amp;#x201D;).&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In
accordance with the Amorcyte Merger Agreement, NeoStem has
deposited into an escrow account with the escrow agent (who is
initially NeoStem&amp;#x2019;s transfer agent), 5,843,483 shares of
NeoStem Common Stock for eventual distribution to the former
Amorcyte stockholders (subject to further adjustment following the
closing, including in connection with any indemnification claims of
NeoStem, all in accordance with the Amorcyte Merger
Agreement).&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Contingent Shares will be issued to the former Amorcyte
stockholders only if certain business milestones are achieved, as
follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="top" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="3%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings"&gt;&amp;#xA7;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="78%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;One-third
of the Contingent Shares (1,364,256 shares) will be issued upon (a)
the completion of Phase 2 clinical trial for Amorcyte&amp;#x2019;s
product candidate AMR-001 and (b) issuance of a statistically
significant analysis demonstrating satisfaction of the primary
clinical end points from the Phase 2 clinical trial, which primary
clinical endpoints are described in the Phase 2 clinical trial
protocol submitted by Amorcyte to the FDA on July 5,
2011.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="top" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="3%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings"&gt;&amp;#xA7;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="78%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;One-third
of the Contingent Shares will be issued following a Type B End of
Phase 2/Pre-Phase 3 meeting with the FDA wherein AMR-001 is
acknowledged in writing by the FDA to be ready for Phase
3.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="top" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="3%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings"&gt;&amp;#xA7;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="78%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;The
remaining one-third of the Contingent Shares will be issued upon
the first dosing of the first patient in the pivotal Phase 3
clinical study for AMR-001.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
merger consideration described above will be distributed to
Amorcyte&amp;#x2019;s former securityholders consistent with applicable
liquidation preferences contained in Amorcyte&amp;#x2019;s governing
documents, all in accordance with the Amorcyte Merger
Agreement.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
issuance of NeoStem securities pursuant to the Amorcyte Merger
Agreement was approved at the 2011 Annual Meeting of Stockholders
of NeoStem held on October 14, 2011 (the &amp;#x201C;NeoStem 2011 Annual
Meeting&amp;#x201D;), on which date the Amorcyte Merger also was
approved at a special meeting of stockholders of
Amorcyte.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
description of the Amorcyte Merger contained in this Note 14 does
not purport to be complete and is qualified in its entirety by
reference to the Amorcyte Merger Agreement, which is attached to
NeoStem&amp;#x2019;s Joint Proxy Statement/Prospectus dated and filed
with the Securities and Exchange Commission on September 16, 2011
(the &amp;#x201C;Joint Proxy Statement/Prospectus&amp;#x201D;), the Warrant
Agreement between NeoStem and Continental Stock Transfer &amp;amp;
Trust Company, and the form of Global Series AMO Warrant attached
thereto, which is filed as Exhibit 4.1 to the Company&amp;#x2019;s
Current Report on Form 8-K dated October 14, 2011 (the &amp;#x201C;Form
8-K&amp;#x201D;) and the escrow agreement, which is filed as Exhibit
10.1 to the Form 8-K, respectively.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;
Amendment to the 2009 Plan and 2009 Non-U.S.
Plan&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;At
the NeoStem 2011 Annual Meeting, the shareholders of NeoStem duly
approved an amendment to the NeoStem, Inc. 2009 Equity Compensation
Plan (the &amp;#x201C;2009 Plan&amp;#x201D;) to increase the number of shares
of NeoStem Common Stock authorized for issuance thereunder by
6,000,000 shares (that is, from 17,750,000 shares to 23,750,000
shares), and NeoStem thereupon effected such amendment to the 2009
Plan. Persons eligible to receive restricted and unrestricted stock
awards, options, stock appreciation rights or other awards under
the 2009 Plan are those employees, consultants and directors of
NeoStem and its subsidiaries who, in the opinion of the
Compensation Committee of NeoStem&amp;#x2019;s Board of Directors, are
in a position to contribute to NeoStem&amp;#x2019;s
success.&amp;#xA0;&amp;#xA0;Concurrently therewith, NeoStem decreased the
number of shares authorized for issuance under the NeoStem, Inc.
2009 Non-U.S. Based Equity Compensation Plan by 3,000,000 (that is,
from 8,700,000 to 5,700,000).&amp;#xA0;&amp;#xA0;The reduction in shares
available for issuance under the 2009 Non-U.S. Plan was effected in
light of the Company&amp;#x2019;s plan to focus its business on cell
therapy manufacturing and development and other related activities
in the United States, and the Company&amp;#x2019;s consideration of the
possible divestiture of its 51% interest in
Erye.&amp;#xA0;&amp;#xA0;Persons eligible to receive warrants, stock
appreciation rights or other awards under the 2009 Non-U.S. Plan
are those service providers of NeoStem and its subsidiaries and
affiliates providing services outside of the United States,
including employees and consultants of NeoStem and its subsidiaries
and affiliates, who, in the opinion of the Compensation Committee,
are in a position to contribute to NeoStem&amp;#x2019;s
success.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">50024</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:NetIncomeLoss contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-28287815</us-gaap:NetIncomeLoss>
  <us-gaap:ProceedsFromNotesPayable contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">10950616</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-1446699</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">7766988</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">&lt;div&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Note 2
&amp;#x2013; Summary of Significant Accounting
Policies&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Basis of Presentation:&lt;/font&gt; The accompanying unaudited
Consolidated Financial Statements have been prepared in accordance
with accounting principles generally accepted in the United States
of America (&amp;#x201C;generally accepted accounting principles&amp;#x201D;)
for interim financial information and with the instructions to Form
10-Q and Article 10 of Regulation S-X of the Securities and
Exchange Commission for interim financial information. Accordingly,
they do not include all of the information and footnotes required
by generally accepted accounting principles for complete financial
statements. In the opinion of management, the accompanying
Consolidated Financial Statements of the Company and its
subsidiaries, which are unaudited, include all normal and recurring
adjustments considered necessary to present fairly the
Company&amp;#x2019;s financial position as of September 30, 2011 and the
results of its operations and its cash flows for the periods
presented. The unaudited consolidated financial statements herein
should be read together with the historical consolidated financial
statements of the Company for the years ended December 31, 2010,
2009 and 2008 included in our Annual Report on Form 10-K for the
year ended December 31, 2010.&amp;#xA0;&amp;#xA0;Operating results for the
three and nine month periods ended September 30, 2011 are not
necessarily indicative of the results that may be expected for the
year ending December&amp;#xA0;31, 2011.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Use of Estimates:&lt;/font&gt;&amp;#xA0;&amp;#xA0;The preparation of financial
statements in conformity with accounting principles generally
accepted in the United States of America requires management to
make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and
liabilities at the date of the consolidated financial statements.
Estimates also affect the reported amounts of revenues and expenses
during the reporting period. Accordingly, actual results could
differ from those estimates.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;
Concentration of Risks:&lt;/font&gt;&amp;#xA0;&amp;#xA0;For the&amp;#xA0;three and
nine months ended September 30, 2011, three major suppliers
provided approximately&amp;#xA0;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;29&lt;/font&gt;%
and &lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;28&lt;/font&gt;%,
respectively, of Erye&amp;#x2019;s purchases of raw
materials.&amp;#xA0;&amp;#xA0;As of September 30, 2011, the total accounts
payable to the three major suppliers represented &lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;14&lt;/font&gt;%
of the total accounts payable balance.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;For
the three and nine months ended September 30, 2010, two major
suppliers provided approximately 17% and 20%, respectively, of
Erye&amp;#x2019;s purchases of raw material.&amp;#xA0;&amp;#xA0;As of December
31, 2010, the total accounts payable to the two major suppliers
was&amp;#xA0;18% of the total accounts payable.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Approximately
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;80&lt;/font&gt;%
of Erye&amp;#x2019;s revenues are derived from products that use
penicillin or cephalosporin as the key active ingredient. These
products are manufactured on two of the eight production lines in
Erye&amp;#x2019;s manufacturing facility. Any issues or incidents that
might disrupt the manufacturing of products requiring penicillin or
cephalosporin could have a material impact on the operating results
of Erye. Any interruption or cessation in production could impact
market sales.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In
addition, over 70% of these drugs are on China&amp;#x2019;s essential
drug list and any policies that might lower the pricing of these
drugs and any policies that could reduce the consumption of these
drugs could have a material impact on operating
results.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Inventories:&lt;/font&gt;&amp;#xA0;&amp;#xA0;Inventories are stated at the
approximate lower of cost or market using the first-in, first-out
basis. The Company reviews its inventory periodically and will
reduce inventory to its net realizable value depending on certain
factors, such as product demand, remaining shelf life, future
marketing plans, obsolescence and slow-moving
inventories.&amp;#xA0;&amp;#xA0;The Company includes in work in process the
cost incurred on projects at PCT that have multiple deliverables
and therefore cannot be recognized as revenue until the project is
completed. The Company reviews these projects periodically to
determine that the value of each project is stated at the lower of
cost or market.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Inventories
consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div align="center"&gt;
&lt;table cellpadding="0" cellspacing="0" width="75%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;September
30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;December
31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="66%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
Raw materials and supplies&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;3,839.8&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;8,043.8&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="66%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
Work in process&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;7,136.5&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;4,792.4&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
Finished goods&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;9,606.0&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;8,187.2&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 4px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
Total inventory&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;20,582.3&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;21,023.4&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Income Taxes:&lt;/font&gt;&amp;#xA0;&amp;#xA0;The Company recognizes (a) the
amount of taxes payable or refundable for the current year and (b)
deferred tax liabilities and assets for the future tax consequences
of events that have been recognized in the Company&amp;#x2019;s
financial statements or tax returns. The Company continues to
evaluate the accounting for uncertainty in tax positions. The
guidance requires companies to recognize in their financial
statements the impact of a tax position if the position is more
likely than not of being sustained on audit. The position
ascertained inherently requires judgment and estimates by
management. As of September 30, 2011, management does not believe
the Company has any material uncertain tax positions that would
require it to measure and reflect the potential lack of
sustainability of a position on audit in its financial statements.
The Company will continue to evaluate its uncertain tax positions
in future periods to determine if measurement and recognition in
its financial statements is necessary. The Company does not believe
there will be any material changes in its unrecognized tax
positions over the next year.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;The Company classifies taxes related to witholding
taxes paid on dividends declared by Erye to the Company that are
reinvested into Erye as general and administrative expense.&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Company recognizes interest and penalties as a component of income
tax expense. There were no interest and penalties recognized for
the three and nine months ended September 30, 2011 and 2010,
respectively.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Company files income tax returns with the U.S. Federal government
and various state and foreign jurisdictions. The statute of
limitations has expired on all consolidated U.S. Federal corporate
income tax returns filed through 2006, and the Internal Revenue
Service is not currently examining any of the post-2006 returns
filed by the Company.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Comprehensive Income (Loss):&lt;/font&gt;&amp;#xA0;&amp;#xA0;The accumulated
other comprehensive income (loss) balance at September 30, 2011 and
December 31, 2010 in the amount of approximately $5,001,600 and
$2,779,100, respectively, is comprised entirely of foreign currency
translation adjustments. Comprehensive loss for the three and nine
months ended September 30, 2011 and 2010 was as follows (in
thousands):&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div align="left"&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Three Months Ended September 30,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Nine Months Ended September 30,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="48%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Net
loss&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(7,328.5&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(5,994.6&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(27,728.7&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(13,040.3&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="48%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Other
comprehensive (loss)/income&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Foreign currency translation&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;712.1&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1,483.4&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2,222.6&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1,651.1&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="48%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Total
other comprehensive (loss)/income&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;712.1&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1,483.4&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2,222.6&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1,651.1&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="48%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Comprehensive
(loss)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(6,616.4&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(4,511.2&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(25,506.1&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(11,389.2&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Comprehensive (loss)/income attributable to noncontrolling
interests&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;366.9&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1,864.0&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1,648.1&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;4,877.8&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Comprehensive
loss attributable to NeoStem, Inc.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(6,983.3&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(6,375.2&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(27,154.2&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(16,267.0&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Goodwill and Other Intangible Assets:&lt;/font&gt;&amp;#xA0;&amp;#xA0;Goodwill is
the excess of purchase price over the fair value of identified net
assets of businesses acquired. The Company&amp;#x2019;s intangible
assets with an indefinite life are related to in process research
and development at Erye, as the Company expects this research and
development to provide the Company with substantial benefit for a
period that extends beyond the foreseeable horizon. Amortized
intangible assets consist of Erye&amp;#x2019;s customer list,
manufacturing technology, standard operating procedures, tradename,
lease rights and patents, as well as patents and rights associated
primarily with the&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;VSEL &lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;TM&lt;/font&gt;
Technology. These intangible assets are amortized on a straight
line basis over their respective useful lives.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Company reviews goodwill and indefinite-lived intangible assets at
least annually for possible impairment. Goodwill and
indefinite-lived intangible assets are reviewed for possible
impairment between annual tests if an event occurs or circumstances
change that would more likely than not reduce the fair value of the
reporting unit below its carrying value. The Company tests its
goodwill and indefinite-lived intangible assets for its Cell
Therapy&amp;#xA0;&amp;#x2013;&amp;#xA0;United States, and its Pharmaceutical
Manufacturing&amp;#xA0;&amp;#x2013;&amp;#xA0;China reporting units on October
31. The Company reviews the carrying value of goodwill and
indefinite-lived intangible assets utilizing a discounted cash flow
model, and, where appropriate, a market value approach is also
utilized to supplement the discounted cash flow model. The Company
makes assumptions regarding estimated future cash flows, discount
rates, long-term growth rates and market values to determine each
reporting unit&amp;#x2019;s estimated fair value. If these estimates or
related assumptions change in the future, the Company may be
required to record impairment charges.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Derivatives:&lt;/font&gt;&amp;#xA0;&amp;#xA0;Derivative instruments, including
derivative instruments embedded in other contracts, are recorded on
the balance sheet as either an asset or liability measured at its
fair value. Changes in the fair value of derivative instruments are
recognized currently in results of operations unless specific hedge
accounting criteria are met. The Company has not entered into
hedging activities to date. As a result of certain financings (see
Note 8), derivative instruments were created that are measured at
fair value and marked to market at each reporting period. Changes
in the derivative value are recorded as other income (expense) on
the consolidated statements of operations.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Evaluation of Long-lived Assets:&lt;/font&gt;&amp;#xA0;&amp;#xA0;The Company
reviews long-lived assets and finite-lived intangibles assets for
impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset exceeds the fair value of the
asset. If other events or changes in circumstances indicate that
the carrying amount of an asset that the Company expects to hold
and use may not be recoverable, the Company will estimate the
undiscounted future cash flows expected to result from the use of
the asset or its eventual disposition, and recognize an impairment
loss. The impairment loss, if determined to be necessary, would be
measured as the amount by which the carrying amount of the assets
exceeds the fair value of the assets.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Share-Based Compensation:&lt;/font&gt;&amp;#xA0;&amp;#xA0;The Company expenses
all share-based payment awards to employees, directors, advisors
and consultants, including grants of stock options, warrants, and
restricted stock, over the requisite service period based on the
grant date fair value of the awards. Advisor and consultant awards
are remeasured each reporting period through vesting. For awards
with performance-based vesting criteria, the Company estimates the
probability of achievement of the performance criteria and
recognizes compensation expense related to those awards expected to
vest. The Company determines the fair value of certain share-based
awards using the Black-Scholes option-pricing model which uses both
historical and current market data to estimate the fair value. This
method incorporates various assumptions such as the risk-free
interest rate, expected volatility, expected dividend yield and
expected life of the options or warrants. The fair value of the
Company&amp;#x2019;s restricted stock and restricted stock units is
based on the closing market price of the Company&amp;#x2019;s common
stock on the date of grant. See Note 9.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Loss Per Share:&lt;/font&gt;&amp;#xA0;&amp;#xA0;Basic loss per share is based on
the weighted effect of all common shares issued and outstanding,
and is calculated by dividing net loss attributable to common
shareholders by the weighted average shares outstanding during the
period. Diluted loss per share, which is calculated by dividing net
loss attributable to common shareholders by the weighted average
number of common shares used in the basic loss per share
calculation plus the number of common shares that would be issued
assuming conversion of all potentially dilutive securities
outstanding, is not presented as such potentially dilutive
securities are anti-dilutive in all periods presented. For the
three and nine months ended September 30, 2011 and 2010, the
Company incurred net losses and therefore no common stock
equivalents were utilized in the calculation of loss per share. At
September 30, 2011 and 2010, the Company excluded the following
potentially dilutive securities:&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div align="center"&gt;
&lt;table cellpadding="0" cellspacing="0" width="75%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" valign="bottom" width="32%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;September
30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="66%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Stock
Options&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;17,749,895&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;13,558,214&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="66%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;35,208,817&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;17,352,028&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="66%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Series
E Preferred Stock, Common stock equivalents&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;4,693,730&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Revenue Recognition:&lt;/font&gt; The Company recognizes revenue from
pharmaceutical and pharmaceutical intermediary product sales when
title has passed, the risks and rewards of ownership have been
transferred to the customer, the fee is fixed and determinable, and
the collection of the related receivable is reasonably assured
which is at the time of delivery. The Company recognizes revenue
for its cell development and manufacturing services based on the
terms of individual contracts.&amp;#xA0;&amp;#xA0;In certain cases, there
are multiple elements that cannot be considered separate
deliverables and therefore the Company recognizes revenue on a
completed contract basis for these arrangements. In other cases,
the Company is paid for time and materials or for fixed monthly
amounts and revenue is recognized when efforts are expended or
contractual terms have been met.&amp;#xA0;&amp;#xA0;The Company recognizes
revenue related to the collection and cryopreservation of cord
blood and autologous adult stem cells when the cryopreservation
process is completed which is twenty four hours after cells have
been collected. Revenue related to advance payments of storage fees
is recognized ratably over the period covered by the advance
payments. The Company earns revenue, in the form of license fees,
from physicians seeking to establish autologous adult stem cell
collection centers. These license fees are typically billed upon
signing of the collection center agreement and qualification of the
physician by the Company&amp;#x2019;s credentialing committee and at
various times during the term of license agreements based on the
terms of the specific agreement. These fees are recognized as
revenue ratably over the appropriate period of time to which the
revenue element relates. The Company also receives licensing fees
from a licensee for use of its technology and knowledge to operate
an adult stem cell banking operation in China, which licensing fees
are recognized as revenues ratably over the appropriate period of
time to which the revenue element relates. In addition, the Company
earns royalties for the use of its name and scientific information
in connection with its License and Referral Agreement with
Ceregenex Corporation, which royalties are recognized as revenue
when they are received.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Revenues
for the three and nine months ended September 30, 2011 and 2010
were comprised of the following (in thousands):&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div align="left"&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" colspan="6" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Three
Months Ended September 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Nine
Months Ended September 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" valign="bottom"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Revenues&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Prescription drugs and intermediary pharmaceutical
products&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;15,513.0&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;16,384.5&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;49,806.0&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;51,528.7&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Stem cell related service revenues&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1,529.1&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;91.1&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;4,266.9&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;187.6&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Stem cell related services - reimbursed
expenses&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;714.0&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1,785.1&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="48%" style="PADDING-BOTTOM: 4px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;17,756.1&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;16,475.6&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;55,858.0&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;51,716.3&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Fair Value Measurements:&lt;/font&gt;&amp;#xA0;&amp;#xA0;Fair value of financial
assets and liabilities that are being measured and reported are
defined as the exchange price that would be received to sell an
asset or paid to transfer a liability in an orderly transaction
between market participants in the principal market at the
measurement date (exit price). The Company is required to classify
fair value measurements in one of the following
categories:&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Level
1 inputs which are defined as quoted prices (unadjusted) in active
markets for identical assets or liabilities that the reporting
entity has the ability to access at the measurement
date.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Level
2 inputs which are defined as inputs other than quoted prices
included within Level 1 that are observable for the assets or
liabilities, either directly or indirectly.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Level
3 inputs are defined as unobservable inputs for the assets or
liabilities. Financial assets and liabilities are classified based
on the lowest level of input that is significant to the fair value
measurement. The Company&amp;#x2019;s assessment of the significance of
a particular input to the fair value measurement requires judgment,
and may affect the valuation of the fair value of assets and
liabilities and their placement within the fair value hierarchy
levels.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Company determined the fair value of funds invested in short term
investments, which are considered trading securities, to be level 1
inputs measured by quoted prices of the securities in active
markets. The Company determined the fair value of funds invested in
money market funds to be level 1. The Company determined the fair
value of the embedded derivative liabilities and warrant derivative
liabilities to be level 3 inputs. These inputs require material
subjectivity because value is derived through the use of a lattice
model that values the derivatives based on probability weighted
discounted cash flows. The following table sets forth by level
within the fair value hierarchy the Company&amp;#x2019;s financial
assets and liabilities that were accounted for at fair value on a
recurring basis as of September 30, 2011, and December 31, 2010 (in
thousands):&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div align="center"&gt;
&lt;table cellpadding="0" cellspacing="0" width="85%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
September 30, 2011&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Fair Value Measurements Using Fair Value
Hierarchy&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Level 1&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Level 2&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Level 3&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="52%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Money
market investments&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2,500.8&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="52%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Short
term investments&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;0.6&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="52%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Embedded
derivative liabilities&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;783.4&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="52%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Warrant
derivative liabilities&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;126.9&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="52%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="9" valign="bottom" width="45%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;December
31, 2010&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Fair Value Measurements Using Fair Value
Hierarchy&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Level 1&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Level 2&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Level 3&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="52%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Money
market investments&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2,501.0&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="52%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Short
term investments&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;0.5&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="52%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Embedded
derivative liabilities&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2,281.8&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="52%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Warrant
derivative liabilities&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;289.6&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Subsequent
to December 31, 2010 the Company reevaluated the characteristics of
the money market savings account, currently recorded as other
assets, and determined it is not tied to underlying securities and
has been reclassified to level 1.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;For
those financial instruments with significant Level 3 inputs, the
following table summarizes the activity for the three and nine
months ended September 30, 2011 by type of instrument (in
thousands):&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div align="center"&gt;
&lt;table cellpadding="0" cellspacing="0" width="87%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="48%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" valign="bottom" width="24%" style="TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;For
the Three Months Ended&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" valign="bottom" width="24%" style="TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;For
the Nine Months Ended&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" valign="bottom" width="24%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;September
30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" valign="bottom" width="24%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;September
30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="48%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Embedded&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Embedded&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Derivatives&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Derivatives&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="48%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Beginning
liability balance&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1,933.7&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;342.3&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;2,281.8&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;289.6&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Change
in fair value recorded in earnings&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(1,150.3&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(215.4&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(1,498.4&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(162.7&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Ending
liability balance&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;783.4&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;126.9&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;783.4&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;126.9&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Some
of the Company&amp;#x2019;s financial instruments are not measured at
fair value on a recurring basis, but are recorded at amounts that
approximate fair value due to their liquid or short-term nature,
such as cash and cash equivalents, restricted cash, accounts
receivable, accounts payable, notes payable and&amp;#xA0;bank
loans.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Foreign Currency Translation:&lt;/font&gt;&amp;#xA0;&amp;#xA0;As the
Company&amp;#x2019;s Chinese pharmaceutical business is a self-contained
and integrated entity, and the Company&amp;#x2019;s Chinese stem cell
business&amp;#x2019; future cash flow is intended to be sufficient to
service its additional financing requirements, the Chinese
subsidiaries&amp;#x2019; functional currency is the Renminbi
(&amp;#x201C;RMB&amp;#x201D;), and the Company&amp;#x2019;s reporting currency is
the US dollar. Results of foreign operations are translated at the
average exchange rates during the period, and assets and
liabilities are translated at the closing rate at the end of each
reporting period. Cash flows are also translated at average
exchange rates for the period, therefore, amounts reported on the
consolidated statement of cash flows will not necessarily agree
with changes in the corresponding balances on the consolidated
balance sheet.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Research and Development Costs:&lt;/font&gt;&amp;#xA0;&amp;#xA0;Research and
development (&amp;#x201C;R&amp;amp;D&amp;#x201D;) expenses include salaries,
benefits, and other headcount related costs, clinical trial and
related clinical manufacturing costs, contract and other outside
service fees including sponsored research agreements, and
facilities and overhead costs. The Company expenses the costs
associated with research and development activities when
incurred.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;To
further drive the Company&amp;#x2019;s cell therapy initiatives, the
Company will continue targeting key governmental agencies,
congressional committees and not-for-profit organizations to
contribute funds for the Company&amp;#x2019;s research and development
programs. The Company accounts for government grants as a deduction
to the related expense in research and development operating
expenses when earned.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;
Statutory Reserves:&lt;/font&gt;&amp;#xA0;&amp;#xA0;Pursuant to laws applicable
to entities incorporated in the PRC, the PRC subsidiaries are
prohibited from distributing their statutory capital and are
required to appropriate from PRC GAAP profit after tax to other
non-distributable reserve funds. These reserve funds include one or
more of the following: (i) a general reserve, (ii) an enterprise
expansion fund and (iii) a staff bonus and welfare fund. Subject to
certain cumulative limits (i.e., 50% of the registered capital of
the relevant company), the general reserve fund requires annual
appropriation at 10% of after tax profit (as determined under
accounting principles generally accepted in the PRC at each
year-end); the appropriation to the other funds are at the
discretion of the subsidiaries.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
general reserve is used to offset extraordinary losses. Subject to
approval by the relevant authorities, a subsidiary may, upon a
resolution passed by the shareholders, convert the general reserve
into registered capital provided that the remaining general reserve
after the conversion shall be at least 25% of the registered
capital of the subsidiary before the capital increase as a result
of the conversion. The staff welfare and bonus reserve is used for
the collective welfare of the employees of the subsidiary. The
enterprise expansion reserve is for the expansion of the
subsidiary&amp;#x2019;s operations and can also be converted to
registered capital upon a resolution passed by the shareholders
subject to approval by the relevant authorities. These reserves
represent appropriations of the retained earnings determined in
accordance with Chinese law, and are not distributable as cash
dividends to the parent company, NeoStem. Statutory reserves are
$2,300,900 and $2,234,600 as of September 30, 2011 and December 31,
2010, respectively.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Relevant
PRC statutory laws and regulations permit payment of dividends by
the Company&amp;#x2019;s PRC subsidiaries only out of their accumulated
earnings, if any, as determined in accordance with PRC accounting
standards and regulations. As a result of these PRC laws and
regulations, the Company&amp;#x2019;s PRC subsidiaries are restricted in
their ability to transfer a portion of their net assets either in
the form of dividends, loans or advances. The restricted amount was
$184,500 at September 30, 2011 and $214,200 at December 31,
2010.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">175000</us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock>
  <us-gaap:GainLossOnSaleOfOtherAssets contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-396635</us-gaap:GainLossOnSaleOfOtherAssets>
  <us-gaap:CostOfRevenue contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">41636950</us-gaap:CostOfRevenue>
  <us-gaap:RepaymentsOfBankDebt contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">1557000</us-gaap:RepaymentsOfBankDebt>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-28795885</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">5453931</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NatureOfOperations contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Note
1&amp;#xA0;&amp;#xA0;&amp;#x2013; The Company&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;!--EFPlaceholder--&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;NeoStem,
Inc. (&amp;#x201C;NeoStem&amp;#x201D; or the &amp;#x201C;Company&amp;#x201D;) was
incorporated under the laws of the State of Delaware in September
1980 under the name Fidelity Medical Services, Inc. The
Company&amp;#x2019;s corporate headquarters are located at 420 Lexington
Avenue, Suite 450, New York, NY 10170.&amp;#xA0;&amp;#xA0;The
Company&amp;#x2019;s telephone number is (212) 584-4180 and its website
address is&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;&amp;#xA0;&amp;#xA0;www.neostem.com&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;NeoStem
is an international biopharmaceutical company operating in three
reportable segments: (i) Cell Therapy&amp;#xA0;&amp;#x2013;&amp;#xA0;United
States; (ii) Regenerative Medicine&amp;#xA0;&amp;#x2013;&amp;#xA0;China; and
(iii) Pharmaceutical
Manufacturing&amp;#xA0;&amp;#x2013;&amp;#xA0;China.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Through
the Cell Therapy&amp;#xA0;&amp;#x2013;&amp;#xA0;United States segment, NeoStem
is focused on the development of proprietary cellular therapies in
oncology, immunology and regenerative medicine and becoming a
single source for collection, storage, manufacturing, therapeutic
development and transportation of cells for cell based medicine and
regenerative science globally&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;.&lt;/font&gt; Within this segment,
the Company is a provider of adult stem cell collection, processing
and storage services in the U.S., enabling healthy individuals to
donate and store their stem cells for personal therapeutic use. In
addition, the Company collects and stores cord blood cells of
newborns which help to ensure a supply of autologous stem cells for
the child should they be needed for future medical
treatment.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Company strengthened its expertise in cellular therapies, for its
Cell Therapy &amp;#x2013; United States segment, with its January 19,
2011 acquisition of Progenitor Cell Therapy, LLC, a Delaware
limited liability company (&amp;#x201C;PCT&amp;#x201D;), pursuant to which
the Company acquired all of the membership interests of PCT, and
PCT is now a wholly-owned subsidiary of NeoStem. PCT is engaged in
a wide range of services in the cell therapy market for the
treatment of human disease, including, but not limited to contract
manufacturing, product and process development, regulatory
consulting, product characterization and comparability, and
storage, distribution, manufacturing and transportation of cell
therapy products. PCT&amp;#x2019;s legacy business relationships also
afford NeoStem introductions to innovative therapeutic
programs.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In
March 2011 PCT&amp;#x2019;s wholly owned subsidiary, Athelos, Inc.
(Athelos), acquired rights and technology for a T-cell based
immunomodulatory therapeutic in exchange for an approximate 20%
interest in Athelos. Athelos expects to initiate Phase 1 studies in
autoimmune disorders in 2012.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Company further strengthened its breadth in cellular therapies
through its October 17, 2011 acquisition of Amorcyte,
Inc.&amp;#xA0;&amp;#xA0;Amorcyte is a development stage cell therapy
company focusing on novel treatments for cardiovascular
disease.&amp;#xA0;&amp;#xA0;Amorcyte&amp;#x2019;s lead product candidate,
AMR-001, is entering a Phase 2 study for the treatment of acute
myocardial infarction (AMI).&amp;#xA0;&amp;#xA0;Amorcyte is currently
recruiting trial sites in connection with the launch of this Phase
2 clinical trial which is expected to start enrolling patients by
the end of the first quarter of 2012.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Company views the PCT and Amorcyte acquisitions as fundamental to
building a foundation in achieving its strategic mission of
capturing the paradigm shift to cell therapy.&amp;#xA0;&amp;#xA0;(See Note
4 and Note 14)&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Through
its Regenerative Medicine&amp;#xA0;&amp;#x2013;&amp;#xA0;China segment, in 2009,
the Company began several China-based, Regenerative Medicine
initiatives including: (i) creating a separate China-based cell
therapy operation, (ii) constructing a stem cell research and
development laboratory and processing facility in Beijing, (iii)
establishing relationships with hospitals to provide cell-based
therapies, and (iv) obtaining product licenses covering several
adult stem cell therapeutics focused on regenerative
medicine.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Company acquired its Pharmaceutical
Manufacturing&amp;#xA0;&amp;#x2013;&amp;#xA0;China segment on October 30, 2009,
when China Biopharmaceuticals Holdings, Inc. (&amp;#x201C;CBH&amp;#x201D;)
merged with and into CBH Acquisition LLC (&amp;#x201C;Merger
Sub&amp;#x201D;), a wholly-owned subsidiary of NeoStem, with Merger Sub
as the surviving entity (the &amp;#x201C;Erye Merger&amp;#x201D;). As a
result of the Erye Merger, NeoStem acquired CBH&amp;#x2019;s 51%
ownership interest in Suzhou Erye Pharmaceutical Company Ltd.
(&amp;#x201C;Erye&amp;#x201D;), a Sino-foreign joint venture with limited
liability organized under the laws of the People&amp;#x2019;s Republic
of China. Erye was founded more than 50 years ago and represents an
established, vertically-integrated pharmaceutical business.
Historically, Erye has concentrated its efforts on the
manufacturing and distribution of generic antibiotic products. In
2010, Erye began transferring its operations to its newly
constructed manufacturing facility. The relocation is continuing as
the new production lines are completed and receive cGMP
certification. As part of its plan to focus its business on
capturing the paradigm shift to cell therapies following the
January 2011 acquisition of PCT, the Company is pursuing strategic
alternatives with respect to its interest in Erye.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">6754953</us-gaap:DepreciationAndAmortization>
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">&lt;div&gt;
&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Note 5
&amp;#x2013; Goodwill and Other Intangible Assets&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
changes in the carrying amount of goodwill by reportable segment
during nine months ended September 30, 2011 were as follows (in
thousands):&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="75%"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="52%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="14%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Pharmaceutical&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="52%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Cell
Therapy -&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="14%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Manufacturing
-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="14%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="14%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;United
States&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="14%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;China&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="14%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
Total&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Balance
as of December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="13%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="13%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;27,002.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="13%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;27,002.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Acquisitions*&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="13%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4,783.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="13%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="13%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4,783.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Foreign
currency exchange rate changes&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;801.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;801.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Balance
as of September 30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4,783.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;27,803.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;32,586.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;*Goodwill
associated with the PCT Merger&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="13%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="13%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="13%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As
of September 30, 2011 and December 31, 2010, the Company&amp;#x2019;s
intangible assets and related accumulated amortization consisted of
the following (in thousands):&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="23%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="31%" colspan="10" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;September
30, 2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="31%" colspan="10" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;December
31, 2010&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="23%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="23%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="11%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Useful
Life&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Gross&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Amortization&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" colspan="2" nowrap="nowrap" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&lt;font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Net&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Gross&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Amortization&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Net&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="23%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Customer
list&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="11%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;10
Years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;19,666.3&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(3,598.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;16,067.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;17,740.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(2,069.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;15,670.3&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="23%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Manufacturing
technology&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="11%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;10
Years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;10,251.3&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(1,247.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;9,003.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;4,220.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(492.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;3,728.2&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="23%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Tradename&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="11%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;10
Years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;2,313.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(284.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;2,028.2&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;983.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(114.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;869.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="23%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;In
process R&amp;amp;D&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="11%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;1,779.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;1,779.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;2,219.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;2,219.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="23%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Standard
operating procedures&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="11%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;10
Years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;1,098.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(210.5&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;887.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;1,066.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(124.5&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;942.3&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="23%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Lease
rights&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="11%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;2
Years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;841.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(806.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;35.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;817.2&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(476.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;340.5&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="23%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;VSEL
patent rights&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="11%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;19
Years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;669.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(132.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;537.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;669.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(105.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;563.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="23%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Patents&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="11%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;8
Years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;203.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(81.2&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;121.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;164.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(31.2&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;133.2&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="23%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;Total
Intangible Assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;36,822.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(6,360.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;30,461.5&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;27,881.5&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;(3,414.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;24,466.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
2011, Erye commenced sales of two products that were previously
accounted for as In Process R&amp;amp;D which has resulted in a
reclassification of approximately $505,500 from In Process R&amp;amp;D
to Manufacturing Technology.&amp;#xA0;&amp;#xA0;Certain of the
Company&amp;#x2019;s intangible assets are recorded on the books of
wholly owned or partially owned subsidiaries and affiliates in
China, and denominated in RMB. &amp;#xA0;As a result, the balance
reported fluctuates based upon the changes in exchange
rates.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
connection with the acquisition of PCT, the following intangible
assets were acquired (in thousands):&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="65%"&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="77%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Customer
list&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="20%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,400.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="77%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Manufacturing
technology&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="20%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5,400.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="77%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Tradename&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,300.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="77%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8,100.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Total
intangible amortization expense was classified in the operating
expense categories for the periods included below as follows (in
thousands):&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="85%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="28%" colspan="6" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Three
Months Ended September 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="28%" colspan="6" nowrap="nowrap" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Nine
Months Ended September 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Cost of revenue&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;388.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;87.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,126.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;259.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Research and development&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;13.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;401.3&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;41.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,185.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Selling, general and administrative&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;547.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,611.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
Total&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;949.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;488.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,779.2&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,454.2&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Estimated
intangible amortization expense on an annual basis for the
succeeding five years is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="25%"&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="45%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="8%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="45%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;880.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="45%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="8%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="45%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,380.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="45%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="8%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="45%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,380.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="45%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2014&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="8%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="45%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,380.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="45%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="8%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="45%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,380.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="45%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="8%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="45%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;16,061.4&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="45%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="8%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="45%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;30,461.5&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-25374409</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestPaidCapitalized contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="INF">235700</us-gaap:InterestPaidCapitalized>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">31828451</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">907628</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-3899053</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">647674</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">234756</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">3406043</us-gaap:RepaymentsOfRelatedPartyDebt>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Note 10
&amp;#x2013; Income Taxes&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;!--EFPlaceholder--&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Tax Reform Act of 1986 enacted a complex set of rules limiting the
utilization of net operating loss carryforwards (&amp;#x201C;NOL&amp;#x201D;)
to offset future taxable income following a corporate ownership
change. The Company&amp;#x2019;s ability to utilize its NOL
carryforwards is limited following a change in ownership in excess
of fifty percentage points during any three-year
period.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Since
the year 2000, the Company has had several changes in ownership
which has resulted in a limitation on the Company&amp;#x2019;s ability
to apply net operating losses to future taxable income and future
ownership changes could result in additional limitations. At
December 31, 2010, the Company had net operating loss carryforwards
of approximately $39,590,500 applicable to future Federal income
taxes. The tax loss carryforwards are subject to annual limitations
and expire at various dates through 2030. The Company has recorded
a full valuation allowance against its net deferred tax asset
because it is more likely than not that such deferred tax assets
will not be realized.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
income tax provision for the three and nine months ended September
30, 2011 and 2010 is related to foreign taxes for our operations in
China.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:InterestPaid contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">1238400</us-gaap:InterestPaid>
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">&lt;div&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Note 4
&amp;#x2013; Acquisitions&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;On
January 19, 2011 (the &amp;#x201C;Closing Date&amp;#x201D;), NBS Acquisition
Company LLC (&amp;#x201C;Subco&amp;#x201D;), a newly formed wholly-owned
subsidiary of NeoStem, merged (the &amp;#x201C;PCT Merger&amp;#x201D;) with
and into Progenitor Cell Therapy, LLC, a Delaware limited liability
company (&amp;#x201C;PCT&amp;#x201D;), with PCT as the surviving entity, in
accordance with the terms of the Agreement and Plan of Merger,
dated September 23, 2010 (the &amp;#x201C;PCT Merger Agreement&amp;#x201D;),
among NeoStem, PCT and Subco.&amp;#xA0;&amp;#xA0;As a result of the
consummation of the PCT Merger, NeoStem acquired all of the
membership interests of PCT, and PCT is now a wholly-owned
subsidiary of NeoStem.&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Founded
by Dr. Andrew L. Pecora and Robert A. Preti, Ph.D., PCT became an
internationally recognized cell therapy services and development
company.&amp;#xA0;&amp;#xA0;They sought to create a business for &amp;#x201C;as
needed&amp;#x201D; development and manufacturing services for the
emerging cell therapy industry and to prepare for eventual
commercialization.&amp;#xA0;&amp;#xA0;With its cell therapy manufacturing
facilities and team of professionals, PCT offers a platform that
can facilitate the preclinical and clinical development and
commercialization of cellular therapies for clients throughout the
world.&amp;#xA0;&amp;#xA0;PCT offers current Good Manufacturing Practices
(cGMP)-compliant cell transportation, manufacturing, storage, and
distribution services and supporting clinical trial design, product
process development, logistics, regulatory and quality systems
development services.&amp;#xA0;&amp;#xA0;In addition, through its network
of contacts throughout the cell therapy industry, PCT is able to
identify early stage development opportunities in the cell therapy
field and opportunistically develop these cell therapies through
proof of concept where they can be further developed and ultimately
commercialized through NeoStem&amp;#x2019;s developing commercial
structure. Dr. Preti now serves as PCT&apos;s President and Chief
Scientific Officer and Dr. Pecora as Chief Medical Officer of
NeoStem and PCT.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;PCT
is engaged in a broad range of services in the cell therapy market
for the treatment of human disease, including but not limited to
contract manufacturing, product and process development, product
and regulatory consulting, and product characterization and
comparability.&amp;#xA0;&amp;#xA0;PCT&amp;#x2019;s expertise in the cell therapy
space, which includes therapeutic vaccines (oncology), various
related cell therapeutics, cell diagnostics, and regenerative
medicine, creates a platform upon which NeoStem intends to build a
therapeutics strategy.&amp;#xA0;&amp;#xA0;NeoStem&amp;#x2019;s goal is to
develop internally, or through partnerships, allogeneic (cells from
a third-party donor) or autologous (cells from oneself) cell
therapeutics technologies that, in the aggregate, comprise the Cell
Therapy &amp;#x2013; United States reportable segment.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In
addition, PCT has assumed NeoStem&amp;#x2019;s adult stem cell business
based on PCT&amp;#x2019;s strategic advantages in meeting cGMP
regulatory requirements in an industry that is widely dispersed
with a range of quality issues.&amp;#xA0;&amp;#xA0;NeoStem believes that
PCT, as a quality leader, is ideally positioned to become a leader
in cell collection, processing and storage (cell banking) which is
synergistic with NeoStem&amp;#x2019;s roots in this
business.&amp;#xA0;&amp;#xA0;In addition, PCT&amp;#x2019;s leadership in the
transportation and distribution of cell therapy products is
complementary to NeoStem&amp;#x2019;s strategic vision of working with
the industry leader as the partner of choice.&amp;#xA0;&amp;#xA0;These
efforts are being bundled together into a new service with
PCT&amp;#x2019;s cord blood banking business into a multigenerational
stem cell collection and storage plan that the Company calls the
&amp;#x201C;Family Plan&amp;#x201D;.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Pursuant
to the terms of the PCT Merger Agreement, all of the membership
interests of PCT outstanding immediately prior to the effective
time of the PCT Merger were converted into the right to receive, in
the aggregate, (i) 10,600,000 shares of the common stock, par value
$0.001 per share, of NeoStem (the &amp;#x201C;NeoStem Common
Stock&amp;#x201D;) (reflecting certain final price adjustments agreed to
at the closing) and (ii) warrants to purchase an aggregate
3,000,000 shares of NeoStem Common Stock as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="top" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="3%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(i)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="83%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;common
stock purchase warrants to purchase one million (1,000,000) shares
of NeoStem Common Stock, exercisable over a seven year period at an
exercise price of $7.00 per share (the &amp;#x201C;$7.00
Warrants&amp;#x201D;), and which will vest only if a specified business
milestone (described in the PCT Merger Agreement) is accomplished
within three (3) years of the Closing Date of the PCT Merger;
and&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="top" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="3%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(ii)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="83%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;common
stock purchase warrants to purchase one million (1,000,000) shares
of NeoStem Common Stock exercisable over a seven year term at an
exercise price of $3.00 per share (the &amp;#x201C;$3.00
Warrants&amp;#x201D;); and&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="top" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="3%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;(iii)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="83%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;common
stock purchase warrants to purchase one million (1,000,000) shares
of NeoStem Common Stock exercisable over a seven year period at an
exercise price of $5.00 per share (the &amp;#x201C;$5.00 Warrants&amp;#x201D;
and, collectively with the $7.00 Warrants and the $3.00 Warrants,
the &amp;#x201C;Warrants&amp;#x201D;).&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Warrants are redeemable in certain
circumstances.&amp;#xA0;&amp;#xA0;Transfer of the shares issuable upon
exercise of the Warrants is restricted until the one year
anniversary of the Closing Date.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In
accordance with the PCT Merger Agreement, NeoStem has deposited
into an escrow account with the escrow agent (who is initially
NeoStem&amp;#x2019;s transfer agent), 10,600,000 shares of NeoStem
Common Stock for eventual distribution to the former members of PCT
(subject to downward adjustment to satisfy any indemnification
claims of NeoStem, all as described in the PCT Merger
Agreement).&amp;#xA0;&amp;#xA0;As of September 30, 2011, approximately
974,000 shares have been distributed to the former members of
PCT.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
issuance of NeoStem securities in the PCT Merger was approved at a
special meeting of shareholders of NeoStem held on January 18, 2011
(the &amp;#x201C;NeoStem Special Meeting&amp;#x201D;), on which date the PCT
Merger was also approved at a special meeting of members of
PCT.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
fair value of the net assets acquired in the PCT Merger was
$12,416,200. The fair value of the equity issued as consideration
by NeoStem was valued at $17,200,000 resulting in the recognition
of goodwill in the amount of $4,783,600. The fair value of the
equities issued by NeoStem included 10,600,000 shares of NeoStem
Common stock valued at $15,900,000 and NeoStem warrants to purchase
up to 3,000,000 shares valued at $1,966,200.&amp;#xA0;&amp;#xA0;A portion
of the consideration paid is contingent upon the accomplishment of
a certain milestone for the $7.00 Warrants.&amp;#xA0;&amp;#xA0;Such
contingent consideration has been classified as equity and will not
be subject to remeasurement.&amp;#xA0;&amp;#xA0;The goodwill that has been
created by this acquisition is reflective of values and
opportunities of utilizing PCT&amp;#x2019;s cell collection, processing
and storage (cell banking) resources and production capacities, as
mentioned above.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
preliminary fair value of assets acquired and liabilities assumed
on January 19, 2011 is as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;div align="center"&gt;
&lt;table cellpadding="0" cellspacing="0" width="40%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="72%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Cash&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="25%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;227,900&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="72%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Accounts
Receivable&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="25%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;442,400&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="72%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Other
Current Assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="25%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;166,200&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="72%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Property,
Plant &amp;amp; Equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="25%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;11,769,000&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="72%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Intangibles&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="25%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;8,100,000&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="72%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="25%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;4,783,600&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="72%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Other
Assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="25%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;654,100&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="72%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="25%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="72%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Accounts
Payable&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="25%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;1,370,900&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="72%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Other
Liabilities&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="25%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;540,500&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="72%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Deferred
Revenues&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="25%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;247,400&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="72%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Amount
Due Related Party&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="25%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;3,000,000&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="72%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Mortgages
Payable&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="25%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;3,784,600&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
total cost of the acquisition, which is still preliminary, has been
allocated to the assets acquired and the liabilities assumed based
upon their estimated fair values at the date of the acquisition.
&amp;#xA0;It is expected the goodwill will be deductible for income tax
purposes.&amp;#xA0;&amp;#xA0;As of September 30, 2011, the preliminary fair
values of the deferred tax liabilities were reduced to zero, from
an initial estimate of $4.3 million, due to the finalization of the
tax treatment of the transaction. As a result, the tax provision
for the nine months ended September 30, 2011 reflects a $178,000
adjustment related to the portion of deferred tax liability
recognized in the first and second quarters of fiscal 2011. In
addition, the fair value of the equity issued as consideration by
NeoStem was reduced by $666,200. The net effect of the updated
values reduced the preliminary goodwill by $4.9 million. This
estimated purchase price allocation continues to be subject to
revision based on additional valuation work that is being
conducted.&amp;#xA0; The final allocation is pending the receipt of
this valuation work and the completion of the Company&amp;#x2019;s
internal review, which is expected during fiscal 2011.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;For
the period since the acquisition (January 19-September 30, 2011),
NeoStem recorded $5,571,500 in revenues and a net loss of
approximately $4,043,300 or $0.05 basic and diluted loss per share
attributable to PCT.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
following supplemental table presents unaudited consolidated pro
forma financial information as if the closing of the acquisition of
PCT had occurred on January 1, 2010 (in thousands, except per share
amounts):&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div align="left"&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
Nine Months Ended September 30,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
Nine Months Ended September 30,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
(As Reported)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
(Proforma)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
(As Reported)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
(Proforma)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
(As Reported)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
(Proforma)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="34%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;Revenues&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;55,858&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;56,240&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;16,476&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;18,883&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;51,716&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;57,575&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 2px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;Cost
of revenues&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;41,637&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;41,961&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;11,233&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;12,996&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;35,016&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;39,561&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="34%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;Gross
profit&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;14,221&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;14,279&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;5,243&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;5,887&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;16,701&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;18,014&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="34%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;Research
and development&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;7,767&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;7,767&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;1,680&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;1,679&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;5,114&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;5,111&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 2px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;Selling,
general, and administrative&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;31,829&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;32,218&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;9,307&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;10,905&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;23,442&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;28,120&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="34%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;Operating
loss&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(25,375&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(25,706&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(5,744&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(6,696&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(11,855&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(15,217&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 2px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;Other
income (expense), net&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(1,447&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(1,482&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;35&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(47&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;6&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(208&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="34%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;Loss
from operations before provision for income taxes and&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="34%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;noncontrolling
interests&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(26,821&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(27,187&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(5,709&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(6,743&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(11,849&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(15,425&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 2px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;Provision
for income taxes&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;908&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;908&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;286&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;286&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;1,191&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;1,191&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="34%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;Net
loss&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(27,729&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(28,905&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(5,995&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(7,029&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(13,040&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(16,616&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="34%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;Less
&amp;#x2013; net income attributable to noncontrolling
interests&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;559&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;559&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;1,146&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;1,146&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;4,086&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;4,086&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 2px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;Preferred
dividends&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;508&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;508&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;154&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;154&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 4px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;Net
loss attributable to NeoStem, Inc. common shareholders&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(28,796&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(29,162&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(7,140&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(8,175&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(17,280&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(20,855&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="34%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;Basic
and diluted loss per share&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(0.35&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(0.35&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(0.13&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(0.12&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(0.36&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;(0.35&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="34%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;Weighted
average common shares outstanding&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;82,775&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;83,513&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;56,777&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;67,377&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;48,599&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%" style="TEXT-ALIGN: right"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"&gt;59,199&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
unaudited supplemental pro forma financial information should not
be considered indicative of the results that would have occurred if
the PCT Merger had been consummated on January 1, 2010, nor are
they indicative of future results.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Athelos
Corporation (&amp;#x201C;Athelos&amp;#x201D;) is a subsidiary of PCT pursuing
the development of T regulatory cells (TRegs) as a therapeutic to
treat disorders of the immune system.&amp;#xA0; Pursuant to a Stock
Purchase and Assignment Agreement dated March 28, 2011, Athelos
issued approximately 20% of its shares to Becton Dickinson and
Company (&amp;#x201C;BD&amp;#x201D;) in exchange for the rights to certain
intellectual property relating to TRegs that BD owned pursuant to a
license agreement between the University of Pennsylvania
(&amp;#x201C;Penn&amp;#x201D;) and BD dated September 28, 2005 (the
&amp;#x201C;Penn License&amp;#x201D;), and a license agreement between ExCell
Therapeutics, LLC and BD dated September 16, 2005, as amended
August 31, 2007 (the &amp;#x201C;ExCell License&amp;#x201D;).&amp;#xA0; Pursuant
to a Stock Purchase and Assignment Agreement dated March 28, 2011,
Athelos took assignment from BD of its rights and obligations under
the Penn License and the ExCell License, including, among other
things, obligations to pay royalties on net sales of licensed
products, maintenance fees and milestones on initiation of clinical
trial stages, license application filings and regulatory
approvals.&amp;#xA0; As expressly anticipated by the parties, Athelos
replaced the assignment of the Penn License with two new direct
licenses: The Amended and Restated Patent License Agreement between
Penn and Athelos dated September 12, 2011, and the Patent License
Agreement between Penn, Athelos and the University of Minnesota
dated September 12, 2011. Athelos and ExCell are in the process of
negotiating a direct license that would replace the existing
assigned ExCell License.&amp;#xA0;&amp;#xA0;Pursuant to the
Stockholders&amp;#x2019; Agreement dated March 28, 2011, Athelos, PCT
and BD have agreed, that, among other things, BD will have certain
anti-dilution protection for the first $5 million of new investment
in Athelos and certain&amp;#xA0; board of directors&amp;#x2019; observer
rights.&amp;#xA0;&amp;#xA0; BD has assigned to Athelos, and Athelos
assumed, all rights, title, interest and obligations of BD under a
consulting agreement dated as of September 16, 2005 between David
Horwitz, M.D. and BD, to be paid retroactively beginning as of
January 1, 2011, for services rendered in advancing the Athelos
TReg research and development platform&lt;font style="DISPLAY: inline; FONT-STYLE: italic"&gt;.&lt;/font&gt;&amp;#xA0;&amp;#xA0;PCT had
preliminarily valued BD&amp;#x2019;s share of the contributed
intellectual properties in the quarter ended March 31, 2011 at
$927,000 and characterized this acquired intangible asset as
in-process research and development which has been recorded as
expense within research and development expense.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In
the quarter ended September 30, 2011, PCT finalized its valuation
of the intellectual properties received, and revised the fair value
to $1,150,000, which is recorded as expense within research and
development expense for the nine months ended September 30,
2011.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-3136189</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">&lt;div&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="bottom" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"&gt;
&lt;font style="DISPLAY: inline"&gt;Note 6&amp;#x2013; Accrued
Liabilities&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Accrued
liabilities are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="65%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="65%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="15%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
September 30, 2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="15%" colspan="2" nowrap="nowrap" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="65%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;VAT
and other taxes&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="14%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,081.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="14%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;126.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="65%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Salaries,
employee benefits and related taxes&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="14%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;911.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="14%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;210.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="65%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Amount
due on patent infringement&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="14%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;770.3&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="14%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;758.5&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="65%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Other&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,099.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,676.3&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="65%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5,863.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,772.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:OperatingExpenses contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">39595439</us-gaap:OperatingExpenses>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">1661049</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">1150000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-1361697</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Note 12
&amp;#x2013; Related Party Transactions&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;At
September 30, 2011, Erye owed EET, the &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;49&lt;/font&gt;%
shareholder of Erye, $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;20,534,100&lt;/font&gt;
which represents dividends paid and loaned back to
Erye.&amp;#xA0;&amp;#xA0;At September 30, 2011 the interest rate on this
loan was &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;6.56&lt;/font&gt;%.&amp;#xA0;&amp;#xA0;In
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;June&lt;/font&gt; 2011
Erye paid EET approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;875,100&lt;/font&gt;
consisting of the net of the following: $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;1,115,000&lt;/font&gt; of
unpaid accrued interest at June 30, 2011, approximately
$&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;408,700&lt;/font&gt;
repayment of a non interest bearing loan due in 2011 and recovery
of cash advances to EET of approximately $&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;648,600&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Pursuant
to the terms and conditions of the Erye Joint Venture Agreement,
dividend distributions to EET and the Company&amp;#x2019;s subsidiary
will be made in proportion to their respective ownership interests
in Erye; provided, however, that for the three-year period
commencing on the first day of the first fiscal quarter after the
Joint Venture Agreement became effective distributions are made as
follows: for undistributed profits generated subsequent to the
acquisition date: (i) the 49% of undistributed profits (after tax)
of the joint venture due EET will be distributed to EET and lent
back to Erye to help finance costs in connection with its
construction of and relocation to a new facility; and (ii) of the
net profit (after tax) of the joint venture due the Company, 45%
will be provided to Erye as part of the new facility construction
fund and will be characterized as additional paid-in capital for
the Company&amp;#x2019;s 51% interest in Erye, and 6% will be
distributed to the Company which has not been paid from the 2010
distribution and is in the amount of approximately $130,000. For
undistributed profits generated prior to the acquisition date: (i)
the 49% of undistributed profits (after tax) of the joint venture
due EET will be distributed to EET and lent back to Erye to help
finance costs in connection with its construction of and relocation
to a new facility; and (ii) of the net profit (after tax) of the
joint venture due the Company, 51% will be provided to Erye as part
of the new facility construction fund and will be characterized as
additional paid-in capital for the Company&amp;#x2019;s 51% interest in
Erye. It was contemplated by the Joint Venture Agreement that the
construction would continue for three years.&amp;#xA0;&amp;#xA0;As such,
45% of the dividend we would be entitled to by reason of our 51%
ownership would remain in Erye through October 2012 to complete the
relocation while EET would loan back their dividend during the same
period at a prevailing bank interest rate.&amp;#xA0;&amp;#xA0;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Upon
a liquidity event of Erye, as contemplated in the joint venture
agreement, the Company will be entitled to the return of its
dividend reinvestments to the extent of the proceeds generated by
the liquidity event.&amp;#xA0;&lt;/font&gt; Repayment of such loans from
EET&amp;#xA0;would occur gradually after the relocation is
completed.&amp;#xA0;&amp;#xA0;In January 2011, a dividend totaling
approximately $13,671,100 based on earnings for&amp;#xA0;&amp;#xA0;Fiscal
Year 2009 was declared and approximately $6,698,800 was distributed
to EET and lent back to Erye and approximately $6,972,300 due the
Company was reinvested and re-characterized as additional paid-in
capital in the business. In April 2011, a dividend totaling
$10,259,700 based on earnings for Fiscal Year 2010 was declared and
approximately $5,027,300 was distributed to EET and lent back to
Erye, and approximately $5,232,400 due the Company was reinvested
and re-characterized as additional paid-in capital in the
business.&amp;#xA0;&amp;#xA0;A 10% withholding tax was required on
dividends payable to the Company.&amp;#xA0;&amp;#xA0;As a result, Erye
withheld approximately $1,220,500 in taxes related to the
Company&amp;#x2019;s Fiscal Year 2009 and 2010 dividend amounts, of
which approximately $526,600 has not been paid to the local Chinese
tax authorities as of September 30, 2011.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Pursuant
to the PCT Merger Agreement, NeoStem agreed to pay off PCT&amp;#x2019;s
credit line with Northern New Jersey Cancer Associates
(&amp;#x201C;NNJCA&amp;#x201D;), in an amount up to $3,000,000, shortly after
the closing of the PCT Merger. On January 21, 2011, NeoStem paid
NNJCA $3,000,000 in full satisfaction of all of PCT&amp;#x2019;s
obligations to NNJCA arising from the underlying line of credit and
security agreement. Dr. Andrew Pecora (who was PCT&amp;#x2019;s Chairman
and CEO prior to the PCT Merger, and who became PCT&amp;#x2019;s Chief
Medical Officer on January 19, 2011 pursuant to an employment
agreement effective upon the closing of the PCT Merger), has served
as Managing Partner of NNJCA since 1996.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
July 13, 2011, NeoStem entered into the Agreement and Plan of
Merger to acquire Amorcyte.&amp;#xA0;&amp;#xA0;Amorcyte had originally been
incorporated as a subsidiary of PCT and was spun off to PCT&amp;#x2019;s
members prior to NeoStem&amp;#x2019;s January 19, 2011 acquisition of
PCT.&amp;#xA0;&amp;#xA0;At the time the Agreement and Plan of Merger was
entered into, Dr. Pecora and Mr. Goldberger were officers of both
PCT and Amorcyte.&amp;#xA0;&amp;#xA0;The Amorcyte acquisition closed on
October 17, 2011.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
order to accelerate Amorcyte&apos;s commencement of its Phase 2 clinical
trial of AMR-001, NeoStem agreed to provide loans to Amorcyte prior
to the closing of the Amorcyte Merger to be used in connection with
the Phase 2 trial. Pursuant to a Loan Agreement entered into on
September 9, 2011, NeoStem loaned Amorcyte prior to the closing of
the Merger an aggregate of $338,500 which was applied towards the
commencement of the Phase 2 trial.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Effective
March 10, 2011, Matthew Henninger entered into a consulting
agreement with PCT, pursuant to which Mr. Henninger was engaged for
a three month term to serve as an advisor to PCT with regard to the
development of the &amp;#x201C;Family Plan,&amp;#x201D; a multi-generational
stem cell collection and storage service. In consideration
therefor, Mr. Henninger was granted an option to purchase 150,000
shares of NeoStem Common Stock under the 2009 Plan at $1.60 per
share (Black Scholes value $129,000) vesting over the term of the
agreement. Pursuant to an amendment and extension of this agreement
in April and May, 2011, respectively, Mr. Henninger&amp;#x2019;s term of
service was extended through September 9, 2011, for which he
received 75,000 shares of NeoStem Common Stock (market value
$115,000), $5,000 per month for a three month period and
reimbursement of health insurance premiums; in September 2011 the
PCT management with approval of the Audit Committee
extended&amp;#xA0;the term&amp;#xA0;further&amp;#xA0;through December 31, 2011,
in connection with which Mr. Henninger received a $25,000 bonus
related to prior performance, a monthly fee of $10,000 and
continued insurance reimbursement. Mr. Henninger is in an exclusive
relationship with the CEO of NeoStem.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During
the nine months ended September 30, 2011, the Company contributed
to The Stem for Life Foundation, a Pennsylvania nonprofit
corporation classified as a tax-exempt organization under Section
501(c)(3) of the Internal Revenue Code of 1986, as amended (the
&amp;#x201C;Code&amp;#x201D;) and as a public charity under Section 509(a)(1)
and 170(b)(1)(A)(vi) of the Code (the &amp;#x201C;Foundation&amp;#x201D;),
whose mission is to promote public awareness, fund research and
development and subsidize stem cell collection and storage
programs, 407,600 shares of previously issued restricted common
stock with a fair value of approximately $607,400. The contribution
of such securities was subject to the approval of the Board of
Directors and the Audit Committee.&amp;#xA0;&amp;#xA0;The Company&amp;#x2019;s
CEO and Chairman is President and a Trustee of the Foundation, its
General Counsel is Secretary and a Trustee of the Foundation and
its Chief Financial Officer is Treasurer of the
Foundation.&lt;/font&gt;&lt;/div&gt;


&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">1903703</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">16516524</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:RepaymentsOfNotesPayable contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">17154753</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:NoncashContributionExpense contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">607363</us-gaap:NoncashContributionExpense>
  <us-gaap:PaidInKindInterest contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">328425</us-gaap:PaidInKindInterest>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">2014566</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:ProfitLoss contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-27728736</us-gaap:ProfitLoss>
  <us-gaap:ProceedsFromBankDebt contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">6149000</us-gaap:ProceedsFromBankDebt>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
  <nbs:ProceedsFromStockOptionAndWarrantExcercises contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">7100</nbs:ProceedsFromStockOptionAndWarrantExcercises>
  <nbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-3433540</nbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
  <nbs:IssuanceOfCommonStockInExchangeForConvertiblePreferredStock contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">2785400</nbs:IssuanceOfCommonStockInExchangeForConvertiblePreferredStock>
  <nbs:SupplementalDividendsFromSubsidiaries contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">11726100</nbs:SupplementalDividendsFromSubsidiaries>
  <nbs:CommonStockIssuedToAcquireBusinesses contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">17200000</nbs:CommonStockIssuedToAcquireBusinesses>
  <nbs:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="shares" decimals="0">82775215</nbs:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <nbs:DividendOnPreferredStockSharesOfCommonStockIssuable contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">622500</nbs:DividendOnPreferredStockSharesOfCommonStockIssuable>
  <nbs:DescriptionOfRecentAccountingPronouncementsTextBlock contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0">&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;Note 3
&amp;#x2013; Recently Adopted Accounting
Pronouncements&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In
December 2010, the FASB issued an update which addresses when to
perform Step 2 of the goodwill impairment test for reporting units
with zero or negative carrying amounts. The update modifies Step 1
of the goodwill impairment test for reporting units with zero or
negative carrying amounts. For those reporting units, an entity is
required to perform Step 2 of the goodwill impairment test if it is
more likely than not that a goodwill impairment exists. In
determining whether it is more likely than not that goodwill
impairment exists, an entity should consider whether there are any
adverse qualitative factors indicating that impairment may exist.
The qualitative factors are consistent with the existing guidance,
which requires that goodwill of a reporting unit be tested for
impairment between annual tests if an event occurs or circumstances
change that would more likely than not reduce the fair value of a
reporting unit below its carrying amount. This update is effective
for fiscal years, and interim periods within those years, beginning
after December 15, 2010. The adoption of this guidance did not have
a material impact on the consolidated financial
statements.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In
December 2010, the FASB issued an update which addresses the
disclosure of supplementary pro forma information for business
combinations. The update requires public entities to disclose pro
forma information for business combinations that occurred in the
current reporting period, including revenue and earnings of the
combined entity for the current reporting period as though the
acquisition date for all business combinations that occurred during
the year had been as of the beginning of the annual reporting
period. If comparative financial statements are presented, the pro
forma revenue and earnings of the combined entity for the
comparable prior reporting period should be reported as though the
acquisition date for all business combinations that occurred during
the current year had been as of the beginning of the comparable
prior annual reporting period. Amendments in this update are
effective prospectively for business combinations for which the
acquisition date is on or after the beginning of the first annual
reporting period beginning on or after December 15, 2010. The
adoption of this guidance did not have a material impact on the
consolidated financial statements.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</nbs:DescriptionOfRecentAccountingPronouncementsTextBlock>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE6286----1110-Q0012_STD_273_20110930_0_455296x440937" unitRef="iso4217_USD" decimals="0">-2098114</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:GrossProfit contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">5242739</us-gaap:GrossProfit>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">1145588</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">45829</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:Revenues contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">16475558</us-gaap:Revenues>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">-5708662</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:InterestExpense contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">10663</us-gaap:InterestExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">-7140226</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">35166</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">1679945</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostOfRevenue contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">11232819</us-gaap:CostOfRevenue>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">-7140226</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">-5743828</us-gaap:OperatingIncomeLoss>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">9306622</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">285976</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:OperatingExpenses contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">10986567</us-gaap:OperatingExpenses>
  <us-gaap:ProfitLoss contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD" decimals="0">-5994638</us-gaap:ProfitLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <nbs:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE6286----1110-Q0012_STD_92_20100930_0" unitRef="shares" decimals="0">56777430</nbs:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <us-gaap:GrossProfit contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">3915400</us-gaap:GrossProfit>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">17971</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">1383826</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:Revenues contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">17756144</us-gaap:Revenues>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="INF">150655</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">-7302313</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:InterestExpense contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">1305820</us-gaap:InterestExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">-7346435</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">78006</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">2483261</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostOfRevenue contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">13840744</us-gaap:CostOfRevenue>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">-7497090</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">-7380319</us-gaap:OperatingIncomeLoss>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">8812458</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">26151</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:OperatingExpenses contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">11295719</us-gaap:OperatingExpenses>
  <us-gaap:ProfitLoss contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD" decimals="0">-7328464</us-gaap:ProfitLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>
  <nbs:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE6286----1110-Q0012_STD_92_20110930_0" unitRef="shares" decimals="0">94102589</nbs:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <context id="eol_PE6286----1110-Q0012_STD_92_20110930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE6286----1110-Q0012_STD_92_20100930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
    </entity>
    <period>
      <startDate>2010-07-01</startDate>
      <endDate>2010-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE6286----1110-Q0012_STD_273_20110930_0_455296x440937">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE6286----1110-Q0012_STD_273_20110930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE6286----1110-Q0012_STD_273_20100930_0_455296x446364">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE6286----1110-Q0012_STD_273_20100930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE6286----1110-Q0012_STD_0_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6286----1110-Q0012_STD_0_20091231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6286----1110-Q0012_STD_0_20110930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
    </entity>
    <period>
      <instant>2011-09-30</instant>
    </period>
  </context>
  <context id="eol_PE6286----1110-Q0012_STD_0_20100930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
    </entity>
    <period>
      <instant>2010-09-30</instant>
    </period>
  </context>
  <context id="eol_PE6286----1110-Q0012_STD_0_20111108_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
    </entity>
    <period>
      <instant>2011-11-08</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>nbs-20110930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.12.8 -->
<!-- Round: 40cd2c42-57e3-45c8-9ccf-d40a656c8aa1 -->
<!-- Creation date: 2011-11-09T02:07:40Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31"
  xmlns:us-types="http://fasb.org/us-types/2011-01-31"
  xmlns:nbs="http://www.neostem.com/20110930"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2011-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31"
  targetNamespace="http://www.neostem.com/20110930"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/DocumentDocumentandEntityInformation" id="DocumentDocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome">
        <link:definition>105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations" id="Role_NotesToFinancialStatementsNatureOfOperations">
        <link:definition>107 - Disclosure - The Company</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>108 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDescriptionOfRecentAccountingPronouncementsTextBlock" id="Role_NotesToFinancialStatementsDescriptionOfRecentAccountingPronouncementsTextBlock">
        <link:definition>109 - Disclosure - Recently Adopted Accounting Pronouncements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" id="Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
        <link:definition>110 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock" id="Role_NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock">
        <link:definition>111 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <link:definition>112 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlock">
        <link:definition>113 - Disclosure - Bank Loans, Notes Payable and Mortgages Payable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock" id="Role_NotesToFinancialStatementsPreferredStockTextBlock">
        <link:definition>114 - Disclosure - Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>115 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>116 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" id="Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
        <link:definition>117 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
        <link:definition>118 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>119 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>120 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="nbs-20110930_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="nbs-20110930_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="nbs-20110930_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="nbs-20110930_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-types/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-types-2011-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd"/>
  <element name="CashPaidDuringPeriodForAbstract" id="nbs_CashPaidDuringPeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockIssuedToAcquireBusinesses" id="nbs_CommonStockIssuedToAcquireBusinesses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfRecentAccountingPronouncementsTextBlock" id="nbs_DescriptionOfRecentAccountingPronouncementsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DividendOnPreferredStockSharesOfCommonStockIssuable" id="nbs_DividendOnPreferredStockSharesOfCommonStockIssuable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentDocumentandEntityInformationAbstract" id="nbs_DocumentDocumentandEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" id="nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IssuanceOfCommonStockInExchangeForConvertiblePreferredStock" id="nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NoncashFinancingActivitiesAbstract" id="nbs_NoncashFinancingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NoncashInvestingActivitiesAbstract" id="nbs_NoncashInvestingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NotesToFinancialStatementsAbstract" id="nbs_NotesToFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreferredStockSharesDesignated" id="nbs_PreferredStockSharesDesignated" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromStockOptionAndWarrantExcercises" id="nbs_ProceedsFromStockOptionAndWarrantExcercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SupplementalDeferredFinancingCosts" id="nbs_SupplementalDeferredFinancingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SupplementalDividendsFromSubsidiaries" id="nbs_SupplementalDividendsFromSubsidiaries" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SupplementalPropertyAndEquipmentNet" id="nbs_SupplementalPropertyAndEquipmentNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageNumberBasicDilutedSharesOutstanding" id="nbs_WeightedAverageNumberBasicDilutedSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>nbs-20110930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.12.8 -->
<!-- Round: 40cd2c42-57e3-45c8-9ccf-d40a656c8aa1 -->
<!-- Creation date: 2011-11-09T02:07:40Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.neostem.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_StatementOfIncome" roleURI="http://www.neostem.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.neostem.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsNatureOfOperations" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsDescriptionOfRecentAccountingPronouncementsTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDescriptionOfRecentAccountingPronouncementsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsPreferredStockTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/DocumentDocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="us-gaap_LoansPayableToBankCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="us-gaap_OtherIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:label="us-gaap_SecuredDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityCarryingAmount" xlink:label="us-gaap_TemporaryEquityCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1.2900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmount" order="1.3100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1.3900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LoansPayableToBankCurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_SecuredDebtCurrent" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_SecuredLongTermDebt" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.2700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="1.2800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.3200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.3300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.3400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.3500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.3600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="1.3700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="1.3800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_TemporaryEquityCarryingAmount" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" order="1.3000" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1.1400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="1.1600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1200" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:label="nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashContributionExpense" xlink:label="us-gaap_NoncashContributionExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="us-gaap_PaymentsOfDividends"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromBankDebt" xlink:label="us-gaap_ProceedsFromBankDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_ProceedsFromStockOptionAndWarrantExcercises" xlink:label="nbs_ProceedsFromStockOptionAndWarrantExcercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="us-gaap_RepaymentsOfBankDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.3600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1.3700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nbs_ProceedsFromStockOptionAndWarrantExcercises" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="1.2700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfSecuredDebt" order="1.2800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromBankDebt" order="1.2900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfBankDebt" order="1.3000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1.3100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="1.3200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="1.3300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" order="1.3400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDividends" order="1.3500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1.2100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.3900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnInvestments" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PaidInKindInterest" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NoncashContributionExpense" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.1400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.1500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" order="1.1800" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDescriptionOfRecentAccountingPronouncementsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>nbs-20110930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.12.8 -->
<!-- Round: 40cd2c42-57e3-45c8-9ccf-d40a656c8aa1 -->
<!-- Creation date: 2011-11-09T02:07:40Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.neostem.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_StatementOfIncome" roleURI="http://www.neostem.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.neostem.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsNatureOfOperations" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsDescriptionOfRecentAccountingPronouncementsTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDescriptionOfRecentAccountingPronouncementsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsPreferredStockTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/DocumentDocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="us-gaap_LoansPayableToBankCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="us-gaap_OtherIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:label="us-gaap_SecuredDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityCarryingAmount" xlink:label="us-gaap_TemporaryEquityCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.4700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.4800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent" order="1.4900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.5000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.5100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LoansPayableToBankCurrent" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_SecuredDebtCurrent" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_SecuredLongTermDebt" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterest" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmount" order="1.3000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_PreferredStockSharesDesignated" xlink:label="nbs_PreferredStockSharesDesignated"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreferencePerShare" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nbs_PreferredStockSharesDesignated" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="nbs_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nbs_WeightedAverageNumberBasicDilutedSharesOutstanding" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_CashPaidDuringPeriodForAbstract" xlink:label="nbs_CashPaidDuringPeriodForAbstract"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_CommonStockIssuedToAcquireBusinesses" xlink:label="nbs_CommonStockIssuedToAcquireBusinesses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_DividendOnPreferredStockSharesOfCommonStockIssuable" xlink:label="nbs_DividendOnPreferredStockSharesOfCommonStockIssuable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:label="nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaidCapitalized" xlink:label="us-gaap_InterestPaidCapitalized"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock" xlink:label="nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashContributionExpense" xlink:label="us-gaap_NoncashContributionExpense"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NoncashFinancingActivitiesAbstract" xlink:label="nbs_NoncashFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NoncashInvestingActivitiesAbstract" xlink:label="nbs_NoncashInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="us-gaap_NotesPayableToBanksMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="us-gaap_PaymentsOfDividends"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromBankDebt" xlink:label="us-gaap_ProceedsFromBankDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_ProceedsFromStockOptionAndWarrantExcercises" xlink:label="nbs_ProceedsFromStockOptionAndWarrantExcercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="us-gaap_RepaymentsOfBankDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_SupplementalDeferredFinancingCosts" xlink:label="nbs_SupplementalDeferredFinancingCosts"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_SupplementalDividendsFromSubsidiaries" xlink:label="nbs_SupplementalDividendsFromSubsidiaries"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_SupplementalPropertyAndEquipmentNet" xlink:label="nbs_SupplementalPropertyAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NoncashContributionExpense" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nbs_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_InterestPaid" order="1.6200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nbs_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.6300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nbs_ProceedsFromStockOptionAndWarrantExcercises" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfSecuredDebt" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromBankDebt" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfBankDebt" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDividends" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nbs_NoncashFinancingActivitiesAbstract" xlink:to="nbs_CommonStockIssuedToAcquireBusinesses" order="1.5600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nbs_NoncashFinancingActivitiesAbstract" xlink:to="nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock" order="1.5700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nbs_NoncashFinancingActivitiesAbstract" xlink:to="nbs_DividendOnPreferredStockSharesOfCommonStockIssuable" order="1.5800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nbs_NoncashFinancingActivitiesAbstract" xlink:to="nbs_SupplementalDeferredFinancingCosts" order="1.5900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nbs_NoncashFinancingActivitiesAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1.6000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nbs_NoncashFinancingActivitiesAbstract" xlink:to="nbs_SupplementalDividendsFromSubsidiaries" order="1.6100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nbs_NoncashInvestingActivitiesAbstract" xlink:to="nbs_SupplementalPropertyAndEquipmentNet" order="1.5400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nbs_NoncashInvestingActivitiesAbstract" xlink:to="us-gaap_InterestPaidCapitalized" order="1.5500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_NotesPayableToBanksMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_LoansPayableMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1.4700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.4800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.4900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.5100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nbs_NoncashInvestingActivitiesAbstract" order="1.5200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nbs_NoncashFinancingActivitiesAbstract" order="1.5300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nbs_CashPaidDuringPeriodForAbstract" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NatureOfOperations" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDescriptionOfRecentAccountingPronouncementsTextBlock">
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_DescriptionOfRecentAccountingPronouncementsTextBlock" xlink:label="nbs_DescriptionOfRecentAccountingPronouncementsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nbs_DescriptionOfRecentAccountingPronouncementsTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>nbs-20110930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.12.8 -->
<!-- Round: 40cd2c42-57e3-45c8-9ccf-d40a656c8aa1 -->
<!-- Creation date: 2011-11-09T02:07:40Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable trade, net of allowance for doubtful accounts of $437,443 and $210,977, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Accounts receivable trade, allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of preferred stock discount and issuance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets, Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US">Cash received in acquisition of PCT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net (decrease)/increase in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net (decrease)/increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_CashPaidDuringPeriodForAbstract" xlink:label="nbs_CashPaidDuringPeriodForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_CashPaidDuringPeriodForAbstract_lbl" xml:lang="en-US">Cash Paid During Period For [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_CashPaidDuringPeriodForAbstract_lbl" xml:lang="en-US">Cash paid during the period for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_CashPaidDuringPeriodForAbstract" xlink:to="nbs_CashPaidDuringPeriodForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_CommonStockIssuedToAcquireBusinesses" xlink:label="nbs_CommonStockIssuedToAcquireBusinesses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_CommonStockIssuedToAcquireBusinesses_lbl" xml:lang="en-US">Common Stock Issued To Acquire Businesses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_CommonStockIssuedToAcquireBusinesses_lbl" xml:lang="en-US">Common stock and warrants issued with the acquisition of PCT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_CommonStockIssuedToAcquireBusinesses" xlink:to="nbs_CommonStockIssuedToAcquireBusinesses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 100,361,443 and 64,221,130 shares, at September 30, 2011 and December 31, 2010, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion of Convertible Redeemable Series C Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Preferred stock, Series B convertible redeemable preferred stock liquidation value, share of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Bank Loans, Notes Payable and Mortgages Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred rent liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Unearned revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Unearned revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent_lbl" xml:lang="en-US">Deferred Tax Assets, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent_lbl" xml:lang="en-US">Deferred income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetCurrent" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent_lbl" xml:lang="en-US">Deferred Tax Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent_lbl" xml:lang="en-US">Deferred income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesCurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US">Deferred Tax Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US">Deferred income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Derivative liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_DescriptionOfRecentAccountingPronouncementsTextBlock" xlink:label="nbs_DescriptionOfRecentAccountingPronouncementsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_DescriptionOfRecentAccountingPronouncementsTextBlock_lbl" xml:lang="en-US">Entire disclosure related to the changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_DescriptionOfRecentAccountingPronouncementsTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_DescriptionOfRecentAccountingPronouncementsTextBlock" xlink:to="nbs_DescriptionOfRecentAccountingPronouncementsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_DividendOnPreferredStockSharesOfCommonStockIssuable" xlink:label="nbs_DividendOnPreferredStockSharesOfCommonStockIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_DividendOnPreferredStockSharesOfCommonStockIssuable_lbl" xml:lang="en-US">Dividend On Preferred Stock, Shares Of Common Stock Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_DividendOnPreferredStockSharesOfCommonStockIssuable_lbl" xml:lang="en-US">Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_DividendOnPreferredStockSharesOfCommonStockIssuable" xlink:to="nbs_DividendOnPreferredStockSharesOfCommonStockIssuable_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_DocumentDocumentandEntityInformationAbstract" xlink:label="nbs_DocumentDocumentandEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_DocumentDocumentandEntityInformationAbstract_lbl" xml:lang="en-US">Document - Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_DocumentDocumentandEntityInformationAbstract_lbl" xml:lang="en-US">Document - Document and Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_DocumentDocumentandEntityInformationAbstract" xlink:to="nbs_DocumentDocumentandEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xml:lang="en-US">Amount due related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Impact of changes of foreign exchange rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitiesTable_lbl" xml:lang="en-US">Entities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitiesTable" xlink:to="dei_EntitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Loss on short term investments</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Loss on short term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xml:lang="en-US">Loss on disposal of assets</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xml:lang="en-US">Loss on disposal of assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Goodwill and Other Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Loss from operations before provision for income taxes and noncontrolling interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Loss from operations before provision for income taxes and noncontrolling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:label="nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_lbl" xml:lang="en-US">The net change during the reporting period in the aggregate amount of accounts payable accrued expenses and other liabilities incurred but not paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_lbl" xml:lang="en-US">Accounts payable, accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:to="nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Unearned revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities, net of the effect of acquisitions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Change in restricted cash used as collateral</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Change in restricted cash used as collateral</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaidCapitalized" xlink:label="us-gaap_InterestPaidCapitalized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidCapitalized_lbl" xml:lang="en-US">Capitalized interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidCapitalized" xlink:to="us-gaap_InterestPaidCapitalized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock" xlink:label="nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock_lbl" xml:lang="en-US">Issuance Of Common Stock In Exchange For Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock_lbl" xml:lang="en-US">Common stock issued pursuant to the redemption of Convertible Redeemable Series E 7% Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock" xlink:to="nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Common stock, stock options and warrants issued as payment for compensation, services rendered and interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity, Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long-term Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableMember_lbl" xml:lang="en-US">Bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableMember" xlink:to="us-gaap_LoansPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="us-gaap_LoansPayableToBankCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableToBankCurrent_lbl" xml:lang="en-US">Loans Payable to Bank, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LoansPayableToBankCurrent_lbl" xml:lang="en-US">Bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableToBankCurrent" xlink:to="us-gaap_LoansPayableToBankCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">The Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss attributable to NeoStem, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss attributable to NeoStem, Inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Less - net (loss) income attributable to noncontrolling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to NeoStem, Inc. common shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to NeoStem, Inc. common shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashContributionExpense" xlink:label="us-gaap_NoncashContributionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashContributionExpense_lbl" xml:lang="en-US">Charitable contributions paid with common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashContributionExpense" xlink:to="us-gaap_NoncashContributionExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NoncashFinancingActivitiesAbstract" xlink:label="nbs_NoncashFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_NoncashFinancingActivitiesAbstract_lbl" xml:lang="en-US">Noncash Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_NoncashFinancingActivitiesAbstract_lbl" xml:lang="en-US">Supplemental schedule of non-cash financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_NoncashFinancingActivitiesAbstract" xlink:to="nbs_NoncashFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NoncashInvestingActivitiesAbstract" xlink:label="nbs_NoncashInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_NoncashInvestingActivitiesAbstract_lbl" xml:lang="en-US">Noncash Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_NoncashInvestingActivitiesAbstract_lbl" xml:lang="en-US">Supplemental Schedule of non-cash investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_NoncashInvestingActivitiesAbstract" xlink:to="nbs_NoncashInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense), Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="us-gaap_NotesPayableToBanksMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableToBanksMember_lbl" xml:lang="en-US">Notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBanksMember" xlink:to="us-gaap_NotesPayableToBanksMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NotesToFinancialStatementsAbstract" xlink:label="nbs_NotesToFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_NotesToFinancialStatementsAbstract" xlink:to="nbs_NotesToFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="us-gaap_OtherIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xml:lang="en-US">Land use rights, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Non-cash interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Repayment of preferred stock</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Repayment of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="us-gaap_PaymentsOfDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividends_lbl" xml:lang="en-US">Payment of dividend</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsOfDividends_lbl" xml:lang="en-US">Payment of dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Purchase of short-term investments</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Purchase of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Acquisition of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Preferred dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_PreferredStockSharesDesignated" xlink:label="nbs_PreferredStockSharesDesignated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_PreferredStockSharesDesignated_lbl" xml:lang="en-US">Preferred Stock, Shares Designated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_PreferredStockSharesDesignated_lbl" xml:lang="en-US">Preferred stock, shares designated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_PreferredStockSharesDesignated" xlink:to="nbs_PreferredStockSharesDesignated_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2011 and December 31, 2010</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaids and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromBankDebt" xlink:label="us-gaap_ProceedsFromBankDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromBankDebt_lbl" xml:lang="en-US">Proceeds of bank loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromBankDebt" xlink:to="us-gaap_ProceedsFromBankDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Net proceeds from issuance of capital stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Payment from related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xml:lang="en-US">Proceeds from short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_ProceedsFromStockOptionAndWarrantExcercises" xlink:label="nbs_ProceedsFromStockOptionAndWarrantExcercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_ProceedsFromStockOptionAndWarrantExcercises_lbl" xml:lang="en-US">The cash inflow associated with the amount received from holders exercising their stock options and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_ProceedsFromStockOptionAndWarrantExcercises_lbl" xml:lang="en-US">Net proceeds from the exercise of options and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_ProceedsFromStockOptionAndWarrantExcercises" xlink:to="nbs_ProceedsFromStockOptionAndWarrantExcercises_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Bad debt expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="us-gaap_RepaymentsOfBankDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl" xml:lang="en-US">Repayment of bank loan</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl" xml:lang="en-US">Repayment of bank loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of notes payable</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment of debt to related party</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment of debt to related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfSecuredDebt_lbl" xml:lang="en-US">Repayment of mortgage loan</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_RepaymentsOfSecuredDebt_lbl" xml:lang="en-US">Repayment of mortgage loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSecuredDebt" xlink:to="us-gaap_RepaymentsOfSecuredDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">Write off of acquired in-process research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:label="us-gaap_SecuredDebtCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtCurrent_lbl" xml:lang="en-US">Mortgages payable - current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtCurrent" xlink:to="us-gaap_SecuredDebtCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredLongTermDebt_lbl" xml:lang="en-US">Mortgages payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredLongTermDebt" xlink:to="us-gaap_SecuredLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general, and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Statement, Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total NeoStem, Inc. shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total NeoStem, Inc. shareholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Shareholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_SupplementalDeferredFinancingCosts" xlink:label="nbs_SupplementalDeferredFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_SupplementalDeferredFinancingCosts_lbl" xml:lang="en-US">Supplemental Deferred financing costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_SupplementalDeferredFinancingCosts_lbl" xml:lang="en-US">Financing costs for capital stock raises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_SupplementalDeferredFinancingCosts" xlink:to="nbs_SupplementalDeferredFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_SupplementalDividendsFromSubsidiaries" xlink:label="nbs_SupplementalDividendsFromSubsidiaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_SupplementalDividendsFromSubsidiaries_lbl" xml:lang="en-US">Supplemental Dividends from Subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_SupplementalDividendsFromSubsidiaries_lbl" xml:lang="en-US">Dividend to Related Party reinvested as loan payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_SupplementalDividendsFromSubsidiaries" xlink:to="nbs_SupplementalDividendsFromSubsidiaries_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_SupplementalPropertyAndEquipmentNet" xlink:label="nbs_SupplementalPropertyAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_SupplementalPropertyAndEquipmentNet_lbl" xml:lang="en-US">Supplemental Property And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_SupplementalPropertyAndEquipmentNet_lbl" xml:lang="en-US">Acquisition of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_SupplementalPropertyAndEquipmentNet" xlink:to="nbs_SupplementalPropertyAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US">Redeemable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityCarryingAmount" xlink:label="us-gaap_TemporaryEquityCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmount_lbl" xml:lang="en-US">Temporary Equity, Carrying Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmount_lbl" xml:lang="en-US">Temporary Equity, Carrying Amount, Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmount" xlink:to="us-gaap_TemporaryEquityCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare_lbl" xml:lang="en-US">Convertible Redeemable Series E Preferred Stock, liquidation value, per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:to="us-gaap_TemporaryEquityLiquidationPreferencePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Convertible Redeemable Series E Preferred Stock, shares designated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Convertible Redeemable Series E Preferred Stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Convertible Redeemable Series E Preferred Stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl" xml:lang="en-US">Convertible Redeemable Series E Preferred Stock; 10,582,011 shares designated, liquidation value $1.00 per share; issued and outstanding 7,838,527 and 10,582,011 shares, at September 30, 2011 and December 31, 2010, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US">Changes in fair value of derivative liability</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US">Changes in fair value of derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="nbs_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nbs_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nbs_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nbs_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:to="nbs_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>nbs-20110930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.12.8 -->
<!-- Round: 40cd2c42-57e3-45c8-9ccf-d40a656c8aa1 -->
<!-- Creation date: 2011-11-09T02:07:40Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.neostem.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_StatementOfIncome" roleURI="http://www.neostem.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.neostem.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsNatureOfOperations" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsDescriptionOfRecentAccountingPronouncementsTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDescriptionOfRecentAccountingPronouncementsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsPreferredStockTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nbs-20110930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/DocumentDocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_DocumentDocumentandEntityInformationAbstract" xlink:label="nbs_DocumentDocumentandEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_DocumentDocumentandEntityInformationAbstract" xlink:to="dei_EntitiesTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_DocumentInformationLineItems" order="100.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="us-gaap_LoansPayableToBankCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="us-gaap_OtherIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:label="us-gaap_SecuredDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityCarryingAmount" xlink:label="us-gaap_TemporaryEquityCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.3700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.3800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="1.3900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="1.4000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.4100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.4200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.4400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1.4500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.4600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.4700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.4800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent" order="1.4900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.5000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.5100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="1.0600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LoansPayableToBankCurrent" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_SecuredDebtCurrent" order="1.1500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="1.1600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.2300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_SecuredLongTermDebt" order="1.2500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.2600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="1.2700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.2000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.2100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.3100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.3200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.3300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.3400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.3500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterest" order="1.0900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" order="1.2900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmount" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_PreferredStockSharesDesignated" xlink:label="nbs_PreferredStockSharesDesignated"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreferencePerShare" order="1.0400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1.0600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.0800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nbs_PreferredStockSharesDesignated" order="1.1000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.1100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.1200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.1300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.1500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.1600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="nbs_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.2000" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.0600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1.1300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="1.1500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nbs_WeightedAverageNumberBasicDilutedSharesOutstanding" order="1.1800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_CashPaidDuringPeriodForAbstract" xlink:label="nbs_CashPaidDuringPeriodForAbstract"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_CommonStockIssuedToAcquireBusinesses" xlink:label="nbs_CommonStockIssuedToAcquireBusinesses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_DividendOnPreferredStockSharesOfCommonStockIssuable" xlink:label="nbs_DividendOnPreferredStockSharesOfCommonStockIssuable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:label="nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaidCapitalized" xlink:label="us-gaap_InterestPaidCapitalized"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock" xlink:label="nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashContributionExpense" xlink:label="us-gaap_NoncashContributionExpense"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NoncashFinancingActivitiesAbstract" xlink:label="nbs_NoncashFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NoncashInvestingActivitiesAbstract" xlink:label="nbs_NoncashInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="us-gaap_NotesPayableToBanksMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="us-gaap_PaymentsOfDividends"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromBankDebt" xlink:label="us-gaap_ProceedsFromBankDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_ProceedsFromStockOptionAndWarrantExcercises" xlink:label="nbs_ProceedsFromStockOptionAndWarrantExcercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="us-gaap_RepaymentsOfBankDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_SupplementalDeferredFinancingCosts" xlink:label="nbs_SupplementalDeferredFinancingCosts"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_SupplementalDividendsFromSubsidiaries" xlink:label="nbs_SupplementalDividendsFromSubsidiaries"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_SupplementalPropertyAndEquipmentNet" xlink:label="nbs_SupplementalPropertyAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.3200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.3300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="1.3400" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1.3500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.3600" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1.3700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets" order="1.3800" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="1.3900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NoncashContributionExpense" order="1.4000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.4100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.4300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_InterestPaid" order="1.6200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.6300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0900" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.1000" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.1100" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.1300" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" order="1.1400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nbs_ProceedsFromStockOptionAndWarrantExcercises" order="1.1500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.1600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="1.1700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfSecuredDebt" order="1.1800" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromBankDebt" order="1.1900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfBankDebt" order="1.2000" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1.2100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="1.2200" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="1.2300" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" order="1.2400" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDividends" order="1.2500" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1.0400" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0600" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.0800" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="1.2900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.3000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NoncashFinancingActivitiesAbstract" xlink:to="nbs_CommonStockIssuedToAcquireBusinesses" order="1.5600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NoncashFinancingActivitiesAbstract" xlink:to="nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock" order="1.5700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NoncashFinancingActivitiesAbstract" xlink:to="nbs_DividendOnPreferredStockSharesOfCommonStockIssuable" order="1.5800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NoncashFinancingActivitiesAbstract" xlink:to="nbs_SupplementalDeferredFinancingCosts" order="1.5900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NoncashFinancingActivitiesAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1.6000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NoncashFinancingActivitiesAbstract" xlink:to="nbs_SupplementalDividendsFromSubsidiaries" order="1.6100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NoncashInvestingActivitiesAbstract" xlink:to="nbs_SupplementalPropertyAndEquipmentNet" order="1.5400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NoncashInvestingActivitiesAbstract" xlink:to="us-gaap_InterestPaidCapitalized" order="1.5500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_NotesPayableToBanksMember" order="1.2700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_LoansPayableMember" order="1.2800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.4400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.4500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.4600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1.4700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.4800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.4900" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.5000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.5100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nbs_NoncashInvestingActivitiesAbstract" order="1.5200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nbs_NoncashFinancingActivitiesAbstract" order="1.5300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="10.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nbs_CashPaidDuringPeriodForAbstract" order="1.0200" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NotesToFinancialStatementsAbstract" xlink:label="nbs_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NatureOfOperations" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NotesToFinancialStatementsAbstract" xlink:label="nbs_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDescriptionOfRecentAccountingPronouncementsTextBlock">
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_DescriptionOfRecentAccountingPronouncementsTextBlock" xlink:label="nbs_DescriptionOfRecentAccountingPronouncementsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NotesToFinancialStatementsAbstract" xlink:label="nbs_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nbs_DescriptionOfRecentAccountingPronouncementsTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NotesToFinancialStatementsAbstract" xlink:label="nbs_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NotesToFinancialStatementsAbstract" xlink:label="nbs_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NotesToFinancialStatementsAbstract" xlink:label="nbs_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NotesToFinancialStatementsAbstract" xlink:label="nbs_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NotesToFinancialStatementsAbstract" xlink:label="nbs_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NotesToFinancialStatementsAbstract" xlink:label="nbs_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NotesToFinancialStatementsAbstract" xlink:label="nbs_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NotesToFinancialStatementsAbstract" xlink:label="nbs_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NotesToFinancialStatementsAbstract" xlink:label="nbs_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NotesToFinancialStatementsAbstract" xlink:label="nbs_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nbs-20110930.xsd#nbs_NotesToFinancialStatementsAbstract" xlink:label="nbs_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nbs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EBPAE"><tr><th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)<br /></strong></div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable trade, allowance for doubtful accounts</a></td><td class="nump">$ 437,443<span /></td><td class="nump">$ 210,977<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Redeemable Series E Preferred Stock, shares designated</a></td><td class="nump">10,582,011<span /></td><td class="nump">10,582,011<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Convertible Redeemable Series E Preferred Stock, liquidation value, per share</a></td><td class="nump">$ 1.00<span /></td><td class="nump">$ 1.00<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Redeemable Series E Preferred Stock, issued</a></td><td class="nump">7,838,527<span /></td><td class="nump">10,582,011<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Redeemable Series E Preferred Stock, outstanding</a></td><td class="nump">7,838,527<span /></td><td class="nump">10,582,011<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td><td class="nump">20,000,000<span /></td><td class="nump">20,000,000<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, Series B convertible redeemable preferred stock liquidation value, share of common stock</a></td><td class="nump">1<span /></td><td class="nump">1<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td><td class="nump">$ 0.01<span /></td><td class="nump">$ 0.01<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbs_PreferredStockSharesDesignated', window );">Preferred stock, shares designated</a></td><td class="nump">825,000<span /></td><td class="nump">825,000<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td><td class="nump">10,000<span /></td><td class="nump">10,000<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td><td class="nump">10,000<span /></td><td class="nump">10,000<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td><td class="nump">$ 0.001<span /></td><td class="nump">$ 0.001<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td><td class="nump">500,000,000<span /></td><td class="nump">500,000,000<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td><td class="nump">100,361,443<span /></td><td class="nump">64,221,130<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td><td class="nump">100,361,443<span /></td><td class="nump">64,221,130<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbs_PreferredStockSharesDesignated"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Shares Designated</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nbs_PreferredStockSharesDesignated</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nbs</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 4<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 310<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6965416&amp;loc=d3e5074-111524<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.4)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 4<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockSharesIssued</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 6<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 29<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 2, 3, 4, 5, 6, 7, 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.28)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 29<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 2, 3, 4, 5, 6, 7, 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 29<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 2, 3, 4, 5, 6, 7, 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.28)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 29<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.28)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 29<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.28)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 4<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquityLiquidationPreferencePerShare</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 2, 3, 4, 5, 6, 7, 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 28<br /><br /> -Subparagraph b<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.27(b))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquitySharesAuthorized</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 28<br /><br /> -Subparagraph b<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.27(b))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquitySharesIssued</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 28<br /><br /> -Subparagraph b<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.27(b))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquitySharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EVUAG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br /></strong></div></th><th class="th" colspan="2">3 Months Ended</th><th class="th" colspan="2">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Sep. 30, 2010</div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Sep. 30, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td><td class="nump">$ 17,756,144<span /></td><td class="nump">$ 16,475,558<span /></td><td class="nump">$ 55,857,980<span /></td><td class="nump">$ 51,716,260<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td><td class="nump">13,840,744<span /></td><td class="nump">11,232,819<span /></td><td class="nump">41,636,950<span /></td><td class="nump">35,015,540<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td><td class="nump">3,915,400<span /></td><td class="nump">5,242,739<span /></td><td class="nump">14,221,030<span /></td><td class="nump">16,700,720<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td><td class="nump">2,483,261<span /></td><td class="nump">1,679,945<span /></td><td class="nump">7,766,988<span /></td><td class="nump">5,113,487<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td><td class="nump">8,812,458<span /></td><td class="nump">9,306,622<span /></td><td class="nump">31,828,451<span /></td><td class="nump">23,442,282<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td><td class="nump">11,295,719<span /></td><td class="nump">10,986,567<span /></td><td class="nump">39,595,439<span /></td><td class="nump">28,555,769<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td><td class="num">(7,380,319)<span /></td><td class="num">(5,743,828)<span /></td><td class="num">(25,374,409)<span /></td><td class="num">(11,855,049)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td><td class="nump">1,383,826<span /></td><td class="nump">45,829<span /></td><td class="nump">1,721,419<span /></td><td class="nump">31,326<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td><td class="num">(1,305,820)<span /></td><td class="num">(10,663)<span /></td><td class="num">(3,168,118)<span /></td><td class="num">(25,380)<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense), Total</a></td><td class="nump">78,006<span /></td><td class="nump">35,166<span /></td><td class="num">(1,446,699)<span /></td><td class="nump">5,946<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss from operations before provision for income taxes and noncontrolling interests</a></td><td class="num">(7,302,313)<span /></td><td class="num">(5,708,662)<span /></td><td class="num">(26,821,108)<span /></td><td class="num">(11,849,103)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td><td class="nump">26,151<span /></td><td class="nump">285,976<span /></td><td class="nump">907,628<span /></td><td class="nump">1,191,179<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td><td class="num">(7,328,464)<span /></td><td class="num">(5,994,638)<span /></td><td class="num">(27,728,736)<span /></td><td class="num">(13,040,282)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less - net (loss) income attributable to noncontrolling interests</a></td><td class="nump">17,971<span /></td><td class="nump">1,145,588<span /></td><td class="nump">559,079<span /></td><td class="nump">4,085,743<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to NeoStem, Inc.</a></td><td class="num">(7,346,435)<span /></td><td class="num">(7,140,226)<span /></td><td class="num">(28,287,815)<span /></td><td class="num">(17,126,025)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred dividends</a></td><td class="nump">150,655<span /></td><td class="text">&#xA0;<span /></td><td class="nump">508,070<span /></td><td class="nump">153,469<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to NeoStem, Inc. common shareholders</a></td><td class="num">$ (7,497,090)<span /></td><td class="num">$ (7,140,226)<span /></td><td class="num">$ (28,795,885)<span /></td><td class="num">$ (17,279,494)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share</a></td><td class="num">$ (0.08)<span /></td><td class="num">$ (0.13)<span /></td><td class="num">$ (0.35)<span /></td><td class="num">$ (0.36)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbs_WeightedAverageNumberBasicDilutedSharesOutstanding', window );">Weighted average common shares outstanding</a></td><td class="nump">94,102,589<span /></td><td class="nump">56,777,430<span /></td><td class="nump">82,775,215<span /></td><td class="nump">48,599,359<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbs_WeightedAverageNumberBasicDilutedSharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nbs_WeightedAverageNumberBasicDilutedSharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nbs</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 2<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.2)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CostOfRevenue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.1,2)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_GrossProfit</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 4<br /><br /> -Section 08<br /><br /> -Paragraph h<br /><br /> -Subparagraph 1(i)<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.4-08.(h)(1)(i))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Income Tax Expense (or Benefit)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 9<br /><br /> -Subparagraph (a),(b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 08<br /><br /> -Paragraph h<br /><br /> -Article 4<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 109<br /><br /> -Paragraph 45<br /><br /> -Subparagraph a, b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.4-08.(h))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 835<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 942<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.9-04.9)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 34<br /><br /> -Paragraph 21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Paragraph 9<br /><br /> -Article 9<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher OTS<br /><br /> -Name Federal Regulation (FR)<br /><br /> -Number Title 12<br /><br /> -Chapter V<br /><br /> -Section 563c.102<br /><br /> -Paragraph 9<br /><br /> -Subsection II<br /><br /> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_InterestExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.22)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.18)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 220<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph A7<br /><br /> -Appendix A<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 130<br /><br /> -Paragraph 10, 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Other Comprehensive Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph d<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 87-21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Net Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.19)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 19<br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28, 29, 30<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 16: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Paragraph 20<br /><br /> -Article 9<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetIncomeLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of net Income or Loss attributable to the noncontrolling interest (if any) deducted in order to derive the portion attributable to the parent.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1A<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=SL4573702-111684<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 55<br /><br /> -Paragraph 4J<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591551-111686<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph c(1)<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph A1, A4, A5<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 55<br /><br /> -Paragraph 4K<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591552-111686<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 128<br /><br /> -Paragraph 9<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 11<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1377-109256<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 7<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.7)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OperatingExpenses</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OperatingIncomeLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 9<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.9)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockDividendsIncomeStatementImpact</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 55<br /><br /> -Paragraph 4J<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591551-111686<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph A1, A4, A5<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph c(1)<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 29<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1A<br /><br /> -Subparagraph (a),(c)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=SL4573702-111684<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 55<br /><br /> -Paragraph 4K<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591552-111686<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 5<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 19<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569616-111683<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProfitLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 985<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 730<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 141<br /><br /> -Paragraph 51<br /><br /> -Subparagraph g<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 2<br /><br /> -Paragraph 12, 13<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 86<br /><br /> -Paragraph 11, 12<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 1<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.1)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_Revenues</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 43<br /><br /> -Chapter 4<br /><br /> -Paragraph 5A<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 4<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.4)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 330<br /><br /> -SubTopic 10<br /><br /> -Section 30<br /><br /> -Paragraph 8<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6386349&amp;loc=d3e3636-108311<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SellingGeneralAndAdministrativeExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E4GAE"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th><th class="th" colspan="1" /></tr><tr><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Nov. 08, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td><td class="text">10-Q<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td><td class="text">false<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td><td class="text">Sep. 30,
         2011<span /></td><td class="text"><span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td><td class="text">2011<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td><td class="text">Q3<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td><td class="text">NBS<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td><td class="text">NEOSTEM, INC.<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td><td class="text">0000320017<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td><td class="text">--12-31<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td><td class="text">Smaller Reporting Company<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td><td class="text">&#xA0;<span /></td><td class="nump">107,324,573<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_AmendmentFlag</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:booleanItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_CurrentFiscalYearEndDate</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:gMonthDayItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:fiscalPeriodItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentFiscalYearFocus</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:gYearItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentInformationLineItems</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentPeriodEndDate</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:dateItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentType</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:submissionTypeItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation 12B<br /><br /> -Number 240<br /><br /> -Section 12b<br /><br /> -Subsection 1<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityCentralIndexKey</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:centralIndexKeyItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityFilerCategory</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:filerCategoryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation 12B<br /><br /> -Number 240<br /><br /> -Section 12b<br /><br /> -Subsection 1<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityRegistrantName</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:normalizedStringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_TradingSymbol</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:normalizedStringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Loans, Notes Payable and Mortgages Payable<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Bank Loans, Notes Payable and Mortgages Payable</a></td><td class="text"><div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 7
&#x2013; Bank Loans, Notes Payable and Mortgages
Payable</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Bank
Loans</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
November 2010, Erye obtained a bank loan of approximately
$3,124,000 from the CITIC Bank International with a variable
interest rate that is currently 6.06% and is due in November
2011.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
May 2011, Erye obtained a bank loan of approximately $3,124,000
from Commercial Bank of China with a variable interest rate that is
currently 7.02% and is due in November 2011.&#xA0;</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
July 2011, Erye obtained a bank loan of approximately $1,562,000
from the <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
Agricultural Bank of China</font></font> with a variable interest
rate that is currently&#xA0;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.56</font>%
and is due in May 2012.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Notes
Payable</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Erye
has approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">3,571,000</font> of
notes payable outstanding as of September 30, 2011. Notes are
payable to the banks who issue bank notes to Erye&#x2019;s
creditors. Notes payable are interest free and usually mature after
a three to six month period. In order to issue notes payable on
behalf of Erye, the banks require collateral, such as cash deposits
which are approximately 30% - 50% of notes to be issued, or
properties owned by Erye. Restricted cash pledged as collateral for
the balance of notes payable at September 30, 2011 and December 31,
2010, amounted to approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,428,000</font>
and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">3,381,400</font>,
respectively.&#xA0; At September 30, 2011 and December 31, 2010,
the restricted cash amounted to <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">40</font>% and
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">35.8</font>%,
respectively, of the notes payable Erye issued, and the remainder
of the notes payable is collateralized by pledging the land use
right Erye owns, which amounted to approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">4,870,500</font>
and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">4,807,800</font> at
September 30, 2011 and December 31, 2010,
respectively.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company has financed certain insurance policies and has notes
payable at September 30, 2011 of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">38,700</font>
related to these policies. These notes require monthly payments and
mature in less than one year.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Mortgages
Payable</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
October 31, 2007, PCT issued a note to borrow $3,120,000 (the
&#x201C;Note&#x201D;) in connection with its $3,818,500 purchase of
condominium units in an existing building in Allendale, New Jersey
(the &#x201C;Property&#x201D;) that PCT uses as a laboratory and stem
cell processing facility. The Note is payable in 239 consecutive
monthly payments of principal and interest, based on a 20 year
amortization schedule; and one final payment of all outstanding
principal plus accrued interest then due. The current monthly
installment is $20,766, which includes interest at an initial rate
of 5.00%; the interest rate and monthly installments payments are
subject to adjustment on October 1, 2017. On that date, upon prior
written notice, the lender has the option to declare the entire
outstanding principal balance, together with all outstanding
interest, due and payable in full. The Note is secured by
substantially all of the assets of PCT, including a first mortgage
on the Property and assignment of an amount approximately equal to
eighteen months debt service held in escrow. The Note matures on
October 1, 2027 if not called by the lender on October 1, 2017. The
note is subject to certain debt service coverage and total debt to
tangible net worth financial covenant ratios measured
semi-annually. The next measurement date for compliance with
financial covenants is December 31, 2011. PCT was not in compliance
with such covenants at the measurement date of June 30, 2011, and
obtained a covenant waiver letter from the lender for all periods
through June 30, 2011. The outstanding balance was approximately
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">2,736,100</font> at
September 30, 2011 of which $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">112,700</font> is
payable within twelve months. On December 6, 2010&#xA0; PCT
Allendale, a wholly-owned subsidiary of PCT, entered into a note
for a second mortgage in the amount of $1 million on the Allendale
Property with TD Bank, N.A.&#xA0; This loan is guaranteed by PCT,
DomaniCell (a wholly-owned subsidiary of PCT, now known as NeoStem
Family Storage, LLC), Northern New Jersey Cancer Associates
(&#x201C;NNJCA&#x201D;) and certain partners of NNJCA and is subject
to a financial covenant starting December 31, 2011. The loan is for
124 months at a fixed rate of 6% for the first 64 months. The loan
is callable for a certain period prior to the interest reset
date.&#xA0;&#xA0; The initial four months was interest only.&#xA0;
The outstanding balance as of September 30, 2011 is $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">939,000</font> of
which $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">75,200</font> is
payable within twelve months.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.19,20,22)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 2, 4<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 19, 20, 22<br /><br /> -Article 5<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 12
&#x2013; Related Party Transactions</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At
September 30, 2011, Erye owed EET, the <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">49</font>%
shareholder of Erye, $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">20,534,100</font>
which represents dividends paid and loaned back to
Erye.&#xA0;&#xA0;At September 30, 2011 the interest rate on this
loan was <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">6.56</font>%.&#xA0;&#xA0;In
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">June</font> 2011
Erye paid EET approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">875,100</font>
consisting of the net of the following: $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,115,000</font> of
unpaid accrued interest at June 30, 2011, approximately
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">408,700</font>
repayment of a non interest bearing loan due in 2011 and recovery
of cash advances to EET of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">648,600</font>.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant
to the terms and conditions of the Erye Joint Venture Agreement,
dividend distributions to EET and the Company&#x2019;s subsidiary
will be made in proportion to their respective ownership interests
in Erye; provided, however, that for the three-year period
commencing on the first day of the first fiscal quarter after the
Joint Venture Agreement became effective distributions are made as
follows: for undistributed profits generated subsequent to the
acquisition date: (i) the 49% of undistributed profits (after tax)
of the joint venture due EET will be distributed to EET and lent
back to Erye to help finance costs in connection with its
construction of and relocation to a new facility; and (ii) of the
net profit (after tax) of the joint venture due the Company, 45%
will be provided to Erye as part of the new facility construction
fund and will be characterized as additional paid-in capital for
the Company&#x2019;s 51% interest in Erye, and 6% will be
distributed to the Company which has not been paid from the 2010
distribution and is in the amount of approximately $130,000. For
undistributed profits generated prior to the acquisition date: (i)
the 49% of undistributed profits (after tax) of the joint venture
due EET will be distributed to EET and lent back to Erye to help
finance costs in connection with its construction of and relocation
to a new facility; and (ii) of the net profit (after tax) of the
joint venture due the Company, 51% will be provided to Erye as part
of the new facility construction fund and will be characterized as
additional paid-in capital for the Company&#x2019;s 51% interest in
Erye. It was contemplated by the Joint Venture Agreement that the
construction would continue for three years.&#xA0;&#xA0;As such,
45% of the dividend we would be entitled to by reason of our 51%
ownership would remain in Erye through October 2012 to complete the
relocation while EET would loan back their dividend during the same
period at a prevailing bank interest rate.&#xA0;&#xA0;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Upon
a liquidity event of Erye, as contemplated in the joint venture
agreement, the Company will be entitled to the return of its
dividend reinvestments to the extent of the proceeds generated by
the liquidity event.&#xA0;</font> Repayment of such loans from
EET&#xA0;would occur gradually after the relocation is
completed.&#xA0;&#xA0;In January 2011, a dividend totaling
approximately $13,671,100 based on earnings for&#xA0;&#xA0;Fiscal
Year 2009 was declared and approximately $6,698,800 was distributed
to EET and lent back to Erye and approximately $6,972,300 due the
Company was reinvested and re-characterized as additional paid-in
capital in the business. In April 2011, a dividend totaling
$10,259,700 based on earnings for Fiscal Year 2010 was declared and
approximately $5,027,300 was distributed to EET and lent back to
Erye, and approximately $5,232,400 due the Company was reinvested
and re-characterized as additional paid-in capital in the
business.&#xA0;&#xA0;A 10% withholding tax was required on
dividends payable to the Company.&#xA0;&#xA0;As a result, Erye
withheld approximately $1,220,500 in taxes related to the
Company&#x2019;s Fiscal Year 2009 and 2010 dividend amounts, of
which approximately $526,600 has not been paid to the local Chinese
tax authorities as of September 30, 2011.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant
to the PCT Merger Agreement, NeoStem agreed to pay off PCT&#x2019;s
credit line with Northern New Jersey Cancer Associates
(&#x201C;NNJCA&#x201D;), in an amount up to $3,000,000, shortly after
the closing of the PCT Merger. On January 21, 2011, NeoStem paid
NNJCA $3,000,000 in full satisfaction of all of PCT&#x2019;s
obligations to NNJCA arising from the underlying line of credit and
security agreement. Dr. Andrew Pecora (who was PCT&#x2019;s Chairman
and CEO prior to the PCT Merger, and who became PCT&#x2019;s Chief
Medical Officer on January 19, 2011 pursuant to an employment
agreement effective upon the closing of the PCT Merger), has served
as Managing Partner of NNJCA since 1996.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
July 13, 2011, NeoStem entered into the Agreement and Plan of
Merger to acquire Amorcyte.&#xA0;&#xA0;Amorcyte had originally been
incorporated as a subsidiary of PCT and was spun off to PCT&#x2019;s
members prior to NeoStem&#x2019;s January 19, 2011 acquisition of
PCT.&#xA0;&#xA0;At the time the Agreement and Plan of Merger was
entered into, Dr. Pecora and Mr. Goldberger were officers of both
PCT and Amorcyte.&#xA0;&#xA0;The Amorcyte acquisition closed on
October 17, 2011.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
order to accelerate Amorcyte's commencement of its Phase 2 clinical
trial of AMR-001, NeoStem agreed to provide loans to Amorcyte prior
to the closing of the Amorcyte Merger to be used in connection with
the Phase 2 trial. Pursuant to a Loan Agreement entered into on
September 9, 2011, NeoStem loaned Amorcyte prior to the closing of
the Merger an aggregate of $338,500 which was applied towards the
commencement of the Phase 2 trial.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective
March 10, 2011, Matthew Henninger entered into a consulting
agreement with PCT, pursuant to which Mr. Henninger was engaged for
a three month term to serve as an advisor to PCT with regard to the
development of the &#x201C;Family Plan,&#x201D; a multi-generational
stem cell collection and storage service. In consideration
therefor, Mr. Henninger was granted an option to purchase 150,000
shares of NeoStem Common Stock under the 2009 Plan at $1.60 per
share (Black Scholes value $129,000) vesting over the term of the
agreement. Pursuant to an amendment and extension of this agreement
in April and May, 2011, respectively, Mr. Henninger&#x2019;s term of
service was extended through September 9, 2011, for which he
received 75,000 shares of NeoStem Common Stock (market value
$115,000), $5,000 per month for a three month period and
reimbursement of health insurance premiums; in September 2011 the
PCT management with approval of the Audit Committee
extended&#xA0;the term&#xA0;further&#xA0;through December 31, 2011,
in connection with which Mr. Henninger received a $25,000 bonus
related to prior performance, a monthly fee of $10,000 and
continued insurance reimbursement. Mr. Henninger is in an exclusive
relationship with the CEO of NeoStem.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During
the nine months ended September 30, 2011, the Company contributed
to The Stem for Life Foundation, a Pennsylvania nonprofit
corporation classified as a tax-exempt organization under Section
501(c)(3) of the Internal Revenue Code of 1986, as amended (the
&#x201C;Code&#x201D;) and as a public charity under Section 509(a)(1)
and 170(b)(1)(A)(vi) of the Code (the &#x201C;Foundation&#x201D;),
whose mission is to promote public awareness, fund research and
development and subsidize stem cell collection and storage
programs, 407,600 shares of previously issued restricted common
stock with a fair value of approximately $607,400. The contribution
of such securities was subject to the approval of the Board of
Directors and the Audit Committee.&#xA0;&#xA0;The Company&#x2019;s
CEO and Chairman is President and a Trustee of the Foundation, its
General Counsel is Secretary and a Trustee of the Foundation and
its Chief Financial Officer is Treasurer of the
Foundation.</font></div>


</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.4-08.(k))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 3A<br /><br /> -Section 04<br /><br /> -Paragraph b<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 57<br /><br /> -Paragraph 1-4<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 850<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 4<br /><br /> -Section 08<br /><br /> -Paragraph k<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 850<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 850<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 850<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 850<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Adopted Accounting Pronouncements<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbs_DescriptionOfRecentAccountingPronouncementsTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td><td class="text"><div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 3
&#x2013; Recently Adopted Accounting
Pronouncements</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
December 2010, the FASB issued an update which addresses when to
perform Step 2 of the goodwill impairment test for reporting units
with zero or negative carrying amounts. The update modifies Step 1
of the goodwill impairment test for reporting units with zero or
negative carrying amounts. For those reporting units, an entity is
required to perform Step 2 of the goodwill impairment test if it is
more likely than not that a goodwill impairment exists. In
determining whether it is more likely than not that goodwill
impairment exists, an entity should consider whether there are any
adverse qualitative factors indicating that impairment may exist.
The qualitative factors are consistent with the existing guidance,
which requires that goodwill of a reporting unit be tested for
impairment between annual tests if an event occurs or circumstances
change that would more likely than not reduce the fair value of a
reporting unit below its carrying amount. This update is effective
for fiscal years, and interim periods within those years, beginning
after December 15, 2010. The adoption of this guidance did not have
a material impact on the consolidated financial
statements.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
December 2010, the FASB issued an update which addresses the
disclosure of supplementary pro forma information for business
combinations. The update requires public entities to disclose pro
forma information for business combinations that occurred in the
current reporting period, including revenue and earnings of the
combined entity for the current reporting period as though the
acquisition date for all business combinations that occurred during
the year had been as of the beginning of the annual reporting
period. If comparative financial statements are presented, the pro
forma revenue and earnings of the combined entity for the
comparable prior reporting period should be reported as though the
acquisition date for all business combinations that occurred during
the current year had been as of the beginning of the comparable
prior annual reporting period. Amendments in this update are
effective prospectively for business combinations for which the
acquisition date is on or after the beginning of the first annual
reporting period beginning on or after December 15, 2010. The
adoption of this guidance did not have a material impact on the
consolidated financial statements.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbs_DescriptionOfRecentAccountingPronouncementsTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure related to the changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nbs_DescriptionOfRecentAccountingPronouncementsTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nbs</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 9
&#x2013; Shareholders&#x2019; Equity</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Common Stock:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
authorized common stock of the Company is 500 million shares, par
value $0.001 per share.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
March 3, 2011, the Company consummated a private placement pursuant
to which five persons and entities acquired an aggregate of
2,343,750 shares of Common Stock for an aggregate consideration of
$3,000,000 (purchase price $1.28 per share). The investors included
Steven S. Myers (one of the Company&#x2019;s directors) (who
purchased 390,625 shares) and Dr. Andrew L. Pecora (the Chief
Medical Officer of the Company&#x2019;s subsidiary PCT, who is also
now the Chief Medical Officer of NeoStem, and the Chief Scientific
Officer of Amorcyte) (who purchased 78,125 shares). On April 5,
2011, the Company consummated a private placement pursuant to which
nine persons and entities acquired an aggregate of 1,244,375 shares
of Common Stock for an aggregate consideration of approximately
$1,592,800 (purchase price $1.28 per share).&#xA0;&#xA0;On June 13,
2011 the Company consummated a private placement pursuant to which
one entity acquired 781,250 shares of Common Stock for an aggregate
consideration of $1,000,000 (purchase price $1.28 per
share).&#xA0;&#xA0;On July 6, 2011, three then key Amorcyte
stockholders (including a fund managed by a then Amorcyte director)
invested an aggregate of $728,000 in a private placement of 568,750
shares of Common Stock (purchase price $1.28 per
share).</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
July 22, 2011, the Company completed an underwritten offering of
13,750,000 units at a purchase price of $1.20 per unit, with each
unit consisting of one share of Common Stock and a five year
warrant to purchase 0.75 of a share of Common Stock at an exercise
price of $1.45 per share (the
&#x201C;Offering&#x201D;).&#xA0;&#xA0;The Company sold securities in
the Offering under the Company&#x2019;s previously filed shelf
registration statement on Form S-3 (333-173855), which was declared
effective by the Securities and Exchange Commission on June 13,
2011.&#xA0;&#xA0;Lazard Capital Markets LLC (&#x201C;Lazard&#x201D;)
and JMP Securities LLC (&#x201C;JMP&#x201D;) acted as representatives
of the underwriters named in an Underwriting Agreement, dated as of
July 19, 2011, by and among the Company, Lazard, JMP and such
underwriters.&#xA0;&#xA0;The Company received gross proceeds of
$16,500,000, prior to deducting underwriting discounts and offering
expenses payable by the Company, for net proceeds of approximately
$14,667,000.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
September 28, 2011, the Company entered into a Common Stock
Purchase Agreement (the &#x201C;Purchase Agreement&#x201D;) with
Aspire Capital Fund, LLC, an Illinois limited liability company
(&#x201C;Aspire Capital&#x201D;), which provides that, subject to
certain terms and conditions, Aspire Capital is committed to
purchase up to an aggregate of $20.0 million worth of shares of the
Company&#x2019;s common stock over the 24-month term of the Purchase
Agreement. At the Company&#x2019;s discretion, it may present Aspire
Capital with purchase notices under the Purchase Agreement from
time to time, to purchase the Company&#x2019;s Common Stock,
provided certain price and other requirements are met.&#xA0;The
purchase price for the shares of stock will be based upon one of
two formulas set forth in the Purchase Agreement depending on the
type of purchase notice we submit to Aspire Capital from time to
time, and will be based on market prices of the Company's common
stock (in the case of regular purchases) or a discount of 5%
applied to volume weighted average prices (in the case of VWAP
purchases), in each case as determined by parameters defined in the
agreement.&#xA0;&#xA0;&#xA0;The Company and Aspire Capital shall
not effect any sales under the Purchase Agreement on any date where
the closing sales price is less than 75% of the closing sales price
on the business day immediately preceding the date of the Purchase
Agreement. The Company&#x2019;s net proceeds will depend on the
purchase price and the frequency of the Company&#x2019;s sales of
shares to Aspire Capital; provided, however, that the maximum
aggregate proceeds from sales of&#xA0;&#xA0;shares is $20.0
million, and the maximum number of shares that may be sold may not
exceed 18,747,906 shares unless shareholder approval is
obtained.&#xA0;&#xA0;The Company&#x2019;s delivery of purchase
notices will be made subject to market conditions, in light of the
Company&#x2019;s capital needs from time to time and under the
limitations contained in the Purchase Agreement. As consideration
for entering into the Purchase Agreement, effective September 30,
2011, we issued 990,099 shares of our Common Stock to Aspire
Capital (the &#x201C;Commitment Shares&#x201D;). The issuance of
shares of common stock to Aspire Capital pursuant to the Purchase
Agreement, including the Commitment Shares, and the sale of those
shares from time to time by Aspire Capital to the public, are
covered by an effective shelf registration statement on Form
S-3.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Warrants:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company has issued common stock purchase warrants from time to time
to investors in private placements and public offerings, and to
certain vendors, underwriters, placement agents and consultants of
the Company. A total of <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">35,208,817</font>
shares of common stock are reserved for issuance upon exercise of
outstanding warrants as of September 30, 2011 at prices ranging
from $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">0.50</font> to
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">7.00</font> and
expiring through January 2018.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During
the three and nine months ended September 30, 2011 and 2010, the
Company issued warrants for services as follows ($ in thousands,
except share data):</font></div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="85%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="28%" colspan="6" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Three Months Ended September 30,</font></font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="28%" colspan="6" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nine
Months Ended September 30,</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
2010</font></font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
2010</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number
of Common Stock Purchase Warrants Issued</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,000</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">370,000</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">627,000</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="40%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Value
of Common Stock Purchase Warrants Issued</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
-</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32.9</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">289.5</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">772.2</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
</div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
weighted average estimated fair value of warrants issued for
services in the three and nine months ended September 30, 2011 was
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">0</font> and
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">0.78</font>,
respectively. The fair value of warrants at the date of grant was
estimated using the Black-Scholes option pricing model. The
expected volatility is based upon historical volatility of the
Company&#x2019;s stock. The expected term is based upon the
contractual term of the warrants.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
range of assumptions used in calculating the fair values of
warrants issued for services during the three and nine months ended
September 30, 2011 and 2010, respectively, were as
follows:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
</div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="75%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="34%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="32%" colspan="3"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Three
Months Ended September 30,</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="32%" colspan="3">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
Nine Months Ended September 30,</font></font></div>
</td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="34%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="34%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Expected term (in years)</font></font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to
5</font></font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
3 <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to
5</font></font></font></div>
</div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
4&#xA0;<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to
5</font></font></font></div>
</div>
</td>
</tr>
<tr bgcolor="white">
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="34%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="2%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="2%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="34%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
Expected volatility</font></font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">81%
- 83%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">91%
- 96%</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">80%
- 86%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">91%
- 99%</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="34%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="2%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="2%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="34%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Expected dividend yield</font></font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0%</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="34%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="2%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="2%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="34%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Risk-free interest rate</font></font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.42%
- 1.53%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.27%
- 1.60%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.42%
- 2.24%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.27%
- 2.04%</font></div>
</td>
</tr>
</table>
</div>
<div>&#xA0;</div>
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="bottom" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Activity
related to warrants outstanding was as follows:</font></div>
</td>
</tr>
</table>
</div>
<div>&#xA0;</div>
<div style="TEXT-ALIGN: center">
<table style="TEXT-ALIGN: center; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="75%">
<tr style="TEXT-ALIGN: center">
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number
of</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Exercise Price</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term
(years)</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic
Value</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Balance at December 31, 2010</font></font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,843,507</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.62</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
Granted</font></font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,812,939</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.23</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
Exercised</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
Expired</font></font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(447,629</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.18</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
Cancelled</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Balance at September 30, 2011</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35,208,817</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.41</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.9</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,600</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Warrants Exercisable at September 30, 2011</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33,933,317</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.29</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.7</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="84%" colspan="16" nowrap="nowrap" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
* Includes 3 million warrants issued pursuant to the PCT Merger
Agreement - See Note 4, and 10,312,500 warrants issued in
the</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
July 22,</font></font> <font size="2">2011 offering</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
</div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company&#x2019;s results include share-based compensation expense of
approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5,600</font> and a
benefit of $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">147,300</font> for
the three months ended September 30, 2011 and 2010, respectively,
and an expense of approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">247,500</font> and
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">417,300</font> for
the nine months ended September 30, 2011 and 2010,
respectively.&#xA0;&#xA0;The total fair value of shares vested for
warrants issued for services during the three and nine months ended
September 30, 2011 was approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">60,100</font> and
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">235,800</font>,
respectively.&#xA0;&#xA0;As of September 30, 2011, there was
approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">93,300</font> of
total unrecognized service cost related to unvested warrants of
which approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">49,500</font> is
related to warrants that vest over a weighted average life of
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">0.25</font> years.
The remaining balance of unrecognized service cost of $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">43,800</font> is
related to warrants that vest based on the accomplishment of
business milestones as to which expense begins to be recognized
when such milestones become probable of being
achieved.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Options:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<!--EFPlaceholder-->At the 2011 Annual Meeting of Shareholders of
the Company held on October 14, 2011, the shareholders approved an
amendment to increase the number of shares of common stock
authorized for issuance under the 2009 Equity Compensation Plan
(the &#x201C;2009 Equity Plan&#x201D;) from 17,750,000 to
23,750,000.&#xA0;&#xA0;Effective October 14, 2011, concurrent with
shareholder approval to increase the number of shares of common
stock authorized for issuance under the 2009 Equity Plan by
6,000,000, the Company&#x2019;s Board of Directors authorized a
decrease in the shares available for issuance under the Non-U.S,
Equity Plan from 8,700,000 to 5,700,000.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company&#x2019;s results include share-based compensation expense of
approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">831,400</font> and
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">2,453,100</font>
for the three months ended September 30, 2011 and 2010,
respectively, and approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5,631,400</font>
and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5,982,500</font>
for the nine months ended September 30, 2011 and 2010,
respectively. Options vesting on the accomplishment of business
milestones will not be recognized for compensation purposes until
such milestones are deemed probable of accomplishment. At September
30, 2011 there were options to purchase <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">654,928</font>
shares outstanding that will vest upon the accomplishment of
business milestones and will be accounted for as an operating
expense when such business milestones are deemed probable of
accomplishment.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
April 4, 2011, the Company entered into an amendment of its May 26,
2006 employment agreement with Dr. Robin L. Smith, pursuant to
which, as previously amended (the &#x201C;Agreement&#x201D;), Dr.
Smith serves as Chairman of the Board and Chief Executive Officer
of the Company. Pursuant to the amendment, (i) the term of the
Agreement was extended from December 31, 2011 to December 31, 2012;
(ii) Dr. Smith will receive cash bonuses on October 1, 2011 and
2012 in the minimum amount of 110% of the prior year&#x2019;s bonus;
(iii) a failure to renew the Agreement at the end of the term
regardless of reason shall be treated as a termination by the
Company without cause; (iv) the Company shall pay Dr. Smith her
base salary and COBRA premiums (a) for one year in the event of a
termination of the agreement by Dr. Smith for other than good
reason and (b) during any period during which she is bound by
non-competition, non-solicitation or similar covenants with the
Company (such payments shall not be made during the time Dr. Smith
is also receiving payments under (iii) or (iv)(a)); (v) Dr. Smith
was granted an option to purchase 1,500,000 shares of Common Stock
at a per share exercise price equal to the closing price of the
Common Stock on the date of the amendment, vesting as to 500,000
shares on each of the date of grant, December 31, 2011 and December
31, 2012; (vi) all other unvested options held by Dr. Smith were
immediately vested; (vii) any vested options previously or
hereafter granted to Dr. Smith during the remainder of the term
shall remain exercisable following termination of employment for
the full option term until the expiration date; (viii) the Company
agreed that, with the exception of the period of time during which
Dr. Smith is a Company affiliate and for 90 days thereafter (during
which time any shares owned by or issued to Dr. Smith will bear the
Company&#x2019;s standard affiliate legend), the Company will not
place legends on shares on Common Stock owned by Dr. Smith
restricting the transfer of such shares so long as such shares are
sold under an effective registration statement, pursuant to Rule
144 or are eligible for sale under Rule 144 without volume
limitations; and (ix) if Dr. Smith ceases to be employed by the
Company and for so long as she continues to own shares of Common
Stock the sale of which would require that the current public
information requirement of Rule 144 be met, the Company will use
its reasonable best efforts to timely meet those requirements or
obtain appropriate extensions or otherwise make available such
information as is required. Except as set forth in the amendment,
the Agreement remains unchanged.&#xA0;&#xA0;Pursuant to the
modification on April 4, 2011 of Dr. Smith&#x2019;s stock options,
the Company recognized $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">723,000</font> of
incremental compensation cost during the nine months ended
September 30, 2011.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
weighted average estimated fair value of stock options granted in
the three and nine months ended September 30, 2011 was
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">0.50</font>
and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1.10</font>,
respectively. The fair value of options at the date of grant was
estimated using the Black-Scholes option pricing model. The
expected volatility is based upon historical volatility of the
Company&#x2019;s stock. The expected term is based upon observation
of actual time elapsed between date of grant and exercise of
options for all employees.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
range of assumptions used in calculating the fair values of options
granted during the three and nine months ended September 30, 2011
and 2010, respectively, were as follows:</font></div>
</div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify">&#xA0;</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="34%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="32%" colspan="3">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Three Months Ended September 30,</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="32%" colspan="3">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Nine Months Ended September 30,</font></font></div>
</td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="34%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="34%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Expected term (in years)</font></font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to
6</font></font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2
to 10</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1
to 10</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2
to 10</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="34%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="34%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
Expected volatility</font></font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">76%
- 84%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">91%
- 99%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">75%
- 85%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">91%
- 122%</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="34%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="34%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Expected dividend yield</font></font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0%</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="34%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="34%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Risk-free interest rate</font></font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.13%
- 1.82%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.42%
- 3.00%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.13%
- 3.45%</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="2%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="15%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.42%
- 3.58%</font></div>
</td>
</tr>
</table>
</div>
<div align="center">&#xA0;</div>
</div>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="59%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Activity
related to stock options outstanding under the U.S. Equity Plans
was as follows:</font></div>
</td>
</tr>
</table>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
&#xA0;</div>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="75%">
<tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="TEXT-ALIGN: center" valign="bottom" width="40%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="TEXT-ALIGN: center" valign="bottom" width="40%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number
of</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Aggregate</font></font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise
Price</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term
(years)</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Intrinsic Value</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance
at December 31, 2010</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,932,214</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.87</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">&#xA0;</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
&#xA0;</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">&#xA0;</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
&#xA0;</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,544,600</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.54</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,000</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.42</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expired</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cancelled</font></div>
</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,071,919</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.74</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance
at September 30, 2011</font></div>
</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,399,895</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.73</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.5</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
-</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Options
Exercisable at September 30, 2011</font></div>
</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,812,002</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.84</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.7</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Activity
related to stock options outstanding under the Non U.S. Equity Plan
was as follows:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="75%">
<tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="TEXT-ALIGN: center" valign="bottom" width="40%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="TEXT-ALIGN: center" valign="bottom" width="40%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number
of</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Aggregate</font></font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise
Price</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term
(years)</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="14%" colspan="3" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Intrinsic Value</font></font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance
at December 31, 2010</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,100,000</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.02</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">&#xA0;</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
&#xA0;</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">&#xA0;</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
&#xA0;</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">650,000</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.74</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expired</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cancelled</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,400,000</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.02</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance
at September 30, 2011</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,350,000</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.94</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.6</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
-</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Options
Exercisable at September 30, 2011</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">950,000</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.07</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.3</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
</div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
total fair value of shares vested during the three and nine months
ended September 30, 2011 was approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,169,300</font>
and $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">3,973,800</font>,
respectively.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
number of remaining shares authorized to be issued under the
various equity plans at September 30, 2011 are as
follows:</font></div>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
&#xA0;</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr>
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non
US Equity</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">US
Equity Plan</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Plan</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares
Authorized for Issuance under 2003 Equity Plan</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,500,000</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares
Authorized for Issuance under 2009 Equity Plan</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,750,000</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares
Authorized for Issuance under Non US Equity Plan</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,700,000</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,250,000</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,700,000</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
Options - US Equity Plan</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(15,399,895</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised
Options</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(97,500</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
Options - Non US Equity Plan</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,350,000</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restricted
stock or equity grants issued under Equity Plans</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,479,085</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(885,000</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
common shares remaining to be issued under the Equity
Plans</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,273,520</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,465,000</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As
of September 30, 2011, there was approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">6,515,400</font> of
total unrecognized compensation costs related to unvested stock
option awards of which approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5,776,100</font> is
related to stock options that vest over a weighted average life of
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1.9</font> years.
The remaining balance of unrecognized compensation costs of
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">739,300</font> is
related to stock options that vest based on the accomplishment of
business milestones which expense begins to be recognized when such
milestones become probable of being achieved.&#xA0;&#xA0;Effective
October 14, 2011, concurrent with shareholder approval to increase
the number of shares of common stock authorized for issuance under
the 2009 Equity Plan by 6,000,000, the Company&#x2019;s Board of
Directors authorized a decrease in the shares available for
issuance under the Non-U.S, Equity Plan from 8,700,000 to
5,700,000.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
</div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Changes in Stockholders Equity:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
changes in Stockholders Equity for the nine months ended September
30, 2011 were as follows:</font></div>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
&#xA0;</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" colspan="6" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
Series B Convertible</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" colspan="6" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" align="right">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="6" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
Preferred Stock</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
Common Stock</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
Shares</font></font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
Amount</font></font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
Shares</font></font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
Amount</font></font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
Additional Paid</font></font></font></div>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">in
Capital</font></font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
Accumulated</font></font></font></font></div>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">Other</font></font></font></div>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">Comprehensive</font></font></div>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">Income</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
Deficit</font></font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
Non-</font></font></font></div>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">Controlling</font></font></div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
Interest in</font></font></div>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">Subsidiary</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
Total</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="28%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
Balance at January 1, 2011</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">10,000</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">100</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">64,221,130</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">63,813</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">141,137,522</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">2,779,066</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(95,320,620</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">37,827,738</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">86,487,619</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="28%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Exercise
of stock options</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">5,000</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">5</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">7,095</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">7,100</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="28%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Share-based
compensation</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">2,394,530</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">2,395</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">8,162,419</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">8,164,814</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="28%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Proceeds
from issuance of common stock</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">19,678,224</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">19,678</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">21,148,004</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">21,167,682</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="28%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Shares
issued for charitable contribution</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">408</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">606,955</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">607,363</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="28%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Repayment
of Series E Preferred Principal and Dividends</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">3,462,559</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">3,462</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">3,404,477</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(508,070</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">2,899,869</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="28%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Foreign
currency translation</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">2,222,569</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(9,652</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">2,212,917</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="28%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Net
income attributable to non-controlling interest</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">559,079</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">559,079</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="28%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Dividends
to related party</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(11,726,099</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(11,726,099</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="28%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Technology
contributed to Athelos by Non-Controlling Interest</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">920,000</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">230,000</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">1,150,000</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="28%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Net
loss attributable to NeoStem, Inc.</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(28,287,815</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="5%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(28,287,815</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="28%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Shares
issued in PCT Merger</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">10,600,000</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">10,600</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">17,189,400</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">17,200,000</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="28%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">
Balance at September 30, 2011</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">10,000</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">100</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">100,361,443</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">100,361</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">192,575,872</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">5,001,635</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(124,116,505</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">26,881,066</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">100,442,529</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 29, 30, 31<br /><br /> -Article 5<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 310<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SAB TOPIC 4.E)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 4<br /><br /> -Subparagraph (SAB TOPIC 4.C)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 2, 3, 4, 5, 6, 7, 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Preferred Stock<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 5<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 08<br /><br /> -Article 4<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /> -Number Topic 4<br /><br /> -Section C<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29-31)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 4<br /><br /> -Section 08<br /><br /> -Paragraph d<br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /> -Number Topic 4<br /><br /> -Section E<br /><br /><br /><br />Reference 16: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 30<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br /><br /><br /><br />Reference 17: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br /><br /><br /><br />Reference 18: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.4-08.(d),(e))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br />Reference 19: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 43<br /><br /> -Chapter 1<br /><br /> -Section B<br /><br /> -Paragraph 7, 11A<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 20: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 21: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 22: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br /><br /><br /><br />Reference 23: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 11<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td><td class="text"><div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 14
&#x2013; Subsequent Events</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">
The Amorcyte Merger</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
October 17, 2011 (the &#x201C;Closing Date&#x201D;), Amo Acquisition
Company I, Inc. (&#x201C;Subco&#x201D;), a newly-formed wholly-owned
subsidiary of NeoStem, Inc. (&#x201C;NeoStem&#x201D; or the
&#x201C;Company&#x201D;), merged (the &#x201C;Amorcyte Merger&#x201D;)
with and into Amorcyte, Inc., a Delaware corporation
(&#x201C;Amorcyte&#x201D;), in accordance with the terms of the
Agreement and Plan of Merger, dated as of July 13, 2011 (the
&#x201C;Amorcyte Merger Agreement&#x201D;), among NeoStem, Amorcyte,
Subco, and Amo Acquisition Company II, LLC (&#x201C;Subco
II&#x201D;).&#xA0;&#xA0;As a result of the consummation of the
Amorcyte Merger, Amorcyte is now a wholly-owned subsidiary of
NeoStem.&#xA0;&#xA0;Amorcyte is a development stage cell therapy
company focusing on novel treatments for cardiovascular disease.
Amorcyte&#x2019;s lead product candidate, AMR-001, is entering a
Phase 2 study for the treatment of acute myocardial infarction
(AMI). We are currently recruiting trial sites in connection with
the launch of this Phase 2 clinical trial which is expected to
start enrolling patients by the end of first quarter of
2012.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the terms of the Amorcyte Merger Agreement, all of the shares of
Amorcyte common stock and Amorcyte Series A Preferred Stock and all
options and warrants to acquire equity of Amorcyte, issued and
outstanding immediately prior to the effective time of the Amorcyte
Merger (the &#x201C;Effective Time&#x201D;), were by virtue of the
Amorcyte Merger cancelled and converted into the right to receive,
in the aggregate:</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;</div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(i)</font></div>
</td>
<td valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,843,483
shares of NeoStem Common Stock (reflecting certain adjustments
taken at the closing, and subject to further adjustment following
the closing in accordance with the Amorcyte Merger Agreement) (the
&#x201C;Base Stock Consideration&#x201D;);</font></div>
</td>
</tr>
</table>
</div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(ii)</font></div>
</td>
<td valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">the
right to receive 4,092,768 shares of NeoStem Common Stock (the
&#x201C;Contingent Shares&#x201D;, and together with the Base Stock
Consideration, the &#x201C;Stock Consideration&#x201D;), which
Contingent Shares will be issued only if certain specified business
milestones (described below) are accomplished;</font></div>
</td>
</tr>
</table>
</div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(iii)</font></div>
</td>
<td valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">warrants
to purchase&#xA0;1,881,008 shares of NeoStem Common Stock
exercisable over a seven (7) year period at an exercise price of
$1.466 per share (the &#x201C;Warrants&#x201D;) (such Warrants are
redeemable in certain circumstances, and transfer of any shares of
NeoStem Common Stock issued upon exercise of the Warrants will be
restricted until one year after the Closing Date); and</font></div>
</td>
</tr>
</table>
</div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(iv)</font></div>
</td>
<td valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">earn
out payments equal to 10% of the net sales of Amorcyte&#x2019;s lead
product candidate AMR-001 (in the event of and following the date
of first commercial sale of AMR-001), provided that in the event
NeoStem sublicenses AMR-001, the applicable earn out payment will
be equal to 30% of any sublicensing fees, and provided further that
NeoStem will be entitled to recover direct out-of-pocket clinical
development costs not previously paid or reimbursed and any costs,
expenses, liabilities and settlement amounts arising out of claims
of patent infringement or otherwise challenging Amorcyte&#x2019;s
right to use intellectual property, by reducing any earn out
payments due by 50% until such costs have been recouped in full
(the &#x201C;Earn Out Payments&#x201D;).</font></div>
</td>
</tr>
</table>
</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#xA0;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
accordance with the Amorcyte Merger Agreement, NeoStem has
deposited into an escrow account with the escrow agent (who is
initially NeoStem&#x2019;s transfer agent), 5,843,483 shares of
NeoStem Common Stock for eventual distribution to the former
Amorcyte stockholders (subject to further adjustment following the
closing, including in connection with any indemnification claims of
NeoStem, all in accordance with the Amorcyte Merger
Agreement).&#xA0;&#xA0;</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Contingent Shares will be issued to the former Amorcyte
stockholders only if certain business milestones are achieved, as
follows:</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#xA7;</font></div>
</td>
<td valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">One-third
of the Contingent Shares (1,364,256 shares) will be issued upon (a)
the completion of Phase 2 clinical trial for Amorcyte&#x2019;s
product candidate AMR-001 and (b) issuance of a statistically
significant analysis demonstrating satisfaction of the primary
clinical end points from the Phase 2 clinical trial, which primary
clinical endpoints are described in the Phase 2 clinical trial
protocol submitted by Amorcyte to the FDA on July 5,
2011.</font></div>
</td>
</tr>
</table>
</div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#xA7;</font></div>
</td>
<td valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">One-third
of the Contingent Shares will be issued following a Type B End of
Phase 2/Pre-Phase 3 meeting with the FDA wherein AMR-001 is
acknowledged in writing by the FDA to be ready for Phase
3.</font></div>
</td>
</tr>
</table>
</div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#xA7;</font></div>
</td>
<td valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
remaining one-third of the Contingent Shares will be issued upon
the first dosing of the first patient in the pivotal Phase 3
clinical study for AMR-001.</font></div>
</td>
</tr>
</table>
</div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
merger consideration described above will be distributed to
Amorcyte&#x2019;s former securityholders consistent with applicable
liquidation preferences contained in Amorcyte&#x2019;s governing
documents, all in accordance with the Amorcyte Merger
Agreement.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
issuance of NeoStem securities pursuant to the Amorcyte Merger
Agreement was approved at the 2011 Annual Meeting of Stockholders
of NeoStem held on October 14, 2011 (the &#x201C;NeoStem 2011 Annual
Meeting&#x201D;), on which date the Amorcyte Merger also was
approved at a special meeting of stockholders of
Amorcyte.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
description of the Amorcyte Merger contained in this Note 14 does
not purport to be complete and is qualified in its entirety by
reference to the Amorcyte Merger Agreement, which is attached to
NeoStem&#x2019;s Joint Proxy Statement/Prospectus dated and filed
with the Securities and Exchange Commission on September 16, 2011
(the &#x201C;Joint Proxy Statement/Prospectus&#x201D;), the Warrant
Agreement between NeoStem and Continental Stock Transfer &amp;
Trust Company, and the form of Global Series AMO Warrant attached
thereto, which is filed as Exhibit 4.1 to the Company&#x2019;s
Current Report on Form 8-K dated October 14, 2011 (the &#x201C;Form
8-K&#x201D;) and the escrow agreement, which is filed as Exhibit
10.1 to the Form 8-K, respectively.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">
Amendment to the 2009 Plan and 2009 Non-U.S.
Plan</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
the NeoStem 2011 Annual Meeting, the shareholders of NeoStem duly
approved an amendment to the NeoStem, Inc. 2009 Equity Compensation
Plan (the &#x201C;2009 Plan&#x201D;) to increase the number of shares
of NeoStem Common Stock authorized for issuance thereunder by
6,000,000 shares (that is, from 17,750,000 shares to 23,750,000
shares), and NeoStem thereupon effected such amendment to the 2009
Plan. Persons eligible to receive restricted and unrestricted stock
awards, options, stock appreciation rights or other awards under
the 2009 Plan are those employees, consultants and directors of
NeoStem and its subsidiaries who, in the opinion of the
Compensation Committee of NeoStem&#x2019;s Board of Directors, are
in a position to contribute to NeoStem&#x2019;s
success.&#xA0;&#xA0;Concurrently therewith, NeoStem decreased the
number of shares authorized for issuance under the NeoStem, Inc.
2009 Non-U.S. Based Equity Compensation Plan by 3,000,000 (that is,
from 8,700,000 to 5,700,000).&#xA0;&#xA0;The reduction in shares
available for issuance under the 2009 Non-U.S. Plan was effected in
light of the Company&#x2019;s plan to focus its business on cell
therapy manufacturing and development and other related activities
in the United States, and the Company&#x2019;s consideration of the
possible divestiture of its 51% interest in
Erye.&#xA0;&#xA0;Persons eligible to receive warrants, stock
appreciation rights or other awards under the 2009 Non-U.S. Plan
are those service providers of NeoStem and its subsidiaries and
affiliates providing services outside of the United States,
including employees and consultants of NeoStem and its subsidiaries
and affiliates, who, in the opinion of the Compensation Committee,
are in a position to contribute to NeoStem&#x2019;s
success.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td><td class="text"><div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 10
&#x2013; Income Taxes</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><!--EFPlaceholder--><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Tax Reform Act of 1986 enacted a complex set of rules limiting the
utilization of net operating loss carryforwards (&#x201C;NOL&#x201D;)
to offset future taxable income following a corporate ownership
change. The Company&#x2019;s ability to utilize its NOL
carryforwards is limited following a change in ownership in excess
of fifty percentage points during any three-year
period.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
the year 2000, the Company has had several changes in ownership
which has resulted in a limitation on the Company&#x2019;s ability
to apply net operating losses to future taxable income and future
ownership changes could result in additional limitations. At
December 31, 2010, the Company had net operating loss carryforwards
of approximately $39,590,500 applicable to future Federal income
taxes. The tax loss carryforwards are subject to annual limitations
and expire at various dates through 2030. The Company has recorded
a full valuation allowance against its net deferred tax asset
because it is more likely than not that such deferred tax assets
will not be realized.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
income tax provision for the three and nine months ended September
30, 2011 and 2010 is related to foreign taxes for our operations in
China.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 109<br /><br /> -Paragraph 136, 172<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 109<br /><br /> -Paragraph 43, 44, 45, 46, 47, 48, 49<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 08<br /><br /> -Paragraph h<br /><br /> -Article 4<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 9<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 15<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.4-08.(h))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock</a></td><td class="text"><div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 8
&#x2013; Preferred Stock</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Convertible
Redeemable Series E 7% Preferred Stock</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
November 19, 2010, the Company sold 10,582,011 Preferred Offering
Units consisting of (i) one share (&#x201C;Preferred Share&#x201D;)
of Series E 7% Senior Convertible Preferred Stock, par value $0.01
per share, of the Company, (ii) a warrant to purchase 0.25 of a
share of Common Stock (consisting of at issuance an aggregate of
1,322,486 warrants, adjusted to an aggregate of 1,452,925 as of
September 30, 2011); and (iii) 0.0155 of a share of Common Stock
(an aggregate of 164,418 shares). Each Preferred Offering Unit was
priced at $0.945 and total gross and net proceeds received by the
Company were $10,000,000 and $8,876,700, respectively.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
the event of any liquidation, dissolution or winding up of the
Company, either voluntary or involuntary, the holders of the
Preferred Shares are entitled to receive, out of the assets of the
Company available for distribution to shareholders, prior and in
preference to any distribution of any assets of the Company to the
holders of any other class or series of equity securities, the
amount of $1.00 per share plus all accrued but unpaid
dividends.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dividends
on the Preferred Shares accrue at a rate of 7% per annum and are
payable monthly in arrears.&#xA0;&#xA0;The Company is required to
redeem 1/27 of the Preferred Shares monthly.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Monthly
dividend and principal payments began on March 21, 2011 and
continue on the 19th of each month thereafter with the final
payment due on May 20, 2013. Payments can be made in cash or, upon
notification to the holders, in shares of Company common stock,
provided certain conditions are satisfied or holders of Preferred
Shares agree to waive the conditions for that payment period. If
the conditions are not satisfied, the Company must make payments in
cash. Payments which are made in stock will be made in shares which
are freely tradable. The price of the shares will be calculated
based on 92% of the average of the lowest 5 days&#x2019; volume
weighted average prices of the 20 trading days prior to the payment
date, and the shares are delivered in tranches beginning in advance
of the applicable payment date.&#xA0;&#xA0;As of September 30,
2011, the Company had issued 3,462,559 shares of Company common
stock in payment of monthly dividends and principal, including
required advanced payments.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company may pre-pay the outstanding balance of the Preferred Shares
in full or in part (in increments of no less than $1,000,000) at
115% of the then outstanding balance, reducing to 110% after
November 19, 2011, with notice of not less than thirty days and
adequate opportunity to convert. If the Company chooses to pre-pay,
the outstanding balance must be paid in cash and the premium may be
paid in cash or shares of Company common stock.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Upon
issuance, the Preferred Shares were convertible at an initial
conversion price of $2.0004. The conversion price is subject to
certain weighted average adjustments upon the occurrence of
specific events, including stock dividends, stock splits,
combinations and reclassifications of the Company&#x2019;s common
stock and if (with certain exceptions) the Company issues or sells
any additional shares of common stock or common stock equivalents
at a price per share less than the conversion price then in effect,
or without consideration.&#xA0;&#xA0;As of September 30, 2011, the
conversion price had been adjusted to $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1.67</font>.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
aggregate of $2,500,000 of the proceeds from the Preferred Offering
was placed in escrow for a maximum of 2.5 years as security for the
Company&#x2019;s obligations relative to the Preferred Shares, and
is included in other assets.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
characteristics of the Series E Preferred Stock: cumulative
dividends, mandatory redemption, no voting rights, and callable by
the Company, require that this instrument be treated as mezzanine
equity. The Company bifurcated the fair value of the embedded
conversion options and redemption options from the preferred stock
since the conversion options and certain redemption options were
determined to not be clearly and closely related to the Series E
Preferred Stock. The Company recorded the fair value of the
embedded conversion and redemption options as long-term derivative
liabilities as the conversion price is not fixed and the forced
redemption option contains substantial premiums over the stated
dividend rate for the preferred stock. The Company also recorded
the fair value of the warrants as a long-term derivative liability
as the number of warrant shares and exercise price of the warrants
is not fixed. The Series E Preferred Stock was discounted by the
fair value of the derivatives liabilities. The fair value of the
preferred stock (net of issuance costs and discounts), the embedded
derivatives, and warrant derivative were approximately
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">5,475,600</font>,
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">783,400</font> and
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">126,900</font>,
respectively, as of September 30, 2011.&#xA0;&#xA0;The Company will
report changes in the fair value of the embedded derivatives and
warrant derivative in earnings within other income (expense), net.
The discount and issuance costs on the preferred stock will be
amortized through May 20, 2013 using the effective interest method
and will be reflected within interest expense. For the nine months
ended September 30, 2011, the Company recorded a decrease in the
fair value of the embedded derivatives of approximately
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,498,400</font>
and a decrease in the warrant derivative of approximately
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">148,400</font>.&#xA0;&#xA0;For
the three months ended September 30, 2011, the Company recorded a
decrease in the fair value of the embedded derivatives of
approximately $<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">1,150,300</font>
and a decrease in the warrant derivative of approximately
$<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">213,000</font>.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">The Company</a></td><td class="text"><div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Note
1&#xA0;&#xA0;&#x2013; The Company</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><!--EFPlaceholder--><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NeoStem,
Inc. (&#x201C;NeoStem&#x201D; or the &#x201C;Company&#x201D;) was
incorporated under the laws of the State of Delaware in September
1980 under the name Fidelity Medical Services, Inc. The
Company&#x2019;s corporate headquarters are located at 420 Lexington
Avenue, Suite 450, New York, NY 10170.&#xA0;&#xA0;The
Company&#x2019;s telephone number is (212) 584-4180 and its website
address is<font style="DISPLAY: inline; FONT-STYLE: italic">&#xA0;&#xA0;www.neostem.com</font>.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NeoStem
is an international biopharmaceutical company operating in three
reportable segments: (i) Cell Therapy&#xA0;&#x2013;&#xA0;United
States; (ii) Regenerative Medicine&#xA0;&#x2013;&#xA0;China; and
(iii) Pharmaceutical
Manufacturing&#xA0;&#x2013;&#xA0;China.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Through
the Cell Therapy&#xA0;&#x2013;&#xA0;United States segment, NeoStem
is focused on the development of proprietary cellular therapies in
oncology, immunology and regenerative medicine and becoming a
single source for collection, storage, manufacturing, therapeutic
development and transportation of cells for cell based medicine and
regenerative science globally<font style="DISPLAY: inline; FONT-STYLE: italic">.</font> Within this segment,
the Company is a provider of adult stem cell collection, processing
and storage services in the U.S., enabling healthy individuals to
donate and store their stem cells for personal therapeutic use. In
addition, the Company collects and stores cord blood cells of
newborns which help to ensure a supply of autologous stem cells for
the child should they be needed for future medical
treatment.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company strengthened its expertise in cellular therapies, for its
Cell Therapy &#x2013; United States segment, with its January 19,
2011 acquisition of Progenitor Cell Therapy, LLC, a Delaware
limited liability company (&#x201C;PCT&#x201D;), pursuant to which
the Company acquired all of the membership interests of PCT, and
PCT is now a wholly-owned subsidiary of NeoStem. PCT is engaged in
a wide range of services in the cell therapy market for the
treatment of human disease, including, but not limited to contract
manufacturing, product and process development, regulatory
consulting, product characterization and comparability, and
storage, distribution, manufacturing and transportation of cell
therapy products. PCT&#x2019;s legacy business relationships also
afford NeoStem introductions to innovative therapeutic
programs.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
March 2011 PCT&#x2019;s wholly owned subsidiary, Athelos, Inc.
(Athelos), acquired rights and technology for a T-cell based
immunomodulatory therapeutic in exchange for an approximate 20%
interest in Athelos. Athelos expects to initiate Phase 1 studies in
autoimmune disorders in 2012.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company further strengthened its breadth in cellular therapies
through its October 17, 2011 acquisition of Amorcyte,
Inc.&#xA0;&#xA0;Amorcyte is a development stage cell therapy
company focusing on novel treatments for cardiovascular
disease.&#xA0;&#xA0;Amorcyte&#x2019;s lead product candidate,
AMR-001, is entering a Phase 2 study for the treatment of acute
myocardial infarction (AMI).&#xA0;&#xA0;Amorcyte is currently
recruiting trial sites in connection with the launch of this Phase
2 clinical trial which is expected to start enrolling patients by
the end of the first quarter of 2012.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company views the PCT and Amorcyte acquisitions as fundamental to
building a foundation in achieving its strategic mission of
capturing the paradigm shift to cell therapy.&#xA0;&#xA0;(See Note
4 and Note 14)</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Through
its Regenerative Medicine&#xA0;&#x2013;&#xA0;China segment, in 2009,
the Company began several China-based, Regenerative Medicine
initiatives including: (i) creating a separate China-based cell
therapy operation, (ii) constructing a stem cell research and
development laboratory and processing facility in Beijing, (iii)
establishing relationships with hospitals to provide cell-based
therapies, and (iv) obtaining product licenses covering several
adult stem cell therapeutics focused on regenerative
medicine.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company acquired its Pharmaceutical
Manufacturing&#xA0;&#x2013;&#xA0;China segment on October 30, 2009,
when China Biopharmaceuticals Holdings, Inc. (&#x201C;CBH&#x201D;)
merged with and into CBH Acquisition LLC (&#x201C;Merger
Sub&#x201D;), a wholly-owned subsidiary of NeoStem, with Merger Sub
as the surviving entity (the &#x201C;Erye Merger&#x201D;). As a
result of the Erye Merger, NeoStem acquired CBH&#x2019;s 51%
ownership interest in Suzhou Erye Pharmaceutical Company Ltd.
(&#x201C;Erye&#x201D;), a Sino-foreign joint venture with limited
liability organized under the laws of the People&#x2019;s Republic
of China. Erye was founded more than 50 years ago and represents an
established, vertically-integrated pharmaceutical business.
Historically, Erye has concentrated its efforts on the
manufacturing and distribution of generic antibiotic products. In
2010, Erye began transferring its operations to its newly
constructed manufacturing facility. The relocation is continuing as
the new production lines are completed and receive cGMP
certification. As part of its plan to focus its business on
capturing the paradigm shift to cell therapies following the
January 2011 acquisition of PCT, the Company is pursuing strategic
alternatives with respect to its interest in Erye.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Name Statement of Position (SOP)<br /><br /> -Publisher AICPA<br /><br /> -Number 94-6<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 275<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NatureOfOperations</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td><td class="text"><div>
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 4
&#x2013; Acquisitions</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
January 19, 2011 (the &#x201C;Closing Date&#x201D;), NBS Acquisition
Company LLC (&#x201C;Subco&#x201D;), a newly formed wholly-owned
subsidiary of NeoStem, merged (the &#x201C;PCT Merger&#x201D;) with
and into Progenitor Cell Therapy, LLC, a Delaware limited liability
company (&#x201C;PCT&#x201D;), with PCT as the surviving entity, in
accordance with the terms of the Agreement and Plan of Merger,
dated September 23, 2010 (the &#x201C;PCT Merger Agreement&#x201D;),
among NeoStem, PCT and Subco.&#xA0;&#xA0;As a result of the
consummation of the PCT Merger, NeoStem acquired all of the
membership interests of PCT, and PCT is now a wholly-owned
subsidiary of NeoStem.&#xA0;&#xA0;</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Founded
by Dr. Andrew L. Pecora and Robert A. Preti, Ph.D., PCT became an
internationally recognized cell therapy services and development
company.&#xA0;&#xA0;They sought to create a business for &#x201C;as
needed&#x201D; development and manufacturing services for the
emerging cell therapy industry and to prepare for eventual
commercialization.&#xA0;&#xA0;With its cell therapy manufacturing
facilities and team of professionals, PCT offers a platform that
can facilitate the preclinical and clinical development and
commercialization of cellular therapies for clients throughout the
world.&#xA0;&#xA0;PCT offers current Good Manufacturing Practices
(cGMP)-compliant cell transportation, manufacturing, storage, and
distribution services and supporting clinical trial design, product
process development, logistics, regulatory and quality systems
development services.&#xA0;&#xA0;In addition, through its network
of contacts throughout the cell therapy industry, PCT is able to
identify early stage development opportunities in the cell therapy
field and opportunistically develop these cell therapies through
proof of concept where they can be further developed and ultimately
commercialized through NeoStem&#x2019;s developing commercial
structure. Dr. Preti now serves as PCT's President and Chief
Scientific Officer and Dr. Pecora as Chief Medical Officer of
NeoStem and PCT.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PCT
is engaged in a broad range of services in the cell therapy market
for the treatment of human disease, including but not limited to
contract manufacturing, product and process development, product
and regulatory consulting, and product characterization and
comparability.&#xA0;&#xA0;PCT&#x2019;s expertise in the cell therapy
space, which includes therapeutic vaccines (oncology), various
related cell therapeutics, cell diagnostics, and regenerative
medicine, creates a platform upon which NeoStem intends to build a
therapeutics strategy.&#xA0;&#xA0;NeoStem&#x2019;s goal is to
develop internally, or through partnerships, allogeneic (cells from
a third-party donor) or autologous (cells from oneself) cell
therapeutics technologies that, in the aggregate, comprise the Cell
Therapy &#x2013; United States reportable segment.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
addition, PCT has assumed NeoStem&#x2019;s adult stem cell business
based on PCT&#x2019;s strategic advantages in meeting cGMP
regulatory requirements in an industry that is widely dispersed
with a range of quality issues.&#xA0;&#xA0;NeoStem believes that
PCT, as a quality leader, is ideally positioned to become a leader
in cell collection, processing and storage (cell banking) which is
synergistic with NeoStem&#x2019;s roots in this
business.&#xA0;&#xA0;In addition, PCT&#x2019;s leadership in the
transportation and distribution of cell therapy products is
complementary to NeoStem&#x2019;s strategic vision of working with
the industry leader as the partner of choice.&#xA0;&#xA0;These
efforts are being bundled together into a new service with
PCT&#x2019;s cord blood banking business into a multigenerational
stem cell collection and storage plan that the Company calls the
&#x201C;Family Plan&#x201D;.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the terms of the PCT Merger Agreement, all of the membership
interests of PCT outstanding immediately prior to the effective
time of the PCT Merger were converted into the right to receive, in
the aggregate, (i) 10,600,000 shares of the common stock, par value
$0.001 per share, of NeoStem (the &#x201C;NeoStem Common
Stock&#x201D;) (reflecting certain final price adjustments agreed to
at the closing) and (ii) warrants to purchase an aggregate
3,000,000 shares of NeoStem Common Stock as follows:</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(i)</font></div>
</td>
<td valign="top" width="83%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">common
stock purchase warrants to purchase one million (1,000,000) shares
of NeoStem Common Stock, exercisable over a seven year period at an
exercise price of $7.00 per share (the &#x201C;$7.00
Warrants&#x201D;), and which will vest only if a specified business
milestone (described in the PCT Merger Agreement) is accomplished
within three (3) years of the Closing Date of the PCT Merger;
and</font></div>
</td>
</tr>
</table>
</div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(ii)</font></div>
</td>
<td valign="top" width="83%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">common
stock purchase warrants to purchase one million (1,000,000) shares
of NeoStem Common Stock exercisable over a seven year term at an
exercise price of $3.00 per share (the &#x201C;$3.00
Warrants&#x201D;); and</font></div>
</td>
</tr>
</table>
</div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(iii)</font></div>
</td>
<td valign="top" width="83%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">common
stock purchase warrants to purchase one million (1,000,000) shares
of NeoStem Common Stock exercisable over a seven year period at an
exercise price of $5.00 per share (the &#x201C;$5.00 Warrants&#x201D;
and, collectively with the $7.00 Warrants and the $3.00 Warrants,
the &#x201C;Warrants&#x201D;).</font></div>
</td>
</tr>
</table>
</div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Warrants are redeemable in certain
circumstances.&#xA0;&#xA0;Transfer of the shares issuable upon
exercise of the Warrants is restricted until the one year
anniversary of the Closing Date.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
accordance with the PCT Merger Agreement, NeoStem has deposited
into an escrow account with the escrow agent (who is initially
NeoStem&#x2019;s transfer agent), 10,600,000 shares of NeoStem
Common Stock for eventual distribution to the former members of PCT
(subject to downward adjustment to satisfy any indemnification
claims of NeoStem, all as described in the PCT Merger
Agreement).&#xA0;&#xA0;As of September 30, 2011, approximately
974,000 shares have been distributed to the former members of
PCT.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
issuance of NeoStem securities in the PCT Merger was approved at a
special meeting of shareholders of NeoStem held on January 18, 2011
(the &#x201C;NeoStem Special Meeting&#x201D;), on which date the PCT
Merger was also approved at a special meeting of members of
PCT.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
fair value of the net assets acquired in the PCT Merger was
$12,416,200. The fair value of the equity issued as consideration
by NeoStem was valued at $17,200,000 resulting in the recognition
of goodwill in the amount of $4,783,600. The fair value of the
equities issued by NeoStem included 10,600,000 shares of NeoStem
Common stock valued at $15,900,000 and NeoStem warrants to purchase
up to 3,000,000 shares valued at $1,966,200.&#xA0;&#xA0;A portion
of the consideration paid is contingent upon the accomplishment of
a certain milestone for the $7.00 Warrants.&#xA0;&#xA0;Such
contingent consideration has been classified as equity and will not
be subject to remeasurement.&#xA0;&#xA0;The goodwill that has been
created by this acquisition is reflective of values and
opportunities of utilizing PCT&#x2019;s cell collection, processing
and storage (cell banking) resources and production capacities, as
mentioned above.</font></div>
</div>
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#xA0;</font></div>
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
preliminary fair value of assets acquired and liabilities assumed
on January 19, 2011 is as follows:</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
</div>
<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="40%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">227,900</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts
Receivable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">442,400</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other
Current Assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">166,200</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Property,
Plant &amp; Equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,769,000</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Intangibles</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,100,000</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Goodwill</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,783,600</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other
Assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">654,100</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="72%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts
Payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,370,900</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other
Liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">540,500</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred
Revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">247,400</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amount
Due Related Party</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,000,000</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Mortgages
Payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,784,600</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div>&#xA0;</div>
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
total cost of the acquisition, which is still preliminary, has been
allocated to the assets acquired and the liabilities assumed based
upon their estimated fair values at the date of the acquisition.
&#xA0;It is expected the goodwill will be deductible for income tax
purposes.&#xA0;&#xA0;As of September 30, 2011, the preliminary fair
values of the deferred tax liabilities were reduced to zero, from
an initial estimate of $4.3 million, due to the finalization of the
tax treatment of the transaction. As a result, the tax provision
for the nine months ended September 30, 2011 reflects a $178,000
adjustment related to the portion of deferred tax liability
recognized in the first and second quarters of fiscal 2011. In
addition, the fair value of the equity issued as consideration by
NeoStem was reduced by $666,200. The net effect of the updated
values reduced the preliminary goodwill by $4.9 million. This
estimated purchase price allocation continues to be subject to
revision based on additional valuation work that is being
conducted.&#xA0; The final allocation is pending the receipt of
this valuation work and the completion of the Company&#x2019;s
internal review, which is expected during fiscal 2011.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
the period since the acquisition (January 19-September 30, 2011),
NeoStem recorded $5,571,500 in revenues and a net loss of
approximately $4,043,300 or $0.05 basic and diluted loss per share
attributable to PCT.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
following supplemental table presents unaudited consolidated pro
forma financial information as if the closing of the acquisition of
PCT had occurred on January 1, 2010 (in thousands, except per share
amounts):</font></div>
</div>
<div>&#xA0;</div>
<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="6" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
Nine Months Ended September 30,</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="6" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
Three Months Ended September 30,</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="6" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
Nine Months Ended September 30,</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
2011</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
2011</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
2010</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
2010</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
2010</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
2010</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
(As Reported)</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
(Proforma)</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
(As Reported)</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
(Proforma)</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
(As Reported)</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
(Proforma)</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">55,858</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">56,240</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">16,476</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">18,883</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">51,716</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">57,575</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Cost
of revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">41,637</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">41,961</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">11,233</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">12,996</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">35,016</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">39,561</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Gross
profit</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">14,221</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">14,279</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">5,243</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">5,887</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">16,701</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">18,014</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Research
and development</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">7,767</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">7,767</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,680</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,679</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">5,114</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">5,111</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Selling,
general, and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">31,829</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">32,218</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">9,307</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">10,905</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">23,442</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">28,120</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Operating
loss</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(25,375</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(25,706</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(5,744</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(6,696</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(11,855</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(15,217</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Other
income (expense), net</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(1,447</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(1,482</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">35</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(47</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">6</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(208</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Loss
from operations before provision for income taxes and</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">noncontrolling
interests</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(26,821</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(27,187</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(5,709</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(6,743</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(11,849</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(15,425</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Provision
for income taxes</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">908</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">908</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">286</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">286</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,191</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,191</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net
loss</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(27,729</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(28,905</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(5,995</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(7,029</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(13,040</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(16,616</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Less
&#x2013; net income attributable to noncontrolling
interests</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">559</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">559</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,146</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,146</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">4,086</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">4,086</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Preferred
dividends</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">508</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">508</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">154</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">154</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net
loss attributable to NeoStem, Inc. common shareholders</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(28,796</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(29,162</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(7,140</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(8,175</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(17,280</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(20,855</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Basic
and diluted loss per share</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(0.35</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(0.35</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(0.13</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(0.12</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(0.36</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(0.35</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="34%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Weighted
average common shares outstanding</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">82,775</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">83,513</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">56,777</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">67,377</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">48,599</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">59,199</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div>&#xA0;</div>
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
unaudited supplemental pro forma financial information should not
be considered indicative of the results that would have occurred if
the PCT Merger had been consummated on January 1, 2010, nor are
they indicative of future results.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Athelos
Corporation (&#x201C;Athelos&#x201D;) is a subsidiary of PCT pursuing
the development of T regulatory cells (TRegs) as a therapeutic to
treat disorders of the immune system.&#xA0; Pursuant to a Stock
Purchase and Assignment Agreement dated March 28, 2011, Athelos
issued approximately 20% of its shares to Becton Dickinson and
Company (&#x201C;BD&#x201D;) in exchange for the rights to certain
intellectual property relating to TRegs that BD owned pursuant to a
license agreement between the University of Pennsylvania
(&#x201C;Penn&#x201D;) and BD dated September 28, 2005 (the
&#x201C;Penn License&#x201D;), and a license agreement between ExCell
Therapeutics, LLC and BD dated September 16, 2005, as amended
August 31, 2007 (the &#x201C;ExCell License&#x201D;).&#xA0; Pursuant
to a Stock Purchase and Assignment Agreement dated March 28, 2011,
Athelos took assignment from BD of its rights and obligations under
the Penn License and the ExCell License, including, among other
things, obligations to pay royalties on net sales of licensed
products, maintenance fees and milestones on initiation of clinical
trial stages, license application filings and regulatory
approvals.&#xA0; As expressly anticipated by the parties, Athelos
replaced the assignment of the Penn License with two new direct
licenses: The Amended and Restated Patent License Agreement between
Penn and Athelos dated September 12, 2011, and the Patent License
Agreement between Penn, Athelos and the University of Minnesota
dated September 12, 2011. Athelos and ExCell are in the process of
negotiating a direct license that would replace the existing
assigned ExCell License.&#xA0;&#xA0;Pursuant to the
Stockholders&#x2019; Agreement dated March 28, 2011, Athelos, PCT
and BD have agreed, that, among other things, BD will have certain
anti-dilution protection for the first $5 million of new investment
in Athelos and certain&#xA0; board of directors&#x2019; observer
rights.&#xA0;&#xA0; BD has assigned to Athelos, and Athelos
assumed, all rights, title, interest and obligations of BD under a
consulting agreement dated as of September 16, 2005 between David
Horwitz, M.D. and BD, to be paid retroactively beginning as of
January 1, 2011, for services rendered in advancing the Athelos
TReg research and development platform<font style="DISPLAY: inline; FONT-STYLE: italic">.</font>&#xA0;&#xA0;PCT had
preliminarily valued BD&#x2019;s share of the contributed
intellectual properties in the quarter ended March 31, 2011 at
$927,000 and characterized this acquired intangible asset as
in-process research and development which has been recorded as
expense within research and development expense.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
the quarter ended September 30, 2011, PCT finalized its valuation
of the intellectual properties received, and revised the fair value
to $1,150,000, which is recorded as expense within research and
development expense for the nine months ended September 30,
2011.</font></div>
</div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 141<br /><br /> -Paragraph 51, 52<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 805<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1500-128463<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 805<br /><br /> -SubTopic 30<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e7000-128479<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 805<br /><br /> -SubTopic 30<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e6927-128479<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 805<br /><br /> -SubTopic 30<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e7008-128479<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 805<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1490-128463<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 805<br /><br /> -SubTopic 30<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e6996-128479<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 805<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4922-128472<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 805<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4934-128472<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 141R<br /><br /> -Appendix F<br /><br /> -Paragraph F4<br /><br /> -Subparagraph e<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 805<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4926-128472<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 805<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1383-128463<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 805<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1392-128463<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 805<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1497-128463<br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 141R<br /><br /> -Paragraph 67-73<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 16: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 805<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 7<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1524-128463<br /><br /><br /><br />Reference 17: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 88-16<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 18: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 805<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1486-128463<br /><br /><br /><br />Reference 19: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 805<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_BusinessCombinationDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets</a></td><td class="text"><div>
<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 5
&#x2013; Goodwill and Other Intangible Assets</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
changes in the carrying amount of goodwill by reportable segment
during nine months ended September 30, 2011 were as follows (in
thousands):</font></div>
</div>
<div>&#xA0;</div>
<div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="75%">
<tr>
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="14%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="14%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pharmaceutical</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="14%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="14%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cell
Therapy -</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="14%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacturing
-</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="14%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="14%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">United
States</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="14%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">China</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="14%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
Total</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance
as of December 31, 2010</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="13%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="13%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,002.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="13%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,002.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acquisitions*</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="13%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,783.6</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="13%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="13%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,783.6</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Foreign
currency exchange rate changes</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">801.1</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">801.1</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance
as of September 30, 2011</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,783.6</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,803.1</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32,586.7</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*Goodwill
associated with the PCT Merger</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="13%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="13%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="13%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div>&#xA0;</div>
<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As
of September 30, 2011 and December 31, 2010, the Company&#x2019;s
intangible assets and related accumulated amortization consisted of
the following (in thousands):</font></div>
</div>
<div>&#xA0;</div>
<div>
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="23%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="11%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="31%" colspan="10" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">September
30, 2011</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="31%" colspan="10" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">December
31, 2010</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Accumulated</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Accumulated</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="23%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="11%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Useful
Life</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Gross</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Amortization</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" colspan="2" nowrap="nowrap" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Net</font></font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Gross</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Amortization</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Net</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="23%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Customer
list</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="11%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">10
Years</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">19,666.3</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(3,598.6</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">16,067.7</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">17,740.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(2,069.7</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">15,670.3</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="23%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Manufacturing
technology</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="11%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">10
Years</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">10,251.3</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(1,247.4</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">9,003.9</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">4,220.6</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(492.4</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">3,728.2</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="23%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Tradename</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="11%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">10
Years</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">2,313.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(284.8</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">2,028.2</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">983.9</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(114.8</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">869.1</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="23%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">In
process R&amp;D</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="11%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Indefinite</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">1,779.9</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">1,779.9</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">2,219.6</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">2,219.6</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="23%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Standard
operating procedures</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="11%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">10
Years</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">1,098.4</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(210.5</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">887.9</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">1,066.8</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(124.5</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">942.3</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="23%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Lease
rights</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="11%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">2
Years</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">841.4</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(806.4</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">35.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">817.2</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(476.7</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">340.5</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="23%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">VSEL
patent rights</font></div>
</td>
<td style="TEXT-ALIGN: center" valign="bottom" width="11%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">19
Years</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">669.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(132.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">537.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">669.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(105.6</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">563.4</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="23%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Patents</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="11%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">8
Years</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">203.1</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(81.2</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">121.9</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">164.4</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(31.2</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">133.2</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="23%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Total
Intangible Assets</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="11%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">36,822.4</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(6,360.9</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">30,461.5</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">27,881.5</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(3,414.9</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">24,466.6</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div>&#xA0;</div>
<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
2011, Erye commenced sales of two products that were previously
accounted for as In Process R&amp;D which has resulted in a
reclassification of approximately $505,500 from In Process R&amp;D
to Manufacturing Technology.&#xA0;&#xA0;Certain of the
Company&#x2019;s intangible assets are recorded on the books of
wholly owned or partially owned subsidiaries and affiliates in
China, and denominated in RMB. &#xA0;As a result, the balance
reported fluctuates based upon the changes in exchange
rates.</font></div>
</div>
<div>&#xA0;</div>
<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
connection with the acquisition of PCT, the following intangible
assets were acquired (in thousands):</font></div>
</div>
<div>&#xA0;</div>
<div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="65%">
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="77%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Customer
list</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="20%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,400.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="77%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacturing
technology</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="20%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,400.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="77%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tradename</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,300.0</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="77%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,100.0</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Total
intangible amortization expense was classified in the operating
expense categories for the periods included below as follows (in
thousands):</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
</div>
<div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="85%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="28%" colspan="6" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Three
Months Ended September 30,</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="28%" colspan="6" nowrap="nowrap" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nine
Months Ended September 30,</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
2010</font></font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
2010</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Cost of revenue</font></font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">388.1</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">87.1</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,126.4</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">259.8</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Research and development</font></font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13.8</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">401.3</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">41.4</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,185.6</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Selling, general and administrative</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">547.9</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,611.4</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.8</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
Total</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">949.8</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">488.4</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,779.2</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,454.2</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div>&#xA0;</div>
<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Estimated
intangible amortization expense on an annual basis for the
succeeding five years is as follows (in thousands):</font></div>
</div>
<div>&#xA0;</div>
<div>
<div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="25%">
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="45%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td valign="bottom" width="8%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="45%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">880.1</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="45%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td valign="bottom" width="8%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="45%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,380.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="45%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>
</td>
<td valign="bottom" width="8%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="45%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,380.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="45%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2014</font></div>
</td>
<td valign="bottom" width="8%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="45%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,380.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="45%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2015</font></div>
</td>
<td valign="bottom" width="8%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="45%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,380.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="45%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Thereafter</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="8%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,061.4</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="45%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="8%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,461.5</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
</div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 350<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 350<br /><br /> -SubTopic 30<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16265-109275<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 142<br /><br /> -Paragraph 42, 43, 44, 45, 46, 47<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 350<br /><br /> -SubTopic 30<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16373-109275<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 350<br /><br /> -SubTopic 30<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 350<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13854-109267<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td><td class="text"><div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 13
&#x2013; Commitments and Contingencies</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company leases office and laboratory facilities and certain
equipment under certain noncancelable operating leases that expire
from time to time through 2015.&#xA0;&#xA0;A summary of future
minimum rental payments required under operating leases that have
initial or remaining terms in excess of one year as of September
30, 2011 are as follows (in thousands):</font></div>
</div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">
Lease Commitments:</font></div>
</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: center" align="left">
<table cellpadding="0" cellspacing="0" width="30%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: center;">
<td valign="bottom" width="60%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Years
ended</font></div>
</td>
<td align="right" valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" colspan="2" nowrap="nowrap" valign="bottom" width="37%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Operating
Leases</font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="35%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">383.8</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012</font></div>
</td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="35%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1259.1</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2013</font></div>
</td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="35%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">898.3</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2014</font></div>
</td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="35%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">629.5</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2015</font></div>
</td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="35%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">587.0</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="60%" style="PADDING-BOTTOM: 2px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thereafter</font></div>
</td>
<td align="right" valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="2%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="35%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">857.2</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="60%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total
minimum lease payments</font></div>
</td>
<td align="right" valign="bottom" width="2%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="2%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="35%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,614.9</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Expense
incurred under operating leases was approximately $535,300 and
$1,672,600 for the three and nine months ended September 30, 2011,
respectively, and $522,800 and $1,139,400 for the three and nine
months ended September 30, 2010, respectively.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">
Contingencies:</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
license agreements with third parties the Company is typically
required to pay maintenance fees, make milestone payments and/or
pay other fees and expenses and pay royalties upon
commercialization of products.&#xA0; The Company also sponsors
research at various academic institutions, which research
agreements generally provide us with an option to license new
technology discovered during the course of the sponsored
research.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
connection with the issuance to investors and service providers of
many of the shares of the Company&#x2019;s common stock and warrants
to purchase common stock previously disclosed and described herein,
the Company granted the holders registration rights providing for
the registration of such shares of common stock and shares of
common stock underlying warrants on a registration statement to be
filed with the Securities and Exchange Commission
(&#x201C;SEC&#x201D;) so as to permit the resale of those shares.
Certain of the registration rights agreements provided for
penalties for failure to file or failure to obtain an effective
registration statement. With respect to satisfying its obligations
to the holders of these registration rights, the Company has been
in various situations. The Company had previously filed a
registration statement as required for some of the holders, and in
May 2011 filed a registration statement for all of the holders
(except for holders whose shares of Common Stock were currently
salable under Rule 144 of the Securities Act or who waived certain
rights); such registration statement was declared effective by the
SEC on September 30, 2011. The Company has certain obligations to
maintain the effectiveness of this registration
statement.&#xA0;&#xA0;Certain holders who had outstanding
registration rights had previously waived their registration rights
or were subject to lock-up agreements. No holder has yet asserted
any claim against the Company with respect to a failure to satisfy
any registration obligations. Were someone to assert a claim
against the Company for breach of registration obligations, the
Company believes it has several defenses that would result in
relieving it from some or any liability, although no assurances can
be given. The Company also notes that damage claims may be limited,
as (i) most shares of Common Stock as to which registration rights
attached are either now registered or currently salable under Rule
144 of the Securities Act or are otherwise currently subject to
other restrictions on sale and (ii) the shares of Common Stock
underlying warrants with registration rights are now registered,
and during much of the relevant periods the warrants with
registration rights generally have been out of the money, were
subject to lock-up agreements and/or the underlying shares of
Common Stock were otherwise subject to restrictions on resale.
Accordingly, were holders to assert claims against the Company
based on breach of the Company&#x2019;s obligation to register, the
Company believes that the Company&#x2019;s maximum exposure would
not be material.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Xiangbei Welman Pharmaceutical Co., Ltd. v Suzhou Erye
Pharmaceutical Co., Ltd. and Hunan Weichu Pharmacy Co.,
Ltd.</font>&#xA0;&#xA0;involves a patent infringement dispute with
respect to a particular antibiotics complex manufactured by Erye
(the &#x201C;Product&#x201D;). The Changsha Intermediate
People&#x2019;s Court in Hunan Province, PRC in the foregoing case
rendered a judgment on May 13, 2010 against Erye as follows: (i)
awarding plaintiff Xiangbei Welman damages and costs of
approximately 5 million RMB (approximately $778,500) against Erye
which was fully accrued for at September 30, 2011; and (ii)
enjoining Erye from manufacturing, marketing and selling the
Product. On March 21, 2011, Changsha Intermediate Court issued a
civil decision suspending the execution of the Preliminary
Injunction. Therefore, Erye is currently free to produce, sell or
offer to sell the product.&#xA0;&#xA0;Following the filing of the
patent infringement dispute, in 2009 Xiangbei Welman brought a
copyright infringement lawsuit against Erye claiming the package
inserts with respect to the Product infringed upon their copyright
and Erye was enjoined from copying and using the package inserts on
the Product and selling the Product with the package inserts and
Xiangbei Welman was awarded 50,000 RMB, or approximately
$7,800.&#xA0; &#xA0;In July 2011, a new copyright infringement
lawsuit was brought by Xiangbei Welman against Erye claiming that
Erye was not complying with the earlier judgment enjoining them
from copying and using the package inserts for the Product. The
Changsha Intermediate Court was applied to for property
preservation and it issued a civil decision freezing Erye&#x2019;s
bank deposits of up to 50 million RMB, or approximately $7.8
million, or sealing up or detaining Erye&#x2019;s other properties
of equal value. Currently this case is pending.&#xA0;&#xA0;As of
September 30, 2011, approximately 13,744,700 RMB (approximately
$2,140,000) of cash had been frozen in six bank accounts, and is
classified in Other Assets.&#xA0;&#xA0;Erye is working with their
counsel to respond.&#xA0;&#xA0;Erye has contended that jurisdiction
is not proper.&#xA0;&#xA0;A similar action was recently instituted
by Welman against Erye in the Guangzhou Intermediate Court to (i)
enjoin Erye from copying and using the package inserts from the
Product and selling the drugs with the aforesaid package inserts
and; (ii) award Welman economic losses of approximately 2,000,000
RMB (approximately $312,400) against Erye and the case is being
reviewed by the Court. Welman made an application for preliminary
injunction to prohibit Erye from copying and using the package
inserts from the Product and selling the drugs with the aforesaid
package inserts and Welman's application was denied by the Court on
September 6, 2011.&#xA0;&#xA0;Welman subsequently obtained a
preliminary injunction from a lower court Guangzhou Haizhu District
People&#x2019;s Court in Guangzhou Province, PRC (the &#x201C;Haizhu
District Court&#x201D;)&#xA0;on September 14, 2011.&#xA0;&#xA0;But
on October 28, 2011, upon the appeal by Erye, the Haizhu District
Court issued a decision withdrawing the preliminary
injunction.&#xA0; The Company cannot reasonably assess the
possibility of additional exposure above the amounts previously
accrued as of September 30, 2011.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Chinese regulatory approvals</font> &#x2013; The Company has
determined that it did not obtain all Chinese regulatory approvals
(and associated registrations) required to reflect the legal title
of its interest in Erye as being held by the proper entity within
our group which is its current beneficial owner as that term is
used under U.S. law.&#xA0; The Company believes it has now
determined what governmental approvals (and associated
registrations) will need to be issued by the Suzhou Municipal
Bureau of Foreign Investment and Commerce and the Suzhou
Administration for Industry and Commerce to remediate these
deficiencies and the Company has had counsel in China prepare these
filings.&#xA0; The Company&#x2019;s management believes these
regulatory deficiencies can be remediated within a reasonable
period of time and should not delay a possible divestiture of the
Company&#x2019;s interests in Erye that is currently under
evaluation.&#xA0; However, the Company requires the cooperation of
the officers of Erye, as to which no assurance can be given, and we
could be compelled to seek to replace those officers or&#xA0;to
commence legal action to obtain the required consents or otherwise
move forward with requisite filings.&#xA0; In addition, even if the
filings are made, no assurance can be given that any unremediated
regulatory deficiencies would not have an adverse effect on the
operating results and liquidity of Erye and the Company and will
not impede or delay efforts to divest the Company&#x2019;s interest
in Erye.&#xA0; In addition, the remediation process is expected to
trigger certain tax liabilities and penalties, however the ultimate
liability will be based on future discussions with the relevant
Chinese authorities.&#xA0;&#xA0;The Company cannot reasonably
assess the exposure as of September 30, 2011.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Amorcyte line of credit &#x2013;</font> On May&#xA0;19, 2006, PCT
entered into a line of credit agreement with Amorcyte Inc.
(&#x201C;Amorcyte&#x201D;), an entity which was spun out of PCT in
2006, whereby PCT agreed to loan Amorcyte up to $500,000 at an
annual interest rate of 5%.&#xA0; The line of credit agreement was
a condition to Amorcyte closing a Series A Preferred Stock
Financing completed during 2006.&#xA0; The Company has not loaned
any amount to Amorcyte under this agreement through September 30,
2011.&#xA0;&#xA0;The line of credit agreement expires on the
earlier of (i)&#xA0;the date on which the Company declares the
outstanding principal and accrued interest due and payable based on
an event of default as defined within the agreement, or
(ii)&#xA0;the date of closing of the first debt or equity financing
of Amorcyte following the initial borrowing of the principal. These
events have not occurred to date.&#xA0;&#xA0;On October 17, 2011,
the Company acquired Amorcyte pursuant to the Amorcyte Agreement
and Plan of Merger, and this line of credit was
cancelled.&#xA0;&#xA0;&#xA0; (See Note 14).</font></div>
</div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 450<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 460<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 8<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name FASB Interpretation (FIN)<br /><br /> -Number 14<br /><br /> -Paragraph 3<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 440<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 5<br /><br /> -Paragraph 9, 10, 11, 12<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.25)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 825<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td><td class="text"><div>
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="bottom" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">
<font style="DISPLAY: inline">Note 6&#x2013; Accrued
Liabilities</font></font></div>
</td>
</tr>
<tr>
<td valign="bottom" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued
liabilities are as follows (in thousands):</font></div>
</td>
</tr>
</table>
</div>
<div>&#xA0;</div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="65%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="65%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="15%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
September 30, 2011</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="15%" colspan="2" nowrap="nowrap" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
December 31, 2010</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="65%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">VAT
and other taxes</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="14%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,081.1</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="14%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">126.6</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="65%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Salaries,
employee benefits and related taxes</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="14%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">911.8</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="14%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">210.6</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="65%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amount
due on patent infringement</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="14%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">770.3</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="14%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">758.5</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="65%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,099.8</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,676.3</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="65%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,863.0</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,772.0</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 19<br /><br /> -Subparagraph a<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 20, 24<br /><br /> -Article 5<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.19(a),20,24)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E6VAI"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br /></strong></div></th><th class="th" colspan="2">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Sep. 30, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td><td class="num">$ (27,728,736)<span /></td><td class="num">$ (13,040,282)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Common stock, stock options and warrants issued as payment for compensation, services rendered and interest expense</a></td><td class="nump">8,164,814<span /></td><td class="nump">7,399,842<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td><td class="nump">6,754,953<span /></td><td class="nump">2,556,994<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss on short term investments</a></td><td class="text">&#xA0;<span /></td><td class="nump">7,215<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of preferred stock discount and issuance cost</a></td><td class="nump">1,903,703<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Changes in fair value of derivative liability</a></td><td class="num">(1,661,049)<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Write off of acquired in-process research and development</a></td><td class="nump">1,150,000<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Loss on disposal of assets</a></td><td class="nump">396,635<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td><td class="nump">328,425<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashContributionExpense', window );">Charitable contributions paid with common stock</a></td><td class="nump">607,363<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td><td class="nump">50,024<span /></td><td class="nump">16,311<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td><td class="num">(678,211)<span /></td><td class="num">(182,417)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of the effect of acquisitions:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td><td class="num">(647,674)<span /></td><td class="num">(461,743)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td><td class="num">(2,489,064)<span /></td><td class="nump">1,278,573<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td><td class="nump">3,136,189<span /></td><td class="num">(1,405,838)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned revenues</a></td><td class="num">(1,361,697)<span /></td><td class="num">(392,040)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td><td class="num">(2,014,566)<span /></td><td class="num">(128,225)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities', window );">Accounts payable, accrued expenses and other current liabilities</a></td><td class="num">(3,433,540)<span /></td><td class="nump">1,175,902<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td><td class="num">(17,522,431)<span /></td><td class="num">(3,175,708)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash received in acquisition of PCT</a></td><td class="nump">227,942<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of short-term investments</a></td><td class="num">(27)<span /></td><td class="num">(2,424,132)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from short-term investments</a></td><td class="text">&#xA0;<span /></td><td class="nump">2,452,015<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of property and equipment</a></td><td class="num">(5,453,931)<span /></td><td class="num">(12,510,648)<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td><td class="num">(3,127,902)<span /></td><td class="num">(11,019,055)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbs_ProceedsFromStockOptionAndWarrantExcercises', window );">Net proceeds from the exercise of options and warrants</a></td><td class="nump">7,100<span /></td><td class="nump">3,101,850<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from issuance of capital stock</a></td><td class="nump">21,167,682<span /></td><td class="nump">13,138,948<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Payment from related party</a></td><td class="nump">644,414<span /></td><td class="nump">566,775<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayment of mortgage loan</a></td><td class="num">(109,492)<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromBankDebt', window );">Proceeds of bank loan</a></td><td class="nump">6,149,000<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Repayment of bank loan</a></td><td class="num">(1,557,000)<span /></td><td class="num">(2,203,650)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td><td class="nump">10,950,616<span /></td><td class="nump">13,256,799<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td><td class="num">(17,154,753)<span /></td><td class="num">(16,644,465)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of debt to related party</a></td><td class="num">(3,406,043)<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock', window );">Repayment of preferred stock</a></td><td class="num">(175,000)<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividend</a></td><td class="text">&#xA0;<span /></td><td class="num">(222,924)<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td><td class="nump">16,516,524<span /></td><td class="nump">10,993,333<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Impact of changes of foreign exchange rates</a></td><td class="nump">234,756<span /></td><td class="nump">108,754<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease)/increase in cash and cash equivalents</a></td><td class="num">(3,899,053)<span /></td><td class="num">(3,092,676)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td><td class="nump">15,612,391<span /></td><td class="nump">7,159,369<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td><td class="nump">11,713,338<span /></td><td class="nump">4,066,693<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbs_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid during the period for:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td><td class="nump">1,238,400<span /></td><td class="nump">219,376<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Taxes</a></td><td class="nump">1,463,100<span /></td><td class="nump">1,784,325<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbs_NoncashInvestingActivitiesAbstract', window );"><strong>Supplemental Schedule of non-cash investing activities</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbs_SupplementalPropertyAndEquipmentNet', window );">Acquisition of property and equipment</a></td><td class="text">&#xA0;<span /></td><td class="nump">348,488<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidCapitalized', window );">Capitalized interest</a></td><td class="nump">235,700<span /></td><td class="nump">307,200<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbs_NoncashFinancingActivitiesAbstract', window );"><strong>Supplemental schedule of non-cash financing activities</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbs_CommonStockIssuedToAcquireBusinesses', window );">Common stock and warrants issued with the acquisition of PCT</a></td><td class="nump">17,200,000<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock', window );">Common stock issued pursuant to the redemption of Convertible Redeemable Series E 7% Preferred Stock</a></td><td class="nump">2,785,400<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbs_DividendOnPreferredStockSharesOfCommonStockIssuable', window );">Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock</a></td><td class="nump">622,500<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbs_SupplementalDeferredFinancingCosts', window );">Financing costs for capital stock raises</a></td><td class="text">&#xA0;<span /></td><td class="nump">75,466<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Convertible Redeemable Series C Preferred Stock</a></td><td class="text">&#xA0;<span /></td><td class="nump">13,720,048<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbs_SupplementalDividendsFromSubsidiaries', window );">Dividend to Related Party reinvested as loan payable</a></td><td class="nump">11,726,100<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rh"><td class="pl" style="border-bottom: 0px;" valign="top"><div class="a">Notes payable</div></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash used as collateral</a></td><td class="nump">2,098,114<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rh"><td class="pl" style="border-bottom: 0px;" valign="top"><div class="a">Bank loans</div></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash used as collateral</a></td><td class="text">&#xA0;<span /></td><td class="nump">$ 1,463,710<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbs_CashPaidDuringPeriodForAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During Period For [Abstract]</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nbs_CashPaidDuringPeriodForAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nbs</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbs_CommonStockIssuedToAcquireBusinesses"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issued To Acquire Businesses</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nbs_CommonStockIssuedToAcquireBusinesses</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nbs</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbs_DividendOnPreferredStockSharesOfCommonStockIssuable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend On Preferred Stock, Shares Of Common Stock Issuable</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nbs_DividendOnPreferredStockSharesOfCommonStockIssuable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nbs</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in the aggregate amount of accounts payable accrued expenses and other liabilities incurred but not paid.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nbs</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock In Exchange For Convertible Preferred Stock</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nbs_IssuanceOfCommonStockInExchangeForConvertiblePreferredStock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nbs</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbs_NoncashFinancingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Financing Activities [Abstract]</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nbs_NoncashFinancingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nbs</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbs_NoncashInvestingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Investing Activities [Abstract]</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nbs_NoncashInvestingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nbs</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbs_ProceedsFromStockOptionAndWarrantExcercises"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options and warrants.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nbs_ProceedsFromStockOptionAndWarrantExcercises</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nbs</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbs_SupplementalDeferredFinancingCosts"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Deferred financing costs</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nbs_SupplementalDeferredFinancingCosts</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nbs</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbs_SupplementalDividendsFromSubsidiaries"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Dividends from Subsidiaries</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nbs_SupplementalDividendsFromSubsidiaries</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nbs</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbs_SupplementalPropertyAndEquipmentNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Property And Equipment Net</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nbs_SupplementalPropertyAndEquipmentNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nbs</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The component of interest expense representing the noncash expenses charged against earnings in the period to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include Noncash Interest Expense.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AmortizationOfFinancingCostsAndDiscounts</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15, 16, 17<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 12<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAcquiredFromAcquisition</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.1)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 1<br /><br /> -Article 5<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 7<br /><br /> -Footnote 1<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 8, 9<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Cash<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 7, 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Cash Equivalents<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 32<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ConversionOfStockAmountConverted1</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Deferred Tax Expense (or Benefit)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 08<br /><br /> -Paragraph h<br /><br /> -Article 4<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /> -Number Topic 6<br /><br /> -Section I<br /><br /> -Subsection 7<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 109<br /><br /> -Paragraph 45<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 109<br /><br /> -Paragraph 289<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 9<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.4-08.(h))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SAB TOPIC 6.I.7)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6889476&amp;loc=d3e330036-122817<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredIncomeTaxExpenseBenefit</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 5<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 360<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DepreciationAndAmortization</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash balances held in foreign currencies.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 25<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 830<br /><br /> -SubTopic 230<br /><br /> -Section 45<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any gains (losses) realized during the period from the sale of investments accounted for under the cost method of accounting and losses recognized for other than temporary impairments (OTTI) of the subject investments.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.7(c),9(a))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 320<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 9<br /><br /> -Subparagraph (c)-(e)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27357-111563<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 115<br /><br /> -Paragraph 13, 22<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 7<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 320<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 10<br /><br /> -Subparagraph (c)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27405-111563<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_GainLossOnInvestments</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) included in results of operations resulting from the sale or disposal of other assets.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_GainLossOnSaleOfOtherAssets</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 25<br /><br /> -Subparagraph (f)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 29<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 27<br /><br /> -Subparagraph f<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeTaxesPaid</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingAssets</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 13<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15, 16, 17<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 12<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInRestrictedCash</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 29<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 25<br /><br /> -Subparagraph (e)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_InterestPaid</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidCapitalized"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period for interest that is capitalized.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 29<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 25<br /><br /> -Subparagraph (e)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_InterestPaidCapitalized</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from financing activity for the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 26<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from investing activity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 26<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 25<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashContributionExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash charitable contributions made by the entity during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NoncashContributionExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaidInKindInterest</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire preferred stock during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 15<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 20<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the entity's earnings to the shareholders.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 15<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 20<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsOfDividends</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15, 17<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 13<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsToAcquireInvestments</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 13<br /><br /> -Subparagraph (c)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 17<br /><br /> -Subparagraph c<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromBankDebt"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from bank borrowing during the year.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 14<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 19<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromBankDebt</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 14<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 19<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 14<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 19<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromNotesPayable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 14<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 19<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromRelatedPartyDebt</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 31<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 12<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 16<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 115<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 55<br /><br /> -Paragraph 4J<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591551-111686<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph A1, A4, A5<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph c(1)<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 29<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1A<br /><br /> -Subparagraph (a),(c)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=SL4573702-111684<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 55<br /><br /> -Paragraph 4K<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591552-111686<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 5<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 19<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569616-111683<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProfitLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.5)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 5<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProvisionForDoubtfulAccounts</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 15<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 20<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RepaymentsOfBankDebt</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 15<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 20<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 15<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 20<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RepaymentsOfRelatedPartyDebt</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 15<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 20<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RepaymentsOfSecuredDebt</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 730<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name FASB Interpretation (FIN)<br /><br /> -Number 4<br /><br /> -Paragraph 5<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 141<br /><br /> -Paragraph 51<br /><br /> -Subparagraph g<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 2<br /><br /> -Paragraph 13<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ResearchAndDevelopmentInProcess</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_UnrealizedGainLossOnDerivatives</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td><td class="text"><div>
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 2
&#x2013; Summary of Significant Accounting
Policies</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Basis of Presentation:</font> The accompanying unaudited
Consolidated Financial Statements have been prepared in accordance
with accounting principles generally accepted in the United States
of America (&#x201C;generally accepted accounting principles&#x201D;)
for interim financial information and with the instructions to Form
10-Q and Article 10 of Regulation S-X of the Securities and
Exchange Commission for interim financial information. Accordingly,
they do not include all of the information and footnotes required
by generally accepted accounting principles for complete financial
statements. In the opinion of management, the accompanying
Consolidated Financial Statements of the Company and its
subsidiaries, which are unaudited, include all normal and recurring
adjustments considered necessary to present fairly the
Company&#x2019;s financial position as of September 30, 2011 and the
results of its operations and its cash flows for the periods
presented. The unaudited consolidated financial statements herein
should be read together with the historical consolidated financial
statements of the Company for the years ended December 31, 2010,
2009 and 2008 included in our Annual Report on Form 10-K for the
year ended December 31, 2010.&#xA0;&#xA0;Operating results for the
three and nine month periods ended September 30, 2011 are not
necessarily indicative of the results that may be expected for the
year ending December&#xA0;31, 2011.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Use of Estimates:</font>&#xA0;&#xA0;The preparation of financial
statements in conformity with accounting principles generally
accepted in the United States of America requires management to
make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and
liabilities at the date of the consolidated financial statements.
Estimates also affect the reported amounts of revenues and expenses
during the reporting period. Accordingly, actual results could
differ from those estimates.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">
Concentration of Risks:</font>&#xA0;&#xA0;For the&#xA0;three and
nine months ended September 30, 2011, three major suppliers
provided approximately&#xA0;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">29</font>%
and <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28</font>%,
respectively, of Erye&#x2019;s purchases of raw
materials.&#xA0;&#xA0;As of September 30, 2011, the total accounts
payable to the three major suppliers represented <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14</font>%
of the total accounts payable balance.</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
the three and nine months ended September 30, 2010, two major
suppliers provided approximately 17% and 20%, respectively, of
Erye&#x2019;s purchases of raw material.&#xA0;&#xA0;As of December
31, 2010, the total accounts payable to the two major suppliers
was&#xA0;18% of the total accounts payable.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Approximately
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">80</font>%
of Erye&#x2019;s revenues are derived from products that use
penicillin or cephalosporin as the key active ingredient. These
products are manufactured on two of the eight production lines in
Erye&#x2019;s manufacturing facility. Any issues or incidents that
might disrupt the manufacturing of products requiring penicillin or
cephalosporin could have a material impact on the operating results
of Erye. Any interruption or cessation in production could impact
market sales.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
addition, over 70% of these drugs are on China&#x2019;s essential
drug list and any policies that might lower the pricing of these
drugs and any policies that could reduce the consumption of these
drugs could have a material impact on operating
results.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
</div>
</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Inventories:</font>&#xA0;&#xA0;Inventories are stated at the
approximate lower of cost or market using the first-in, first-out
basis. The Company reviews its inventory periodically and will
reduce inventory to its net realizable value depending on certain
factors, such as product demand, remaining shelf life, future
marketing plans, obsolescence and slow-moving
inventories.&#xA0;&#xA0;The Company includes in work in process the
cost incurred on projects at PCT that have multiple deliverables
and therefore cannot be recognized as revenue until the project is
completed. The Company reviews these projects periodically to
determine that the value of each project is stated at the lower of
cost or market.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inventories
consisted of the following (in thousands):</font></div>
</div>
<div>&#xA0;</div>
<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="66%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September
30, 2011</font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December
31, 2010</font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="66%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
Raw materials and supplies</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,839.8</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,043.8</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="66%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
Work in process</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,136.5</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,792.4</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
Finished goods</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,606.0</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,187.2</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
Total inventory</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,582.3</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21,023.4</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div>&#xA0;</div>
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Income Taxes:</font>&#xA0;&#xA0;The Company recognizes (a) the
amount of taxes payable or refundable for the current year and (b)
deferred tax liabilities and assets for the future tax consequences
of events that have been recognized in the Company&#x2019;s
financial statements or tax returns. The Company continues to
evaluate the accounting for uncertainty in tax positions. The
guidance requires companies to recognize in their financial
statements the impact of a tax position if the position is more
likely than not of being sustained on audit. The position
ascertained inherently requires judgment and estimates by
management. As of September 30, 2011, management does not believe
the Company has any material uncertain tax positions that would
require it to measure and reflect the potential lack of
sustainability of a position on audit in its financial statements.
The Company will continue to evaluate its uncertain tax positions
in future periods to determine if measurement and recognition in
its financial statements is necessary. The Company does not believe
there will be any material changes in its unrecognized tax
positions over the next year.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify">The Company classifies taxes related to witholding
taxes paid on dividends declared by Erye to the Company that are
reinvested into Erye as general and administrative expense.</div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company recognizes interest and penalties as a component of income
tax expense. There were no interest and penalties recognized for
the three and nine months ended September 30, 2011 and 2010,
respectively.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company files income tax returns with the U.S. Federal government
and various state and foreign jurisdictions. The statute of
limitations has expired on all consolidated U.S. Federal corporate
income tax returns filed through 2006, and the Internal Revenue
Service is not currently examining any of the post-2006 returns
filed by the Company.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Comprehensive Income (Loss):</font>&#xA0;&#xA0;The accumulated
other comprehensive income (loss) balance at September 30, 2011 and
December 31, 2010 in the amount of approximately $5,001,600 and
$2,779,100, respectively, is comprised entirely of foreign currency
translation adjustments. Comprehensive loss for the three and nine
months ended September 30, 2011 and 2010 was as follows (in
thousands):</font></div>
</div>
<div>&#xA0;</div>
<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="6" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Three Months Ended September 30,</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="6" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Nine Months Ended September 30,</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net
loss</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,328.5</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,994.6</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(27,728.7</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(13,040.3</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other
comprehensive (loss)/income</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Foreign currency translation</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">712.1</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,483.4</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,222.6</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,651.1</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total
other comprehensive (loss)/income</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">712.1</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,483.4</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,222.6</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,651.1</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Comprehensive
(loss)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,616.4</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,511.2</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(25,506.1</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,389.2</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Comprehensive (loss)/income attributable to noncontrolling
interests</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">366.9</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,864.0</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,648.1</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,877.8</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Comprehensive
loss attributable to NeoStem, Inc.</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,983.3</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,375.2</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(27,154.2</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(16,267.0</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr>
</table>
</div>
</div>
<div>&#xA0;</div>
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Goodwill and Other Intangible Assets:</font>&#xA0;&#xA0;Goodwill is
the excess of purchase price over the fair value of identified net
assets of businesses acquired. The Company&#x2019;s intangible
assets with an indefinite life are related to in process research
and development at Erye, as the Company expects this research and
development to provide the Company with substantial benefit for a
period that extends beyond the foreseeable horizon. Amortized
intangible assets consist of Erye&#x2019;s customer list,
manufacturing technology, standard operating procedures, tradename,
lease rights and patents, as well as patents and rights associated
primarily with the&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;VSEL <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font>
Technology. These intangible assets are amortized on a straight
line basis over their respective useful lives.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company reviews goodwill and indefinite-lived intangible assets at
least annually for possible impairment. Goodwill and
indefinite-lived intangible assets are reviewed for possible
impairment between annual tests if an event occurs or circumstances
change that would more likely than not reduce the fair value of the
reporting unit below its carrying value. The Company tests its
goodwill and indefinite-lived intangible assets for its Cell
Therapy&#xA0;&#x2013;&#xA0;United States, and its Pharmaceutical
Manufacturing&#xA0;&#x2013;&#xA0;China reporting units on October
31. The Company reviews the carrying value of goodwill and
indefinite-lived intangible assets utilizing a discounted cash flow
model, and, where appropriate, a market value approach is also
utilized to supplement the discounted cash flow model. The Company
makes assumptions regarding estimated future cash flows, discount
rates, long-term growth rates and market values to determine each
reporting unit&#x2019;s estimated fair value. If these estimates or
related assumptions change in the future, the Company may be
required to record impairment charges.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Derivatives:</font>&#xA0;&#xA0;Derivative instruments, including
derivative instruments embedded in other contracts, are recorded on
the balance sheet as either an asset or liability measured at its
fair value. Changes in the fair value of derivative instruments are
recognized currently in results of operations unless specific hedge
accounting criteria are met. The Company has not entered into
hedging activities to date. As a result of certain financings (see
Note 8), derivative instruments were created that are measured at
fair value and marked to market at each reporting period. Changes
in the derivative value are recorded as other income (expense) on
the consolidated statements of operations.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Evaluation of Long-lived Assets:</font>&#xA0;&#xA0;The Company
reviews long-lived assets and finite-lived intangibles assets for
impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset exceeds the fair value of the
asset. If other events or changes in circumstances indicate that
the carrying amount of an asset that the Company expects to hold
and use may not be recoverable, the Company will estimate the
undiscounted future cash flows expected to result from the use of
the asset or its eventual disposition, and recognize an impairment
loss. The impairment loss, if determined to be necessary, would be
measured as the amount by which the carrying amount of the assets
exceeds the fair value of the assets.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Share-Based Compensation:</font>&#xA0;&#xA0;The Company expenses
all share-based payment awards to employees, directors, advisors
and consultants, including grants of stock options, warrants, and
restricted stock, over the requisite service period based on the
grant date fair value of the awards. Advisor and consultant awards
are remeasured each reporting period through vesting. For awards
with performance-based vesting criteria, the Company estimates the
probability of achievement of the performance criteria and
recognizes compensation expense related to those awards expected to
vest. The Company determines the fair value of certain share-based
awards using the Black-Scholes option-pricing model which uses both
historical and current market data to estimate the fair value. This
method incorporates various assumptions such as the risk-free
interest rate, expected volatility, expected dividend yield and
expected life of the options or warrants. The fair value of the
Company&#x2019;s restricted stock and restricted stock units is
based on the closing market price of the Company&#x2019;s common
stock on the date of grant. See Note 9.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Loss Per Share:</font>&#xA0;&#xA0;Basic loss per share is based on
the weighted effect of all common shares issued and outstanding,
and is calculated by dividing net loss attributable to common
shareholders by the weighted average shares outstanding during the
period. Diluted loss per share, which is calculated by dividing net
loss attributable to common shareholders by the weighted average
number of common shares used in the basic loss per share
calculation plus the number of common shares that would be issued
assuming conversion of all potentially dilutive securities
outstanding, is not presented as such potentially dilutive
securities are anti-dilutive in all periods presented. For the
three and nine months ended September 30, 2011 and 2010, the
Company incurred net losses and therefore no common stock
equivalents were utilized in the calculation of loss per share. At
September 30, 2011 and 2010, the Company excluded the following
potentially dilutive securities:</font></div>
</div>
<div>&#xA0;</div>
<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="66%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="6" nowrap="nowrap" valign="bottom" width="32%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September
30,</font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="66%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
2011</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
2010</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="66%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock
Options</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,749,895</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,558,214</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="66%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,208,817</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,352,028</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="66%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series
E Preferred Stock, Common stock equivalents</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,693,730</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div>&#xA0;</div>
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Revenue Recognition:</font> The Company recognizes revenue from
pharmaceutical and pharmaceutical intermediary product sales when
title has passed, the risks and rewards of ownership have been
transferred to the customer, the fee is fixed and determinable, and
the collection of the related receivable is reasonably assured
which is at the time of delivery. The Company recognizes revenue
for its cell development and manufacturing services based on the
terms of individual contracts.&#xA0;&#xA0;In certain cases, there
are multiple elements that cannot be considered separate
deliverables and therefore the Company recognizes revenue on a
completed contract basis for these arrangements. In other cases,
the Company is paid for time and materials or for fixed monthly
amounts and revenue is recognized when efforts are expended or
contractual terms have been met.&#xA0;&#xA0;The Company recognizes
revenue related to the collection and cryopreservation of cord
blood and autologous adult stem cells when the cryopreservation
process is completed which is twenty four hours after cells have
been collected. Revenue related to advance payments of storage fees
is recognized ratably over the period covered by the advance
payments. The Company earns revenue, in the form of license fees,
from physicians seeking to establish autologous adult stem cell
collection centers. These license fees are typically billed upon
signing of the collection center agreement and qualification of the
physician by the Company&#x2019;s credentialing committee and at
various times during the term of license agreements based on the
terms of the specific agreement. These fees are recognized as
revenue ratably over the appropriate period of time to which the
revenue element relates. The Company also receives licensing fees
from a licensee for use of its technology and knowledge to operate
an adult stem cell banking operation in China, which licensing fees
are recognized as revenues ratably over the appropriate period of
time to which the revenue element relates. In addition, the Company
earns royalties for the use of its name and scientific information
in connection with its License and Referral Agreement with
Ceregenex Corporation, which royalties are recognized as revenue
when they are received.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenues
for the three and nine months ended September 30, 2011 and 2010
were comprised of the following (in thousands):</font></div>
</div>
<div>&#xA0;</div>
<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" colspan="6" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three
Months Ended September 30,</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="6" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine
Months Ended September 30,</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
2010</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
2010</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revenues</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Prescription drugs and intermediary pharmaceutical
products</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,513.0</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,384.5</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,806.0</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">51,528.7</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Stem cell related service revenues</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,529.1</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">91.1</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,266.9</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">187.6</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="48%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Stem cell related services - reimbursed
expenses</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">714.0</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,785.1</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="48%" style="PADDING-BOTTOM: 4px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,756.1</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,475.6</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">55,858.0</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">51,716.3</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div>&#xA0;</div>
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Fair Value Measurements:</font>&#xA0;&#xA0;Fair value of financial
assets and liabilities that are being measured and reported are
defined as the exchange price that would be received to sell an
asset or paid to transfer a liability in an orderly transaction
between market participants in the principal market at the
measurement date (exit price). The Company is required to classify
fair value measurements in one of the following
categories:</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
1 inputs which are defined as quoted prices (unadjusted) in active
markets for identical assets or liabilities that the reporting
entity has the ability to access at the measurement
date.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
2 inputs which are defined as inputs other than quoted prices
included within Level 1 that are observable for the assets or
liabilities, either directly or indirectly.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
3 inputs are defined as unobservable inputs for the assets or
liabilities. Financial assets and liabilities are classified based
on the lowest level of input that is significant to the fair value
measurement. The Company&#x2019;s assessment of the significance of
a particular input to the fair value measurement requires judgment,
and may affect the valuation of the fair value of assets and
liabilities and their placement within the fair value hierarchy
levels.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company determined the fair value of funds invested in short term
investments, which are considered trading securities, to be level 1
inputs measured by quoted prices of the securities in active
markets. The Company determined the fair value of funds invested in
money market funds to be level 1. The Company determined the fair
value of the embedded derivative liabilities and warrant derivative
liabilities to be level 3 inputs. These inputs require material
subjectivity because value is derived through the use of a lattice
model that values the derivatives based on probability weighted
discounted cash flows. The following table sets forth by level
within the fair value hierarchy the Company&#x2019;s financial
assets and liabilities that were accounted for at fair value on a
recurring basis as of September 30, 2011, and December 31, 2010 (in
thousands):</font></div>
</div>
<div>&#xA0;</div>
<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="85%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="10" nowrap="nowrap" valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
September 30, 2011</font></font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="10" nowrap="nowrap" valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Fair Value Measurements Using Fair Value
Hierarchy</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Level 1</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Level 2</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Level 3</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Money
market investments</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,500.8</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Short
term investments</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.6</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Embedded
derivative liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">783.4</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrant
derivative liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">126.9</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="9" valign="bottom" width="45%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December
31, 2010</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="10" nowrap="nowrap" valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Fair Value Measurements Using Fair Value
Hierarchy</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Level 1</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Level 2</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Level 3</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Money
market investments</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,501.0</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Short
term investments</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.5</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Embedded
derivative liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,281.8</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrant
derivative liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">289.6</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div>&#xA0;</div>
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subsequent
to December 31, 2010 the Company reevaluated the characteristics of
the money market savings account, currently recorded as other
assets, and determined it is not tied to underlying securities and
has been reclassified to level 1.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
those financial instruments with significant Level 3 inputs, the
following table summarizes the activity for the three and nine
months ended September 30, 2011 by type of instrument (in
thousands):</font></div>
</div>
<div>&#xA0;</div>
<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="87%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="6" nowrap="nowrap" valign="bottom" width="24%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For
the Three Months Ended</font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="6" nowrap="nowrap" valign="bottom" width="24%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For
the Nine Months Ended</font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="6" nowrap="nowrap" valign="bottom" width="24%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September
30, 2011</font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="6" nowrap="nowrap" valign="bottom" width="24%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September
30, 2011</font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Embedded</font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Embedded</font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Derivatives</font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Derivatives</font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" nowrap="nowrap" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Beginning
liability balance</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,933.7</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">342.3</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,281.8</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">289.6</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Change
in fair value recorded in earnings</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,150.3</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(215.4</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,498.4</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(162.7</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Ending
liability balance</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">783.4</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">126.9</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">783.4</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">126.9</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div>&#xA0;</div>
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Some
of the Company&#x2019;s financial instruments are not measured at
fair value on a recurring basis, but are recorded at amounts that
approximate fair value due to their liquid or short-term nature,
such as cash and cash equivalents, restricted cash, accounts
receivable, accounts payable, notes payable and&#xA0;bank
loans.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Foreign Currency Translation:</font>&#xA0;&#xA0;As the
Company&#x2019;s Chinese pharmaceutical business is a self-contained
and integrated entity, and the Company&#x2019;s Chinese stem cell
business&#x2019; future cash flow is intended to be sufficient to
service its additional financing requirements, the Chinese
subsidiaries&#x2019; functional currency is the Renminbi
(&#x201C;RMB&#x201D;), and the Company&#x2019;s reporting currency is
the US dollar. Results of foreign operations are translated at the
average exchange rates during the period, and assets and
liabilities are translated at the closing rate at the end of each
reporting period. Cash flows are also translated at average
exchange rates for the period, therefore, amounts reported on the
consolidated statement of cash flows will not necessarily agree
with changes in the corresponding balances on the consolidated
balance sheet.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Research and Development Costs:</font>&#xA0;&#xA0;Research and
development (&#x201C;R&amp;D&#x201D;) expenses include salaries,
benefits, and other headcount related costs, clinical trial and
related clinical manufacturing costs, contract and other outside
service fees including sponsored research agreements, and
facilities and overhead costs. The Company expenses the costs
associated with research and development activities when
incurred.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
further drive the Company&#x2019;s cell therapy initiatives, the
Company will continue targeting key governmental agencies,
congressional committees and not-for-profit organizations to
contribute funds for the Company&#x2019;s research and development
programs. The Company accounts for government grants as a deduction
to the related expense in research and development operating
expenses when earned.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">
Statutory Reserves:</font>&#xA0;&#xA0;Pursuant to laws applicable
to entities incorporated in the PRC, the PRC subsidiaries are
prohibited from distributing their statutory capital and are
required to appropriate from PRC GAAP profit after tax to other
non-distributable reserve funds. These reserve funds include one or
more of the following: (i) a general reserve, (ii) an enterprise
expansion fund and (iii) a staff bonus and welfare fund. Subject to
certain cumulative limits (i.e., 50% of the registered capital of
the relevant company), the general reserve fund requires annual
appropriation at 10% of after tax profit (as determined under
accounting principles generally accepted in the PRC at each
year-end); the appropriation to the other funds are at the
discretion of the subsidiaries.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
general reserve is used to offset extraordinary losses. Subject to
approval by the relevant authorities, a subsidiary may, upon a
resolution passed by the shareholders, convert the general reserve
into registered capital provided that the remaining general reserve
after the conversion shall be at least 25% of the registered
capital of the subsidiary before the capital increase as a result
of the conversion. The staff welfare and bonus reserve is used for
the collective welfare of the employees of the subsidiary. The
enterprise expansion reserve is for the expansion of the
subsidiary&#x2019;s operations and can also be converted to
registered capital upon a resolution passed by the shareholders
subject to approval by the relevant authorities. These reserves
represent appropriations of the retained earnings determined in
accordance with Chinese law, and are not distributable as cash
dividends to the parent company, NeoStem. Statutory reserves are
$2,300,900 and $2,234,600 as of September 30, 2011 and December 31,
2010, respectively.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Relevant
PRC statutory laws and regulations permit payment of dividends by
the Company&#x2019;s PRC subsidiaries only out of their accumulated
earnings, if any, as determined in accordance with PRC accounting
standards and regulations. As a result of these PRC laws and
regulations, the Company&#x2019;s PRC subsidiaries are restricted in
their ability to transfer a portion of their net assets either in
the form of dividends, loans or advances. The restricted amount was
$184,500 at September 30, 2011 and $214,200 at December 31,
2010.</font></div>
</div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 22<br /><br /> -Paragraph 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 11
&#x2013; Segment Information</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.3pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company&#x2019;s financial information broken down by reportable
segment was as follows (in thousands):</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="28%" colspan="6" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Three
Months Ended September 30,</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="28%" colspan="6" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Nine Months Ended September 30,</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="40%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Revenues</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Pharmaceutical Manufacturing - China</font></font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,513.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,384.5</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">49,806.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">51,528.7</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Cell Therapy - United States</font></font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,177.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">61.1</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,837.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">157.6</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Regenerative Medicine - China</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">66.1</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30.0</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">215.0</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30.0</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,756.1</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,475.6</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">55,858.0</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">51,716.3</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="40%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Loss from operations</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Pharmaceutical Manufacturing - China</font></font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">717.9</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap">&#xA0;</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,552.6</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,480.1</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,302.3</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Cell Therapy - United States</font></font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,996.1</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,304.6</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9,957.7</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,917.2</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Regenerative Medicine - China</font></font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(681.8</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(321.9</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,847.1</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,058.7</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
Corporate office</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,420.3</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,669.9</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(17,049.7</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13,181.4</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7,380.3</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,743.8</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(25,374.4</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(11,855.0</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="40%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Total assets</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">September
30, 2011</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="13%" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
December 31, 2010</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Pharmaceutical Manufacturing - China</font></font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">124,045.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">125,458.1</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Cell Therapy - United States</font></font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,445.4</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,101.9</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Regenerative Medicine - China</font></font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,640.0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,949.8</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
Corporate office</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,084.3</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,514.9</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">168,214.7</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">143,024.7</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 280<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 12<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8595-108599<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 280<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 10<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8538-108599<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 280<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 33<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8971-108599<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 280<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 34<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8981-108599<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 280<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 29<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8864-108599<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 280<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8380-108599<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 280<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 35<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8984-108599<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 280<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 41<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9038-108599<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 280<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 32<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8933-108599<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 131<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 280<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 30<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8906-108599<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 280<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 26<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8844-108599<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 280<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 40<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9031-108599<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 280<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 42<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9054-108599<br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 280<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 31<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8924-108599<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SegmentReportingDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E4OBG"><tr><th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (USD $)<br /></strong></div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td><td class="nump">$ 11,713,338<span /></td><td class="nump">$ 15,612,391<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short term investments</a></td><td class="nump">555<span /></td><td class="nump">512<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td><td class="nump">1,427,827<span /></td><td class="nump">3,381,369<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable trade, net of allowance for doubtful accounts of $437,443 and $210,977, respectively</a></td><td class="nump">8,944,803<span /></td><td class="nump">5,871,474<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td><td class="nump">20,582,284<span /></td><td class="nump">21,023,388<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetCurrent', window );">Deferred income taxes</a></td><td class="nump">621,105<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td><td class="nump">1,808,695<span /></td><td class="nump">993,711<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td><td class="nump">45,098,607<span /></td><td class="nump">46,882,845<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td><td class="nump">49,571,589<span /></td><td class="nump">36,998,241<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Land use rights, net</a></td><td class="nump">4,870,549<span /></td><td class="nump">4,807,834<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td><td class="nump">32,586,656<span /></td><td class="nump">27,002,044<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td><td class="nump">30,461,547<span /></td><td class="nump">24,466,597<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td><td class="nump">5,625,734<span /></td><td class="nump">2,867,188<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets, Total</a></td><td class="nump">168,214,682<span /></td><td class="nump">143,024,749<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td><td class="nump">9,896,278<span /></td><td class="nump">14,286,929<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td><td class="nump">5,863,031<span /></td><td class="nump">2,772,019<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableToBankCurrent', window );">Bank loans</a></td><td class="nump">7,810,000<span /></td><td class="nump">3,034,000<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td><td class="nump">3,766,272<span /></td><td class="nump">9,568,398<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebtCurrent', window );">Mortgages payable - current</a></td><td class="nump">187,935<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td><td class="nump">589,230<span /></td><td class="nump">1,242,911<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesCurrent', window );">Deferred income taxes</a></td><td class="nump">338,054<span /></td><td class="nump">232,075<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Unearned revenues</a></td><td class="nump">3,066,851<span /></td><td class="nump">1,708,280<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td><td class="nump">31,517,651<span /></td><td class="nump">32,844,612<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term Liabilities</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred income taxes</a></td><td class="nump">5,655,744<span /></td><td class="nump">5,959,508<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent liability</a></td><td class="nump">10,743<span /></td><td class="nump">45,489<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Unearned revenues</a></td><td class="nump">180,808<span /></td><td class="nump">282,518<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Mortgages payable</a></td><td class="nump">3,487,175<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td><td class="nump">910,318<span /></td><td class="nump">2,571,367<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Amount due related parties</a></td><td class="nump">20,534,147<span /></td><td class="nump">8,301,361<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td><td class="nump">30,778,935<span /></td><td class="nump">17,160,243<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Redeemable Securities</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Convertible Redeemable Series E Preferred Stock; 10,582,011 shares designated, liquidation value $1.00 per share; issued and outstanding 7,838,527 and 10,582,011 shares, at September 30, 2011 and December 31, 2010, respectively</a></td><td class="nump">5,475,567<span /></td><td class="nump">6,532,275<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmount', window );">Temporary Equity, Carrying Amount, Total</a></td><td class="nump">5,475,567<span /></td><td class="nump">6,532,275<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2011 and December 31, 2010</a></td><td class="nump">100<span /></td><td class="nump">100<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 100,361,443 and 64,221,130 shares, at September 30, 2011 and December 31, 2010, respectively</a></td><td class="nump">100,361<span /></td><td class="nump">63,813<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td><td class="nump">192,575,872<span /></td><td class="nump">141,137,522<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td><td class="num">(124,116,505)<span /></td><td class="num">(95,320,620)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td><td class="nump">5,001,635<span /></td><td class="nump">2,779,066<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total NeoStem, Inc. shareholders' equity</a></td><td class="nump">73,561,463<span /></td><td class="nump">48,659,881<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td><td class="nump">26,881,066<span /></td><td class="nump">37,827,738<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td><td class="nump">100,442,529<span /></td><td class="nump">86,487,619<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and Equity, Total</a></td><td class="nump">$ 168,214,682<span /></td><td class="nump">$ 143,024,749<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.19(a))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccountsPayableCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 3<br /><br /><br /><br /> -Subparagraph a(1)<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.3-4)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 15<br /><br /><br /><br /> -Subparagraph b(1)<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 9<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 15<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 20<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 109<br /><br /><br /><br /> -Section Appendix E<br /><br /><br /><br /> -Paragraph 289<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Interpretation (FIN)<br /><br /><br /><br /> -Number 48<br /><br /><br /><br /> -Paragraph 15, 21<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccruedIncomeTaxesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 20<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 220<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 13<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 130<br /><br /><br /><br /> -Paragraph 14, 17, 26<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Staff Position (FSP)<br /><br /><br /><br /> -Number FAS115-1/124-1<br /><br /><br /><br /> -Paragraph 15D<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 220<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 11<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 04<br /><br /><br /><br /> -Article 3<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 220<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 14<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e681-108580<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.30(a)(1))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 12<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Concepts (CON)<br /><br /><br /><br /> -Number 6<br /><br /><br /><br /> -Paragraph 25<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 18<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.18)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_Assets</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 3<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 9<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.9)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AssetsCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 7<br /><br /><br /><br /> -Footnote 1<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 230<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 8, 9<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (a)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Cash<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 7, 26<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Cash Equivalents<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 942<br /><br /><br /><br /> -SubTopic 210<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.9-03.17)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 17<br /><br /><br /><br /> -Article 9<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 25<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 944<br /><br /><br /><br /> -SubTopic 210<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.7-03.(a),19)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 450<br /><br /><br /><br /> -SubTopic 20<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 5<br /><br /><br /><br /> -Paragraph 8, 9<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.25)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 30<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.26(c))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Technical Bulletin (FTB)<br /><br /><br /><br /> -Number 85-3<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 13<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /> -Subparagraph b<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 840<br /><br /><br /><br /> -SubTopic 20<br /><br /><br /><br /> -Section 25<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (a)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6453417&amp;loc=d3e39927-112707<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredRentCreditNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -Subparagraph (b)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 7, 8<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /><br /><br /> -Number Topic 13<br /><br /><br /><br /> -Section A<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 605<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 605<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -Subparagraph (b)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 7, 8<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /><br /><br /> -Number Topic 13<br /><br /><br /><br /> -Section A<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 48<br /><br /><br /><br /> -Paragraph 6<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of the aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference. An unrecognized tax benefit that is directly related to a position taken in a tax year that results in a net operating loss carryforward is presented as a reduction of the related deferred tax asset.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 740<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (b)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 740<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 5<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31928-109318<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 109<br /><br /><br /><br /> -Paragraph 41, 42, 43<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 740<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 9<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31958-109318<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 740<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31917-109318<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 740<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 6<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31931-109318<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredTaxAssetsNetCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the current portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A current taxable temporary difference is a difference between the tax basis and the carrying amount of a current asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise separates deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, is classified according to the expected reversal date of the temporary difference.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 740<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31917-109318<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 740<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 6<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31931-109318<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 109<br /><br /><br /><br /> -Paragraph 41, 42, 43<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 740<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 9<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31958-109318<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 740<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 740<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 6<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredTaxLiabilitiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise separates deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 740<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 9<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31958-109318<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 109<br /><br /><br /><br /> -Paragraph 41, 42<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 740<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31917-109318<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 740<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 6<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31931-109318<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredTaxLiabilitiesNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of after one year or beyond the normal operating cycle, if longer, net of the effects of master netting arrangements.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 815<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 6<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 107<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Staff Position (FSP)<br /><br /><br /><br /> -Number FIN39-1<br /><br /><br /><br /> -Paragraph 10A, 10B<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 7<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 815<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 5<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 825<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -Subparagraph (a)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 133<br /><br /><br /><br /> -Paragraph 4, 17<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 825<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 15<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13495-108611<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DerivativeLiabilitiesNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 235<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.4-08.(k)(1))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 850<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (d)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 4<br /><br /><br /><br /> -Section 08<br /><br /><br /><br /> -Paragraph k<br /><br /><br /><br /> -Subparagraph 1<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.23)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 57<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph d<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 23<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DueToRelatedPartiesNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 142<br /><br /><br /><br /> -Paragraph 45<br /><br /><br /><br /> -Subparagraph e<br /><br /><br /><br /> -Clause 1<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 142<br /><br /><br /><br /> -Paragraph 43<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 141R<br /><br /><br /><br /> -Paragraph 68<br /><br /><br /><br /> -Subparagraph l<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 142<br /><br /><br /><br /> -Paragraph 45<br /><br /><br /><br /> -Subparagraph e<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 141R<br /><br /><br /><br /> -Paragraph 34<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 350<br /><br /><br /><br /> -SubTopic 20<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 350<br /><br /><br /><br /> -SubTopic 20<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 141R<br /><br /><br /><br /> -Paragraph 72<br /><br /><br /><br /> -Subparagraph d<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_Goodwill</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 142<br /><br /><br /><br /> -Paragraph 42, 45<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 350<br /><br /><br /><br /> -SubTopic 30<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph ((a)(1),(b))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 350<br /><br /><br /><br /> -SubTopic 30<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.6(a))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 330<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 35<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (b)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_InventoryNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 32<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.32)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 25<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 21<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.21)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 22, 23, 24, 25, 26, 27<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.22-26)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableToBankCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 19, 20<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LoansPayableToBankCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.31)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 51<br /><br /><br /><br /> -Paragraph A3<br /><br /><br /><br /> -Appendix A<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 27<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 51<br /><br /><br /><br /> -Paragraph 38<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 20<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Number 51<br /><br /><br /><br /> -Paragraph 26<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_MinorityInterest</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 19, 20<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.19,20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NotesPayableCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 17<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.17)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net carrying amount as of the balance sheet date of other indefinite-lived and finite-lived intangible assets that are not separately presented on the statement of financial position.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherIntangibleAssetsNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 129<br /><br /><br /><br /> -Paragraph 2, 3, 4, 5, 6, 7, 8<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 505<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.3-04)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.28)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 04<br /><br /><br /><br /> -Article 3<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 29<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.13)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 13<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 5<br /><br /><br /><br /> -Subparagraph b, c<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 360<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Audit and Accounting Guide (AAG)<br /><br /><br /><br /> -Number AAG-BRD<br /><br /><br /><br /> -Chapter 4<br /><br /><br /><br /> -Paragraph 80<br /><br /><br /><br /> -Subparagraph Exhibit 4-8, 3<br /><br /><br /><br /> -IssueDate 2006-05-01<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.31(a)(3))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 04<br /><br /><br /><br /> -Article 3<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebtCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 19, 20<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SecuredDebtCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer), excluding the current portion, if any. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 22<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.22)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SecuredLongTermDebt</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph g<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.2)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ShortTermInvestments</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.29-31)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 51<br /><br /><br /><br /> -Paragraph A3<br /><br /><br /><br /> -Appendix A<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 29, 30, 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /><br /><br /> -Number Topic 4<br /><br /><br /><br /> -Section E<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 310<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SAB TOPIC 4.E)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquity</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of Stockholders' Equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity. This excludes temporary equity and is sometimes called permanent equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 810<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 16<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4568740-111683<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 810<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 55<br /><br /><br /><br /> -Paragraph 4I<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4590271-111686<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Number 51<br /><br /><br /><br /> -Paragraph 26<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 51<br /><br /><br /><br /> -Paragraph A3<br /><br /><br /><br /> -Appendix A<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 51<br /><br /><br /><br /> -Paragraph 25<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 810<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 15<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4568447-111683<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquityAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmount"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value (book value) of an entity's issued and outstanding stock which is not included within permanent equity in Stockholders Equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.27(b))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /><br /><br /> -Number D-98<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 4<br /><br /><br /><br /> -Section 08<br /><br /><br /><br /> -Paragraph i<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 28<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquityCarryingAmount</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of temporary equity outstanding, excluding additional paid in capital. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /><br /><br /> -Number D-98<br /><br /><br /><br /> -Paragraph 2,4,5,6<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 129<br /><br /><br /><br /> -Paragraph 2,3,4,5,6,7,8<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 4<br /><br /><br /><br /> -Section 08<br /><br /><br /><br /> -Paragraph d<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 28<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.3.0.15</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ReportType />
  <ContextCount>11</ContextCount>
  <ElementCount>149</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>true</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/DocumentDocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/StatementOfIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations</Role>
      <ShortName>The Company</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Recently Adopted Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDescriptionOfRecentAccountingPronouncementsTextBlock</Role>
      <ShortName>Recently Adopted Accounting Pronouncements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock</Role>
      <ShortName>Acquisitions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</Role>
      <ShortName>Accrued Liabilities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Bank Loans, Notes Payable and Mortgages Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock</Role>
      <ShortName>Bank Loans, Notes Payable and Mortgages Payable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock</Role>
      <ShortName>Preferred Stock</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Shareholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock</Role>
      <ShortName>Segment Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</Role>
      <ShortName>Related Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neostem.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 103 - Statement - CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>nbs-20110930.xml</File>
    <File>nbs-20110930.xsd</File>
    <File>nbs-20110930_cal.xml</File>
    <File>nbs-20110930_def.xml</File>
    <File>nbs-20110930_lab.xml</File>
    <File>nbs-20110930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>38
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7T)!3$%.0T5?4TA%1513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0T].4T],241!5$5$7T)!3$%.0T5?4TA%15137U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7U-4051%345.5%-?3T9?3U!%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%-?3T9?0T%3/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^5&AE7T-O;7!A
M;GD\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM
M87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#<N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y296-E;G1L>5]!9&]P=&5D7T%C8V]U;G1I
M;F=?4'(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!
M8W%U:7-I=&EO;G,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y';V]D=VEL;%]A;F1?3W1H97)?26YT86YG:6)L95\\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!8V-R=65D7TQI86)I;&ET
M:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0F%N
M:U],;V%N<U].;W1E<U]087EA8FQE7V%N9%]-/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$R+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4')E9F5R<F5D7U-T;V-K/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#$S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4VAA<F5H;VQD97)S7T5Q
M=6ET>3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN
M8V]M95]487AE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-E9VUE;G1?26YF;W)M871I;VX\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,38N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y296QA=&5D7U!A<G1Y7U1R86YS86-T:6]N<SPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE
M;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$X+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4W5B<V5Q=65N=%]%=F5N=',\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z17AC
M96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R:W-H
M965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z06-T
M:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O
M=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z
M4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\
M(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A
M9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!84"!O
M<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P131'044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C=6UE
M;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DYO=BX@,#@L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@26YF;W)M871I
M;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/C$P+5$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#YF86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N
M9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y397`@,S`L
M#0H)"3(P,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@
M4&5R:6]D($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y1
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5')A9&EN9R!3>6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/DY"4SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^3D5/4U1%32P@24Y#+CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-E;G1R
M86P@26YD97@@2V5Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XP
M,#`P,S(P,#$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!996%R($5N9"!$871E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XM+3$R+3,Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@1FEL
M97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E-M
M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL
M(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`W+#,R-"PU-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S$Q-C@Q-6-F7SDU.3-?-#!C85\Y9#<W7S0W.61F,3<V
M-F(U,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q,38X,35C9E\Y
M-3DS7S0P8V%?.60W-U\T-SED9C$W-C9B-3$O5V]R:W-H965T<R]3:&5E=#`R
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%-$]"1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#
M3TY33TQ)1$%4140@0D%,04Y#12!32$5%5%,@*%531"`F;F)S<#LD*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0W5R<F5N="!!<W-E=',\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`Q,2PW
M,3,L,S,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)FYB<W`[)"`Q-2PV,3(L,SDQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&]R="!T97)M(&EN=F5S=&UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-34\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M<W1R:6-T960@8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PT,C<L.#(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPS.#$L,S8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE('1R861E
M+"!N970@;V8@86QL;W=A;F-E(&9O<B!D;W5B=&9U;"!A8V-O=6YT<R!O9B`F
M;F)S<#LD-#,W+#0T,R!A;F0@)FYB<W`[)#(Q,"PY-S<L(')E<W!E8W1I=F5L
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PY-#0L.#`S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PX
M-S$L-#<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G9E;G1O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(P+#4X,BPR.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,2PP,C,L,S@X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!I;F-O;64@=&%X
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R,2PQ,#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M97!A:61S(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PX,#@L-CDU/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3DS+#<Q,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U
M<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M-2PP.3@L-C`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#8L.#@R+#@T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='DL('!L86YT(&%N9"!E<75I
M<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#DL
M-3<Q+#4X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,V+#DY."PR-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DQA;F0@=7-E(')I9VAT<RP@;F5T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#@W,"PU-#D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#@P-RPX,S0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=O;V1W:6QL/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,BPU
M.#8L-C4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C<L,#`R+#`T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^26YT86YG:6)L92!A<W-E=',L(&YE=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`L-#8Q+#4T-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T+#0V-BPU
M.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-2PV,C4L-S,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPX-C<L,3@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-S971S+"!4;W1A;#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38X+#(Q-"PV.#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#,L,#(T+#<T
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#=7)R96YT($QI86)I;&ET:65S/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL.#DV+#(W.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#(X
M-BPY,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L.#8S+#`S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S<R+#`Q.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%N:R!L;V%N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPX,3`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP,S0L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.;W1E<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#<V-BPR-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY+#4V."PS.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUO<G1G86=E<R!P87EA8FQE("T@
M8W5R<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@W+#DS
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YC;VUE('1A>&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4X.2PR,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#(T,BPY,3$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(&EN8V]M92!T
M87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,X+#`U-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S
M,BPP-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E5N96%R;F5D(')E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#`V-BPX-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<P."PR.#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT
M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,2PU,3<L-C4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S(L.#0T+#8Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,;VYG+71E<FT@3&EA8FEL
M:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5F97)R960@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#8U-2PW-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU+#DU.2PU,#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E;G0@
M;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PW
M-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT-2PT.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E5N96%R;F5D(')E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ.#`L.#`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C@R+#4Q.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36]R=&=A9V5S('!A>6%B
M;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-#@W+#$W-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5R:79A=&EV92!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3$P+#,Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L-3<Q+#,V-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT(&1U92!R96QA=&5D
M('!A<G1I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#4S
M-"PQ-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX+#,P,2PS-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L;VYG+71E<FT@;&EA8FEL:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#<W."PY,S4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPQ
M-C`L,C0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E)E9&5E;6%B;&4@4V5C=7)I=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!2961E96UA8FQE(%-E
M<FEE<R!%(%!R969E<G)E9"!3=&]C:SL@,3`L-3@R+#`Q,2!S:&%R97,@9&5S
M:6=N871E9"P@;&EQ=6ED871I;VX@=F%L=64@)FYB<W`[)#$N,#`@<&5R('-H
M87)E.R!I<W-U960@86YD(&]U='-T86YD:6YG(#<L.#,X+#4R-R!A;F0@,3`L
M-3@R+#`Q,2!S:&%R97,L(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,2!A;F0@1&5C
M96UB97(@,S$L(#(P,3`L(')E<W!E8W1I=F5L>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PT-S4L-38W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPU,S(L,C<U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&5M<&]R87)Y
M($5Q=6ET>2P@0V%R<GEI;F<@06UO=6YT+"!4;W1A;#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-2PT-S4L-38W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPU,S(L,C<U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-H87)E:&]L9&5R<R<@17%U:71Y/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:SL@875T:&]R:7IE
M9"P@,C`L,#`P+#`P,"!S:&%R97,@4V5R:65S($(@8V]N=F5R=&EB;&4@<F5D
M965M86)L92!P<F5F97)R960@<W1O8VL@;&EQ=6ED871I;VX@=F%L=64L(#$@
M<VAA<F4@;V8@8V]M;6]N('-T;V-K+"`F;F)S<#LD+C`Q('!A<B!V86QU93L@
M.#(U+#`P,"!S:&%R97,@9&5S:6=N871E9#L@:7-S=65D(&%N9"!O=71S=&%N
M9&EN9RP@,3`L,#`P('-H87)E<R!A="!397!T96UB97(@,S`L(#(P,3$@86YD
M($1E8V5M8F5R(#,Q+"`R,#$P/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@)FYB<W`[)"XP,#$@<&%R('9A
M;'5E+"!A=71H;W)I>F5D(#4P,"PP,#`L,#`P('-H87)E<SL@:7-S=65D(&%N
M9"!O=71S=&%N9&EN9RP@,3`P+#,V,2PT-#,@86YD(#8T+#(R,2PQ,S`@<VAA
M<F5S+"!A="!397!T96UB97(@,S`L(#(P,3$@86YD($1E8V5M8F5R(#,Q+"`R
M,#$P+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P,"PS-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV,RPX,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3(L-3<U+#@W,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T
M,2PQ,S<L-3(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D969I8VET/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q,C0L,3$V+#4P-2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y-2PS,C`L-C(P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M=6UU;&%T960@;W1H97(@8V]M<')E:&5N<VEV92!I;F-O;64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`Q+#8S-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S<Y+#`V-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L($YE;U-T96TL($EN8RX@<VAA<F5H;VQD97)S)R!E<75I='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<S+#4V,2PT-C,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT."PV-3DL.#@Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.;VYC;VYT<F]L;&EN9R!I;G1E<F5S=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(V+#@X,2PP-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-RPX,C<L-S,X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@97%U
M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L-#0R+#4R
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@V+#0X-RPV,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y,:6%B:6QI=&EE<R!A;F0@17%U:71Y+"!4;W1A;#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`Q-C@L,C$T
M+#8X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B9N8G-P.R0@,30S+#`R-"PW-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S$Q-C@Q-6-F7SDU.3-?-#!C85\Y9#<W7S0W
M.61F,3<V-F(U,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q,38X
M,35C9E\Y-3DS7S0P8V%?.60W-U\T-SED9C$W-C9B-3$O5V]R:W-H965T<R]3
M:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%0E!!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T
M<F]N9SY#3TY33TQ)1$%4140@0D%,04Y#12!32$5%5%,@*%!A<F5N=&AE=&EC
M86PI("A54T0@)FYB<W`[)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE('1R
M861E+"!A;&QO=V%N8V4@9F]R(&1O=6)T9G5L(&%C8V]U;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#0S-RPT-#,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD
M(#(Q,"PY-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;G9E<G1I8FQE(%)E9&5E;6%B;&4@4V5R:65S($4@4')E
M9F5R<F5D(%-T;V-K+"!S:&%R97,@9&5S:6=N871E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3`L-3@R+#`Q,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#4X,BPP,3$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E
M<G1I8FQE(%)E9&5E;6%B;&4@4V5R:65S($4@4')E9F5R<F5D(%-T;V-K+"!L
M:7%U:61A=&EO;B!V86QU92P@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XF;F)S<#LD(#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE
M(%)E9&5E;6%B;&4@4V5R:65S($4@4')E9F5R<F5D(%-T;V-K+"!I<W-U960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L.#,X+#4R-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#4X
M,BPP,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;G9E<G1I8FQE(%)E9&5E;6%B;&4@4V5R:65S($4@4')E9F5R
M<F5D(%-T;V-K+"!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-RPX,S@L-3(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3`L-3@R+#`Q,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K
M+"!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!397)I97,@
M0B!C;VYV97)T:6)L92!R961E96UA8FQE('!R969E<G)E9"!S=&]C:R!L:7%U
M:61A=&EO;B!V86QU92P@<VAA<F4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!P
M87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P
M.R0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B9N8G-P.R0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@
M9&5S:6=N871E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#(U
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@R-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@:7-S=65D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E
M9"!S=&]C:RP@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,"XP,#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF
M;F)S<#LD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL(&%U=&AO<FEZ960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,"PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`P+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!S=&]C:RP@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,#`L,S8Q+#0T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8T+#(R,2PQ,S`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:RP@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P,"PS-C$L-#0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C0L,C(Q+#$S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?,3$V.#$U8V9?.34Y,U\T,&-A7SED-S=?-#<Y
M9&8Q-S8V8C4Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$Q-C@Q
M-6-F7SDU.3-?-#!C85\Y9#<W7S0W.61F,3<V-F(U,2]7;W)K<VAE971S+U-H
M965T,#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5654%'/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D-/3E-/3$E$051%1"!35$%414U%3E13($]&($]015)!5$E/3E,@*%53
M1"`F;F)S<#LD*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3`\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#$W+#<U-BPQ-#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#$V
M+#0W-2PU-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XF;F)S<#LD(#4U+#@U-RPY.#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#4Q+#<Q-BPR-C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O<W0@;V8@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$S+#@T,"PW-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,2PR,S(L.#$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$L-C,V+#DU,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U+#`Q-2PU-#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y'<F]S<R!P<F]F:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L.3$U+#0P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4L,C0R+#<S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$T+#(R,2PP,S`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPW,#`L-S(P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E
M87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L-#@S+#(V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-C<Y+#DT-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-S8V+#DX.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,3$S+#0X-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4V5L;&EN9RP@9V5N97)A;"P@86YD(&%D;6EN:7-T<F%T:79E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#@Q,BPT-3@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#,P-BPV,C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PX
M,C@L-#4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C,L-#0R+#(X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!%>'!E;G-E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L,CDU+#<Q.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#DX-BPU-C<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M.2PU.34L-#,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C@L-34U+#<V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!L;W-S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#,X,"PS,3DI/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PW-#,L.#(X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(U
M+#,W-"PT,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,3$L.#4U+#`T.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W1H97(@:6YC;VUE("AE
M>'!E;G-E*3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W1H97(@:6YC;VUE("AE>'!E;G-E*2P@;F5T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,X,RPX,C8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-2PX,CD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<R,2PT,3D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,2PS,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$L,S`U+#@R,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q,"PV-C,I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPQ-C@L,3$X*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(U+#,X,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.;VYO<&5R871I;F<@26YC;VUE("A%>'!E;G-E*2P@5&]T86P\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<X+#`P-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U+#$V-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-#0V+#8Y
M.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU+#DT-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQO<W,@9G)O;2!O<&5R871I;VYS(&)E9F]R92!P<F]V:7-I
M;VX@9F]R(&EN8V]M92!T87AE<R!A;F0@;F]N8V]N=')O;&QI;F<@:6YT97)E
M<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#,P,BPS,3,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-2PW,#@L-C8R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(V+#@R,2PQ,#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3$L.#0Y+#$P,RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W9I<VEO;B!F
M;W(@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-BPQ-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR.#4L.3<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3`W+#8R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3DQ+#$W.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#,R."PT-C0I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PY.30L
M-C,X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(W+#<R."PW,S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3,L,#0P+#(X,BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,@+2!N970@*&QO<W,I
M(&EN8V]M92!A='1R:6)U=&%B;&4@=&\@;F]N8V]N=')O;&QI;F<@:6YT97)E
M<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPY-S$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$T
M-2PU.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU-3DL,#<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-"PP.#4L-S0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@871T<FEB=71A8FQE
M('1O($YE;U-T96TL($EN8RX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#<L,S0V+#0S-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@W+#$T,"PR,C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C@L,C@W+#@Q-2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-RPQ,C8L,#(U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')E9F5R<F5D(&1I=FED96YD<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,34P+#8U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4P."PP-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3,L-#8Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@871T
M<FEB=71A8FQE('1O($YE;U-T96TL($EN8RX@8V]M;6]N('-H87)E:&]L9&5R
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@W+#0Y
M-RPP.3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XF;F)S<#LD("@W+#$T,"PR,C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@R."PW.34L.#@U*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB
M<W`[)"`H,3<L,C<Y+#0Y-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VEC(&%N9"!D:6QU=&5D(&QO<W,@<&5R
M('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@
M*#`N,#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XF;F)S<#LD("@P+C$S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H,"XS-2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#`N,S8I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y796EG:'1E9"!A=F5R86=E(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDT+#$P,BPU.#D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-BPW
M-S<L-#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#(L-S<U+#(Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0X+#4Y.2PS-3D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S$Q-C@Q-6-F7SDU.3-?-#!C85\Y9#<W
M7S0W.61F,3<V-F(U,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q
M,38X,35C9E\Y-3DS7S0P8V%?.60W-U\T-SED9C$W-C9B-3$O5V]R:W-H965T
M<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%-E9!23X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!#05-(($9,3U=3
M("A54T0@)FYB<W`[)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@9G)O;2!O<&5R871I;F<@
M86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)FYB<W`[)"`H,C<L-S(X+#<S-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#$S+#`T,"PR.#(I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL92!N970@;&]S<R!T;R!N
M970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VLL('-T;V-K(&]P=&EO;G,@86YD('=A<G)A;G1S(&ES<W5E9"!A<R!P87EM
M96YT(&9O<B!C;VUP96YS871I;VXL('-E<G9I8V5S(')E;F1E<F5D(&%N9"!I
M;G1E<F5S="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX+#$V-"PX,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW+#,Y.2PX-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I
M>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#<U-"PY
M-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#4U-BPY.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQO<W,@;VX@<VAO<G0@=&5R;2!I;G9E<W1M96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPR,34\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA
M=&EO;B!O9B!P<F5F97)R960@<W1O8VL@9&ES8V]U;G0@86YD(&ES<W5A;F-E
M(&-O<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3`S+#<P
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0VAA;F=E<R!I;B!F86ER('9A;'5E(&]F(&1E<FEV871I=F4@;&EA8FEL
M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#8V,2PP-#DI
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y7<FET92!O9F8@;V8@86-Q=6ER960@:6XM<')O8V5S<R!R97-E87)C:"!A
M;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,34P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3&]S<R!O;B!D:7-P;W-A;"!O9B!A<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y-BPV,S4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUC87-H(&EN
M=&5R97-T(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,R."PT,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-H87)I=&%B;&4@8V]N=')I8G5T:6]N<R!P86ED('=I=&@@
M8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M,#<L,S8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y"860@9&5B="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU,"PP,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-BPS,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(&EN8V]M92!T87AE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C<X+#(Q,2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.#(L
M-#$W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN(&]P97)A=&EN9R!A<W-E=',@86YD
M(&QI86)I;&ET:65S+"!N970@;V8@=&AE(&5F9F5C="!O9B!A8W%U:7-I=&EO
M;G,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V-#<L-C<T*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0V,2PW-#,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-O=6YT<R!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R+#0X.2PP-C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PR-S@L-3<S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<GD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3,V+#$X.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-#`U+#@S."D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E5N96%R;F5D(')E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q+#,V,2PV.3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,SDR+#`T,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPP,30L-38V*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$R."PR,C4I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8V-O=6YT<R!P87EA8FQE+"!A8V-R=65D(&5X<&5N<V5S(&%N9"!O=&AE<B!C
M=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@S+#0S,RPU-#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PQ-S4L.3`R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O
M<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,3<L-3(R+#0S,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@S+#$W-2PW,#@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO
M=W,@9G)O;2!I;G9E<W1I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!R96-E:79E9"!I;B!A
M8W%U:7-I=&EO;B!O9B!00U0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(R-RPY-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!U<F-H87-E(&]F('-H;W)T+71E<FT@:6YV97-T;65N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(W*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L-#(T+#$S
M,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;V-E961S(&9R;VT@<VAO<G0M=&5R;2!I;G9E<W1M96YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPT-3(L,#$U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8W%U:7-I
M=&EO;B!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@U+#0U,RPY,S$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(L-3$P+#8T."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M8V%S:"!U<V5D(&EN(&EN=F5S=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S+#$R-RPY,#(I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$L,#$Y+#`U-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V%S:"!F;&]W<R!F<F]M(&9I;F%N8VEN9R!A8W1I=FET:65S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M<')O8V5E9',@9G)O;2!T:&4@97AE<F-I<V4@;V8@;W!T:6]N<R!A;F0@=V%R
M<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,3`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ
M,#$L.#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@<')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C87!I=&%L
M('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PQ-C<L
M-C@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3,L,3,X+#DT.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4&%Y;65N="!F<F]M(')E;&%T960@<&%R='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8T-"PT,30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-C8L-S<U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M97!A>6UE;G0@;V8@;6]R=&=A9V4@;&]A;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,3`Y+#0Y,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&]F(&)A;FL@;&]A;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ-#DL,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297!A
M>6UE;G0@;V8@8F%N:R!L;V%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q+#4U-RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,BPR,#,L-C4P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!N;W1E
M<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PY
M-3`L-C$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3,L,C4V+#<Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5P87EM96YT(&]F(&YO=&5S('!A>6%B;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$W+#$U-"PW-3,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,38L
M-C0T+#0V-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E<&%Y;65N="!O9B!D96)T('1O(')E;&%T960@<&%R='D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-#`V+#`T,RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M<&%Y;65N="!O9B!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$W-2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT(&]F(&1I=FED96YD/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,C(L.3(T*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C
M87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPU,38L-3(T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L.3DS+#,S,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26UP86-T(&]F(&-H86YG97,@;V8@9F]R96EG;B!E>&-H86YG92!R871E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,T+#<U-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P."PW-30\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@*&1E8W)E87-E*2]I;F-R96%S92!I;B!C87-H(&%N9"!C87-H(&5Q
M=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#@Y
M.2PP-3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,RPP.3(L-C<V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A
M="!B96=I;FYI;F<@;V8@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,34L-C$R+#,Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<L,34Y+#,V.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I
M=F%L96YT<R!A="!E;F0@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,2PW,3,L,S,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP-C8L-CDS/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@
M<&%I9"!D=7)I;F<@=&AE('!E<FEO9"!F;W(Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(S."PT,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3DL,S<V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y487AE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT-C,L,3`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW.#0L
M,S(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-U<'!L96UE;G1A;"!38VAE9'5L92!O9B!N;VXM8V%S
M:"!I;G9E<W1I;F<@86-T:79I=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8W%U:7-I=&EO;B!O9B!P<F]P97)T>2!A
M;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-#@L-#@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#87!I=&%L:7IE9"!I;G1E<F5S=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C,U+#<P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,P-RPR,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE
M;65N=&%L('-C:&5D=6QE(&]F(&YO;BUC87-H(&9I;F%N8VEN9R!A8W1I=FET
M:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:R!A;F0@=V%R<F%N=',@:7-S=65D('=I=&@@=&AE(&%C
M<75I<VET:6]N(&]F(%!#5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3<L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!P=7)S=6%N="!T
M;R!T:&4@<F5D96UP=&EO;B!O9B!#;VYV97)T:6)L92!2961E96UA8FQE(%-E
M<FEE<R!%(#<E(%!R969E<G)E9"!3=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPW.#4L-#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D(&EN
M('!A>6UE;G0@;V8@9&EV:61E;F1S(&9O<B!T:&4@0V]N=F5R=&EB;&4@4F5D
M965M86)L92!397)I97,@12`W)2!0<F5F97)R960@4W1O8VL\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8R,BPU,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I;F%N8VEN9R!C;W-T
M<R!F;W(@8V%P:71A;"!S=&]C:R!R86ES97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<U+#0V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!O9B!#;VYV97)T:6)L
M92!2961E96UA8FQE(%-E<FEE<R!#(%!R969E<G)E9"!3=&]C:SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L-S(P+#`T.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&EV:61E;F0@
M=&\@4F5L871E9"!087)T>2!R96EN=F5S=&5D(&%S(&QO86X@<&%Y86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L-S(V+#$P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T
M97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-A<V@@9FQO=W,@9G)O;2!I;G9E<W1I;F<@86-T:79I=&EE<SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA
M;F=E(&EN(')E<W1R:6-T960@8V%S:"!U<V5D(&%S(&-O;&QA=&5R86P\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#DX+#$Q-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%N:R!L
M;V%N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-A<V@@9FQO=W,@9G)O;2!I;G9E<W1I;F<@86-T:79I=&EE<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN
M(')E<W1R:6-T960@8V%S:"!U<V5D(&%S(&-O;&QA=&5R86P\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,2PT-C,L-S$P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E1H92!#;VUP86YY/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1H92!#;VUP86YY/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I=B!S='EL93TS1"=$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
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M,T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[(%1%6%0M24Y$
M14Y4.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#,N-G!T)R!A;&EG;CTS1&IU<W1I
M9GD^/"$M+45&4&QA8V5H;VQD97(M+3X\8G(@+SX\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M
M24Y$14Y4.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#,N-G!T)R!A;&EG;CTS1&IU
M<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/DYE;U-T
M96TL#0I);F,N("@F(W@R,#%#.TYE;U-T96TF(W@R,#%$.R!O<B!T:&4@)B-X
M,C`Q0SM#;VUP86YY)B-X,C`Q1#LI('=A<PT*:6YC;W)P;W)A=&5D('5N9&5R
M('1H92!L87=S(&]F('1H92!3=&%T92!O9B!$96QA=V%R92!I;B!397!T96UB
M97(-"C$Y.#`@=6YD97(@=&AE(&YA;64@1FED96QI='D@365D:6-A;"!397)V
M:6-E<RP@26YC+B!4:&4-"D-O;7!A;GDF(W@R,#$Y.W,@8V]R<&]R871E(&AE
M861Q=6%R=&5R<R!A<F4@;&]C871E9"!A="`T,C`@3&5X:6YG=&]N#0I!=F5N
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M14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9
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M<F%P>28C>$$P.R8C>#(P,3,[)B-X03`[56YI=&5D#0I3=&%T97,[("AI:2D@
M4F5G96YE<F%T:79E($UE9&EC:6YE)B-X03`[)B-X,C`Q,SLF(WA!,#M#:&EN
M83L@86YD#0HH:6EI*2!0:&%R;6%C975T:6-A;`T*36%N=69A8W1U<FEN9R8C
M>$$P.R8C>#(P,3,[)B-X03`[0VAI;F$N/"]F;VYT/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=$25-03$%9.B!B;&]C:SL@5$585"U)3D1%3E0Z(#!P="<^/&)R
M("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4
M.B`S+C9P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SY4:')O=6=H#0IT:&4@0V5L;"!4:&5R87!Y)B-X03`[
M)B-X,C`Q,SLF(WA!,#M5;FET960@4W1A=&5S('-E9VUE;G0L($YE;U-T96T-
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M;`T*=')E871M96YT+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E3
M4$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*
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M>2`Q.2P-"C(P,3$@86-Q=6ES:71I;VX@;V8@4')O9V5N:71O<B!#96QL(%1H
M97)A<'DL($Q,0RP@82!$96QA=V%R90T*;&EM:71E9"!L:6%B:6QI='D@8V]M
M<&%N>2`H)B-X,C`Q0SM00U0F(W@R,#%$.RDL('!U<G-U86YT('1O('=H:6-H
M#0IT:&4@0V]M<&%N>2!A8W%U:7)E9"!A;&P@;V8@=&AE(&UE;6)E<G-H:7`@
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M6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z
M(#$X<'0[($U!4D=)3BU224=(5#H@,RXV<'0G(&%L:6=N/3-$:G5S=&EF>3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^26X-"DUA<F-H(#(P
M,3$@4$-4)B-X,C`Q.3MS('=H;VQL>2!O=VYE9"!S=6)S:61I87)Y+"!!=&AE
M;&]S+"!);F,N#0HH071H96QO<RDL(&%C<75I<F5D(')I9VAT<R!A;F0@=&5C
M:&YO;&]G>2!F;W(@82!4+6-E;&P@8F%S960-"FEM;75N;VUO9'5L871O<GD@
M=&AE<F%P975T:6,@:6X@97AC:&%N9V4@9F]R(&%N(&%P<')O>&EM871E(#(P
M)0T*:6YT97)E<W0@:6X@071H96QO<RX@071H96QO<R!E>'!E8W1S('1O(&EN
M:71I871E(%!H87-E(#$@<W1U9&EE<R!I;@T*875T;VEM;75N92!D:7-O<F1E
M<G,@:6X@,C`Q,BX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,
M05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M(%1%6%0M24Y$14Y4.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY4
M:&4-"D-O;7!A;GD@9G5R=&AE<B!S=')E;F=T:&5N960@:71S(&)R96%D=&@@
M:6X@8V5L;'5L87(@=&AE<F%P:65S#0IT:')O=6=H(&ET<R!/8W1O8F5R(#$W
M+"`R,#$Q(&%C<75I<VET:6]N(&]F($%M;W)C>71E+`T*26YC+B8C>$$P.R8C
M>$$P.T%M;W)C>71E(&ES(&$@9&5V96QO<&UE;G0@<W1A9V4@8V5L;"!T:&5R
M87!Y#0IC;VUP86YY(&9O8W5S:6YG(&]N(&YO=F5L('1R96%T;65N=',@9F]R
M(&-A<F1I;W9A<V-U;&%R#0ID:7-E87-E+B8C>$$P.R8C>$$P.T%M;W)C>71E
M)B-X,C`Q.3MS(&QE860@<')O9'5C="!C86YD:61A=&4L#0I!35(M,#`Q+"!I
M<R!E;G1E<FEN9R!A(%!H87-E(#(@<W1U9'D@9F]R('1H92!T<F5A=&UE;G0@
M;V8@86-U=&4-"FUY;V-A<F1I86P@:6YF87)C=&EO;B`H04U)*2XF(WA!,#LF
M(WA!,#M!;6]R8WET92!I<R!C=7)R96YT;'D-"G)E8W)U:71I;F<@=')I86P@
M<VET97,@:6X@8V]N;F5C=&EO;B!W:71H('1H92!L875N8V@@;V8@=&AI<R!0
M:&%S90T*,B!C;&EN:6-A;"!T<FEA;"!W:&EC:"!I<R!E>'!E8W1E9"!T;R!S
M=&%R="!E;G)O;&QI;F<@<&%T:65N=',@8GD-"G1H92!E;F0@;V8@=&AE(&9I
M<G-T('%U87)T97(@;V8@,C`Q,BX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[(%1%6%0M24Y$14Y4.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#,N
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M5#H@,3AP=#L@34%21TE.+5))1TA4.B`S+C9P="<@86QI9VX],T1J=7-T:69Y
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY4:')O=6=H#0II
M=',@4F5G96YE<F%T:79E($UE9&EC:6YE)B-X03`[)B-X,C`Q,SLF(WA!,#M#
M:&EN82!S96=M96YT+"!I;B`R,#`Y+`T*=&AE($-O;7!A;GD@8F5G86X@<V5V
M97)A;"!#:&EN82UB87-E9"P@4F5G96YE<F%T:79E($UE9&EC:6YE#0II;FET
M:6%T:79E<R!I;F-L=61I;F<Z("AI*2!C<F5A=&EN9R!A('-E<&%R871E($-H
M:6YA+6)A<V5D(&-E;&P-"G1H97)A<'D@;W!E<F%T:6]N+"`H:6DI(&-O;G-T
M<G5C=&EN9R!A('-T96T@8V5L;"!R97-E87)C:"!A;F0-"F1E=F5L;W!M96YT
M(&QA8F]R871O<GD@86YD('!R;V-E<W-I;F<@9F%C:6QI='D@:6X@0F5I:FEN
M9RP@*&EI:2D-"F5S=&%B;&ES:&EN9R!R96QA=&EO;G-H:7!S('=I=&@@:&]S
M<&ET86QS('1O('!R;W9I9&4@8V5L;"UB87-E9`T*=&AE<F%P:65S+"!A;F0@
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M3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`Q.'!T.R!-05)'24XM4DE'2%0Z
M(#,N-G!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/E1H90T*0V]M<&%N>2!A8W%U:7)E9"!I=',@4&AA<FUA
M8V5U=&EC86P-"DUA;G5F86-T=7)I;F<F(WA!,#LF(W@R,#$S.R8C>$$P.T-H
M:6YA('-E9VUE;G0@;VX@3V-T;V)E<B`S,"P@,C`P.2P-"G=H96X@0VAI;F$@
M0FEO<&AA<FUA8V5U=&EC86QS($AO;&1I;F=S+"!);F,N("@F(W@R,#%#.T-"
M2"8C>#(P,40[*0T*;65R9V5D('=I=&@@86YD(&EN=&\@0T)(($%C<75I<VET
M:6]N($Q,0R`H)B-X,C`Q0SM-97)G97(-"E-U8B8C>#(P,40[*2P@82!W:&]L
M;'DM;W=N960@<W5B<VED:6%R>2!O9B!.96]3=&5M+"!W:71H($UE<F=E<B!3
M=6(-"F%S('1H92!S=7)V:79I;F<@96YT:71Y("AT:&4@)B-X,C`Q0SM%<GEE
M($UE<F=E<B8C>#(P,40[*2X@07,@80T*<F5S=6QT(&]F('1H92!%<GEE($UE
M<F=E<BP@3F5O4W1E;2!A8W%U:7)E9"!#0D@F(W@R,#$Y.W,@-3$E#0IO=VYE
M<G-H:7`@:6YT97)E<W0@:6X@4W5Z:&]U($5R>64@4&AA<FUA8V5U=&EC86P@
M0V]M<&%N>2!,=&0N#0HH)B-X,C`Q0SM%<GEE)B-X,C`Q1#LI+"!A(%-I;F\M
M9F]R96EG;B!J;VEN="!V96YT=7)E('=I=&@@;&EM:71E9`T*;&EA8FEL:71Y
M(&]R9V%N:7IE9"!U;F1E<B!T:&4@;&%W<R!O9B!T:&4@4&5O<&QE)B-X,C`Q
M.3MS(%)E<'5B;&EC#0IO9B!#:&EN82X@17)Y92!W87,@9F]U;F1E9"!M;W)E
M('1H86X@-3`@>65A<G,@86=O(&%N9"!R97!R97-E;G1S(&%N#0IE<W1A8FQI
M<VAE9"P@=F5R=&EC86QL>2UI;G1E9W)A=&5D('!H87)M86-E=71I8V%L(&)U
M<VEN97-S+@T*2&ES=&]R:6-A;&QY+"!%<GEE(&AA<R!C;VYC96YT<F%T960@
M:71S(&5F9F]R=',@;VX@=&AE#0IM86YU9F%C='5R:6YG(&%N9"!D:7-T<FEB
M=71I;VX@;V8@9V5N97)I8R!A;G1I8FEO=&EC('!R;V1U8W1S+B!);@T*,C`Q
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M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C
M;W5N=&EN9R!0;VQI8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@
M4&]L:6-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^
M#0H\9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!415A4+41%0T]2051)3TXZ('5N9&5R;&EN92<^3F]T
M92`R#0HF(W@R,#$S.R!3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I
M;F<-"E!O;&EC:65S/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
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M=&EC;&4@,3`@;V8@4F5G=6QA=&EO;B!3+5@@;V8@=&AE(%-E8W5R:71I97,@
M86YD#0I%>&-H86YG92!#;VUM:7-S:6]N(&9O<B!I;G1E<FEM(&9I;F%N8VEA
M;"!I;F9O<FUA=&EO;BX@06-C;W)D:6YG;'DL#0IT:&5Y(&1O(&YO="!I;F-L
M=61E(&%L;"!O9B!T:&4@:6YF;W)M871I;VX@86YD(&9O;W1N;W1E<R!R97%U
M:7)E9`T*8GD@9V5N97)A;&QY(&%C8V5P=&5D(&%C8V]U;G1I;F<@<')I;F-I
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M#0I#;VUP86YY)B-X,C`Q.3MS(&9I;F%N8VEA;"!P;W-I=&EO;B!A<R!O9B!3
M97!T96UB97(@,S`L(#(P,3$@86YD('1H90T*<F5S=6QT<R!O9B!I=',@;W!E
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M1&5C96UB97(@,S$L(#(P,3`L#0HR,#`Y(&%N9"`R,#`X(&EN8VQU9&5D(&EN
M(&]U<B!!;FYU86P@4F5P;W)T(&]N($9O<FT@,3`M2R!F;W(@=&AE#0IY96%R
M(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$P+B8C>$$P.R8C>$$P.T]P97)A=&EN
M9R!R97-U;'1S(&9O<B!T:&4-"G1H<F5E(&%N9"!N:6YE(&UO;G1H('!E<FEO
M9',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$Q(&%R92!N;W0-"FYE8V5S<V%R
M:6QY(&EN9&EC871I=F4@;V8@=&AE(')E<W5L=',@=&AA="!M87D@8F4@97AP
M96-T960@9F]R('1H90T*>65A<B!E;F1I;F<@1&5C96UB97(F(WA!,#LS,2P@
M,C`Q,2X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L
M;V-K.R!415A4+4E.1$5.5#H@,'!T)SXF(WA!,#L\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M
M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,RXS<'0G(&%L:6=N/3-$:G5S
M=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-464Q%.B!I=&%L:6,G
M/@T*57-E(&]F($5S=&EM871E<SH\+V9O;G0^)B-X03`[)B-X03`[5&AE('!R
M97!A<F%T:6]N(&]F(&9I;F%N8VEA;`T*<W1A=&5M96YT<R!I;B!C;VYF;W)M
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M.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U35%E,13H@:71A;&EC
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"D-O;F-E;G1R871I
M;VX@;V8@4FES:W,Z/"]F;VYT/B8C>$$P.R8C>$$P.T9O<B!T:&4F(WA!,#MT
M:')E92!A;F0-"FYI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q
M,2P@=&AR964@;6%J;W(@<W5P<&QI97)S#0IP<F]V:61E9"!A<'!R;WAI;6%T
M96QY)B-X03`[/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/C(Y
M/"]F;VYT/B4-"F%N9"`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^,C@\+V9O;G0^)2P-"G)E<W!E8W1I=F5L>2P@;V8@17)Y928C>#(P,3D[
M<R!P=7)C:&%S97,@;V8@<F%W#0IM871E<FEA;',N)B-X03`[)B-X03`[07,@
M;V8@4V5P=&5M8F5R(#,P+"`R,#$Q+"!T:&4@=&]T86P@86-C;W5N=',-"G!A
M>6%B;&4@=&\@=&AE('1H<F5E(&UA:F]R('-U<'!L:65R<R!R97!R97-E;G1E
M9"`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^,30\+V9O;G0^
M)0T*;V8@=&AE('1O=&%L(&%C8V]U;G1S('!A>6%B;&4@8F%L86YC92X\+V9O
M;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C
M:SL@5$585"U)3D1%3E0Z(#!P="<^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE
M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.
M1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY&;W(-"G1H92!T
M:')E92!A;F0@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$P
M+"!T=V\@;6%J;W(-"G-U<'!L:65R<R!P<F]V:61E9"!A<'!R;WAI;6%T96QY
M(#$W)2!A;F0@,C`E+"!R97-P96-T:79E;'DL(&]F#0I%<GEE)B-X,C`Q.3MS
M('!U<F-H87-E<R!O9B!R87<@;6%T97)I86PN)B-X03`[)B-X03`[07,@;V8@
M1&5C96UB97(-"C,Q+"`R,#$P+"!T:&4@=&]T86P@86-C;W5N=',@<&%Y86)L
M92!T;R!T:&4@='=O(&UA:F]R('-U<'!L:65R<PT*=V%S)B-X03`[,3@E(&]F
M('1H92!T;W1A;"!A8V-O=6YT<R!P87EA8FQE+CPO9F]N=#X\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G
M/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`S+C-P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SY!<'!R;WAI;6%T96QY#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^.#`\+V9O;G0^)0T*;V8@17)Y928C>#(P
M,3D[<R!R979E;G5E<R!A<F4@9&5R:79E9"!F<F]M('!R;V1U8W1S('1H870@
M=7-E#0IP96YI8VEL;&EN(&]R(&-E<&AA;&]S<&]R:6X@87,@=&AE(&ME>2!A
M8W1I=F4@:6YG<F5D:65N="X@5&AE<V4-"G!R;V1U8W1S(&%R92!M86YU9F%C
M='5R960@;VX@='=O(&]F('1H92!E:6=H="!P<F]D=6-T:6]N(&QI;F5S(&EN
M#0I%<GEE)B-X,C`Q.3MS(&UA;G5F86-T=7)I;F<@9F%C:6QI='DN($%N>2!I
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M3E0Z(#!P=#L@34%21TE.+5))1TA4.B`S+C-P="<@86QI9VX],T1J=7-T:69Y
M/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`S+C-P="<@86QI9VX],T1J=7-T:69Y/@T*/&1I=B!S='EL93TS1"=$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"CQD
M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,
M24=..B!J=7-T:69Y)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SY);@T*861D:71I;VXL(&]V97(@-S`E(&]F('1H97-E(&1R=6=S(&%R
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M1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
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M86XG/DEN=F5N=&]R:65S#0IC;VYS:7-T960@;V8@=&AE(&9O;&QO=VEN9R`H
M:6X@=&AO=7-A;F1S*3H\+V9O;G0^/"]D:78^#0H\+V1I=CX-"CQD:78^)B-X
M03`[/"]D:78^#0H\9&EV/@T*/&1I=B!A;&EG;CTS1&-E;G1E<CX-"CQT86)L
M92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$-S4E
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0V-B4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$U)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9&EV('-T>6QE/3-$
M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R
M)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY397!T96UB
M97(-"C,P+"`R,#$Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
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M(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^
M#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^1&5C96UB97(-
M"C,Q+"`R,#$P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$
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M5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)
M1TXZ(&QE9G0G/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SX-"E)A=R!M871E<FEA;',@86YD('-U<'!L:65S/"]F;VYT/CPO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXS+#@S.2XX/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B9N
M8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q-"4@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/C@L,#0S+C@\+V9O;G0^/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-
M"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#8V)3X-"CQD:78@<W1Y;&4],T0G1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86XG/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
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M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXW+#$S-BXU/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^-"PW.3(N-#PO9F]N=#X\+W1D/@T*/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G
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M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
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M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX\9F]N
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4
M+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,30E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S
M;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXX+#$X-RXR/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
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M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^#0I4;W1A;"!I;G9E;G1O<GD\+V9O;G0^/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB<W`[)#PO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/C(P+#4X,BXS/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`T<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/C(Q+#`R,RXT
M/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@[
M(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*
M/"]D:78^#0H\+V1I=CX-"CQD:78^)B-X03`[/"]D:78^#0H\9&EV/@T*/&1I
M=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
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M=&5S(&)Y#0IM86YA9V5M96YT+B!!<R!O9B!397!T96UB97(@,S`L(#(P,3$L
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M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X
M03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3Y4:&4@0V]M<&%N>2!C;&%S<VEF:65S
M('1A>&5S(')E;&%T960@=&\@=VET:&]L9&EN9PT*=&%X97,@<&%I9"!O;B!D
M:79I9&5N9',@9&5C;&%R960@8GD@17)Y92!T;R!T:&4@0V]M<&%N>2!T:&%T
M(&%R90T*<F5I;G9E<W1E9"!I;G1O($5R>64@87,@9V5N97)A;"!A;F0@861M
M:6YI<W1R871I=F4@97AP96YS92X\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E3
M4$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*
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M8F5R(#,P+"`R,#$Q(&%N9"`R,#$P+`T*<F5S<&5C=&EV96QY+CPO9F]N=#X\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$
M14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9
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M97)N;65N=`T*86YD('9A<FEO=7,@<W1A=&4@86YD(&9O<F5I9VX@:G5R:7-D
M:6-T:6]N<RX@5&AE('-T871U=&4@;V8-"FQI;6ET871I;VYS(&AA<R!E>'!I
M<F5D(&]N(&%L;"!C;VYS;VQI9&%T960@52Y3+B!&961E<F%L(&-O<G!O<F%T
M90T*:6YC;VUE('1A>"!R971U<FYS(&9I;&5D('1H<F]U9V@@,C`P-BP@86YD
M('1H92!);G1E<FYA;"!2979E;G5E#0I397)V:6-E(&ES(&YO="!C=7)R96YT
M;'D@97AA;6EN:6YG(&%N>2!O9B!T:&4@<&]S="TR,#`V(')E='5R;G,-"F9I
M;&5D(&)Y('1H92!#;VUP86YY+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/B8C>$$P.SPO
M9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`S+C-P
M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M4U193$4Z(&ET86QI8R<^#0I#;VUP<F5H96YS:79E($EN8V]M92`H3&]S<RDZ
M/"]F;VYT/B8C>$$P.R8C>$$P.U1H92!A8V-U;75L871E9`T*;W1H97(@8V]M
M<')E:&5N<VEV92!I;F-O;64@*&QO<W,I(&)A;&%N8V4@870@4V5P=&5M8F5R
M(#,P+"`R,#$Q(&%N9`T*1&5C96UB97(@,S$L(#(P,3`@:6X@=&AE(&%M;W5N
M="!O9B!A<'!R;WAI;6%T96QY("9N8G-P.R0U+#`P,2PV,#`@86YD#0HF;F)S
M<#LD,BPW-SDL,3`P+"!R97-P96-T:79E;'DL(&ES(&-O;7!R:7-E9"!E;G1I
M<F5L>2!O9B!F;W)E:6=N(&-U<G)E;F-Y#0IT<F%N<VQA=&EO;B!A9&IU<W1M
M96YT<RX@0V]M<')E:&5N<VEV92!L;W-S(&9O<B!T:&4@=&AR964@86YD(&YI
M;F4-"FUO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3$@86YD(#(P,3`@
M=V%S(&%S(&9O;&QO=W,@*&EN#0IT:&]U<V%N9',I.CPO9F]N=#X\+V1I=CX-
M"CPO9&EV/@T*/&1I=CXF(WA!,#L\+V1I=CX-"CQD:78^#0H\9&EV(&%L:6=N
M/3-$;&5F=#X-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
M,T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*/&9O;G0@<W1Y;&4],T0G1$E3
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M.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#$P<'0G/@T*5&AR964@36]N=&AS($5N9&5D(%-E
M<'1E;6)E<B`S,"P\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
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M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%
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M=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*/&9O;G0@<W1Y
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M1TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,C`Q,3PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!L969T
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)SX-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N)SXR,#$P/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'
M3CH@8V5N=&5R)SX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(
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M)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
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M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^,C`Q,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T."4^#0H\9&EV('-T>6QE/3-$
M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
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M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)FYB<W`[)#PO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^*#<L,S(X+C4\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86XG/BD\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
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M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXI/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0HF
M;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3`E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXH,C<L-S(X+C<\+V9O;G0^/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86XG/BD\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,"4@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B@Q,RPP-#`N,SPO
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M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/D]T:&5R#0IC;VUP<F5H96YS
M:79E("AL;W-S*2]I;F-O;64\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P
M)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
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M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
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M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF
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M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
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M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)SX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG
M:'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXW,3(N,3PO
M9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!4
M15A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXQ+#0X,RXT/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/C(L,C(R+C8\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
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M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX\
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M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W
M:&ET93X-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-#@E/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
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M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-
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M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO
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M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
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M.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SXQ+#8U,2XQ/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^
M#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0X
M)3X-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/D-O;7!R96AE;G-I=F4-"BAL;W-S*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,"4@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B@V+#8Q
M-BXT/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXI/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[
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M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXI/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXH,3$L,S@Y+C(\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86XG/BD\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS
M1'=H:71E/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0T."4@<W1Y;&4],T0G4$%$1$E.1RU,1494.B`P<'0[(%!!1$1)3D<M
M0D]45$]-.B`R<'@[($U!4D=)3BU,1494.B`Y<'0G/@T*/&1I=B!S='EL93TS
M1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@5$585"U)3D1%
M3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0G/@T*0V]M<')E:&5N
M<VEV92`H;&]S<RDO:6YC;VUE(&%T=')I8G5T86)L92!T;R!N;VYC;VYT<F]L
M;&EN9PT*:6YT97)E<W1S/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)SX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG
M:'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXS-C8N.3PO
M9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!4
M15A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXQ+#@V-"XP/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/C$L-C0X+C$\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX\
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M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C
M0T-&1D-#/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0T."4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^#0H\9&EV
M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4
M15A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY#;VUP<F5H
M96YS:79E#0IL;W-S(&%T=')I8G5T86)L92!T;R!.96]3=&5M+"!);F,N/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T
M<'@G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4
M+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;B<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$P)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@
M9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/B@V+#DX,RXS/"]F;VYT/CPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXI/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXH
M-BPS-S4N,CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@-'!X.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^*3PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG
M:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#1P>"<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*#(W+#$U-"XR/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@[(%1%6%0M04Q)
M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXI
M/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
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M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXH,38L,C8W+C`\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#1P>#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/BD\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\+V1I=CX-"CQD:78^)B-X03`[/"]D
M:78^#0H\9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`S+C9P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
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M:6X@<')O8V5S<R!R97-E87)C:`T*86YD(&1E=F5L;W!M96YT(&%T($5R>64L
M(&%S('1H92!#;VUP86YY(&5X<&5C=',@=&AI<R!R97-E87)C:"!A;F0-"F1E
M=F5L;W!M96YT('1O('!R;W9I9&4@=&AE($-O;7!A;GD@=VET:"!S=6)S=&%N
M=&EA;"!B96YE9FET(&9O<B!A#0IP97)I;V0@=&AA="!E>'1E;F1S(&)E>6]N
M9"!T:&4@9F]R97-E96%B;&4@:&]R:7IO;BX@06UO<G1I>F5D#0II;G1A;F=I
M8FQE(&%S<V5T<R!C;VYS:7-T(&]F($5R>64F(W@R,#$Y.W,@8W5S=&]M97(@
M;&ES="P-"FUA;G5F86-T=7)I;F<@=&5C:&YO;&]G>2P@<W1A;F1A<F0@;W!E
M<F%T:6YG('!R;V-E9'5R97,L('1R861E;F%M92P-"FQE87-E(')I9VAT<R!A
M;F0@<&%T96YT<RP@87,@=V5L;"!A<R!P871E;G1S(&%N9"!R:6=H=',@87-S
M;V-I871E9`T*<')I;6%R:6QY('=I=&@@=&AE)B-X03`[)B-X03`[)B-X03`[
M)B-X03`[)B-X03`[5E-%3"`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@-S`E.R!615)424-!3"U!3$E'3CH@=&5X="UT;W`G
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M1TE.+5))1TA4.B`S+C9P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SY4:&4-"D-O;7!A;GD@<F5V:65W<R!G
M;V]D=VEL;"!A;F0@:6YD969I;FET92UL:79E9"!I;G1A;F=I8FQE(&%S<V5T
M<R!A=`T*;&5A<W0@86YN=6%L;'D@9F]R('!O<W-I8FQE(&EM<&%I<FUE;G0N
M($=O;V1W:6QL(&%N9`T*:6YD969I;FET92UL:79E9"!I;G1A;F=I8FQE(&%S
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M:6)L92!A<W-E=',@9F]R(&ET<R!#96QL#0I4:&5R87!Y)B-X03`[)B-X,C`Q
M,SLF(WA!,#M5;FET960@4W1A=&5S+"!A;F0@:71S(%!H87)M86-E=71I8V%L
M#0I-86YU9F%C='5R:6YG)B-X03`[)B-X,C`Q,SLF(WA!,#M#:&EN82!R97!O
M<G1I;F<@=6YI=',@;VX@3V-T;V)E<@T*,S$N(%1H92!#;VUP86YY(')E=FEE
M=W,@=&AE(&-A<G)Y:6YG('9A;'5E(&]F(&=O;V1W:6QL(&%N9`T*:6YD969I
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M87)E(')E8V]R9&5D(&%S(&]T:&5R(&EN8V]M92`H97AP96YS92D@;VX-"G1H
M92!C;VYS;VQI9&%T960@<W1A=&5M96YT<R!O9B!O<&5R871I;VYS+CPO9F]N
M=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M
M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`S+C9P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
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M<V5D($-O;7!E;G-A=&EO;CH\+V9O;G0^)B-X03`[)B-X03`[5&AE($-O;7!A
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M<F9O<FUA;F-E(&-R:71E<FEA(&%N9`T*<F5C;V=N:7IE<R!C;VUP96YS871I
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M8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)
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M=6QD(&)E(&ES<W5E9`T*87-S=6UI;F<@8V]N=F5R<VEO;B!O9B!A;&P@<&]T
M96YT:6%L;'D@9&EL=71I=F4@<V5C=7)I=&EE<PT*;W5T<W1A;F1I;F<L(&ES
M(&YO="!P<F5S96YT960@87,@<W5C:"!P;W1E;G1I86QL>2!D:6QU=&EV90T*
M<V5C=7)I=&EE<R!A<F4@86YT:2UD:6QU=&EV92!I;B!A;&P@<&5R:6]D<R!P
M<F5S96YT960N($9O<B!T:&4-"G1H<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E
M9"!397!T96UB97(@,S`L(#(P,3$@86YD(#(P,3`L('1H90T*0V]M<&%N>2!I
M;F-U<G)E9"!N970@;&]S<V5S(&%N9"!T:&5R969O<F4@;F\@8V]M;6]N('-T
M;V-K#0IE<75I=F%L96YT<R!W97)E('5T:6QI>F5D(&EN('1H92!C86QC=6QA
M=&EO;B!O9B!L;W-S('!E<B!S:&%R92X@070-"E-E<'1E;6)E<B`S,"P@,C`Q
M,2!A;F0@,C`Q,"P@=&AE($-O;7!A;GD@97AC;'5D960@=&AE(&9O;&QO=VEN
M9PT*<&]T96YT:6%L;'D@9&EL=71I=F4@<V5C=7)I=&EE<SH\+V9O;G0^/"]D
M:78^#0H\+V1I=CX-"CQD:78^)B-X03`[/"]D:78^#0H\9&EV/@T*/&1I=B!A
M;&EG;CTS1&-E;G1E<CX-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P
M86-I;F<],T0P('=I9'1H/3-$-S4E('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"CQT<CX-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-B4@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#8@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,R)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E
M;G1E<B<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M=#L@5$585"U!3$E'3CH@8V5N=&5R)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SY397!T96UB97(-"C,P+#PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)
M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-C8E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$U)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9&EV
M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4
M15A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'
M3CH@8V5N=&5R)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0HR,#$Q/"]F
M;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
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M1TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0G/@T*,C`Q,#PO9F]N=#X\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
M(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0V-B4^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SY3=&]C:PT*3W!T:6]N<SPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M<F]M86XG/C$W+#<T.2PX.34\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$58
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M(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXQ,RPU-3@L,C$T/"]F;VYT/CPO=&0^#0H\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
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M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SY787)R86YT<SPO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[
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M/C,U+#(P."PX,3<\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
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M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXQ-RPS-3(L,#(X/"]F;VYT/CPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C
M;VQO<CTS1"-#0T9&0T,^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#8V)3X-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)
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M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
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M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M<F]M86XG/BT\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L
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M<R!P87-S960L('1H92!R:7-K<R!A;F0@<F5W87)D<R!O9B!O=VYE<G-H:7`@
M:&%V92!B965N#0IT<F%N<V9E<G)E9"!T;R!T:&4@8W5S=&]M97(L('1H92!F
M964@:7,@9FEX960@86YD(&1E=&5R;6EN86)L92P@86YD#0IT:&4@8V]L;&5C
M=&EO;B!O9B!T:&4@<F5L871E9"!R96-E:79A8FQE(&ES(')E87-O;F%B;'D@
M87-S=7)E9`T*=VAI8V@@:7,@870@=&AE('1I;64@;V8@9&5L:79E<GDN(%1H
M92!#;VUP86YY(')E8V]G;FEZ97,@<F5V96YU90T*9F]R(&ET<R!C96QL(&1E
M=F5L;W!M96YT(&%N9"!M86YU9F%C='5R:6YG('-E<G9I8V5S(&)A<V5D(&]N
M('1H90T*=&5R;7,@;V8@:6YD:79I9'5A;"!C;VYT<F%C=',N)B-X03`[)B-X
M03`[26X@8V5R=&%I;B!C87-E<RP@=&AE<F4-"F%R92!M=6QT:7!L92!E;&5M
M96YT<R!T:&%T(&-A;FYO="!B92!C;VYS:61E<F5D('-E<&%R871E#0ID96QI
M=F5R86)L97,@86YD('1H97)E9F]R92!T:&4@0V]M<&%N>2!R96-O9VYI>F5S
M(')E=F5N=64@;VX@80T*8V]M<&QE=&5D(&-O;G1R86-T(&)A<VES(&9O<B!T
M:&5S92!A<G)A;F=E;65N=',N($EN(&]T:&5R(&-A<V5S+`T*=&AE($-O;7!A
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M(&-R>6]P<F5S97)V871I;VX@;V8@8V]R9`T*8FQO;V0@86YD(&%U=&]L;V=O
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M(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3$@86YD(#(P,3`-"G=E
M<F4@8V]M<')I<V5D(&]F('1H92!F;VQL;W=I;F<@*&EN('1H;W5S86YD<RDZ
M/"]F;VYT/CPO9&EV/@T*/"]D:78^#0H\9&EV/B8C>$$P.SPO9&EV/@T*/&1I
M=CX-"CQD:78@86QI9VX],T1L969T/@T*/'1A8FQE(&-E;&QP861D:6YG/3-$
M,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-
M"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#8@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60G/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
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M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R
M:6=H="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#8@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9&EV('-T
M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4
M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@
M8V5N=&5R)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY.
M:6YE#0I-;VYT:',@16YD960@4V5P=&5M8F5R(#,P+#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!L969T
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9&EV
M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4
M15A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'
M3CH@8V5N=&5R)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
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M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R)SX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)
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M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L
M<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)SX-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SY2979E;G5E<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
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M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[(%1%6%0M24Y$14Y4
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T)SX-"E!R97-C<FEP=&EO
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M/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,34L-3$S+C`\+V9O;G0^
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I
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M<R!N97<@<F]M86XG/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,38L
M,S@T+C4\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
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M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)FYB<W`[)#PO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^-#DL.#`V+C`\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$58
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M(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)FYB<W`[
M)#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P
M)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^-3$L-3(X+C<\+V9O;G0^/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
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M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
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M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
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M+C$\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
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M24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SXY,2XQ/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
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M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
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M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
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M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P="<^
M#0I3=&5M(&-E;&P@<F5L871E9"!S97)V:6-E<R`M(')E:6UB=7)S960-"F5X
M<&5N<V5S/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,
M24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3`E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXM/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
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M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
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M;2!W:61T:#TS1#$P)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0T."4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P
M>"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
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M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXQ-RPW-38N,3PO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L969T)SX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ
M-BPT-S4N-CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@-'!X.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX]
M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@-'!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
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M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
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M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@-'!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
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M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXU,2PW,38N,SPO9F]N=#X\+W1D/@T*/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L969T
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/"]D:78^#0H\
M9&EV/B8C>$$P.SPO9&EV/@T*/&1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`Q.'!T
M.R!-05)'24XM4DE'2%0Z(#,N,W!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U35%E,13H@:71A;&EC)SX-"D9A:7(@5F%L
M=64@365A<W5R96UE;G1S.CPO9F]N=#XF(WA!,#LF(WA!,#M&86ER('9A;'5E
M(&]F(&9I;F%N8VEA;`T*87-S971S(&%N9"!L:6%B:6QI=&EE<R!T:&%T(&%R
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M;65A<W5R96UE;G0@9&%T92`H97AI="!P<FEC92DN(%1H92!#;VUP86YY(&ES
M(')E<75I<F5D('1O(&-L87-S:69Y#0IF86ER('9A;'5E(&UE87-U<F5M96YT
M<R!I;B!O;F4@;V8@=&AE(&9O;&QO=VEN9PT*8V%T96=O<FEE<SH\+V9O;G0^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.
M1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`Q.'!T
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M5#H@,3AP=#L@34%21TE.+5))1TA4.B`S+C-P="<@86QI9VX],T1J=7-T:69Y
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY,979E;`T*,B!I
M;G!U=',@=VAI8V@@87)E(&1E9FEN960@87,@:6YP=71S(&]T:&5R('1H86X@
M<75O=&5D('!R:6-E<PT*:6YC;'5D960@=VET:&EN($QE=F5L(#$@=&AA="!A
M<F4@;V)S97)V86)L92!F;W(@=&AE(&%S<V5T<R!O<@T*;&EA8FEL:71I97,L
M(&5I=&AE<B!D:7)E8W1L>2!O<B!I;F1I<F5C=&QY+CPO9F]N=#X\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P
M<'0G/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#$X<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/DQE=F5L#0HS(&EN<'5T<R!A<F4@9&5F:6YE
M9"!A<R!U;F]B<V5R=F%B;&4@:6YP=71S(&9O<B!T:&4@87-S971S(&]R#0IL
M:6%B:6QI=&EE<RX@1FEN86YC:6%L(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@
M87)E(&-L87-S:69I960@8F%S960-"F]N('1H92!L;W=E<W0@;&5V96P@;V8@
M:6YP=70@=&AA="!I<R!S:6=N:69I8V%N="!T;R!T:&4@9F%I<B!V86QU90T*
M;65A<W5R96UE;G0N(%1H92!#;VUP86YY)B-X,C`Q.3MS(&%S<V5S<VUE;G0@
M;V8@=&AE('-I9VYI9FEC86YC92!O9@T*82!P87)T:6-U;&%R(&EN<'5T('1O
M('1H92!F86ER('9A;'5E(&UE87-U<F5M96YT(')E<75I<F5S(&IU9&=M96YT
M+`T*86YD(&UA>2!A9F9E8W0@=&AE('9A;'5A=&EO;B!O9B!T:&4@9F%I<B!V
M86QU92!O9B!A<W-E=',@86YD#0IL:6%B:6QI=&EE<R!A;F0@=&AE:7(@<&QA
M8V5M96YT('=I=&AI;B!T:&4@9F%I<B!V86QU92!H:65R87)C:'D-"FQE=F5L
M<RX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K
M.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$
M14Y4.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY4:&4-"D-O;7!A
M;GD@9&5T97)M:6YE9"!T:&4@9F%I<B!V86QU92!O9B!F=6YD<R!I;G9E<W1E
M9"!I;B!S:&]R="!T97)M#0II;G9E<W1M96YT<RP@=VAI8V@@87)E(&-O;G-I
M9&5R960@=')A9&EN9R!S96-U<FET:65S+"!T;R!B92!L979E;"`Q#0II;G!U
M=',@;65A<W5R960@8GD@<75O=&5D('!R:6-E<R!O9B!T:&4@<V5C=7)I=&EE
M<R!I;B!A8W1I=F4-"FUA<FME=',N(%1H92!#;VUP86YY(&1E=&5R;6EN960@
M=&AE(&9A:7(@=F%L=64@;V8@9G5N9',@:6YV97-T960@:6X-"FUO;F5Y(&UA
M<FME="!F=6YD<R!T;R!B92!L979E;"`Q+B!4:&4@0V]M<&%N>2!D971E<FUI
M;F5D('1H92!F86ER#0IV86QU92!O9B!T:&4@96UB961D960@9&5R:79A=&EV
M92!L:6%B:6QI=&EE<R!A;F0@=V%R<F%N="!D97)I=F%T:79E#0IL:6%B:6QI
M=&EE<R!T;R!B92!L979E;"`S(&EN<'5T<RX@5&AE<V4@:6YP=71S(')E<75I
M<F4@;6%T97)I86P-"G-U8FIE8W1I=FET>2!B96-A=7-E('9A;'5E(&ES(&1E
M<FEV960@=&AR;W5G:"!T:&4@=7-E(&]F(&$@;&%T=&EC90T*;6]D96P@=&AA
M="!V86QU97,@=&AE(&1E<FEV871I=F5S(&)A<V5D(&]N('!R;V)A8FEL:71Y
M('=E:6=H=&5D#0ID:7-C;W5N=&5D(&-A<V@@9FQO=W,N(%1H92!F;VQL;W=I
M;F<@=&%B;&4@<V5T<R!F;W)T:"!B>2!L979E;`T*=VET:&EN('1H92!F86ER
M('9A;'5E(&AI97)A<F-H>2!T:&4@0V]M<&%N>28C>#(P,3D[<R!F:6YA;F-I
M86P-"F%S<V5T<R!A;F0@;&EA8FEL:71I97,@=&AA="!W97)E(&%C8V]U;G1E
M9"!F;W(@870@9F%I<B!V86QU92!O;B!A#0IR96-U<G)I;F<@8F%S:7,@87,@
M;V8@4V5P=&5M8F5R(#,P+"`R,#$Q+"!A;F0@1&5C96UB97(@,S$L(#(P,3`@
M*&EN#0IT:&]U<V%N9',I.CPO9F]N=#X\+V1I=CX-"CPO9&EV/@T*/&1I=CXF
M(WA!,#L\+V1I=CX-"CQD:78^#0H\9&EV(&%L:6=N/3-$8V5N=&5R/@T*/'1A
M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0X
M-24@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#4R)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N
M/3-$,3`@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#0V)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86XG/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T)SX-"E-E<'1E;6)E<B`S,"P@,C`Q,3PO9F]N=#X\+V9O
M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,3`@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0V)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^
M#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$58
M5"U!3$E'3CH@8V5N=&5R)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M4TE:13H@,3!P="<^#0I&86ER(%9A;'5E($UE87-U<F5M96YT<R!5<VEN9R!&
M86ER(%9A;'5E#0I(:65R87)C:'D\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,30E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)SX-"CQD:78@
M<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%
M6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=.
M.B!C96YT97(G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T)SX-"DQE=F5L(#$\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>#L@5$585"U!3$E'3CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$T)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9&EV('-T
M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4
M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@
M8V5N=&5R)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P
M="<^#0I,979E;"`R/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
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M3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&-E
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M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
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M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY-;VYE>0T*
M;6%R:V5T(&EN=F5S=&UE;G1S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,R4@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/C(L-3`P+C@\
M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D
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M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXM/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,B4^
M#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY3
M:&]R=`T*=&5R;2!I;G9E<W1M96YT<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3,E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXP+C8\+V9O;G0^/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
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M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3,E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXM/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,B4^#0H\9&EV('-T>6QE/3-$
M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY%;6)E9&1E9`T*9&5R:79A
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M(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXM/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C
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M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R
M:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
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M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N)SY787)R86YT#0ID97)I=F%T:79E(&QI
M86)I;&ET:65S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M<R!N97<@<F]M86XG/BT\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!
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M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SXM/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^,3(V+CD\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
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M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!
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M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3,E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-
M"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-3(E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
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M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/D1E8V5M8F5R#0HS,2P@,C`Q,#PO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!L969T)SX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0U,B4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P
M>"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,3`@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#0V)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9&EV
M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4
M15A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'
M3CH@8V5N=&5R)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M,3!P="<^#0I&86ER(%9A;'5E($UE87-U<F5M96YT<R!5<VEN9R!&86ER(%9A
M;'5E#0I(:65R87)C:'D\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>#L@5$585"U!3$E'3CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3(E('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<B<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@
M5$585"U!3$E'3CH@8V5N=&5R)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P="<^#0I,979E;"`Q/"]F;VYT/CPO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M
M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
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M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)SX-
M"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4
M+4%,24=..B!C96YT97(G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86XG/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T)SX-"DQE=F5L(#,\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
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M86XG/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$S)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^+3PO9F]N=#X\+W1D
M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO
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M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXR+#4P,2XP
M/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/BT\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
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M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
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M24Q9.B!T:6UE<R!N97<@<F]M86XG/C`N-3PO9F]N=#X\+W1D/@T*/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R
M:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
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M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3,E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXM/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)3X-"CQD:78@<W1Y;&4],T0G1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/D5M8F5D9&5D#0ID97)I=F%T:79E
M(&QI86)I;&ET:65S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
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M:6UE<R!N97<@<F]M86XG/BT\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$58
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M(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXM/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C
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M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-3(E/@T*/&1I=B!S='EL93TS1"=$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^5V%R<F%N=`T*9&5R:79A=&EV92!L:6%B
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M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXM/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^+3PO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE
M/@T*/"]D:78^#0H\+V1I=CX-"CQD:78^)B-X03`[/"]D:78^#0H\9&EV/@T*
M/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@5$585"U)3D1%3E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/E-U8G-E<75E;G0-"G1O($1E8V5M8F5R(#,Q+"`R,#$P('1H92!#;VUP86YY
M(')E979A;'5A=&5D('1H92!C:&%R86-T97)I<W1I8W,@;V8-"G1H92!M;VYE
M>2!M87)K970@<V%V:6YG<R!A8V-O=6YT+"!C=7)R96YT;'D@<F5C;W)D960@
M87,@;W1H97(-"F%S<V5T<RP@86YD(&1E=&5R;6EN960@:70@:7,@;F]T('1I
M960@=&\@=6YD97)L>6EN9R!S96-U<FET:65S(&%N9`T*:&%S(&)E96X@<F5C
M;&%S<VEF:65D('1O(&QE=F5L(#$N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=$25-03$%9.B!B;&]C:SL@5$585"U)3D1%3E0Z(#!P="<^/&)R("\^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`S
M+C-P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SY&;W(-"G1H;W-E(&9I;F%N8VEA;"!I;G-T<G5M96YT<R!W
M:71H('-I9VYI9FEC86YT($QE=F5L(#,@:6YP=71S+"!T:&4-"F9O;&QO=VEN
M9R!T86)L92!S=6UM87)I>F5S('1H92!A8W1I=FET>2!F;W(@=&AE('1H<F5E
M(&%N9"!N:6YE#0IM;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$Q(&)Y
M('1Y<&4@;V8@:6YS=')U;65N="`H:6X-"G1H;W5S86YD<RDZ/"]F;VYT/CPO
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M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,C0E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<B<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@
M5$585"U!3$E'3CH@8V5N=&5R)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SY&;W(-"G1H92!4:')E92!-;VYT:',@16YD960\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
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M;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M
M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!C
M96YT97(G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/D9O
M<@T*=&AE($YI;F4@36]N=&AS($5N9&5D/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)SX\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0X)2!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!C96YT97(G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!C96YT97(G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,C0E('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)SX-"CQD
M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,
M24=..B!C96YT97(G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/E-E<'1E;6)E<@T*,S`L(#(P,3$\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!C
M96YT97(G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!C
M96YT97(G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C0E('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R
M)SX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!4
M15A4+4%,24=..B!C96YT97(G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86XG/E-E<'1E;6)E<@T*,S`L(#(P,3$\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4+4%,
M24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#0X)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L
M<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$Q)2!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G/@T*/&1I=B!S
M='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$58
M5"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ
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M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
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M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[
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M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$Q)2!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G/@T*/&1I=B!S='EL
M93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)
M3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&-E
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M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
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M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>#L@5$585"U!3$E'
M3CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E
M;G1E<B<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M=#L@5$585"U!3$E'3CH@8V5N=&5R)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SY$97)I=F%T:79E<SPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ
M(&-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ
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M1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[
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M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!C96YT
M97(G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)SX-
M"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4
M+4%,24=..B!C96YT97(G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86XG/D1E<FEV871I=F5S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>#L@5$585"U!3$E'3CH@8V5N=&5R
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>#L@5$585"U!3$E'3CH@8V5N=&5R
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\
M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!
M3$E'3CH@8V5N=&5R)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SY787)R86YT<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0X)3X-"CQD:78@<W1Y
M;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M
M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
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M<F]M86XG/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^#0HF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SXS-#(N,SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0HF;F)S<#LD/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXR+#(X,2XX/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B9N8G-P
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M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M8F=C;VQO<CTS1'=H:71E/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0T."4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P
M>"<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
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M:61T:#TS1#$P)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^*#$L,34P+C,\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>#L@5$585"U!3$E'3CH@;&5F="<^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/BD\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
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M;2!W:61T:#TS1#$P)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^*#$L-#DX+C0\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>#L@5$585"U!3$E'3CH@;&5F="<^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/BD\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B@Q
M-C(N-SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^*3PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R
M/3-$(T-#1D9#0SX-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-#@E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/@T*
M/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
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M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
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M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXW.#,N
M-#PO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X
M.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@-'!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
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M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ,C8N.3PO9F]N=#X\+W1D/@T*
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L
M969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
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M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXW.#,N-#PO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
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M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ,C8N
M.3PO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X
M.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-
M"CPO9&EV/@T*/"]D:78^#0H\9&EV/B8C>$$P.SPO9&EV/@T*/&1I=CX-"CQD
M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M(%1%6%0M24Y$14Y4.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#,N-G!T)R!A;&EG
M;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/E-O;64-"F]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&9I;F%N8VEA;"!I;G-T
M<G5M96YT<R!A<F4@;F]T(&UE87-U<F5D(&%T#0IF86ER('9A;'5E(&]N(&$@
M<F5C=7)R:6YG(&)A<VES+"!B=70@87)E(')E8V]R9&5D(&%T(&%M;W5N=',@
M=&AA=`T*87!P<F]X:6UA=&4@9F%I<B!V86QU92!D=64@=&\@=&AE:7(@;&EQ
M=6ED(&]R('-H;W)T+71E<FT@;F%T=7)E+`T*<W5C:"!A<R!C87-H(&%N9"!C
M87-H(&5Q=6EV86QE;G1S+"!R97-T<FEC=&5D(&-A<V@L(&%C8V]U;G1S#0IR
M96-E:79A8FQE+"!A8V-O=6YT<R!P87EA8FQE+"!N;W1E<R!P87EA8FQE(&%N
M9"8C>$$P.V)A;FL-"FQO86YS+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`S+C9P
M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
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M>28C>#(P,3D[<R!#:&EN97-E('-T96T@8V5L;`T*8G5S:6YE<W,F(W@R,#$Y
M.R!F=71U<F4@8V%S:"!F;&]W(&ES(&EN=&5N9&5D('1O(&)E('-U9F9I8VEE
M;G0@=&\-"G-E<G9I8V4@:71S(&%D9&ET:6]N86P@9FEN86YC:6YG(')E<75I
M<F5M96YT<RP@=&AE($-H:6YE<V4-"G-U8G-I9&EA<FEE<R8C>#(P,3D[(&9U
M;F-T:6]N86P@8W5R<F5N8WD@:7,@=&AE(%)E;FUI;F)I#0HH)B-X,C`Q0SM2
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M;&]P;65N="!#;W-T<SH\+V9O;G0^)B-X03`[)B-X03`[4F5S96%R8V@@86YD
M#0ID979E;&]P;65N="`H)B-X,C`Q0SM2)F%M<#M$)B-X,C`Q1#LI(&5X<&5N
M<V5S(&EN8VQU9&4@<V%L87)I97,L#0IB96YE9FET<RP@86YD(&]T:&5R(&AE
M861C;W5N="!R96QA=&5D(&-O<W1S+"!C;&EN:6-A;"!T<FEA;"!A;F0-"G)E
M;&%T960@8VQI;FEC86P@;6%N=69A8W1U<FEN9R!C;W-T<RP@8V]N=')A8W0@
M86YD(&]T:&5R(&]U='-I9&4-"G-E<G9I8V4@9F5E<R!I;F-L=61I;F<@<W!O
M;G-O<F5D(')E<V5A<F-H(&%G<F5E;65N=',L(&%N9`T*9F%C:6QI=&EE<R!A
M;F0@;W9E<FAE860@8V]S=',N(%1H92!#;VUP86YY(&5X<&5N<V5S('1H92!C
M;W-T<PT*87-S;V-I871E9"!W:71H(')E<V5A<F-H(&%N9"!D979E;&]P;65N
M="!A8W1I=FET:65S('=H96X-"FEN8W5R<F5D+CPO9F]N=#X\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G
M/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@
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M<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB
M<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`S+C9P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
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M(&9O;&QO=VEN9SH@*&DI(&$@9V5N97)A;"!R97-E<G9E+"`H:6DI(&%N(&5N
M=&5R<')I<V4-"F5X<&%N<VEO;B!F=6YD(&%N9"`H:6EI*2!A('-T869F(&)O
M;G5S(&%N9"!W96QF87)E(&9U;F0N(%-U8FIE8W0@=&\-"F-E<G1A:6X@8W5M
M=6QA=&EV92!L:6UI=',@*&DN92XL(#4P)2!O9B!T:&4@<F5G:7-T97)E9"!C
M87!I=&%L(&]F#0IT:&4@<F5L979A;G0@8V]M<&%N>2DL('1H92!G96YE<F%L
M(')E<V5R=F4@9G5N9"!R97%U:7)E<R!A;FYU86P-"F%P<')O<')I871I;VX@
M870@,3`E(&]F(&%F=&5R('1A>"!P<F]F:70@*&%S(&1E=&5R;6EN960@=6YD
M97(-"F%C8V]U;G1I;F<@<')I;F-I<&QE<R!G96YE<F%L;'D@86-C97!T960@
M:6X@=&AE(%!20R!A="!E86-H#0IY96%R+65N9"D[('1H92!A<'!R;W!R:6%T
M:6]N('1O('1H92!O=&AE<B!F=6YD<R!A<F4@870@=&AE#0ID:7-C<F5T:6]N
M(&]F('1H92!S=6)S:61I87)I97,N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=$25-03$%9.B!B;&]C:SL@5$585"U)3D1%3E0Z(#!P="<^)B-X03`[
M/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`S
M+C9P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
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M(')E<W5L=`T*;V8@=&AE(&-O;G9E<G-I;VXN(%1H92!S=&%F9B!W96QF87)E
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M(&1I<W1R:6)U=&%B;&4@87,@8V%S:`T*9&EV:61E;F1S('1O('1H92!P87)E
M;G0@8V]M<&%N>2P@3F5O4W1E;2X@4W1A='5T;W)Y(')E<V5R=F5S(&%R90T*
M)FYB<W`[)#(L,S`P+#DP,"!A;F0@)FYB<W`[)#(L,C,T+#8P,"!A<R!O9B!3
M97!T96UB97(@,S`L(#(P,3$@86YD($1E8V5M8F5R(#,Q+`T*,C`Q,"P@<F5S
M<&5C=&EV96QY+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!
M63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I
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M97,N(%1H92!R97-T<FEC=&5D(&%M;W5N="!W87,-"B9N8G-P.R0Q.#0L-3`P
M(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,2!A;F0@)FYB<W`[)#(Q-"PR,#`@870@
M1&5C96UB97(@,S$L#0HR,#$P+CPO9F]N=#X\+V1I=CX-"CPO9&EV/@T*/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14Q'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)E8V5N=&QY($%D;W!T960@
M06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y296-E;G1L>2!!9&]P=&5D($%C8V]U;G1I
M;F<@4')O;F]U;F-E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
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M.B`S+C-P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SY);@T*1&5C96UB97(@,C`Q,"P@=&AE($9!4T(@:7-S
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M:6YG#0IA9G1E<B!$96-E;6)E<B`Q-2P@,C`Q,"X@5&AE(&%D;W!T:6]N(&]F
M('1H:7,@9W5I9&%N8V4@9&ED(&YO="!H879E#0IA(&UA=&5R:6%L(&EM<&%C
M="!O;B!T:&4@8V]N<V]L:61A=&5D(&9I;F%N8VEA;`T*<W1A=&5M96YT<RX\
M+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!4
M15A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4
M.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY);@T*1&5C96UB97(@
M,C`Q,"P@=&AE($9!4T(@:7-S=65D(&%N('5P9&%T92!W:&EC:"!A9&1R97-S
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M<B`Q-2P@,C`Q,"X@5&AE#0IA9&]P=&EO;B!O9B!T:&ES(&=U:61A;F-E(&1I
M9"!N;W0@:&%V92!A(&UA=&5R:6%L(&EM<&%C="!O;B!T:&4-"F-O;G-O;&ED
M871E9"!F:6YA;F-I86P@<W1A=&5M96YT<RX\+V9O;G0^/"]D:78^#0H\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$Q
M-C@Q-6-F7SDU.3-?-#!C85\Y9#<W7S0W.61F,3<V-F(U,0T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\Q,38X,35C9E\Y-3DS7S0P8V%?.60W-U\T
M-SED9C$W-C9B-3$O5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M3$<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^06-Q=6ES:71I;VYS/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C<75I<VET:6]N
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD:78^
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M($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`Q.'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SY/;@T*2F%N=6%R>2`Q.2P@,C`Q,2`H=&AE("8C
M>#(P,4,[0VQO<VEN9R!$871E)B-X,C`Q1#LI+"!.0E,@06-Q=6ES:71I;VX-
M"D-O;7!A;GD@3$Q#("@F(W@R,#%#.U-U8F-O)B-X,C`Q1#LI+"!A(&YE=VQY
M(&9O<FUE9"!W:&]L;'DM;W=N960-"G-U8G-I9&EA<GD@;V8@3F5O4W1E;2P@
M;65R9V5D("AT:&4@)B-X,C`Q0SM00U0@365R9V5R)B-X,C`Q1#LI('=I=&@-
M"F%N9"!I;G1O(%!R;V=E;FET;W(@0V5L;"!4:&5R87!Y+"!,3$,L(&$@1&5L
M87=A<F4@;&EM:71E9"!L:6%B:6QI='D-"F-O;7!A;GD@*"8C>#(P,4,[4$-4
M)B-X,C`Q1#LI+"!W:71H(%!#5"!A<R!T:&4@<W5R=FEV:6YG(&5N=&ET>2P@
M:6X-"F%C8V]R9&%N8V4@=VET:"!T:&4@=&5R;7,@;V8@=&AE($%G<F5E;65N
M="!A;F0@4&QA;B!O9B!-97)G97(L#0ID871E9"!397!T96UB97(@,C,L(#(P
M,3`@*'1H92`F(W@R,#%#.U!#5"!-97)G97(@06=R965M96YT)B-X,C`Q1#LI
M+`T*86UO;F<@3F5O4W1E;2P@4$-4(&%N9"!3=6)C;RXF(WA!,#LF(WA!,#M!
M<R!A(')E<W5L="!O9B!T:&4-"F-O;G-U;6UA=&EO;B!O9B!T:&4@4$-4($UE
M<F=E<BP@3F5O4W1E;2!A8W%U:7)E9"!A;&P@;V8@=&AE#0IM96UB97)S:&EP
M(&EN=&5R97-T<R!O9B!00U0L(&%N9"!00U0@:7,@;F]W(&$@=VAO;&QY+6]W
M;F5D#0IS=6)S:61I87)Y(&]F($YE;U-T96TN)B-X03`[)B-X03`[/"]F;VYT
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@5$585"U)
M3D1%3E0Z(#!P="<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^1F]U;F1E9`T*8GD@1'(N($%N
M9')E=R!,+B!096-O<F$@86YD(%)O8F5R="!!+B!0<F5T:2P@4&@N1"XL(%!#
M5"!B96-A;64@86X-"FEN=&5R;F%T:6]N86QL>2!R96-O9VYI>F5D(&-E;&P@
M=&AE<F%P>2!S97)V:6-E<R!A;F0@9&5V96QO<&UE;G0-"F-O;7!A;GDN)B-X
M03`[)B-X03`[5&AE>2!S;W5G:'0@=&\@8W)E871E(&$@8G5S:6YE<W,@9F]R
M("8C>#(P,4,[87,-"FYE961E9"8C>#(P,40[(&1E=F5L;W!M96YT(&%N9"!M
M86YU9F%C='5R:6YG('-E<G9I8V5S(&9O<B!T:&4-"F5M97)G:6YG(&-E;&P@
M=&AE<F%P>2!I;F1U<W1R>2!A;F0@=&\@<')E<&%R92!F;W(@979E;G1U86P-
M"F-O;6UE<F-I86QI>F%T:6]N+B8C>$$P.R8C>$$P.U=I=&@@:71S(&-E;&P@
M=&AE<F%P>2!M86YU9F%C='5R:6YG#0IF86-I;&ET:65S(&%N9"!T96%M(&]F
M('!R;V9E<W-I;VYA;',L(%!#5"!O9F9E<G,@82!P;&%T9F]R;2!T:&%T#0IC
M86X@9F%C:6QI=&%T92!T:&4@<')E8VQI;FEC86P@86YD(&-L:6YI8V%L(&1E
M=F5L;W!M96YT(&%N9`T*8V]M;65R8VEA;&EZ871I;VX@;V8@8V5L;'5L87(@
M=&AE<F%P:65S(&9O<B!C;&EE;G1S('1H<F]U9VAO=70@=&AE#0IW;W)L9"XF
M(WA!,#LF(WA!,#M00U0@;V9F97)S(&-U<G)E;G0@1V]O9"!-86YU9F%C='5R
M:6YG(%!R86-T:6-E<PT**&-'35`I+6-O;7!L:6%N="!C96QL('1R86YS<&]R
M=&%T:6]N+"!M86YU9F%C='5R:6YG+"!S=&]R86=E+"!A;F0-"F1I<W1R:6)U
M=&EO;B!S97)V:6-E<R!A;F0@<W5P<&]R=&EN9R!C;&EN:6-A;"!T<FEA;"!D
M97-I9VXL('!R;V1U8W0-"G!R;V-E<W,@9&5V96QO<&UE;G0L(&QO9VES=&EC
M<RP@<F5G=6QA=&]R>2!A;F0@<75A;&ET>2!S>7-T96US#0ID979E;&]P;65N
M="!S97)V:6-E<RXF(WA!,#LF(WA!,#M);B!A9&1I=&EO;BP@=&AR;W5G:"!I
M=',@;F5T=V]R:PT*;V8@8V]N=&%C=',@=&AR;W5G:&]U="!T:&4@8V5L;"!T
M:&5R87!Y(&EN9'5S=')Y+"!00U0@:7,@86)L92!T;PT*:61E;G1I9GD@96%R
M;'D@<W1A9V4@9&5V96QO<&UE;G0@;W!P;W)T=6YI=&EE<R!I;B!T:&4@8V5L
M;"!T:&5R87!Y#0IF:65L9"!A;F0@;W!P;W)T=6YI<W1I8V%L;'D@9&5V96QO
M<"!T:&5S92!C96QL('1H97)A<&EE<R!T:')O=6=H#0IP<F]O9B!O9B!C;VYC
M97!T('=H97)E('1H97D@8V%N(&)E(&9U<G1H97(@9&5V96QO<&5D(&%N9"!U
M;'1I;6%T96QY#0IC;VUM97)C:6%L:7IE9"!T:')O=6=H($YE;U-T96TF(W@R
M,#$Y.W,@9&5V96QO<&EN9R!C;VUM97)C:6%L#0IS=')U8W1U<F4N($1R+B!0
M<F5T:2!N;W<@<V5R=F5S(&%S(%!#5"=S(%!R97-I9&5N="!A;F0@0VAI968-
M"E-C:65N=&EF:6,@3V9F:6-E<B!A;F0@1'(N(%!E8V]R82!A<R!#:&EE9B!-
M961I8V%L($]F9FEC97(@;V8-"DYE;U-T96T@86YD(%!#5"X\+V9O;G0^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.
M5#H@,'!T)SXF(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`Q.'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SY00U0-"FES(&5N9V%G960@:6X@82!B
M<F]A9"!R86YG92!O9B!S97)V:6-E<R!I;B!T:&4@8V5L;"!T:&5R87!Y(&UA
M<FME=`T*9F]R('1H92!T<F5A=&UE;G0@;V8@:'5M86X@9&ES96%S92P@:6YC
M;'5D:6YG(&)U="!N;W0@;&EM:71E9"!T;PT*8V]N=')A8W0@;6%N=69A8W1U
M<FEN9RP@<')O9'5C="!A;F0@<')O8V5S<R!D979E;&]P;65N="P@<')O9'5C
M=`T*86YD(')E9W5L871O<GD@8V]N<W5L=&EN9RP@86YD('!R;V1U8W0@8VAA
M<F%C=&5R:7IA=&EO;B!A;F0-"F-O;7!A<F%B:6QI='DN)B-X03`[)B-X03`[
M4$-4)B-X,C`Q.3MS(&5X<&5R=&ES92!I;B!T:&4@8V5L;"!T:&5R87!Y#0IS
M<&%C92P@=VAI8V@@:6YC;'5D97,@=&AE<F%P975T:6,@=F%C8VEN97,@*&]N
M8V]L;V=Y*2P@=F%R:6]U<PT*<F5L871E9"!C96QL('1H97)A<&5U=&EC<RP@
M8V5L;"!D:6%G;F]S=&EC<RP@86YD(')E9V5N97)A=&EV90T*;65D:6-I;F4L
M(&-R96%T97,@82!P;&%T9F]R;2!U<&]N('=H:6-H($YE;U-T96T@:6YT96YD
M<R!T;R!B=6EL9"!A#0IT:&5R87!E=71I8W,@<W1R871E9WDN)B-X03`[)B-X
M03`[3F5O4W1E;28C>#(P,3D[<R!G;V%L(&ES('1O#0ID979E;&]P(&EN=&5R
M;F%L;'DL(&]R('1H<F]U9V@@<&%R=&YE<G-H:7!S+"!A;&QO9V5N96EC("AC
M96QL<R!F<F]M#0IA('1H:7)D+7!A<G1Y(&1O;F]R*2!O<B!A=71O;&]G;W5S
M("AC96QL<R!F<F]M(&]N97-E;&8I(&-E;&P-"G1H97)A<&5U=&EC<R!T96-H
M;F]L;V=I97,@=&AA="P@:6X@=&AE(&%G9W)E9V%T92P@8V]M<')I<V4@=&AE
M($-E;&P-"E1H97)A<'D@)B-X,C`Q,SL@56YI=&5D(%-T871E<R!R97!O<G1A
M8FQE('-E9VUE;G0N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-0
M3$%9.B!B;&]C:SL@5$585"U)3D1%3E0Z(#!P="<^/&)R("\^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M26X-"F%D9&ET:6]N+"!00U0@:&%S(&%S<W5M960@3F5O4W1E;28C>#(P,3D[
M<R!A9'5L="!S=&5M(&-E;&P@8G5S:6YE<W,-"F)A<V5D(&]N(%!#5"8C>#(P
M,3D[<R!S=')A=&5G:6,@861V86YT86=E<R!I;B!M965T:6YG(&-'35`-"G)E
M9W5L871O<GD@<F5Q=6ER96UE;G1S(&EN(&%N(&EN9'5S=')Y('1H870@:7,@
M=VED96QY(&1I<W!E<G-E9`T*=VET:"!A(')A;F=E(&]F('%U86QI='D@:7-S
M=65S+B8C>$$P.R8C>$$P.TYE;U-T96T@8F5L:65V97,@=&AA=`T*4$-4+"!A
M<R!A('%U86QI='D@;&5A9&5R+"!I<R!I9&5A;&QY('!O<VET:6]N960@=&\@
M8F5C;VUE(&$@;&5A9&5R#0II;B!C96QL(&-O;&QE8W1I;VXL('!R;V-E<W-I
M;F<@86YD('-T;W)A9V4@*&-E;&P@8F%N:VEN9RD@=VAI8V@@:7,-"G-Y;F5R
M9VES=&EC('=I=&@@3F5O4W1E;28C>#(P,3D[<R!R;V]T<R!I;B!T:&ES#0IB
M=7-I;F5S<RXF(WA!,#LF(WA!,#M);B!A9&1I=&EO;BP@4$-4)B-X,C`Q.3MS
M(&QE861E<G-H:7`@:6X@=&AE#0IT<F%N<W!O<G1A=&EO;B!A;F0@9&ES=')I
M8G5T:6]N(&]F(&-E;&P@=&AE<F%P>2!P<F]D=6-T<R!I<PT*8V]M<&QE;65N
M=&%R>2!T;R!.96]3=&5M)B-X,C`Q.3MS('-T<F%T96=I8R!V:7-I;VX@;V8@
M=V]R:VEN9R!W:71H#0IT:&4@:6YD=7-T<GD@;&5A9&5R(&%S('1H92!P87)T
M;F5R(&]F(&-H;VEC92XF(WA!,#LF(WA!,#M4:&5S90T*969F;W)T<R!A<F4@
M8F5I;F<@8G5N9&QE9"!T;V=E=&AE<B!I;G1O(&$@;F5W('-E<G9I8V4@=VET
M:`T*4$-4)B-X,C`Q.3MS(&-O<F0@8FQO;V0@8F%N:VEN9R!B=7-I;F5S<R!I
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M;6)E<G-H:7`-"FEN=&5R97-T<R!O9B!00U0@;W5T<W1A;F1I;F<@:6UM961I
M871E;'D@<')I;W(@=&\@=&AE(&5F9F5C=&EV90T*=&EM92!O9B!T:&4@4$-4
M($UE<F=E<B!W97)E(&-O;G9E<G1E9"!I;G1O('1H92!R:6=H="!T;R!R96-E
M:79E+"!I;@T*=&AE(&%G9W)E9V%T92P@*&DI(#$P+#8P,"PP,#`@<VAA<F5S
M(&]F('1H92!C;VUM;VX@<W1O8VLL('!A<B!V86QU90T*)FYB<W`[)#`N,#`Q
M('!E<B!S:&%R92P@;V8@3F5O4W1E;2`H=&AE("8C>#(P,4,[3F5O4W1E;2!#
M;VUM;VX-"E-T;V-K)B-X,C`Q1#LI("AR969L96-T:6YG(&-E<G1A:6X@9FEN
M86P@<')I8V4@861J=7-T;65N=',@86=R965D('1O#0IA="!T:&4@8VQO<VEN
M9RD@86YD("AI:2D@=V%R<F%N=',@=&\@<'5R8VAA<V4@86X@86=G<F5G871E
M#0HS+#`P,"PP,#`@<VAA<F5S(&]F($YE;U-T96T@0V]M;6]N(%-T;V-K(&%S
M(&9O;&QO=W,Z/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9
M.B!B;&]C:SL@5$585"U)3D1%3E0Z(#!P="<^/&)R("\^/"]D:78^#0H\9&EV
M/@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED
M=&@],T0Q,#`E('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N)SX-"CQT<CX-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0S)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,R4^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXH:2D\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#@S)3X-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/F-O;6UO;@T*<W1O8VL@<'5R8VAA<V4@=V%R
M<F%N=',@=&\@<'5R8VAA<V4@;VYE(&UI;&QI;VX@*#$L,#`P+#`P,"D@<VAA
M<F5S#0IO9B!.96]3=&5M($-O;6UO;B!3=&]C:RP@97AE<F-I<V%B;&4@;W9E
M<B!A('-E=F5N('EE87(@<&5R:6]D(&%T(&%N#0IE>&5R8VES92!P<FEC92!O
M9B`F;F)S<#LD-RXP,"!P97(@<VAA<F4@*'1H92`F(W@R,#%#.R9N8G-P.R0W
M+C`P#0I787)R86YT<R8C>#(P,40[*2P@86YD('=H:6-H('=I;&P@=F5S="!O
M;FQY(&EF(&$@<W!E8VEF:65D(&)U<VEN97-S#0IM:6QE<W1O;F4@*&1E<V-R
M:6)E9"!I;B!T:&4@4$-4($UE<F=E<B!!9W)E96UE;G0I(&ES(&%C8V]M<&QI
M<VAE9`T*=VET:&EN('1H<F5E("@S*2!Y96%R<R!O9B!T:&4@0VQO<VEN9R!$
M871E(&]F('1H92!00U0@365R9V5R.PT*86YD/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)
M4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX-
M"CQD:78^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$
M,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*/'1R/@T*/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#,E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0S)3X-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/BAI:2D\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#@S)3X-"CQD:78@<W1Y;&4],T0G1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/F-O;6UO;@T*<W1O8VL@<'5R8VAA
M<V4@=V%R<F%N=',@=&\@<'5R8VAA<V4@;VYE(&UI;&QI;VX@*#$L,#`P+#`P
M,"D@<VAA<F5S#0IO9B!.96]3=&5M($-O;6UO;B!3=&]C:R!E>&5R8VES86)L
M92!O=F5R(&$@<V5V96X@>65A<B!T97)M(&%T(&%N#0IE>&5R8VES92!P<FEC
M92!O9B`F;F)S<#LD,RXP,"!P97(@<VAA<F4@*'1H92`F(W@R,#%#.R9N8G-P
M.R0S+C`P#0I787)R86YT<R8C>#(P,40[*3L@86YD/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$
M)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I
M=CX-"CQD:78^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG
M/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*/'1R/@T*/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#,E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0S)3X-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/BAI:6DI/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0X,R4^#0H\9&EV('-T>6QE/3-$)T1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SYC;VUM;VX-"G-T;V-K('!U
M<F-H87-E('=A<G)A;G1S('1O('!U<F-H87-E(&]N92!M:6QL:6]N("@Q+#`P
M,"PP,#`I('-H87)E<PT*;V8@3F5O4W1E;2!#;VUM;VX@4W1O8VL@97AE<F-I
M<V%B;&4@;W9E<B!A('-E=F5N('EE87(@<&5R:6]D(&%T(&%N#0IE>&5R8VES
M92!P<FEC92!O9B`F;F)S<#LD-2XP,"!P97(@<VAA<F4@*'1H92`F(W@R,#%#
M.R9N8G-P.R0U+C`P(%=A<G)A;G1S)B-X,C`Q1#L-"F%N9"P@8V]L;&5C=&EV
M96QY('=I=&@@=&AE("9N8G-P.R0W+C`P(%=A<G)A;G1S(&%N9"!T:&4@)FYB
M<W`[)#,N,#`@5V%R<F%N=',L#0IT:&4@)B-X,C`Q0SM787)R86YT<R8C>#(P
M,40[*2X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$
M14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9
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M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`Q
M.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY);@T*86-C;W)D86YC92!W
M:71H('1H92!00U0@365R9V5R($%G<F5E;65N="P@3F5O4W1E;2!H87,@9&5P
M;W-I=&5D#0II;G1O(&%N(&5S8W)O=R!A8V-O=6YT('=I=&@@=&AE(&5S8W)O
M=R!A9V5N="`H=VAO(&ES(&EN:71I86QL>0T*3F5O4W1E;28C>#(P,3D[<R!T
M<F%N<V9E<B!A9V5N="DL(#$P+#8P,"PP,#`@<VAA<F5S(&]F($YE;U-T96T-
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M97(@,S`L(#(P,3$L(&%P<')O>&EM871E;'D-"CDW-"PP,#`@<VAA<F5S(&AA
M=F4@8F5E;B!D:7-T<FEB=71E9"!T;R!T:&4@9F]R;65R(&UE;6)E<G,@;V8-
M"E!#5"X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L
M;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M
M24Y$14Y4.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T
M:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY4:&4-"FES
M<W5A;F-E(&]F($YE;U-T96T@<V5C=7)I=&EE<R!I;B!T:&4@4$-4($UE<F=E
M<B!W87,@87!P<F]V960@870@80T*<W!E8VEA;"!M965T:6YG(&]F('-H87)E
M:&]L9&5R<R!O9B!.96]3=&5M(&AE;&0@;VX@2F%N=6%R>2`Q."P@,C`Q,0T*
M*'1H92`F(W@R,#%#.TYE;U-T96T@4W!E8VEA;"!-965T:6YG)B-X,C`Q1#LI
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M5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^5&AE#0IF86ER('9A
M;'5E(&]F('1H92!N970@87-S971S(&%C<75I<F5D(&EN('1H92!00U0@365R
M9V5R('=A<PT*)FYB<W`[)#$R+#0Q-BPR,#`N(%1H92!F86ER('9A;'5E(&]F
M('1H92!E<75I='D@:7-S=65D(&%S(&-O;G-I9&5R871I;VX-"F)Y($YE;U-T
M96T@=V%S('9A;'5E9"!A="`F;F)S<#LD,3<L,C`P+#`P,"!R97-U;'1I;F<@
M:6X@=&AE(')E8V]G;FET:6]N#0IO9B!G;V]D=VEL;"!I;B!T:&4@86UO=6YT
M(&]F("9N8G-P.R0T+#<X,RPV,#`N(%1H92!F86ER('9A;'5E(&]F('1H90T*
M97%U:71I97,@:7-S=65D(&)Y($YE;U-T96T@:6YC;'5D960@,3`L-C`P+#`P
M,"!S:&%R97,@;V8@3F5O4W1E;0T*0V]M;6]N('-T;V-K('9A;'5E9"!A="`F
M;F)S<#LD,34L.3`P+#`P,"!A;F0@3F5O4W1E;2!W87)R86YT<R!T;R!P=7)C
M:&%S90T*=7`@=&\@,RPP,#`L,#`P('-H87)E<R!V86QU960@870@)FYB<W`[
M)#$L.38V+#(P,"XF(WA!,#LF(WA!,#M!('!O<G1I;VX-"F]F('1H92!C;VYS
M:61E<F%T:6]N('!A:60@:7,@8V]N=&EN9V5N="!U<&]N('1H92!A8V-O;7!L
M:7-H;65N="!O9@T*82!C97)T86EN(&UI;&5S=&]N92!F;W(@=&AE("9N8G-P
M.R0W+C`P(%=A<G)A;G1S+B8C>$$P.R8C>$$P.U-U8V@-"F-O;G1I;F=E;G0@
M8V]N<VED97)A=&EO;B!H87,@8F5E;B!C;&%S<VEF:65D(&%S(&5Q=6ET>2!A
M;F0@=VEL;"!N;W0-"F)E('-U8FIE8W0@=&\@<F5M96%S=7)E;65N="XF(WA!
M,#LF(WA!,#M4:&4@9V]O9'=I;&P@=&AA="!H87,@8F5E;@T*8W)E871E9"!B
M>2!T:&ES(&%C<75I<VET:6]N(&ES(')E9FQE8W1I=F4@;V8@=F%L=65S(&%N
M9`T*;W!P;W)T=6YI=&EE<R!O9B!U=&EL:7II;F<@4$-4)B-X,C`Q.3MS(&-E
M;&P@8V]L;&5C=&EO;BP@<')O8V5S<VEN9PT*86YD('-T;W)A9V4@*&-E;&P@
M8F%N:VEN9RD@<F5S;W5R8V5S(&%N9"!P<F]D=6-T:6]N(&-A<&%C:71I97,L
M(&%S#0IM96YT:6]N960@86)O=F4N/"]F;VYT/CPO9&EV/@T*/"]D:78^#0H\
M9&EV/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SXF(WA!,#L\
M+V9O;G0^/"]D:78^#0H\9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^5&AE#0IP<F5L:6UI;F%R>2!F86ER('9A
M;'5E(&]F(&%S<V5T<R!A8W%U:7)E9"!A;F0@;&EA8FEL:71I97,@87-S=6UE
M9`T*;VX@2F%N=6%R>2`Q.2P@,C`Q,2!I<R!A<R!F;VQL;W=S.CPO9F]N=#X\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^#0H\+V1I=CX-"CQD:78^
M#0H\9&EV(&%L:6=N/3-$8V5N=&5R/@T*/'1A8FQE(&-E;&QP861D:6YG/3-$
M,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0T,"4@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
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M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N)SY#87-H/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R-24@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/C(R-RPY,#`\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L
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M"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/D%C
M8V]U;G1S#0I296-E:79A8FQE/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,B4^#0H\9&EV('-T
M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4
M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
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M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,C4E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ-C8L,C`P/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
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M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY0<F]P97)T>2P-"E!L86YT("9A
M;7`[($5Q=6EP;65N=#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/C$Q+#<V.2PP,#`\+V9O
M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
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M3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
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M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C4E('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SXX+#$P,"PP,#`\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
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M8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/D=O;V1W:6QL/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(U)2!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^-"PW
M.#,L-C`P/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<R)3X-
M"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/D]T
M:&5R#0I!<W-E=',\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,C4E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXV-30L,3`P/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
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M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,C4E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I
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M3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
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M(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C4E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXQ+#,W,"PY,#`\+V9O;G0^/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
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M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!
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M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
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M97<@<F]M86XG/C4T,"PU,#`\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$58
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M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^1&5F97)R960-"E)E=F5N=65S/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
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M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S(E/@T*
M/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
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M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
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M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/C,L,#`P
M+#`P,#PO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F
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M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY-;W)T
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M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,C4E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXS+#<X-"PV,#`\+V9O
M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
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M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SY4:&4-"G1O=&%L(&-O<W0@;V8@=&AE(&%C<75I
M<VET:6]N+"!W:&EC:"!I<R!S=&EL;"!P<F5L:6UI;F%R>2P@:&%S(&)E96X-
M"F%L;&]C871E9"!T;R!T:&4@87-S971S(&%C<75I<F5D(&%N9"!T:&4@;&EA
M8FEL:71I97,@87-S=6UE9"!B87-E9`T*=7!O;B!T:&5I<B!E<W1I;6%T960@
M9F%I<B!V86QU97,@870@=&AE(&1A=&4@;V8@=&AE(&%C<75I<VET:6]N+@T*
M)B-X03`[270@:7,@97AP96-T960@=&AE(&=O;V1W:6QL('=I;&P@8F4@9&5D
M=6-T:6)L92!F;W(@:6YC;VUE('1A>`T*<'5R<&]S97,N)B-X03`[)B-X03`[
M07,@;V8@4V5P=&5M8F5R(#,P+"`R,#$Q+"!T:&4@<')E;&EM:6YA<GD@9F%I
M<@T*=F%L=65S(&]F('1H92!D969E<G)E9"!T87@@;&EA8FEL:71I97,@=V5R
M92!R961U8V5D('1O('IE<F\L(&9R;VT-"F%N(&EN:71I86P@97-T:6UA=&4@
M;V8@)FYB<W`[)#0N,R!M:6QL:6]N+"!D=64@=&\@=&AE(&9I;F%L:7IA=&EO
M;B!O9B!T:&4-"G1A>"!T<F5A=&UE;G0@;V8@=&AE('1R86YS86-T:6]N+B!!
M<R!A(')E<W5L="P@=&AE('1A>"!P<F]V:7-I;VX-"F9O<B!T:&4@;FEN92!M
M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$Q(')E9FQE8W1S(&$@)FYB
M<W`[)#$W."PP,#`-"F%D:G5S=&UE;G0@<F5L871E9"!T;R!T:&4@<&]R=&EO
M;B!O9B!D969E<G)E9"!T87@@;&EA8FEL:71Y#0IR96-O9VYI>F5D(&EN('1H
M92!F:7)S="!A;F0@<V5C;VYD('%U87)T97)S(&]F(&9I<V-A;"`R,#$Q+B!)
M;@T*861D:71I;VXL('1H92!F86ER('9A;'5E(&]F('1H92!E<75I='D@:7-S
M=65D(&%S(&-O;G-I9&5R871I;VX@8GD-"DYE;U-T96T@=V%S(')E9'5C960@
M8GD@)FYB<W`[)#8V-BPR,#`N(%1H92!N970@969F96-T(&]F('1H92!U<&1A
M=&5D#0IV86QU97,@<F5D=6-E9"!T:&4@<')E;&EM:6YA<GD@9V]O9'=I;&P@
M8GD@)FYB<W`[)#0N.2!M:6QL:6]N+B!4:&ES#0IE<W1I;6%T960@<'5R8VAA
M<V4@<')I8V4@86QL;V-A=&EO;B!C;VYT:6YU97,@=&\@8F4@<W5B:F5C="!T
M;PT*<F5V:7-I;VX@8F%S960@;VX@861D:71I;VYA;"!V86QU871I;VX@=V]R
M:R!T:&%T(&ES(&)E:6YG#0IC;VYD=6-T960N)B-X03`[(%1H92!F:6YA;"!A
M;&QO8V%T:6]N(&ES('!E;F1I;F<@=&AE(')E8V5I<'0@;V8-"G1H:7,@=F%L
M=6%T:6]N('=O<FL@86YD('1H92!C;VUP;&5T:6]N(&]F('1H92!#;VUP86YY
M)B-X,C`Q.3MS#0II;G1E<FYA;"!R979I97<L('=H:6-H(&ES(&5X<&5C=&5D
M(&1U<FEN9R!F:7-C86P@,C`Q,2X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/D9O<@T*=&AE('!E<FEO9"!S:6YC92!T:&4@86-Q=6ES:71I;VX@
M*$IA;G5A<GD@,3DM4V5P=&5M8F5R(#,P+"`R,#$Q*2P-"DYE;U-T96T@<F5C
M;W)D960@)FYB<W`[)#4L-3<Q+#4P,"!I;B!R979E;G5E<R!A;F0@82!N970@
M;&]S<R!O9@T*87!P<F]X:6UA=&5L>2`F;F)S<#LD-"PP-#,L,S`P(&]R("9N
M8G-P.R0P+C`U(&)A<VEC(&%N9"!D:6QU=&5D(&QO<W,@<&5R('-H87)E#0IA
M='1R:6)U=&%B;&4@=&\@4$-4+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
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M<VET:6]N(&]F#0I00U0@:&%D(&]C8W5R<F5D(&]N($IA;G5A<GD@,2P@,C`Q
M,"`H:6X@=&AO=7-A;F1S+"!E>&-E<'0@<&5R('-H87)E#0IA;6]U;G1S*3H\
M+V9O;G0^/"]D:78^#0H\+V1I=CX-"CQD:78^)B-X03`[/"]D:78^#0H\9&EV
M/@T*/&1I=B!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P
M(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*
M/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/
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M34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z
M(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0I.:6YE($UO
M;G1H<R!%;F1E9"!397!T96UB97(@,S`L/"]F;VYT/CPO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!C96YT
M97(G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO
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M5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)
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M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M
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M1TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0I.:6YE($UO;G1H
M<R!%;F1E9"!397!T96UB97(@,S`L/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!C96YT97(G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>#L@5$585"U!3$E'3CH@8V5N=&5R
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>#L@5$585"U!3$E'3CH@8V5N=&5R)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0HF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)SX-"CQD:78@
M<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%
M6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=.
M.B!C96YT97(G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/@T*,C`Q,3PO9F]N=#X\+V1I=CX-"CPO=&0^
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M.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z
M(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0HR,#$Q/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
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M(')O;6%N)SX-"C(P,3`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&YO=W)A
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M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)SX-
M"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4
M+4%,24=..B!C96YT97(G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*,C`Q,#PO9F]N=#X\+V1I=CX-
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M+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0HR
M,#$P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[
M(%1%6%0M04Q)1TXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%
M.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9&EV('-T>6QE
M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.
M1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@8V5N
M=&5R)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U7
M14E'2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SX-"C(P,3`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
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M/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&-E;G1E
M<B<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(
M5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E
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M+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)SX-"CQD:78@<W1Y;&4]
M,T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$
M14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!C96YT
M97(G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%
M24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE
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M.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z
M(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0HH07,@4F5P
M;W)T960I/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^#0H\9&EV('-T
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M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!
M3$E'3CH@8V5N=&5R)SX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T.R!415A4+4%,24=..B!C96YT97(G/@T*/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T**$%S
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M5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^#0HH4')O9F]R;6$I/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE
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M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
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M05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#@E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/C4U+#@U
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M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P
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M.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M;6%N)SXQ-BPT-S8\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)FYB<W`[)#PO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N
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M(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N
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M;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:
M13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B9N8G-P
M.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X
M)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXU-RPU-S4\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G
M8V]L;W(],T1W:&ET93X-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,S0E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY#
M;W-T#0IO9B!R979E;G5E<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI
M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)SX\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/
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M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
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M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ,2PR,S,\+V9O;G0^/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>#L@5$585"U!3$E'
M3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#@E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@
M5$585"U!3$E'3CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
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M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)
M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P
M>"<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F
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M,T0X)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXS.2PU-C$\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S-"4^#0H\9&EV('-T>6QE/3-$)T1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/D=R;W-S#0IP<F]F:70\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
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M;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
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M;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
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M;F5W(')O;6%N)SXQ-"PR-SD\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^-2PR-#,\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V
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M.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^-2PX.#<\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H
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M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M."4@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^,38L-S`Q/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-
M"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#@E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/C$X+#`Q-#PO9F]N=#X\+W1D/@T*
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M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/E)E<V5A<F-H#0IA;F0@9&5V96QO<&UE;G0\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
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M05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/C<L-S8W/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/C<L-S8W/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
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M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/C$L-C@P/"]F;VYT/CPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG
M:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
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M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86XG/C$L-C<Y/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-
M"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#@E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/C4L,3$T/"]F;VYT/CPO=&0^#0H\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/C4L,3$Q/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-
M"CQT<B!B9V-O;&]R/3-$(T-#1D9#0SX-"CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,S0E('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SY396QL:6YG+`T*9V5N97)A;"P@86YD(&%D;6EN:7-T<F%T:79E
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
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M1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
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M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXS,BPR,3@\+V9O
M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>#L@5$58
M5"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#@E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S
M;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/CDL,S`W/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
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M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXQ,"PY,#4\+V9O
M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>#L@5$58
M5"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#@E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S
M;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE
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M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^
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M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%
M6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$
M=VAI=&4^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,T)3X-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^3W!E<F%T:6YG#0IL;W-S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[
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M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/BD\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[
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M.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXH,C4L-S`V/"]F
M;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/BD\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[
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M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO
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M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X
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M;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
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M;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
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M(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86XG/D]T:&5R#0II;F-O;64@*&5X<&5N<V4I+"!N970\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
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M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SXH,2PT-#<\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
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M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N)SXH,2PT.#(\+V9O;G0^/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ
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M5$]-.B`R<'@G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@
M5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/BD\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[
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M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SY,;W-S#0IF<F]M(&]P97)A=&EO;G,@8F5F;W)E('!R;W9I
M<VEO;B!F;W(@:6YC;VUE('1A>&5S(&%N9#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M
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M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
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M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F
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M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P
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M93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$."4@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T
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M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G
M8V]L;W(],T0C0T-&1D-#/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S-"4^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/FYO;F-O;G1R;VQL:6YG#0II;G1E<F5S=',\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86XG/B@R-BPX,C$\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$58
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M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86XG/B@R-RPQ.#<\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$58
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M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N
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M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO
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M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/BD\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
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M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/BD\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
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M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
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M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/
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M=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#@E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-
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M:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^.3`X
M/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[
M(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0X)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SXR.#8\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^
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M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG
M:'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/C(X-CPO9F]N
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M.B`R<'@G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$."4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O
M;&ED.R!415A4+4%,24=..B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^,2PQ.3$\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/C$L,3DQ/"]F;VYT
M/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M
M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T-#
M1D9#0SX-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,S0E/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B@R-RPW,CD\+V9O;G0^/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B@R."PY,#4\+V9O;G0^/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#@E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/
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M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
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M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/BD\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-
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M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/BD\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-
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M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
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M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T
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M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
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M;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
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M93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0HF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)2!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXU-3D\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^,2PQ-#8\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^,2PQ-#8\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^-"PP.#8\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V
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M.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^-"PP.#8\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L
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M5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/E!R
M969E<G)E9`T*9&EV:61E;F1S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^-3`X/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
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M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SXU,#@\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#)P>#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX]
M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#@E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/BT\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>#L@5$585"U!3$E'3CH@;&5F="<^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
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M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/BT\
M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>#L@
M5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#@E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P
M>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T
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M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^
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M:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M
M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI
M=&4^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,T)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"CQD:78@<W1Y
M;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M
M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
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M/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/BD\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B9N8G-P.R0\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R
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M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!4
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M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T
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M.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX\9F]N="!S
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M.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B@X+#$W-3PO
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M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4
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M05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/B@Q-RPR.#`\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
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M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXH,C`L.#4U/"]F
M;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@[(%1%
M6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/BD\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&
M0T,^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,T)3X-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
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M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
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M;VUA;B<^*#`N,S4\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/B@P+C$S/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/BD\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C
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M;B<^*#`N,3(\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
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M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/B@P+C,U/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/BD\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S-"4^#0H\9&EV('-T
M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4
M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/E=E:6=H=&5D#0IA
M=F5R86=E(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
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M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
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M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
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M;6%N)SXX,RPU,3,\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO
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M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@.'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/C8W+#,W-SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE
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M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H
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M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
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M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/@T*/"]D:78^#0H\+V1I=CX-"CQD:78^)B-X03`[/"]D:78^#0H\9&EV
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M(&]N($IA;G5A<GD@,2P@,C`Q,"P@;F]R(&%R90T*=&AE>2!I;F1I8V%T:79E
M(&]F(&9U='5R92!R97-U;'1S+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO
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M(&1E=F5L;W!M96YT(&]F(%0@<F5G=6QA=&]R>2!C96QL<R`H5%)E9W,I(&%S
M(&$@=&AE<F%P975T:6,@=&\-"G1R96%T(&1I<V]R9&5R<R!O9B!T:&4@:6UM
M=6YE('-Y<W1E;2XF(WA!,#L@4'5R<W5A;G0@=&\@82!3=&]C:PT*4'5R8VAA
M<V4@86YD($%S<VEG;FUE;G0@06=R965M96YT(&1A=&5D($UA<F-H(#(X+"`R
M,#$Q+"!!=&AE;&]S#0II<W-U960@87!P<F]X:6UA=&5L>2`R,"4@;V8@:71S
M('-H87)E<R!T;R!"96-T;VX@1&EC:VEN<V]N(&%N9`T*0V]M<&%N>2`H)B-X
M,C`Q0SM"1"8C>#(P,40[*2!I;B!E>&-H86YG92!F;W(@=&AE(')I9VAT<R!T
M;R!C97)T86EN#0II;G1E;&QE8W1U86P@<')O<&5R='D@<F5L871I;F<@=&\@
M5%)E9W,@=&AA="!"1"!O=VYE9"!P=7)S=6%N="!T;R!A#0IL:6-E;G-E(&%G
M<F5E;65N="!B971W965N('1H92!5;FEV97)S:71Y(&]F(%!E;FYS>6QV86YI
M80T**"8C>#(P,4,[4&5N;B8C>#(P,40[*2!A;F0@0D0@9&%T960@4V5P=&5M
M8F5R(#(X+"`R,#`U("AT:&4-"B8C>#(P,4,[4&5N;B!,:6-E;G-E)B-X,C`Q
M1#LI+"!A;F0@82!L:6-E;G-E(&%G<F5E;65N="!B971W965N($5X0V5L;`T*
M5&AE<F%P975T:6-S+"!,3$,@86YD($)$(&1A=&5D(%-E<'1E;6)E<B`Q-BP@
M,C`P-2P@87,@86UE;F1E9`T*075G=7-T(#,Q+"`R,#`W("AT:&4@)B-X,C`Q
M0SM%>$-E;&P@3&EC96YS928C>#(P,40[*2XF(WA!,#L@4'5R<W5A;G0-"G1O
M(&$@4W1O8VL@4'5R8VAA<V4@86YD($%S<VEG;FUE;G0@06=R965M96YT(&1A
M=&5D($UA<F-H(#(X+"`R,#$Q+`T*071H96QO<R!T;V]K(&%S<VEG;FUE;G0@
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M8V5N<V4@=VET:"!T=V\@;F5W(&1I<F5C=`T*;&EC96YS97,Z(%1H92!!;65N
M9&5D(&%N9"!297-T871E9"!0871E;G0@3&EC96YS92!!9W)E96UE;G0@8F5T
M=V5E;@T*4&5N;B!A;F0@071H96QO<R!D871E9"!397!T96UB97(@,3(L(#(P
M,3$L(&%N9"!T:&4@4&%T96YT($QI8V5N<V4-"D%G<F5E;65N="!B971W965N
M(%!E;FXL($%T:&5L;W,@86YD('1H92!5;FEV97)S:71Y(&]F($UI;FYE<V]T
M80T*9&%T960@4V5P=&5M8F5R(#$R+"`R,#$Q+B!!=&AE;&]S(&%N9"!%>$-E
M;&P@87)E(&EN('1H92!P<F]C97-S(&]F#0IN96=O=&EA=&EN9R!A(&1I<F5C
M="!L:6-E;G-E('1H870@=V]U;&0@<F5P;&%C92!T:&4@97AI<W1I;F<-"F%S
M<VEG;F5D($5X0V5L;"!,:6-E;G-E+B8C>$$P.R8C>$$P.U!U<G-U86YT('1O
M('1H90T*4W1O8VMH;VQD97)S)B-X,C`Q.3L@06=R965M96YT(&1A=&5D($UA
M<F-H(#(X+"`R,#$Q+"!!=&AE;&]S+"!00U0-"F%N9"!"1"!H879E(&%G<F5E
M9"P@=&AA="P@86UO;F<@;W1H97(@=&AI;F=S+"!"1"!W:6QL(&AA=F4@8V5R
M=&%I;@T*86YT:2UD:6QU=&EO;B!P<F]T96-T:6]N(&9O<B!T:&4@9FER<W0@
M)FYB<W`[)#4@;6EL;&EO;B!O9B!N97<@:6YV97-T;65N=`T*:6X@071H96QO
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M8F5R(#$V+"`R,#`U(&)E='=E96X@1&%V:60-"DAO<G=I='HL($TN1"X@86YD
M($)$+"!T;R!B92!P86ED(')E=')O86-T:79E;'D@8F5G:6YN:6YG(&%S(&]F
M#0I*86YU87)Y(#$L(#(P,3$L(&9O<B!S97)V:6-E<R!R96YD97)E9"!I;B!A
M9'9A;F-I;F<@=&AE($%T:&5L;W,-"E1296<@<F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT('!L871F;W)M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-464Q%.B!I=&%L:6,G/BX\+V9O;G0^)B-X03`[)B-X03`[4$-4
M(&AA9`T*<')E;&EM:6YA<FEL>2!V86QU960@0D0F(W@R,#$Y.W,@<VAA<F4@
M;V8@=&AE(&-O;G1R:6)U=&5D#0II;G1E;&QE8W1U86P@<')O<&5R=&EE<R!I
M;B!T:&4@<75A<G1E<B!E;F1E9"!-87)C:"`S,2P@,C`Q,2!A=`T*)FYB<W`[
M)#DR-RPP,#`@86YD(&-H87)A8W1E<FEZ960@=&AI<R!A8W%U:7)E9"!I;G1A
M;F=I8FQE(&%S<V5T(&%S#0II;BUP<F]C97-S(')E<V5A<F-H(&%N9"!D979E
M;&]P;65N="!W:&EC:"!H87,@8F5E;B!R96-O<F1E9"!A<PT*97AP96YS92!W
M:71H:6X@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N<V4N/"]F;VYT
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@5$585"U)
M3D1%3E0Z(#!P="<^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^26X-"G1H92!Q=6%R=&5R(&5N
M9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,2P@4$-4(&9I;F%L:7IE9"!I=',@=F%L
M=6%T:6]N#0IO9B!T:&4@:6YT96QL96-T=6%L('!R;W!E<G1I97,@<F5C96EV
M960L(&%N9"!R979I<V5D('1H92!F86ER('9A;'5E#0IT;R`F;F)S<#LD,2PQ
M-3`L,#`P+"!W:&EC:"!I<R!R96-O<F1E9"!A<R!E>'!E;G-E('=I=&AI;B!R
M97-E87)C:"!A;F0-"F1E=F5L;W!M96YT(&5X<&5N<V4@9F]R('1H92!N:6YE
M(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L#0HR,#$Q+CPO9F]N=#X\+V1I
M=CX-"CPO9&EV/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14Q'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D=O
M;V1W:6QL(&%N9"!/=&AE<B!);G1A;F=I8FQE($%S<V5T<SQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y';V]D=VEL;"!A;F0@3W1H
M97(@26YT86YG:6)L92!!<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQD:78^#0H\9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!415A4+41%0T]2051)3TXZ('5N
M9&5R;&EN92<^3F]T92`U#0HF(W@R,#$S.R!';V]D=VEL;"!A;F0@3W1H97(@
M26YT86YG:6)L92!!<W-E=',\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R
M("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY4:&4-"F-H86YG97,@:6X@=&AE(&-A<G)Y:6YG(&%M;W5N="!O
M9B!G;V]D=VEL;"!B>2!R97!O<G1A8FQE('-E9VUE;G0-"F1U<FEN9R!N:6YE
M(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3$@=V5R92!A<R!F;VQL
M;W=S("AI;@T*=&AO=7-A;F1S*3H\+V9O;G0^/"]D:78^#0H\+V1I=CX-"CQD
M:78^)B-X03`[/"]D:78^#0H\9&EV/@T*/&1I=B!A;&EG;CTS1&-E;G1E<CX-
M"CQT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0W-24^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,30E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
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M1TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/E!H87)M86-E=71I8V%L/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#4R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D-E;&P-"E1H97)A<'D@+3PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY-86YU9F%C='5R:6YG#0HM/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#4R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/E5N:71E9`T*4W1A=&5S/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@
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M93TS1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^0VAI
M;F$\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E
M;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX-"E1O=&%L/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&
M0T,^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3(E(&%L:6=N/3-$
M;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/D)A;&%N8V4-"F%S(&]F($1E8V5M8F5R(#,Q+"`R,#$P/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3,E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
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M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^,C<L,#`R+C`\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C<L,#`R+C`\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T
M<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-3(E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$S)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXT+#<X,RXV/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
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M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
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M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^.#`Q
M+C$\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@
M<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^.#`Q+C$\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-3(E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D)A;&%N8V4-"F%S(&]F(%-E<'1E
M;6)E<B`S,"P@,C`Q,3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT+#<X,RXV/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/C(W+#@P,RXQ/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U
M8FQE.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXJ1V]O9'=I;&P-"F%S<V]C:6%T
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-
M"CPO9&EV/@T*/"]D:78^#0H\9&EV/B8C>$$P.SPO9&EV/@T*/&1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D%S
M#0IO9B!397!T96UB97(@,S`L(#(P,3$@86YD($1E8V5M8F5R(#,Q+"`R,#$P
M+"!T:&4@0V]M<&%N>28C>#(P,3D[<PT*:6YT86YG:6)L92!A<W-E=',@86YD
M(')E;&%T960@86-C=6UU;&%T960@86UO<G1I>F%T:6]N(&-O;G-I<W1E9"!O
M9@T*=&AE(&9O;&QO=VEN9R`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^/"]D:78^
M#0H\+V1I=CX-"CQD:78^)B-X03`[/"]D:78^#0H\9&EV/@T*/&1I=B!A;&EG
M;CTS1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<CX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R,R4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S$E(&-O;'-P86X],T0Q,"!N
M;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M.'!T)SY397!T96UB97(-"C,P+"`R,#$Q/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!C
M96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,Q)2!C;VQS<&%N/3-$
M,3`@;F]W<F%P/3-$;F]W<F%P/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^1&5C96UB97(-"C,Q+"`R,#$P/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R,R4^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
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M)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
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M,B!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&-O
M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,24^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`X<'0G/E5S969U;`T*3&EF93PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#DE(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A
M<#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
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M;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Y)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`X<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^3F5T/"]F;VYT/CPO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
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M;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`X<'0G/D=R;W-S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SY!;6]R=&EZ
M871I;VX\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M.24@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/DYE=#PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$
M(T-#1D9#0SX-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,R4@86QI
M9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
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M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`X<'0G/C$P#0I996%R<SPO9F]N=#X\+V1I=CX-
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M;CL@1D].5"U325I%.B`X<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0X)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/C$Y+#8V-BXS/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)FYB<W`[)#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0X)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`X<'0G/C$V+#`V-RXW/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M($9/3E0M4TE:13H@.'!T)SXQ-RPW-#`N,#PO9F]N=#X\+W1D/@T*/'1D('-T
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M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
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M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^*3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXQ-2PV-S`N,SPO9F]N=#X\+W1D
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M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`X<'0G/DUA;G5F86-T=7)I;F<-"G1E8VAN;VQO
M9WD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*/&1I
M=B!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T
M)SXQ,`T*665A<G,\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C$P+#(U,2XS/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B@Q+#(T-RXT/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BD\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D
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M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXY+#`P,RXY/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@.'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C0L,C(P+C8\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
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M1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BD\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T-#1D9#0SX-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R,R4@86QI9VX],T1L969T/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SY4<F%D96YA
M;64\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*/&1I
M=B!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T
M)SXQ,`T*665A<G,\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C(L,S$S+C`\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M;VUA;CL@1D].5"U325I%.B`X<'0G/BD\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXR+#`R."XR/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/CDX,RXY/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B@Q,30N.#PO
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M25I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^.#8Y+C$\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R,R4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
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M+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D
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M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C$L-S<Y+CD\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M25I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C(L,C$Y
M+C8\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(S)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/E-T86YD87)D
M#0IO<&5R871I;F<@<')O8V5D=7)E<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,24^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`X<'0G/C$P#0I996%R<SPO9F]N=#X\+V1I=CX-
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M;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
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M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^*3PO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/C@X-RXY/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0X)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`X<'0G/C$L,#8V+C@\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#@E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#AP="<^*#$R-"XU/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/BD\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0HF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$."4^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@.'!T)SXY-#(N,SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H
M:71E/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(S)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/DQE87-E#0IR:6=H=',\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3$E/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@.'!T)SXR#0I996%R<SPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#@E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^.#0Q+C0\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
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M1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#@E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^*#@P
M-BXT/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BD\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C@Q
M-RXR/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
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M;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#@E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M,S0P+C4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(S)2!A;&EG;CTS1&QE9G0^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/E9314P-
M"G!A=&5N="!R:6=H=',\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3$E/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@.'!T)SXQ.0T*665A<G,\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C8V.2XP/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B@Q,S(N
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M5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#@E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^-3,W+C`\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
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M1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#@E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^-C8Y
M+C`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
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M;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BD\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P
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M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(S)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`X<'0G/E!A=&5N=',\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.
M1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*
M/&1I=B!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
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M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C(P,RXQ/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
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M:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0X)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T
M)SXH.#$N,CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W
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M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG
M:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`X<'0G/C$R,2XY/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0X)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXQ-C0N
M-#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
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M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^*3PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXQ,S,N,CPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
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M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#@E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`X<'0G/C,V+#@R,BXT/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M."4^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^*#8L,S8P+CD\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#AP="<^*3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[
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M+5-)6D4Z(#AP="<^,S`L-#8Q+C4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B9N8G-P.R0\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0X)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXR-RPX.#$N
M-3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG
M:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`X<'0G/B@S+#0Q-"XY/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BD\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)FYB<W`[)#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S
M;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#@E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C(T+#0V
M-BXV/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^
M#0H\+V1I=CX-"CPO9&EV/@T*/&1I=CXF(WA!,#L\+V1I=CX-"CQD:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY)
M;@T*,C`Q,2P@17)Y92!C;VUM96YC960@<V%L97,@;V8@='=O('!R;V1U8W1S
M('1H870@=V5R92!P<F5V:6]U<VQY#0IA8V-O=6YT960@9F]R(&%S($EN(%!R
M;V-E<W,@4B9A;7`[1"!W:&EC:"!H87,@<F5S=6QT960@:6X@80T*<F5C;&%S
M<VEF:6-A=&EO;B!O9B!A<'!R;WAI;6%T96QY("9N8G-P.R0U,#4L-3`P(&9R
M;VT@26X@4')O8V5S<R!2)F%M<#M$#0IT;R!-86YU9F%C='5R:6YG(%1E8VAN
M;VQO9WDN)B-X03`[)B-X03`[0V5R=&%I;B!O9B!T:&4-"D-O;7!A;GDF(W@R
M,#$Y.W,@:6YT86YG:6)L92!A<W-E=',@87)E(')E8V]R9&5D(&]N('1H92!B
M;V]K<R!O9@T*=VAO;&QY(&]W;F5D(&]R('!A<G1I86QL>2!O=VYE9"!S=6)S
M:61I87)I97,@86YD(&%F9FEL:6%T97,@:6X-"D-H:6YA+"!A;F0@9&5N;VUI
M;F%T960@:6X@4DU"+B`F(WA!,#M!<R!A(')E<W5L="P@=&AE(&)A;&%N8V4-
M"G)E<&]R=&5D(&9L=6-T=6%T97,@8F%S960@=7!O;B!T:&4@8VAA;F=E<R!I
M;B!E>&-H86YG90T*<F%T97,N/"]F;VYT/CPO9&EV/@T*/"]D:78^#0H\9&EV
M/B8C>$$P.SPO9&EV/@T*/&1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DEN#0IC;VYN96-T:6]N('=I=&@@=&AE
M(&%C<75I<VET:6]N(&]F(%!#5"P@=&AE(&9O;&QO=VEN9R!I;G1A;F=I8FQE
M#0IA<W-E=',@=V5R92!A8W%U:7)E9"`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^
M/"]D:78^#0H\+V1I=CX-"CQD:78^)B-X03`[/"]D:78^#0H\9&EV/@T*/&1I
M=B!A;&EG;CTS1&-E;G1E<CX-"CQT86)L92!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0V-24^#0H\='(@8F=C
M;VQO<CTS1"-#0T9&0T,^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-S<E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,C`E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/C$L-#`P+C`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S<E(&%L:6=N/3-$;&5F
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
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M3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(P)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU
M+#0P,"XP/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-S<E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
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M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,C`E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXQ+#,P,"XP/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<W)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U
M8FQE.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[
M)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R,"4^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C@L,3`P+C`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T
M<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CPO9&EV/@T*/&1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
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M;&]W<R`H:6X-"G1H;W5S86YD<RDZ/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#XF
M(WA!,#L\+V1I=CX-"CPO9&EV/@T*/&1I=CX-"CQD:78@86QI9VX],T1C96YT
M97(^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$.#4E/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(X)2!C;VQS<&%N/3-$-B!N;W=R87`],T1N
M;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(X)2!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-#`E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N
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M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^,C`Q,3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P
M>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/@T*/&1I
M=B!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*,C`Q,#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-
M"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"C(P,3`\+V9O;G0^
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
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M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS.#@N,3PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
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M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+#$R-BXT/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P="<^#0I297-E87)C
M:"!A;F0@9&5V96QO<&UE;G0\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
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M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT,#$N,SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
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M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
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M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXQ+#$X-2XV/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&
M0T,^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-#`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T)SX-"E-E;&QI
M;F<L(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]F;VYT/CPO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXU-#<N.3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R
M:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXM/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
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M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^#0I4;W1A;#PO9F]N=#X\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
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M:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXT.#@N-#PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO
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M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D
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M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV
M/@T*/"]D:78^#0H\9&EV/B8C>$$P.SPO9&EV/@T*/&1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D5S=&EM871E9`T*
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M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXR,#$Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0X)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0U)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
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M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0U)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXS+#,X,"XP/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&
M0T,^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#4E(&%L:6=N/3-$
M<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^,C`Q,SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$."4@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#4E/@T*/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C,L,S@P+C`\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T
M<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-#4E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C`Q-#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
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M<'0G/C,L,S@P+C`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T-#1D9#
M0SX-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T-24@86QI9VX],T1R
M:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXR,#$U/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0X)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
M"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T-24^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,RPS.#`N,#PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T-24@86QI
M9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY4:&5R96%F=&5R/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0X)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T
M-24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$V+#`V,2XT
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO
M<CTS1"-#0T9&0T,^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#4E/@T*/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#0U)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,S`L-#8Q
M+C4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^
M#0H\+V1I=CX-"CPO9&EV/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$<^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^06-C<G5E9"!,:6%B:6QI=&EE<SQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D($QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I=B!A
M;&EG;CTS1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<CX-"CQT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[
M(%1%6%0M1$5#3U)!5$E/3CH@=6YD97)L:6YE)SX-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN92<^3F]T92`V)B-X,C`Q,SL@06-C<G5E9`T*3&EA
M8FEL:71I97,\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
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M5"U325I%.B`Q,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$-C4E/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8U)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0I397!T96UB97(@,S`L
M(#(P,3$\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
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M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN92<^#0I$96-E;6)E<B`S,2P@,C`Q,#PO9F]N=#X\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(]
M,T0C0T-&1D-#/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%
M6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-24^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P<'0[($1)
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M(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^#0HF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$T)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXQ,C8N-CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
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M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E-A;&%R:65S+`T*96UP;&]Y
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M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$T)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXY,3$N.#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#
M0T9&0T,^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)
M3D1%3E0Z(#!P=#L@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8U)3X-"CQD:78@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!;6]U;G0-
M"F1U92!O;B!P871E;G0@:6YF<FEN9V5M96YT/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-"4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M-S<P+C,\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
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M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$T)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXW-3@N-3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET
M93X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,G!X.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-C4E/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/D]T:&5R/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M
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M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^,2PV-S8N,SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#8U)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXU+#@V,RXP/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,30E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR
M+#<W,BXP/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%3$<^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M0F%N:R!,;V%N<RP@3F]T97,@4&%Y86)L92!A;F0@36]R=&=A9V5S(%!A>6%B
M;&4\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%N
M:R!,;V%N<RP@3F]T97,@4&%Y86)L92!A;F0@36]R=&=A9V5S(%!A>6%B;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\9&EV('-T
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M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,RXS<'0G(&%L:6=N
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M15A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`S+C-P="<@86QI9VX]
M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY)
M;@T*3F]V96UB97(@,C`Q,"P@17)Y92!O8G1A:6YE9"!A(&)A;FL@;&]A;B!O
M9B!A<'!R;WAI;6%T96QY#0HF;F)S<#LD,RPQ,C0L,#`P(&9R;VT@=&AE($-)
M5$E#($)A;FL@26YT97)N871I;VYA;"!W:71H(&$@=F%R:6%B;&4-"FEN=&5R
M97-T(')A=&4@=&AA="!I<R!C=7)R96YT;'D@-BXP-B4@86YD(&ES(&1U92!I
M;B!.;W9E;6)E<@T*,C`Q,2X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[(%1%6%0M24Y$14Y4.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#,N,W!T
M)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/DEN#0I-87D@,C`Q,2P@17)Y92!O8G1A:6YE9"!A(&)A;FL@;&]A
M;B!O9B!A<'!R;WAI;6%T96QY("9N8G-P.R0S+#$R-"PP,#`-"F9R;VT@0V]M
M;65R8VEA;"!"86YK(&]F($-H:6YA('=I=&@@82!V87)I86)L92!I;G1E<F5S
M="!R871E('1H870@:7,-"F-U<G)E;G1L>2`W+C`R)2!A;F0@:7,@9'5E(&EN
M($YO=F5M8F5R(#(P,3$N)B-X03`[/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=$25-03$%9.B!B;&]C:SL@5$585"U)3D1%3E0Z(#!P="<^/&)R("\^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`S
M+C-P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SY);@T*2G5L>2`R,#$Q+"!%<GEE(&]B=&%I;F5D(&$@8F%N
M:R!L;V%N(&]F(&%P<')O>&EM871E;'D@)FYB<W`[)#$L-38R+#`P,`T*9G)O
M;2!T:&4@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0I!9W)I8W5L='5R86P@0F%N:R!O9B!#:&EN83PO9F]N
M=#X\+V9O;G0^('=I=&@@82!V87)I86)L92!I;G1E<F5S=`T*<F%T92!T:&%T
M(&ES(&-U<G)E;G1L>28C>$$P.SQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
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M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4
M.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#,N,W!T)R!A;&EG;CTS1&IU<W1I9GD^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/D5R>64-"FAA<R!A
M<'!R;WAI;6%T96QY("9N8G-P.R0\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/C,L-3<Q+#`P
M,#PO9F]N=#X@;V8-"FYO=&5S('!A>6%B;&4@;W5T<W1A;F1I;F<@87,@;V8@
M4V5P=&5M8F5R(#,P+"`R,#$Q+B!.;W1E<R!A<F4-"G!A>6%B;&4@=&\@=&AE
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M;'D@,S`E("T@-3`E(&]F(&YO=&5S('1O(&)E(&ES<W5E9"P@;W(-"G!R;W!E
M<G1I97,@;W=N960@8GD@17)Y92X@4F5S=')I8W1E9"!C87-H('!L961G960@
M87,@8V]L;&%T97)A;"!F;W(-"G1H92!B86QA;F-E(&]F(&YO=&5S('!A>6%B
M;&4@870@4V5P=&5M8F5R(#,P+"`R,#$Q(&%N9"!$96-E;6)E<B`S,2P-"C(P
M,3`L(&%M;W5N=&5D('1O(&%P<')O>&EM871E;'D@)FYB<W`[)#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^,2PT,C@L,#`P/"]F;VYT/@T*86YD("9N8G-P.R0\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/C,L,S@Q+#0P,#PO9F]N=#XL#0IR97-P96-T:79E;'DN)B-X
M03`[($%T(%-E<'1E;6)E<B`S,"P@,C`Q,2!A;F0@1&5C96UB97(@,S$L(#(P
M,3`L#0IT:&4@<F5S=')I8W1E9"!C87-H(&%M;W5N=&5D('1O(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^-#`\+V9O;G0^)2!A;F0-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^,S4N
M.#PO9F]N=#XE+`T*<F5S<&5C=&EV96QY+"!O9B!T:&4@;F]T97,@<&%Y86)L
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M,#PO9F]N=#X-"F%N9"`F;F)S<#LD/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SXT+#@P-RPX
M,#`\+V9O;G0^(&%T#0I397!T96UB97(@,S`L(#(P,3$@86YD($1E8V5M8F5R
M(#,Q+"`R,#$P+`T*<F5S<&5C=&EV96QY+CPO9F]N=#X\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB
M<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2
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M(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,2!O9B!A<'!R;WAI;6%T96QY("9N8G-P
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M5"U)3D1%3E0Z(#!P="<^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)
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M5#H@,3AP=#L@34%21TE.+5))1TA4.B`S+C-P="<@86QI9VX],T1J=7-T:69Y
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY/;@T*3V-T;V)E
M<B`S,2P@,C`P-RP@4$-4(&ES<W5E9"!A(&YO=&4@=&\@8F]R<F]W("9N8G-P
M.R0S+#$R,"PP,#`@*'1H90T*)B-X,C`Q0SM.;W1E)B-X,C`Q1#LI(&EN(&-O
M;FYE8W1I;VX@=VET:"!I=',@)FYB<W`[)#,L.#$X+#4P,"!P=7)C:&%S92!O
M9@T*8V]N9&]M:6YI=6T@=6YI=',@:6X@86X@97AI<W1I;F<@8G5I;&1I;F<@
M:6X@06QL96YD86QE+"!.97<@2F5R<V5Y#0HH=&AE("8C>#(P,4,[4')O<&5R
M='DF(W@R,#%$.RD@=&AA="!00U0@=7-E<R!A<R!A(&QA8F]R871O<GD@86YD
M('-T96T-"F-E;&P@<')O8V5S<VEN9R!F86-I;&ET>2X@5&AE($YO=&4@:7,@
M<&%Y86)L92!I;B`R,SD@8V]N<V5C=71I=F4-"FUO;G1H;'D@<&%Y;65N=',@
M;V8@<')I;F-I<&%L(&%N9"!I;G1E<F5S="P@8F%S960@;VX@82`R,"!Y96%R
M#0IA;6]R=&EZ871I;VX@<V-H961U;&4[(&%N9"!O;F4@9FEN86P@<&%Y;65N
M="!O9B!A;&P@;W5T<W1A;F1I;F<-"G!R:6YC:7!A;"!P;'5S(&%C8W)U960@
M:6YT97)E<W0@=&AE;B!D=64N(%1H92!C=7)R96YT(&UO;G1H;'D-"FEN<W1A
M;&QM96YT(&ES("9N8G-P.R0R,"PW-C8L('=H:6-H(&EN8VQU9&5S(&EN=&5R
M97-T(&%T(&%N(&EN:71I86P@<F%T90T*;V8@-2XP,"4[('1H92!I;G1E<F5S
M="!R871E(&%N9"!M;VYT:&QY(&EN<W1A;&QM96YT<R!P87EM96YT<R!A<F4-
M"G-U8FIE8W0@=&\@861J=7-T;65N="!O;B!/8W1O8F5R(#$L(#(P,3<N($]N
M('1H870@9&%T92P@=7!O;B!P<FEO<@T*=W)I='1E;B!N;W1I8V4L('1H92!L
M96YD97(@:&%S('1H92!O<'1I;VX@=&\@9&5C;&%R92!T:&4@96YT:7)E#0IO
M=71S=&%N9&EN9R!P<FEN8VEP86P@8F%L86YC92P@=&]G971H97(@=VET:"!A
M;&P@;W5T<W1A;F1I;F<-"FEN=&5R97-T+"!D=64@86YD('!A>6%B;&4@:6X@
M9G5L;"X@5&AE($YO=&4@:7,@<V5C=7)E9"!B>0T*<W5B<W1A;G1I86QL>2!A
M;&P@;V8@=&AE(&%S<V5T<R!O9B!00U0L(&EN8VQU9&EN9R!A(&9I<G-T(&UO
M<G1G86=E#0IO;B!T:&4@4')O<&5R='D@86YD(&%S<VEG;FUE;G0@;V8@86X@
M86UO=6YT(&%P<')O>&EM871E;'D@97%U86P@=&\-"F5I9VAT965N(&UO;G1H
M<R!D96)T('-E<G9I8V4@:&5L9"!I;B!E<V-R;W<N(%1H92!.;W1E(&UA='5R
M97,@;VX-"D]C=&]B97(@,2P@,C`R-R!I9B!N;W0@8V%L;&5D(&)Y('1H92!L
M96YD97(@;VX@3V-T;V)E<B`Q+"`R,#$W+B!4:&4-"FYO=&4@:7,@<W5B:F5C
M="!T;R!C97)T86EN(&1E8G0@<V5R=FEC92!C;W9E<F%G92!A;F0@=&]T86P@
M9&5B="!T;PT*=&%N9VEB;&4@;F5T('=O<G1H(&9I;F%N8VEA;"!C;W9E;F%N
M="!R871I;W,@;65A<W5R960-"G-E;6DM86YN=6%L;'DN(%1H92!N97AT(&UE
M87-U<F5M96YT(&1A=&4@9F]R(&-O;7!L:6%N8V4@=VET:`T*9FEN86YC:6%L
M(&-O=F5N86YT<R!I<R!$96-E;6)E<B`S,2P@,C`Q,2X@4$-4('=A<R!N;W0@
M:6X@8V]M<&QI86YC90T*=VET:"!S=6-H(&-O=F5N86YT<R!A="!T:&4@;65A
M<W5R96UE;G0@9&%T92!O9B!*=6YE(#,P+"`R,#$Q+"!A;F0-"F]B=&%I;F5D
M(&$@8V]V96YA;G0@=V%I=F5R(&QE='1E<B!F<F]M('1H92!L96YD97(@9F]R
M(&%L;"!P97)I;V1S#0IT:')O=6=H($IU;F4@,S`L(#(P,3$N(%1H92!O=71S
M=&%N9&EN9R!B86QA;F-E('=A<R!A<'!R;WAI;6%T96QY#0HF;F)S<#LD/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SXR+#<S-BPQ,#`\+V9O;G0^(&%T#0I397!T96UB97(@
M,S`L(#(P,3$@;V8@=VAI8V@@)FYB<W`[)#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^,3$R
M+#<P,#PO9F]N=#X@:7,-"G!A>6%B;&4@=VET:&EN('1W96QV92!M;VYT:',N
M($]N($1E8V5M8F5R(#8L(#(P,3`F(WA!,#L@4$-4#0I!;&QE;F1A;&4L(&$@
M=VAO;&QY+6]W;F5D('-U8G-I9&EA<GD@;V8@4$-4+"!E;G1E<F5D(&EN=&\@
M82!N;W1E#0IF;W(@82!S96-O;F0@;6]R=&=A9V4@:6X@=&AE(&%M;W5N="!O
M9B`F;F)S<#LD,2!M:6QL:6]N(&]N('1H92!!;&QE;F1A;&4-"E!R;W!E<G1Y
M('=I=&@@5$0@0F%N:RP@3BY!+B8C>$$P.R!4:&ES(&QO86X@:7,@9W5A<F%N
M=&5E9"!B>2!00U0L#0I$;VUA;FE#96QL("AA('=H;VQL>2UO=VYE9"!S=6)S
M:61I87)Y(&]F(%!#5"P@;F]W(&MN;W=N(&%S($YE;U-T96T-"D9A;6EL>2!3
M=&]R86=E+"!,3$,I+"!.;W)T:&5R;B!.97<@2F5R<V5Y($-A;F-E<B!!<W-O
M8VEA=&5S#0HH)B-X,C`Q0SM.3DI#028C>#(P,40[*2!A;F0@8V5R=&%I;B!P
M87)T;F5R<R!O9B!.3DI#02!A;F0@:7,@<W5B:F5C=`T*=&\@82!F:6YA;F-I
M86P@8V]V96YA;G0@<W1A<G1I;F<@1&5C96UB97(@,S$L(#(P,3$N(%1H92!L
M;V%N(&ES(&9O<@T*,3(T(&UO;G1H<R!A="!A(&9I>&5D(')A=&4@;V8@-B4@
M9F]R('1H92!F:7)S="`V-"!M;VYT:',N(%1H92!L;V%N#0II<R!C86QL86)L
M92!F;W(@82!C97)T86EN('!E<FEO9"!P<FEO<B!T;R!T:&4@:6YT97)E<W0@
M<F5S970-"F1A=&4N)B-X03`[)B-X03`[(%1H92!I;FET:6%L(&9O=7(@;6]N
M=&AS('=A<R!I;G1E<F5S="!O;FQY+B8C>$$P.PT*5&AE(&]U='-T86YD:6YG
M(&)A;&%N8V4@87,@;V8@4V5P=&5M8F5R(#,P+"`R,#$Q(&ES("9N8G-P.R0\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/CDS.2PP,#`\+V9O;G0^(&]F#0IW:&EC:"`F;F)S
M<#LD/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SXW-2PR,#`\+V9O;G0^(&ES#0IP87EA8FQE
M('=I=&AI;B!T=V5L=F4@;6]N=&AS+CPO9F]N=#X\+V1I=CX-"CPO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3$V.#$U
M8V9?.34Y,U\T,&-A7SED-S=?-#<Y9&8Q-S8V8C4Q#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S$Q-C@Q-6-F7SDU.3-?-#!C85\Y9#<W7S0W.61F
M,3<V-F(U,2]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,1SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0<F5F97)R960@4W1O8VL\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D(%-T
M;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I
M=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!415A4+41%0T]2051)3TXZ('5N9&5R;&EN92<^3F]T92`X#0HF(W@R
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M4$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q
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M1494.B`P<'0[(%1%6%0M24Y$14Y4.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SY/;@T*3F]V96UB97(@,3DL(#(P,3`L('1H92!#;VUP86YY('-O
M;&0@,3`L-3@R+#`Q,2!0<F5F97)R960@3V9F97)I;F<-"E5N:71S(&-O;G-I
M<W1I;F<@;V8@*&DI(&]N92!S:&%R92`H)B-X,C`Q0SM0<F5F97)R960@4VAA
M<F4F(W@R,#%$.RD-"F]F(%-E<FEE<R!%(#<E(%-E;FEO<B!#;VYV97)T:6)L
M92!0<F5F97)R960@4W1O8VLL('!A<B!V86QU92`F;F)S<#LD,"XP,0T*<&5R
M('-H87)E+"!O9B!T:&4@0V]M<&%N>2P@*&EI*2!A('=A<G)A;G0@=&\@<'5R
M8VAA<V4@,"XR-2!O9B!A#0IS:&%R92!O9B!#;VUM;VX@4W1O8VL@*&-O;G-I
M<W1I;F<@;V8@870@:7-S=6%N8V4@86X@86=G<F5G871E(&]F#0HQ+#,R,BPT
M.#8@=V%R<F%N=',L(&%D:G5S=&5D('1O(&%N(&%G9W)E9V%T92!O9B`Q+#0U
M,BPY,C4@87,@;V8-"E-E<'1E;6)E<B`S,"P@,C`Q,2D[(&%N9"`H:6EI*2`P
M+C`Q-34@;V8@82!S:&%R92!O9B!#;VUM;VX@4W1O8VL-"BAA;B!A9V=R96=A
M=&4@;V8@,38T+#0Q."!S:&%R97,I+B!%86-H(%!R969E<G)E9"!/9F9E<FEN
M9R!5;FET('=A<PT*<')I8V5D(&%T("9N8G-P.R0P+CDT-2!A;F0@=&]T86P@
M9W)O<W,@86YD(&YE="!P<F]C965D<R!R96-E:79E9"!B>2!T:&4-"D-O;7!A
M;GD@=V5R92`F;F)S<#LD,3`L,#`P+#`P,"!A;F0@)FYB<W`[)#@L.#<V+#<P
M,"P@<F5S<&5C=&EV96QY+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV
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M="!O9B`F;F)S<#LD,2XP,"!P97(@<VAA<F4@<&QU<R!A;&P@86-C<G5E9"!B
M=70@=6YP86ED#0ID:79I9&5N9',N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=$25-03$%9.B!B;&]C:SL@5$585"U)3D1%3E0Z(#!P="<^/&)R("\^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`S
M+C-P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
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M,T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO
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M96YT<R!B96=A;B!O;B!-87)C:"`R,2P@,C`Q,2!A;F0-"F-O;G1I;G5E(&]N
M('1H92`Q.71H(&]F(&5A8V@@;6]N=&@@=&AE<F5A9G1E<B!W:71H('1H92!F
M:6YA;`T*<&%Y;65N="!D=64@;VX@36%Y(#(P+"`R,#$S+B!087EM96YT<R!C
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M<R!P<FEO<B!T;R!T:&4@<&%Y;65N=`T*9&%T92P@86YD('1H92!S:&%R97,@
M87)E(&1E;&EV97)E9"!I;B!T<F%N8VAE<R!B96=I;FYI;F<@:6X@861V86YC
M90T*;V8@=&AE(&%P<&QI8V%B;&4@<&%Y;65N="!D871E+B8C>$$P.R8C>$$P
M.T%S(&]F(%-E<'1E;6)E<B`S,"P-"C(P,3$L('1H92!#;VUP86YY(&AA9"!I
M<W-U960@,RPT-C(L-34Y('-H87)E<R!O9B!#;VUP86YY(&-O;6UO;@T*<W1O
M8VL@:6X@<&%Y;65N="!O9B!M;VYT:&QY(&1I=FED96YD<R!A;F0@<')I;F-I
M<&%L+"!I;F-L=61I;F<-"G)E<75I<F5D(&%D=F%N8V5D('!A>6UE;G1S+CPO
M9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[(%1%
M6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$
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M;65N=',@;V8@;F\@;&5S<R!T:&%N("9N8G-P.R0Q+#`P,"PP,#`I(&%T#0HQ
M,34E(&]F('1H92!T:&5N(&]U='-T86YD:6YG(&)A;&%N8V4L(')E9'5C:6YG
M('1O(#$Q,"4@869T97(-"DYO=F5M8F5R(#$Y+"`R,#$Q+"!W:71H(&YO=&EC
M92!O9B!N;W0@;&5S<R!T:&%N('1H:7)T>2!D87ES(&%N9`T*861E<75A=&4@
M;W!P;W)T=6YI='D@=&\@8V]N=F5R="X@268@=&AE($-O;7!A;GD@8VAO;W-E
M<R!T;R!P<F4M<&%Y+`T*=&AE(&]U='-T86YD:6YG(&)A;&%N8V4@;75S="!B
M92!P86ED(&EN(&-A<V@@86YD('1H92!P<F5M:75M(&UA>2!B90T*<&%I9"!I
M;B!C87-H(&]R('-H87)E<R!O9B!#;VUP86YY(&-O;6UO;B!S=&]C:RX\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4
M+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`Q
M.'!T.R!-05)'24XM4DE'2%0Z(#,N,W!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/E5P;VX-"FES<W5A;F-E
M+"!T:&4@4')E9F5R<F5D(%-H87)E<R!W97)E(&-O;G9E<G1I8FQE(&%T(&%N
M(&EN:71I86P-"F-O;G9E<G-I;VX@<')I8V4@;V8@)FYB<W`[)#(N,#`P-"X@
M5&AE(&-O;G9E<G-I;VX@<')I8V4@:7,@<W5B:F5C="!T;PT*8V5R=&%I;B!W
M96EG:'1E9"!A=F5R86=E(&%D:G5S=&UE;G1S('5P;VX@=&AE(&]C8W5R<F5N
M8V4@;V8-"G-P96-I9FEC(&5V96YT<RP@:6YC;'5D:6YG('-T;V-K(&1I=FED
M96YD<RP@<W1O8VL@<W!L:71S+`T*8V]M8FEN871I;VYS(&%N9"!R96-L87-S
M:69I8V%T:6]N<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!C;VUM;VX-"G-T
M;V-K(&%N9"!I9B`H=VET:"!C97)T86EN(&5X8V5P=&EO;G,I('1H92!#;VUP
M86YY(&ES<W5E<R!O<B!S96QL<PT*86YY(&%D9&ET:6]N86P@<VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:R!O<B!C;VUM;VX@<W1O8VL@97%U:79A;&5N=',-"F%T
M(&$@<')I8V4@<&5R('-H87)E(&QE<W,@=&AA;B!T:&4@8V]N=F5R<VEO;B!P
M<FEC92!T:&5N(&EN(&5F9F5C="P-"F]R('=I=&AO=70@8V]N<VED97)A=&EO
M;BXF(WA!,#LF(WA!,#M!<R!O9B!397!T96UB97(@,S`L(#(P,3$L('1H90T*
M8V]N=F5R<VEO;B!P<FEC92!H860@8F5E;B!A9&IU<W1E9"!T;R`F;F)S<#LD
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SXQ+C8W/"]F;VYT/BX\+V9O;G0^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T
M)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`Q.'!T.R!-05)'24XM
M4DE'2%0Z(#,N,W!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/D%N#0IA9V=R96=A=&4@;V8@)FYB<W`[)#(L
M-3`P+#`P,"!O9B!T:&4@<')O8V5E9',@9G)O;2!T:&4@4')E9F5R<F5D($]F
M9F5R:6YG#0IW87,@<&QA8V5D(&EN(&5S8W)O=R!F;W(@82!M87AI;75M(&]F
M(#(N-2!Y96%R<R!A<R!S96-U<FET>2!F;W(@=&AE#0I#;VUP86YY)B-X,C`Q
M.3MS(&]B;&EG871I;VYS(')E;&%T:79E('1O('1H92!0<F5F97)R960@4VAA
M<F5S+"!A;F0-"FES(&EN8VQU9&5D(&EN(&]T:&5R(&%S<V5T<RX\+V9O;G0^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.
M1$5.5#H@,'!T)SXF(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`Q.'!T
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M5&EM97,@3F5W(%)O;6%N)SXW.#,L-#`P/"]F;VYT/B!A;F0-"B9N8G-P.R0\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/C$R-BPY,#`\+V9O;G0^+`T*<F5S<&5C=&EV96QY
M+"!A<R!O9B!397!T96UB97(@,S`L(#(P,3$N)B-X03`[)B-X03`[5&AE($-O
M;7!A;GD@=VEL;`T*<F5P;W)T(&-H86YG97,@:6X@=&AE(&9A:7(@=F%L=64@
M;V8@=&AE(&5M8F5D9&5D(&1E<FEV871I=F5S(&%N9`T*=V%R<F%N="!D97)I
M=F%T:79E(&EN(&5A<FYI;F=S('=I=&AI;B!O=&AE<B!I;F-O;64@*&5X<&5N
M<V4I+"!N970N#0I4:&4@9&ES8V]U;G0@86YD(&ES<W5A;F-E(&-O<W1S(&]N
M('1H92!P<F5F97)R960@<W1O8VL@=VEL;"!B90T*86UO<G1I>F5D('1H<F]U
M9V@@36%Y(#(P+"`R,#$S('5S:6YG('1H92!E9F9E8W1I=F4@:6YT97)E<W0@
M;65T:&]D#0IA;F0@=VEL;"!B92!R969L96-T960@=VET:&EN(&EN=&5R97-T
M(&5X<&5N<V4N($9O<B!T:&4@;FEN92!M;VYT:',-"F5N9&5D(%-E<'1E;6)E
M<B`S,"P@,C`Q,2P@=&AE($-O;7!A;GD@<F5C;W)D960@82!D96-R96%S92!I
M;B!T:&4-"F9A:7(@=F%L=64@;V8@=&AE(&5M8F5D9&5D(&1E<FEV871I=F5S
M(&]F(&%P<')O>&EM871E;'D-"B9N8G-P.R0\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/C$L
M-#DX+#0P,#PO9F]N=#X-"F%N9"!A(&1E8W)E87-E(&EN('1H92!W87)R86YT
M(&1E<FEV871I=F4@;V8@87!P<F]X:6UA=&5L>0T*)FYB<W`[)#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^,30X+#0P,#PO9F]N=#XN)B-X03`[)B-X03`[1F]R#0IT:&4@
M=&AR964@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,2P@=&AE($-O
M;7!A;GD@<F5C;W)D960@80T*9&5C<F5A<V4@:6X@=&AE(&9A:7(@=F%L=64@
M;V8@=&AE(&5M8F5D9&5D(&1E<FEV871I=F5S(&]F#0IA<'!R;WAI;6%T96QY
M("9N8G-P.R0\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/C$L,34P+#,P,#PO9F]N=#X-"F%N
M9"!A(&1E8W)E87-E(&EN('1H92!W87)R86YT(&1E<FEV871I=F4@;V8@87!P
M<F]X:6UA=&5L>0T*)FYB<W`[)#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^,C$S+#`P,#PO
M9F]N=#XN/"]F;VYT/CPO9&EV/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q'/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-H87)E:&]L9&5R<R<@17%U:71Y/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E:&]L9&5R<R<@17%U:71Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF
M>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!4
M15A4+41%0T]2051)3TXZ('5N9&5R;&EN92<^3F]T92`Y#0HF(W@R,#$S.R!3
M:&%R96AO;&1E<G,F(W@R,#$Y.R!%<75I='D\+V9O;G0^/"]F;VYT/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
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M8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,RXS<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^5&AE#0IA=71H;W)I>F5D(&-O;6UO;B!S
M=&]C:R!O9B!T:&4@0V]M<&%N>2!I<R`U,#`@;6EL;&EO;B!S:&%R97,L('!A
M<@T*=F%L=64@)FYB<W`[)#`N,#`Q('!E<B!S:&%R92X\+V9O;G0^/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY/;@T*36%R8V@@,RP@,C`Q,2P@=&AE($-O
M;7!A;GD@8V]N<W5M;6%T960@82!P<FEV871E('!L86-E;65N="!P=7)S=6%N
M=`T*=&\@=VAI8V@@9FEV92!P97)S;VYS(&%N9"!E;G1I=&EE<R!A8W%U:7)E
M9"!A;B!A9V=R96=A=&4@;V8-"C(L,S0S+#<U,"!S:&%R97,@;V8@0V]M;6]N
M(%-T;V-K(&9O<B!A;B!A9V=R96=A=&4@8V]N<VED97)A=&EO;B!O9@T*)FYB
M<W`[)#,L,#`P+#`P,"`H<'5R8VAA<V4@<')I8V4@)FYB<W`[)#$N,C@@<&5R
M('-H87)E*2X@5&AE(&EN=F5S=&]R<R!I;F-L=61E9`T*4W1E=F5N(%,N($UY
M97)S("AO;F4@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@9&ER96-T;W)S*2`H
M=VAO#0IP=7)C:&%S960@,SDP+#8R-2!S:&%R97,I(&%N9"!$<BX@06YD<F5W
M($PN(%!E8V]R82`H=&AE($-H:65F#0I-961I8V%L($]F9FEC97(@;V8@=&AE
M($-O;7!A;GDF(W@R,#$Y.W,@<W5B<VED:6%R>2!00U0L('=H;R!I<R!A;'-O
M#0IN;W<@=&AE($-H:65F($UE9&EC86P@3V9F:6-E<B!O9B!.96]3=&5M+"!A
M;F0@=&AE($-H:65F(%-C:65N=&EF:6,-"D]F9FEC97(@;V8@06UO<F-Y=&4I
M("AW:&\@<'5R8VAA<V5D(#<X+#$R-2!S:&%R97,I+B!/;B!!<')I;"`U+`T*
M,C`Q,2P@=&AE($-O;7!A;GD@8V]N<W5M;6%T960@82!P<FEV871E('!L86-E
M;65N="!P=7)S=6%N="!T;R!W:&EC:`T*;FEN92!P97)S;VYS(&%N9"!E;G1I
M=&EE<R!A8W%U:7)E9"!A;B!A9V=R96=A=&4@;V8@,2PR-#0L,S<U('-H87)E
M<PT*;V8@0V]M;6]N(%-T;V-K(&9O<B!A;B!A9V=R96=A=&4@8V]N<VED97)A
M=&EO;B!O9B!A<'!R;WAI;6%T96QY#0HF;F)S<#LD,2PU.3(L.#`P("AP=7)C
M:&%S92!P<FEC92`F;F)S<#LD,2XR."!P97(@<VAA<F4I+B8C>$$P.R8C>$$P
M.T]N($IU;F4@,3,L#0HR,#$Q('1H92!#;VUP86YY(&-O;G-U;6UA=&5D(&$@
M<')I=F%T92!P;&%C96UE;G0@<'5R<W5A;G0@=&\@=VAI8V@-"F]N92!E;G1I
M='D@86-Q=6ER960@-S@Q+#(U,"!S:&%R97,@;V8@0V]M;6]N(%-T;V-K(&9O
M<B!A;B!A9V=R96=A=&4-"F-O;G-I9&5R871I;VX@;V8@)FYB<W`[)#$L,#`P
M+#`P,"`H<'5R8VAA<V4@<')I8V4@)FYB<W`[)#$N,C@@<&5R#0IS:&%R92DN
M)B-X03`[)B-X03`[3VX@2G5L>2`V+"`R,#$Q+"!T:')E92!T:&5N(&ME>2!!
M;6]R8WET90T*<W1O8VMH;VQD97)S("AI;F-L=61I;F<@82!F=6YD(&UA;F%G
M960@8GD@82!T:&5N($%M;W)C>71E(&1I<F5C=&]R*0T*:6YV97-T960@86X@
M86=G<F5G871E(&]F("9N8G-P.R0W,C@L,#`P(&EN(&$@<')I=F%T92!P;&%C
M96UE;G0@;V8@-38X+#<U,`T*<VAA<F5S(&]F($-O;6UO;B!3=&]C:R`H<'5R
M8VAA<V4@<')I8V4@)FYB<W`[)#$N,C@@<&5R#0IS:&%R92DN/"]F;VYT/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`Q.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^3VX-"DIU;'D@,C(L(#(P,3$L('1H
M92!#;VUP86YY(&-O;7!L971E9"!A;B!U;F1E<G=R:71T96X@;V9F97)I;F<@
M;V8-"C$S+#<U,"PP,#`@=6YI=',@870@82!P=7)C:&%S92!P<FEC92!O9B`F
M;F)S<#LD,2XR,"!P97(@=6YI="P@=VET:"!E86-H#0IU;FET(&-O;G-I<W1I
M;F<@;V8@;VYE('-H87)E(&]F($-O;6UO;B!3=&]C:R!A;F0@82!F:79E('EE
M87(-"G=A<G)A;G0@=&\@<'5R8VAA<V4@,"XW-2!O9B!A('-H87)E(&]F($-O
M;6UO;B!3=&]C:R!A="!A;B!E>&5R8VES90T*<')I8V4@;V8@)FYB<W`[)#$N
M-#4@<&5R('-H87)E("AT:&4-"B8C>#(P,4,[3V9F97)I;F<F(W@R,#%$.RDN
M)B-X03`[)B-X03`[5&AE($-O;7!A;GD@<V]L9"!S96-U<FET:65S(&EN#0IT
M:&4@3V9F97)I;F<@=6YD97(@=&AE($-O;7!A;GDF(W@R,#$Y.W,@<')E=FEO
M=7-L>2!F:6QE9"!S:&5L9@T*<F5G:7-T<F%T:6]N('-T871E;65N="!O;B!&
M;W)M(%,M,R`H,S,S+3$W,S@U-2DL('=H:6-H('=A<R!D96-L87)E9`T*969F
M96-T:79E(&)Y('1H92!396-U<FET:65S(&%N9"!%>&-H86YG92!#;VUM:7-S
M:6]N(&]N($IU;F4@,3,L#0HR,#$Q+B8C>$$P.R8C>$$P.TQA>F%R9"!#87!I
M=&%L($UA<FME=',@3$Q#("@F(W@R,#%#.TQA>F%R9"8C>#(P,40[*0T*86YD
M($I-4"!396-U<FET:65S($Q,0R`H)B-X,C`Q0SM*35`F(W@R,#%$.RD@86-T
M960@87,@<F5P<F5S96YT871I=F5S#0IO9B!T:&4@=6YD97)W<FET97)S(&YA
M;65D(&EN(&%N(%5N9&5R=W)I=&EN9R!!9W)E96UE;G0L(&1A=&5D(&%S(&]F
M#0I*=6QY(#$Y+"`R,#$Q+"!B>2!A;F0@86UO;F<@=&AE($-O;7!A;GDL($QA
M>F%R9"P@2DU0(&%N9"!S=6-H#0IU;F1E<G=R:71E<G,N)B-X03`[)B-X03`[
M5&AE($-O;7!A;GD@<F5C96EV960@9W)O<W,@<')O8V5E9',@;V8-"B9N8G-P
M.R0Q-BPU,#`L,#`P+"!P<FEO<B!T;R!D961U8W1I;F<@=6YD97)W<FET:6YG
M(&1I<V-O=6YT<R!A;F0@;V9F97)I;F<-"F5X<&5N<V5S('!A>6%B;&4@8GD@
M=&AE($-O;7!A;GDL(&9O<B!N970@<')O8V5E9',@;V8@87!P<F]X:6UA=&5L
M>0T*)FYB<W`[)#$T+#8V-RPP,#`N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`Q.'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`S
M+C9P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY/;@T*4V5P=&5M8F5R(#(X+"`R,#$Q+"!T:&4@0V]M<&%N
M>2!E;G1E<F5D(&EN=&\@82!#;VUM;VX@4W1O8VL-"E!U<F-H87-E($%G<F5E
M;65N="`H=&AE("8C>#(P,4,[4'5R8VAA<V4@06=R965M96YT)B-X,C`Q1#LI
M('=I=&@-"D%S<&ER92!#87!I=&%L($9U;F0L($Q,0RP@86X@26QL:6YO:7,@
M;&EM:71E9"!L:6%B:6QI='D@8V]M<&%N>0T**"8C>#(P,4,[07-P:7)E($-A
M<&ET86PF(W@R,#%$.RDL('=H:6-H('!R;W9I9&5S('1H870L('-U8FIE8W0@
M=&\-"F-E<G1A:6X@=&5R;7,@86YD(&-O;F1I=&EO;G,L($%S<&ER92!#87!I
M=&%L(&ES(&-O;6UI='1E9"!T;PT*<'5R8VAA<V4@=7`@=&\@86X@86=G<F5G
M871E(&]F("9N8G-P.R0R,"XP(&UI;&QI;VX@=V]R=&@@;V8@<VAA<F5S(&]F
M('1H90T*0V]M<&%N>28C>#(P,3D[<R!C;VUM;VX@<W1O8VL@;W9E<B!T:&4@
M,C0M;6]N=&@@=&5R;2!O9B!T:&4@4'5R8VAA<V4-"D%G<F5E;65N="X@070@
M=&AE($-O;7!A;GDF(W@R,#$Y.W,@9&ES8W)E=&EO;BP@:70@;6%Y('!R97-E
M;G0@07-P:7)E#0I#87!I=&%L('=I=&@@<'5R8VAA<V4@;F]T:6-E<R!U;F1E
M<B!T:&4@4'5R8VAA<V4@06=R965M96YT(&9R;VT-"G1I;64@=&\@=&EM92P@
M=&\@<'5R8VAA<V4@=&AE($-O;7!A;GDF(W@R,#$Y.W,@0V]M;6]N(%-T;V-K
M+`T*<')O=FED960@8V5R=&%I;B!P<FEC92!A;F0@;W1H97(@<F5Q=6ER96UE
M;G1S(&%R92!M970N)B-X03`[5&AE#0IP=7)C:&%S92!P<FEC92!F;W(@=&AE
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M('9O;'5M92!W96EG:'1E9"!A=F5R86=E('!R:6-E<R`H:6X@=&AE(&-A<V4@
M;V8@5E=!4`T*<'5R8VAA<V5S*2P@:6X@96%C:"!C87-E(&%S(&1E=&5R;6EN
M960@8GD@<&%R86UE=&5R<R!D969I;F5D(&EN('1H90T*86=R965M96YT+B8C
M>$$P.R8C>$$P.R8C>$$P.U1H92!#;VUP86YY(&%N9"!!<W!I<F4@0V%P:71A
M;"!S:&%L;`T*;F]T(&5F9F5C="!A;GD@<V%L97,@=6YD97(@=&AE(%!U<F-H
M87-E($%G<F5E;65N="!O;B!A;GD@9&%T92!W:&5R90T*=&AE(&-L;W-I;F<@
M<V%L97,@<')I8V4@:7,@;&5S<R!T:&%N(#<U)2!O9B!T:&4@8VQO<VEN9R!S
M86QE<R!P<FEC90T*;VX@=&AE(&)U<VEN97-S(&1A>2!I;6UE9&EA=&5L>2!P
M<F5C961I;F<@=&AE(&1A=&4@;V8@=&AE(%!U<F-H87-E#0I!9W)E96UE;G0N
M(%1H92!#;VUP86YY)B-X,C`Q.3MS(&YE="!P<F]C965D<R!W:6QL(&1E<&5N
M9"!O;B!T:&4-"G!U<F-H87-E('!R:6-E(&%N9"!T:&4@9G)E<75E;F-Y(&]F
M('1H92!#;VUP86YY)B-X,C`Q.3MS('-A;&5S(&]F#0IS:&%R97,@=&\@07-P
M:7)E($-A<&ET86P[('!R;W9I9&5D+"!H;W=E=F5R+"!T:&%T('1H92!M87AI
M;75M#0IA9V=R96=A=&4@<')O8V5E9',@9G)O;2!S86QE<R!O9B8C>$$P.R8C
M>$$P.W-H87)E<R!I<R`F;F)S<#LD,C`N,`T*;6EL;&EO;BP@86YD('1H92!M
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M;&EG:'0@;V8@=&AE#0I#;VUP86YY)B-X,C`Q.3MS(&-A<&ET86P@;F5E9',@
M9G)O;2!T:6UE('1O('1I;64@86YD('5N9&5R('1H90T*;&EM:71A=&EO;G,@
M8V]N=&%I;F5D(&EN('1H92!0=7)C:&%S92!!9W)E96UE;G0N($%S(&-O;G-I
M9&5R871I;VX-"F9O<B!E;G1E<FEN9R!I;G1O('1H92!0=7)C:&%S92!!9W)E
M96UE;G0L(&5F9F5C=&EV92!397!T96UB97(@,S`L#0HR,#$Q+"!W92!I<W-U
M960@.3DP+#`Y.2!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C:R!T;R!!<W!I
M<F4-"D-A<&ET86P@*'1H92`F(W@R,#%#.T-O;6UI=&UE;G0@4VAA<F5S)B-X
M,C`Q1#LI+B!4:&4@:7-S=6%N8V4@;V8-"G-H87)E<R!O9B!C;VUM;VX@<W1O
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M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^)B-X03`[/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
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M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,3AP=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,RXS<'0G(&%L:6=N
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M(%-E<'1E;6)E<B`S,"P@,C`Q,2!A="!P<FEC97,@<F%N9VEN9PT*9G)O;2`F
M;F)S<#LD/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SXP+C4P/"]F;VYT/B!T;PT*)FYB<W`[
M)#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^-RXP,#PO9F]N=#X@86YD#0IE>'!I<FEN9R!T
M:')O=6=H($IA;G5A<GD@,C`Q."X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\
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M;F1E9"!397!T96UB97(@,S`L(#(P,3$@86YD(#(P,3`L('1H90T*0V]M<&%N
M>2!I<W-U960@=V%R<F%N=',@9F]R('-E<G9I8V5S(&%S(&9O;&QO=W,@*"9N
M8G-P.R0@:6X@=&AO=7-A;F1S+`T*97AC97!T('-H87)E(&1A=&$I.CPO9F]N
M=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I
M=B!A;&EG;CTS1&-E;G1E<CX-"CQT86)L92!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-24^#0H\='(^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-#`E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!C96YT97(G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(X)2!C;VQS<&%N/3-$-B!N;W=R87`],T1N
M;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,C@E(&-O;'-P86X],T0V(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/DYI;F4-"DUO;G1H<R!%;F1E9"!397!T96UB97(@,S`L/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.1RU"3U143TTZ(#)P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([(%!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O
M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(P,3$\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E
M;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX-"C(P,3`\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!C96YT97(G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXR,#$Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([(%!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,G!X('-O;&ED.R!415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E
M(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
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M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T
M<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXR-2PP,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
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M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS-S`L,#`P/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^-C(W+#`P,#PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0T,"4@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
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M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C
M0T-&1D-#/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY686QU90T*
M;V8@0V]M;6]N(%-T;V-K(%!U<F-H87-E(%=A<G)A;G1S($ES<W5E9#PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T
M<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX-"BT\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*
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M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N
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M.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
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M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD
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M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-
M"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VLG/B8C>$$P.SPO9&EV/@T*/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`Q.'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`S+C-P="<@86QI
M9VX],T1J=7-T:69Y/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,3AP
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
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M<B`S,"P@,C`Q,2!W87,-"B9N8G-P.R0\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/C`\+V9O
M;G0^(&%N9`T*)FYB<W`[)#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
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M:6QI='D@;V8@=&AE#0I#;VUP86YY)B-X,C`Q.3MS('-T;V-K+B!4:&4@97AP
M96-T960@=&5R;2!I<R!B87-E9"!U<&]N('1H90T*8V]N=')A8W1U86P@=&5R
M;2!O9B!T:&4@=V%R<F%N=',N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`Q.'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`S+C-P
M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY4:&4-"G)A;F=E(&]F(&%S<W5M<'1I;VYS('5S960@:6X@8V%L
M8W5L871I;F<@=&AE(&9A:7(@=F%L=65S(&]F#0IW87)R86YT<R!I<W-U960@
M9F]R('-E<G9I8V5S(&1U<FEN9R!T:&4@=&AR964@86YD(&YI;F4@;6]N=&AS
M(&5N9&5D#0I397!T96UB97(@,S`L(#(P,3$@86YD(#(P,3`L(')E<W!E8W1I
M=F5L>2P@=V5R92!A<PT*9F]L;&]W<SH\+V9O;G0^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T
M:69Y/B8C>$$P.SPO9&EV/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`Q.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`S+C-P="<@86QI9VX],T1J=7-T:69Y/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M.R!415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,R)2!C;VQS<&%N/3-$,SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^5&AR964-"DUO;G1H<R!%;F1E9"!397!T96UB97(@,S`L/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$
M24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED.R!415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,R)2!C;VQS<&%N/3-$,SX-"CQD:78@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX-"DYI;F4@36]N=&AS($5N9&5D(%-E<'1E
M;6)E<B`S,"P\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\
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M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR
M,#$Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/&1I=B!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^
M#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C`Q,#PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$U)3X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@
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M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXR,#$P/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,T)3X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
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M34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C,-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SYT;PT*-3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU/"]F
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M96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^#0HS(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SYT;PT*-3PO9F]N=#X\+V9O;G0^/"]F
M;VYT/CPO9&EV/@T*/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQD
M:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"C0F(WA!
M,#L\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^=&\-"C4\+V9O
M;G0^/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO9&EV/@T*/"]T9#X-"CPO='(^
M#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$U)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&
M1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,T)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
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M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXX,24-"BT@.#,E/"]F;VYT/CPO9&EV
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M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
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M97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^.#`E#0HM(#@V)3PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$U)3X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/CDQ)0T*+2`Y.24\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,S0E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,S0E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T)SX-"D5X<&5C=&5D
M(&1I=FED96YD('EI96QD/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-24^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXP)3PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-
M"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C`E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$U)3X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C`E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S
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M='EL93TS1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS
M1"-#0T9&0T,^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S0E(&%L
M:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T)SX-"E)I<VLM9G)E92!I;G1E<F5S="!R871E/"]F;VYT
M/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXP+C0R)0T*+2`Q+C4S)3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQD:78@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$N
M,C<E#0HM(#$N-C`E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS
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M1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+C(W)0T*+2`R
M+C`T)3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO
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M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY796EG:'1E9#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO
M=W)A<#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/E=E:6=H=&5D/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY296UA:6YI;F<\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^3G5M8F5R#0IO9CPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^06=G<F5G871E/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,R4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY3:&%R97,\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
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M5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y
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M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^5&5R;0T**'EE87)S*3PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQD
M:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/DEN=')I;G-I8PT*5F%L=64\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS1&QE9G0^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P="<^
M#0I"86QA;F-E(&%T($1E8V5M8F5R(#,Q+"`R,#$P/"]F;VYT/CPO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
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M<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E(&%L:6=N/3-$;&5F
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"D=R86YT960\
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,RPX,3(L.3,Y/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXJ/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(N,C,\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
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M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS
M1"-#0T9&0T,^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E(&%L
M:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
M"D5X97)C:7-E9#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^#0HF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS1&QE9G0^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^#0I%>'!I<F5D/"]F
M;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^*#0T-RPV,CD\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/BD\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
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M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXM/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
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M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,"4@86QI
M9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*0F%L86YC92!A="!397!T96UB97(@,S`L(#(P,3$\
M+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^,S4L,C`X+#@Q-SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
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M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U
M8FQE.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR+CD\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L
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M25I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^,RPV,#`\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0T,"4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0G/@T*5V%R<F%N=',@17AE<F-I<V%B
M;&4@870@4V5P=&5M8F5R(#,P+"`R,#$Q/"]F;VYT/CPO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
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M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE
M.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR+C(Y/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$R)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#@T)2!C;VQS<&%N/3-$,38@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T)SX-"BH@26YC;'5D
M97,@,R!M:6QL:6]N('=A<G)A;G1S(&ES<W5E9"!P=7)S=6%N="!T;R!T:&4@
M4$-4($UE<F=E<@T*06=R965M96YT("T@4V5E($YO=&4@-"P@86YD(#$P+#,Q
M,BPU,#`@=V%R<F%N=',@:7-S=65D(&EN#0IT:&4\+V9O;G0^/"]F;VYT/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*2G5L>2`R,BP\+V9O;G0^/"]F;VYT/B`\9F]N="!S:7IE/3-$
M,CXR,#$Q(&]F9F5R:6YG/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^
M#0H\+V1I=CX-"CPO9&EV/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/B8C>$$P.SPO
M9&EV/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`Q.'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`S+C-P="<@86QI9VX],T1J=7-T:69Y/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,S9P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,RXS<'0G(&%L:6=N/3-$:G5S=&EF>3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^5&AE#0I#;VUP86YY
M)B-X,C`Q.3MS(')E<W5L=',@:6YC;'5D92!S:&%R92UB87-E9"!C;VUP96YS
M871I;VX@97AP96YS92!O9@T*87!P<F]X:6UA=&5L>2`F;F)S<#LD/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SXU+#8P,#PO9F]N=#X@86YD(&$-"F)E;F5F:70@;V8@)FYB
M<W`[)#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^,30W+#,P,#PO9F]N=#X@9F]R#0IT:&4@
M=&AR964@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,2!A;F0@,C`Q
M,"P@<F5S<&5C=&EV96QY+`T*86YD(&%N(&5X<&5N<V4@;V8@87!P<F]X:6UA
M=&5L>2`F;F)S<#LD/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SXR-#<L-3`P/"]F;VYT/B!A
M;F0-"B9N8G-P.R0\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/C0Q-RPS,#`\+V9O;G0^(&9O
M<@T*=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,2!A
M;F0@,C`Q,"P-"G)E<W!E8W1I=F5L>2XF(WA!,#LF(WA!,#M4:&4@=&]T86P@
M9F%I<B!V86QU92!O9B!S:&%R97,@=F5S=&5D(&9O<@T*=V%R<F%N=',@:7-S
M=65D(&9O<B!S97)V:6-E<R!D=7)I;F<@=&AE('1H<F5E(&%N9"!N:6YE(&UO
M;G1H<R!E;F1E9`T*4V5P=&5M8F5R(#,P+"`R,#$Q('=A<R!A<'!R;WAI;6%T
M96QY("9N8G-P.R0\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/C8P+#$P,#PO9F]N=#X@86YD
M#0HF;F)S<#LD/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SXR,S4L.#`P/"]F;VYT/BP-"G)E
M<W!E8W1I=F5L>2XF(WA!,#LF(WA!,#M!<R!O9B!397!T96UB97(@,S`L(#(P
M,3$L('1H97)E('=A<PT*87!P<F]X:6UA=&5L>2`F;F)S<#LD/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SXY,RPS,#`\+V9O;G0^(&]F#0IT;W1A;"!U;G)E8V]G;FEZ960@
M<V5R=FEC92!C;W-T(')E;&%T960@=&\@=6YV97-T960@=V%R<F%N=',@;V8-
M"G=H:6-H(&%P<')O>&EM871E;'D@)FYB<W`[)#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M-#DL-3`P/"]F;VYT/B!I<PT*<F5L871E9"!T;R!W87)R86YT<R!T:&%T('9E
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M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
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M14Y4.B`Q.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`S+C-P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"CPA+2U%1E!L86-E:&]L9&5R
M+2T^070@=&AE(#(P,3$@06YN=6%L($UE971I;F<@;V8@4VAA<F5H;VQD97)S
M(&]F#0IT:&4@0V]M<&%N>2!H96QD(&]N($]C=&]B97(@,30L(#(P,3$L('1H
M92!S:&%R96AO;&1E<G,@87!P<F]V960@86X-"F%M96YD;65N="!T;R!I;F-R
M96%S92!T:&4@;G5M8F5R(&]F('-H87)E<R!O9B!C;VUM;VX@<W1O8VL-"F%U
M=&AO<FEZ960@9F]R(&ES<W5A;F-E('5N9&5R('1H92`R,#`Y($5Q=6ET>2!#
M;VUP96YS871I;VX@4&QA;@T**'1H92`F(W@R,#%#.S(P,#D@17%U:71Y(%!L
M86XF(W@R,#%$.RD@9G)O;2`Q-RPW-3`L,#`P('1O#0HR,RPW-3`L,#`P+B8C
M>$$P.R8C>$$P.T5F9F5C=&EV92!/8W1O8F5R(#$T+"`R,#$Q+"!C;VYC=7)R
M96YT('=I=&@-"G-H87)E:&]L9&5R(&%P<')O=F%L('1O(&EN8W)E87-E('1H
M92!N=6UB97(@;V8@<VAA<F5S(&]F(&-O;6UO;@T*<W1O8VL@875T:&]R:7IE
M9"!F;W(@:7-S=6%N8V4@=6YD97(@=&AE(#(P,#D@17%U:71Y(%!L86X@8GD-
M"C8L,#`P+#`P,"P@=&AE($-O;7!A;GDF(W@R,#$Y.W,@0F]A<F0@;V8@1&ER
M96-T;W)S(&%U=&AO<FEZ960@80T*9&5C<F5A<V4@:6X@=&AE('-H87)E<R!A
M=F%I;&%B;&4@9F]R(&ES<W5A;F-E('5N9&5R('1H92!.;VXM52Y3+`T*17%U
M:71Y(%!L86X@9G)O;2`X+#<P,"PP,#`@=&\@-2PW,#`L,#`P+CPO9F]N=#X\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,RXS<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^5&AE#0I#;VUP86YY)B-X,C`Q
M.3MS(')E<W5L=',@:6YC;'5D92!S:&%R92UB87-E9"!C;VUP96YS871I;VX@
M97AP96YS92!O9@T*87!P<F]X:6UA=&5L>2`F;F)S<#LD/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SXX,S$L-#`P/"]F;VYT/B!A;F0-"B9N8G-P.R0\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/C(L-#4S+#$P,#PO9F]N=#X-"F9O<B!T:&4@=&AR964@;6]N=&AS(&5N
M9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,2!A;F0@,C`Q,"P-"G)E<W!E8W1I=F5L
M>2P@86YD(&%P<')O>&EM871E;'D@)FYB<W`[)#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M-2PV,S$L-#`P/"]F;VYT/@T*86YD("9N8G-P.R0\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/C4L.3@R+#4P,#PO9F]N=#X-"F9O<B!T:&4@;FEN92!M;VYT:',@96YD960@
M4V5P=&5M8F5R(#,P+"`R,#$Q(&%N9"`R,#$P+`T*<F5S<&5C=&EV96QY+B!/
M<'1I;VYS('9E<W1I;F<@;VX@=&AE(&%C8V]M<&QI<VAM96YT(&]F(&)U<VEN
M97-S#0IM:6QE<W1O;F5S('=I;&P@;F]T(&)E(')E8V]G;FEZ960@9F]R(&-O
M;7!E;G-A=&EO;B!P=7)P;W-E<R!U;G1I;`T*<W5C:"!M:6QE<W1O;F5S(&%R
M92!D965M960@<')O8F%B;&4@;V8@86-C;VUP;&ES:&UE;G0N($%T(%-E<'1E
M;6)E<@T*,S`L(#(P,3$@=&AE<F4@=V5R92!O<'1I;VYS('1O('!U<F-H87-E
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M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/
M;@T*07!R:6P@-"P@,C`Q,2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&%N
M(&%M96YD;65N="!O9B!I=',@36%Y(#(V+`T*,C`P-B!E;7!L;WEM96YT(&%G
M<F5E;65N="!W:71H($1R+B!2;V)I;B!,+B!3;6ET:"P@<'5R<W5A;G0@=&\-
M"G=H:6-H+"!A<R!P<F5V:6]U<VQY(&%M96YD960@*'1H92`F(W@R,#%#.T%G
M<F5E;65N="8C>#(P,40[*2P@1'(N#0I3;6ET:"!S97)V97,@87,@0VAA:7)M
M86X@;V8@=&AE($)O87)D(&%N9"!#:&EE9B!%>&5C=71I=F4@3V9F:6-E<@T*
M;V8@=&AE($-O;7!A;GDN(%!U<G-U86YT('1O('1H92!A;65N9&UE;G0L("AI
M*2!T:&4@=&5R;2!O9B!T:&4-"D%G<F5E;65N="!W87,@97AT96YD960@9G)O
M;2!$96-E;6)E<B`S,2P@,C`Q,2!T;R!$96-E;6)E<B`S,2P@,C`Q,CL-"BAI
M:2D@1'(N(%-M:71H('=I;&P@<F5C96EV92!C87-H(&)O;G5S97,@;VX@3V-T
M;V)E<B`Q+"`R,#$Q(&%N9`T*,C`Q,B!I;B!T:&4@;6EN:6UU;2!A;6]U;G0@
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M<&%N>2`H<W5C:"!P87EM96YT<R!S:&%L;"!N;W0@8F4@;6%D92!D=7)I;F<@
M=&AE('1I;64@1'(N(%-M:71H#0II<R!A;'-O(')E8V5I=FEN9R!P87EM96YT
M<R!U;F1E<B`H:6EI*2!O<B`H:78I*&$I*3L@*'8I($1R+B!3;6ET:`T*=V%S
M(&=R86YT960@86X@;W!T:6]N('1O('!U<F-H87-E(#$L-3`P+#`P,"!S:&%R
M97,@;V8@0V]M;6]N(%-T;V-K#0IA="!A('!E<B!S:&%R92!E>&5R8VES92!P
M<FEC92!E<75A;"!T;R!T:&4@8VQO<VEN9R!P<FEC92!O9B!T:&4-"D-O;6UO
M;B!3=&]C:R!O;B!T:&4@9&%T92!O9B!T:&4@86UE;F1M96YT+"!V97-T:6YG
M(&%S('1O(#4P,"PP,#`-"G-H87)E<R!O;B!E86-H(&]F('1H92!D871E(&]F
M(&=R86YT+"!$96-E;6)E<B`S,2P@,C`Q,2!A;F0@1&5C96UB97(-"C,Q+"`R
M,#$R.R`H=FDI(&%L;"!O=&AE<B!U;G9E<W1E9"!O<'1I;VYS(&AE;&0@8GD@
M1'(N(%-M:71H('=E<F4-"FEM;65D:6%T96QY('9E<W1E9#L@*'9I:2D@86YY
M('9E<W1E9"!O<'1I;VYS('!R979I;W5S;'D@;W(-"FAE<F5A9G1E<B!G<F%N
M=&5D('1O($1R+B!3;6ET:"!D=7)I;F<@=&AE(')E;6%I;F1E<B!O9B!T:&4@
M=&5R;0T*<VAA;&P@<F5M86EN(&5X97)C:7-A8FQE(&9O;&QO=VEN9R!T97)M
M:6YA=&EO;B!O9B!E;7!L;WEM96YT(&9O<@T*=&AE(&9U;&P@;W!T:6]N('1E
M<FT@=6YT:6P@=&AE(&5X<&ER871I;VX@9&%T93L@*'9I:6DI('1H92!#;VUP
M86YY#0IA9W)E960@=&AA="P@=VET:"!T:&4@97AC97!T:6]N(&]F('1H92!P
M97)I;V0@;V8@=&EM92!D=7)I;F<@=VAI8V@-"D1R+B!3;6ET:"!I<R!A($-O
M;7!A;GD@869F:6QI871E(&%N9"!F;W(@.3`@9&%Y<R!T:&5R96%F=&5R("AD
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M('-A;&4@=6YD97(@4G5L92`Q-#0@=VET:&]U="!V;VQU;64-"FQI;6ET871I
M;VYS.R!A;F0@*&EX*2!I9B!$<BX@4VUI=&@@8V5A<V5S('1O(&)E(&5M<&QO
M>65D(&)Y('1H90T*0V]M<&%N>2!A;F0@9F]R('-O(&QO;F<@87,@<VAE(&-O
M;G1I;G5E<R!T;R!O=VX@<VAA<F5S(&]F($-O;6UO;@T*4W1O8VL@=&AE('-A
M;&4@;V8@=VAI8V@@=V]U;&0@<F5Q=6ER92!T:&%T('1H92!C=7)R96YT('!U
M8FQI8PT*:6YF;W)M871I;VX@<F5Q=6ER96UE;G0@;V8@4G5L92`Q-#0@8F4@
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M;V8@1'(N(%-M:71H)B-X,C`Q.3MS('-T;V-K(&]P=&EO;G,L#0IT:&4@0V]M
M<&%N>2!R96-O9VYI>F5D("9N8G-P.R0\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/C<R,RPP
M,#`\+V9O;G0^(&]F#0II;F-R96UE;G1A;"!C;VUP96YS871I;VX@8V]S="!D
M=7)I;F<@=&AE(&YI;F4@;6]N=&AS(&5N9&5D#0I397!T96UB97(@,S`L(#(P
M,3$N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`Q.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`S+C-P="<@86QI9VX],T1J=7-T
M:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"G=E
M:6=H=&5D(&%V97)A9V4@97-T:6UA=&5D(&9A:7(@=F%L=64@;V8@<W1O8VL@
M;W!T:6]N<R!G<F%N=&5D(&EN#0IT:&4@=&AR964@86YD(&YI;F4@;6]N=&AS
M(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,2!W87,-"B9N8G-P.R0\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/C`N-3`\+V9O;G0^#0IA;F0@)FYB<W`[)#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^,2XQ,#PO9F]N=#XL#0IR97-P96-T:79E;'DN(%1H92!F86ER('9A
M;'5E(&]F(&]P=&EO;G,@870@=&AE(&1A=&4@;V8@9W)A;G0@=V%S#0IE<W1I
M;6%T960@=7-I;F<@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I;F<@
M;6]D96PN(%1H90T*97AP96-T960@=F]L871I;&ET>2!I<R!B87-E9"!U<&]N
M(&AI<W1O<FEC86P@=F]L871I;&ET>2!O9B!T:&4-"D-O;7!A;GDF(W@R,#$Y
M.W,@<W1O8VLN(%1H92!E>'!E8W1E9"!T97)M(&ES(&)A<V5D('5P;VX@;V)S
M97)V871I;VX-"F]F(&%C='5A;"!T:6UE(&5L87!S960@8F5T=V5E;B!D871E
M(&]F(&=R86YT(&%N9"!E>&5R8VES92!O9@T*;W!T:6]N<R!F;W(@86QL(&5M
M<&QO>65E<RX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@
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M('1H<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P
M,3$-"F%N9"`R,#$P+"!R97-P96-T:79E;'DL('=E<F4@87,@9F]L;&]W<SH\
M+V9O;G0^/"]D:78^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#,N,W!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<^#0H\9&EV/@T*/&1I=B!A;&EG;CTS1&-E;G1E
M<CX-"CQT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0X,"4^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$
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M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P="<^#0I4:')E
M92!-;VYT:',@16YD960@4V5P=&5M8F5R(#,P+#PO9F]N=#X\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
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M.B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
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M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!4
M15A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U
M)3X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXR,#$P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/&1I=B!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C`Q,3PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!C96YT97(G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQD:78@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(P,3`\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T-#1D9#0SX-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S-"4@86QI9VX],T1L969T/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*17AP96-T960@=&5R;2`H:6X@>65A<G,I/"]F;VYT/CPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^=&\-"C8\+V9O;G0^/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/&1I=B!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQD:78@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
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M15A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^
M#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,0T*=&\@,3`\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-24^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR#0IT;R`Q,#PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S-"4@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$U)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S0E(&%L:6=N/3-$;&5F=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"D5X<&5C=&5D('9O;&%T
M:6QI='D\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$U)3X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/C<V)0T*+2`X-"4\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
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M93TS1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQD:78@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CDQ)0T*+2`Q,C(E
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
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M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
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M.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C`E
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/&1I=B!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-
M"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C`E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$U)3X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C`E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$U)3X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C`E/"]F;VYT/CPO9&EV/@T*/"]T
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q-24^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
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M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
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M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C`N,3,E#0HM(#$N.#(E/"]F;VYT
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M97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-24^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXP+C$S)0T*+2`S+C0U)3PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$U)3X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/C`N-#(E#0HM(#,N-3@E/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV(&%L:6=N/3-$8V5N
M=&5R/B8C>$$P.SPO9&EV/@T*/"]D:78^#0H\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)SX-"CQT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0U.24^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
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M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"B8C>$$P.SPO9&EV/@T*/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O
M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/E=E:6=H=&5D/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY!=F5R86=E/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0T,"4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY796EG:'1E9#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,"4^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DYU
M;6)E<@T*;V8\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^079E<F%G93PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,R4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
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M34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T)SX-"D%G9W)E9V%T93PO9F]N=#X\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E-H87)E<SPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D5X97)C:7-E
M#0I0<FEC93PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
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M1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.1RU"3U14
M3TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@
M5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,R4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E(&%L:6=N/3-$;&5F=#X-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D)A
M;&%N8V4-"F%T($1E8V5M8F5R(#,Q+"`R,#$P/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/CDL.3,R+#(Q-#PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T
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M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E(&%L:6=N/3-$;&5F=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-RPU-#0L-C`P/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
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M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
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M03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY%>&5R8VES960\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M*#4L,#`P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT
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M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXQ+C0R/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI
M=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E(&%L:6=N/3-$
M;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M+3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXM/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
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M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
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M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^0V%N8V5L;&5D/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^*#(L,#<Q+#DQ.3PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O
M;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXQ+C<T/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=.
M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!4
M15A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$
M=VAI=&4^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E(&%L:6=N/3-$;&5F=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D)A;&%N8V4-
M"F%T(%-E<'1E;6)E<B`S,"P@,C`Q,3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-
M.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-.B`T<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
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M1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
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M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE
M.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"BT\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C
M;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,B4^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY/<'1I;VYS#0I%>&5R8VES86)L92!A="!397!T96UB97(@,S`L(#(P
M,3$\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R
M:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXX+#@Q,BPP,#(\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXQ+C@T/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C8N-SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,RXS<'0G(&%L:6=N/3-$:G5S
M=&EF>3XF(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#,N,W!T)R!A;&EG;CTS1&IU<W1I9GD^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1J=7-T:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF
M>3X-"CQD:78@86QI9VX],T1C96YT97(^#0H\=&%B;&4@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S4E/@T*
M/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O
M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/E=E:6=H=&5D/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!=F5R86=E/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0T,"4^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
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M34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY296UA:6YI;F<\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<CX-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#0P)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
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M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E3
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
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M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
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M.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M4TE:13H@,3!P="<^#0I!9V=R96=A=&4\+V9O;G0^/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-#`E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS
M1&YO=W)A<#X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/E-H87)E<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
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M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^17AE<F-I<V4-"E!R:6-E/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY497)M#0HH>65A<G,I/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$T)2!C;VQS<&%N/3-$,R!N;W=R87`],T1N;W=R
M87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P="<^#0I);G1R:6YS:6,@5F%L=64\+V9O;G0^/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E(&%L:6=N/3-$;&5F
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/D)A;&%N8V4-"F%T($1E8V5M8F5R(#,Q+"`R,#$P/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^,RPQ,#`L,#`P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O
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M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS
M1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2!A;&EG
M;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY'<F%N=&5D/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-C4P+#`P,#PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
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M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^
M#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%>&5R8VES960\+V9O;G0^
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXM/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
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M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS1&QE9G0^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%>'!I
M<F5D/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C
M0T-&1D-#/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#86YC96QL
M960\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N
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M($9/3E0M4TE:13H@,3!P="<^*#$L-#`P+#`P,#PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*3PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
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M9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY"86QA;F-E#0IA="!3
M97!T96UB97(@,S`L(#(P,3$\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR+#,U,"PP,#`\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L
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M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R
M:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+CDT/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U
M8FQE.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
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M;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@
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M33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
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M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@
M,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0T,"4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^3W!T:6]N<PT*17AE<F-I<V%B;&4@
M870@4V5P=&5M8F5R(#,P+"`R,#$Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^.34P+#`P
M,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
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M-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXX+C,\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B
M;&4^#0H\+V1I=CX-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3XF(WA!,#L\+V1I=CX-
M"CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,3AP=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,RXS<'0G(&%L:6=N/3-$:G5S=&EF>3X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"G1O=&%L(&9A:7(@=F%L
M=64@;V8@<VAA<F5S('9E<W1E9"!D=7)I;F<@=&AE('1H<F5E(&%N9"!N:6YE
M(&UO;G1H<PT*96YD960@4V5P=&5M8F5R(#,P+"`R,#$Q('=A<R!A<'!R;WAI
M;6%T96QY("9N8G-P.R0\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/C$L,38Y+#,P,#PO9F]N
M=#X-"F%N9"`F;F)S<#LD/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SXS+#DW,RPX,#`\+V9O
M;G0^+`T*<F5S<&5C=&EV96QY+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^5&AE#0IN=6UB97(@;V8@<F5M86EN:6YG('-H87)E<R!A=71H;W)I>F5D
M('1O(&)E(&ES<W5E9"!U;F1E<B!T:&4-"G9A<FEO=7,@97%U:71Y('!L86YS
M(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,2!A<F4@87,-"F9O;&QO=W,Z/"]F;VYT
M/CPO9&EV/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0HF(WA!,#L\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)SX-"CQD:78@86QI9VX],T1C96YT97(^#0H\=&%B;&4@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$.#`E/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#<P)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY.
M;VX-"E53($5Q=6ET>3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-S`E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N
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M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^55,-"D5Q=6ET>2!0;&%N/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y
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M1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-S`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/E-H87)E<PT*075T:&]R:7IE9"!F;W(@27-S
M=6%N8V4@=6YD97(@,C`P,R!%<75I='D@4&QA;CPO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
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M/C(L-3`P+#`P,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI
M=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$
M;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/E-H87)E<PT*075T:&]R:7IE9"!F;W(@27-S=6%N8V4@=6YD97(@,C`P
M.2!%<75I='D@4&QA;CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$W+#<U,"PP,#`\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
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M3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXM
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-S`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^."PW,#`L,#`P/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M,"PP,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
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M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXX+#<P,"PP,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
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M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT
M<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-S`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/D5X97)C:7-E9`T*3W!T:6]N<SPO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B@Y-RPU,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/BD\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C
M0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)2!A;&EG
M;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY/=71S=&%N9&EN9PT*3W!T:6]N<R`M($YO;B!54R!%<75I='D@
M4&QA;CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,BPS-3`L,#`P/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4@86QI9VX]
M,T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^4F5S=')I8W1E9`T*<W1O8VL@;W(@97%U:71Y(&=R86YT<R!I<W-U
M960@=6YD97(@17%U:71Y(%!L86YS/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[
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M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/BD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B@X.#4L,#`P/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#<P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY4;W1A;`T*8V]M;6]N('-H87)E<R!R96UA
M:6YI;F<@=&\@8F4@:7-S=65D('5N9&5R('1H92!%<75I='D-"E!L86YS/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE
M.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M-'!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^-2PT-C4L,#`P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\+W1A8FQE/@T*/"]D:78^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#,N,W!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X
M03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`Q.'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`S+C-P="<@86QI9VX],T1J=7-T:69Y/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D%S#0IO9B!397!T96UB97(@
M,S`L(#(P,3$L('1H97)E('=A<R!A<'!R;WAI;6%T96QY("9N8G-P.R0\9F]N
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M97<@4F]M86XG/C<S.2PS,#`\+V9O;G0^(&ES#0IR96QA=&5D('1O('-T;V-K
M(&]P=&EO;G,@=&AA="!V97-T(&)A<V5D(&]N('1H92!A8V-O;7!L:7-H;65N
M="!O9@T*8G5S:6YE<W,@;6EL97-T;VYE<R!W:&EC:"!E>'!E;G-E(&)E9VEN
M<R!T;R!B92!R96-O9VYI>F5D('=H96X@<W5C:`T*;6EL97-T;VYE<R!B96-O
M;64@<')O8F%B;&4@;V8@8F5I;F<@86-H:65V960N)B-X03`[)B-X03`[169F
M96-T:79E#0I/8W1O8F5R(#$T+"`R,#$Q+"!C;VYC=7)R96YT('=I=&@@<VAA
M<F5H;VQD97(@87!P<F]V86P@=&\@:6YC<F5A<V4-"G1H92!N=6UB97(@;V8@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A=71H;W)I>F5D(&9O<B!I<W-U86YC
M92!U;F1E<@T*=&AE(#(P,#D@17%U:71Y(%!L86X@8GD@-BPP,#`L,#`P+"!T
M:&4@0V]M<&%N>28C>#(P,3D[<R!";V%R9"!O9@T*1&ER96-T;W)S(&%U=&AO
M<FEZ960@82!D96-R96%S92!I;B!T:&4@<VAA<F5S(&%V86EL86)L92!F;W(-
M"FES<W5A;F-E('5N9&5R('1H92!.;VXM52Y3+"!%<75I='D@4&QA;B!F<F]M
M(#@L-S`P+#`P,"!T;PT*-2PW,#`L,#`P+CPO9F]N=#X\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/B8C
M>$$P.SPO9&EV/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`Q.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`S+C-P="<@86QI9VX],T1J=7-T:69Y/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF
M>3X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I#:&%N9V5S(&EN(%-T
M;V-K:&]L9&5R<R!%<75I='DZ/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3XF
M(WA!,#L\+V1I=CX-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF
M>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^5&AE#0IC:&%N
M9V5S(&EN(%-T;V-K:&]L9&5R<R!%<75I='D@9F]R('1H92!N:6YE(&UO;G1H
M<R!E;F1E9"!397!T96UB97(-"C,P+"`R,#$Q('=E<F4@87,@9F]L;&]W<SH\
M+V9O;G0^/"]D:78^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"B8C>$$P.SPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G/@T*/&1I=B!A;&EG;CTS1&QE9G0^#0H\=&%B
M;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$,3`P)3X-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&YO=W)A
M<#TS1&YO=W)A<#X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*4V5R:65S
M($(@0V]N=F5R=&EB;&4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
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M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/@T*/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0G
M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!C96YT97(G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
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M+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@;F]W<F%P/3-$
M;F]W<F%P/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"D-O;6UO;B!3=&]C:SPO9F]N
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M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;3X\
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.
M1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M96YT97([(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,G!X('-O;&ED.R!415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-
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M='EL93TS1"=415A4+4%,24=..B!C96YT97([(%!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<B<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A
M<#X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@
M5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
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M24=..B!C96YT97([(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)SX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`X<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E
M<CX-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY/=&AE<CPO9F]N
M=#X\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY#;VUP<F5H
M96YS:79E/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY);F-O;64\+V9O
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M.B`R<'@G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E
M;G1E<B<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO
M=W)A<#X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
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M97([(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-
M"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M25I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY#;VYT<F]L;&EN9SPO9F]N
M=#X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SX-"DEN=&5R97-T(&EN/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SY3=6)S:61I87)Y/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
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M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(X)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SX-"D)A;&%N8V4@870@2F%N=6%R>2`Q+"`R,#$Q/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
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M13H@.'!T)SXQ,"PP,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)FYB<W`[)#PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0U)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`X<'0G/C$P,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
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M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0HF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^#0H\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@.'!T)SXV-"PR,C$L,3,P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C$T,2PQ,S<L-3(R/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@.'!T)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXR+#<W.2PP
M-C8\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
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M;CL@1D].5"U325I%.B`X<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0U)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/B@Y-2PS,C`L-C(P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BD\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
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M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
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M)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`X<'0G/D5X97)C:7-E#0IO9B!S=&]C:R!O<'1I;VYS/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M.B`X<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[
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M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#4E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#AP="<^-2PP,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0HF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@.'!T)SXW+#`Y-3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
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M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M25I%.B`X<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
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M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
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M1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C(L,SDT
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M.'!T)SXX+#$V,BPT,3D\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#4E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#AP="<^+3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M25I%.B`X<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$
M=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C@E(&%L:6=N
M/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
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M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
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M5"U325I%.B`X<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT
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M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
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M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^,C$L,30X+#`P-#PO9F]N=#X\+W1D
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D
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M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BT\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXR,2PQ-C<L-C@R/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T-#1D9#0SX-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R."4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
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M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BT\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
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M5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
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M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@.'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C0P.#PO9F]N
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BT\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
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M1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C8P-RPS
M-C,\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R."4@86QI9VX],T1L969T/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F
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M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0U)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`X<'0G/C,L-#8R+#4U.3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
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M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
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M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
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M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXH-3`X+#`W,#PO9F]N=#X\
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/@T*/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^+3PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
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M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(X)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/D9O<F5I9VX-"F-U<G)E;F-Y
M('1R86YS;&%T:6]N/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
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M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
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M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M;VUA;CL@1D].5"U325I%.B`X<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
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M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BT\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M;CL@1D].5"U325I%.B`X<'0G/BD\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
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M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R."4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BT\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
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M1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BT\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
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M5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
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M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C4U.2PP-SD\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
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M1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#4E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^-34Y
M+#`W.3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C@E(&%L:6=N/3-$;&5F=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^1&EV:61E
M;F1S#0IT;R!R96QA=&5D('!A<G1Y/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^
M#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXM/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BT\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D
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M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BT\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXM/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T
M)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B@Q,2PW,C8L,#DY/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/BD\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#AP="<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXH,3$L-S(V+#`Y.3PO
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M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT
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M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M25I%.B`X<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^+3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
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M13H@.'!T)SXY,C`L,#`P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0U)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`X<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT
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M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
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M4TE:13H@.'!T)SXR,S`L,#`P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M1D].5"U325I%.B`X<'0G/C$L,34P+#`P,#PO9F]N=#X\+W1D/@T*/'1D('-T
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M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
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M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
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M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M;VUA;CL@1D].5"U325I%.B`X<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
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M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
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M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M;CL@1D].5"U325I%.B`X<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^+3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
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M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
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M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
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M;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
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M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#AP="<^+3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
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M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^,3`L-C`P+#`P,#PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#AP="<^,3`L-C`P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXQ-RPQ.#DL-#`P
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
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M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX]
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M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXQ-RPR,#`L,#`P/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T-#1D9#
M0SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R."4@86QI9VX],T1L969T/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^#0I"86QA;F-E(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,3PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#4E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/C$P+#`P,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
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M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!
M3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C$P,#PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S
M;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^,3`P+#,V,2PT-#,\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`X<'0G/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXQ,#`L,S8Q/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[
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M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B9N8G-P.R0\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0U)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXU+#`P
M,2PV,S4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`X<'0G/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@.'!T)SXH,3(T+#$Q-BPU,#4\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^*3PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
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M="<^,C8L.#@Q+#`V-CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#AP="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/C$P,"PT-#(L-3(Y/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D
M:78^#0H\+V1I=CX-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?,3$V.#$U8V9?.34Y,U\T,&-A7SED-S=?-#<Y9&8Q
M-S8V8C4Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$Q-C@Q-6-F
M7SDU.3-?-#!C85\Y9#<W7S0W.61F,3<V-F(U,2]7;W)K<VAE971S+U-H965T
M,34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5,1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)
M;F-O;64@5&%X97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YC;VUE(%1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!415A4+41%0T]2051)3TXZ('5N9&5R;&EN
M92<^3F]T92`Q,`T*)B-X,C`Q,SL@26YC;VUE(%1A>&5S/"]F;VYT/CPO9F]N
M=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&IU<W1I9GD^/"$M+45&4&QA8V5H;VQD97(M+3X\8G(@
M+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`Q.'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SY4:&4-"E1A>"!2969O<FT@06-T(&]F(#$Y.#8@96YA8W1E
M9"!A(&-O;7!L97@@<V5T(&]F(')U;&5S(&QI;6ET:6YG('1H90T*=71I;&EZ
M871I;VX@;V8@;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',@*"8C
M>#(P,4,[3D],)B-X,C`Q1#LI#0IT;R!O9F9S970@9G5T=7)E('1A>&%B;&4@
M:6YC;VUE(&9O;&QO=VEN9R!A(&-O<G!O<F%T92!O=VYE<G-H:7`-"F-H86YG
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M,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^4VEN8V4-"G1H92!Y96%R
M(#(P,#`L('1H92!#;VUP86YY(&AA<R!H860@<V5V97)A;"!C:&%N9V5S(&EN
M(&]W;F5R<VAI<`T*=VAI8V@@:&%S(')E<W5L=&5D(&EN(&$@;&EM:71A=&EO
M;B!O;B!T:&4@0V]M<&%N>28C>#(P,3D[<R!A8FEL:71Y#0IT;R!A<'!L>2!N
M970@;W!E<F%T:6YG(&QO<W-E<R!T;R!F=71U<F4@=&%X86)L92!I;F-O;64@
M86YD(&9U='5R90T*;W=N97)S:&EP(&-H86YG97,@8V]U;&0@<F5S=6QT(&EN
M(&%D9&ET:6]N86P@;&EM:71A=&EO;G,N($%T#0I$96-E;6)E<B`S,2P@,C`Q
M,"P@=&AE($-O;7!A;GD@:&%D(&YE="!O<&5R871I;F<@;&]S<R!C87)R>69O
M<G=A<F1S#0IO9B!A<'!R;WAI;6%T96QY("9N8G-P.R0S.2PU.3`L-3`P(&%P
M<&QI8V%B;&4@=&\@9G5T=7)E($9E9&5R86P@:6YC;VUE#0IT87AE<RX@5&AE
M('1A>"!L;W-S(&-A<G)Y9F]R=V%R9',@87)E('-U8FIE8W0@=&\@86YN=6%L
M(&QI;6ET871I;VYS#0IA;F0@97AP:7)E(&%T('9A<FEO=7,@9&%T97,@=&AR
M;W5G:"`R,#,P+B!4:&4@0V]M<&%N>2!H87,@<F5C;W)D960-"F$@9G5L;"!V
M86QU871I;VX@86QL;W=A;F-E(&%G86EN<W0@:71S(&YE="!D969E<G)E9"!T
M87@@87-S970-"F)E8V%U<V4@:70@:7,@;6]R92!L:6ME;'D@=&AA;B!N;W0@
M=&AA="!S=6-H(&1E9F5R<F5D('1A>"!A<W-E=',-"G=I;&P@;F]T(&)E(')E
M86QI>F5D+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@
M8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I=B!S
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M;VYT:',@96YD960@4V5P=&5M8F5R#0HS,"P@,C`Q,2!A;F0@,C`Q,"!I<R!R
M96QA=&5D('1O(&9O<F5I9VX@=&%X97,@9F]R(&]U<B!O<&5R871I;VYS(&EN
M#0I#:&EN82X\+V9O;G0^/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$<^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4V5G;65N="!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y396=M96YT($EN9F]R;6%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF
M>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!4
M15A4+41%0T]2051)3TXZ('5N9&5R;&EN92<^3F]T92`Q,0T*)B-X,C`Q,SL@
M4V5G;65N="!);F9O<FUA=&EO;CPO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\
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M;65N="!W87,@87,@9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1J=7-T:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"CQD
M:78@86QI9VX],T1C96YT97(^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3`E/@T*/'1R/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#0P)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(X)2!C;VQS<&%N
M/3-$-B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
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M+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
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M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0P)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-
M"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C(P,3$\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4
M+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR,#$P/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
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M(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^,C`Q,3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/C(P,3`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M
M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,"4^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
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M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
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M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
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M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
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M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[
M)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^,34L-3$S+C`\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
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M<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,38L,S@T+C4\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
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M3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M-#DL.#`V+C`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^-3$L-3(X+C<\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R
M/3-$=VAI=&4^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU,1494.B`P<'0[($U!
M4D=)3BU,1494.B`Y<'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2!A
M;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR+#$W-RXP/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
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M.#,W+C`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
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M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXQ-3<N-CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&
M1D-#/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%!!1$1)
M3D<M3$5&5#H@,'!T.R!-05)'24XM3$5&5#H@.7!T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0T,"4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#$X<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T)SX-"E)E9V5N97)A=&EV
M92!-961I8VEN92`M($-H:6YA/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O
M;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXV-BXQ
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C,P+C`\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
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M="<^,C$U+C`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,S`N,#PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0T,"4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ-RPW-38N,3PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
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M5$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXQ-BPT-S4N-CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T
M<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXU-2PX-3@N,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU,2PW,38N,SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(]
M,T0C0T-&1D-#/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%
M6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,"4^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P<'0[($1)
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
M"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^
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M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T)SX-"E!H87)M86-E=71I8V%L
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M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^-S$W+CD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O
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M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,RPT.#`N,3PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXY+#,P,BXS
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU,1494.B`P<'0[($U!4D=)3BU,1494.B`Y<'0G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
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M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXH,BPY.38N,3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
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M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXH,BPS,#0N-CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
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M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXH.2PY-3<N-SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^*3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH-BPY,3<N,CPO9F]N=#X\+W1D
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M.B`P<'0[($U!4D=)3BU,1494.B`Y<'0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH
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M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
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M9'1H/3-$-#`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9
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M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXH-"PT,C`N,SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^*3PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W
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M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/BD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B@Q-RPP-#DN-SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH
M,3,L,3@Q+C0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/BD\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C
M;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D
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M25I%.B`Q,'!T)SXI/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R
M:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH-2PW-#,N.#PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*3PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^*#(U+#,W-"XT/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,3$L.#4U+C`\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/BD\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#
M0T9&0T,^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)
M3D1%3E0Z(#!P=#L@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L
M<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,R4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(]
M,T1W:&ET93X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,G!X.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-#`E/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!L969T.R!4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E3
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!C96YT97(G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY397!T96UB97(-"C,P+"`R,#$Q/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P="<^#0I$96-E;6)E<B`S,2P@,C`Q,#PO9F]N=#X\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
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M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C
M;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU,1494.B`P
M<'0[($U!4D=)3BU,1494.B`Y<'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#0P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#$P<'0G/@T*4&AA<FUA8V5U=&EC86P@36%N=69A
M8W1U<FEN9R`M($-H:6YA/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,C0L
M,#0U+C`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU,1494.B`P<'0[($U!4D=)3BU,1494.B`Y
M<'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS1&QE9G0^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
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M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXR."PT-#4N-#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$L,3`Q+CD\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L
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M93L@1D].5"U325I%.B`Q,'!T)SX-"E)E9V5N97)A=&EV92!-961I8VEN92`M
M($-H:6YA/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(L-C0P+C`\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT+#DT
M.2XX/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>#L@4$%$1$E.1RU,1494.B`P<'0[($U!4D=)3BU,
M1494.B`Y<'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P
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M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
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M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L
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M,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@
M,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0P)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXQ-C@L,C$T+C<\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
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M;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C$T,RPP,C0N-SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@
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M(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\+V1I=CX-"CPO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3$V.#$U8V9?.34Y
M,U\T,&-A7SED-S=?-#<Y9&8Q-S8V8C4Q#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S$Q-C@Q-6-F7SDU.3-?-#!C85\Y9#<W7S0W.61F,3<V-F(U
M,2]7;W)K<VAE971S+U-H965T,3<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,1SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<SQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296QA=&5D
M(%!A<G1Y(%1R86YS86-T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/&1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
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M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,RXS<'0G(&%L:6=N/3-$
M:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^070-
M"E-E<'1E;6)E<B`S,"P@,C`Q,2P@17)Y92!O=V5D($5%5"P@=&AE(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^-#D\+V9O;G0^)0T*<VAA<F5H;VQD97(@;V8@17)Y92P@
M)FYB<W`[)#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^,C`L-3,T+#$P,#PO9F]N=#X-"G=H
M:6-H(')E<')E<V5N=',@9&EV:61E;F1S('!A:60@86YD(&QO86YE9"!B86-K
M('1O#0I%<GEE+B8C>$$P.R8C>$$P.T%T(%-E<'1E;6)E<B`S,"P@,C`Q,2!T
M:&4@:6YT97)E<W0@<F%T92!O;B!T:&ES#0IL;V%N('=A<R`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/C8N-38\+V9O;G0^)2XF(WA!,#LF(WA!,#M);@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SY*=6YE/"]F;VYT/B`R,#$Q#0I%<GEE('!A:60@1454(&%P<')O
M>&EM871E;'D@)FYB<W`[)#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^.#<U+#$P,#PO9F]N
M=#X-"F-O;G-I<W1I;F<@;V8@=&AE(&YE="!O9B!T:&4@9F]L;&]W:6YG.B`F
M;F)S<#LD/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SXQ+#$Q-2PP,#`\+V9O;G0^(&]F#0IU
M;G!A:60@86-C<G5E9"!I;G1E<F5S="!A="!*=6YE(#,P+"`R,#$Q+"!A<'!R
M;WAI;6%T96QY#0HF;F)S<#LD/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SXT,#@L-S`P/"]F
M;VYT/@T*<F5P87EM96YT(&]F(&$@;F]N(&EN=&5R97-T(&)E87)I;F<@;&]A
M;B!D=64@:6X@,C`Q,2!A;F0@<F5C;W9E<GD-"F]F(&-A<V@@861V86YC97,@
M=&\@1454(&]F(&%P<')O>&EM871E;'D@)FYB<W`[)#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^-C0X+#8P,#PO9F]N=#XN/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`Q.'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`S+C-P
M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY0=7)S=6%N=`T*=&\@=&AE('1E<FUS(&%N9"!C;VYD:71I;VYS
M(&]F('1H92!%<GEE($IO:6YT(%9E;G1U<F4@06=R965M96YT+`T*9&EV:61E
M;F0@9&ES=')I8G5T:6]N<R!T;R!%150@86YD('1H92!#;VUP86YY)B-X,C`Q
M.3MS('-U8G-I9&EA<GD-"G=I;&P@8F4@;6%D92!I;B!P<F]P;W)T:6]N('1O
M('1H96ER(')E<W!E8W1I=F4@;W=N97)S:&EP(&EN=&5R97-T<PT*:6X@17)Y
M93L@<')O=FED960L(&AO=V5V97(L('1H870@9F]R('1H92!T:')E92UY96%R
M('!E<FEO9`T*8V]M;65N8VEN9R!O;B!T:&4@9FER<W0@9&%Y(&]F('1H92!F
M:7)S="!F:7-C86P@<75A<G1E<B!A9G1E<B!T:&4-"DIO:6YT(%9E;G1U<F4@
M06=R965M96YT(&)E8V%M92!E9F9E8W1I=F4@9&ES=')I8G5T:6]N<R!A<F4@
M;6%D92!A<PT*9F]L;&]W<SH@9F]R('5N9&ES=')I8G5T960@<')O9FET<R!G
M96YE<F%T960@<W5B<V5Q=65N="!T;R!T:&4-"F%C<75I<VET:6]N(&1A=&4Z
M("AI*2!T:&4@-#DE(&]F('5N9&ES=')I8G5T960@<')O9FET<R`H869T97(@
M=&%X*0T*;V8@=&AE(&IO:6YT('9E;G1U<F4@9'5E($5%5"!W:6QL(&)E(&1I
M<W1R:6)U=&5D('1O($5%5"!A;F0@;&5N=`T*8F%C:R!T;R!%<GEE('1O(&AE
M;'`@9FEN86YC92!C;W-T<R!I;B!C;VYN96-T:6]N('=I=&@@:71S#0IC;VYS
M=')U8W1I;VX@;V8@86YD(')E;&]C871I;VX@=&\@82!N97<@9F%C:6QI='D[
M(&%N9"`H:6DI(&]F('1H90T*;F5T('!R;V9I="`H869T97(@=&%X*2!O9B!T
M:&4@:F]I;G0@=F5N='5R92!D=64@=&AE($-O;7!A;GDL(#0U)0T*=VEL;"!B
M92!P<F]V:61E9"!T;R!%<GEE(&%S('!A<G0@;V8@=&AE(&YE=R!F86-I;&ET
M>2!C;VYS=')U8W1I;VX-"F9U;F0@86YD('=I;&P@8F4@8VAA<F%C=&5R:7IE
M9"!A<R!A9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;"!F;W(-"G1H92!#;VUP
M86YY)B-X,C`Q.3MS(#4Q)2!I;G1E<F5S="!I;B!%<GEE+"!A;F0@-B4@=VEL
M;"!B90T*9&ES=')I8G5T960@=&\@=&AE($-O;7!A;GD@=VAI8V@@:&%S(&YO
M="!B965N('!A:60@9G)O;2!T:&4@,C`Q,`T*9&ES=')I8G5T:6]N(&%N9"!I
M<R!I;B!T:&4@86UO=6YT(&]F(&%P<')O>&EM871E;'D@)FYB<W`[)#$S,"PP
M,#`N($9O<@T*=6YD:7-T<FEB=71E9"!P<F]F:71S(&=E;F5R871E9"!P<FEO
M<B!T;R!T:&4@86-Q=6ES:71I;VX@9&%T93H@*&DI#0IT:&4@-#DE(&]F('5N
M9&ES=')I8G5T960@<')O9FET<R`H869T97(@=&%X*2!O9B!T:&4@:F]I;G0@
M=F5N='5R90T*9'5E($5%5"!W:6QL(&)E(&1I<W1R:6)U=&5D('1O($5%5"!A
M;F0@;&5N="!B86-K('1O($5R>64@=&\@:&5L<`T*9FEN86YC92!C;W-T<R!I
M;B!C;VYN96-T:6]N('=I=&@@:71S(&-O;G-T<G5C=&EO;B!O9B!A;F0@<F5L
M;V-A=&EO;@T*=&\@82!N97<@9F%C:6QI='D[(&%N9"`H:6DI(&]F('1H92!N
M970@<')O9FET("AA9G1E<B!T87@I(&]F('1H90T*:F]I;G0@=F5N='5R92!D
M=64@=&AE($-O;7!A;GDL(#4Q)2!W:6QL(&)E('!R;W9I9&5D('1O($5R>64@
M87,@<&%R=`T*;V8@=&AE(&YE=R!F86-I;&ET>2!C;VYS=')U8W1I;VX@9G5N
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M<R!S=6-H+`T*-#4E(&]F('1H92!D:79I9&5N9"!W92!W;W5L9"!B92!E;G1I
M=&QE9"!T;R!B>2!R96%S;VX@;V8@;W5R(#4Q)0T*;W=N97)S:&EP('=O=6QD
M(')E;6%I;B!I;B!%<GEE('1H<F]U9V@@3V-T;V)E<B`R,#$R('1O(&-O;7!L
M971E('1H90T*<F5L;V-A=&EO;B!W:&EL92!%150@=V]U;&0@;&]A;B!B86-K
M('1H96ER(&1I=FED96YD(&1U<FEN9R!T:&4@<V%M90T*<&5R:6]D(&%T(&$@
M<')E=F%I;&EN9R!B86YK(&EN=&5R97-T(')A=&4N)B-X03`[)B-X03`[/&9O
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M+B8C>$$P.R8C>$$P.TEN($IA;G5A<GD@,C`Q,2P@82!D:79I9&5N9"!T;W1A
M;&EN9PT*87!P<F]X:6UA=&5L>2`F;F)S<#LD,3,L-C<Q+#$P,"!B87-E9"!O
M;B!E87)N:6YG<R!F;W(F(WA!,#LF(WA!,#M&:7-C86P-"EEE87(@,C`P.2!W
M87,@9&5C;&%R960@86YD(&%P<')O>&EM871E;'D@)FYB<W`[)#8L-CDX+#@P
M,"!W87,@9&ES=')I8G5T960-"G1O($5%5"!A;F0@;&5N="!B86-K('1O($5R
M>64@86YD(&%P<')O>&EM871E;'D@)FYB<W`[)#8L.3<R+#,P,"!D=64@=&AE
M#0I#;VUP86YY('=A<R!R96EN=F5S=&5D(&%N9"!R92UC:&%R86-T97)I>F5D
M(&%S(&%D9&ET:6]N86P@<&%I9"UI;@T*8V%P:71A;"!I;B!T:&4@8G5S:6YE
M<W,N($EN($%P<FEL(#(P,3$L(&$@9&EV:61E;F0@=&]T86QI;F<-"B9N8G-P
M.R0Q,"PR-3DL-S`P(&)A<V5D(&]N(&5A<FYI;F=S(&9O<B!&:7-C86P@665A
M<B`R,#$P('=A<R!D96-L87)E9"!A;F0-"F%P<')O>&EM871E;'D@)FYB<W`[
M)#4L,#(W+#,P,"!W87,@9&ES=')I8G5T960@=&\@1454(&%N9"!L96YT(&)A
M8VL@=&\-"D5R>64L(&%N9"!A<'!R;WAI;6%T96QY("9N8G-P.R0U+#(S,BPT
M,#`@9'5E('1H92!#;VUP86YY('=A<R!R96EN=F5S=&5D#0IA;F0@<F4M8VAA
M<F%C=&5R:7IE9"!A<R!A9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;"!I;B!T
M:&4-"F)U<VEN97-S+B8C>$$P.R8C>$$P.T$@,3`E('=I=&AH;VQD:6YG('1A
M>"!W87,@<F5Q=6ER960@;VX-"F1I=FED96YD<R!P87EA8FQE('1O('1H92!#
M;VUP86YY+B8C>$$P.R8C>$$P.T%S(&$@<F5S=6QT+"!%<GEE#0IW:71H:&5L
M9"!A<'!R;WAI;6%T96QY("9N8G-P.R0Q+#(R,"PU,#`@:6X@=&%X97,@<F5L
M871E9"!T;R!T:&4-"D-O;7!A;GDF(W@R,#$Y.W,@1FES8V%L(%EE87(@,C`P
M.2!A;F0@,C`Q,"!D:79I9&5N9"!A;6]U;G1S+"!O9@T*=VAI8V@@87!P<F]X
M:6UA=&5L>2`F;F)S<#LD-3(V+#8P,"!H87,@;F]T(&)E96X@<&%I9"!T;R!T
M:&4@;&]C86P@0VAI;F5S90T*=&%X(&%U=&AO<FET:65S(&%S(&]F(%-E<'1E
M;6)E<B`S,"P@,C`Q,2X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#$X<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY0=7)S=6%N=`T*=&\@=&AE(%!#5"!-97)G97(@06=R965M96YT+"!.96]3
M=&5M(&%G<F5E9"!T;R!P87D@;V9F(%!#5"8C>#(P,3D[<PT*8W)E9&ET(&QI
M;F4@=VET:"!.;W)T:&5R;B!.97<@2F5R<V5Y($-A;F-E<B!!<W-O8VEA=&5S
M#0HH)B-X,C`Q0SM.3DI#028C>#(P,40[*2P@:6X@86X@86UO=6YT('5P('1O
M("9N8G-P.R0S+#`P,"PP,#`L('-H;W)T;'D@869T97(-"G1H92!C;&]S:6YG
M(&]F('1H92!00U0@365R9V5R+B!/;B!*86YU87)Y(#(Q+"`R,#$Q+"!.96]3
M=&5M('!A:60-"DY.2D-!("9N8G-P.R0S+#`P,"PP,#`@:6X@9G5L;"!S871I
M<V9A8W1I;VX@;V8@86QL(&]F(%!#5"8C>#(P,3D[<PT*;V)L:6=A=&EO;G,@
M=&\@3DY*0T$@87)I<VEN9R!F<F]M('1H92!U;F1E<FQY:6YG(&QI;F4@;V8@
M8W)E9&ET(&%N9`T*<V5C=7)I='D@86=R965M96YT+B!$<BX@06YD<F5W(%!E
M8V]R82`H=VAO('=A<R!00U0F(W@R,#$Y.W,@0VAA:7)M86X-"F%N9"!#14\@
M<')I;W(@=&\@=&AE(%!#5"!-97)G97(L(&%N9"!W:&\@8F5C86UE(%!#5"8C
M>#(P,3D[<R!#:&EE9@T*365D:6-A;"!/9F9I8V5R(&]N($IA;G5A<GD@,3DL
M(#(P,3$@<'5R<W5A;G0@=&\@86X@96UP;&]Y;65N=`T*86=R965M96YT(&5F
M9F5C=&EV92!U<&]N('1H92!C;&]S:6YG(&]F('1H92!00U0@365R9V5R*2P@
M:&%S('-E<G9E9`T*87,@36%N86=I;F<@4&%R=&YE<B!O9B!.3DI#02!S:6YC
M92`Q.3DV+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU
M<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]N#0I*
M=6QY(#$S+"`R,#$Q+"!.96]3=&5M(&5N=&5R960@:6YT;R!T:&4@06=R965M
M96YT(&%N9"!0;&%N(&]F#0I-97)G97(@=&\@86-Q=6ER92!!;6]R8WET92XF
M(WA!,#LF(WA!,#M!;6]R8WET92!H860@;W)I9VEN86QL>2!B965N#0II;F-O
M<G!O<F%T960@87,@82!S=6)S:61I87)Y(&]F(%!#5"!A;F0@=V%S('-P=6X@
M;V9F('1O(%!#5"8C>#(P,3D[<PT*;65M8F5R<R!P<FEO<B!T;R!.96]3=&5M
M)B-X,C`Q.3MS($IA;G5A<GD@,3DL(#(P,3$@86-Q=6ES:71I;VX@;V8-"E!#
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M.B`Q.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS
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M('=I=&@-"G1H92!0:&%S92`R('1R:6%L+B!0=7)S=6%N="!T;R!A($QO86X@
M06=R965M96YT(&5N=&5R960@:6YT;R!O;@T*4V5P=&5M8F5R(#DL(#(P,3$L
M($YE;U-T96T@;&]A;F5D($%M;W)C>71E('!R:6]R('1O('1H92!C;&]S:6YG
M(&]F#0IT:&4@365R9V5R(&%N(&%G9W)E9V%T92!O9B`F;F)S<#LD,S,X+#4P
M,"!W:&EC:"!W87,@87!P;&EE9"!T;W=A<F1S('1H90T*8V]M;65N8V5M96YT
M(&]F('1H92!0:&%S92`R('1R:6%L+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,3AP=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/D5F9F5C=&EV90T*36%R8V@@,3`L(#(P,3$L($UA='1H97<@
M2&5N;FEN9V5R(&5N=&5R960@:6YT;R!A(&-O;G-U;'1I;F<-"F%G<F5E;65N
M="!W:71H(%!#5"P@<'5R<W5A;G0@=&\@=VAI8V@@37(N($AE;FYI;F=E<B!W
M87,@96YG86=E9"!F;W(-"F$@=&AR964@;6]N=&@@=&5R;2!T;R!S97)V92!A
M<R!A;B!A9'9I<V]R('1O(%!#5"!W:71H(')E9V%R9"!T;R!T:&4-"F1E=F5L
M;W!M96YT(&]F('1H92`F(W@R,#%#.T9A;6EL>2!0;&%N+"8C>#(P,40[(&$@
M;75L=&DM9V5N97)A=&EO;F%L#0IS=&5M(&-E;&P@8V]L;&5C=&EO;B!A;F0@
M<W1O<F%G92!S97)V:6-E+B!);B!C;VYS:61E<F%T:6]N#0IT:&5R969O<BP@
M37(N($AE;FYI;F=E<B!W87,@9W)A;G1E9"!A;B!O<'1I;VX@=&\@<'5R8VAA
M<V4@,34P+#`P,`T*<VAA<F5S(&]F($YE;U-T96T@0V]M;6]N(%-T;V-K('5N
M9&5R('1H92`R,#`Y(%!L86X@870@)FYB<W`[)#$N-C`@<&5R#0IS:&%R92`H
M0FQA8VL@4V-H;VQE<R!V86QU92`F;F)S<#LD,3(Y+#`P,"D@=F5S=&EN9R!O
M=F5R('1H92!T97)M(&]F('1H90T*86=R965M96YT+B!0=7)S=6%N="!T;R!A
M;B!A;65N9&UE;G0@86YD(&5X=&5N<VEO;B!O9B!T:&ES(&%G<F5E;65N=`T*
M:6X@07!R:6P@86YD($UA>2P@,C`Q,2P@<F5S<&5C=&EV96QY+"!-<BX@2&5N
M;FEN9V5R)B-X,C`Q.3MS('1E<FT@;V8-"G-E<G9I8V4@=V%S(&5X=&5N9&5D
M('1H<F]U9V@@4V5P=&5M8F5R(#DL(#(P,3$L(&9O<B!W:&EC:"!H90T*<F5C
M96EV960@-S4L,#`P('-H87)E<R!O9B!.96]3=&5M($-O;6UO;B!3=&]C:R`H
M;6%R:V5T('9A;'5E#0HF;F)S<#LD,3$U+#`P,"DL("9N8G-P.R0U+#`P,"!P
M97(@;6]N=&@@9F]R(&$@=&AR964@;6]N=&@@<&5R:6]D(&%N9`T*<F5I;6)U
M<G-E;65N="!O9B!H96%L=&@@:6YS=7)A;F-E('!R96UI=6US.R!I;B!397!T
M96UB97(@,C`Q,2!T:&4-"E!#5"!M86YA9V5M96YT('=I=&@@87!P<F]V86P@
M;V8@=&AE($%U9&ET($-O;6UI='1E90T*97AT96YD960F(WA!,#MT:&4@=&5R
M;28C>$$P.V9U<G1H97(F(WA!,#MT:')O=6=H($1E8V5M8F5R(#,Q+"`R,#$Q
M+`T*:6X@8V]N;F5C=&EO;B!W:71H('=H:6-H($UR+B!(96YN:6YG97(@<F5C
M96EV960@82`F;F)S<#LD,C4L,#`P(&)O;G5S#0IR96QA=&5D('1O('!R:6]R
M('!E<F9O<FUA;F-E+"!A(&UO;G1H;'D@9F5E(&]F("9N8G-P.R0Q,"PP,#`@
M86YD#0IC;VYT:6YU960@:6YS=7)A;F-E(')E:6UB=7)S96UE;G0N($UR+B!(
M96YN:6YG97(@:7,@:6X@86X@97AC;'5S:79E#0IR96QA=&EO;G-H:7`@=VET
M:"!T:&4@0T5/(&]F($YE;U-T96TN/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`Q.'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<^1'5R:6YG#0IT:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M
M8F5R(#,P+"`R,#$Q+"!T:&4@0V]M<&%N>2!C;VYT<FEB=71E9`T*=&\@5&AE
M(%-T96T@9F]R($QI9F4@1F]U;F1A=&EO;BP@82!096YN<WEL=F%N:6$@;F]N
M<')O9FET#0IC;W)P;W)A=&EO;B!C;&%S<VEF:65D(&%S(&$@=&%X+65X96UP
M="!O<F=A;FEZ871I;VX@=6YD97(@4V5C=&EO;@T*-3`Q*&,I*#,I(&]F('1H
M92!);G1E<FYA;"!2979E;G5E($-O9&4@;V8@,3DX-BP@87,@86UE;F1E9"`H
M=&AE#0HF(W@R,#%#.T-O9&4F(W@R,#%$.RD@86YD(&%S(&$@<'5B;&EC(&-H
M87)I='D@=6YD97(@4V5C=&EO;B`U,#DH82DH,2D-"F%N9"`Q-S`H8BDH,2DH
M02DH=FDI(&]F('1H92!#;V1E("AT:&4@)B-X,C`Q0SM&;W5N9&%T:6]N)B-X
M,C`Q1#LI+`T*=VAO<V4@;6ES<VEO;B!I<R!T;R!P<F]M;W1E('!U8FQI8R!A
M=V%R96YE<W,L(&9U;F0@<F5S96%R8V@@86YD#0ID979E;&]P;65N="!A;F0@
M<W5B<VED:7IE('-T96T@8V5L;"!C;VQL96-T:6]N(&%N9"!S=&]R86=E#0IP
M<F]G<F%M<RP@-#`W+#8P,"!S:&%R97,@;V8@<')E=FEO=7-L>2!I<W-U960@
M<F5S=')I8W1E9"!C;VUM;VX-"G-T;V-K('=I=&@@82!F86ER('9A;'5E(&]F
M(&%P<')O>&EM871E;'D@)FYB<W`[)#8P-RPT,#`N(%1H92!C;VYT<FEB=71I
M;VX-"F]F('-U8V@@<V5C=7)I=&EE<R!W87,@<W5B:F5C="!T;R!T:&4@87!P
M<F]V86P@;V8@=&AE($)O87)D(&]F#0I$:7)E8W1O<G,@86YD('1H92!!=61I
M="!#;VUM:71T964N)B-X03`[)B-X03`[5&AE($-O;7!A;GDF(W@R,#$Y.W,-
M"D-%3R!A;F0@0VAA:7)M86X@:7,@4')E<VED96YT(&%N9"!A(%1R=7-T964@
M;V8@=&AE($9O=6YD871I;VXL(&ET<PT*1V5N97)A;"!#;W5N<V5L(&ES(%-E
M8W)E=&%R>2!A;F0@82!4<G5S=&5E(&]F('1H92!&;W5N9&%T:6]N(&%N9`T*
M:71S($-H:65F($9I;F%N8VEA;"!/9F9I8V5R(&ES(%1R96%S=7)E<B!O9B!T
M:&4-"D9O=6YD871I;VXN/"]F;VYT/CPO9&EV/@T*#0H-"CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3$V.#$U8V9?
M.34Y,U\T,&-A7SED-S=?-#<Y9&8Q-S8V8C4Q#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S$Q-C@Q-6-F7SDU.3-?-#!C85\Y9#<W7S0W.61F,3<V
M-F(U,2]7;W)K<VAE971S+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,1SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N
M8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`Q.'!T.R!-
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M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y
M;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M
M24Y$14Y4.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T
M:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY4:&4-"D-O
M;7!A;GD@;&5A<V5S(&]F9FEC92!A;F0@;&%B;W)A=&]R>2!F86-I;&ET:65S
M(&%N9"!C97)T86EN#0IE<75I<&UE;G0@=6YD97(@8V5R=&%I;B!N;VYC86YC
M96QA8FQE(&]P97)A=&EN9R!L96%S97,@=&AA="!E>'!I<F4-"F9R;VT@=&EM
M92!T;R!T:6UE('1H<F]U9V@@,C`Q-2XF(WA!,#LF(WA!,#M!('-U;6UA<GD@
M;V8@9G5T=7)E#0IM:6YI;75M(')E;G1A;"!P87EM96YT<R!R97%U:7)E9"!U
M;F1E<B!O<&5R871I;F<@;&5A<V5S('1H870@:&%V90T*:6YI=&EA;"!O<B!R
M96UA:6YI;F<@=&5R;7,@:6X@97AC97-S(&]F(&]N92!Y96%R(&%S(&]F(%-E
M<'1E;6)E<@T*,S`L(#(P,3$@87)E(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD
M<RDZ/"]F;VYT/CPO9&EV/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,
M05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+5-464Q%.B!I
M=&%L:6,[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*3&5A<V4@
M0V]M;6ET;65N=',Z/"]F;VYT/CPO9&EV/@T*/"]D:78^#0H\9&EV('-T>6QE
M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.
M1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`S+C-P="<@86QI9VX],T1J=7-T
M:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*/&1I=B!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$;&5F=#X-"CQT86)L92!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,S`E('-T
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M;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M
M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!L
M969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY996%R
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M:#TS1#,W)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L
M:60G/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/D]P97)A=&EN9PT*3&5A<V5S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
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M1RU,1494.B`P<'0[($U!4D=)3BU,1494.B`Y<'0[(%1%6%0M24Y$14Y4.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!L969T)SX-"CQD
M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[
M(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,
M24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SXR,#$Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)2!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B9N
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M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#8P)2!S='EL93TS1"=0041$24Y'+4Q%1E0Z(#!P=#L@34%21TE.+4Q%
M1E0Z(#EP=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[
M(%1%6%0M04Q)1TXZ(&QE9G0G/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@5$585"U)3D1%3E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@<W1Y
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M.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S4E('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SXQ,C4Y+C$\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L
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M1$E.1RU,1494.B`P<'0[($U!4D=)3BU,1494.B`Y<'0[(%1%6%0M24Y$14Y4
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!L969T)SX-
M"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y
M<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4
M+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SXR,#$S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-
M"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,U)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^.#DX+C,\+V9O;G0^/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-
M"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-C`E('-T>6QE/3-$)U!!1$1)3D<M3$5&5#H@,'!T.R!-05)'24XM
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,C`Q-#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
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M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C`E('-T>6QE/3-$)U!!
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M;VUA;B<^,C`Q-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R
M:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
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M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,
M24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,S4E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXX-3<N,CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#8P)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X
M.R!415A4+4%,24=..B!L969T)SX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY4;W1A;`T*;6EN:6UU;2!L96%S
M92!P87EM96YT<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R
M:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@-'!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S-24@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXT+#8Q-"XY/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@[(%1%6%0M04Q)
M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[(%1%6%0M24Y$14Y4.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#,N
M,W!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE
M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.
M1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`S+C-P="<@86QI9VX],T1J=7-T
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M97,@=V%S(&%P<')O>&EM871E;'D@)FYB<W`[)#4S-2PS,#`@86YD#0HF;F)S
M<#LD,2PV-S(L-C`P(&9O<B!T:&4@=&AR964@86YD(&YI;F4@;6]N=&AS(&5N
M9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,2P-"G)E<W!E8W1I=F5L>2P@86YD("9N
M8G-P.R0U,C(L.#`P(&%N9"`F;F)S<#LD,2PQ,SDL-#`P(&9O<B!T:&4@=&AR
M964@86YD(&YI;F4-"FUO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3`L
M(')E<W!E8W1I=F5L>2X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)
M4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SXF(WA!,#L\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+5-464Q%
M.B!I=&%L:6,[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*0V]N
M=&EN9V5N8VEE<SH\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,
M05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M(%1%6%0M24Y$14Y4.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY5
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M92!C;W5R<V4@;V8@=&AE('-P;VYS;W)E9`T*<F5S96%R8V@N/"]F;VYT/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@5$585"U)3D1%
M3E0Z(#!P="<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^26X-"F-O;FYE8W1I;VX@=VET:"!T
M:&4@:7-S=6%N8V4@=&\@:6YV97-T;W)S(&%N9"!S97)V:6-E('!R;W9I9&5R
M<R!O9@T*;6%N>2!O9B!T:&4@<VAA<F5S(&]F('1H92!#;VUP86YY)B-X,C`Q
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M:7)E9"!F;W(@<V]M92!O9B!T:&4@:&]L9&5R<RP@86YD(&EN#0I-87D@,C`Q
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M;6)E<B`S,"P@,C`Q,2X@5&AE($-O;7!A;GD@:&%S(&-E<G1A:6X@;V)L:6=A
M=&EO;G,@=&\-"FUA:6YT86EN('1H92!E9F9E8W1I=F5N97-S(&]F('1H:7,@
M<F5G:7-T<F%T:6]N#0IS=&%T96UE;G0N)B-X03`[)B-X03`[0V5R=&%I;B!H
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M;7,@;6%Y(&)E(&QI;6ET960L#0IA<R`H:2D@;6]S="!S:&%R97,@;V8@0V]M
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M=')A=&EO;B!R:6=H=',@87)E(&YO=R!R96=I<W1E<F5D+`T*86YD(&1U<FEN
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M;GDF(W@R,#$Y.W,@;6%X:6UU;2!E>'!O<W5R92!W;W5L9`T*;F]T(&)E(&UA
M=&5R:6%L+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@
M8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I=B!S
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M=6YA;B!796EC:'4@4&AA<FUA8WD@0V\N+`T*3'1D+CPO9F]N=#XF(WA!,#LF
M(WA!,#MI;G9O;'9E<R!A('!A=&5N="!I;F9R:6YG96UE;G0@9&ES<'5T92!W
M:71H#0IR97-P96-T('1O(&$@<&%R=&EC=6QA<B!A;G1I8FEO=&EC<R!C;VUP
M;&5X(&UA;G5F86-T=7)E9"!B>2!%<GEE#0HH=&AE("8C>#(P,4,[4')O9'5C
M="8C>#(P,40[*2X@5&AE($-H86YG<VAA($EN=&5R;65D:6%T90T*4&5O<&QE
M)B-X,C`Q.3MS($-O=7)T(&EN($AU;F%N(%!R;W9I;F-E+"!04D,@:6X@=&AE
M(&9O<F5G;VEN9R!C87-E#0IR96YD97)E9"!A(&IU9&=M96YT(&]N($UA>2`Q
M,RP@,C`Q,"!A9V%I;G-T($5R>64@87,@9F]L;&]W<SH@*&DI#0IA=V%R9&EN
M9R!P;&%I;G1I9F8@6&EA;F=B96D@5V5L;6%N(&1A;6%G97,@86YD(&-O<W1S
M(&]F#0IA<'!R;WAI;6%T96QY(#4@;6EL;&EO;B!234(@*&%P<')O>&EM871E
M;'D@)FYB<W`[)#<W."PU,#`I(&%G86EN<W0@17)Y90T*=VAI8V@@=V%S(&9U
M;&QY(&%C8W)U960@9F]R(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,3L@86YD("AI
M:2D-"F5N:F]I;FEN9R!%<GEE(&9R;VT@;6%N=69A8W1U<FEN9RP@;6%R:V5T
M:6YG(&%N9"!S96QL:6YG('1H90T*4')O9'5C="X@3VX@36%R8V@@,C$L(#(P
M,3$L($-H86YG<VAA($EN=&5R;65D:6%T92!#;W5R="!I<W-U960@80T*8VEV
M:6P@9&5C:7-I;VX@<W5S<&5N9&EN9R!T:&4@97AE8W5T:6]N(&]F('1H92!0
M<F5L:6UI;F%R>0T*26YJ=6YC=&EO;BX@5&AE<F5F;W)E+"!%<GEE(&ES(&-U
M<G)E;G1L>2!F<F5E('1O('!R;V1U8V4L('-E;&P@;W(-"F]F9F5R('1O('-E
M;&P@=&AE('!R;V1U8W0N)B-X03`[)B-X03`[1F]L;&]W:6YG('1H92!F:6QI
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M=V%S(&%W87)D960@-3`L,#`P(%)-0BP@;W(@87!P<F]X:6UA=&5L>0T*)FYB
M<W`[)#<L.#`P+B8C>$$P.R`F(WA!,#M);B!*=6QY(#(P,3$L(&$@;F5W(&-O
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M<VEO;B!F<F5E>FEN9R!%<GEE)B-X,C`Q.3MS#0IB86YK(&1E<&]S:71S(&]F
M('5P('1O(#4P(&UI;&QI;VX@4DU"+"!O<B!A<'!R;WAI;6%T96QY("9N8G-P
M.R0W+C@-"FUI;&QI;VXL(&]R('-E86QI;F<@=7`@;W(@9&5T86EN:6YG($5R
M>64F(W@R,#$Y.W,@;W1H97(@<')O<&5R=&EE<PT*;V8@97%U86P@=F%L=64N
M($-U<G)E;G1L>2!T:&ES(&-A<V4@:7,@<&5N9&EN9RXF(WA!,#LF(WA!,#M!
M<R!O9@T*4V5P=&5M8F5R(#,P+"`R,#$Q+"!A<'!R;WAI;6%T96QY(#$S+#<T
M-"PW,#`@4DU"("AA<'!R;WAI;6%T96QY#0HF;F)S<#LD,BPQ-#`L,#`P*2!O
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M9B!A<'!R;WAI;6%T96QY(#(L,#`P+#`P,`T*4DU"("AA<'!R;WAI;6%T96QY
M("9N8G-P.R0S,3(L-#`P*2!A9V%I;G-T($5R>64@86YD('1H92!C87-E(&ES
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M(&]N#0I397!T96UB97(@-BP@,C`Q,2XF(WA!,#LF(WA!,#M796QM86X@<W5B
M<V5Q=65N=&QY(&]B=&%I;F5D(&$-"G!R96QI;6EN87)Y(&EN:G5N8W1I;VX@
M9G)O;2!A(&QO=V5R(&-O=7)T($=U86YG>FAO=2!(86EZ:'4@1&ES=')I8W0-
M"E!E;W!L928C>#(P,3D[<R!#;W5R="!I;B!'=6%N9WIH;W4@4')O=FEN8V4L
M(%!20R`H=&AE("8C>#(P,4,[2&%I>FAU#0I$:7-T<FEC="!#;W5R="8C>#(P
M,40[*28C>$$P.V]N(%-E<'1E;6)E<B`Q-"P@,C`Q,2XF(WA!,#LF(WA!,#M"
M=70-"F]N($]C=&]B97(@,C@L(#(P,3$L('5P;VX@=&AE(&%P<&5A;"!B>2!%
M<GEE+"!T:&4@2&%I>FAU($1I<W1R:6-T#0I#;W5R="!I<W-U960@82!D96-I
M<VEO;B!W:71H9')A=VEN9R!T:&4@<')E;&EM:6YA<GD-"FEN:G5N8W1I;VXN
M)B-X03`[(%1H92!#;VUP86YY(&-A;FYO="!R96%S;VYA8FQY(&%S<V5S<R!T
M:&4-"G!O<W-I8FEL:71Y(&]F(&%D9&ET:6]N86P@97AP;W-U<F4@86)O=F4@
M=&AE(&%M;W5N=',@<')E=FEO=7-L>0T*86-C<G5E9"!A<R!O9B!397!T96UB
M97(@,S`L(#(P,3$N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-0
M3$%9.B!B;&]C:SL@5$585"U)3D1%3E0Z(#!P="<^)B-X03`[/"]D:78^#0H\
M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-464Q%.B!I
M=&%L:6,G/@T*0VAI;F5S92!R96=U;&%T;W)Y(&%P<')O=F%L<SPO9F]N=#X@
M)B-X,C`Q,SL@5&AE($-O;7!A;GD@:&%S#0ID971E<FUI;F5D('1H870@:70@
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M;W5N<V5L(&EN($-H:6YA('!R97!A<F4@=&AE<V4-"F9I;&EN9W,N)B-X03`[
M(%1H92!#;VUP86YY)B-X,C`Q.3MS(&UA;F%G96UE;G0@8F5L:65V97,@=&AE
M<V4-"G)E9W5L871O<GD@9&5F:6-I96YC:65S(&-A;B!B92!R96UE9&EA=&5D
M('=I=&AI;B!A(')E87-O;F%B;&4-"G!E<FEO9"!O9B!T:6UE(&%N9"!S:&]U
M;&0@;F]T(&1E;&%Y(&$@<&]S<VEB;&4@9&EV97-T:71U<F4@;V8@=&AE#0I#
M;VUP86YY)B-X,C`Q.3MS(&EN=&5R97-T<R!I;B!%<GEE('1H870@:7,@8W5R
M<F5N=&QY('5N9&5R#0IE=F%L=6%T:6]N+B8C>$$P.R!(;W=E=F5R+"!T:&4@
M0V]M<&%N>2!R97%U:7)E<R!T:&4@8V]O<&5R871I;VX@;V8-"G1H92!O9F9I
M8V5R<R!O9B!%<GEE+"!A<R!T;R!W:&EC:"!N;R!A<W-U<F%N8V4@8V%N(&)E
M(&=I=F5N+"!A;F0@=V4-"F-O=6QD(&)E(&-O;7!E;&QE9"!T;R!S965K('1O
M(')E<&QA8V4@=&AO<V4@;V9F:6-E<G,@;W(F(WA!,#MT;PT*8V]M;65N8V4@
M;&5G86P@86-T:6]N('1O(&]B=&%I;B!T:&4@<F5Q=6ER960@8V]N<V5N=',@
M;W(@;W1H97)W:7-E#0IM;W9E(&9O<G=A<F0@=VET:"!R97%U:7-I=&4@9FEL
M:6YG<RXF(WA!,#L@26X@861D:71I;VXL(&5V96X@:68@=&AE#0IF:6QI;F=S
M(&%R92!M861E+"!N;R!A<W-U<F%N8V4@8V%N(&)E(&=I=F5N('1H870@86YY
M('5N<F5M961I871E9`T*<F5G=6QA=&]R>2!D969I8VEE;F-I97,@=V]U;&0@
M;F]T(&AA=F4@86X@861V97)S92!E9F9E8W0@;VX@=&AE#0IO<&5R871I;F<@
M<F5S=6QT<R!A;F0@;&EQ=6ED:71Y(&]F($5R>64@86YD('1H92!#;VUP86YY
M(&%N9"!W:6QL#0IN;W0@:6UP961E(&]R(&1E;&%Y(&5F9F]R=',@=&\@9&EV
M97-T('1H92!#;VUP86YY)B-X,C`Q.3MS(&EN=&5R97-T#0II;B!%<GEE+B8C
M>$$P.R!);B!A9&1I=&EO;BP@=&AE(')E;65D:6%T:6]N('!R;V-E<W,@:7,@
M97AP96-T960@=&\-"G1R:6=G97(@8V5R=&%I;B!T87@@;&EA8FEL:71I97,@
M86YD('!E;F%L=&EE<RP@:&]W979E<B!T:&4@=6QT:6UA=&4-"FQI86)I;&ET
M>2!W:6QL(&)E(&)A<V5D(&]N(&9U='5R92!D:7-C=7-S:6]N<R!W:71H('1H
M92!R96QE=F%N=`T*0VAI;F5S92!A=71H;W)I=&EE<RXF(WA!,#LF(WA!,#M4
M:&4@0V]M<&%N>2!C86YN;W0@<F5A<V]N86)L>0T*87-S97-S('1H92!E>'!O
M<W5R92!A<R!O9B!397!T96UB97(@,S`L(#(P,3$N/"]F;VYT/CPO9&EV/@T*
M/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@5$585"U)3D1%3E0Z(#!P
M="<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,3AP=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-464Q%.B!I=&%L:6,G/@T*06UO<F-Y=&4@;&EN92!O9B!C
M<F5D:70@)B-X,C`Q,SL\+V9O;G0^($]N($UA>28C>$$P.S$Y+"`R,#`V+"!0
M0U0-"F5N=&5R960@:6YT;R!A(&QI;F4@;V8@8W)E9&ET(&%G<F5E;65N="!W
M:71H($%M;W)C>71E($EN8RX-"B@F(W@R,#%#.T%M;W)C>71E)B-X,C`Q1#LI
M+"!A;B!E;G1I='D@=VAI8V@@=V%S('-P=6X@;W5T(&]F(%!#5"!I;@T*,C`P
M-BP@=VAE<F5B>2!00U0@86=R965D('1O(&QO86X@06UO<F-Y=&4@=7`@=&\@
M)FYB<W`[)#4P,"PP,#`@870@86X-"F%N;G5A;"!I;G1E<F5S="!R871E(&]F
M(#4E+B8C>$$P.R!4:&4@;&EN92!O9B!C<F5D:70@86=R965M96YT('=A<PT*
M82!C;VYD:71I;VX@=&\@06UO<F-Y=&4@8VQO<VEN9R!A(%-E<FEE<R!!(%!R
M969E<G)E9"!3=&]C:PT*1FEN86YC:6YG(&-O;7!L971E9"!D=7)I;F<@,C`P
M-BXF(WA!,#L@5&AE($-O;7!A;GD@:&%S(&YO="!L;V%N960-"F%N>2!A;6]U
M;G0@=&\@06UO<F-Y=&4@=6YD97(@=&AI<R!A9W)E96UE;G0@=&AR;W5G:"!3
M97!T96UB97(@,S`L#0HR,#$Q+B8C>$$P.R8C>$$P.U1H92!L:6YE(&]F(&-R
M961I="!A9W)E96UE;G0@97AP:7)E<R!O;B!T:&4-"F5A<FQI97(@;V8@*&DI
M)B-X03`[=&AE(&1A=&4@;VX@=VAI8V@@=&AE($-O;7!A;GD@9&5C;&%R97,@
M=&AE#0IO=71S=&%N9&EN9R!P<FEN8VEP86P@86YD(&%C8W)U960@:6YT97)E
M<W0@9'5E(&%N9"!P87EA8FQE(&)A<V5D(&]N#0IA;B!E=F5N="!O9B!D969A
M=6QT(&%S(&1E9FEN960@=VET:&EN('1H92!A9W)E96UE;G0L(&]R#0HH:6DI
M)B-X03`[=&AE(&1A=&4@;V8@8VQO<VEN9R!O9B!T:&4@9FER<W0@9&5B="!O
M<B!E<75I='D@9FEN86YC:6YG#0IO9B!!;6]R8WET92!F;VQL;W=I;F<@=&AE
M(&EN:71I86P@8F]R<F]W:6YG(&]F('1H92!P<FEN8VEP86PN(%1H97-E#0IE
M=F5N=',@:&%V92!N;W0@;V-C=7)R960@=&\@9&%T92XF(WA!,#LF(WA!,#M/
M;B!/8W1O8F5R(#$W+"`R,#$Q+`T*=&AE($-O;7!A;GD@86-Q=6ER960@06UO
M<F-Y=&4@<'5R<W5A;G0@=&\@=&AE($%M;W)C>71E($%G<F5E;65N=`T*86YD
M(%!L86X@;V8@365R9V5R+"!A;F0@=&AI<R!L:6YE(&]F(&-R961I="!W87,-
M"F-A;F-E;&QE9"XF(WA!,#LF(WA!,#LF(WA!,#L@*%-E92!.;W1E(#$T*2X\
M+V9O;G0^/"]D:78^#0H\+V1I=CX-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3$V.#$U8V9?.34Y,U\T,&-A7SED
M-S=?-#<Y9&8Q-S8V8C4Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S$Q-C@Q-6-F7SDU.3-?-#!C85\Y9#<W7S0W.61F,3<V-F(U,2]7;W)K<VAE
M971S+U-H965T,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,1SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY3=6)S97%U96YT($5V96YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)S97%U96YT($5V96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD:78@<W1Y;&4],T0G
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@5$585"U$14-/
M4D%424]..B!U;F1E<FQI;F4G/DYO=&4@,30-"B8C>#(P,3,[(%-U8G-E<75E
M;G0@179E;G1S/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
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M6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z
M(#(W<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/D]N#0I/8W1O8F5R(#$W
M+"`R,#$Q("AT:&4@)B-X,C`Q0SM#;&]S:6YG($1A=&4F(W@R,#%$.RDL($%M
M;R!!8W%U:7-I=&EO;@T*0V]M<&%N>2!)+"!);F,N("@F(W@R,#%#.U-U8F-O
M)B-X,C`Q1#LI+"!A(&YE=VQY+69O<FUE9"!W:&]L;'DM;W=N960-"G-U8G-I
M9&EA<GD@;V8@3F5O4W1E;2P@26YC+B`H)B-X,C`Q0SM.96]3=&5M)B-X,C`Q
M1#L@;W(@=&AE#0HF(W@R,#%#.T-O;7!A;GDF(W@R,#%$.RDL(&UE<F=E9"`H
M=&AE("8C>#(P,4,[06UO<F-Y=&4@365R9V5R)B-X,C`Q1#LI#0IW:71H(&%N
M9"!I;G1O($%M;W)C>71E+"!);F,N+"!A($1E;&%W87)E(&-O<G!O<F%T:6]N
M#0HH)B-X,C`Q0SM!;6]R8WET928C>#(P,40[*2P@:6X@86-C;W)D86YC92!W
M:71H('1H92!T97)M<R!O9B!T:&4-"D%G<F5E;65N="!A;F0@4&QA;B!O9B!-
M97)G97(L(&1A=&5D(&%S(&]F($IU;'D@,3,L(#(P,3$@*'1H90T*)B-X,C`Q
M0SM!;6]R8WET92!-97)G97(@06=R965M96YT)B-X,C`Q1#LI+"!A;6]N9R!.
M96]3=&5M+"!!;6]R8WET92P-"E-U8F-O+"!A;F0@06UO($%C<75I<VET:6]N
M($-O;7!A;GD@24DL($Q,0R`H)B-X,C`Q0SM3=6)C;PT*24DF(W@R,#%$.RDN
M)B-X03`[)B-X03`[07,@82!R97-U;'0@;V8@=&AE(&-O;G-U;6UA=&EO;B!O
M9B!T:&4-"D%M;W)C>71E($UE<F=E<BP@06UO<F-Y=&4@:7,@;F]W(&$@=VAO
M;&QY+6]W;F5D('-U8G-I9&EA<GD@;V8-"DYE;U-T96TN)B-X03`[)B-X03`[
M06UO<F-Y=&4@:7,@82!D979E;&]P;65N="!S=&%G92!C96QL('1H97)A<'D-
M"F-O;7!A;GD@9F]C=7-I;F<@;VX@;F]V96P@=')E871M96YT<R!F;W(@8V%R
M9&EO=F%S8W5L87(@9&ES96%S92X-"D%M;W)C>71E)B-X,C`Q.3MS(&QE860@
M<')O9'5C="!C86YD:61A=&4L($%-4BTP,#$L(&ES(&5N=&5R:6YG(&$-"E!H
M87-E(#(@<W1U9'D@9F]R('1H92!T<F5A=&UE;G0@;V8@86-U=&4@;7EO8V%R
M9&EA;"!I;F9A<F-T:6]N#0HH04U)*2X@5V4@87)E(&-U<G)E;G1L>2!R96-R
M=6ET:6YG('1R:6%L('-I=&5S(&EN(&-O;FYE8W1I;VX@=VET:`T*=&AE(&QA
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M+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$
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M96-T:79E('1I;64@;V8@=&AE($%M;W)C>71E#0I-97)G97(@*'1H92`F(W@R
M,#%#.T5F9F5C=&EV92!4:6UE)B-X,C`Q1#LI+"!W97)E(&)Y('9I<G1U92!O
M9B!T:&4-"D%M;W)C>71E($UE<F=E<B!C86YC96QL960@86YD(&-O;G9E<G1E
M9"!I;G1O('1H92!R:6=H="!T;R!R96-E:79E+`T*:6X@=&AE(&%G9W)E9V%T
M93H\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K
M.R!415A4+4E.1$5.5#H@,'!T)SXF(WA!,#L\+V1I=CX-"CQD:78^#0H\=&%B
M;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P
M,"4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#<E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0W)3X-
M"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
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M.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9
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M,C`Q0SM"87-E(%-T;V-K($-O;G-I9&5R871I;VXF(W@R,#%$.RD[/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV
M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\
M8G(@+SX\+V1I=CX-"CQD:78^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E
M;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#<E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0W)3X-"CQD:78@<W1Y;&4],T0G1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/BAI:2D\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#<V)3X-"CQD:78@<W1Y
M;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M
M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I
M9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/G1H90T*<FEG
M:'0@=&\@<F5C96EV92`T+#`Y,BPW-C@@<VAA<F5S(&]F($YE;U-T96T@0V]M
M;6]N(%-T;V-K("AT:&4-"B8C>#(P,4,[0V]N=&EN9V5N="!3:&%R97,F(W@R
M,#%$.RP@86YD('1O9V5T:&5R('=I=&@@=&AE($)A<V4@4W1O8VL-"D-O;G-I
M9&5R871I;VXL('1H92`F(W@R,#%#.U-T;V-K($-O;G-I9&5R871I;VXF(W@R
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M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#<E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0W)3X-"CQD:78@<W1Y;&4],T0G1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/BAI:6DI/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0W-B4^#0H\9&EV('-T
M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4
M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T
M:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SYW87)R86YT
M<PT*=&\@<'5R8VAA<V4F(WA!,#LQ+#@X,2PP,#@@<VAA<F5S(&]F($YE;U-T
M96T@0V]M;6]N(%-T;V-K#0IE>&5R8VES86)L92!O=F5R(&$@<V5V96X@*#<I
M('EE87(@<&5R:6]D(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F#0HF;F)S<#LD
M,2XT-C8@<&5R('-H87)E("AT:&4@)B-X,C`Q0SM787)R86YT<R8C>#(P,40[
M*2`H<W5C:"!787)R86YT<R!A<F4-"G)E9&5E;6%B;&4@:6X@8V5R=&%I;B!C
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M9STS1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"CQT<CX-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0W)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$-R4^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SXH:78I/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0W-B4^#0H\9&EV('-T>6QE/3-$)T1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SYE87)N#0IO=70@<&%Y;65N
M=',@97%U86P@=&\@,3`E(&]F('1H92!N970@<V%L97,@;V8@06UO<F-Y=&4F
M(W@R,#$Y.W,@;&5A9`T*<')O9'5C="!C86YD:61A=&4@04U2+3`P,2`H:6X@
M=&AE(&5V96YT(&]F(&%N9"!F;VQL;W=I;F<@=&AE(&1A=&4-"F]F(&9I<G-T
M(&-O;6UE<F-I86P@<V%L92!O9B!!35(M,#`Q*2P@<')O=FED960@=&AA="!I
M;B!T:&4@979E;G0-"DYE;U-T96T@<W5B;&EC96YS97,@04U2+3`P,2P@=&AE
M(&%P<&QI8V%B;&4@96%R;B!O=70@<&%Y;65N="!W:6QL#0IB92!E<75A;"!T
M;R`S,"4@;V8@86YY('-U8FQI8V5N<VEN9R!F965S+"!A;F0@<')O=FED960@
M9G5R=&AE<B!T:&%T#0I.96]3=&5M('=I;&P@8F4@96YT:71L960@=&\@<F5C
M;W9E<B!D:7)E8W0@;W5T+6]F+7!O8VME="!C;&EN:6-A;`T*9&5V96QO<&UE
M;G0@8V]S=',@;F]T('!R979I;W5S;'D@<&%I9"!O<B!R96EM8G5R<V5D(&%N
M9"!A;GD@8V]S=',L#0IE>'!E;G-E<RP@;&EA8FEL:71I97,@86YD('-E='1L
M96UE;G0@86UO=6YT<R!A<FES:6YG(&]U="!O9B!C;&%I;7,-"F]F('!A=&5N
M="!I;F9R:6YG96UE;G0@;W(@;W1H97)W:7-E(&-H86QL96YG:6YG($%M;W)C
M>71E)B-X,C`Q.3MS#0IR:6=H="!T;R!U<V4@:6YT96QL96-T=6%L('!R;W!E
M<G1Y+"!B>2!R961U8VEN9R!A;GD@96%R;B!O=70-"G!A>6UE;G1S(&1U92!B
M>2`U,"4@=6YT:6P@<W5C:"!C;W-T<R!H879E(&)E96X@<F5C;W5P960@:6X@
M9G5L;`T**'1H92`F(W@R,#%#.T5A<FX@3W5T(%!A>6UE;G1S)B-X,C`Q1#LI
M+CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^)B-X03`[/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9
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M=')A;G-F97(@86=E;G0I+"`U+#@T,RPT.#,@<VAA<F5S(&]F#0I.96]3=&5M
M($-O;6UO;B!3=&]C:R!F;W(@979E;G1U86P@9&ES=')I8G5T:6]N('1O('1H
M92!F;W)M97(-"D%M;W)C>71E('-T;V-K:&]L9&5R<R`H<W5B:F5C="!T;R!F
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M6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$
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M/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0X)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,R4^#0H\9&EV('-T>6QE/3-$
M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=VEN9V1I;F=S)SXF(WA!-SL\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#<X)3X-"CQD:78@
M<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%
M6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU
M<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/D]N92UT
M:&ER9`T*;V8@=&AE($-O;G1I;F=E;G0@4VAA<F5S("@Q+#,V-"PR-38@<VAA
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M8W)I8F5D(&EN('1H92!0:&%S92`R(&-L:6YI8V%L('1R:6%L#0IP<F]T;V-O
M;"!S=6)M:71T960@8GD@06UO<F-Y=&4@=&\@=&AE($9$02!O;B!*=6QY(#4L
M#0HR,#$Q+CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-
M"CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@5$585"U)
M3D1%3E0Z(#!P="<^/&)R("\^/"]D:78^#0H\9&EV/@T*/'1A8FQE(&-E;&QP
M861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0X)3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,R4^#0H\9&EV('-T
M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4
M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T
M:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=VEN9V1I;F=S)SXF(WA!-SL\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#<X)3X-
M"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/D]N92UT:&ER9`T*;V8@=&AE($-O;G1I;F=E;G0@4VAA<F5S('=I;&P@8F4@
M:7-S=65D(&9O;&QO=VEN9R!A(%1Y<&4@0B!%;F0@;V8-"E!H87-E(#(O4')E
M+5!H87-E(#,@;65E=&EN9R!W:71H('1H92!&1$$@=VAE<F5I;B!!35(M,#`Q
M(&ES#0IA8VMN;W=L961G960@:6X@=W)I=&EN9R!B>2!T:&4@1D1!('1O(&)E
M(')E861Y(&9O<B!0:&%S90T*,RX\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T
M<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@
M8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I=CX-
M"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H
M/3-$,3`P)2!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
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M1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('=I;F=D:6YG<R<^
M)B-X03<[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0W."4^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
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M4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`R-W!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
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M63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I
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M9B!.96]3=&5M(&AE;&0@;VX@3V-T;V)E<B`Q-"P@,C`Q,2`H=&AE("8C>#(P
M,4,[3F5O4W1E;2`R,#$Q($%N;G5A;`T*365E=&EN9R8C>#(P,40[*2P@;VX@
M=VAI8V@@9&%T92!T:&4@06UO<F-Y=&4@365R9V5R(&%L<V\@=V%S#0IA<'!R
M;W9E9"!A="!A('-P96-I86P@;65E=&EN9R!O9B!S=&]C:VAO;&1E<G,@;V8-
M"D%M;W)C>71E+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!
M63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I
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M:6-H(&ES(&%T=&%C:&5D('1O#0I.96]3=&5M)B-X,C`Q.3MS($IO:6YT(%!R
M;WAY(%-T871E;65N="]0<F]S<&5C='5S(&1A=&5D(&%N9"!F:6QE9`T*=VET
M:"!T:&4@4V5C=7)I=&EE<R!A;F0@17AC:&%N9V4@0V]M;6ES<VEO;B!O;B!3
M97!T96UB97(@,38L(#(P,3$-"BAT:&4@)B-X,C`Q0SM*;VEN="!0<F]X>2!3
M=&%T96UE;G0O4')O<W!E8W1U<R8C>#(P,40[*2P@=&AE(%=A<G)A;G0-"D%G
M<F5E;65N="!B971W965N($YE;U-T96T@86YD($-O;G1I;F5N=&%L(%-T;V-K
M(%1R86YS9F5R("9A;7`[#0I4<G5S="!#;VUP86YY+"!A;F0@=&AE(&9O<FT@
M;V8@1VQO8F%L(%-E<FEE<R!!34\@5V%R<F%N="!A='1A8VAE9`T*=&AE<F5T
M;RP@=VAI8V@@:7,@9FEL960@87,@17AH:6)I="`T+C$@=&\@=&AE($-O;7!A
M;GDF(W@R,#$Y.W,-"D-U<G)E;G0@4F5P;W)T(&]N($9O<FT@."U+(&1A=&5D
M($]C=&]B97(@,30L(#(P,3$@*'1H92`F(W@R,#%#.T9O<FT-"C@M2R8C>#(P
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M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[(%1%6%0M1$5#3U)!5$E/3CH@=6YD97)L
M:6YE)SX-"D%M96YD;65N="!T;R!T:&4@,C`P.2!0;&%N(&%N9"`R,#`Y($YO
M;BU5+E,N#0I0;&%N/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/D%T#0IT:&4@3F5O4W1E;2`R,#$Q($%N;G5A;"!-965T:6YG+"!T
M:&4@<VAA<F5H;VQD97)S(&]F($YE;U-T96T@9'5L>0T*87!P<F]V960@86X@
M86UE;F1M96YT('1O('1H92!.96]3=&5M+"!);F,N(#(P,#D@17%U:71Y($-O
M;7!E;G-A=&EO;@T*4&QA;B`H=&AE("8C>#(P,4,[,C`P.2!0;&%N)B-X,C`Q
M1#LI('1O(&EN8W)E87-E('1H92!N=6UB97(@;V8@<VAA<F5S#0IO9B!.96]3
M=&5M($-O;6UO;B!3=&]C:R!A=71H;W)I>F5D(&9O<B!I<W-U86YC92!T:&5R
M975N9&5R(&)Y#0HV+#`P,"PP,#`@<VAA<F5S("AT:&%T(&ES+"!F<F]M(#$W
M+#<U,"PP,#`@<VAA<F5S('1O(#(S+#<U,"PP,#`-"G-H87)E<RDL(&%N9"!.
M96]3=&5M('1H97)E=7!O;B!E9F9E8W1E9"!S=6-H(&%M96YD;65N="!T;R!T
M:&4@,C`P.0T*4&QA;BX@4&5R<V]N<R!E;&EG:6)L92!T;R!R96-E:79E(')E
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M92!T;R!.96]3=&5M)B-X,C`Q.3MS#0IS=6-C97-S+B8C>$$P.R8C>$$P.T-O
M;F-U<G)E;G1L>2!T:&5R97=I=&@L($YE;U-T96T@9&5C<F5A<V5D('1H90T*
M;G5M8F5R(&]F('-H87)E<R!A=71H;W)I>F5D(&9O<B!I<W-U86YC92!U;F1E
M<B!T:&4@3F5O4W1E;2P@26YC+@T*,C`P.2!.;VXM52Y3+B!"87-E9"!%<75I
M='D@0V]M<&5N<V%T:6]N(%!L86X@8GD@,RPP,#`L,#`P("AT:&%T(&ES+`T*
M9G)O;2`X+#<P,"PP,#`@=&\@-2PW,#`L,#`P*2XF(WA!,#LF(WA!,#M4:&4@
M<F5D=6-T:6]N(&EN('-H87)E<PT*879A:6QA8FQE(&9O<B!I<W-U86YC92!U
M;F1E<B!T:&4@,C`P.2!.;VXM52Y3+B!0;&%N('=A<R!E9F9E8W1E9"!I;@T*
M;&EG:'0@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@<&QA;B!T;R!F;V-U<R!I
M=',@8G5S:6YE<W,@;VX@8V5L;`T*=&AE<F%P>2!M86YU9F%C='5R:6YG(&%N
M9"!D979E;&]P;65N="!A;F0@;W1H97(@<F5L871E9"!A8W1I=FET:65S#0II
M;B!T:&4@56YI=&5D(%-T871E<RP@86YD('1H92!#;VUP86YY)B-X,C`Q.3MS
M(&-O;G-I9&5R871I;VX@;V8@=&AE#0IP;W-S:6)L92!D:79E<W1I='5R92!O
M9B!I=',@-3$E(&EN=&5R97-T(&EN#0I%<GEE+B8C>$$P.R8C>$$P.U!E<G-O
M;G,@96QI9VEB;&4@=&\@<F5C96EV92!W87)R86YT<RP@<W1O8VL-"F%P<')E
M8VEA=&EO;B!R:6=H=',@;W(@;W1H97(@87=A<F1S('5N9&5R('1H92`R,#`Y
M($YO;BU5+E,N(%!L86X-"F%R92!T:&]S92!S97)V:6-E('!R;W9I9&5R<R!O
M9B!.96]3=&5M(&%N9"!I=',@<W5B<VED:6%R:65S(&%N9`T*869F:6QI871E
M<R!P<F]V:61I;F<@<V5R=FEC97,@;W5T<VED92!O9B!T:&4@56YI=&5D(%-T
M871E<RP-"FEN8VQU9&EN9R!E;7!L;WEE97,@86YD(&-O;G-U;'1A;G1S(&]F
M($YE;U-T96T@86YD(&ET<R!S=6)S:61I87)I97,-"F%N9"!A9F9I;&EA=&5S
M+"!W:&\L(&EN('1H92!O<&EN:6]N(&]F('1H92!#;VUP96YS871I;VX@0V]M
M;6ET=&5E+`T*87)E(&EN(&$@<&]S:71I;VX@=&\@8V]N=')I8G5T92!T;R!.
M96]3=&5M)B-X,C`Q.3MS#0IS=6-C97-S+CPO9F]N=#X\+V1I=CX-"CPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3$V
M.#$U8V9?.34Y,U\T,&-A7SED-S=?-#<Y9&8Q-S8V8C4Q#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S$Q-C@Q-6-F7SDU.3-?-#!C85\Y9#<W7S0W
M.61F,3<V-F(U,2]7;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM
M;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F
M:6-E(CX-"B`\;SI-86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#`S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970P-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,3$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#$U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q.2YH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X=%!A<G1?
H,3$V.#$U8V9?.34Y,U\T,&-A7SED-S=?-#<Y9&8Q-S8V8C4Q+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>39
<FILENAME>0001144204-11-062961-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-11-062961-xbrl.zip
M4$L#!!0````(`,F`:C\=H?C=?``!`%6J#@`0`!P`;F)S+3(P,3$P.3,P+GAM
M;%54"0`#R3R\3LD\O$YU>`L``00E#@``!#D!``#L7>E3XTB6_TX$_T,NVSM1
M%6$;W0=T]82+HY99P`S0UWRI$%(:-"U+WI0,N/_Z?2\EV2E9LBU`@H[8Z@/*
M3F7^WLMWYY/TX]^?)P%YI"SVH_#+GCR0]@@-W<CSP_LO>[.X[\2N[^^1.'%"
MSPFBD'[9F]-X[^\_[>[\^!_]/CDY_C:\)J,P\$-*SOH7-&'^,_G-I0%E3@(?
MA7BI2\EQY,XF-$QZY,Z)J4>BD/SV]?J<*`.9D(<DF1[L[S\]/0VH=^^P?L0G
M'+C19)_T^_EBOZ0X#P@Q!K(RL(2OKJ-9Z!T037(]Q=64OFY2M:_IKM6W77?<
M]S3),73#M1Q'%JXZ8M1)8$;B`=8#HDBRW(=_)?M64@XD\T"3_B6.CJ9SYM\_
M).23^QD&2WH?KRCPH`<4NP,R#`)RC4-C<DUCRAZI-\AF>KYC`0&NA_&7/8%N
M_'@0L?M]F%?=]S.V[:4C#_#;8,UX6/H/Y.MB/'Y0&/^D\M&R;=O[_-M\J!]'
MFB*;Z\"D(Q9SQW[5S#!4WO_MXOS&?:`3IU^FP(4-2MA\<25?(J;NX#YZW,^^
MW.<;(,E]5<XO\ZA??0E\43'<#Q]IG%1?D7Y7<5%X5]R*D$9Q0B=<^G"T9*O2
M8FP4AK-)-;.\A.TG\RG=AT%]&$69[RZNVWQ1\0+0O7O'F2XN&COQ';\@^Z*"
M#O@&9XHKK^'?5%R$0+P2C[/M-/;3+PM#D\JA>CHTV0,))X3+>'`0<TFXIF/"
M!>X`(7S9B_W)-$"QX)\YS&510+<3;7[%`Z/C+WNP9_U\;P;/L?<"P=]>I_93
MJD#D#D["Q$_F1]%D$H4W2>3^<?/@,!J/9@DWD6`VB1N%"7U.KA$FC8+O5R>&
M8AE]^",#WOX_04^4[S>WQ]^E[T@!?&9]!_F:A7YZ3<QGW",>=?V)$\!VGEV>
M[OTD2Z:J:+JI_KB_'9`4="8N!T=._#`,/?QQ\K\S_]$)P!C'P^3(86P.HW]Q
M@AEMB%U"[A>P9Z;B^\\WQR(!TMY/FF08A@W@&P$JTC!*'B@;QC%-XLLH=&>,
MP25-^=T`LVXHP&]MB;D20!'C,1U3^-B[=9ZS@30Y:AVIH<!P?0ET#8HBW*$+
M;GD6@/OS.'$@4%-&'V@8^X\47%DTH>=1C)>/QC!9F\R&2PU5H*$AM")=Y[YS
MYP=^XM.X?>ZKLBZ;ABXOL:\N7X1W2R?3B#ELCJ*?S%/='<Z2AXCY?T)T]%JL
MM39$MW#\$N@&(-6R?4T?:3BC'3`6C(8E\K4:01'E-4T<B,2\$X>%8$=B08[@
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M,*15'AJ6)4-$L$197GQ5YOQDPFTE6$_`!;:2AB[XLK=%^1S[!Z$/N60"JK!(
M%W,8-Q24%SQI%-[?4C8YIG>MADR:9<JFX!(KEJ\-E3LQ=JIDFI8M1OJ5".JL
M<I@<P4\_Z<8P2Z:F5MGE512U]N[5%8+MHWLT?)H(>/OZ`$1.*6W"X/83$D5*
M_Q0BN#4XJD*&]GV>IDNV94AF.7"H]'1"ZMUM$JI:DJY5E@`V!?'?HLA[\H.@
M370*9!B&+MCN?-$2]V;T-KJF/#FZ<EAG1@G\LZK)FK#%:Y%LX;`[4/CMO'8C
ME>_&3&U2^$ZKF(W\@6S**FC:J\J8QY3!N,1_I%V[7EN&'+^09ZQ%4NO20!]&
M["9!U>#T75'&-^XMH7^?4O9]5834O9^D`4Q3Z>/J<)7<A@>.VX]")[AR?,A<
MCIRIGSAM6C_95G13MTPQ]:P&44(:!-$3GJ*=1NPXFMTEXUFPFE%WX`!5LQ!6
M-,*UC7OLJ)ROZT#')A=9)_^\E`29AA/>^T#=HJ[>%F)N+"&:!Z]NEXX@*E"L
M]4CG/OSP^%%W:FXA"^I2:150@8%H])O@J\RF,(WIHKYH%A*5U<5K4RGP"=PD
M/42!1UF<TMEM=6L3FLW10+M%ART"@:J*0W%<!]6D.H@5KOTH"A\IQ(J@F?7D
M_#R-PG0@=K.TQEW10S9&59+KR`GC*V>.5OTV^NJ$?[2O>Z95DH]:$"4#T:76
MF:H.&;<AN,9-:K:2D;>N8QMK`E5*5C+0>30[G*"/;]-':Z:N&_4I31%(:><?
M(I9@C>N,=_KPPE^;4'71,U2LO<YLO6,$K?`(6JZS:MO%T%<L@MF3^57@A`EX
M%]R=*5+=;AE=LW53UBU;!%\/9*U(<^).GMU@AFEFQSD!U\U-LKX5P@W6I?T2
MGBZMU/#6H"C"O8P2FIOT#BIDIF$H8@Y6L7SU*6IG$&W+!HA"AEZ-8)/'.PLS
MH;D"JP0R,TP2YM_-DM1U8H(#%+`H"&!(!P<WX(0T3=$5>YV;?`GF\E'>2E:T
MT)XN2IR29LBZ6$+<!E!*0G@75\:_QS3V[T.TQ6VIKZ7H7'<W(VB]$B?9LJ+*
MVT9>LFZKAOVJ0MQ;]!-*#3##-*9L6:5D?GT_8;L->HW0FZ9=.'U]WP:])M!5
MQ=)`.:MSXPX:]%:Q?N`&O2:,E4W)4BQIM:36:8->$\1]6U<5R5`$S._5G]=0
M^>`*NZ!\[].?UP2U;:NF7,PT/E)[7B,3HEIRP=]\E/:\)D3HEBEKIK8:7K;4
MGM?(E&BJI``X4<9;;,]KYK<577Z_]KQ&7%0TQ997^WA;[L]K`M%`3>J@/:_1
M#LN2`AINB;%[^^UY;QT6M-"?U\A$8O^R*1Z.=]6?MP'E^OZ\MSB&;!8SR098
M.K4R&.V@_ZT)5DW7Q&+;N_2_;:TEAJ8HLJRN*T1UT_ZV->+W:W]K)`2&!4&^
MII<=<^OM;XTL.$3U9O4=<"VUOS4+WR5)D<3>@_;;WYK@LU1)+C3-OU_WVUL[
MQ8[:WQK`_ECM;XU<EV[`:%M^5=7M;=O?&FFA;H*4BSV>[]O_MA;[1^]_:Y;;
M@5\V=>4C];\U3`]L4VS__C#];XVR?QO^J;K-K-/^MZT19_UODFFMW(+_GOUO
M+U':-^Q_>^,6LU=6:-ZIQ>PMG6T[+6:-^/K!6LRVY^X';#%K5+"05.U=6LP:
M95^6H=N6)?"ZFQ:SMTR[V^XP:U1^U%5%$3/%;CO,&CEL\<3RG3K,7NCN/E2'
M62.;8-BVI6@%\!^HPZQ9]+1)UM^UPVQK`_.^'6:-SCMUPU)M(<+NIL.L61`'
M$]E*\23Y8[:8-2I@&9IE&O)?K\.L41JJ:08$`Q^CPVQK]7UIA]DW%L4Q&-]Q
MDWX0Q52;/IE.-DQ),L6&$&'E%9_D4NK%IRR:",71>;-G.KP`HVX8IEEXSE$]
MD)(!I,FR%>MME?0%=&B2I1>>J-`87OV&W#@!O7"2&1XX\O/$(*`NZGD\&K\H
M7GL!?8JFPQ4U&[4EP)7]P^(JS//H>]3[.O\YQM/\=#PZ;9CAD2?@K1(&4TBR
M+8FW/&R/K+1GSIS3>1L-7;#+C':W.1#7J4)(O0Y)1>T+!!(C02?AXHA"FS4R
MM8I:!<A&J?Y5BZ3LKEQ&G9@>T_3G6;A:I&Q9:A33XH\L;0)IA8B\<P7#TG9=
M@6EIJJ(7X(J+EYO3>/M/NT*K8[N`8A3:%=-EM[(3HUQ,NK(3JFSJIEADWAY8
MR?T[?HA.811V91_ZIB*:[DH`ZS+N8Q\I#+TXE1J>X>)%9Y.IX[;H5]-:G*YJ
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M@2O+^'C)PCT0]5#*IC9.1N,L=FTW8=(A`]>U0K586+O,S&F6!([&>-[7>B5'
M4235T`OA_"J"=26<1\</T@*)4`3/ZIQ?G=AWVS8!BFEKME97PMD(;T,QH/:T
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MT5U";!B:IAEZ=<)1GQ"O;A8WX<NR??ON1H80IG08LP6DE2($A`L=Q+0JB'HA
MY%JN7')XV5,F\JXWGA1A`NT'LT9=&-O`K&_0ZTL#57`=&U`M>TAN9M-IP,\.
MG"!/B5[<G?>2[%ZS-+Q/>TLL8O.+<!*/2>EHFJ5&60D>'#UEKM^VFU%E"?*?
M13_,UJ"6E-2?H6::G-WSGWNM//P2FO5;#N)-W9:4E,(W`+ND_%>*[]2EWO`1
M5/Z>7LXF=Y1Q4<WD]!5W\=42NJH^O"M;![>@VRF1S7%5*U3N#Q>N!"M7+1]1
MZ1H^TVD[))M<1/&9*"_%_5W3=<4VGL%MJ8:VI?V%L::\-M@H@DM)P3>IYF^F
M/O5C%^P(3\U.X;/F?,\?NO;3/[.7M-9.O5S]ECDH#S?SR5W4H'>PO.+EUYMT
MR<)\RV5.^.MBK^D]S_G!-#J3YG''<K63T<WMR46/G%T>#<3WT1876"X_!"YX
MG!.!TUPG%^N.8;]INEYAQC*=IWY`V1$D;/<1:WY:O5CN!N0+)B(0,6'Q#*P)
M/N+,"><BR86UZJ3J=^JP5\I4>JOSFJE7U[Z=3U^QR?AE<4&<;W655*Q/(%;`
M%[Z_BKZ^9/?Q1I+:Z<L;?00#F!.<A1Y]_A_ZBJW&]G(57V%N%EZO7)Q^N7K6
M)+W<@5>3#P.4OIKM<-WT;]<@V_#-E(HLJ9TWR#9Z`3(D.;)6?>JWOD&65W32
M$K^'H_GOL?^B@GVC-P[A.8I2JA16X]C4BX]9W#'(2A#%,T9O`?'7`,:\7!C_
M%B2'GO_XM_OD<'<G^PN)DSF^J/WVY+?;_MGE\<GE[0&1ILDA.3Z[N3H?_GY`
M[G#50W(QO/YV=MD_/SG-1V2?7)]]^^_THSWB!/Y]^&7OW[,X\<?S/5P*%QH#
MY'REQ;Q^&/@A/22GH\O;_NGPXNP</KSU)Q#'7M(G<AU-G##[]N;L7R<'1.:K
M\@]^/4D7!6_H[2T)6KL.)_'XY&AT/;P]&UT>P'8"L_$[/@.RF]@PCS.9'O[G
M,S!./20\PLMV9?F%?4C2+<(U]W'1G-#B7U[*[`7?[AC9?_5LF[=.':A;;EZZ
M&[>_G\-V\(,25UCMC3<T/6DD7#$./@1S9:M=[KZ.DWS*VP>ZN^.(-V]Q)L;(
M1!*-"21A>;A#_)CHDD0F?A"@64PSHAZ9.FQWYY'?'?T#?R@%@10\_7;P%]Z&
M;NP3GW(4[NY<8`<%47L$+7"OP'<PX/%L,N%WYSADRA]60LDT<%R>II'IC&$_
M8;*[DT3DZ<&'><;^(\5MB.%2`KDFH1C)8,KO9,X%/B7._3VC]SA9--[=47JJ
MIO9,7<IV%K=?U"DRCECQ*@3F>UEW'I_C![4'(13^1SX!+/<!S]H`L0NR(0\4
M:RD:GP<$9`^8ADUY$8OA-[QCB7J[.S<)%H+)S8!<S($$\BD*:4D61=L:$P\(
M<G&2S^33TT.TNY,O[1'5EGJ&HF<D?>:\.&8#,@P]!IMR/B!7U(V80S[QV1]\
M"E1<4,^'D(N,QF-`SM:N'<_N@`>^`QG&U=%M#_@?H:*`?P<<8?1$%O.2BFDO
M:0343GH<UW+DC>OCAL&PW1UA-)[>N_.$IF22)96FU9.71`[(*"1#X'I`]![L
MZXL%BN3R!)2`:#<3*"+W%$WKJ6:.:W>GL4`19SIET;./4(,YB)?<TVVE9VTC
M7MDV#:7#Y6_`EW_,@!!9S?CR6K:@9').S)=\,"V@?'LMVMU9H1K(W*A%NSN;
MZ`SFQ%B:$T8I$AN2/R!!R@4))A'"2/+)S^^-!/K'$.X0,%G./=!T!_2EE^>7
M+I3N\^Y.JL05(O"#J5B<##^LY"@,T0T+;4Y&SBJ[MF#`__N8+7T,EPE%J?8Q
MDVE`LSWD@>X3\Y.$HCR.(?<&D4#[+G,'P;<4DQO0_@0WMKA%7(('BL2U$8>!
M5?23!T(=5!G\(%5T?G\8CD8MXINYLOMH:9S4F\TIQAE/:4$<57"QJC0`&X/&
MHFZ2!(FBSVD)';R#@%+3ES:#^P`QH#\Z'&7$+S\[/JQ6N5N!F3'H$XGQ+7&I
MB?2!]\CL?+:4P?4^9<KHHQ_-8MBML1_`GL0/-`#NLZRNQNU$G-^]`>PCIQ&;
MD)N^2CZIJMJ73=72]<^]+!AX<F),.@,@$;PKY1T-R%%0:H1PLP2*[,X['3@/
M_9@_.28JV\U*%IP[?SK,(_DC#2"B^0,/!\_/C\@GD:GIN`)+(0:%I?]Q<26B
M6;D0OB]<!3:72VQ,&+:YQ5BS1LI25X.T+209S5OH3&`TFJ*0_)Q_@=LQ!)/%
M6=DCGI/-B-+.]46V<WU!(XCR"))U+VY>CZ04]3@!."2>I9*^7'RCS#!^XQNL
M?8]5%1"!M'*11E6RT=-3A]!#'0,/`O(/L=+,31;BE!/C^7'6IXY(<NV%?<^[
M)Z;9>7.V_0LBT#&%-!&77O6_6L\P3`3R5S:[ZL#HUO#>T"GHZAWH//C#"NM+
M><L.RB;LJU.P7KL[5[F=6XAI&JR*FK$ZIJ@H:']W=X;Q%)SV0D%/06YZJ&48
M?I(S[`V,('0-_(F/2A!D9V^I<P"8NSL%;2S.5E@OMSS3M#DB!F(=4"Z(E?\-
MM@>$%X(>RO!]"P0(GZ2B"CXA??((Y)0EI'[,$U-T2!Z_>F'[9U-4A96X0X%$
M=)&H/D4,O`]\O`PQN*&OM+W%!/@Q,].*UH=/81:$F^<#.=.!L3G7(;%(UN4I
ML<LHDM@CX`0GSIQD9BLC&#!E%'.'N:`RC!*\)4SP&Q5",6;1!/P,R"2R!'_V
M"FZR%I8H;CUTCVE'"\FW*/67W)K@F2R8*A[IIC>)H=^<T&10L&K"!J47HVW!
M]9<[D#*8/RKC#FP13V-F4^YKTG0T>8KP,GP%!V198)?&?!M19*KI]R@8.!Z\
M1F&ZP0F>?,!:)3Z2)XJB".*$_"F)&G*19$Q,N9DF9T6DL,*$N[>4OG@E19Q&
M\4*8LB@;PVL^R$4H<`'(*Q#'%O`@/<7<8&'!>7C\7^`:I]/`YX)/'J-@-D$"
MTI-FXJ1'S3F*\@J__#J\6NY%#'H)`S`,2T?PN``E&M][@OY@ZC#PD=Q9>G3,
M/_T_]KZTMW$C:_>[`/V'NGT[@/L%K9#4GGXS@-OV!#U(W'W;S@3S*2B1)8L3
MBM1PL5OSZ^^I(BF1$K50(BTN9S!)+)LJGCKU/&>IY901ZI*N()[FR=)]&M?;
MAGH!`*;)$V./!($($0$3-0^AV[;$D]P_@W%AG"NBIZ;M\B$/6@C`QFT8<X71
ML<BP_T,T."G/\@Q._&WBPY_XEW0@I3&'0,$0/H\35&,"5?PQ/30P.^G_M(MD
M"<\JP!3@=076#<9$$P)3SC9F:<O]LQ"B2YPV(<.V@/TQ,L9@\F?V*P/@2,(L
MBT;G%)R\/^?#')G1E;""$=$+TH8\?"6H7=C==BLTO.M9C;!Y8HDM$3%3+`3@
M=A"8):)F_C.`@X<K_.W@X*5A;RB-Y4'T%=\2@^NN9]J#*.5%^`D8T$EPC\^A
MB&O#-#,3HB]G&3<7`J:"5Q'YYU1G,2\6V8"XYP*^F)R<![Q,2`=KK>&XX1:*
M6]&AW1(N.3@#*Y9S:(R:*60!+^0FYU+:+6Z!19C!H2SBC/3O2F2=(*S#EJZ\
MFDAZY003E03'8PA)Q^.84;=])YEZK6"X]FQ;L<OZ`HA@^<1-)EO!-&%X8CH.
M<7A?PEEOV_+XA,T.QDID/><1LBLIS!K$G`+!J-J\B5"*[;$#.[HA1_CZA3\Q
M#4WB+I-/^KR(D$\D%3&=BU2/[,_T(*"\[N8>@*_I4NSJT;&3'F^Y=A2=O\=U
MHRSK1I&?!TY%-B'!R)5+"V=M4M@BUBSBBP#;LX1!=A"09Y7/1KR,91(OX$VA
M#2F1]$NQV48(E*+6Q%2OZ0F91+"Y]@M@/*%93EO@^EF:$XKJ]B55'DDC99B`
MUDXKQN-IGA,X?"Z`&^V5Z1/1<32+):2V8SL<5RH6<Q=)TRTR3CX-%H:)#J\6
MQ^<$Q'"\/[^3<J<O)[HG!B:'AH<=>:-AZ*Z8RS"<P&0[MO\\(_^@EL^78*"C
MHVK/3+PAA^_\8&:(@S]8(.#4$"L](MEU(6#@>6`:EN!!OE532L0XD1%8TQWP
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MRA/MYT^JO)5\5),;7VJWGH3E^RTP>/?;!B_+GJT=@YFFS*PH31FT4@`UA[Z5
MIB](NLQ*?H#OM5M9V--,POR8<+.I+O?<3D=NN!140K.0WJUNW"RHM34+/$E`
MZB,ID!29`]1,38I)>7E[S)!V2#ND'?HB)`62HM*^*)C.K3;I-G(_,GD&@-G.
MS^_^[^WMW_]^>_LN30F;7>X=R/RVIC$+7KDM<KHTJ)RQ?5YDM5LA6JXEP96"
MI\$LBX:54LUPI]H[$)_HMC\Q6=+@B8&JK!7?U2N'[['9W2VUL'Y=G^)@TZW8
M`<"5S(J=3)S(8@1#5II>((DN1R*USX\0().02<BD\_K5'<I():024NG\?@W4
M89.IM#-+?9T9'DOFJ%GRT,LBL`+LR$KI0I+0U;'G$P4_CK4ER9^S:+QD+-T+
MZ9(Z-01XF36.`$>`(\`1X`AP!#@N=UUBN>N?O'9BR5:[2I;&56AZY'V]9D4*
M,>0IBV@-G''!R4MDY[G3_VIGC/1!^B!]3EN''HT[?>0/\@?Y<U)WAD.UHS:5
M/XD\]T=Q;C_VN;!:/)<I/U'$V]ZP^K$H5[-5-8_!.X-RWU-J."2XPP#2\%7]
MBK">Q=3FU::C.A9AV:V,%3->J9M+192T<BBY5'`9CA(M2[S<L+L(JE*9RZ`,
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ML64;1CP,MV..FU=&*:*LT!&51-#HB(PQ89ZKC=#+G6&NJ2FK&3A2=BTC.!`<
M:#D0''E:CI.V]AQ3G?6HI/"H".9-R\)>)`[=BC3O$_-8_`X0?E>:^^'D$'.?
M#6@$+[J%M,IK8J>L-A8Y*.7=U-@@-*6,.0YS"8:YVJ@J9-*BF_'&@]SLWAYV
M(%>0*V7D2B\YVE4A399SOF\<P5^6D7MH5[8=3[M-6T4DK9922RM;M=18$4E+
MI]1LLRY[;&R=#DT5XM+OMW<<X23*J>H<*3^T6]=DU/T!\]\FC/<X&._Q(.MX
ME]GQ-GM(1W)`X<Q#BA2NY'A'%!YG&N\<*D>E1B<8'6+(73I12^&5:J'&BDA:
M.J5B.EC`TCETVM"9I9.EP<R4$AN8]!TW#C)&BCC.!8QSM;6U#U9H3$H#,C0F
M51AG3#?+-R>VOP)!>4EVH')"OQR"'\ZA$,28EUY:5,Q+\\M+OQGN7]=3?I3=
MX!Z<N1YQJ,<P+STYQ.CT5#&WK73ZN"#9C#%7.NHP'/,!IA+-&/,5S]6.VL,Q
M;\28KWBN=N1L8YZMA%?*H.PJ1[(1NKQ!,1)%EO=4(]E$08TBK!M>L\?PEKQ>
ME2E*37GVNC25[7NN1RVN+5Z1BL#_CZSH4S!0=E-V!VS2B%D,E#;KVAPGZ]Y;
MH<J;1959MJ/O(B^5YZG8=06(#<1&4[%1F,./N8<"5/1'6,CS_/`>\5@J/**M
MRFWZ%2,S1'3%$8W80&PT%1L5C<QN@LKJ&)C5#(YHJC`P0T0CHH_`1JGVI)R.
ME.UN%.R8"]47SIC4U(Q5-$[\QN;4L`SK&0%9,T"B7\5(L5Z(KJB)??#Y51/\
M6G&TL1B?ECP^Q7DCM)TELIVW]NKB/X1DF8WG"1M?3\9NM3;%WCP_.^PY]<Q(
MS0&<\P59/;E4>[RSB*Z42O+]=[`40-B*.)O'&768FP]-L]W04S[NGHSSDAV$
M+1;R==J^?UR3*85[F*,9+B-?'4/+^UQDHYF$'J/T'N.).?-VZVK7+4\(]Q,<
M1\DRFCPOK&M(QO,9<G;#<@VMW?HGOS@>B9&2#9U6E8'G0!ATM#Y1DUH:(]0C
M=TP+KW)6)))^C>+QT*N<=<HR.U`8WZ'1(FO_%'FT6U6D4:\K]>5A$1HOF05"
M@)\,\/=5PW5GH#8=T>65#?=P(#80&V6,Q8^O7-G,2#RCV_R%U_Y(V^R:9TA>
MKIGFD@0LE8W(E:XT4E1IW!U7V`[]#P;BB.O-B%SM5AC1&'5AU(780&S@['C5
M8_)HP;Z@J/SR/,:`)1?1KQM@=3`01UPW#M?EE0TC+<0&8J.,43C.B^<<@R\,
M!^?%,6PY7O2K7F\H#=0JSXJG[)#%8+S9J!YTE%&%$8TQ%\9<B`W$1CEFQ4\X
M=X'1^A'>]9;O-3?-\^+UFI\!2QZ$.284JERGC@N3RC1C6?4C,TT^2X840@KA
MZ>,C$';6<<M2]`\QAYA#S+W=RL4.</8P3\IP[O:1+;SPX*TL#MXJ!61'^X:D
M8F$>=(7HMC\Q69WBO%V]NEB@U^U+JCR21LK)!WJW+>$A%);+$B*;D$WY'5KH
MI9AUY!'RJ)*]NB"/3EZW1QHAC;+VZNAJ%=5@3U<:R"EE?9K!G\LL`9:":CCI
M7RVW6[9)?YP50RXAEY!+R"7D$G*I%EQ:-W%QR>NS]3LCFI`8N(Q9[67,/ZC#
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MIK8C+"X8<##89`Z_G[F$63JH8'MN5@C&;WR3N.X63/.,%]""!%KA$L<517+7
MDPKR]U,T%5X5=5[C/66?<BQHY'C=M%MQY71BE%[]],0U;GO4)%-J.-R4^D)I
M`H$N>6&N!R\1[]]TD?!+XC+GQ=#@0=WG%IVL!Y`+L25MNY4B[BMU\Q^C@2PI
M10V1VNU+HXW&C]'UC<LUNZT!B:O-85P1!;!ZW-W&$S<?P:C[EL,T^]D"'ZU'
MHPDFQ_6`5R;E8P\QE6^%.%A!@#<`8;PVRW_D>N-M<ADN5^]*GI48WHQZ`J/$
M?@&%4O+*>!((3U'X3)\9,8UI8"W/%TSNJ/VD6.+NWTZ[Q4GDL#DU+,Z!27A0
M#L9ZMW;SL:2][A80C]!5X%?`FW"V4HT[&--P9R)(YJJ:^"Z\WG5YO`W/V_`S
M`8[RQL201[9UPIX-2_Q^POL?=90C@UG$]>'16`L3>&#."*!E(M;<0`,3!OH"
MR&LS@[TPO7.I`/O8N.=M!-A`11!)//WK5P@E#*"LH<7>=5(P$O[BC_M`D(EM
MZF&`]67!HPSWI_P&8M6EB4-^S-9:WO%C`1%=T('_<WU]__>O)M78#%3)G.MK
M_K<;3_!+N+@;R_+!V/[&F,<M!/<"W+\&CP?6E#\;QH9DQDS!SR^:9W-'H?1B
MCB)PS=%7A?E]X08/$E8*%-8%C8&3$$LZ#)@NOF/YPN.L'3O\!'0$WPS:`+W"
M=WUO9CO"4'''SGV\L&(^^&TG[(D\)O?_\0UO*21=!:70=7CY%7]F'=;>?HP_
MSQ]9_^WNXP<RA7R*0*PS[,N2#`FX9[=;:C?ZF.H_[R%O%/XU13&:;6F^X_"^
MOQK>K-V*:2E4$@S`\6J!!KA>2#:U\&Z2R;+=&O!.B'](;&"30?\GFSHZ?^.=
M`<;3L_EHKM\&4;?.0E$-:SWP\-`+-4QA0G=(]&!;U[]W'B$DB8LE%#Z2AG*D
M;]*//N1H>.O-][)G<*.N(O4*"WNE7K^[%56W6QR%)R1NR8`YF)`K(J5-44F0
M)>;2_'BD;H6K:Y6<E:Z1T!N+H$VXC1T1&XD"MG8K%F^]&J9)+-M+!F?"9B0`
MN?"=A>W"%WS+,TRP>QMQ&^"8Z'P*54_$;DDI.N0FMH6JW5IU+LQL^+_LL#M@
M>>"=VHQ;MAP2O7Y/&JNCC0&(S+GON1[H-TA-J1<H103!_B)C``RC)+X]";[B
M6V%BS$-C,*_V`A(.3\2S$<7787!J@ZEZY=%P0K&E,,WJL,@(-P?#_`4<]LW"
M,4R2")6B@`H4"0CDL_H`/ABL=:`$2#;`;/]&ET0=``/!FP\(`_W;2_%WNEH^
MX&$%N7,Z(,8$'/*O'?(XAU])\=6',"F6."86#GLQ;-\%0R9>!Z_?"I%6BQ.)
MV$CBKVFW1/,B:PSRK]L9-9PYA]I4="Z('S@N;R%_FO(-C9H?A$?3*22:0,/P
MR5`-'?)U8Z%DI0>)7!D?`BO.G'GXAOCB"9^D8=^]H!\BE+AC6FC(E(CK]M8O
M50#6E0%-<\4%'1(D`H/$N*0:=8$=MN5S`Q2/>->VD8^)HD8QT!QR[+D_!\DY
M`[F@BB+_$*D$$`"$Y&EYTCN+-P2B@"R4SW69OL-GOD`2/KG/O[SN+`U"=^AL
MU##7"C?/SZ!RDQ,9?L]C,QX_SVA@%3SXA9AZ@-$27S"LP,).EH$V(S1R)(%E
M@LY#MS^"YE\^)-`:M+@`2*ZU-N/#R<,)XE*3.LM@W+]\^G;#@38W_+E+KN@'
M89#`O`@=1#J#W#I0%<24<;G"OJTA/HF_4;3$S3>WG!9YMFV=:T#TF;_\:O(A
MFO7C0H/Y,VP]^DTP4>!"ZP;7/L2F(BRV(#(5SL<SN`02X;_@QS,TR&P#F1SB
M&F`E*?=2(+>8NA#42ZCP2IA54!&7VPTU%CJ[.87X*SX?"09DW:]V"R2BIFN'
M&.1/K=H)8N@`);8C1@:4^@'&Z.5#O`G.AN?@?N/`]@O9XXY-X5&!"+37F<5M
MD'`]A@D7X(QK+7@`R!5<S<8Q#-$\^X\?Y"N\!YIINT).\:>(G/'FHMA`!P2N
MQG5-[BB""&9Q0LG67A*B4@KJ#+\7M2$Z**7PG(]^]%MP]1'304F<7#`0`6Q6
MLX:1XQ=I;0)C/"Z``9F#$S2"F"_XBFB+-V9%OUDU$C.K?%*:AQ=T"JA>C0>W
M0JL7Q&`03-#I0;JWYG0`G>"/T2"$R95IVJ_BVTG.Q+S#:EY^ZO-NAS#@%E0$
M4P'[^'T?P9>Y9H.N&0G&`Q@X!W41HT@KN,-7-;:(4S4D&?_$01TG6[NU[C5'
M^,J:4'`&)M>N&#?.ZK$,DBS=(#8+E'<5-!5-ZHK60U,D$/)J,3%T8<*YJ>8P
M,*).@J5)&RP",>&Q5@*9[!D@^B'IJZ.XM=U:\"F5\"&!TC5>D]B/I(LQ%)[S
M@"W>R@@`.MQIF.O[PC:)ML`.F';`C/BO*<<E&"8]-`E\16DU^P!NP(#6@S&%
M;GDL8%E\&\(WWX06E%Z/JTSP&^(@(TK:P89'"3M_D/#G(J_P8IO^'+YK@AD,
MC*(;K,-=&=\_$&,:4[O&9P>B"=@`EH$B$K8R&O9X5[E1@0C,L/S@^Z#"+4,%
M$8A0KYAZH$'4'\#CU?9!,P[8*(,[T5GH+Z,)F(4_`8L.O+;@M?-`3>'#4<RU
MZC6WU\Q+00"X1FC!<T,W*R@YX8$[C(/M>$)J#E.P`W/&N`"0Q,1?XPK[8$\\
M3FR16(+YY*@388PKC$GDXEZYX9W3OUAL<H7#(=D'RI>^HE?H'0BX.#V%/IFP
M!9QZUH;M#>S#.K8(+`UW->`HK&<^ZYTRU;41J$%B9^L&!'6A$;)((M@5DT@1
M*C99)Q@2&$\I.<T8RPISR(6':I=[E>V%)C'CQOL.#BV1>8J%D)B%/FJYL!P)
M457FJK;6PW@@,!=AZL9Z;QPG*U\:[H+:MZ2;-J,A%C)S@)3<Z1<T<:-TE/WK
MMX2OZ255%"DGM':),"GH\EJYOAN!^A/?P7W]J,ULDQO7P)WS0(X_`*QFIGA7
M,&N@\>^"`P!^F'SBE@?/8@I1S%;,P.O8\$W@4>R96#B8YG1A6(/.K-H7\4FR
M97O"TTS!2I$T4LT3X2</`YA)%_S!"?->&;,V^LW'8Q6Z<K9'6A(S(V#'0[?$
M7"1N%N(ZW#>(G`W"K7FH4]\5G(3$T=1\DZZ"FS5.W1A0VZV(QL=MSDAA<L"W
ME'TVP8P>=<,H^>"*X84&)\-:;F+C=3ZKNXF7)=\<"JN)B:GX5N@@](BM_!Z]
M$9'P>TK<!>6&Y>=W<O!Y074]^ASMJ9;C9Q$2>[1/.IG?[97J;$.6*A"A^G?V
M3(WO/N_NV828:"]_^)1CS^^3,!V_!1;C?MMB9-DKG4-%B"*OIGL+V*7!Y*@9
M=43K,6A]X.ZM`+!NG&I!Z[ES^WW_A]I@,+T<1-;3"E%G3[!R"(Y2@R.E0BF"
M`\&!E@/!D:?ER%8/>$_$4:MCLZ?%A_>)Z;`KPPIV\Z?<4YX#<QN!9J605OFF
MFL';#HI:GS$Y^DPY0CEAF/GQ*))?6%>128R&CK:"H]V@T3Z%VSF4,DD-NZJ-
M@RI)7A/J54ER5#FJO%(JQ_3ZY/0Z8^'R^^V]+IAWGZK.X>"'=NN:C'H_8`#;
MA/$>*V*\QV,<[T:,][`?\+N/X]V(\0[YK:AJI@'''+5$H623V5<ER5'EJ/)*
MJ1QSU`*6@*'3ALY/>R\-9NJ8B9XZ#O(;1ZC5UA:NS2+($&3E5!N"#$%6,I!A
M?E^B,!PSGVI(CBI'E5=*Y9C?YY???S/<OZZG_-"J(>K_\:+VU,MTIP\&+(F`
MI:-T@[6)SBC;XD23+4G5Q[RGBC'O=N2WSHIPS"_,\VZGAZO.31GS%<_[H],3
MT_VWFJ67/CG^JK$+EG!Y@\HLBGQ$:99C>GI.&8G^^`A,%Z/BG!%]PXL5&=XR
M<1U.LLY9O#[X^OZ$WSN/G?B-#FY0\#5#M:.CZ?%V^CWY.K^B"R-=LA;2L+^'
M<#L(TI/+<+"Z,G=>[I&U&R]8HZ8*7L*8H&)WCB)6$"OY8"7\B[AFO022GA"N
M'PVB:H?R?X1%7\]/W.J$W_+*AK;M[2?6,=)#A)_K3LHX`LWMQA$8JUR?:C(T
ME9W?;4C`>!-<#G!^O(AX+K?@:",O'&EF[U]/KBS:2C<R2)J:#4U-NM&0,"._
M>:F&X**REK\A@/XF[G(SK&=$-"*ZBH-1LFY@Y%S6D4$WL$>)#WYP$[(]13_0
MK&XT!.`X/XA13IWP?`O-.<$=IXAIQ'0M,'U<DUMGY&Z>GQWV_/:GXDK'BI-R
MCVPW,I5C/TE.G2G?"!9SW51#S,?CC#K,S8OW]8%2G?N&-,FLY/OPJOMVZZMC
M:+EE1/7!5`Y]*TU?D!^9E?S$G'F[=;7K*CUD![*CP>PX,4?[;'F.8;F&1OY)
M33_O3"TXV%EMAN52-8>G9W6JFO.)FM32(%2A'KEC&N.+%*2K2"2?"ZN#<V#5
MFR\Z=&ZE,+';FX>P,PI^0.%%5M$82^.N*JE*KPB%E\R6(-IS0OO[BH%<Z8R&
MS<!W!:++K!C>>$..0,O:,,(!X5!=..109;AN<?0O#K5RV;6,,41S(N:AU._U
MI(&<DFC5SF8@VIN.=J73;TAJ6,-8"<'<X+(H"&F$=,T@C8L!>S8N8!J#AB.#
MZ%=]2:YT#I.R"0$1C@B/IRX]M<+XQC@/P=S0.`\AC9"N&:1Q]24E<5D8#J8M
M:#2RB'[=`%N!*$>4-P+E&.35'LF-"O(0T@CIFD$ZVY)+*%_6H_-URFIN^<D,
MT\PMKVG&,;*C=GY6K5/'V:@"NG6E2O)0D<;*^%0+5=9C8Z<O^B"/*MNIB_%(
MZ0Q/WOQ65@9E'ZH3>%.2N`N9<RGFG!\C(W\N+SGR!_E3NL0S9<%L!]%Z#4H[
MXR4!'MG""VL"R*(F@%)8+KI/Q:4G/0A/=-N?F*Q.IFQ7KRX71?>E[G@LC<;]
M_&S9`=R5S)8AI9!2>2>F7213UGZ$?RG9->?(H\OQ:-A!GW0JC8J,9NO)HJ/+
MYE2#/`4TV6ZE['QI(#DOL^I:"B+CPDU].H739R7K&1*JVIU"0I6@9UG[4:&T
M$[F$7"HSE]9-7%SR^NRBS8@F)$:I%SV;M-?VR\(S;,MMM\(:*'1B,O*V"Z`8
M.E>D4Q=S]R-II*B2+)]<BZ+J1@WYA'S*=>USA)MR,0E%%IW5K4'GY!L1&DLB
MS#XQ^ZPS,1+9YX\>SZ9BGY,)4^+3KN11&9V2/78[W5C^^&_?]8SI,JTC%Y&A
M@'1Y3X<S@>%)@.$!P/!M-QAN-,]X,;QEN^4PDWI,)YX-S8.@Q`[2:6+[GNM1
M2S>L9^);.J31WHR1!]LBOW<>.^3^/SY\GWPUJ=5NO5*7P/^GMFG:K^Y/!_+L
MPF89SD5)K@*L7Q7^,;PD,69#Q$Q%*$@V0A-^NMA=4`U&Y^=W<O!Y074]^AR:
MEV$_;ODWKCW?,S]T>>M:YA!OEVQ'7W-9.J=5(?^$V$!LG(2-DF:_<77C/;JB
MT3\8'Z(\BF?4";_EE0UMV]NO"F(DAXC.ZCY*A^E3NU%1_1^!JLKU"3%5>DS5
M(22\>6$.?6;G1X2(YW(+CC;RPK%D]OY%868%T599P9$F)>Y&?3%5AU`BO]DE
M!'2Y!6\(H+^Q.34LPWI&1".BJS@8)>L&1L<-H$D=#/^#SX^WM%OV%"T_0KH6
MD,9Y/L1SG?!\"\TY5/-\:B*F$=.UP/1Q36X=$[AY?G;8,_52C'NS6'%2?I'M
M6$$Y=G[DU)E2[!0YX5@7F@O1Z..,.LS-B^=5/UZ#M$!:B$;#:A6LW?KJ&%IN
M&0_R`_E1"WX\,6?>;ETM&77<E`O?D!W(CK1N]>+LZ-:6'2?F8)\MSS$LU]#(
M/ZGIGYZ)92M-W)!"5/';=^Z8%M:>4D3M*3FC!:OT,:9JUR*XS'W274F194F6
M4X!2NZ,LB.^3\7WT[0$E@;7:.;WD65T0?7G93L3PQAMR!%K6AA$."(?JPB%+
M0=>&Q,J_.-3*O@<7HX:&1<6#/L;$B.ZZHEOI#$\N8EH7:%]>-@1S!32.D$9(
M(Z0ODJ0T>4H_6J3'1`5-Q5[14VXLK9V%0%PCKAN'Z\O+ADBN@,81T@AIA#0N
MHKQQ=K(P',Q-T$Q@#(>X1EPW#M>7EPV17`&-(Z01T@CI\JR=A/(U^<[N6WY0
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MT(_.@:F%#(18C>[$(3^>W=J;3-,<CR[+%X``3#EL3@V+`RE$%_6]F>T8_P7D
M>#:9,&*XK@\??`"3P]'6;KU0Q[!]E[#_^(:W)`N36F[Z3`^!)@D%*$YMT[1?
MW9\.3?WLU6_"I.=Z,^(>$_9V0H0O"S$0WC`9\V]B0BT4)9NS(?R4N[N@&HSS
MS^_DX/."ZGKT.71](SD>76W<";_#70Y+<<=[F2.L7;(=?8-NZ0*J"L5.5:_(
MA=<PBT8?;*O=^OV1W`N7<]H"0H51O+$4=4P2O6^M;2B7*HMNWAX.9+5H]/?'
M=BM@-/D*060^M*[ZLG,=]F,@%S(K&0EPVB[[/2ZN3KLK'D5VWF[=K-/SJ>V0
MSY"<\U/E87JNRG*7G&Y1*^=SZ[/OZT+W8DM]O.X=\5U;?#>A-G,.-Q(TUEF.
MT5FB,3E6=&4H#?$B:`1X;0'>:&^9UQ'N9OK2!]LBJ^GY,R;SFC<57.T-E64[
MSG>R":OZI!E2""F4TY9D:5C/HO1OG%!?'G65(ST&\&=.Y\J2BADJ`KRV`#_;
M-U4(W[@,FJ*\+[[G>M3B&U?;K?#$.;D^+_5$*](P*W*E]*7N>"R-QOT*VY'#
M=RPAL!L&[$9/X#9WN3,LN,+TE4M$#XB&8J\''`_YSI\*FPOT?@AJ]'Z8%.Y)
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M%LQR*5_:@`^NQ\,QDWI!D4[?"DO"BHD<Z(U8`B'TE3JZRXM\OLX,;99_'_K2
M<#B0E,T^&"XORKJ2+IQ="I=EO!GU1`5;8K^`KBEY9=RZP:,4/M-G1DQCRH0>
MSA=0Z8R3HBT9==Q.N_4$X>HZGIU04QQE`TT=TCJ7*P?-#;O;E7*/U=N$NO``
M2,1C;JIQ(4W#G<T9",3%F_@N".&Z9&Z8\+P-/X<`8-]Y=Q@$[\\&;U*$\;'^
MOLX81/N^-FNW8M^=P`-S1@`[$U&!%+0T85QM5)L9[(7IG9@16OUT/YT&17G;
MK2^:9W->*;V(5YIM:;[C<(E?#6\69!@SV^29A$`I.`@NGF%I#H/N`B>@K^NB
MM6%&`C]%*8K0%4T>43021Q2#-C;/_)/)D@RXAQ/_")7>@D*IM0R[`@*//[KD
MDPU<$NJ],T!CGNTD*N52HK-`5)!9M!)5TWVAABG4!A*U6TF1Q(,/MG7]>^=1
M2D@U!=]%5IN=017M5C_ZE'N-XXK5[SX[<][G3P('\?2O7\%#&&"&#2WVKI-\
M3/B+/^X#02:`\K"3MS-J/<-W`3&/'+\!`=P0"(=*)9>\MGOA99+?'!IYU=[6
M]@Z[L%S"VJTKN9.-0N[MUKJ2.Q,%M@G6U\Y:7WMCGNX-JFM#H'1\>>W+9ZJ;
M25J!TP.C?6:RF/K)JXJ2@[I5E-RKS$?F&/#-3Q#E0-+@>`;/:$^:JCT\[5)P
M/?.\0%,H\4;G\^X`4B\J:XFP<*::+Z[*G<.>7O(6AQV''8<=AQV''8<=AQV'
MO?'#GM,5*671_U$;K;92\C+F5R=LD,.D/:'LKPZ;,L?A4X!\PC"??/W(O7PE
M-4\7H?+;T2$GZ.<V+QZ[C/"--'H;+.S5#_!Y@JAV#JV"@5%)8%4E.XH(0@25
M5E9$4!E'I4JR(H+*."I5DA415)HYH[0IA"K!K>KRYSIM5+O;0U=Z?9L,-;@+
M9'OHSLK-LZ"R7.8#688L*X!E-W/;AQ%#EB'+D&7HRY!ER++*L@Q]&;*L4BPK
M;`FUH',3;[I`^48V0]<-?NB5FN0K-?0#QF.W):F@C@VKW;JE"W[R$&UF>6UF
M:?=%E=B05M5NQ[:^5#OLN[A=K]=K;C3-G_NB6D,6#_4&[FJ7S/5YR1=>F*7A
MBN9E*APV8Y9KO*0<X;Q@]S];O&!(S4*6/%U^:>(8S/VJ/\-RQZ:&9N`42XEI
MANE"(].%>L6[;_0:7@ZK\9&=Y3FV"0T^9^E\59WEQ2'WF2N(5]8S4BZ(NB#8
M'OV):^@&=98U\^<82^=P#JQ$OKN2<;.H<9]SU%R3?;"GW2JHCFIQ"<)>T'P*
M*\52C_R#6CZ89J($E?@R@N<R9=B++`=0W`ULH[6Q*?`"MGYQ@BL5O7HMATH7
MB.MC</V^8G!&+".6:V:C!SU)515)Z2*V$=OUL-.#KC12N@AGA',MX*STN'D>
M2GU514PCIFN!:54:\BMM!P-$-"*Z%HB^&O>EKBI+@]-O8+P\I@]?R(Q0KC^4
M(=88J4-IV!U5%\EHG1'2,7E'`ZDW&DH#95Q_2.]<U'J=&1YKV)*6:/'^.W,T
M@U^GQ^_0BU\ON*U)7+W"F=%`\)3M6'4S%0AIA#1"&B%=84B?=4T[PAIA75)8
M(Z01TO6"]%"2QPAKA'7-8(TQ-4(:(8V01D@CI"^-%(1T@R`]E!JQ(1W/:&WK
M3M3PO9Y0E^GMEF;/%\QR*5_0VE8EKF>AO4`7B)!&2".D$=+EA[0J=<<]J8_'
ML1#:=80V+@`@K&L&ZY&D#%2IUX2MI0CM9D$;XVN$-$(:(8V01DA?&BD(Z09!
MFL?4/6FD].H/;3RNM:FYKXZM,::[[=84'B*&Z_JB^*`])9H]G]L6$6>XMM6*
M:UUH/]`E(J01T@AIA'3Y(:V,I<%P)*EJ`\(\Q'83L8VX1ES7"]>\5FQO),DR
MVFS$=LVPC2$V0AHAC9!&2".D+XT4A'2#(,V#ZL%0&HP:4.$;SW-MZTZ<YW+;
M+;[4Q70RM1VBP:\,CTY,1C1XEV-,?#S@A58$'2-"&B&-D$9((Z01T@CI4D"Z
M)^-"%X*Z9J`>R`-IW,?SB@CLF@$;`Q"$-$(:(8V01DA?&BD(Z09!>B`/I>Z@
M`1<SXY&N3<U]8PNZG#/+$U=P/3+'@*_<DZ\.FS+'83K\9%B:L:`FH99.[HP7
M0V>6CO=SH3E!#XF01D@CI!'2E81T5^H-5*G?Q^I8".TZ0AMAC;"N':SEGM0;
M#A':".UZ01OC:X1TS2!]U9='DCRL<+GP#PAH!#3::(1T;2&M2J/Q6!H-&C`'
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M?)4+`AN!C;8:(8V01D@CI*L&:;6+X0<"NX;`5B2EWQ!HXQ&N;=V):H6F[;I;
MM0H?F/WHL;E$/EM:9UNQN,J%%@2C/80T0AHAC9!&2".D$=((:80T0AHAC9!&
M2".D$=)UA?25.I+4T5`:*?WJ@AO/OB"FT4PCI.L+Z2:8Z2S'N4*9OM[<W7U^
M^.7ZTY>GIR^__434Q?>=W:S9:M?CC#K,;;<,U_69#NV0K[=/Y#?F/#-G6\][
ME[A.4&9IK<RG+]_N[K^M^C`QJ?87[PEQ;=/0/Y*L5JAJ?3K*0I7(Y7XD66%7
M-C^,[$'V('N0/<B>"[%'D:6!?-:^+Z01TJ@\?;HHC9!"2"&DT*D4&DK*:"SU
MD$9((Z01ID/('F0/L@?9@^Q!]B![RHHT9$^>"9#:Z*FX;.<R&[V*'7[^XSYX
MX<0V];`SGZA)+8T1ZI%'MO#8?,(<TI4EHLJ*LJU_7-M&HU;PQ&AS#1I2Z(TI
M]+Y6S$':(&W0\YS!'ZD[4*1>KXL\0AZA^SF)/D@=I`Y2)R-UQJK4'_:ET5!%
M^B!]D#[9^M*79%F1!MV3#^L@>9`\327/E:+V)$492'VY;OPY?%`9:8.T.;&L
M[T`:C11)'@QJ1AIT.LB>-YDKZ/4@Z5%/OB]SFSZ]2])'D<]9N_Y1%,^-?4ZN
MLJ9^^M\????ZF=+%3X^>K?TULTV=.>[]?WS#6S[8'KLS7,VT7=]A3^R[]XDO
M1/^MW2+D?Z.O/3#OLZ79<_:K[;HWL2*^3_:#;8D++8,K*Z,;*PG_';3UC4U_
M?L=L\\^O]P-U-+B&_RF*(E__/PC#U3\?G^[^5(?=/_GRL3SNRG_*[XAO&<&W
M#-?NJ<KPS]\?[]X1G6G&G)KNS^_D=W_K]\?R<+SN5&;IMCIW2]W95\=^,72F
M?UK^[C+]L_79>H%'X5LWFF>\&)X!`UIDKZZ[BCH<RVJB7T<*ENS05[J<,\MS
MG^P;#<;88<$WQ.\*[8(Z7`N_3XBDN%^\&7-@H.P%<Z@GAHD/YOWW!;-<5JC`
MRE!5>DH,2OME2<H-?W(8==D="_[[V;K1--N'_GUC&C->1)'K0M7=&XWE06\M
M_3$2;?4!NO=$OS/W*S7T8I7=&W3!FB?$C;\\*=DW]L(LOV#.]?NC_G`\BLD4
MO38IS*T]GQL!=F\LG5_1"]!@E@;42[&=)XO\-VZT$Q8\MG7H\$:AQ.8B9;2]
M=ZC;Z<9V#_W;!RLR7:9O5,KXMGPW*L6W'FVYS@U/^R0\[0-XVF_<T\9ZL_<]
M0OJ[^]LOWVZ>/G^!0,&WP"?ROXD6N%<D2G=5E@8&J?N1Q&!`J*63!!"V??CN
MS5!OH.AD;/'&;R\"O/(.Z!X'J4SX>9JQ=@L&>T&M)4208$E=8D^G!M_Z!L-N
MTHD-WL%VEF1*-<,,8@/^%XTY'C6L=HN!RUMPH`2XBOX`@:6E\2UTIG`.*R\3
MO<2;48^P[PMPE^W6%$)'$4CRFQ*"_\X<VW^>\>UV_4YLA%<_W1#7G\\I"&9/
MR=3W?-[.W+",N3\G#HA#3;(('3-\%GY9#T5,%V9&7Z`):,$SX+NV`]^:0T?X
M8Q!+S5U>WX9]UYC+-41LBY$EHPZAXN-JDV"[%>T2)-1A_*]3B,CL5Y=<P?>]
MF>V[H#[WPT\'>',TCC=1NT+*Q"$_OC$GLX/U&/OW^/2O7^$W!@RIH1UE$W_E
MPQJW8;EI.U=7]):6*R593WU9_"F-\2QBE\T+KC8!@IL+JNM`$QYGB,_N`FQ%
M^#E,-;LRY)KA*_9;J:U\<ENB0X9NHXFXS,[N?GY,;HS>D3,/8ATY<2`RSZI<
M"!5GN)JT$?@76$L7_`688/T0'3=F.Q*38SNWI:\')FWR+0<'FM:K#)-JR5YH
M-N<)?%:W)F%V];`[7'=Q/XC>(M+-.E692:U?(A<=&O.4F',O8H[4J+(7,SO8
M<4$4Y7+G5MR$1;W>/H01_&:<LWO9"\%<7I;SR)QPWN-8:W5YBW38DKZ=HMNM
MPW/YN^QB/UW@M84J1.+NJ-L9'90YNR6JC-%)*8J*)B<7DY.RXPU-3@$FYWS!
M+V1[%+4_[AS>5EQCXX,13W'F)^6H!YH?-#]KT4?C4>?P>:`:6Q\,?8JR/3VT
M/6A[]HD^4,>=PYMR:VQ[,/(ISOJD``NM#UJ?M>C]T;!SN*)`C:W/>9%/8G:]
MT(7,RJV//<V8P^C4RWQW3CU6QP[+?=*Z:2D[%;==V3>F%]2M47_8.7S2%A?6
M3C-XO9V]KH'ELCUJKG=?B4U5J\U7;VS,>E4V9B`\T6U_8K*W8T@NJVZ9>E.H
M%>M)`Z77.7R`YGP[MIO19;%C60[05'O/V]MN`;_PGMWPB`;?JZKYSIYMK:_4
M)72Q<.SOQIQZS%R2]_UN7^K*,M_"VVZ]5Z3!4.57KI"I[1!O)O;=LF#KKP72
MD3E(/G.)V+.54@A3:K<<YBX8/YT#S4OBB^_[JBJ-@G<0>(72%==1['@%N(V]
M[X!_QU_1.>!.,F^4O<3F\;)LDTULZC^T1;8L6Y`O3+[?.=7:+5"Q.+)%GP',
MP2;S5\.;`;@-1X?8QQ$;Y3G<H\WU!GQ<+@R-FN:2TR;<D>[9/%(B?*>YQRQ1
M<W;*F"O!;_X"_ADF<SV^UWRUEQV(\Z,-$O!OV?P,EWA>\(D%AB'XP/_NV$MJ
M"DG\A6VU6YH]GS-',T!5_P5+85M\ZSK8!]W7/#>VS9X\Q02GIFL3%[[OVGS_
M)K"144>;\=*X+]0Q;!_>IU&=S0T-]`K*]WS>-'3A=6;`<]$7VJV8L@!T8*Q`
M%?SU_,P?\4,-4A!J(60#U41J!F?8;GE,FUD0E3\OB6ZXFOW"N`)UWQ%;]&?\
M!)KOP,/0)_XI%)GI:YESMQ[UQ/AG`17+XD87QB$$-B/\GE^!4!@90YQQ!$0(
ML+G,>>%G1L+!=/B9"+#L'#[1:(B[@J-/(;;61X[&'_GQMSGX`N@'/UC&6WVE
MCD,!+3#TP!(?!I"*4Y*QQQ8.>^$0-`-,F+8+D.#?U9FK.<8$/O%I%<,"5Q5G
MXS-OF-/O_[?W[LV-X\B>Z/^*T'?`K=M]P[5!NT6]U34S$2Y7U9R:[7ILV7UF
MSU\=$`E)[*)(#1]VJ3_]S4P`?$B4)=F2+5DXNS-3MDDPD?CE`XG,!/Q.%0D#
M4,=>G$12,,A)C=6$$&`C%#I\O/08S"=.`>3Y])9FD?U)RE_V-UF&-<>Q]409
M_)&7/Q`G8+FIO`9X,,1:&5`);KXFUP)\@+PLY_T/8!*H=%G\$,<>BOU9SN>K
M-]?OK_(?W[UYS4"ZP4]`#HMHZB5,SC'FOI(D8*F:PP68#%7=H]:QBF4%*5=P
M<"7S0#DI;82NP(A[?AH1EG!*K/RK<$B?`64@1B-I_%&,JQASP?Z-S%!>`KX<
MPQ/QB#CK(5.'(#7TDD12<<WE/.+*F5@E_0W8`_Z+`-VN3/'%H.SDR!<EG3GA
M;A&:<LWXJAD@_S.#@+R)PVFFQA2ETK?"@JM/H-BIODB-N@HO.!!HV(5Q``U8
MQ#23?]=LN"NL,KYP)8%*-?3L#@2(D:<9)&B[`!I4^B&]SF\I_--NM_5W"H"\
MA.6`C\#@@'!8P4+5F.3PZS=2>E;,`/U75S@^1[YD.&##.7ZH7@,DH\`LNZ6+
M:Q%G16D%*`!04$.!V>54F"7R+P2JQ@N,>5DKP-PSU%45I6GI*+"5H!"F";P8
MN)3/7B4S"WA1W`*BO*@*F?4:LA67)4Z'?RK4HV4Y3V<%^;M@GT-%"W%A+A!J
MH*L3-(K(&^"M-X4W.!KN$MSO%F2*%Z53"9@<HZP/<P:#7!*%@&5T8'`,^C8,
M19]%?V#YNXC*820XH`)68-78ED2`?FDH?$^`/0)QIXG&\`-X%P">D72(J,#O
M+DQ]%^>4^@E)4D2O237!J`91"A[(#59#>GR(%8^XK?&Q<&\\80%-(HW0"@*J
M.`PR%&R,F+E8=IJ",-'?=OF4@U:FB<?@VR'-\`70M\(%T\2Q//`U;+>`&RND
M4.IH[5)50((G"7`--0)P77CD&@;AG7J8?"6862;';%F,Z[5[Y1C')8_SSHM%
M<:`,@X!+^BQVGH@\1\H9BC0:$]1?9Q[,LNP.%"=9KU49107%"DL#!)5GB*P,
M,I]PFDH424OEBUL8#JV<%[K2-R]]HEHR<T<5ZT/)`J`XZV&!=`$`05D$Y7"?
M,"K'G=XJS++@'2PKW9S;A:$7F2MM-=AF[(`0H8[Q%469'LIE3P&P0O(`R1R=
M)Q@QE[^5OEHNBY(DN0"KQ))$8.584_Z#XL:P?:'N`E)0ZS40'Y02#%U$L&4Q
MSOM&SON&0Q:#!2H<\'\]\!R'P@.][<-H["M`<\H=`=LYV+7"VEU8[+?$O6"W
M[#K]"Q0B>Q_-8;E7/H>B^%\I;&IA1%!;J1YQ3L_4:_A0>5$K;"IL-$(?0<1A
M2YN@6^`%(Q1OZ2.`US]+$Y%)<,%@T2[<27TLT@X2;^B%\"-M,V:^^`&X"M(1
M=[!RW$6?0D[F#&%:])>_RNUQR6=6NAX];9!?1LUVIL+U@#Y@APAA_#+$KV!G
MBH0K=E"?&S`A%OOZ[8HI]P,LGQB'J!,<'I.WBUJ"/+P_4W=,LP5Q0_?/;LG8
M6";'2'NAUOQ7M":@"D&_T=YEYJ.?XXU&;'&-I5U2)?U@?:0F*@<-.QB&\%'4
MOWUZR\X6(HJ]7M_J-!JO2[34:])0H0<W2E%[<L>)4N7>5EZJ\R8S$%@C^F<H
M*^]I8F2:\^6"WV-X)/HN*-@I]Y_4]4BJ'[5B%^P+<@M#%4U;Q2NKUTPO#UAV
MZ:8[WJWG4_^4F#S2%%!%WIOT$W^`:=2[/_S%5W0DIE[`(]"B'X,_TX"T,Z$D
M$KBNEIP(N).YV1QA&!2W740N/(*38+A1"L$1C<C/PM_@%U2,IM+I_$!KKHF#
M30'^4U*&4:*5(F,A\)J-QF`)%$/JO9`0)\+9G"QA>0B?W\4I.$TE_)%MT73,
MN/,=D(6[)30\\9)#*1E'T\K&=BE.I?S>[-/2IM,G$$\2'`@EA`4^I5&0Q@M?
M9_KCZ+H7/[B`F>SWV;9Z<0"*ER_RB>+K*&-`3(=NZ$$)L<A7*@I)O?93#R/B
MQ0A;_L^/`?M7ZL\50#D=_%2SO5[3?,<OZU4"U;5(V*IEX3!$QD<TKZ0+I;>E
M9RYX!%8[RG5.+HSPYZEJUK$9VW7(/Y-(V6[D'AE41Q9``85&<0!@)/AL"7!Q
MAG&\Z%:Z';0=SH66+<@L2M=?6H.4E#$Z.L%W>!*\#0H/C`!U^+%.HZCHEI<1
M=-U%'X^YZ1GZ>RPX80@&@)]<D?!<;2TX3.08J[F`4XU2SF#/#P;SEONIN&!7
MF6:@?2<:`5082O-4-T&1ZKKB8&:!<C`8O7;;ZDF$+NAP@&?3LML$X-<4PN+Q
MA+:DY.W">O\%_P/*(O9^,.(=5[VV5%`")@,@BV-OA,L&#U)O,78)+F<IK)S_
M2VO#NS#Z7D2?%Z'*20$^OG)U01^XJX>@O3VVH*+#(W(S_P0#$;O2/P;M(W$N
M^;ZJD0R(!SD)*MQ)T1A'+H4.:..&&02M2KZ4^?YG"J@FKZ@"UC"7L]RP%:S:
MAG)$_7$*MFU)@;E1.HYS(>9H=&)L<[8P%.G2-W(?1JI+3TD`&T,,X?MA+)L`
M+4"HB?#`_]1K56Y`RV[B*=_K!9<DD"%6#6;043($<NN).^EVR6T!,.E"DS+E
M+KXI]8`CI5TJ@H*9]3(SJVSH!!R\9%/.YF9)LW:E:5C%6;2M2S9"3>'_XZ!;
MWL2E&<A@5N`MS)I,4R[`717!JD*J8@]L!6-0'!*?,DXJO98"?UB!/31##NMZ
MA]V9Z)LY5O^+>W^!8_[.DWO*-=YK_E[9@UURFN6P]9H>5PY1\J'S>95B>';[
M'@Z\38%">/R+DX3X<+.OU9WV&Y#EH).U/R]#N$N3+/M[N='`578CGCE3*Q"W
MZJ3,X0$J&VQ(&`9\B%XORE*L7#$0+$]&E$BZ7-?#P8#8;./+A^&MD-.8DH(M
M!`5!<I4+O=!Q*@]['L79^-%NCZ\F\'=Y4@![2NJ)1CH0S'<YR:T@":TWBZ'H
M>@V\!#QH";3!\M`C=\E,Z5,/\/KO^QKL4E'7`+A"!XV,6XJ.Q:]9\709-B`^
MN=Q`AR_&`#<P:!CK`PRA^^/I/K;:+G&EIME$^)FND@84?,$$X8MR@@%4$",V
M!C=TIN*27DQ#JCT.#!.(D>=0.[6[0%"O-!D*`@:0VY#&6?;*[Q?7%[BO6"5<
MBS'>(+PK\?(.!Q[CH7`PE>W?,GZQ!7:5(WW`KSMPZ<#OE@P;"JT9U-Q5L.-3
M&L!<9ICI^!:$E:<HA1_`&@!L6=[R5;5+I(/VW`#*,>JU2Q>S)+,@(YJUCX$+
MD,?U+;Y(*Z>="#JBPMDB-V6Z1C9R\9@#?3;M/L%R(H8XJI`91DK5('*#N.JT
M?S$R%W"UXRO$\H2,3F2X+)'EX/Y1Y+2["BQT3J7T(BI#BL+2-A7;_<ES4HK/
MHQRXPN=SC."0RO3!"'O4"!AC-=G6MI)BC>8X@[.4L>+&.Y4I'`+];KZHS_\+
MS.2MBF1FO%7R%*LL`Y5H10$`N:^4+1/E>:*T.\5P??'40#.(S@RD_WPGR.E%
M8:/3[1EX'Q**L1#?)1)F/D=0T#%=_K$H)QR#[Y3>@=^0<LXS]TCI%1D'5ZH!
M_+V8XM(`P2S.C-E8MQ2*(M]0[=GA#=@IZ=A""3JP>=6&S&+84)9Y:GG4PQ2D
M1X_.6LT&N4;(Z#3(@;,:8W<94"@FCZZB"VL6ZR,\)GT!T$]91IP\]9%2XWLP
M(5>9X9*;FIW>X*J`3I`Q:`]6Q!5R@X>XA(^$Z.\!8R4N5X>V-1SIT!@_M9)W
M<FWDW''50'51JTE`+J;U.)2L`&L,'LQX7&BSF?`?V4F55@O90;O%)A+.\M0!
M?C>E$&5VM"4U'ZQ#%ON7K30IF2*E](&"[ZO/4');R%.`I#PEJG38[O6.\-A+
MNT<%'^BIO!L3_B_[-Y?3,'+F"1Y+!J1E'5`38&R+WDS9SZ'XZCQ?;7N`2]6`
M/<S7JQO<[,I31Q`"#,<O#)N=C$E\95__&#@7"RDK^F^E_8-%R2'*'\F"S?$L
MS<[G@`@ZYI4DW6$L%BPZ_I:^[<IS.A@E^[:,`_W4D1M=1DH)=\P!AFDR1RE"
MDPSC=WY>-**KIXB.'T>=*^4=/Y-]%;.6:*<*J(_HO!4CRB-!J;WJ7/2#A[F!
M=#A`QQ=)GOF&TUOE-$U4G`^GJ<_\Y=:B1('TP"CLE-.L6_"61!&YN6)S=B\#
M9*??.-/,.LH(SYYYA;T@[;B)OX%:U:)>5LD@:D-5R*H`=0F[473.2`'JG5*V
M9&XJ=%(DG7EK=8<<(;-%@`$CPS$W@';J(^E52N>%MF1Z,A8%Z3&$4D7W*%M/
M=3HP\B*D0`SI$%W0513P2[6>Y(=G"S$JQ?)U+^)A&$7RMVK(;+84446S37.(
MI3VDG82C4L/12`%=E2OV)=])V[TLH[MD"!WE+604SM((DP"S$'[VATO-'AFN
M_^IS.A_Y)*(QNE/2Q`+`%B!"DB$;18/34TEF`=MGUT(PV;&\_7J=15AW0\AV
MK>[+;?*O!07'OXD9N`+PVI/UQE_.,U]OGW9IC%;8GE6FJIBXOFD!VD8-Z^UZ
MN6&]6A`P'^"<3<F'6H;'1M[#.@YOYSU4^`;K^R)L7$RSTR735<@KME9*99$E
MS'B,IU#?P8-W88./^^6(!$+N\6*U)'2F\]`^Z$\#_<TB7?LC(/^4^J-JO5TH
M62.[5>R@O?$%3$L]N1=[=JM:MT'CY^('BP6Q#[K6K%T:[YENE'KPC6P'1/F:
M7L\KJTW[/Q?:3'<K[_K:,\8+,-X#)V^PDJQ>^R0+R-XO%Y!M67N\HA7'@=U)
M^'0B\,`[;9Y5&JKN"]B#A"S<1[`;J=F?RMDRSJ`H^8RN^C;2=?*BMM!&XK0M
MZ#[O-#T,_6&W?K[W(H>7HC\>T`3_A0JX$08C#`V[H@&<$08C#*<I#,8R&&$P
MPF`LPY;[H.4IKVRA<W^H::.]TPI@K?KPH<!J]2F*OKUY2[S='^]\7L7S:.WQ
M[#ISJ1O<\4BLP8;!AL&&P8;!AL'&GKS`-4V5%W9/]]Q2<:_/M^*VZH<?<:Y+
MZ-SKZ=A&0RX=W"QT9/A4+)UGY[(N8'GI=N%%'NAF=ALAVIOL;W+#:06]][?"
MMIM[I-CN6!V[M<%]%\>OJPRJ3P?57:O5;V]PAY1!M4'UT:"Z/;#ZC:[1U0;5
M+PG5'=OJ-/L7O1-`]38W;IF]TL[V2E?88PL;=?'9'/9&OP?8DI-=8Y_7BN"Z
MV2/M6T,]CO!G5%5-R^YM<C?@\6LJ@^[30W?7OJA(]##0-M`^>FAWK'[+*&Z#
M[I>);KO3N^B>`+8?==A4NIO4[*H>OZOZ)F3C?+JPXY-P/0=KB79P]'2R.9:;
MZ+ZCF]1F>G$?[FSWX>[LL2=G&BDR4K2;:;4:#W>;C109*3JH23V;%#7MCA$C
M(T9&C(PQ>H:SP\)U]L?:A^`^TH],4\!4F!NF0U\<A*K8.%U@J\D\FXJP>U:O
ML].=WSKH'9::,")D1.CQR9/M7N?A$64C0D:$3ER$.AVKW^GOTEDU(F1$Z+1$
MR+9Z=O>B=:HB]*##3M-Q88-E4+^HZ+CP6QBKZ^*R^U]>4O<%DVYQ!!P_,#5D
M(&T@;2!]X`PVD#:0-I`VD'Y)D#:U<J:OR+&)T!Z5UK%5]?;LWL7@R=14>54-
MY$X2<DVKTVF>1"&$`?7)@+IEM?L-4Y=I0/V20#VP6HWFPX]VC@C4IC^BZ?EA
M5-0Q!UW.FM9@\(B$P@-05J^-X36H7D)UJ]$^ZLV20;5!]2*J!]:@TSOJ5G(&
MU0;5BZCN6@.[=]%\N:@V9STOJX.'45$GIZ+Z]D7_Y2HH@^D3Q'2K:3_A$:;!
MM,'T_C%M6_UVSP2S#*I?&*H;G>/N(/_0#9+I?+C_?=.68G051K,0-E6"A:.1
MYXC';*16K^1+*:(T?7.>H);RK&VUFXU=UE(>1N^<];Z`$2`C0+L0H([5[0X>
MOALT`G1T6#,"M%L7O6<UVH.'^^B'*D&F":(1I:<6I99E]^V+]DL3I?T=$IH&
MB(<D4*9OSE[50\]J]7>ZUSN,OCD/=E6-Y!C)V723UVNW'GZ,;23'2,Z)2DZS
M8[5Z[5VZI$9TC.B<A.C8MM7O[/1VB*,0G8-N;[A;=JA?5/0;/)726$<$B8A6
M@[(%LX#ECV<<_M@\W-#=`28.[!1">SUK-PAZP0AZ?MI,+M41<-Q`VD#:0'J?
MDWC`*<E&YT.FD_A6GOU-F'"?\3@6R;8=Q$_VF'@'/MZ]:)+C'S*>:-!K,4O$
M="BB>JW5L%BS85>DZV^"H&,Y]WVR%(K#VMX8T=A3OO:2Y_).."10K&63/%7$
MVHQP/52XCM1M.VQ'>4LT[2\\_?A%,(+Q_)0;P3C`13AVP3"M#4V+]L.4+-.%
M=2.*[6;;:K0?<?1\1,K*P/J$8-VQVIW^43<Y,`<8A^E^F@,,`VD#Z8/G^(%!
MVK0W-"W@CT5TC+):)KW9M]JP3WIP=OL1J2H#[].#MVW9C>/N=&A\2X/G$_4M
M#:0-I%\8I,W!DND'?T328_15Q8[)ZK8;YF#)H/M%HKMM#=J#H[[NP'B7!L\G
MZET:2!M(OS!([Z`SGND-;WK#'TLQC&DGNM/H?\MJ]-LOKS>\:<QK).F))<FV
M.G;[Y36)-Y4RQ^AWFTH9(QA&,(Q@'+)@[.I:LV-MZFX\S#U-ZG%-0@_.L>SV
MK29XEN;R%"-!1H(>)$'MEM5H&@DR+JAQ08T+:@3#"(81C&WV9K\D?.B+PL_E
MDZG*G_[V2QJ?CSF?_7HMQE,1)-_$+(P2+QB_\V+'#^,T$C?B1_(6#_[^4:\Q
M]C?]`CS)Y_A*_&5T+1QXT'TGA@ES@%AXXYL8_?V5"/T_OK[O-OO=<_@_V[8;
MY_^GT;";?US?O/NCV6O]@8WS&H-6XX_&*Y8&GGS+B\-VT^[]\?OUNU?,%8XW
MY7[\]U>-5_^`9]N#9D[T"AK*A'Z-Q$A$\*?K!":1S>;!A/X#&5CB9N'P='TK
MMI4M.BO.3O],X\0;S;>`6;'-Y1*V%J!X0U#\#%#\AE#<5.W0!-Z]O_KR[?+F
MXQ>0I#1P181_HQ$^AXE@_4S3`.-:(&9Z#1@MPC*J5Q^IWL/<159F?!I&[)>M
M1]M^J5H7K2-?K*LPN!4@[Z`X,+78%6**2H1=B\B#S[UGO9]?PMJMRU'8?NFV
M6J<O0;WV.;R5_0WM@>QO:+%D(MA5.)WQ8(X;,1>&LSK]I@6JIL#T+R/X!RCD
M>@V+8V-46[$7HXIFX8B=>:]9&`@63W@DV%DN=%=O"NN&?\S_].[-ZWH-WBTN
M\K4(O#!B!3PLKKO%9CQ"TY@*]E/CHF'7:S.8#GW80E(*T[&`+B",LSL>11QX
MF81LED;.A,>"-2Z:'7R>UVN2:O@WO#<-`_DA=E:>(D^8%\<I#QS!>,#X>!R)
ML4S/J-=LJ]5L6NU^5W\JMAAW<3V!;OCJP@O,MMJ=IC4`"GA,`V2=7)ENY/KZ
M#;SEX@Q@"CC1CB2755);KYTM?:/;MMIV7SX?O[Y@[[DSJ5A1JG8&NF/@9.0Y
M\!>8*K!VT.X0!0GU)QY'81S3SX%(V"P*'2'<F$7"$=XMO#.<(^<Q;44BZ4X`
MD3\!E!H-^@^]^E/?ZO>Z5@]^!6_&,^%@_8`_OS`"O(D`?P0!1GB+6_`U"`S`
M:-_[3^JY//'"P&(N0#3T4_R!@1S=>8&+*YS.E&1DZV,QX<'/($GP>)#P:([/
M>T'VH]0+$]`'(HJSMQ>$&0`!JPS$>(DO@:[P`)*8)EH:96OK10H8O^6>3VI^
M!)\&RI/(&TK282!"K?H\R'R$:@$AY`4(4Z1"H"22;,W+;RO&E#Z;:3AX@:@H
MS`Q_'1(S'!]>0D;$4B?!'P5P-P'%B&Z=E\`O+?D^GX:I7(2?[`N`=Z:$V,Q/
M@2^^S[CC1"F*!K`B#6;<<^LUP)[GBL"-CQGRCW4XM@+].\TQ,!8!+>4R"(G1
MJ+8X4QES:$QP27@0I%,"#CP)R.%S0ASHS63BSX$L^'TD>`3KD6]VLG_=%(#C
MH;(#,$0$]'HM(C>%V;\T>QIC2X2ISYBUWG"M/TE^Y6)"*P?"'SC>#(R0WF:Q
M(5@Y$/2`?>)@SEE3-FNV\?%Z#7=47@"`4'BQ!\F$1!GM'RT)_AI6?90(U)'R
M9S;R`NX31/`;S)4#?.)S&)J&;UVPKYH`!SX_!!QQ5R"('![#)R(+-&T("BH(
M@4N>P[4R*ZA2"Q^7)EG9<$*7(VUY3"X.:K@0&>`R!]P@CA\(09/C<%+EQC!T
M//+@`5!6!566(1`\"B4;X!&0FKSC6*J'E!3&0LV;3$!P]*Q!9KS0O6`?1]+4
M+'P7)I9_N^PZ3@$:P(_O(E\EU-7(F0+?[B8>+`(.I5E'4X95`(598*CB$#T.
MRA:>'\$\0&*3B+LHPA?8KH61PZ+%3[^CAG*X[Z0^J`-@QA`\/A>7<]#\.3-+
MX&+R<?:V']X)F$&'N7P>YU[JX`V9R"DHCSN!<2?TC]2;]/7,PC0;1!S:6QQ"
MV2RU^HHG@&P@R))^54XRSL\5/BP0*@^8/@P4.!-!0/>"`,=$5>7>HOM)7C/-
M8#;S`66HT#+4PO"5JNR2Z"RYF?4:RDQY%2?<)3<7R&A9[6[3ZG0&*^$*GC,M
M'I"FOP_/:-V:F;JR$*,`.'[JTEXBTZAJ:FX&'J,S-]29-T6?:@K:"KRC<^`B
M+2MX87'"I1,XY#YM7E88JWH-EG&4@NR0(XC;K`1V'P$N5R2D],*K0<A\`4X2
M:(T`7!_MWL,N"\!MVYU,O.`_0=7WT?-W4P=_`[)AVXV?&2GBY;TI0).4,VI3
M23>JG_SKR<2+P#4C82/%#[KC/RG9_QF&#S&21PZ?([>3J-5*8'<F81@#0W%;
M*)EF2:U7Q3;2;T.4-,_-5+Z68WA]ZH&C@?P?DI]1>"B,UBA\@_4-L?X[65>]
M#;>JG2[:>3J%"`+ZA0ACL&-HX.6?8C3-F?GXJ0D^?*,MC<K2`^#ZQ>GP3]BM
MDN>G;?*2/9`[?BDJZ`A($71@YR`W*[C1QTTO^@9R$Q<7M*&RA)G:M-0O8E#R
M\"`2/AV"CZ*L,2`/-ENX8<E<C<7-3M&*Q0LZF_92(W9&$J9G)'XX8"!PI-<E
M02&+H#9&O@^J@O97KO0,P"_+X5V$-3Y?^AF5_2WW<=XP!'KKDK_YWJDHW!4+
M03H%Z1R-8#&`):'TWW"S2=$:EUH2A,&F)I!E%K`"%V@+AT($I4C.3]N=LU2A
MV+[HEI,+C/QO*/^7`-]2C.LG<%!4?$E!/XM,C:)PNJ`@\ACF'0?_S.>.]+9$
M[$3A'3G#'%3X#V\*JAS&:UYTV!PWAQBE4Q&`N?*9<Z-;EK)P")Q0TA@)7S;(
M4$[@HJJRI-GR8J4$)#4R%"&C%SM'1OE$[Z7@@GP@!WC*'?`D,&;K9+HP"R\O
M!))_94XZ3>4"%>(R%@`@`"\ZC.;HJ(CI3$;6P.^Y#2D63*?/<NUPCR%#6,.Y
M]!RR\)KR;.7N"CP57.,XB5+RDL&-2&#_2;8C9E/QUU\<?'P@0T:;I!G2RG?H
MC=+(H8=IF\H]'?]6,T1MYKK"+:FP<%:T$WH>V:\SZ9AE7(EE'#GV`D<LJM_B
M:-I85(R*IA=X*6`1IC`?4ICHL^%NS`=!@ET!C>"#V^7/I7S(IXHK50HSDG]4
MX@=8O3!R5W$#>*C84:1_!1>`^7X8C,^17MB`16"=)!Q\CP\]G^)]^%"E,8(E
MQ;F-O!_"S1Q!4`X.KL32Q^B<%]A&K@0ZE^B,:+\1P`ICRQUA(G>L602$`EI*
MYRRN5IDQW(_#C#L2CLM@T><3."U>.7NF)P^05G,/4C*8,(0^2=$;5R!0_!"1
MX\4+FW']'5)O&9\DP:M$$@\A,)3K8&BU<*:P/(N<VI@5UDH.7X&)!;ZQ,SS$
M@#]F)SI.&"=R.OK[\6MK0;H*'Y72KYE1X!TYG[`OCT*P(K!R&,S:@<O0L=J]
MCM5ME-OD6#L9N]>'G?["R-(P[<+7:7:MP3+9Q<,?2YZ!53AF:V.R&.K!P7"W
M![LY'HQ%3.&3>_5D"3TTT8J%1+>`1QAYB<G%S`PSJ,=P*MB9^#$302P`)8"E
MBWH-Z=+8D=YU&5MJ.["(1!6MH@,%V*_\17HM"M/QI!1Z9&E,.V:<!CF_DD80
M70Q:307XP+@!1E"J\!=\QX?GA*O)SYY6E%^P#TJKH.V181L05]`Y*(_57O*R
M$N:8&@.V+!:*\57B6LEY/'G9N:#85GO07X*SY,P2J54"O!^JVLLT58(;5D0J
M;L"`T&O"MET25%7EB6Z\),"IXNQWLMVQ[$[#:AW8DC2QF'UI2>[WMI?3U58D
M=94SOS`7K"*/S61^[3'SJ[>0^?66!]_9;R$/P'3C`S$>29#GCC#\!*IWS,<8
M!%6_/L;THA>9&H8+5Z_1RAWCFCS[UOAC,>E+)GR]C^:@5(>X&R$#/D39\$,>
M5&G:ED5W?S4:^9;QZN/-QRLI41_1IY`A2=C-4"R1@YV)/$ZI?)G+09L8V@K#
M;D#&0Q.P+MV+1O=GY2S1@2L8`4VL/)TRH;$MUEDZC.@7;+[$+%]A\-QPB3&M
M#'=TL*"TQGAH@5U=%Y>75:YNO98O;^^BT5RUO$L.OEGGC=?Y7ZG_D(6VK4ZW
M65AHE.4]4+@XY$.LQN4X\IS43])H$86KC<!*?,(.L5+]E,&W8RYT+SK=$GD_
M2X\WEP0EK<UC47$OU%4\;I_OV?41*J!Z;8+1Q%UO'%M6IV<O;=)HDQJ0"Z^S
M^8K']2MC2<KM+Z4!JL`S*DW,-0KE0:=4HO(3\`3.L'3&`R8.=GQ>$D:Q'E4/
MB&>8F5G$C"6R?FF<<M_'[`Q0:$*G.W"UR<=D5^^'2DS+\J\P?]<5E#\DB5J8
M,IB!H9AP?X3311*MPE3TX8,3^AAACS#K)DXQ\2J6*0FNF(6QA]'9/"&KO'ZM
MQL_LG'4:/ZN\"\F+H5#901;#2`6\,,-3=@P=W`4R8HNT7+!O`A-R*?Q$'YSY
MPAW+XXZ<*`QKRW!'(3>E/$]0V<MK24Q])QSU6UMF,L$?95*N2KG??1RCW>PO
MP5%J]9V@O=6WEZ)$"['2@L/$+C=BC?3Y)9>CA44ILNOQ$VB7*?]9AE9WP)C.
M0O_LGY<"R"JF588.N48:K?I\)A)3<)5<E+_*E[PB/BD:"Y`F\.KPJR\E&K0(
M'00J#^P.`PM*EO8)PK;5[S7PS'L_((3A&SWXS^)I0%)5H;(2:R^EM./Y\OC0
MGF(^,J5$Z@-7+XC3B-3D+/0]QU/G;_AL(!V9^[7F\HY@!\+9QVJ>!3"6SW7C
MG%XZGXNUS&DKI1-&L[QA4AS*6,*\\Z0@+#'#A(SC2(MX@0[SRPB4/KNL8R7F
M%R<)<[T)6I=]O;K1N=><1(0\KC#"W"2*TLA$IS,Z9"N66*(/6JJK9+)B($`E
M'`9R8XQ%FS!*W^ZC^<CK(-&=QBS_<.H%F,*:4GDG9IMC/J"J?QRFGN^J+/1+
MWQ>!RWWP.'%6_Q)1+.;UVAF%$TJ%G^0<SLN4T2X<9YK&0B<A\"$VNL:,&]1G
M,>@M3++T?9G,%=/)YX@[E),@C_@IQN\5S';`FJT!Y0`*)Y4Y'$MJ!?1?7DHB
M:\FDIVZQK#Z`8QH_JICL0%86<<3.1+BI+V11)NHA*A<IYKUCR5=A)T+5E+IN
MA4K"5#E8MC^@;$8W5:4,*BRAM2$&3V$HWZ?A8:H_P?+WNEWM9:B,L3@?KI3F
M2C$Y\G$Z%XW&SV_(=2D'['`B>1U4]JVXH(=QKY1GOA;R6Y%5&L#2[O<NV)=`
MKJXL<:`$6*J!@$U&Y"4)3%9F<LN="H((WIZH%!.5)0-?<3&K-9(I2%A:B$04
M=W@Y6[.,\B0<"SJ<ER&@Q87(UQE#+U2-D.,&4][+H(IE"P?*Z2HDZV#R$HZ\
M6-0(8"YF\7)`1H1G\DI5%LK6I#S(:C1`]3C(H!,HKW'!0&,ZNT\YQS+5&%BH
MCH1=['$1B^B6$E6%7\AC+$Q&VM"8=HNEY6KV,/D7TW(P@RU+M=&+4K6ZY)\$
MFD4Y*+1W4J+("75*=%9`3'_'J0`[QY27C3DX=\"EB7)U$+;X8H#GOY3'B[EQ
M'`]-P1^(Q=0[QW(^7`DYQT#\2/036?4+Y4HYX$?Y'OE*"(EZ;?D+,<YCT7NU
M+T@WW4F72JI1/1+`&-%%^^A\$,KN$\M4P*K^*P4UD9_5DU=3"-5F4Z7*K`AX
MGV`]6A::56M!6:FH"RDR$.-.3J:'E(:7#*FJ6[A;#,WLYOC<ZK6ZEKWA1@$3
MQTAK[6(;;C>77$XZ=]`RK=)=DCOAW^H4"E).V6)WY4ZEL)>&1:_7"H:-8S0(
M<'8NPQJH!3S7HRII)?""=`II\U"9:T`991"#_@A)MTH%H#,;BA7#;.KY/B4'
MRK]EG\;<1Z4F"&TW[RC\#:;VXK*X^;_!C%**\\/_CE...1-"RC&25Z^]0X9Y
M=*_YV?K9!.!B?(?_"M`B?Q;A-=G@#QS(G&-N'LJRQ7[[[>HU'I]'J&N#@O5G
M5PBUB%W&<0A"1GN14A.(SY__=759=@2*J:18:Q2H$D9Z5!\:*3T#H`])L2ZI
M"8`[]0FJDN0;JNJ3+*)(D]UL:_U)U0<R=5-7#'=_SM(LI0;OMC/TZ*$HFS%+
M^I7+G4V"!+1<]I=;7-CVJ.J_RL0?^H*VW:,PC32A*+[9*&%0"@')I+,JH5\5
M!25'XO$R.&@-JN.R.Y/R7L=J;BWD6Z?OK,C,*:?O?!;)%8\G7U5)[MOY[^`K
M?@R^S*C6)!A?8J1#I@KOL^G4N=WK-)OMEIV3OSEE][6BR@KL/U)FXS4F(*,=
M^SB=<6>/C;0^?O[PZA^=1K_1:ZQ*J+J?M,5)R<*/#V`_/ZK4RR_1->C4+Z/W
MLHG#/I>G:=O=7K??+$YE'4'E"63/C&CNEX'[;Y5#_2&,KJ5C%7^)KGSN3?<+
MM;[=;??M=CZ5K4A;F!6MW&]A3'RXDJ7Y@$T%4MBPO16@1X5\[H;_$/$G+PBQ
MTN:C4GOPN?(HDGN?*.GU8W`K=,W=7L6O"8L+;_0+7'FZJ2WR5+[]7B;R[G7>
M+;O;M^W2K$L?7TQUE-*;35D]]58$8N3MMRO?>;>'*U34[O<24Z;\&IPBV&X!
ML]]38>91I6EN>;G9\\<1:7=JMQ>2-/,U8'(1CC&XN-NE>E3FS;:K(OW)2]BX
M./,$K_6.QB(ZQC5H]IZ]T5X6/^DISWLI/GH%7B?M7/A"]-;")6"7#IB"F"JL
M\W.ACQ8#;791[K`'8N.$"R-P[.T*.SZP/U,L`2GL_V10*]\`JNU>U<CJ3\6Q
MF:Y^+4UEL1*6:)@B?MSEB2\"K-P14(;P`K6SUL]*ZG!>[X3/[S@E-\@+$HE!
M9U4?6*`'8]H.UDAD<2'9J$)$T[P[V27VRZ$P#M+PU9>9=))2BT([KMI=41:>
MW2HL;YDI"]-DV<B+2P6[EW&^"MF,ZS5:6'EVO8"(K.CCXT?:EE<`HE[[^+'T
MI54U\1PWIZF?M6O#('HZG7+=2TVRI3R9G$Q9!GEW;\2D7E.SJR:A,!+6@]P*
M/YS1"L"V=@ST8`P#(PY\-J<F"#3Q4>C(DJ@0P\KPCJRHE8X@A0!YY'KA+8^Q
M"1#UE\,RDXM\*N6Z;5]PW+N';HI['MQ.RS#VY:=OYV#A+:2.8CX4XZW7OM+A
M21-H3-VL)CRG@:*Z3HHQV'E(I,"^W@M&/'(48$%_O+Y@_Y8Y0WG.;"2<"%Q`
MRC:(\"58<%G4MG"@(U,Z?)X&SD0N$U"HJ7)`=7D.QHYI#'5D$%/IEY.H#F84
M.X%)1;!N%%B')9?=M>8J^.[BP#(8\I\4'J8:4$JV.9JLQ6<V!5_3"+=.,H*U
MJ&T636VN(JSB44/67:,@AJ6^&DI!R+^HXMK+I>):.G;`>LEB,7=6#HP!-D>>
MQZN6A_#U7/OJ<TF*81<"3MX4S(LG3RM*D:^\2A%;C2].N%Y3,UXR#N^S]Y"=
M"ZJ2JFL!G;=>E!2J>Q?9Z*""IV,-"C+*5C`Z5DM90)2Y4VA72<V/*$BKNTO\
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M<^7*".,1!6TD\WE*&]`U*LO2C5V7",G:5RB'$T\\,55%:VS5/H^Z:H.:%3$H
M[JGG"W"$X0=VYF(.C#?$O\,V\NZUK&QP9!9'/!&NT99&6[Y$;6G49<:-O/54
MX;Z/'":VU>]C6=DZO5FOJ<Y6LN`*4[0PM^<6G,2SWFM*$M4Y'S+U<JD15KWV
MDWW1[G8+#2Z7]KOZ(+6<''-&66;_SGIU80YDE-^+@]$@W1C<BYQTBOMQ1[>E
MPN;1\4CVZZ)+7?+X0:5]4*J6$C:S.:@->T9"UJ>H4$24@O+VLZ1\6=<F.P04
M0MOR'A.C=8W6?7E:]]8H7<T,;)9&H<$\?5QG+S.[D74%QYS?F/M2ZZZ.Q%-I
M:3D4KR/QU).<(HSY+3ANO@F7[0%U\KN,73MY1PO\-GU:#O8:KY915RW(_@"%
ML7-U&:=#'U1Z@"4+V8%`4N[`CPQ@A?FKYG1#D?.A)?E`.EF/2+4-0JONC!@=
M9T"B<CJT<[QPXP[9)M>+,$8!%)R'H_,9(`98K<\!L"-8?JXB&])A@O,L$K=>
MF,94)N'1;1*1\*;#-(I5]%3V*H^I`;5J'`>TEOIC8H1$)$"//#:C-%>T69X\
MGY$7`3F4&T2+,H/5P9J&8(2'*?(M^#"UU[M#VP,&&_-AJ>2R$B.%W5`:RRQ+
M'V,[*;74E/FS%@:*LU;S.`V]0MD='[(5`SR&9<[2F*GL;N3/A,,FB_H_(XO3
MF>S.B^4"%<4N[W'L+S!5?=/%PM';DYN_@U$6E8D*.VC[<MCG/MBF9:OPGY7Y
MH!.\B4T5Z&<)YEF3:APT)>VB1M2_ITWTF6QB@,<9GJI963K#1QV;N8CT&FC!
M+(ZZUEO$HTY2CRALB[=VJ1:X4ZROSJ9*AU3ZDIJS#8.IJB>[#L/F]345I6W4
MHCYPQ33(;]V1^J8X#7FFMEE8MI`'4'UN;DX_MZAI7A/C*>&F<$18PLUB($B'
M?U@A^B-C/1,/X(DE_S$69""<XIT?YIW6-J)_J-N(UK%YSJC9$`1Q:?:]K8*2
MJ[81_6-C1A4@O@3B'._U<;/^',OJX\RV6MVVU>QT]=VFBQJ%0AEG_+6^PVPZ
M\X5.9UJ1(H-F;86ON7HK0A>T#E_GK9[E!:T)WI"6X.!8;8>%GF27**>,^_,8
M>X`)L*A@.ZE.0UVIQIU"RA4&D:8\PHPG32CFX\Q"CQ*<LLLM*F>CBX0KQU!#
MR#O'=+1<[7NJAR,6@#(.T3\>3K&6ERK-,J.I-/B'=Y>8CD6)<1UKLP:.)O)C
M5/9!:RFCLG>@LA?T<^[E<W8SGPGVEKVG9,,LK_*7KY$XE_]NL:D0I"8S;QT5
MS1U>X8GM*)0NQET/=["(5;4:PQNZ(IE)J1(:\379Q"P27&5MTC?JM9;14T9/
M&3WUDO44;49E_S>9-Z[4%MM4:\F[??/Z<%<><JG7Y>]4#K7VIV;>+36_4)JL
MX(CE>>-*@1V-`CKB4,14Y0<7$U,*3C`?AGB%CUKU++:ETN6K3RM4U$+?#J?#
M%?2).!$Z4I<?%.#E4O])<1\AKY+25]G'^H8H:;JJOS;&4']`N89NZ-!E8O$#
MXUHF@7]SW!3W=]F9D%QQ/`&9J21_O0]:S?2\&\NM<'6N*=4/75)G&WA#NCK8
MO:$0_B+7*@L08[N?8HN>]JH2,_U&X0N8>4^?6$C(PE@J[1E=V2M[.51-UXO=
M852M.`$N4[*`]&E.>CER5ZA;,*#;''12+\V*,8&E0H>BQJ`"(%58"[8)>[#0
M$5\:T?58TO%5L1"A&ZS@T:3,I\,&DTFL.FXE<^I^E2FG%<@N'E]D-48\23AV
M2R.E67GZ\"^,0&`_K!_87$;U=`"//Z2VH6FLR^SP7-?SL6(QTV?7N=3AG]__
MD+=^T1$%2*EJJ9,W/K%EKQ^[XLAN'14+`E+(ABD*]%`D=WA&J$4-J9*>!/P5
MI$(>FMSH\Q8:%/]3K]U$>*-T=F%DX09!NGSTGWXXQ/=5.<^G+_KK&8/)%X&U
M"@O,)WYA@>+['Q-OZ"6L?6'KQ:NZK[1>NU)]Y[[)6]2`>Q^0@O[Y_U;+L%[-
MX`OU&KRQW.&G=$*UC)5%<NLUNY$3K`G!VS2/KZ/L,Q^QKAMR;2WX):R52QA7
MR]%L-`:R(A97EG[Z'`;GOU]<7\"^'7Z_O#"'OTI5O4"?<)DN$[FCJ+#4VA>P
M\B+`W*1F+[@IQIASBXR=!!?6K5S@3>NF&N*@1A!!K&JH:6F7A#M;]84^GB&>
MR<JKVY+2%:$R)E_R6$H'R#Q-)F%$O;5Q^Y/Y5J3,"(1D>[K888H:GJH3Z3-U
M@8<EH]]VS^IU2@\`2<V6_J6N!WHM-:NF1'Z$,AVIT)!*E:EI=P78)4LNV%?@
M.19,"H"$I^X-T%GXA71(:@P>%'ZA;M3%<G6\6%C57>I[W7'-T',B`R\O%<[2
M8)A\1\JD1$A!^J@Y9ACC)7XS/YQ3]A!5;?L)#[)K3#$=*(S*)_ED]9,X+\]&
MVW(W"2V]80UGL#\MU'T7$2*-;)*(HA]<MNQO0RXWU._TYRV9O(K;$T8I#2I3
M`%T7N;O"GZH&PSX%#K9_K3R`!QN;%TW3JJ*/D&=1Z'L%73F/17BN1*$$X)+8
MX&%&0=]1,81;)49RB89SULKPFP%7W;M#+;/I+S#SCOZA.L_@AGK6X_$3CHT%
M$$JZ^"WW\BYT%>27Z26J</.1P=X+<">*6519_*/B.O,9OH>I&EAN3]#)#MXQ
MR4)@,I2JS<>+LU,\Q$IEC3R"L)!T1GUS"=NZ/3C/VI-EY;>_!Y3S0NY8G/M$
ME:25=_'93;\A>('(%A=OM$P\:B*.-_T"Z1W[Y[R7'LZ?[JJH8OM]$J_3RZU,
MOC<5Y!7K`B-D$JT;J*I$P+*NKY1>*LGF(_"DJ/&B>I-.%55C+NH0"(/IA2XS
M&7FO<VLR?:(+IS.5LH8*=9MG1H5UCU)AU3K%DFQXG*)8$T);:@"XLNO34F^Y
M6P\W%^"1O@O383)*_4N9B+7?KF.=1J/9+K646TG'4M/"O+'8GANC]9O]7M_N
ME/H2YA]?W:4/]ZJQOH9SGR3"LYU&U^Y6]^8KDK'`Q#`(=2]%.:&GZ+AV;K?;
MW>Y@4.#G*CK*Y'X3L>"1,[D,W'>YXGT*DGL](+A?:!)W+RD+C=?R]`@%99CE
M5W5AQ)ZZL#W!]NXX6[(UESJR3:>J351AG5B^4.`BJZ4ZQLW?@6_1Y9`W__,;
MC.DE0)2CUAJ\3T_VGL>^PD%"IK2<Y$@-A67A*WA.:-S3@(.53S!NA)6YL&PR
MOO,AZZJ<1<&*R>_@V\RX['1=.&'0?;HR(.BV_%C:,18!7I^$#?/!+L^2/+^H
MY'K0%O%R*F"WQ,L-K"H&J/S20NLP\H2I1].TT"O:"S"D)KT-:GFC8XEXZ4$D
M/6O:/,HP%BH3V5$G2CP'+)/=0$Y_$^/4EX-<G_]?[<J4PY'@4%;$(]=2=4'R
M%*$'YL_E55USYH:J`SU=\U!L![0XGU$8)D'Q0AV@`_8?F_(P[Y>/8>&,0&H/
MI=!`U]$M.'(`8CY6X;QD`6J;`*R\Z=!.9:$WG2?R&[4BD:/7*O$D0%;(VSPB
M7(N(/E_HZY%M$X"00*"7B/H,"T.EZ+`1]R*YA<S:["V<\&7D9V[IRO;::L-"
M59+@.L=ZYQ%F+6$S]YEN8!MA=G+6/2QK\:]H$Z[L/)[-G2:3\34G+"X(+F7%
M8/0C3'U7Y[I4E/-//-B^1'0673UJ$0&+RZ4IQKI//#/`DJ6JF\!HLZ.BA7V]
M<*0-L,6YBG,M1)Y!`/^W_D"]1I6E*SY0N77+NE\SO0;96/*^120G`/U:NG%1
M3Z)J32.ZL*I>T_#QZ,(4ERH-;K-=E?X:;?:G?$YU6KK=VM)TBBWK<]JSWO6[
MMI]/=;_5D]ZB]'#[^;LL<'X/Y.&=&(OU`2OB,-(29N&&:D&1Y2FHH3U]A\,:
M(TF%0JNM)"L82:7@XX+VI5.V*?^.QRQJ-OJ"F72J&KT1)#D%?A144>#0(*A:
M/0P1J@MM\-W%ZCXW:Y%/E7QYGDS^#L:2"B\E61EFL:ODO9KK`JQG/@,\:[Z?
M8O@=;-E31:(N3:S77!E^RM\BOJMK58N&%N-/J'ZTX#JH,.%];S3*KV&A**LF
MRYP\/40L][*9J1ZT).L;?0C#R("^7*J_>?'W#?3!!ZG0\U]DM@7L1&9<5EL5
M=)KPA2G_$T:*4TP/HCR/K`*X=&?/7J\J;PY*TU47E>_C0QO<X[ITVW+6P4,*
M/;^CJR$%UB54GPQ<KG#.I)\J+Z-2*CE>N@JZ<E50D6B/;!]\L=N+"Z"49IG8
M[-8R=<M+A3HZ0I?A"373!WW==)4CN%)6X;^3NU!B`O<G&A35DLKLWL_*X_VY
MG+=@D9E=CV^FX7T/NK7K6*]ESO9]@-'@UM,H*IP['N>CV_VL4T/U4,8SW>A4
MOWS?VAZ^T&]4J(QE;.4^$E5[11[F")!KHXK:E'-(]UF#!^4Y>"\9WCW/P"6=
M</#ZP(7R:,>+H/@NYO+8#L,08]A38[*SNM4W*Y237\M/`^7-F@@^!2VZS%!3
M@'87N1!G)W+E*91/%?-K0"^QZ!L3L^FP#=UJEQQPV3%C2I\`QS5*9^J&OM(X
M=!>HHE9ZU=)-+'``[R`MLH#\0QD8XYF,,D_>DA3J`,G"YC-;%T4PQH&0)/(V
MD,FQ.@?#"\1RALAOR;'1WD7?==^41PC@3H7F^>7V"6W1?CZE'KK\[>,_/__*
MEK^WCY84KNO)EHW4,Z:7->:!;8X;I6,ING@L.X$M6ED0`:J"+D*%/1(\"D(;
M)UF+F.Q&<AG^(.GSPSMUYHT-T?)2"505ZF.5;TOP4]:#*-Q(4,R$S8=8)Y69
M1&8QN2>5H)7>S3WR<]]/Q^IZ/3Q6@[=@!1BIW"1,4WB8D$SA!9UHK]+DI%U6
MZ*1X1DS]AY26E;=*9!4]YQX(B_P7M0X:XM&+#,OJ8"CV4!)W,CO&4P3,5<A!
M%H&K<P=,EE&PSI_#1#KLQB3PDDB8]U_DL=UR/T6+/5.QPC#K^%>OH16CS"J9
MN19GUU:X`MCMHM>IBYSBB?!'(*DC`9-(T19K:T+F#K81F)<VC$.P+`XE>E,W
M)^#-^12\6WEY<L;2E1E*FA.%2ZGQ9M_ORJJAE5/]7$+*O*',+?(*X*_8#89"
M1GCS+BD`DN8IR"I&RF!6/MZ/BVQ1>2:4[H4WJV%)/IZ24)3;"<<!Y7/QS.]1
M39VD"J(/49FH/NUPJ]=1JL.,LM)"8K3-%7B)`VX<B%H<72X7@$EP*KO7WRH#
M,,.<8D0&NB,.+#VI7UT0;[JTGDJLL@*^O*I8MH@+TQC0$K]>U_VELL1VX_L:
MD)MJ]@Y=$%,L@-VF0K?7.90"W6&8).$T(ZS;S0G[>OGNW<?/_SQ_^^7FYLNG
M7UES]F,W'LLC2W@5Y91]]VK51.SU\WC>63@A`@,(;[["2Y4B/OO[*_F_J^=4
M0,W;+]_>O?^6S6GH<^<[SHQ1Y+WL;BYA=;_>[=+G=LSD+&I3K^EXWSJI7^#]
MIOR^%T/E2>_JKC\C&T8V'L'DY6"A$0WY0]'\16PX!HR%T=]?_;]75Q\^7%V]
M*C%A`^.X`RQD?'D*X"U\;-?+L/LAZ[5OA?BX:CTK0]E;Y1\^5$,^OQ9<+WI/
MM\#UVD\/IK==3;!<@;U1W++ZK<%%?RW5VRN\0]-M!M0G`^J^U6BW3@+4*PWV
MW<1+Q*LJ]!/9]]GN)PBM[I5U^Y"`?Y=#=\:R/KT2V@'ASZ.->I;=ZEYT3D`;
M&72?'KK;5F_0O&B?`+JWVQQO:FTW"R,;2ZP%Y8,7T*V%;!R&[I,8XL,.`JZG
M>YLXWR'(V68J;IM9Y2IP#],:6-U&]Z(B@'@:(4,C2$:0=K5KM_N]B^:I"M(^
MMO*K&-`VSD6E<W%#&=Y9)M)S>A?M8U:*0#QSPW3HBZ>3LYT$*;>:S5ZU8;-A
M=?K-B]83J,/V(:I#(T)&A!XK0K;5:+;V$ILX"A':HB7^XQ/^3BT%&WM.L1O^
M8]-2^3RE5F7EQG@=ETK"IA)N2MK$`;,B-;I[=I0&;M;5D'+_57MB><.XO&\+
M4W!'@E*(88BE<G55E:Y'D'G/]"2FC%*[-T=UGZ&++.-"UG%VWZO*)585^=6M
MDRL;<.!7X5.1@*\&"YGBLG0^I5ZE]9K`K&'=;;W0)``)3P.5[IW,B08847<?
MD6/6:V.\1`!3MK.N`+(#BR=;H6:34'/PHA4="ZBGC*J7P.O+BM_"&Q<I>SK[
M.6;3,*)+#+X+:IO"`VI4`Z\.!:6<`XIE3W)LE()]2R0/]!#8:4#-C?B+N=S4
MQ#.;QI^I.\Y:1N9=#;`I;-[WX(*MKO,M=$?`/NA,IHC[>"^DK/_4ZS'!;OS!
M/*\;R=A>YK@$R)UL$*#H!!%!-D\%I\8(L@/-R-<="V9A(JME&)D$S/E6G)%@
MG4MF9XS5S-)]V%>T2"BBB2ZJT)!"6C)`X0`KID*M-I5(Z-8G\&J>TPXKKN:4
MK8&"DJI3@Q%6T(?HR'KLE)%?N0Y1?ME&:15D#Z58LP)[ZF8""9.A)I]J8:B,
MB?H/BQ]221Q\><_3]*HNJ1T?5")V^8^5RM4=6&'AL4-)Z+M4ZJ'UL4>R"W1B
M2:6+EQ7"")&\\P]K&1<:RJO^(A&U/<+M9)S=6TQ/\ZS9B53/[A2CVM1SX5;H
MSAT76S'JV5N$/VG9PTVA-U71I&:];.GJ>!%P7]I`^/]D"\)`2$/KD0&G!<[X
MC>*)`BBHO=&JL0J2-WI0];RMBN&I'=0QMO$_K-7'"Q-BM9Y%/R/OZT5MA3\(
ME^1-WA>$REE63MURT/BI*DM2W>-`9L<!&-W(BUW/R3T,>BBE#CYH[J=>HCJ8
MH=4$%'FJA(O["QW$2A0X(5X_PA/J`;Y$M;S_`0`5IN,)-@GKYDV?/R(B`^H/
M1L5<]=JU:H[L25.2]_\6/_A4%KPAC\+,9TG.<4C]-738?*G%"MK+=#38[^8!
MV1R)">@<U/9J*W&&G8$7"[-6["7`,TZG*1DL\-FIB9U3&E/AZLS',75S%"RY
MJU9&]=I2(SGMYN=;DW)/CY\Z5J-A6]U&0P[P4]/J]0:6W6@LMOCPI!<.L@1`
MDW?I^(1(+6<2M`[XL@G>":-:2A8:%EZP,L=P5ME>IJQZP1_>4/?*>Z=B52(7
M8X$<ZO(GKY!;2"PYUALL=:CDH(_X[CTV.?!ROJS8I[N^V,<4^&P[I#[_(67R
M2:J0]\LJY#$'0ALNVE&<51I9,K*T3I8^XT[(B-*6Q_Y';UQ7G-8=BT;8H)36
M:(0]U)(?D\@:L)\8V'=='6[`;L!^L&`WFMV`_63`?LJ:???U3.W^T5</?Q9)
MO88!YBV!8>H>G[JU0.-9RAW/>E:KV3_J:M[7C[2!!LPO!LP=:S!H7W0-F`V8
MCQ_,S9[5`]7<,V@V:#Y^--LMJ]%N[*7^YT#0O.N"QQ>P^_B"N3RR&W>>[B*S
M>'Z1.3U;;DN,@GC"!BS/HRFV(/QP5<5.8'/(M!E(&T@;2!M(&T@?,FT&T@;2
M3WE8LGA>5-B25!XAE78N@UEQ<3?=[PP.:;^S[9!JOA\6*@=8H7!@>1EW?XAS
MV(EX)]7(JO&P6>VU[T3/;EY49%&<1ALK(T9&C'8S+=MJ]Y^F>XL1)"-(+UB0
MFE:SV=S+*:\1I$/`G!&D)[-(W8Y]NJZ=.;!;8ATU#*VNP7_,L9TYY3^Q6-J^
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M7BQO\A8_'`&[W7#$9FGD3'@LV"S"&Y;QVFBZ<';$O0B!F0JZ1]S%*VU'G@#P
MXM4!G#Z,?QFF,<P`?H2]L_.?%.^&EI=(JUN6%1'-ACUX0Q>7*]JS,>C^:A[`
MGUPQ\@(O$<SW1@*OE2]>5^\%0&%(5$<B%ARHEC=;N^)6^.$,K]#%JW_QXGD+
M;[PMWE./5Y\["?[.RU^7-_H67X?/P#=N8;*EMXG".!W&0'OB<9\-10"D)G0Y
M+Z_79B+R0KRZ&CXO?B0B<&-X9!ZJZZSQ`N!8"(HH3,+(^RL,+MCE-(P2O%V=
MSL;U>BJ6X*7:7DS7$>-TRBQT`*KA%%;)AT>L>@TPEHZXDZ017H.="&<2A'XX
MGEL,Z75YY+(0*.0)_IE8Z*9`D(7=A&!5^53`(+Y`")!ZC.5%\,#W((F)DW<"
M\1?KW]'?]:-Q'#J>O*$9`#3ED>?/LRO)JZ!X_[_^^_K];VP;`>PU?G[#_OO]
MMYN/5Y>_:668P"J<)^&,9.CF4TD\ZK6;C$4$U%BPY15`\'&]1'37.1`3<9PT
M7HD>"#;DL$29N("LY-=!LS06H]2'!;H5\7'?=O^$.K)TVWTD;CUQ%[-Q4?WE
M&N(<6>M6K5LBL0RJ(`A2[@,844AG81S38QX,[T4H[!>LJ%I1"M</3AH)"8,_
M%X>%M[-Q0?*3.R$"10!@,897O1&J.+S.'J3:<=((H!,QQXN<=(IB"GJM7@,]
M'(R%U"-W8>J[#!"(VO`[7B4.OP[`<TB`!#=U1(623I"#D9@A;$'64Y@,4..'
M=V!20&_P*)KC[^GYDH[61"9`Q+8<1S[@\%>@)/!F8=`TL_F2:(/N:A7$_'<<
MTF77"6@.U#'X*1CCZX1'4^Z(-/$<K#?_5%1MZ\:\FG@!9^7IQRBZ7YPD'&*_
MZ99=GK4&&7*RS!WDYGA;>`#5OO<7CL&9Z\4.WB@/#SH\GK`1K`)>VNX*GZ9K
ML3O@E)"WS8/B!#[`[QGHS^\B4330WSC8*=`SW(_#>DU^0=K#.)W-?"'-%M!?
M]4%&WRO-&<W%=T%Z.YW.L)$<VL,Q&`FD&U!`%]\#NE-@NLB'@D727P"(R57S
MPV!\GHAHRL91>`<:GWY/BUF<1XS4N@(?1+TI.!KN\C*5#5R!B@S>%^PCX1N4
MM?XS2A`.)#V$XH24'(''0#)"4[%*%GW*YR`9^+;T6)#$2#@AV,J"),,XT?AX
M-/CQ.KGOP(&ZY6@Z-_!E\X=A8##*Z50Z*E[@^*E+V89NY2,,+V5V79)=IEM9
M!&#5'?)S2+DC!,C@2S=YR'W4S2R>"(`SN$#"H_=`$Y/0HQ+W/3X$L4P`56!X
M4D03Z&_2I47\7A$HXPR5)<V]@F"@"3'JA..`Q%XV@DS`&,`HX&^DOO3!E7^'
MV$\#'UUD=$7`77?81+AC]+4=DET4."<")08:AV8\%4E9)\)6@(P,W4DGU1PH
M'AR%%!OZ-U[B*:$&R0-/%NA4Q"`MCH@2#N2!L@36P4LQ.P/OMU[['()GWW]M
MK9KL'>I#)Q+2X4<;*`G,>%KD9ZYE2':5OD'_&Q5FKEVD:YYQ'_6X5)<Y#6J\
MXO(##R0^5';K&>X?@EB\SH"!'CJ>;A.Q,9HQ.8G28AC%L6_%\1X7CYB-G/\-
M#9*TSIMNC$NF4?L#?CZ.]OP`;2NL?UQPA$I^(!CX0.#V@+P^Z>_E.J#D^J&?
M!1Y/(A!</"D[)+`-20,2K4SKX.Y=N/$J%Y`>(HLI4;P%`21X"N+W$)!1N;3!
M#F&+Z[MR9P[;(+*TJ$^&4KR`'[@/MA;VU^!E:;,NIY`&!8=FR1E1G]-VFU3/
M*`JG-"I^-1S).61*&EU!8@.ZY#`T>.X>PD;ZGIF*I3A$MH0R)4#JQ\+"XB\M
M].@SIX;H@!D&`N,3/(*]M_3?T<?(-9A<,,7.(<Q[XCF358N=D0]*Z][U5D\9
M9;-O97,-[J`X?\MC6$N$+E@$4CU;:1FF3`FL*NQ.P;'`,8<TYHS/91#K#MQQ
M$B4QG?GA7`CRO@&D21BAI^+>>C'\2PH96B+`/R_[0."2<V6/X@26!:P2F20`
M)D!-/DS[&BS*B#Q'FC%XT,HC@.0<QQB/BT5TB\%!%>B2Y(:!%%7Z$OD"5=BD
MN8"3(&EF98K5GV$B9'TS2:DTXC!>%*;C";M%51&,+]@''%"-0"$G>!"T\!15
MFN*I>C9S>LJ*)]]*T$Q@NS74OAQJ.V?B@<Z@-5'3*7R@X$=)/BH5$E-_-(T-
MO=S%2&8R"6/-F:(FJ]>0VK([EJF8*N'7KE8!1,!*.2Y&9<?TSEL\$3F_=D`O
MXYZ)<'".P5Y\@':(2A&E&,,=@LD`?\\#,$2X"9<K)OU.[6;!6G."9T%EE_9J
M-Q.,,X-O.0E=\J$B6$KB\RV'I4S+^\\XQ5BLG&#DQ=_/1Q'ZB[IDB+:55LZH
MVQ`[H.,B%7X)^@A#U"Z;>P+T+BU)]D<*)ZL55'*`-D%+@N1XA1VMC&`O"HPR
M(`N_E,$'Y$)16)@#MH/8+AFI0NZC(B@7@KWA=(H^IQ)BY;PBSS%"@>1?L&LA
M&#G7`V,#]FT#?L,<P:^@(,D8K-?\8"U@$T:9A:`[I*1B/$>C0KHI=P(#RZCX
M1B.`+"D?,`YR\>5+"*8X%01M%J8)Q?8!2I:T`A[&]WPGE4H&?`L2"(1:(*3'
MLI39F$$+AT>G340QOEDBB*/#-A::AL*'F:L.'$ASJFW6.\]/2>)*$[:4@KF7
MR!7YET4>K"&R7@M2V.%'I!I+K$MCN>F76_KE%:G7-%VHLF=^*I71JN$*`=JA
M4.M"7G<Z)5L3!D!0K#8EN)"S$`]./`I'N\@BW'?&`M0J[:7KM>*"(IO08Y[A
MJ5$@8UM21U8-`^N7C2-/+>")\^PC,&DB@-8GSL>4QI/6#LRJD/OI`.-S,,]D
M`G8IP(WPM9@E@IC0:E@,=))-#^*-\E9)1Z*61R/A9GA3D4#<@`@\`8,Y96Q$
M90;Z&=P+4+CYYC\+;ZJE*BX*<+*\9N!3`&;6$5APN]`S$OI$SH=M!(6*UBS-
MKVLTZN,/M)7&<RC@4DS1)@EPA._/N(O`^/NKQBOZ.9YQ1_^L,@5ZG3Q58*OS
M_0<6S"-]Q63SE9D:W>[ZJHV]E,:?7/6)$R(P@/#NJTWS2UK-AQ5Q+&%UU]G_
M:SZW8R9G.J1>`R6R3N!/LI;DA8GZO44OQR/IS8TEW>X82=_/NM5KZ'0LK]G)
M:Q`C;4;:'M1F!GUW(T_K+/(.JCO18.\/:T]2P7DM=Y)?9%!O2Z"8=FG/UBZM
M_3Q=GGM6KSVP^H/.6L(/MU^::6-N`+X2X"VKT^E;3?N8FQ(_US5-+\`<_EN=
M:!E#:/3$O1WP.E:ST;?Z=N\$](0!^.D!'#R]5J=I-9K[:`9T:``W.\/*H'Y$
M)ZOOV==(C`0=35[+!*>KPBDD*QQ"&JMIE,K][<6Z@Y;5:^VCOOO0=(K!]^GA
M^_P$<'VLO0I:QY`<]PTS[%/!OLE<V.7<Z(7JRRQC-E(O8@Y_O38K58'*:O3R
MKR@U="I<CT=S+&EW4P?(Y9C?BE47]5KB)5AL3S7K<2Q<*TLN5=7K0F;)8KG.
M72"B>.+-X/%;P8:"WH=M=*R\!LK8%5G9O1QJ)"B-;^3]4"EY.E%75C=0_JFL
M$_)]+`J7&4PRJUJFO\'T!7@>5)2,'.!QB"_/*34VPH2R+&E.U5H@[F6Q&-:@
M1//%8M9%=M9KNC87LX;*?1*H>JK8-T"E>,<+R=TX*6(3%HC<>BZ63V1%<Q=5
M&8\?@RPOV8&A8DNF@,D<[VGJ)]X,IBQ\53!%N70.#U2-"'4^<*GR+!8S'E%-
MC)HPE]4VI:2RY'Y`8>%^O88)V;Z@TEA%NJK>'\D<.,S&QL#)6-)TP3YF]8$T
M`[F46:8;@LJ3!>"T))*9E`ON4V(Q_D4B@Y+I_#E,GNHZ-/@D<;3L66T?`A?S
M/\-(59I3YC@5(T8X!4FXK"C'-<G02C5\ZZH.<MY0F1-]OY227H(JY7Q'\Y#2
M!:/;+`,/R^/J-5!CH00]3Q/LHT`)W2X6X<2)F,H<-3D?&G=A(,JSISX>GLR5
METN3H3VY@T7`LOTT8I,0*^7Y*,&UH&%QVD`"SEL1C,F,WY:GQ-U;2M-7516Z
M%(*R64%ZL12PQ'^`&HE?5OZ@J@ZH9DFFJU)!@QP6)J'&+4NAX%&0P<_*BCW#
M:$H9C"!A6`R`WP=44<G2;#*//<?CF`@OQ'=*J:74>J#&BR?W\!A1D2V9/,R-
M=4>+XI<(3<E\AJH3)CCTX"67I3-*_@6+@I]4RFEI0,;'D1"9SO@/X`_+2GE!
MHZ'"5E/03*I.90<NRE1+F20[G7I)HC)/L>9,EP9(\YYG%Q/>B]S+2%JIK/"M
MK`(V>USS)N-)8?5Y42X6D5`HTM>HP(^@[,-2955<^0A*NRDX+D`$2_F5]@<Z
MY*1PJA*4A`FNYTK0415MI,GS]B[$M^_@B?E8X8N$R,)3U+3!(E2`40%!*RM.
M16A2QP2=G+U(R!*#-*KC#1F$5GB!0VPE@SXBR:XJR2M`J%Y3$A7.N4\YSDIG
M%YF"/6R(';'CR39%#DR/"G6DPD%;%`:!0C:5"N%[OVE`P:O?*$@`VO4R`SP^
M5Z]=@?2/12!^`$FRC(5HE'/*R5K)+K3C4A/.]4.X\NY1UVH\H3NJ5'LLO1G2
M!P]+6(>%H`IS;/KLD=H8E9/!V1FI:]!!\$K\^LE2OQ<VI%LE?MN-QJ%E?A]T
M-M?]08WCR%Y5Q&^3\+U1,MI3A'SWVH#Q9D*%@Y^D0GB_K!"VC/!NR-6C2!\[
M=NSO'.TO.O7R,[QG!&&3T[+C-65'1>PV6=0'8ZP*4KH'[E77#9R,'*X[BCX6
M>[0K0+]H>[27@[9]%PH<F32=MCUXT>)C3(4Q%:>"=6,JGG$#=)^8/8'#O4_V
MZ#CREBM?P82CT2;/3^R&<O-TZ5D/]Z>>GYEFY<W*FY4W*V]6_O`K**IN3BXX
M124W:3!+'N!<#0[)N=IV2#7?KY&(G<BCZGWF1NDX5K>.%-,[%^X$4>F>%7Z<
M*=W8=VK[3B[L>\HRL([5L5M[N9#OT'9U!M6G@^JNU>JW+TP3"X/J%X1J;,S2
MZ!I=;5#]DE#=L:U.LW]Q"GT6=MV/Q6RA-ME"76<I_KKV15_6$:T,>)N-TA'4
M`#^3;PGJ:G!1<=C\XM250??IH7M@&V@;:+](:+>M9K=[,3#H-NA^@>BV^[V+
M[@E@^\D/HBHSELS6ZOZM5<S.X5?>=)A&=.6>OM+Q*79:AYW6NY[N;3(;#T$B
M-U.%V\QJKR60/;N]EQ#J460V&C$R8K2;:>VC%9H1H4-`FQ&A)Q(AV^KU.WL)
MMQA!.@3,&4$RMNAP#A2WV/WJ.;</I#SLL6JB?<QJ`HAG;I@.??%T^-M)#L%6
ML]FOH>U9O4[W22QM^Q#5A!$A(T*/SZAL]SI[B3`;$3(B=`HBU.E8_4[_26*/
M1H2,"+U($;*MGMV]:)VJ"!W!W0QV?_D4\T@N9_C`O8C]-_=3P3X)CE<,4`OM
MA2ZW%6WDZ<5;>C$<L9$7\,#QL!(/;U90+>U]CP\]WZ-.R-31'SL=#P4VU9W*
MC[FJ]?TLC/`DE4?4UQ]&D\V2L1&O^.%,L`D_FT68OTKCW(6I[^+%`+IM,O:3
MCO%,E@>*`NRX3PWYL8^]NK>!.FA+DN;8Z9H'\)0K(G\N'^&.;`P]%,D=M=#G
MT7<8:<:CQ'.\&=ZAJ'NW`S$!_LK7#\G;&.JU:<Y%YF+GZS/QPTLD\:_++;^I
MT_Q_4D]=)^'X0#B`I%X;Y;PM#$??#@.QU*&X7G/@0^,0K[9:UY[X4/I'/[O(
M_(;W7M1K-@PQ2Y-8=>Y&@!;P]Y\T1%C2XL7L+`VXBV0)]S7!!^""UPY(!,@>
MY!XULZ<+2J0<P.^6Q$#V/$?,T^KA&P#(B0*\!BC>5N#0C0CJE0(60$I@R8^E
M6?BA+';SWL56?Y-7?,`Z!>7EQW[QCI]BTU1L`0_K3Z,R.U=MX9"NL\!&W;HK
M>8:">JT``XL)CS[C@O`["3;-C^@N%?G3,:]KX\E7M:57;F$]TZ"P'NJ1^Y?E
M@GW0=HRM,&/X#:6H/;S^@U.JC[QJ@H$Z%G$"7A/B@F['@8]*>("NITLU\)8,
M8(*Z7"57]"7#43(3Y>LRD*PX)NNB;[3(AG4$W:_`E<%*?1YI$A8_5]0EV@C%
M[,_4'>-O++PL`F^OF3,^&@$DZ6U\L7C#1W$X^$W.L!)/]<T\\.@,G.C\#@5]
M"4H^R,03$8^<"5A`8F%LY&`C.;A!OT,[%?K&*>%6K-$H#5Q4=+<"C1C:L'@"
M5HCN4D']AK\G5\,JJ,C"Y4O@);GR6B@GC90F`VR!(R8Q;^,@)&B9?S><+UA1
M#=MLB`I36O:3MIL2#`).TES[9?+O)2+7CHZWSJCAR0.=#H6+>A^8X.%M1;>"
M+2+\3MZQ77BD+`5%`K3"TC?/*)8I,<PNC:K7XG3X)]Y.<HONP%`X'&\WD:2!
M/J%/$=51F(XGQ>M/P,_E":@`Y&CHPB=)!]&;TL?(R2S<EC.+PJ%V/NX$[FE1
MM[E>[.`M57A/%H\G;`1:3BU0?D>&O)TB5EY0,L%E]Z5Z7B/KJV\&VG!/0==W
M@*.D:$0-#[\M@H1N^XH0;W1YD+SDBQ,2ER\&H5O:V#O85\A?V_3K!MX"@A=^
M/?DU($N-%;>Z"*3?.;1[0!1AG>;Z#(?G/H)]>&[&<U.>]8>R&^N;B^I#\>[#
MLASVVPY]VR%UDO:27"_SS.1.O!1!W:3BX>`SJIY)9A_K^QYC<^#[8Y_L=[KO
M+O]KO?9?VEM9HT4>U2W8Z!2C4YZQQWC%+>-&I6RK4E1(T*@)(U)&I'8I4DTC
M4D:DC$CM4J0J,DI.7J1V7VF/ON[^X/8DA?*?,)ZN8_.L<$JP)69,?XZ'154?
MGM#6>I:V'$VKTVA<]/<09#LT=6%`?3*@WD>]G8&S@;.!\T%4BIZ(*W>-Z1[U
M&F8\/,*1,VKA"5NK/8]^:)Q$8S5C\$X/V:=@^0RN#:Y?(JY->*Z">>]5>BI6
M3E7EIQKGSJB*TU,5Q@0:7!M<&UR_!%SW^JV+]@E@VP3LEECW;UE79'P[HRN,
M#30VT.#:X-K@^B7AVFZ>QOU,^_+M#E4(#IDV(Z#[X?CQ2ZFQ0`;@!N`&X`;@
MQPKP'5R/<`SEN<?;F^-%WIR2E7`-5O<JZ#QLAOOM+Z(;_=1KNM//'G3$<9<^
MO2S%\;(J)DVOD*VYO.60BA+3*\3HF!/5,:8JV_0.>78T&I$R(O50D3*]0XQ(
M&9$RO4-,<<+Q]@XQ87I3B7Z\07ESZG0R<,;F-_9>+CPTH#:@-CKZ(&*3)^*\
MF6XA)L-BPVXAG1/0$,;@G1ZR3\'R&5P;7+]$7)N`G.D68E2%417&!!I<&UP;
M7)\(KIM6LV^?1/MU$[(S_4*,MC!6T%A!@VN#:X/K4\!ULS\XB=;L)=_N%[KT
MOO!SV6LI_:1^6/A.U2./=?/L_OU^WI]IG'BC^2XX>4.<_`R<_):?SJ;#6/PG
M%>CM)2'3E8Q,%S*R9"+853B=\6#.(B$``RE/A$N_=R8\XDX"3B+0Z,0L',$@
M\/LIYNLQE:X7\ULO&,>,.TZ8!HG%G#2*X'L^CN>$D0N#<7@77HSJ-1['(HDM
MQ@.7N0(/C6%B+O,2Y@$(P@3@@!\/61J`<^K/L7`J%C`D>:;X6KTV@>&&0@0X
MO@\#>B/UCB^+(R[6.+#W+.:BAYXMRS!BOVP]V@.@T;IH/1TX/H01+F@8"S;R
M`AXX'O=AN#B)4EFX=N<E$Q8#*<!B!W8,3"7VPD.S%)<1%K5>&X6^'][A2I$$
MLCB=`C:\O^![B!9`D'?K)7,V"B/Z13(!H!$"`B"\7@,X)9.8B0"A<BUFB8)H
M@R!JL^&<)?.9`/@5B&-G7D#$IS&,%+_^==VNY='RK]9D*>5:3MH1OC_CK@ML
M^/NKQBOZ.9YQ1_^LE&F_EVO3K?3B`RT8[7DWL53M_B'8_^/Q5+*:@N[&-07-
M=K4E?6$U`TJK"'9#<OY)2O=[E.XM(PN/<U#VVQ-@;T[MWDLZ#,9WB/'/,,"I
M0WPAPKJIM=FX;N<P9OG0?C('.I='RO8)U\1E'FJ]IEW4O0O]\>#J)<W%R,B+
MDI&#BUB9G=FA5'MOZHL?MU3JM+X3]%%?Q#9LIX!^WCD93+U$3!DE:0#]H@!M
ME*0)#IWRQO=APG3"&]]W64;EMFF4)BAT'',QLO'(M&,C&$8PC&`8HV%DP\C&
M,1F-`SP^V$&UNCY=..)RIK=B[`6!%XSK-5W%-&=#[O/`$5O"YGA..0XK4_[A
MO<H:SW.AIC5HM2YZ>X[`'(+&,*`^&5"WVLV+BI[+!M(&TL<*Z=,I4S>@/AU0
MGV)UW@XZ+ZPY%SKV;<S5A`=C4:]Y`1OA56&W=)%85D,'OQ8\PFW.MGOA3?7*
M.MX>NLXYPBLQ-U!,V\PJ5UQ[F-:9;=F=QEX\S&>-O;S>F6$V`G0PDSI(`6K:
MG8NV$1\C/D9\'F9_VH.^$2`C0$:`'BA`W>9>8MZ'+#[[.3%;-?/V\6]#WP?N
MDQZEK6/E8<KW&O$&XID;ID-?/)T@["0,MM5L]JJM>OW6D]CZ]B&>\QOY,?+S
MV"/N9O=B8.3'R(^1'V-_C/P8^3'VQS0F7=M]LON$K4G#J:C7PE&Q!:F:=[-A
M#][$*YI2\DA0I]"IX'$:87?1I%XKG)B&`>-X;)I&$?:D'/+8BRTV3!-Z,^])
M"C]/L6,I=JG$(?AL%H4_O"E/1/$`UH7_)"$2";_RO?^DGLO"B,5X[>4YW7H9
M\`3HL.JU.'4FV.O4X?&$^EO2/P2\`D,A[19\'B;B.=AA%?]HZ;:I<;T&E`EX
M$*"2_Y;-^%S^!F8LLA]Q\!PB0QY\A_UZR(/X6%J?5L0WGA1[&PYY\S^_P9A>
M`D0Y*J[S(8P$4,BNJ,NM,V<W$?#=YXD7!@L]2',9SOYU&<N6J95POYK`IV/!
M9A,>3;DCTL1S`/O#-,;?Q]@AE[-8^*-S!S[!L7$NH#;`U(!$C"-JVPLH\Y*Y
M[*^[4J[TA^)$3*E1:;VF/U)\D(U2!+9$\<@/[Y`"_!8U:@69&&*OU]'(<SQL
MR)J$(`$BNO4<`2P#6EW70Z[`%)0@@S1&*`V1F$II(`HE,2@]P]AS/1[A%11E
M,@)'#>1HKGNRM^PW$4R]8.C5:V?Y*U=OOGUZF__X[LWK-?R(Q`R$&<DKC"_[
M^_U^#9;3]WET`=^*4S_!+LC8R99`$,Y$1"LOM5*BH""U"RTTOX4GQH*)'PZE
M=S!<IAB4"NDF_`(,X86NI%!V1Y9=C@L7<E0/SAP_C(FGJ+'4[V!MD$#!G0EJ
M%#TO^9$+=J674H[)_3A<&%@17*\M4*R;]VIRL9VS0#Y8F1J5GX-A0`/3Y`&F
M%..FL>,$_H<Z]P)]3D['G>?[I,\#T']Q#,OOSQD?1P(&H/[#D@Q$GIQU"$L4
MST(*4^K89*R^R8J?!%3+OX*R%B(QNG'?NA$D1/#(D;;O';:*#F>TXE=AG,3K
MM6/Q?;R<)A^@+-WT`_[G74G*0<AF(H@)*HZ?NK#NL/ZH3L`V#T4@1IYN/4[=
MR-E$<)?L+$!7"H"#A%H@65Y`NA=L-?PWD9,]HO\&_$I'W$FD*.LW87K8,[WP
ME3!-0*^)7#F.1$8BM3>?(6;1D8FR^2/\E8ZDC\-W,EV``X.0(O'RJQ?LIM#$
M/6."%(<870O0*R'X44@^B5147*@BGU6O;OS.W40$F(Q&*M$]%N%Y=J_V!JS@
M*(UHY=T(;U9::7;0\I(>Y3,P.`&P7=:`6B4?02I(Q)47H"O*H[$@G?Y=S-D8
MD1#@TB%,QV"Z)-KA<8!0'"NK&4ZG7I((A1Y0MN>@N<_!W06)`&=VS`/O+V7'
MT(H3B#WPF`7:7C=7_BNL9S68ZC7X`+@ETP6`9KXMCII/@(VIS@_]9P[#N"G9
M?+JU`#^MQ4_!&ZW!2A0KLXRG6)DT()PI@?)XL'R\AN`:;'V:A-$<G2;0>F(#
MY?\UC>*4DQ_)?(X.RFP&(^)VAT!`GJTG-6<8@:=!<%!.P==O5Y;^!RLZDNCF
M$!`GWM##%T:PF6>N%TN`*R<,=G9Q1K+#9UXBM;Y\6_FLY/+2)G$6>;1)Q*'P
M@_^\O/S*E#3Q$>P)04I_X-/JTHL@#,ZS3]+^+9)LD>)%XA$O_#*S86$`_XGP
MEH2(KD#`668W+OS*SKS7("\@^0!Y7P]AP:_Q]P&CZER@-R:/#N0/50)]@>8'
MC]'[,/O1B`W#()4JX@YV&>@@XH,7[#H=_BD<Z>$[(L*M!WC*T]375\=-T=\_
M\R[$A<4ZC9\UF9$8PZQ%1)M=R51]A0B(L[C%U7:D5G@MEV]A'I)0Q7^D+$BY
MKW;JM`@X&7!:;?G-G/=J,<Y`F11N&:$[1>!UJ8#(+P;;[7@S'P97G_9)06'[
MTB*X\"/2IYZ##CD'+_OU&WFY18D4I:NDW9?+2&ZVV@P`!IQ(T).*0T6H[EPM
MW1]#.EH#BYQ<Q`EL!]-82F@X&L$F"NP$^&%A!!X6!YF&G1(8@3*2:>EN<8,]
M9R5(\C29A/+"&0ME0Z\17GD#6^MTAJ!#M0`[C916<X8;-U</%,/^74Q"'\`F
M/4(P<4D5O-&]`HHKQ`0I\VB7/5$;.]@S@]@A9I<&4;"7NQ_X%HDX$`%NPY#`
MYPL>)ZS9J1!,$.A,,LN(G,/+N+^3`ZN'0%HB&$Q(*QW1CCB+X>5?EP9?*A6M
M2E"M2`6SN&@CW4S?`;4F'-(I^BTUM)C._'".#LP2F?0M4&Z9HF.YGBM\2;LP
M^1_E2(6XPX)?4]S<4RPOD/OEH9XI79,4(A"6UD]BA&T$$:)`H9)M`LH%>T&A
MPQG^@(\5]5&<K[<,%V45)*6[EP*I$B.7]LJT0=`1(C#$EC:$M$DOFS$5ZT3-
MAG!%?:=4X(SC'5!:NUL@P^$U;/]!`C,[J\F71O:GIM5J-*Q!HT'?@Q^;K;;5
MQ1]I&A7W`LE=9GZA5;V&-UI1C'4F8>3/C\77>W:U^DT!K5XC%RI;)>F*D14>
MI[Z"U0RQDV`T6@=T<@`,YU*8*_<*2^Y9&(#!A1VR0BHX8@!%Z5J@<M)XM9@'
MYAV!Q!>PRQ:A2]8ZL_`@7`E0SR-W:187[#)78NK[L;3V>M(DV_IY:_46J,KK
M+(;ZY555-#N54Y>HN-L(H,L9A>DRE02/!6#!5#!0>.1-J"%0CTU+#+<81?[Q
M3(*[MQ0,D^JW\'T9H6-W''3%3W:_;750KI)50O53TVY;3?G(LH"M$ZGJG_[V
M2QJ?CSF?_7J=WR=VF:W3U]#',')\`W;[+4K,/^HUQOZFW_DJD19_"*-O8I;"
MI@^,T)?1UT@``T'Q7B?PRF7@RE_`-EC0;VC;#"-^$Z._OQ*A_\?7]]UFOWL.
M_V?;=N/\_S0:=O./ZYMW?S1[K3]P_HU!J_%'XQ6XBIY\RXO#=M/N_?'[];M7
M@#S'FX(1P!N]_F'W@(N-?%X/I+$\T7^"GOX-G)4OP37WX>TON/B7$@G[G,QY
M:]#MMCKY;.XAI$PQQO:^C+[!]AO#$_NDL6UW6]U!I\#RTK?+9,$2J/7X,GK+
M@^_OQ##9+QPZG5X)#U44E&G\+)*/L)F="F3TY2WW?+2J-R'HF&D8$#J4C_"6
MQYZS7P`T^[U!I]\O0&!+\JHE]B:\=&C[]C5"ARJ9?_51\`/W/?Q6AFOV.:U.
MN],:M.QE*5U/U\):T2$OR$'N%3Z4[G_L\!1_MXGB_WXOAQC"LC[$B=B@7)ZH
M?_?^ZLNWRYN/7S[_JB[ZA+_1")_#!)Q!NRI`E)O<UIMB0''9'#W(W2LQ>K`#
M!^W_.3]__P%0Y2A'__S\13N0RL,')P&4QD7YQ$;]K7A:P]1^K/C8DF^%ASKD
MM)1B?H08>IG\-+7'P8T%[1??"?@U.F#@'!;NH;$'_4;AU8!/!?L`+A2Y8Y^$
M2V<ZU_*(!IPJFL3-RK/ZC!PZ1/I/RF$W&$F_#Y9+'Z:VFPWVF_@!_DV"H>Q+
MLE,6NTX]>+'=:5C$P_\)H^_PK_\!3ML]<*\JL+^:D`3\]MD$@X1!2GX:['7/
MFG;S->OTV^=MNR_W4QB@NQ/@H:)X<=>-9$+!0T.\533>W=U=!"+$I((+L!HE
M233;L.VD"!"/&Q#*MH@"KK(?AEZXD!NB]M?YB8>,6=+AN3R.ES?RBC$9/1DN
MOL)SIQMY[E2M7O/?_AYXM!$CZ8K?R+CR-R%C4!2I(=&!V:X;"4,*_(W<5<FP
M\]?27.JU3\4#U8V&,[#:.&@:A>EXHG;F6Z^_5*ZQQE$6SB&8CD*'PG@J`Z-T
M$#=B,APE$@PHXH$G[*8C=>@I#W/JM3#`DKPQ;.Z]Z30-Z-]ZLY[C;*IP)@.)
M`I"/<.>PP8?_18R'L.6B_7$61PP#"W@88CZ+53ZNMQ0)A+URJ@%E"N'6G*1'
M;\OI.F<Y.')OR''&19(H5)!3&V-.%)`S]L,A'BH\5-&6$<[^[243DG`O7XQ2
MN$4FB:GP<42'(BZ&-[)4KQ)SX#G,N:$X"<Y;,8NI3(4LY^;WB^L+BXD`E`DR
M'4R>GTSPS)JB$"DXVQ0(=4%+)7*!<"21':VI;TL&@JJ*29T5E@`#P1=@<\DV
M>9*XXJP4T7$^-IE@%^4O=-7@>+84B+MA&`5XWNLY$Z#4GS$Z/,1440KFSV88
M<1IA0!61%J;Q`H$J%CWQ?!>S/%.?,L<P',X"(5P9L-:Y<5/I.,`[D>`)KH?1
M2=L<Y.@%CH%_X"5-!$7U,.SU`W=EGCSI7U8<%BV"A\DM177&2IN$%<J+PH3X
MC7^!2D"]9`]D:,MF'/>$L:>E'O:&(-,>X*VD-"WVVV]7>#2D74W,UIO2M_*J
M66V:2X[PUZN;A<3$6>'8FS!;%F?NJ+-G/,U1GNZ4/-IXXLVD?R!BF94(@ZMT
M(?@7*H(@O`,B[V#[X<_/PSMD;>%X!][(HO+J!5@"$']U)("Y]YC]ASF`\.RB
M3BAEKTQY]%TD^I"E(`WXYB2%)<>3`SPYLO+,)YF4C:<*FGO``YU`5:\M*&S0
M59@30AI`Z:VBK;%T:#>,YC+S$-1>Z44'W`T83D0JUT6>ZB"?([5FBGN9R<C3
M!%`?E?.]5IL)6D#BBOIR3/PMN^V^&'-GGN?V4GH+1A5@56,Z9\)SO1&J.+5(
MN-9R/)6G`[\(0MDVOFS-LK0;HXDVTT1H=SY1)A$I@:7%DA+$%B7(8I?`=S]4
MNT5P:]7/F&^LY99J;*3=2H0S4=X-"@IG-^>Y,P&N%#D_4UABB>*2?<3N;SHA
MEUX.6+%>H=GXF0Z321G@PXJ2"_T/TJ=H0`DWE&HFT`$'_6H#)T$>E3.&9I$H
M$0A_+)6(2.2!%<UC!E3CF0R;S@5<,G!#4)$N&J(J\X8ZA#QV>O2+DX2XM;=[
M^I"F;*8NIV'DS!.A8B^5A0?J$>D?%OW=.$&/KZC-47TJXM&U1VT'WP%=(S`A
M5BEVY0SSR/5`"<4.TD\9+JCD[R5A41%R-U?1(":4NPTSN?ST[;S1L"UIEU!M
MH]95F&T29N?9J7[)WG`GQ2C'=!X2>92V,`+Q)G:=P<*]7LLB60>0^',JRXE2
M3V:*438PQE!(),#(!-*3EBZ%C$BE`>@1LM0P#E$+OL5B1K'T3CTMEM+TP4I$
M"<PU`FU#R4F@VXG3^DA5)??3,:`7@:"KN!/^\MCE\_E<SUM/W,EL:?2"4%%G
M2"C(&26F8DH75]FVN.$9IK!)D+@<A?@W`@,=2D\\<4OQF`3W%Q@I'(,:GWJQ
MRCVAQ)ND4`8"7HCKC:>PY?!&Y`T61;(2L&?70C`9,&\3W?AO9K<K.N(8&-P;
M%<%%>GA0*]]9D)UL#!:VY$/P]0)XZ);2MNB5<[+Y5O5'T9)GR>"YNRR#=YA_
ME4C(Q0)!DXCBD`L>:);#I#)"T2].(O0AY0A95"!:67KA\R$&NM$A*;C>^+XJ
M2L`X`'LKO#_)VZ;07KT&;@@&"P#,5/15=&Y)5T["F#*ER"%1X0JBY%QY0X6=
MGDQ4O7W-PF&B<N"TP?!A1T+IW0[FD5,UA60S!A+*<8^"-U6*617#-F`TU!H8
M5?H059IYO2A0CP_O:L'"9=(^D$Q4(1FCE'[YX-O%R'C,_BLDU:R/<DK;\*NW
M_U7:AN.Z1V-=':-**D,&C['+@JL%N_[R.)_P+7![KM/A8KWA!MMN%8F0@V!J
M*A;JJ.Q&V&N3^9#UG.QL\:CL?307ZLW2EV52$R6GYEE-K/!T%KO-%ZO$#?3)
M.C;L)I#P<I"!#M32OR9A*@<L+W"F[GY+W(N%>DQ\?(E!UUX0GNM*RC]#^`J[
MA>EB5(WXHH("Q4YDJE1EY1G@5Q'._`4'$W-Q0!,YE*8J3PTD^7=HT-%J8R17
M1BM!37<:#%.\@8GC4`6A56XE;N(*B@W5-R:!XMQAG0LUN"OJ=X$I_^5A;$&^
M84DJ)IP2"?`:+571@,$OW/DG<59(N1QZ*(8F</:DP\#!X("7H1?BEC&//N#^
M5J9&TB>E/=+I9Y'V4@KYKKA)3*CW@:^"*60TD%$E2K0%T`EG=/1)+E"L*Y:(
M8%5,B[T49ED,@Z'*D4>FN-_P!1V:$L>Q$!Y^^\]/7V7!`:6+)918?(E%\!$A
M&TF<^9S2[DFARWV5#JG@B>L6/I9'1:ZJKD*R7<<'*T.#&&Q;"+Q3+(^,D';X
M0*)]=8*'MEP7W\U4MB_26Y0N7)Y-T^L*>3I+J2GEU)5WB&!'I@1?!BYZMXF.
M@>TS]Z;;Z[0'G59.Z#V$+&3!A:&+96_PT$=PMH.Q-_2%3#Y[Y\58]PP3SE(%
M=YN(4VF5EW-NUMOIG67EK#"_JZQU,8EGAUDYK`/C%*/K>I%(9BD]D.6+Q>1J
M/3`W9QV[MW.ICF+Q<F=JL=Z=1]&<M*A,XD5EKSD_G+/E4WYPWZ7*"_!H<@H4
M3C""@F:N(M_W3D24QR]5'U9Q4:)QF,:PK/'K7S?41@_O7J/8NG2/I)J3Y.U]
MC7F662G/\F8<.TZ@)J*?9WBRJ'Y6785ZG>+=AYM=3M]I;G,!S\8D5[#M86VM
M#I>V]L^O[KL'=4--M5?2BPJCV$WJOK94%=,X3/[__*K<T^WY*:U@MU(#CP?1
MHOXOC5^51/L0F[`WS):W5NMT\&FA^'!I,QKN"2:QT-#=V.R#0/3>W.VMKW#?
MBD57%"W7R4/G1M$:=^$8W852:+U>,SA^:>KUH(3NR+!QG\.PHJ<P7IBTSIDX
MD(79AG3[H"B__UZD/>CT(_%)RB4WNU'E;]B6.#DP&7[Y>"_W,#=^C73/\;C6
M2,"C)."1YQ9&&`Y%&/8P)&Q]PZ0JOGCRXK;=M8'WN(I+XG>8QY,;,>^M;*=-
M:4I4:)^W!L+#Q,:6T#GJR,.Z3=#>U$"]MOZBF`IZU]SCT]HCQ17AB!>WR31P
M/ADX-WM6H]&\J-!V!M4&U0;5!X_JE;[=W<1+Q$EZ=H4L]_A_&3?N233$XPA_
M1E71MO!NS.X):`J#[M-#M]FM&%R_1%R?CM;>+G;WP"/@E^3]J3LMZ[7L^L/2
MY7_Z!KZ'188?>%QQ8-IGF_.*3;33T4UJ,\UU2/;XV(\@C`@9$=K-M/H-^\(V
M8F3$R(B1$:,G")JND+?V";G4"T?ERX6WNW&F[V/ID:DPF`ISPW3HBX/081N?
MWVPUF6?378_<_2]KKW7(.RSM923(2-#C#TC[C=8N'0`C0D:$3DJ$6DVKT^]>
M]$Y5A$SBP1+K_I?N(H2><AQB<RC=AD]W9%5=[K;SEX]@SVL.M`Z9XP>F.@RD
M#:0-I`^<P0;2)P[IDH/W"W6P*_R\X\9Y>_'UMN\6O56#P\N8VO"NN'=\J:!H
M]97K=-N)[C6I;DJ7O6-]>?EF?HL\-DXL-3R-O1A_C3WXY8WJNNGK&;5<?/+6
MAPM^_!,T/K0;C7LZ'S[@N*QY6"IDJZ.6/2CN_K&6MS^<\!T6]+;L8D&OW=A[
M7Q0]Z\)MP:N/:8[RN,\`\B@!J0TBX'%EB>U)X/$!3?^:.X]C/@"+:VS.0=)V
MN*0-GK9=UL-US^%L80PNCK<CE&;09;Z76;<E,7`\`-*,FC*X,+@X,.:_!%P8
M\V7@>$!P-&IJ']O9`XF^[F99=&N]AP=DC[)GGV;>[[$8I7Z]]ILW$@_3?2\T
M_+9R#B_<%OXS"N.7V=+71)@-Q*6[5SAM-4A_#-+WF']Y:*!_`2FM&4L71MQZ
M@'THM\\B65[@U3\8*37VZ*78(^-R&8B_<(@;E\L@_3207NG'G"#`=W(]`88-
M7Y#C?97&,#M,EO*]>`<P67?MR,L)4]J->NU_!(^V=9.>I^;W:0X,]L7KO70&
M[^^/7GM@=;O=B]8^>'Q8.M4`^B0`?=:R.H/^,39"U3-X;7!L</S&[EJ-;N_A
MS12>'\=&,1M`%P'=LWKMQC'>0&(`;0!=Y6DT04,/CEE#&T_#X!@4<\?J]AJG
ML`7<08.F%Q94^\2#=,2=)(V\8%RO)<*9!,"2\=S$UTQ\[3"5ZSY;I>Q3RS:L
M9L<^!2UKD'U:R#ZSK6:[=]$^7F0;/]@`ND#XP&HT6A>#X\6ST=0&V%6$MZUF
MLW',1R,&V`;8E2Y(>]`T#HB!\PN!<\OJ-?L7S>/%L\ES>SCO;B+NBH!/'UA1
M:D)P)@1GU&HEX4VK9;?,`;0!]DL#]EFSW[[H'R^NC?MKX%S2TXW3<'\-L$\+
MV(.^"2L;6+\X6)_9MG$_#)Q?"IS[W<'#KP%]?C2;9+B'<NYC4*_-HM`1<<R^
M$1OQ/^],'&X;%KIBY`4`(!.(,QIV9;36ZO4&QA,VP'YIP#XWD#:0?EF0-KK:
M`/M%`KMI->V!288SP'YIP#9.B('T"X/TR>AJDQ"WS+OKA`<NC]QZ+9R)B"=X
ME3.%Z=PT$CMH_7HZT3F3)6=T[08;OL:@?\S)],:),,"NSI*S&Q>=X\6U.:8V
M<"X>4_=[)BQG8/W28`WN1[=[S-E$!M@&V-59<LVV<3\,G%\(G`?MYBDT,S)9
M<HN<^TWP6-1K!#P3?=LFB&V";T:KKMO4M6T3>C.P?FFP/NLWNL>,:^/[&C@7
M^[-T3!<!@^J7ANJ^W3-%UP;6+PW69^U>UUS28.#\0N#<:A_U(;9)A'LX[_[[
M^OUO]=J,)P)&-?&WK4\6!R8`9]3K&L*[W8'9VQE8OS18G]FMYC'CVCC!!LX%
MPCNMWC&CV6AI`VOC?!A8GPBLS^Q&YYB+]XSS8>!<=#ZZK6,^R]Y'YILB[NOE
MNW<?/__S_.V7FYLOGWYES=F/E?-]8;&YKQ25VUD\[@W;AI<O*$C7?UB,[@$`
M/%CE_/;+MW?OOV5S&/K<^8XS87'H>ZY:P"V4]['-:2/%OOM)-1NMA[?]W%)>
M#TW7&PDR$K2++#_[X0DD!RI!ZWU_(SA&<!Y[,MFT'U[*>Z""8TR/D:`GE*!N
M^^%[<B-!1H(.9T[/Y;RUC/-F!,<(SO:FI]5Z<8*SGRQ-$R6^"1/NUVL?@X0'
M8V_H"W89Q^*A8>.'AXB?6ZR-OGT2??O3"U*SK:[5;S:-DV]DQ\C.UKY]UVIU
M&R\NQ&3<>R,R>S,W#:O=M1]>:76@(F/,C9&=_9^D]ZQ^W\B.D1TC.P\(PUIM
MNVU<-2,R1F0V-3=M<-6Z#T\P/U"1>5`,]I>$#WU1^+D<1RS]I'Y8^$[5(WL.
MN/Z9QHDWFC^`CS?$Q\_`QV]+?+1UFBI>Z]QLV+;%WD=SP9QP.A6!(P`/W(>W
MPQ%+[D*\4<9-G21FR80G[$Y$`GXE;KTPC?UYO<8=)TR#!-X:A1'C,?L8L*_+
M=T6SNXGG3-@$'HA$G/KX@A<P7J]%PO%Y''LCS^&)%P;X73Z#K_[PICP1_IS]
MU&ETK$ZCP48`BA7CUVM)R#[Q(!UQ)TDCO`KG1CB3(/3#\?RBL)39OZY$E'"/
M/I=,1+UV%4YG/)BK!X`O@S<QD)@%I#D%I!F'^0/)8>3"#(!:>)<-P_`[\JM>
MNYN$/E`<W@7XUXC->)1X//]5G`YCS_5XY`&#>>`R/AIYO@?SQ&\!$1,OX!;]
MQ15!.(6?%*>^?7I[P7+J+^%UQ4E+TL!]#HN'_)R%$:V'#\N6TM!#'L,OTIFB
MUYG`I.B+3/R0/\![^.3%NH#[R0J*$P:!<`B@=UXR(3YRYS^I%WL:M5^O;N1:
MC``$X1UB,,</2(H$$$D0O1G!FIQYN"0@2[#D\>M?]\Y^Q3#5W*)@!5`]:I9M
MK)*)0\P1OA_/N`,3_ONKAOQYQEU7_ZP,1+=3/&EY:.N27N]%''QEV+H"Z(93
M$=5KOA<GZ];_(,JK,MJ/J[[*SLLS-O;R-O?BFHT]4FQ;[4;C&"M@MX;*#MJ*
MOS0-4?)JP,_)W!JC+)Y$6>RS&G.O6J-CM,:NTFU>FDZYB3CL+_A4;*E##B\8
M]0C]<KC1J">:U&:Z:2_^3.LQFNG``E-[=7)62%Q[C;+:FU%Y_&'/?:0?F;*`
MJ3`W3&'K?!#:XG'!ZU63>38MT;?LW6J)=<@[8"WQ@/CU8;HG&P7<[F/1\<].
M)3L78\O3,$J\OV3\6_R8B2`6[(['3(?&90P88XO95>_UFG[0X8D8AQ12QA@\
M/@4/>:&+$5['3S%2/11^>(?A>1F;C#'P"'O)C2./3\#H>\*8AQO4["\$-1_K
M+;?WN2'<>Z+&`5%^OQ^\VISUP0Z`-P9+#W_L5MJ$/4M$`<;[V/E-(B'JM4\P
MZB1F[P-4#M=BEHCI4$2LU;`>MB-\:2[Z:>UU'RP.R[/=LW#LE:V?X3TC&EON
M7D_;XAVEN)?W=^LN.F@554!S"XMX%/W5,B9C)LSC!?Q!7>H.3L1W.K>#F8L1
MBNV9O-&02T=F($L581LC6$:PC&`9:V.$P@C%(ZS-END;>[!%+W`7][!D3-R[
MO:2TB`>Z.U=AG&`"<"1N19!6Y%28)*TCS.BTFWNDN-7O/[RI\A&IF7LA_?RT
M&1`_ZH"^9S!LU/)+0K1MV<WN,5YB8D!M0+TRUM`97/1/`-([J!TQ&QJ:[S<1
M"QXY$U6(>BO\<#85045YFMG9''/YR7YM:>LDM([9X9P"F-L-^Z)UZF@VBOIE
M8MLV.QX#[1<);=C/]X_RBMW#*X$U6R.:[[7PX<]CBXU%("+NRRX^[M0+O#C!
MRHS;1YW_G&P6X@D6V&K-MX=I==J]%],JT92O&-%Y0M$Y-V)CK(\1H<=YW5W[
M$7M*(TA&D`YJ4L\F2/V'1]"/78AVT"/%[&8?&?:A1@5F-WL\:O`9NI?O4?L-
MVH_(6SAV_6<VL49BMC_)Z?>-VVWLC9&>A^7)6;W>X,5<66SDQ\C/4X=]VIWV
MZ<K/\=\WL\^F=^_CA.YS<=<WOH-_<OS_0<I]O+K$R_K:U6MQZCA"8!<V-O)N
M!9L+'L4,GBBWMGO*.S7*"_.,O>B:.[E@H]VITNA[1MY>3<<#:NU77]5UH,;N
M0!*%]E`:T>[LD>)^OW$2)6R[*(UXB7JAPEDQ>N'($@CWJB!:5JMO[M`X;>>A
M(N_?*`FC)(R2,'Z$5A$507>C(HR*,"K"^!&YDN@8)6&4A%$2V_H1#\GN>G'J
MXV8B(L%'B8BV5"(/X-[A*I@C.-)[SDQ4K9SV,"V[:S6Z)YS3O9/RROON']NK
M8=GOI7U'IB_,I7W[5!2MAM4&15'AZYI;^^X]>:[^Z6^_I/'YF//9K_\,0_?.
M\_W+P/V8':!?QK%(XG=>[/AAG$;B1OQ(WJ+K\H]ZC;&_Z7>_Z$OC/@9..!6_
MA7',')@!//U-C/[^2H3^'U_?=YO][CG\GVW;C?/_TVC8S3^N;][]T>RU_L`C
MU,:@U?BC\8JE@2??\N*PW;1[?_Q^_>X5<X7C3;D?XX'T/\Z;G5:OW6X,<O(K
M2"C3^!$/S$6<?.6>>\5G7@(K_I=P]T?GQ\\?7OVCV>KT&HV<S!54E$E5->#_
ME!7@L""7I?KO]_I>OCURN&7WF_UVQ\XIWXRH19[C6MSP'^JO;^'ED9?LE?)!
MHP>#%3E>24.9T"L>3V!*^#_O_Y-ZH`U$D,1?Z99#&`!<XUB\$_)_]XOL5G\P
M:'1:.?W;D+;$_=)?/P9?(S$#X+T3(Q%%PE4<@=&_).#_2V'?Z_2Z[5ZWURXM
MS@-(+$_S_6@DG.3+Z/T/9P)J2WSCB?@25+-MKY-KMMJ]3C>?W#:$E:?T#7@P
MQX9X\9?1-^%C6M-7'B7S=V*X7^%IM1O=1KN`OOLH62'K%=;BP33_0^VH*[?7
MZS?3RQOPU=OK/],X\4;S+>S[O]_+48:A[RX9]?MSV#9UQ6D"[]Y???EV>?/Q
M"[@P:>"*"/]&(WP.$P%?RT)2>)CXALF58+`4(EYV)E9O[9^,M?_/^?G[#U_!
MOQ038)V(SL_U7X81^V77Q-G]72_\5JM\@VF%L!8,P!]&4W;I4"]_>]#O,A%P
M!R2*<1"0Z<P7L"<7LM-_ZL-`OC?UT*61J8EIXODZE1$>"?!)[?0PGUPN'D5S
M^,@=C]R8G>6@N'KS^<MO^8_OWKRNUY(01AGA]T9I`L+*$OZ#<@@]"1^9[8AC
M(W71+(0O"1;>@?F/)]ZL7I-*[8+!!-D5D,^#>?Z)P9N8\2$0G,P9?$G2#F.#
M"@92X.42J9Z:*["B]%GZ`A"4?Q9_$#\<$<?U&C!AY(W@`\`%S(?D\.PL]%#-
MNVE$0P3P=;R0]!SS..LU>6WQQ</E8!'UKUXP<*\!"`+O<)99L*S9:#0LNOU9
MK3:;\!C^`ULM<4NMBN1ZQ:4%J]?N)IXSH6?!\4W]1-XUS>6**S@'Q7$K442`
MY;.9/Z]`/GP3_EJ-8^R?)/\"B,E@I$EUPM1W%6%$ENMZ2!+,)J<OOF"72;T&
M3HJZJM.V&%[[LL@-=ZU0$FAA%E'X@[*5838_M0969]"P.HT&S<]SB/I\/A^$
M2]R5\P$^H%Z78@?_K))\#F_%Z?!/\#YP')7I7)A/O89<$3]F'CS)$]C]@ERD
M(#9`4HP2$Z;C"4RQU2B)MUI$T`8NYEESH-#W<>N<RF7D*+H<4,/XF'M!G)"\
M(T]<Y<X1Q1R=N'IM*!R>QJ@34/ZG(9#B>]^1)0DL#FR[$_P'(#H%^"P/`)/`
M[2H]-Q1`EMQ)&>'>W"HI"4&6`B)OO1@745_Q3GJ3I">`;\#ZT*VUHGQK;;W6
M:I`LV/0D"@4N9B0]10(QK"M,B!%J:?`PC;2,`!09WA-_-?$"OF[EED,6][F<
MJS?_>W6@[6:KWUZUX2_3]#:-@;%Q#,(UA.DC-_;N.AL_>K4?W5YPHR\=V)[%
M9`UVY4:?DH;Y`G+]+PZ6)YJ#LZN4Q!EJEJ)?>@5P1U/Y#O1%R4&UV.>WU\4U
MP&NPI!7Z[;>KLG-[G0Z=<.%MC@%7L"7H<X,FNH.=AC\_1P?`Q2J?8>RY'I(&
M]OBS"*]!G5EL*J(Q/+M$Y->K&_8)_Q:5/L+NO&0B32DXG2'[&H5C`2H"=-R5
M`,N$9ZI\-K>08"3H'6C%.TYF3OJZOI<Y-XZ:V]G"=Q=FA5]D2`Z/24F#JKCU
M;I&!X/_"0!:I4^Z@B29#3"^0.A?1-,;9X@^78]#MN*LGK0T[,=I1R"E:]9I+
MRCN_FKS9DO[.?9S)QRR3#-2`Z1CG3";JX:NT:!>%L'?VKTOP8+1+)@E&_@1Q
M.IUFNQ\D)/^XI8=G'`&#?@+X(MG+4YJ&VCY(=4RL@`$LR0$8"<Q6$-[!ES>`
M2B791BULHA8^A*AZ@;'#.7L7@6,=N!$\\-L%^XJ.):?U^!;">B7L$GX9B<0#
MT$PNWEU([*#;2&X]%?J)2%I.6.XYN:;C0$;U40`3*8"P/P$I@3WCXG43F=A5
MKB>(+[R*GC!YT1B@!"O!V5#9;7)FBL+`P24-!'CK;E$$BA\D`H`3Z0CV_7*+
MFM&6E2`*5$/XI](<O,"%A0$4XA!`S@SCI)&@U_!:P`1<?)H/O.UX7$<**F?V
M;U0*Z)J7OE"BJUZ#?Z)N\A3;$L&G*`'@*(Y@\L3R6*Y(.`+?'&5V!EX?Q3C0
M;\<]/GB3<A3D'(HL4.T`<F"/(QO;9C\L,*EB)OAQI#?U>:1H]A3;8!0*[JJ-
M2Y@FDI-W8>2[E1PHD.VDL*^`K^+Y%_M46INO$?P3%Z=>.W/^^>GKZW,*TW@<
M'I>LBW@0S\)(;JNL,@LMD!H`]%A8<D8NGI5XPY0F4X)DG,YP$%ISS1!XE-@2
M@U!:R'4W=8"G\`\,?A3Y9<$6<`QC>PZL1R3&P"#XK@3*?P`5&(*)YS&H+9A'
MD<^:ADH.?<SWPE:V(U3;.>#K=]K)HF\*TUWD?#5R+:UFU?X6Y-=%JS6:,\$C
M$-^8(CA%"D/B"[K=G@PK+`X.,/4$;.!QKMG#R`K2!VHH?#@NO>?ENUQB*4Q%
MSL8!FP<&0$0$USE#",/F<I1&^*(>4,@/@GU2F_@R7''CHQBF[$4YHJ%&H>7.
M7@-+DT0I0D=<D&(DS4<F"==)4`4R.02S,(9!X,\Q\8](@0V4&-5KUXY''/4<
M]F4$_PTDXU]I.*5=8_DL&$Z7<*:?"^'US(A*D[CSK?3]1<_':<^`3P!DW!B/
M^5B'MH91R%T64?02@)4)>P6"06=$WS$<DNV[T<Y(](_8)(7O,-`<>#B&SIWC
MIU2<#FJ$(A_:E41Q0FE$C;6HAI3RH&6MU!^9=L$G"AJ$G"X_H4'4RS20,^'X
M'1%IU:PU-E@DY=&NTKIE2<"*?-![L:B6;:Q)AUG+`**<.PDN_EF`'G78+;BZ
M:(S9&<AN"'IP#DZRBF;5:SH,41B57@,]2;\"MVX<A$ISJKG3\38>:*/;""("
MHUO*]I=,7#J#>4O*M-B@.Q*X%(H<IAYJ)8J>9E]E=%8NQM7,J505XQ`#?S$M
MK]9FRNL!!6<QPHQ4-<#[1$4W<3:^CYL1`3PZH_)^-HK"*<;LDHD7N>?X-"C(
M,`BCUS@*3Q-D'P8!"\^S$'@K_-%KXM?";!+A3`)\26I3GEAZ%?D8]@)CF*I%
MYQH1+C!%2FD0M2TJN$ZPV?X](!A?)\1G\&W0J%)'`S%&D)JPWD;:Z"/N_C*S
MC?860[8\AKT3<+<28MS%?1:Z!U(HM'L+'CKH'!=C\TMRJX`,X.+N+:>3%U)N
M4R&D%P/.$HI?IDDB0=LR.D@F%1GD#BT%>0'C=V#.T&A[,2B%&+<(M'GEN1[5
MWHP'\UGAMFA9'`KP"6\5,.LUN=-#`=9C^(*[N'&$#\-WR5T`PTJ,DX%+V&?0
M\8%Z$G<;DD&@9WSA2`XK=2K/FESM\$D18D,>?(>_O-8*#%@:SP-T[E'ER*UY
MY9*`0Y(H8X$OZ159[Z<M+92D71^<D5-<]EGEEJCHF2HW.[-/2NG'1+\\IL1E
MQ`TQ<*F2_AP>*J8,8Z+/B&R2,1/4!AD`))$ZI*'T&-$Q"<%LKMJ<Q;A7&H$R
M3N2)QU!(PQBX/JW@6)#/1J$9B@9I.ZQH6&(6!DU0S&$?H)8NW^NI4:9H#K6-
MP"T0NFU:<G)@E,`PP_`*@;QX6H0>:BQ7I+B'_,"G'D`10S+%3>0CU-\.H[DO
MTG]+HSCE&`N`!5X*E%7%MZQ";(GEH245CBC$EAALAV!/$Y##YDW1G9!'?F`1
MT7#+[PG*$B*'`Q-%*[Y\A]L1\,5NP5<2*M:(CU`.+@X#FVH!`\C@WX(!/O->
M`RNL;J-A-1H-%H/K)K+IX?8#-Z,)+)2%DD>'>4#)3XV+1L/&@W7YAE4(?BU'
M`?4?KF@XV(;@>.50Z5DD1B0<%-<`Y0/J:.3A,2LP`P\,75QG:1\X<EJZM$IH
M'!DE?DUR=>;!E.YX!'HL(6=KED;@D<:"NCKIF==K+9SPPJ3+E#(BM-#::5TO
MIYU[&86,9?)V%CLO+79FTFG)#6PO76SVM!+SZY*/[W^\U.^IE%ZM$Z:3<):1
MU=HFZWLK$AYP!UL%80=W\K45#T"2UYV0;L"*_HO@A:,T#6FN7`%4:H403Z\]
MWT>[?&9KI?!::06*8U6I!0MVIQB:B4DPPUOT4"C3)9#I,#*7"+,G,!2MGA5*
MG<&8/_5`A>8:=%EKT@/UVK\5S8OG5X&K_$;*<@!7-H&9@/'P1DC'3#C>R`,M
MF;OK,$=X"&=[!MMD!QPZ&8Y89<=>4RS.D2'->*(=;GH#C_[/6J]5^SME+8IG
M=<MFZ@V%#[9!Z!:E#$;Q&L7[C(K7:-ZGU+QK%"\ZZ/>HW=8ZM=M:K7;?,*/"
MC`I[F2K,Z+`#TF%KG<?..BU&#U0I,7+#K"P8=8L!ARP+2#JE^C5YL(^_;A5_
M;<D@0O%SE=IR;<+FH6C*XXQ,48INOE01YCB[X+JKY'8=1JG7'"]RTBE&FE8=
MYM]@S'<D@ZJ4-B8#(AA'I]'P,*L`0_54]FW*Z,40,16KI$'B47B89$,65O`@
M`*1%L4J36MPMF-.;S4]O*G+WJJ.06NW@"8\KZ/!"=3_'E'^&6T#,9X/Q8,7R
MP?3OQWC$?'8W">D(!%,L\!`D2P(HA\83#2!Z#;:GE2%%]2IE:N::L)BA5#YJ
M4'%,2M&,="A5!4_KM;-""8,;W@58VU"($^*O8YYX\6A.=3Y>X(II@+D/7*:+
M.C[WID6Z9."6N+5R>UROY?OC5<F),&*>&ZGSWZUR64>]-NBUB^R9\%L\HA!!
MS@)YSE3)`3J=,%*S12D#JK)`&D\M&+%PTJB4.E0,JN-I(*[8K9!V&-,-!&;B
M9*>8F+F!BR>+%$OQXPDF'0&"LP3GOD0!H'95</Q:C?Y)CKX0[LF2"5R=*D<R
M4"36C\,RQ:R"8`.A!T-HQ#UU_J%-&%8NR5JC/*^X$DGUVD]VTVK;7:O94"53
MRZ/A$;@^O'91#6%ZC>>JHT1*B-58P?6F=VFA?[)[."YI$YD630=*DA"5\RJ'
M@"^-51N/+!=C2NH??<JVU>NW4&VOH!`\`"314YX!!A?GA>062K]Q-]/\TK,N
M3J%C#=1;Z'3F$UUVN>NU=(8_+YW?%(>S!EW)[$H=S2B=4G%$'G056,VPP0!:
M/4R8`E:B,:%T'N)7%A!5.5B8,Z-/K/(0J\[6*CO4E=1<I\Y$)F>I;Y6)0?--
M=@'L51S+H"[\2J&%PL"JS`U+YHIU?9A/P;%82";(5)^2YX"@(VC]-2"(<IIH
MC3'-0")<)D!(AV^D]@^XOL3Z6.9YE9,RX8^RN)<29I>.U%<G3,ALLQ49$[#<
M(<!!Y<>J%`2DS.$8T<`O8SX'YF@%*F6##T$Q;EI#5@JB[$&A;%,5<%S[Z97J
M<Q8)3$8,T!R65<NB"L4EU:4OE%XNTY,`606#JBN&2E?O/.)\]FG2(-8L[OV7
M]VP8P&L_1_QN34.ZX@5/JWII]9I/$CO:\I*IK;B!35NVC**5&M?MI/O;OH.?
M%2W05C6$S=_?,=F;W/2S@EZ\I6IUW]V]4=QL]M##64OU0C>YAW+]&:&R36_=
M$]$+ES+(`O[(-TK%HNBFT1-/H2<>3_@S*8QV&W:,IZTP3MF5H'9VL%]6U8>R
ML9W1&49GW$>Z+8,>IZPS3M?)^!IAUYQD;M5K6!Z0R"@S_H=A(TFJY3,*Q"B0
M>Q6(;?6Z`PRJGK(..66_(^_M;;P-HRSN);UOV?(`YI1UQ>GZ&_I"`*,FC)JX
M-Y"ACY5/64V<LDNA0ADFA&&TQ7K2NYTVNA6GK"L>Z5(\KQ@8@3TQ@=V"\!<L
MLZ=LW_/3S:]\;HXVC<I8&V6T6KV&R88XU<"!V@_\EJ?X&85A%,9]I'?:=/_)
M*:N+4W8P]&5_F#YU*X+4*`RC,-9D6[9[IYX\=;K^Q265--5K[U+!U)V4C"ZE
M-%K#:(W[2,\JRDY9;YRRH_$IC!)LTVY"&49E;*HR>OWV*1YNWM^BI;J.\O[^
MP$^@.YZBSC$)$[SJ-(SUY53%RMGLL@)L@HU%MX6J2*M0?(OM^1U>Z`!152.)
MOZ^HDV34EQVKI&7)LA<Q$<N;2-Q"Y67,5/-<M]"NL4#J15$J/U('=KR.@5J\
M),6Z8?JO(5[,0D6X6*F(U<_YY9'UVBR-9F&\HOG,ZHX9ZD:@4MEHO::H5Q27
M+OXL<H.Z(D=(D^3B7R(*+7W+0:`[FF2LD17P%RW=S,EB;BJR_AO8B;APSY!L
ME`X?+%W&(6_GX$',J1;Y@A4N*I.3*=VDF5_I<<\%FADW=,$U#OF3W>NCFX*]
M_+-V)X4[-8EOLL(=Z:IDT1S[[V?78:EF`",OBN4](#'\3=X/%"6JM\7(B_%"
M&"3F@I4O$D@>T-"`#?-F,M300*_5<,Y^ZG8+K1*PS8+L@JU'3F=T!5V&A6R9
M%P"3813';%\,].+BN-BN/I>+K)^7:C<MY8\JRD,LS,>O4-/_0H$]<E`UL,^N
M0BC<#YS?>XN][;-K#*@-/=7[H[B(XOU3LNT"=;TN$`#OS(1L$JX:.@AO)CL/
M4&'^PG>T9I"M^(OWX55=GYQ=DN8SG(RX*VBH3-S5;=E%`*SQBPZE;\CSVH,/
M821;I:EV;C'>F+VH9]E97M-^OBSW>$.BEA)]M3+[J6-U>C9="0V2&ZF@&"T]
M)W&A2Y^I-T7Y+NFVU6BWK!:\!ZH'F[AW$+IX3P==\^!3TR%Z.>LMATW693\B
M?>_T$?6-.0!_(+^P'J]Q4Y=C^$QR$Y153#WMTX"G+EUQ@THR]#UYQR8L'IF)
M*2>]$%`['R^@W\B+)&)L^%SH@5]AR76S'[J!/'3H0KMR=R)]?2>9@3"-`0TQ
M]K>FZ\Z*2*#(2OQZ79^%Q[M_BYL]Y48?:2-3[>,K8KY>OGOW\?,_S]]^N;GY
M\NE7UIS]>&[??MT>?PWEV^VM^KLFW0D1`$!N]]7:?9:B[^V7;^_>?\LF,O2Y
M\QVGPTCXE!I1FZ^E?AR[5DAK/K=COFXTXLI+MS?["!@M=&H_2:?V_;)3N[RF
MFT=9-ESB"K"N9/2SPO?)Z'_THAJ9W%PF'\WL&[IF81L1.DRI>4K4';LJ.'FI
M,9;L:.&[<*3THN3R12K+3-DT3U39/)K9&*$Y%I%_D6;8B(L1E^-'UHN<E!&7
M'8A+15Z!$9<7.2DC+D9<C+@8<3'B8L3%B(L1EZ-`E@GY'=-J&3VP`V:?7<;L
MF\#T2N%N>V7JRU<(1FZ,W*R0FZ]12'EK1FB,T!BA,<;&R(V1&V-LC-`8H3D4
MH3'&QLB-D9OC,S9;%H<_5W1P!STF6NW#[3&Q&?<.K(/5WJ.F>^DKL2E0'WQ)
M:'^WS20VH[?3L?J=_EJ2GZ&1Q,Y18N!\`G#N6LWV0?9%,7`V<-Z:7KMKM7M=
M`V<#YY<!Y[[5[[<,G`V<7P2<.[;5LXUV-G!^(7#N69U>Y^7#>=?=BS$^=$_8
M[,AC1U=AG-1KX2CK^+2G(-(Z#AZX5MDF/'T`,K"1ZMEF3KEJVOVDVK;5;?7V
MH)AV'>1^9N-K1.@PYG28(C3H5I3!&A$R(G2(<SI`$;)MJ]G:1_#"B-"SP\V(
MT-.(4-,:#/81,#$B].QP,R+T)"+4ZEB-O<0<C0@].]R,"#V-"`VLSLGNA4QZ
MW#+O_AF%<5ROS:)PY"5["F\>JGP^S\'(3O7*$YY?MZUF<Q^:X\"4A,'UZ>&Z
M-S"X-KA^6;CN6,VV23<RL'YQL.[W]W$<:F!M8/V\R<Z]AO&N#:Y?&J[[5L-N
MOWQ<[R.O[K@#2]]$+'CD3/#R5Y>YXE;XX0SOXC-!)J,N5A'>LWI=X]T96!M8
M&U@;6!\ZK&VKVS?UQ@;6+P_6YD#`P/JEP;ICV:>P$S>P/CU8GT#@=#^Y2^LR
M!8\W_'0M?'AS;-5K8Q&(B/L6PS@4=Z=>X,5)Q!/O5NPI%&7R+P]C3H>8?VE;
M_>8^G,MCR+\T(F1$:`<BU+2:]CZZ]AD1>G:X&1%Z$A$:6*V&Z2E@).C0%N9X
M),AN6(/&/OH%&1%Z=K@9$7H2$6JVK':[:43(B-"!+<P1B5#?LIO[.($]!A$R
M*7>+G/LR$QC7#,;UFA_&YL8#<VJRDO"S9L=J'7/#RXJK7PR>3QO/O<81]R,V
M>#9X+N(9X-P^XFP-`V<#YR*<NU9W+\W/#)P-G)\!SK9M]3O&>S9X?BEX[EA-
M^X@K5-;@V23/;1E(2B8BJM>\P`FG@IV)'S,1Q.*U!8_MJWS31+D/8TX'&.4^
MLZUV^Z6E*^S.`AO).8PY':CD]%_:$:N1'",Y3]!J^H5)C4E,,.+SA(;'^&M&
M;(S8;#LI<[>!D9Y#6YCCD9ZS9N.EE04]-*YYLBEPO]%M!B/X!0ME-EP8Q&PH
M1F$DV"P*;[T8?L/@1Z:BFPG_`:/PP-TRL&F.1%[TD<@69!_LJ<A.('/`I!DT
M&S0;-!LT&S0?'FD&S0;-!LT&S0;-AT>:0;-!\U,ER1UW."D(`P<&C$)J)H<9
M<8F(1)R8VDJC-.Z)0W>M_C%?E6FRPPV>2WCN6?8Q7[IF\&SPO%!;V3CB!N\&
MS@;.Y=K*WC'?]&K@;."\6%O9-NK9X/FEX+ECM9LOMU9X'SE(ZY+\CC>@]%6G
M(-5KBSE(>PHIF83)PYC3`29,#EY<OJ1).#;R8^3'R(^1GV.0GV;?%+P8^3FT
MA3'R8^3'R,\IR(]MV8-]'-,;"7IVM!D),A)D\N6>/+SY623F[@%S(K(^GZBW
METM0#^-$Q.#YU/#<W]-E<`;/!L_/DA\W&!@X&SB_$#CWK(;Q-@R<7PJ<[9;5
M:._CTC^#9X/GY\!SU^K:+_=N&-.C:ZE'E\`>70JNS8;=>H/W"NA<.)XDD3=,
M$S[T!4M"9DHPC5+9FO!.YX@=OCT<X3P[H0;4!M0&U`;452>([2-V_@RL#:P-
MK`VL3P36;:NQEYQ#`VL#:P/KX\Q86I<>>+R!JJ^1&(DH$FZ]!N1[K@A<4Z5I
M<BR?.,>R8ZK,C/P<W,(8^3'R8^3G%.3GW$B/D9X#6Q@C/49ZC/2\?.FQ.VTC
M/T9^#FQAC/P<OOP\95NZ]M%'.K.ZS:7TN\\BO$[$U&(?`^>".>%T&@8LGO!(
M3$+?%=%3!T3;1ZS4@';FABEP]LG$Y:=]*;-5<]GO!;]]JS=XBIXG[<.YX]?(
MC)&91\G,P+*[32,S1F:,S&Q>,6COI<+*B(P1F1<J,GW+[NVC9MR(C!&9%RHR
M=L]J]HV9,3)C9&;SW4S#ZG=.S,Z81G/++'O+8\^IUWC@,M?STT2XC,*7,Q')
MZ.2>PI)'H'B>,-U[%[KE"3L--"Y:IJV1`;$!L0&Q`?$S@]@V-U8:$!\]B/=Q
MKF)`;$#\I.[$$5<^&A`;$+]TG]@TD%MDV+\%P@G+<OFMB/A8E/+28A:F29SP
MP/6"L0D#F:K_583WFU9O+V>6!Y8*:W!]8KAN69UCWEX;7!M<5Q9R=T%?]PRN
M#:Y?%JZ[/:ME<&UP_=)PW>Y;G8%I66MP_<)PW1E8]F'BVF[LKX;R%RH)+/Q<
M#J24?E(_+'RGZI''!J&:O?NC4'^F<>*-YKO@Y`UQ\C-P\EO&R9N)J-?2@*>N
MARE(<3J;^6(J@H3[;!:%;!1&4\Y&7L`#QX/?>0'])O$H6!6F/L(DJ=>&&,(*
M8L\5$0SC!:[GP$.W@H4CEDP$BT2<^DD,_^8)NZ/W)AS_[#AI1*^,ZC5\\.O5
M#?LDHK&(X`&7#84(:.1T"E^%Y^"[_^)!RJ,YLRW6;-@-"RB(&(\$#3!?^/@H
M3=(H^_[%FG#:/>NX&#K,5F08L5^V'NVP47$)C/3#N%Z["J-9&,GE/LLOO+C2
M3^2_>O?F-?-BQ@%"0X"!APL$[,?EG*51G-+5%[C`KKB%-V>(,7S@!I9FG/H\
M">$%1_A^S,YNOHEQ_)IQ'`Y>`>4CTL1S6!+"$)$`!+E>'$98O*OQY4VG:2!8
M/(\3,;W(Y99]Q8]S^%82PFC7"7"_7H-?.A,>"X;I=Y=Q##PE>B['D2#T,Y?`
M]HG#<ZS9)Z`!W#*^>'&<PM_Y#&3DAX?(].?PS,](C@<P5W%<^.9;X23`O'>>
M\]T+8O@7?!+Y.IWQ8%[FZ=MW"^P,F/@!=`9C@7(HY0@-`PWLB"CA7B#O$_%]
M^$PJ978&?Y@#5X&GP'1\E/@I1>_M.Q;>!4#ZK,B7>LWW'!$@0S(.#$5RA\*'
M7_T]`&F*8B^1:RJ"()[[MSSPX,W2%/!/Y4D@A^&CDI_78@;+,P39ECQM=-A9
M@AIH<0SVFZ2G-)9%@W&VFM;W/ZZ`%?7:30Z:V&*__7:UB@R[*\FP"&PPEHM!
M^<MT#/+%6J1@&CVBD15)E-^I)+(*>X#:#'SL@=@#JB3X8,'"[T!N]N((["*M
MJX2>0@B.'@Y!6Y#PQBR%J45*Q1883,_A+\M3L@!\CI_B`02P9AH"CD*41!P`
M?@=,+8X-LYMQ@%PXYW[BX?E%0!?BQ-P7)*%JQ8"U@$\W=1(88,H1N&A7`-U"
M2(JG'KP!\B+'\`(O\:3R@4$<T&:@V'W4`6B*XH2/!0R4P0%,%RE^>'SDX5T[
M<LQ<O]1K)+#@Q\3%9;J,0<YF(*\Q"#$LE^=X,UJ"X9Q8,^,1SJH@_I&8^=P1
MDG.%I5#*J,3@.R^9L.0N)!?&]2(0U$S<8E"_\/RE!!Y1^PWF3Q__"O\-0^IA
M+A?!#EH,/T,H4LA80G=3*RZ]RN5!`5-+(H2#9C/-WBLK@$]>`"L4)B#]JSYY
M41I"@0MT(BHUXFD4.L!P&*U>"\0XI'4&E''%HFQ5"PZ#XCJ]+WYX<4(V1;)?
MN`L(+BQP_J^B,2"]0R*I^T!D8CQXLZDEL-#`R2QND$#R:$@KN1817I(=ID4'
MGKSS@%)Z/%/C"+QS2@5'``-_$F`#85FI_I$7@5+ZJ8-"XBN90$QYP2U@!FE%
M6U#BNQJ\@/5AR",7WY1L#A>F'0YC$=VBG$LU4LE%.=6899P';F;\*."1UB:=
M(C,X3%>."(SQ$I\4C+P&:TE3`7'P`=)7:)G(^?,E.!86A=/#R]H\`_,[?NN!
MTOFO,`(I_,MBGR[>72A38"'50Q1N#Y&51"%WT&<$%3`48P`X?5`"M.QPPG_C
MDB"C`&J@<%%XI=?+N'N+CC*:791KS0<TP.B""D(1Y?P7O"!`=8)>]8:.W,W_
M_`:>G`<>NN>0M[;@U%;A'KPP\*91_0K?FX(W'WDP45"$Z,44_8[!&^6\:%U&
M5Y=A/Q74WE6N!NI[)=3_`2[!HC*IS:3(M!33&`=X_C1H]JQ&HR'!"9\!GHO(
M^XLT*7J/SG]23[(R`;?'PQ8N@"$P)1R=KN!<JXV5O+R;>/!;1"?M'`#CZ">Z
M]#XH^4PC>\'J,=1S.]\KW+^9?.!.P>X_ZT[A8R!]BO+2YR+9:FB900SB/M*G
MY49/!>%',E^O:2]^!;Y@&07(IFLI@W[KQ<KXCK@721R3D_63;=F=!D+,4E#P
MXB((V#T8`&.V#(),^X(^$`R4>3*)JR99KY'56Y>M4?G3WWY)X_,QY[-?WZ8Q
M?":.87LP!%8A;]YYL0,Z!/:P-^)'\A8Q\8]ZC;&_Z7<^!@YLB6+Q3LC__1A\
M!(,0@&I'SJ'XPGO?Q.COKT3H__'U?;?9[Y[#_]FVW3C_/XV&W?SC^N;='\U>
MZP^<0F/0:OS1>`7ZUY-OP4ZKW;1[?_Q^_>X5B(D#NQT__ONKQJM_G+?L5M?N
M#W+Z[Z6E3/:EXX1ID,1?^1S#,I>!"[^)0!W]YO$A>&^X[A5S?_"$_E$9LUE,
M]5&Q+^H=I83DOF#4DL2\DEO8&4<;@$RBGV?<=?7/.FC6:!23F$H94LO!PFHR
M"TIC.:]IO1K96>;3ILQ1O_CW>_G%(;A=2IF]>W_UY=OES<<OGW^5AA]'WRS\
M24]]!F>)=4L7<BHTU6L%/"U+YX:)50L9;">P5C(,I'GHYSPD)QX4Z2CT_?`N
M9F=D^\,T!@T:O_[UP5R]/SJ[63Q6\P0V`&"+GE:@NYU[Y'E%B2[VMUP552^/
MM^.%W>+<X@&DVP=%^?V=+%=/`O@/Q@:7'O[8?+5X&O($HEV`\3XXN8%>A0WR
MDB?W8"6:+\GB,=$;MB6\JA;C(,"V[3Q*QZX',XL]B<SR;/<L0/MEZT;R`YZP
M$A]U6F7$9YUWM:8]Q$HFK,SMOQ\K&]G?18BN^?!#0+LWD_G?ERI"J:*0_$>5
M)WPO\(Y.@RTE(CR'K[))%=+*W(^5!+?W2''3:O3MBPH3_W@N'YC.,:`^&5#;
MS>[%^@K1XX?T-F5VQHANN0C7W.<8Q+3J-3&=^>%<"#84@1AYB3YE]NE,RIC7
MI]-$CR/\&572P+8OUM_I=_PJR6#[]+#=M!NG;6[-KG4G9P]3/!ZLU]Q48"K8
M3"8N><$H\H(Q)8$8(VL4T7VD]WJ-B_5%Q,>OB`RV3Q#;G?[%^L8/QX_MG>QI
M5]_V9NSNTLI\P2#QEJ;UA`Z_*EIJ[Z1:\H`FM9E:VT_T>3!X^+[XV(_!C"`9
M0=I1Q-OJ]KH/]WV/79`>M#,_G=PLHRX>.JF-3[Z.0DMTK'ZW=;'^^IX7JB6,
M_!CY>:2[VNLU=RD_[:.2GP?TUL@+11Y8_5$N(?DR$Q%5C;Z7M3K[K79I#3J#
M3KM5J'99^GZ9O-^#2,AJIW]R+_@MC.,OP3L1>;?4FV*_Q-K=KMUH%VA=0TR9
M\F^J*@J6Y5U>$O4Q^*JJ[_9*N=UIP/_EE*\A9ETQU#LQ$MA@Y!N\&Z1BOP51
M6`_5'?3N*XA:H&>1\91$\)5'R?PFXD',J03X"0JA#JDV9:'.<),ZHDW=\375
M1E1'9#>+_2A:;YA:%4;+PHKKLJPA-RH77<?EC&<;M9:I*`?==M%:%ZU'E8QN
MNG+R9"^I*BNPV/MH+EAXAY7\[V\L*KI\U-?I8^URFZN?ZS6J;I8E_UCCC%^U
MV$^/_U*S875:;<MNE#V">DW6H48".TR`YHH9K)WGBL"-9?$Y9@_Y(<="^B'Z
M.=CE!JFJK+V_3"J*:[/:6:JG!YM$1Z9845VOX<CLCL<[X&7WHE,^V/^YDD0L
M"7[\Q_Z5!N4K\&BFDC.2;X"2A08\.UC%?J]3L834VHKZ3>BR>&QOHOXI*^'@
M;[_N@@#;`@N(!<SER6,;@C20>)&>4J&!0L*06P51*K%%96P^4HX:?:NWQ!<`
M-9_KSB<<'-0@IVH(5AL91@#$4WPO4(T`*%O."6\%=F3!QBX\GJC.";)G$JXL
M#KCKQ>VV^U9W81);5/F?MMHN-3-"W,,Z3U6;D3!PO:QY!W430BG]5PA@8/\-
M\,`.;%E'%:M>TQH0^WC)[A*ZCQ`)M6HZHYID+32GR-J+@6;%+BI#P:;<)7AA
MQX`PHJ8IDD8OP@K_F7!D-[B[0$3QQ)ME(*6F$D3L&WP9B7(M-@$C!."4+5RR
M!@#)!.@_GP.J\8Y.+W11+4QA0M3N(PP*/5I</L^4`_UB!/X;][,F"7R44#L8
M4:^MX!',RN%3P<1HI(@O<PJ+<&G6V-="E>+^2J2"0Z.?Q"Y?44@9JF,1X%Z%
M.OP-8_&?5!2:X%#7C9@6D!JK_,K.O-=$?7M`'<VJQSQ3T^`_7F<-'/ZDZ=RJ
MZ:#4XX+J=2J.4EAKGUK7*-LGH0/_.Q'^3#4>1*\=%@N7&*`6J+XXU%C)PS5$
M]9Q$J:,[1:E\W%`U@Z+F6[CK'7$']Y;S-_3$F0>SE'1C#Z)$3:PX+[9R6@5\
M6JS=^3D'H\91-A<>4P>IW'+DA+`BY;"0:2#=`3U6N44*MMQQI:!A>PRP!>?(
M$3[#7C"X^+(51Z78=.R?<]6L,"^[:71_UI]#N2PM4&&T0F.5($QD<Q6R1M1]
M#!_$XK;"")YL=8?]-U1W&$X9716*W6Y1QXX+]@&GL`[`,Y"]2%-7"5W)ADVQ
M6[G&,N]L0^RR*NC":FZ`778_=%7CN'NQR^Z%;KVV!KL(C'70S<1[)7;96NB"
MFKD7NZLU_@)TE7/,/B;DUM(V>#KSBPW;5BE5TN?$E!+MLKL8#N1AA$`2`^\P
M5/;5+;`NT1`Y$S!E(/MZ(3*K=B?4F,`'^"[VNR*>#K$M(X_E2H=IA%,#WF9F
M2;<YP]9X6DB1E#`=3]@7)PFI<R+LZZG_(_#*%XF0$RJH.Y!47V&7QB,'3$*4
M+&)N?--(=ZJ*P=C4:]*NH3_)`0OBEE,7/7@W^%[>7E3R9`\^Q^\SE`'L^`AB
M[B+H,&J2Y/NV10`H5;,@RUG?,*NLTA14BTLD>]7":X'JIUAP5B*1MUJ+]</B
M1U+H_$?]J81;U%?#N=1'"W.X6!%G9=^*/C6"C!8P)D4+V']_D[\HUY=:Z+)Q
MQ-V4^]C!4'L711OHD9F4B'%7;-NRQKIJ$Y$C)0FQVQAUVUM4W5:W9^.."5`2
MR_:\(#0!-5\$0:KZT`=RANJU_T%7JMEH#$B.7>'X/%)-$!>^TK6Z@[[5AX_0
MD[DF)OVX6A57#C7H-:T6#*4T8=Z+%<?62ZSHB,3Y!B88.*OTF(+?4+5Q`B45
ML$LP6/Y]+/W);EC-S@"W5]5,9))C3#',;BPQ;&E=8`?9[-$T%SBVRG9)K6I5
ML:QC-5M-JYVSC%5S3!89;\8R5N88>'^:997:%C3"SV0S,6Y#.HO_4%]7#>-0
M3Q3C*G2LL.##K-+D7'6'EB$H].3@0\)?8H1M-3'(`XQ`JK'.*Z_Z"DM8*ANP
M\O(!WI%/M(X9&J1OA&U51SI@M+@*S2[N72L\,#5)%'6?74V0C=@,#3C$TV02
M1JIMST*O1!TL..;][^/ZW#UN]UOH4Y[O;&&4\!H8K)J`ZL:XX8@:89=0`4H#
M<.MAH]-`-8G]#'O7B0#+@[3\"WP",6=7Z$)&V"<X=#R`0KS0</GSYW]=72YT
M2<8^E(%VM],94O%3BWKB45^\&#"1:#LA;1,>+A2"6_G<+MB7@EG(^E_J:2+^
MZC6BH?`))&"4@FV-P?;$(YX[M_"[L(H5"\V$Y8`\\HBH;(<A8_5S"BHATS!T
M)'E(*C`68`?1OF;F_H*]@QE<!FX$#/V*70`Y.[N;A*0Z%JD`T>%>!`"0>NSJ
M_9?R5B-GBM22.([:I5<,Y0D0Y$\".]'[[,MHY.$J%GO7#U3HMM2'&_0^%9?*
M9JYYN],\#)#.5*1AY9(!`%!'4!]7U,DQ^\0#/L9G\0`CD&%OR6(8`38H]F#0
M-6I@(S7P!=#QKQ2$!QR?!5F@9DTR+"L!D^\[$"Y??1Z0=E=*`Y=;=CMEE],P
M<N8KO&K]1[H-`93Y&%MH4I-:0;W?'=6A7UG:BO;[!%9$Q"P-2!7!IY=%<$IF
M(<XQK^95!O82?(L;<)P=#+SJW(*":,#DU<S1"O6.NK46^&F1("L)QA<^P8__
M!%]@J%X0U+"6I(SLW#!,)D2,[$=\'X-E`V[%Y.)T4,*49Z'W7G;/&,TMI`5/
M@NB:!HEV1_BT)\K8_?_Q61B_B9F*HPJ]Z\'`R%?JD=]<ZOH.?[[\].V\T;`K
MK:V,8*@M$_:EUBM+N,ZL]X+VS)[*A1/VA6DL=Y0+<1O51%_11U1=+%PS\1MN
MN7.(EU0#XBEWPP:+:D2=!);I9DMD2R(4N6CMQ_"U,9W\C<`4M_KDITI/$H6?
MFN,3C^YXY,8Z"E+F^_*\#,XWP?E[;9Y!NU,W83L[B?O$$^#J'?LO01W%J4-R
M`0R<Y>W-BP:?_$%07U;)/Y#+B;HO'PX75P1C/H8A*03,5?"*>A73(0V^2NX`
M60AJ4H[7IR@[(+^%X(GR?<S")2V+]U]\X%/L'XYJVRHZGS"?*4[F7(4_:,\'
MGAD"&_MF8G<X7XD2*N8X">GV:]5+G?;+^AHA'0`%CUC`Q*R*>8\C8`SM@%DX
MTZ'^F;Y?0S6"5B?^9!:TD%W)V[;EA1RRT[P,8</FC&P13V"[=]%MX%&/&H"=
MO:4TQ&L'-J%"=J\6\%1S@%]YS7`33+)YJT8CUNLH;,$G_5KV^.C6D<P24C@I
M5OZR[(FNWY3=_2F:0":0SS7(\C,N?[[`I[+Y5B2AKTP,E^C!3U+45T4:*[03
M1B'4"0`%&V4[;M:CDVJVAL%G4QY]%XENT_V3.N`&1_4G^3XP6<$5OU,&L(Y)
MHH<?"6\Z!.YE"FLBN(^!=!"AB&+MLTA,O70:OT&]7;AM1B5)2)=@BOYP0<[T
MI2"9-<#+L&@*7I((@8WC)8=RIT&O;_Z;44J;M^(CDIN+'0#Q*I>*PX`JV<[X
MS-E/3<FJ81BD=`%)%G>0!@+81!=S`1,PS$2\`PD="6D0[(9NNT^Q;PITNP6^
ME3A[L4"&/,+A=!N1G\:DY^3U0B"J%+>F*TXPT`*;IAP%QGIL9#W>41A>&O0U
M7>:5-!9C<*7[&?"N)_@;B2"*TF_>2+`/(6@X6BQ$1O'R)DS8D"='B(K\IB_'
MQZL]1I[>4R3\Q[GX`5M3$+IH#&_^)9^3FO-:J./+3L,^<UZ?M;*3J8]HZC#J
MIY,OKT*7\&@/^MWBE4L5MT#AH\LW21$YLW3H>PZ=,.%VOT0%ZS0&9_SUF?U:
M;N/M7N-LB#^>7;X^N\T/S8B2I7N=<E:50RH8DX/-`)MZ<2RCZ<K9G&+"H**'
M@V<E,(9IR=.PU7<+D.F3^[2_L"WU_=:1+DT"4S>%@=N-'D4!<XV+YS1>F.+5
M1>I2,CREB3P'U8-#:A@-,.IAJ>P*5R94G,5VX0-M/(N]*=[]H>]HH.,(%6?!
MH")M*]/AGWAACSZ175"F;]6%,_7:.WWC3);@L:!H5V[/JJ*J]1HJ&XK4J+@-
MKLI7F#Q&5!-U5=A-!+(KLLM,BJ)`9SO_)#_%AR^D02Q\'.(:4W43W.2N&4*N
M*^Y5*-S#/F27).IX#XQV@P=^:22#+@3R?(#[]"/^O^K4^2URA!=N7)AB;HP4
MW2\C16TPOL+C:4RNAO<I"+W?].Y!H]5KM`J5`!M259[+9Y%<\7CR51U8OYW_
M#GNUCT'V^B5Z0Q*C^TVS[\#_;[;SZ6Q.V&+FMSKUB[^,,`M95T;LE_R>W6GW
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MM3U?M=1NM3IM-<4=4%N8>HS1"$=\&<E-._'L(VA2>?/LAS`"!7N+%W'!P.!?
MR?(EN;/?JT[J]6'">L8/)S*?Z77A<NMW.E>`8*+/3/;N+]B]9C=#ZD;TY.07
M9TZ>_DUX*4^0]+5A^Z:^UVS(VKQ-R<F)_[?`,EWA7L(BP9[F<XI;6M(J2J60
MFHF_I$F<@%^-@;3'3V59T\$L^F`_.DV[(V>Q/5WYG/2:?0G*B%.OC!8XM'=W
MKMML=O3J/("VPL1$[$3>3+KDWP3>0Z,4#,P?]&L`_Y2G!O&>ZQ&WO`QQYX&<
M\EUEU76(]U6<[*@DL;54D8AK`OOU2S><H9>0+T^]5EZ@!Y8H;G:CY:8!N1W<
M:?G86I>M;[7,XK:8J25C;A\NK]_J*`L/6#K#E',5N>6N&TD5?#?!6]-#2J?%
MF"R&XV:LJ0,(XS!T*?/4F\XP<$&)R;@GP8!=)*B`!;0?RGLL<]'87R(*&?PU
MP!,^S`)QP).A/!B5-R;#-8J>:>AB["Z6W[6SY.UM/LR*WZ4;FE=]^`-E2V-P
M;&$(BR+&F%H[I^S3+%4/(V?;<<;#(V$:9!I&F$G['6-5"9A^2H6CM&Y>^3I=
M$TUYF!B!PXB]1Q?[PAK192@T+%L]JAZS7EL:M#B_>*)3R.GH*AN>#J_DC7D!
MWC[NXB7:=%DJ>&&2HY@>A3$QV![2Y>64D`U?+GQORN?RFQ=TLWWEZ_@-5:68
MG6L4[\EFX]1SZ70@+TBE]8C+$Y6%?.6EQ+/P1";%T@EC@31]T3(/`KRR%9^*
M<;F0-3)3&Y.38P2OXT5..D4KZF`6FW3<BM=[5ZX"`"955WXOQ"VI^K!,I1_>
MR:**,DI1.F"5E7C`OT1^7HO85]59E.TO<[LHV=V;JL.G6-\6*W&NGLMNB89U
MI8SK3&'8'7G5DY1*[JJS27V@IU>"N9Y+<\1[P/'<%F.PE..`#'8275.&RXIM
M3^C`9Z2#C!C4A=^0CM_Y3<5/J-<?9Y^?3JO+8_$LQBJ3\S/_/9KC:0"C(SAL
M4HW_FUW>KG.;*>%"W^M;UMF9,*JS!-(KGJR&51^EX@("[#V?8,4O2.$B"8RR
MV@@@`G\,DH*02YACXJCCI^1[1^K`AHZD=2JZCF#+;\"(2OOIZIU5`^.I#5X1
M.IY4UQO*4U^LQ=A@%F[AM(R*,3$OCI*A>59]FE_@KGZAU%-&F"YU`<,PHD(:
M'BEUFL7P<^DBW:J*][$\5-5YZ*6XAU5L!:=D*09\$W<$\OQVB6?*I`RU717[
M8Z->MXW9F5./9U-(_B*#F>;OI<YN4&6`N1[F6)F3)[8"1_,DAGLPG6<B5#,!
M/H"ZME!DNTR_+,J5-!?-B&)]X?G"2-7J'8WZ)OJ=K5+OLA9M6;^SS=5[?D;T
MT,W;NH#TM^Q($0\W'KK5^Z/=Z30'W1_M-OS<VS#8VQCT;;M]7V2Z3%QY*O\$
M5,4R/+PYU8,F$MW88N?=:;9AJH5V2X7O+AU<P0S"J<!H]64B#RY0DFY"/,[`
MHXS0Q[J@[8\JMB<;&-OI]/NETZOMJ%MHR(7^+CP8ZF,".=C69T/;SZ3=Z3>+
MG;GN)63QY(WT]Q:ALP<PNMON=8#5Q8,V^=4ER5/,QS#@E4S4`?+5N0LHBK>8
M"R?D<S=8@O3)"[#$9ZY7Y!*/F8JCO`<%F<P_P88DA+_D]8M[G.YYI]?H=[O-
MDM0^U<06.2K??@(,VHUN\71RX<OWJ(&]+D7/;C>:S>X*&5\ZUWUZT6UU[.+)
MX\926]45[BE6N=L;#-J==?WI*HG&I`:TR5MVHGN(8F^VFGV[H!%+G[[/)&'1
MM]3XA1"Q;)<54US\&=&ZGK@5#2*?2-8ZO7:KW^Q7=(A<)7'7@LRI2D/"-I@N
M1JC`H:']R!/@&9X$35U0U9N15&6W0&VKO[Z5-R/ND^YFOS/H=1<MS!().^L8
M^A![,.AW.]W>Q@U#'Y)`\1"4@O[JMOKKTR=VEIJP`9'W9B;8K0=D)NSSQ''5
MA"H/'`$"/5`,C<<=..Y@1[-=MUM;GKX__XYFNR/J0<\^T/W,5O-H]<&2=)]V
M1[,=HWN=KMUNK]O1E$^?LRP'2?VU#G%\E!&1?='[\?,'H+C3Z':*:7E;4'8T
MN[2M<HIZK4:S9;>.?Y>VG60U.OUFXRGV:5LN1KO;+J;@/<4^;:L,NWZC\<S[
MM*W2Q]K]5K-K/_T^;4LUWV[TBEKT^?9IVZ&U/>@U!HW#V:=M*6O]1LNNZN3_
MM/NT;8CN]^UFNQA!?,9]VE9RV+4[]E-OT[;+R6P..KU*-.QZF[8E2)M],`E/
MODU[>`)YHW^0V[0-\T(';;O1[/0'C]NF*=J8YVY%&[T,K\MS8O43_$RU;)C-
M%;'8F8!'^O=7DR29_?K++W=W=Q>Q<"[&X>TO5Q__]ZM_8&9NJPGC]_[V2_Z:
M'OB7TLA_DR>=^7=@$E'R#GQ>+`6QSQN]\P8(;?[;[$%PD0N/#<YQ6ZM_IS]5
M&/QOORB&/(@[C4/D3F,S[C3VR)U[CU7WS2SDAQBC[_2/O_T81K[K_2I^S'S/
M\9)/\H#<]::RA\'?7V7&2N^GKAT1<&#`Y0\O?O6/W)G,2\UN0BR4B>58?_NE
M\A/_`.XK&AZ&;_N9\;V8`WU(`#\<]C06`=YM==M'"7!L"*0!OD=D-S9;NB?0
M38>JNI^;/0UBCMULV0?`'"]`YR61<[:;YRU@C?[=CN?<&!S<G&&1]SOG@U'O
MA77.M/:^YGPH@E_"]I[GC+_K']:<[7-<ZOXV<Z8D>IRPVA[I5Z:R@\4_Y*__
M]HO^60Z!;RV\7]S4+@ZB_O8K_&V[D8H[3SVH;)^<SQ_?@YT:[M[#W)IO\G7)
MF^KW:=AW(@BGF(1:/7`5;_(QEU_^VR\%VK.I2Y\`_O'_`U!+`P04````"`#)
M@&H_+CXLS+4.```BRP``%``<`&YB<RTR,#$Q,#DS,%]C86PN>&UL550)``/)
M/+Q.R3R\3G5X"P`!!"4.```$.0$``.U=;6_C-A+^7J#_0>=^N0/JV$EVMYM@
MTR)ONP@NNPZ<;*^X+P4MT0Y1F71)*2_]]3>D;$NR18FRK:7H'E`T66=(SC.B
MAS/#F=&'7UZFH?>$N2",GG4.#_H=#U.?!81.SCI?[[OG]Y<W-YU??O[^NP__
MZ':]ZZM/YT-O0$-"L7?3_8PC3EZ\WWP<8HXB[#V@%T;9]-6[1*$?ARB":;U;
M0O\8(8%_].3_`P\^^NUB>.L='1QZWF,4S4Y[O>?GYP,<3!#O,C7Y@<^F/:_;
M72S\:\+BJ??NX/#HX'WF+T,6T^#4>]/W@R/_S5'W[4_XN/OFK?^^>^+[XV[P
MIH_>O7WGOT?H,#/JDN.$N0#8/O6.^H>'7?BO?_+0/SKM_W3ZIO_?+#6;O7(R
M>8R\?_K_`N+^VZX<D1/'C]X-]0^\\S#TAI)4>$,L,'_"P<%\IG`N!P]D3L59
M)P/]9<3#`\8G/9C[N+<@['S_G9<0G[X(DAOP?+P@/^S]]OGVWG_$4]0E5$2(
M^KF!<K*BH8<G)R<]]=>$6I!3H6:Y9;X2C0&#GI9"_JN[(.O*C[J'1]WCPX,7
M$71^E@M^X"S$0SSV%`^GT>L,GW4$F<Y"W)E_]LCQ^*Q#1T))NW]RW)?#?[AB
M?CS%-%K\1#2XIA&)7F_HF/&I8K[CR>F_#F]R*"AF(L)3M;FB^5;M2<*>T9R]
M+1D?PL#?[R/8<7*)P?@CH?"T"`KOF"!RA<L0"4'&!`=U^3><]1LBN$,<UWX,
M-::.'G%$?!3N'!-\C=D4;\'Y?()=\W6)Q./'D#V+&QH0COUH"Q;7Y]H)MU]8
MA,4#6SZZY8KB"XIBC@?CP4P>%/`T15WN:\W=,)I[,J&P$WU$HW/?AP,H@O/R
MCH7$)S`"OT07(?/_V!U"P_4:1GV%A<_)3$IX,!YB'^>XX8`DAK-'D38@@XU6
M;U@B%[&`DU^(2S8=P5\E;U=$^"$3L"$;D('A>@VC_L18\$S"\)P&-_*DG)!1
MB,^%P/"0FD1?<]V&I3#??.(.O2+)!PW@$Q[CX):@$0GAR,+-BF-3!AK7$J.H
M4=RZ!1K&=0>C,.<XN(]@M09PZ19H^BR3JSVR,``/Z_K/&$Q>2=OH$S1?LF'L
MB:4&3FNC<$M7:?KIXHG\.<0SQN5!V>QS-5BL8;Q#',*OTD.(7A\XH@+YRB)L
M%'>=11O&#Y;!E$3)^4"#2Z:L(TS]I@^CFNLVO>OCD<!_QO#K]5-#YJA^B3DV
M/XV`R0!8#B/08AI(+S_Y5*ZURT!%PD%OA85&^3(,0"@>@`N05&[E4`:=&,\_
M]OG"*K(T1F*DPDNQZ$X0FO7D?NCA,!*+3]0.Z?8/YU&F'^8?_[YB)UW&7$8/
M%BN%:(3#LTX%<<\BW]+7(4^2FR\X,N.^<(@E#-(B79Z`6%0"T-!;Y#YC3QMQ
M7T!OB?MX&JN3:1`]8@XJ>L;Q(Z:"/.%$PK=,"-@A@S&(6H^IUBQ6D`:!TC.@
M<1"!S7.)9B1"H0Z1AMH*Y\I[U3&:_-$>7Q6[/4=C@TL9Q936!OR0;L03"I7]
M$5TBSE_!_O@5A3'6<&\VU@HJ,*4853Y2*8!5,AN\7LU=UB$([Q)^DN@+HW[I
MMBD=8A<#&')QA7V@(6X!WS4$OTIODWLX,Q)%4FG<E(VPC,#80B@?TQX4QIM)
M.\P.%@Z*/`+#I!Z4\E%6D,3X@67""D8X2L?80+$(V&L87O[9!F^K-PB@3*Y?
M_#"6F2\5?!L-M8-)AB(8?P6.M+QG2&SPF/F.@?FU'@G6\%TYS#*6<K7?$EU?
M1RNV1Q?>,D07\9@'=H'H'Q7"UM+;X/XSH8RK\%R$.18ZIM?(;/"JHIU&8;(B
M2AL<JY#$7`M7[>AB6FM<%YPB98P7D=O@/7]+6>:@%E%:XGB&2'#],L-4R&OR
MS$8HW^4F(^T@8C/,H]>[4"8$T4`>@3,9>]?OH=(A-C`,0<EQXH.MNDT4I^XL
M=I!&B%`<7"-.@1&1B:B"%T5\HGMF!@-MX+G'H#LE"Z,*A[V`T"*_MXQ.'C"?
M2G;*&<Y16N'XD?%(<B"M=9'<JNI8+B*UPK.I)=\2VWV=C1LZ]^'N9/8"H^<1
MJ)91'"5VI#09&(TX"X&5284UMZ/);<CE`4]GC"/^FO"]4)_G4WFQJ(%;/J8%
M*)3R7_KH]:Z+-IIJB3ESVW[.\_`1]Q=+PJ]K5^WY>HHY14_$T^2.OTLB/%V,
M'W,V7;LW6BS&=%<V'N.P0575S_M^O^,]8UFWHOX-_YIQHCR2L\Y1QXL%,,=F
M"=2VHBLWBU*P)_L`5N]#+($>]O<!:!J,2X$=[@,PLPAD"OIH'T!K'/84Y;%K
M*%=LX"Q80\\FU4S.[>L2\,5&;(K5N>U<@K6V,YN*89_V>WG&6HKYS1YASM^Y
MI!C?[A'&TKOZ%/*[/8)L%#1,H?_D#G33"[BL-(HNNI;@CQS2Y%N"+S19CASR
M)S;!7Q$16,KAV"'K91,Y["IBE`K,S8UC8`"LWB&FYKU#1[\Q9%V.>(K:(6/`
M#'7)G7R*VB%[P`QUX?UXBM=-(Z#,A2NXZ4GA.A0SK/55+BI625'OG<ZN2&--
MS1R'HHGUD*\F?J>0W;1HUC-AJI]WL67K4'"B-O[BDH44NYN6BBGVM9*!%+B;
MQDHY\,(<@!2RFY9*U;.N2(9/X;MIN%3`+\^@3\$[9,:8^:F%&7JIT^E0M,8,
M[WJ]7`K6H0/,#*PV=R'%[-#!98;9)($NA>_0\67XR.O6<:>R<.A<VVT^5GG<
M+BLBA\Z^YD2T7J20"LBA\]$H=ZTDM&V8)I;*9A.7N(UM6?(-5>VR.>^>:J7P
M7D2RM:3RC339@'D:*T65')3]'6=C;=YXEL).&>+B3/H(7\^D%U0,7ZBT/^L%
M'C..,X&V506D6CQF9TF^H)]Q],B"ZJSH;\F!/0D#W_/[Z0M,L7X_Z*@ME=TJ
M\<Y9T7*<I[)2#(>C=`-H^,S36.=RBXSU^O/81_N$2)BPF'$!Y_;1!1+$-\):
M/8N=4DS*$F4E12Z9+?_&Z.FM%#@N6)DSH?O^K--9Y;;R^UY$::V`M.X6J1AD
MOYCTBCR1`"S(></4I4UX,YTAOZ1&TWP*2\6:<-B6;*H,@:5"3`Q.ELQ:O0*S
M-F2J9*)\*Y6/L8-"6>0Z&2__;*<`49V<G\#LXDAV+S\/IH02$7$5GB\7M>%@
MJWYW@4N2C]\MGHV3F>X5Z%:\1DV">[?=&"VX;+FJD*(3V,GL6LN"++$)G"P+
M*W3"5FK^EJ>KDT5$E0@W\/`TZ98MUT$;.G=:63F:@+D#,=0SJS4)FVW?+57>
MSUK5H8EN=*D0NI8$UN)NFG+HEC]U;6!AI1JOS*-QL@[-"+BIH^%DE5I)E"97
M+IZUUITLLS0$6K`C-*5X+?].KP=(\HKK&QK43G88,)%?P561IK&`Z6:Q=C^\
M_NI*&_WQIS+AXB^%<WFS3B<R%B`+RN0K;U0AE":H8SS<6E=]'[XB8$#*;XOZ
M/<D8T%V*EXQHSWL![C#L::D).$8"7^'D9QDDTREL]NVN=Q5<-<H.DAE\C4FB
M-,%FR7PWM"CT(VP@N!Z/00\-QM<O_B.B$SP$936@Q5M(`ZG6%%;23A"A\HP9
MT.KTBV):NUS?@^P&XTP5?R7OZR/J(5A[:1E\\/NJ[KBAJZ_Q3(K0%D;=HO-`
M)N]]A?%=S6HICT7#=]I"1)_44CVT'9A6JFZ,`:V.:P>:1<.3]9UH-J8=*-3V
M7[I0I1K!<'`[<,W[EBRV3F'_$F.<1I.U`W>^`Y,QPI5A5K`($8/Y#T>-BM:"
M=/^#.$>@R#XR?H_Y$_&Q&/#+$)&I]M'5FL-2YI:4,/BJ,A@=7+Q^%=(*7;H^
MYWY$GHJ.MPTF:!&^Q/[9`E_1!"W"ERK!#?$536`IW\X']F1\25VP@2M1F7"G
M&V`ERTB5*/R;R%!7::)G`:$=?E^55P#Z:8AG,0>O1X#ZRM]<@1Y+/L"@V]0G
M6E";S683^6"\O)BK0)6EM,GQ`YL'>:H]P-(AK<"@;19LBD@_@:4L0Q_C0(6W
M93N>DB[WA:2V>5Y:,#QQNTM;R!L,M(TGVRK(`$6.W#;OV=?9&^ZCM2&V,<C-
M\!E%L;S#4"^D#T/LJ^LB66%6J;XVF&D'P:'<LO*`&LSF(<ZY.7_]XF/ND_6$
M^KJC_Y\(7<C?$Q$@,;`BKE@\BL9QN(@IZ3G6#[&3!CU;&@T5QT`AJ6V>#=2F
MEMPV[X9JLW2(;0R9CF\&[&>IVU.Z(.-6H`FU:J9JE`TD7RG'*"1_X2"]?T@;
M^.B05(VRFI:PR27L2BZG<<3!R?9\#0FH,.3D9%NSA@14&'-TLF?*M@*J=V_M
M9,^4^G%G*:#:QKB3W?,VDTT=[]W)#GN[$\NZ1>ADS[WM!*(U+S4M^%J>K;J[
MW9'Z9TZ^2F!WNZ)`$/G.2G^;+9%W?YU\L\+NMH5.&"[5U>Y.&B5G2;[+Y5Y+
M9.-K0TU[S+^%L'(WC9I&F6X*HB2]8NT]?+J,=B<;W&\GC_(+74W[^[W>(1M=
M'3GY!JP=[YR2:W3-:P3V>A]5)R9JWO[DIE1*TK\JFS2XU`)F._@U,SR=?$7J
M=A(J+0%RLHAW.WEHBFTTE>M[K3O,*RV=K&K?3CB5UX9N5H1O)Y3*6V$G&TOM
M2J$4U,%INI_L]28IRI?6M$399S&4I;V[VC!L.T.U)`7,R>X0VQIF%57FFBX2
M^RR338ON-.WI]EK-FA7X.MNO;J>2R176:EK7_<U$LE8Y[>3+A7<ME>+:9<U[
MB/=RQ^RLD\)V;S/^MCV0U'WH`UN^QF?9$TE\D=%J:=4O>V+9>(>/GK][,J%D
M3'P9(DZ>D7IE54A\>`@/L.1%*"_I6L7S%18^)[,D["`/JQSO'.:(J9^0MA3!
M12P(!8?WDDU'\%>YL(R6A$S`9FDISY\8"YY)&*J6;1&B$R*_R$K#M9[W5?5#
M@[D&RFB<UH.0J06M9S)_W=]2)M??UB=I6R_;I:?7>D[O\43^'.*9C!#32>L9
MSJ;P/'!$!4JNE5O/N&P]39)+"'4AKLY`3'T7%-I]/!+XSU@V`'XR/*P_].3R
M([`IX1__`U!+`P04````"`#)@&H_).@YQS<8```TM0$`%``<`&YB<RTR,#$Q
M,#DS,%]D968N>&UL550)``/)/+Q.R3R\3G5X"P`!!"4.```$.0$``.U=;7/;
M.)+^OE7['W3>+[=5*\MV[,S$E>R67U.N=6*7[.S.W9<414(R;BA"`Y*.O;_^
M&GP11`D@`9H40(534R./A`;[:8#=#:"[\?$?+W-_\(QHB$GP:>]P_V!O@`*7
M>#B8?=K[]C`\>[BXN=G[Q]___*>/_S4<#JXN/Y^-!W>!CP,TN!E^01'%+X/?
M7.0CZD1H\.B\D(#,7P>7:(H#'$&O@UL<_#YQ0O2W`?NO-X"O?CL?WPZ.]@\'
M@Z<H6IR.1C]^_-A'WLRA0Y+TO>^2^6@P'.;/_5?*X>G@_?[AT?ZO*[^,21QX
MIX/C`]<[<H^/AB>_H'?#XQ/WU^$'UYT.O>,#Y_W)>_=7QSE<H;J@R$F8\X#K
MT\'1P>'A$/X]^/!X<'1Z\,OI\<'_KK8FBU>*9T_1X+_=OT+C@Y,AHRA(XV^#
MF\#='YSY_F#,FH:#,0H1?4;>?M:3G\EA`"(/PD][*]!?)M3?)W0V@K[?C?*&
M>W_^TR!M?/H2X@+!CW=Y\\/1;U]N']PG-'>&.`@C)W`+A*PS$>GAAP\?1LFO
MJZV!#R]:-E]EZV24_IBV#O%IF#SSEKB)(!7@#*0MV/\-\V9#]M7P\&CX[G#_
M)?3V_LX>^)$2'XW1=)!P?!J]+M"GO1#/%S[:R[Y[HFCZ:2^8A,G8''QX=\#(
M_W))W'B.@BC_=`+O*HAP]'H33`F=)\SO#5CWW\8W!10!(F&$YLE4C+)Y/6(-
M1TI]CM[(^!@(OS]$,#_9(^ZFUSB`L<6.?T_"Y,6Z\)TPQ%.,/%W^%7O=(H)[
MAR+M8=#H.GI"$78=OW%,\-*3.7H#YUD'3?-UX81/US[Y$=X$'J;(C=[`XF9?
MC7#[E40H?"3+H5L^,?SJ1#%%=].[!;,J,)JA+O=:?;>,Y@'/`IB)KA-$9ZX+
MYBH"XWI/?.QBH$`OT;E/W-^;0ZCXO)917Z+0I7C!)'PW'2,7%;BA@"0&2Y4T
M;4$&M9[>LD3.XQ#\A#"\(/,)_,IXN\2AZY,0)F0+,E!\7LNH/Q/B_<"^?Q9X
M-\Q2SO#$1V=AB&"0VD2O^=R6I9!-OO#>>748'X$'W]`8>;?8F6`?3!9J5QQU
M&6A=2TRB5G'+'M`RKGN@0I0B[R&"I[6`2_:`MFT9>]H3\3U8CUW]$8/+R]JV
M.H+JCVP9>^JIP0JW5;BE3VE[=-&,?8[1@E!F*-L=5X6'M8QWC'SXDZT0HM='
MZ@2AXR8>8:NX=1[:,G[P#.8X2NU#X%V0Q#M"@=NV,=)\;MNS/IZ$Z(\8_KQZ
M;LD=E3\BP^905Q6>9!<EWY]AVR<G"6S']_<&6<>K()94.(A&'IZ/LC8C1M`B
M/_`H%+!=O*&'ID[L1WK<;9)OAU<R=W!0F]64NDU.DR<,YV@^0523S0)IBSP^
M01?4C2=HN)2,'J>B#C)^O>5&,]MG+O`,+QD*/+8]EG[+NFIRAR]A`%B`%[GP
M7)_MB1(J%%8",43N_HP\CSR$1TQ3L3\2E34\.,RV/?\"7WT_@T=[[/'7OC/+
MN_.="?(_[6W^/FJ=GXN8LKVT:]#1CO\_R*%7@7<).D[`FK1I^USF8Y8^^QY1
M3+QK^"X4L"EONVT^F8S4N.0MM\?CRK2'UPS=P%M3QJBP^?:X3<=1/CG%[;;'
MWR-T6\)6\G/[W"0*C6T)L@T!`3O%W[?$S^L%"(`Z_@TH[I=_HE<97QOMML8?
M^*XD2!:E#T\.1>%='+%3-W9B*F>VC&A;G%]FGHR$Q\M55Z5];JZQC^@%O'<S
M0N6C7&RU+=[&:(9#F%U!]-692U^-]6;M<W>+9HZ?/OOL!8L4\'J+]GF")2R;
MQ0^O\PGQ!1P5?U_RP]VV,UKD#'R^O)O,_5-;N60T4TKF"L8H?R01Z;H!H1ZB
MG_8.#P[V#^`?:)UXM*=L:8J\3WL1C1'_$M:OX&I>^<E:#USE=&-C;[``ZT)A
M)#[M'>T-XA!PD.1$PFE-#FN+@;=(I&BK<H'L'QPR<70:V9I7S:$==1Z:Q`'B
M$-_M#,0-KYF#/-XQD(4E#(=YTGF8:[:#0WO?>6AB1X(C_&5'$&ZXZQSBKYV'
M*-_OX"@_=!ZET!]?`CP\V!&`Y0LWCM>0@R/<(UU'+5RRYS`W5@=\DIH:PXU=
M]'5`DA5-<>3RA:LNGH^CXN9PFQO&BB&5M9=C4R><)#*.P^',<1;IF@SY49A_
ML[XXR[[^OA;YD>FTM95:1>/ZR\BW\\VBM_`SX^8KBM2X%Y(8PL!B;)9G^BBL
M!"!I;Y#[E0@A)>X%[0UQ'\_CY*S]+GH"VT;F"XJ>F$)Z1JF$;TD8P@RYFX*H
MY9BT>C&"U/-PJOCN'0R3Y\)9X,A9WXRI:FV$\R0>3\9H^J,YOLXFS'=WI=.]
MV,@<GQ5O9:&-<2Z5A+K>U@37+.J=1:?`!PL[>W;\)%XENG`H?06?\5^.'Z_O
M#>O1&D$E#[V182FA,(4@\^-+AV"]F0E>+[,@S3%([P(^<?25!&[IZUI*8A;#
M,PKB"O]1TM@"OC4$O][>)/?@4Z0JL=+Y+:,PC$#9@RRGL0>%\F22DIG!0L$4
M1>"XZD$IIS*")$:/9"605@E'*<VN',+7EVF>,",1W_)G$[RM9_"`:KMZ<?V8
M[=U5\*U$:@83"P4F]!4XDO*^TF2WP@OJRVU%"X$_NID=(I%E)9F-6"H62\KD
MAK&5&WU++/TF&^K2MV&]JF/3[;'D0D[4!2^@,8*".$&^9_Y(SIW@]XHI+VUO
M@OLO.$@.4L!4(HI"&=,;S4SPFN38*!UEB%J:X#C9-LY\CZKW4MS6&-<"WZF,
M<5%S$[P7<V/+-HE$+0UQO'"P=_6R0$'(DK-7)D+Y+%>A-(.(+!"-7N]]5H8B
M\)A#LF";B/(Y5$IB`L,8E!S%+JP7W[(7K-N+&:01+#N1=^70`!@)5TZ]6"$O
M%\O&3('0!)X'!+J3L3"IV#03-#3([RT)9H^(SAD[Y0P76AKA^(G0B''`UJAA
M>CP@8UG4U`C/>8S&K22%J:2A47Y%&3J21F;X5%R#6[+JUEYG6[:RWF3G)LAV
MM.Y9+042G$5@<B9QE*XOF"M)@H@2'UB957CY#77>7;EHSX4W/<2$G![1?$&H
M0U^5)K^LM06<YX[3V9R%?:GQOT9C`8K$[5ON2>L%\]3J:OL1NSF[XK@:%NU9
M;+&Q`;<,_7QG7^"\.KCR11'':%_DO#I&^<8!QV=?S+PZ/G[<M,1S;%^(O#H>
MM:,UCM6^_#_-N;FY%<?!V9<!J*LY5]'8E^Q7H>4W02ENO'#,]N7^:6,6+ZTY
M1/OR_K0A:N^L<?3VI09JHR_/;.!0;7=U%*`6@QPX--L]'`5HI1%Z'*GMOHX"
M4J73B27B$]N](94W5(;-E/=C-I'.Q%CIAL:L#E]9*(?-Y1X:QBX*J+"Y%$03
M\$OS&VPN$=$$>.G&GLU%(YH`WO3.K\V5*!I6$I(82ILK5:BH>;G7O1X\9#SS
MOPVDLKQ=#K83UD\!;$GH'0?;"5NG`%88_<9A=L*JJ>R`",(W.,I.F##UUU14
M'("#[83]T5LME^NE73$WLK1)CM3>/1!-#5PZGO;N?RB%GE?/8>%)PE$GS*L>
M;'$2,X?<"2.K"WDC=YCC[82U5<,KC#_D2#MA<55'MB('EJ/NA.E51%V>+\LQ
M=\+ZJF&N'%]#]G>C5G%U>&IQJZ,8%+J#I8KU!+)^,LX'V-[-;35DZCL\'+.M
MU0O+8YHM+F&H,I@Z6V_"Y"0>&F7O'I3^/GRQ2@_':*]OK(=1&JK)H=KK$^M!
M54D0XJCM]8PU!UBWA"`7@;TN\UM/5E91VNLBMY,+4"X9T?F1O9L\[4MH,Z_<
MYK+9)F=.O?P=FVMT*^::E)Q>*Z9%<-?7WBE57PCK&2Y<]7:U!/:]P];A3RC"
M+G!IHAJI[Y,?P!VZ)O22Q)-H&ON;$9D5-56U^C!<)1,D?D>3P?&2=^H>T:0`
MO@2;"J5A1&G]_K,X>H+9_Q\^6>5(-BBL0'`3AK$Z]UEK*SB77WJG1&(&0_",
MP+K"BUE<@Z]*]]L"=%72<'4+8P.:?D^[4E^P!6Z^'_6U[82;0YJ*6Y'8/"Y%
M]5U!I(=CXU)X^$+XA$L4XEG`Q+;&E@*!+:(MM2LE!+;P7VU=JJCZ\B*[4UYD
M;4ETB^'#2VY\2F<!`C^\0C5J=6$!1D4-645E#9)2A51&80V":I542=9^;A":
M.K&_7+-V-CFHR60G<"[-(^J/_!L^\M?;PNE"RI<:\$HST87TKEI0*ZQ^%S*[
MWC#$N?WL0A[7&V"*;^2T.`=+#6O5ZK<+N59J2&OML77CL%1_H.7;-]TX!BU#
MK+)[TH7CR?HO\(9*MCA]L#Y*R1W)7?>CE$['NI`^J`VWQ/I8G#Y8$^;F.]IU
MMTGU$G-#+I,M8<"&PA[2D$`300T7P-W=-$M7DAY;KK8QL;.61X_F.O;<";%[
M%GB7V(\W#UQ4J:PZS#1S=1LE87A/R51:IW^UA9G+SO)@V6O0`VE9EA@&]0[T
M1;*H#\_1E%"TD@R]'CT((U[L)5TY?D%@RKSJ*O3;Y,"<A('OK$S7.0J0?#[(
M6IOA/!5OQHJ4XV*K/F0@E<M7%/%)*9%=L8UQ+M]0G5Z_'_-HGQWLIRRN>&]9
M^&]BRY2P5O=BYCJN@*0*E(F<,5O^%LO;6\5]14G\:CHC5W;E+&7,R+3!9CNC
MW%9J+U%+8U>BZ4[X"B+S$3>7^!E[L/8)4\:6JYF;^4+^`FAU8>CZ,7!G2B;5
M2@-#5XLA6#2STL>7L"#S27(-0/E4*J<Q@R)92\IDO/S9S)5:B1_P&1Q;ZO@@
MLS-O#JM_II]9]8=R42L2]U%F-D29"4,[_XWP["E"WMDSC.`,?8W9SEOB)V7;
M!E5A/34[Z4),C`41,0H;HLK.V<8-#R4VN@MUJ6H!WUA$=Z$,1BVD*J-KJ@Q&
M'^C5['$'=S!V)X9K;:M^=R*V"KO0NQ.05>&J[TY(EJK'O#N!68(=D]V)Q1)N
ML.Q.K)6"[]#],"LCQV>[$[<E/1/;I:`MOM&U._%9-8Z+=B=::^U$;W?BL_0V
MGG<G:$O[.-!X'%=CT"LC?KI0^+TZ%+K.;J/Q0O`_>;`>NW+RVB<_0/]XF")0
M.2:*$7G_%V>.%RO0#);-Q<EUD%QA@)X`3L'.,W7IG;]^"]F=$4OO_LR%Q5E:
M([;\T+J51YDX43B;LR)I_TG\WF6IJ6#&]E7"1+6$:2:@3`ZJY$:*U+#K4%WP
MS,%*,B<]^3LMH26+ZBRA,(:@^D)7.99*6GM0@57#;/'D4N2$Z!*EGUK@)%TT
M<`*6O,H.]BYCR@H+)L^Y)E2B)50HFF"*NSQI</XCR2;O>1R"=0TWPU:4R<P5
ME0H359*PEQ;JR_+@D'<HFPR5=";0Y-=>Z,625E&90;(`DXX3)<]V,E=TOA2%
MG**!B9^O=NX"89K5=&V&"\[*Z_9B)-!_.@6'ZFYZ]>(^.<$,C<'KN@O$&E`R
M'EI=]"D`G^'!S(6["ZI#X<5MS7+]`"-Y-UVY6+J2]TT*HV'W[%X^+$MA66_5
M@$)9=QEN@K4++K/KY?*CC?S:[I5+)00*IHE>#0V#A&]>#T0^-M6D=F!:NY9*
M&=`ZG1UHF/()X&F;,U&-Q@X4R]5Q5I&Z8A6NT8$E^-CKS;<`RG2S(K$=N,"!
M6K"U3O9JY(>'F3[3Q*G4F1VXQV#P*79AC<&<*&6$:V0F\\1*[>Q*$],\9N]S
M2?T^6>LFW`/F_@<N*JX)@MR;AF6]M%:+R"UX0V]&AF');[JX#KQ_.Y0Z8-.!
MU0=$G[$+RR5ZX3M8&C^MUT>?CIA*;?4Z[B^%,Y4U\0H:&DK5$^UY+[>%^9ZW
M!(=&!W;CJ\IYT^_((KSI0O<-XRGJP&Y\]<:SK".+\`K.I/1PBCJP&U^]\;3M
M\(Z%[P";+(0M">K!)*C,&)81-.`F9;VKJT-%HN984W^S%8G,C'J$<F/_2,Z=
MX/>PU#F0MS>23)K<./5/S"(H2ZL3"!J:X?<UV=(%/W6,%C$%)ST$-[;HEX,_
MRPNIBOS^M_9F$OG==!E=5H%JM:5)CI<'FM7;]Z4D5F``(P1F)WJ]]V&Y!%.#
M'=4LYO+KM#0Z,)1,[B+D)5'33!==HHD\,5[0U#3/RY4L3<],\GL\*Q%("$WC
M6;4."B@*S4WS/D;)=;+W#LQNQ7FT06(:`YL,7YPH9E%][#"6^#YRDRP$5@*O
M4GW5Z*F1NWY6'LL,U-TB.^K/MG6N7EQ$72P.0-&A[NM="/E[QBS<15"Q7\ZQ
MG,1,M8O%TFFH,`/"IJ9Y5E";TN:F>5=4FZ4DIC$\(#>F[+YT)?976]M3H88=
M=8$FE*J9*BHC%4A<%#@4DV]!N$!N<@FM,(ZGNGVGN7_3-8L_8;V:7)""PY;R
MMKM99:<A/N/%(BU0X?AY`L9-,"5TG@9>EN]QJE(WX"ZN/BH_UB_F"@B\1`6B
MIEG+-R\2QS2>A-C#CB"B1IVN80;SE?SJ(OXK$FU=JE"9F++?`HK2<WD>>WB)
M*'Y.JB+(5$,5E;ELMC93C@K)UWIG\/QF>WN3E[<ENM+H=2XH>Q.=MR4H2=0S
M%Y&]*=/;$I%ZMAR7FKT)U]N26J72Y\*R-T5[6\*J7"IR8=F;Y+U]E25(>>""
MLK<\S[8$)3IUY?*QMZ+/MN13%DFQE-.QO25\MC:/2K>>N:3LK02T/;>S(OV3
M"ZOWT74R0;C<['/9-5+%1?5FTV#\)<#W]DV,V@#7$OLX1OL&L<ZD5)G2:DDR
M7:BSU[1D1.F%72B<U[0<"DE\72BKU[0`-G(RNU"%KVDAB),$NU"2KYXD&DO`
M-E_<[R>\6*!V2@R_^5HCEJ@+=0S?)A*=F,,NE#9L7AJ;X2M=J'O8C!RD(3#&
M"R`:F0H\<JP3=Y$T/@4$^&V^H:3Q\2]&X1F_L<3(')#)P%Z'N7D9E)B$(WO=
MY8;>A[H)2EQ$]A[L-BNB0B83A[_KKJ1.6CZ72N=<2H7DSL+506758;MPD5`S
M8BC/F>O"S4,-R:%.3DX7[BMJ:9J4I"5VX4ZC9J2B4R"C"Y<A-2.5ZCI97;@Y
MJ7XQB<HK98XZMT;5C9-KY=R8!ZQT;HVK&XZB4:B%2\6^5:]>59!\1UBMKOD2
M]XE]5J8>[C>5F>/BL,^\U!-'K2K?7`SV699Z8E!)GN&H[;,L^JB7*[3J^P!X
M'(E])J&!X98G)''@5FM]1<]1.=&)3W3[UJ/ZL$7Q7X5"IQRNO>O+RIS:8IRM
MM'85]X[M,V"UL(JJ=W*0ALQ3?ZEZX]<1UE_''-NGQ!I!7ZK^.'J+==I;T)<:
M>X[>OE6+'GJ]:VDX;HNUNQ)NO=O+.&[[UB--X-ZXBXX#MF\IHFGK5,LK<"_-
M/E]<#;*JZ\J1VAM=H(Q434^?F#H`Y+&D:.K$?E2!5E1AI3";Y:ZK^3C3TKC9
MYJ!^/[(`K"TW!=L(K&*H,XA'-@=$:Q;E6>YY5R55\>%54[W;O`@Z6=4_DDRA
M.OYR^,*O[!2=)6:GZR$2A/4OAK;K=L'=NFE$,$Y%1DL:]H706BXIUB>I]#M:
M6]S5$*@"7>-CHV_1B--DAU5]P+,`W%J715ZE:7+,9R`^=F$-\PB///?9F7!O
M:2VTM(IC)[$0:L2]1>XM<F^1=\8BJZJ,WDI;9:4O4>A2G'#&,I1<5!@^"GW$
M@9LVK6FSA05C:SVVJ/YJ=].^D>]=CMXT]Z:Y-\T6'"/54[2]D;;*2.<1Y1=D
M/H%?V8-9%5^8OS%%#2REZVM!1<[$VE&1N+?7O;WN[75OKW?>7NLJU=Y*6V6E
M/Q/B_<"^?Y;4KW:"&<N`2BOC-6JM[;)J]36RIKS$&ENSD]YZ]]:[M]Z]]6[1
M>NNJM=Z*6V7%UTNZ!EY6U76EBJLEB^^ZK(JU9]W>^N5Y;^![`]\;^)_&P-=6
MN[VEM\K2LQJ<EEAR&2MB-2AKW5OBWA+WEKBWQ#^-)9:JS=[26F5IBZ6Q=FX+
M?+?LE6RPQ(9`UKJWM+VE[2WMSEA:J5+H+:U5EC89GB?B`^]A>@$3:[O#Q\^[
M97M_*@NV53Y57PL9!%7ZWC[W]ME$]I7Z!.\MME46>WGK]`X;Z?J*NU0Z8EU=
M2M([&C^AH]&;XMX4;\\4EZNLWOI:97T?T@DW1@M"64;<#AOA'3-@"@,GL1(*
ME+U)[DUR;Y)WQB0K*8O>,EMEF5=O2WZD3A`ZZ>66O87NB(76&4"Q\=#IH;?8
MO<7N+?;.6&PMY=%;;JLL-[OR$*?WJB;W4B>E9E#@VI,XI<FA6%%J=M('9]OH
MI/0FO#?AO0EOYRHF327;6W&KK#B[R17]$<.?5\^H?O7/WI#UAJS3D6/2UT#"
MLK1];X9[,VSD@D#I!.XMKMSB?ARQ1TR<$,'__#]02P,$%`````@`R8!J/]]D
MKPCC)0``]><!`!0`'`!N8G,M,C`Q,3`Y,S!?;&%B+GAM;%54"0`#R3R\3LD\
MO$YU>`L``00E#@``!#D!``#E77EO(\>5_S]`OD/MK!>Q`>J:PS,>VPFH8PPA
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MU2,EB[L2?1U_PX@/W^QQCHXE)N@\B_?1-$W1-2<MT#4N,+W'R7Y54EK9`3%S
M9\6/+UJJ/\QHNI_3Q0$K^]5!3?CBCW]`DOC]0T$Z#%]>U>1'!__X>'$3W^%E
MM$>RHHRRN,/("U.Q'GWWW7<'XE=)79#WA2CE(H^%:1P$1%H*_M=>3;;'O]H[
M>KGWZFC_H4A>_)E7^`/-4WR-YTC(\+Y\7.$?7Q1DN4KQB^J[.XKG:BE22@\X
M_T&&%\R!":_AW1ZK1-;PG]77+Q`G^GQ]WI0B2E@7!^MB;Q%%*UE(RG%:%_7B
M0(HGON30[0B('TJ<);QD^2WG-QA*%L]M+`KEQ>9QI\"46SNG2I5%6?.HF(D"
M:Y$Y\@YP6C9*""SN'1[5RE=?_VL:QRPVRN(J>HQF*9YF"?N&KG%R0:(924E)
M<'%*BCC-BS7%MTRU8R;-K[4HP@`_OGAJ:0>-YKR\CNX4%_F:QGB4,7DINQ7Q
M7^F,E[A,67F\Q</9WN>;%W^N2T-5<2C*$E05B%HEHDV1Z!=>*!*E_L\/4M;=
MJL]:Z5E>X`N?5N@KK%)L2KNPCFA<B\<^6C2K*`[BG+5=JW*OX^,YS9=/1V$M
M7+X;.QW`A_/)FE*<E6X@J(GA@K&2P!9K*TD=$,1Z=C8@J*TB)$"N<8S)/9?H
M$R[=8*)D`0"+2@X;9&C#@TH:)6P@EN$2Y7,4I6G^A0^'T#RG*,G7LW*^3E%4
M,S*2KUZ_>CMY_?J5:-N_>GET./GN[=L)*[)8X;@D]SA]#`&*)H^J`*DU(Q`L
M>:O*1L?Y$K.Y`2ZLF-30^P6D6@@-&B4A*CEE((V8V>@]V!B4!<1,JR=VPHR"
MWC]FAD*X#ZTFJ&(!'#QNI4,:S/#0C!L%[#6Z`L%^O5RG?!IZ6=YA>I(O5Q3?
MX:Q@79$,SXN\*%BC?CEG<:KWX:A2_(;(&-'TH*M+03DO!L7M<A`1!0'C<!M'
M]M`YVE0@F$T2PI>+HO0J(JP/.8E6I(RT`-!0^\2@6@0=UAIJUJV39(]D*)8,
MH/@R&[V#(X.Z,'CYWW51+EDS6]SF;*#*E"5BG+K!]&U^$A5W5S2_)PE.CA\_
M%WQP<KGBR\LD6TSYR%RTU]-9P8;\L794\!Q5>47J[N77PKRI"I4YGU/)RL1<
M*F45\6_YYYA5A]9\&9]%0E[7PR95=47O8>/B^<#5#:IG\@Q(1-;SY`\Y/:UF
MR<.9I&4`/JH,GS$T1K#Q2PV6-0;06-C&K1V0CS;=]N@M<+R_R.\/$DPD<-F'
M/E[95_^:LIA+>-Q]2*-%S^7#WSW@;%"I#D,U#>)$$+C0FH_[7*T&2&NTS&E)
M_BVV("_G'TC&$,C:RY.\*(MIEO`5>8%`7;R[LOML@QQETD)GP\X7+=DT8(Y9
MT"6H*//X5Y14_&(1DQ3%6K1',2L=M/D9Z<=.RS/&8"`@+0JLAZ#\T2?`1(TZ
M^(@?GV5!J<S93,*XG&07;()N<^C95,>;'2!NY(>#F6V6TR7R#CO;S.+FYNSV
M!MZ]QN'\4!$X=UL&VAT:[\XV#Y1%)*-8TJ`(O.'9C;1^<6H:D`^4`D>I4]O4
MIX5"K:6EJJB0OL,$08*]X5*I!X&,XW5!,EP4)_ERQL9L?/3F?K[,D=DC=MPD
MTJX9_+8FA5AY!872.)^TL35"?0BP\=4U860V$?K`5&X97.-/$X='6!G$T#5,
M?,U5KCW)===HP\(GA%<GMY`0<_!$&U<V_<'`E"7\GS,FS7V4\J7=:7D24?K(
M9IY_C](U-OG3RNL;8#:!3%#CZPABG1]OV)]E&+?"E.3)69:8AG+/H@Z*2H39
M]WPY10CQC/K=E!$M032<X07),KX_P_1\Q!$%;R9<8VS08#B9)YRFXTIX_CR+
M*8X*?(KEOZ/\KRD"O"%1RZ6!YR=<HJ^3BN:;`U)Q(;&-[K.IL<X8`U(6-B+-
MT+4'IL%DX^(SFQ4BZ`Z_>W4H;_7,"E$G/\APNJ8L]&5='W*JF8>Z<.PXH)(\
M7O--E$@Q$G40Q]3,<S8D^9!D1(P3_5+S/L^5$U4+\41%^$D:E$A%RCM<=<%\
M"Q7D],`(7''XNRH/TAOERR61!Q-X9.89/VN`LYA@W6Z%B<-G7Z,70X>D#8=H
M63L\H,VJW0>=5M2B>6`P<E_1&5E(&&!S7^$QXB^T2X'/KW&@$>>XV+6%?78Q
MF&&UYMD-W\4_+XHU3F[S:F6D7GP;--O.;+Z'-0XR&6"59TCP(LF,;G-4L:,-
MO]_AS9,5DJ<S>*!\83/5B$<-D=I](>6=&/B$L9`W%HK-(,C51%!=6"7<540O
MZ4W)C]*+M0(V7+NYBZAV.N[`Z;FSLHCC@,,)&W13=,^YH%MJ1Z_TFV<7&P`#
M30A23-?E74[)OS=9(O0>'7#``*LOAA.@HH8\$$3IS*]!DE+I(!`D6U-7MU74
MD,B1(CBA1G:!02&F:VXC6EJ*!H&4RW7)4_[P5$VNOFJS0&*F)8<3</(-?5#H
M4;C`"*&^WL`X,FYM]LE@\&+<_^I@Y*O]P\.CS4BGW4>A-X>'DT/Y'RJ$)[ZO
MQ^-\C-Z"UP0=,;I7WQXUJ2&^?3UY^?)H<O2J9IWP[;4;!A6\G&&*7AU.1`XQ
M07R*X^K;(_'M83@))71^UP`6>&<MSZJD=)=S(<YTR4]]RZ_9\.](BQP;GU<8
M6X31XKKFXQ/#BISPFT?7.,%X*2XAW6#*UYI.T%5S)4#4`0LQ1Z]U,>=B)3@0
M"LLW1AZ,!SZO\FRC@A$)XTKR#M11XFF@>]6]GS*I87J,XA:,Z0;&_0LM*?EM
M31)YWZ5JQT6KRR,A;K7W\##?"A=#X(^W.DPH%.7E_!K?X\PP8FC3>(5OJV)M
MFUJ(Q%!44@$O62N,V45&7Z'GOUU9'23^0(HX2O^)(WJ6):=1V7>VD=33G4M=
M_9:SW9(><09TQL=JC`7J,J;-VO6]3*.J$`W!*9Z5[MN`.FJ/C8-&!`U6CJ/L
M5W211QD;Y7_*2]S-`/HQI^4B6FR^A6Q%+)YHMR<F&\"`2/9V3=:QLX<5S@I\
MC#,\)[H+)38NKZ`RBJ(!5\V%JHQQC`]5C.CKBO4;J%WB)ZI$6DGP8*/""5K=
MZ+!K#ADEUZP#.&'_DO(3T]]X0]#(`A`?*CEL2!)]=9U3#G3%Q,4!*B!IM89%
MD1A-FF^8:HA!D-.6P(:9BAH\A>(HZ3]G;#R7"<3#STG,,%&C?*!C`/@>T43V
MZ>%0[MXX-D#?L`2"=:L.(</=M5U7:0H)>C98D=>`K=F^31P`P%>(88,^'RW7
M:4,85S!M_1:JA#98-L!(%0<ZC8$CP3ECM)D')AJ<LRYWXB&D]-%/4B;`B'!+
M)&W7.IRH<!X;:=G`8\-]I#0(CW!&3-NJ%':0N(VAC+K#A,J*XIB('4?^#E`K
M_9S6C7H.KP&B%4,+I`V'6,^.6CRP@++ZH(LEL^8P,*+D/N*G?,8UN&8NKW`R
MBJ*%5,T5RC,0CH[HXLFN^@YN_)SB(J9D)1-;\B2Z65FEU.772&F>L8\QEHFE
M-?MJ6Q?C^4;0-C)J$';&>"@6B4ZK.W44R^<?RES<HXGO&#DN9&Z<N@ZTHJRW
M)*N4]_SL4[I.1*KR)%_5%VXR_*7+T)9JPHJ.2I0(/6:L=%X3YUCB\BY/^!G`
M99-W%<_G..:/2F5H+O.51BDJ^#6%I5S+SC`B[(]BW^LMIATZ07*GCVC*#8C%
M6XBUX;HE0=UA>DIPU7>:MC;8+AH'PG/%9\EEICH+=#GOW;?BF\\JEV]1BN^F
M8;R(NKZG*@E=9OU#D!,DBT.7_/QD[XJA;N/^^0)Q9RIW;A=6!YA9N[>*'D5+
MPUJUI*JK$$GI>:ME/C]ZAM[^5PA'2)\8`TT(;VGJ741P!?SZ7]8S\+ZK?#S/
MF"N6<K2J3U4RBMUWS(Z031>L%2O:0\U'WG?*<E"K(*B<)B$IZ27:ML!K$V9C
M;?7\YQ=K4>11N3HK2[SN7Z(WTWHZP:@5P`:LZ@QCDP&(L4`=8;0:O#[#:%;6
M-S+X(4HW7&PH05#15.^("7&N-2!$#`RMQD-737]H:+54%VR"=L[G9P:?*,D]
MXT(E@PT<G3Z'<R'!!M+KN)J_#Q2MWO[0<E5G*]4<B5?3><9'IW(;,*HN!/H@
MO-'`?2`,%?2'@%M6K,'VXF?/_N9UVMS,::!]VS9=WZ6-#B"+]FO,G_`3RXE7
M$75;LC?R^%RP-PFB?TZ*+UHFZ\TJZDJR@B[9N[BALV!O51T"36<1Y?F6BSHK
MS7%4D%@\696N2VU*#QN71T191-%>F6%48IJ;2#KY9N@*4WES$Q)9CBYI8\O%
M""#H$IL,E_.S![GA<<W`?YFIT_#J_#NF")^X&R&7!H3GRU44BP70>CN(?62C
M1DP6&<)5N8BR@D%;NFV<V`'G6$L]__A(K/NP!OA6L24Q_-W3"*E3J6%CD=.@
M7P05V(Q(:<!ZF#14Q)-''T\8AFB4GF<)?O@K?M09>4#GT\/]RDV>?D05,1+4
MB)&#>EQGX([GE0IZ0X![PBE')K_8&)]TJ@9*:\=PLY,(FX)JG%MZ('J^-%3C
M$'6:+R/2WV`:_.P5);).,QY^D42P/43/>%T/M[3PY<L/),7TA(T_%CG5]PY=
M*J^>[51M=K`@134MK)N5=NUZ>ZB9+Z=?XP7ANWI9^2E::D=[?3*O;N_6;?;[
MAA9Q8EC'JVW;];Q".8BYZ$^LL;E@D_S+[#R[QX7,G:Z9W*EI/<XNE0)H<,'I
M^#&^XBZG)2HQ72*R87K:<00A]KJQ;4OP@PPO(OT*T?,JX&OJ:\1,>XZK5Q<6
MZC=L6GTYORSO,#4^`6_B`(']0`P+=A)2K/*"393R^4[><=X!\)]'!?_0UV)(
M'0!JM4'"(,^3+R35@JW^V2?`JSHU4*A_!G5\SVH=+[?%AW3I-$O.^0FN!3\A
M*F'FGN!K9"$`\'"3S`(BL;TAXA!M"@O@L?#M?*B"X0@S@8"5L@;QBN;Z[&!M
M"I\PVU2KPQ"G0)($YGE+5QE76AF]X7GHY@Y8>XI`(%%F">/],W_`6KX6M2;9
MXG*%J3BB5!QCOO'49!/#Q4>2Y50<CF4#<C:B%;'6+H7OVI2/'\75(ON,RJ<$
M'B/)HUJFT2,'),J;.M%,5,ICXYZ(E-S\7D7[)K;H&S*&;28Q4S+E=Z)()1#0
M>[;_;TSIJUT""/IVN^?;GW#MZDU]:U)S4\9&[;V]&HB@.Z`@8=Z0`U\`<;3Z
M$(1J?>$`P\#N/ELQLGB'CEH.,WYNH7-_N%A]B!J#JJ#0P05_R-GFI8H*`B"R
M:@TFP@%#UXY*_[<T`76Y4ZKI`%),C\O#?*4=4P6!#WL2YMTE7U9>SF7%4QP5
M^!3+?\^SZF9_465R9W_2-4ZJVOE#P&*YIY40I.>G797J^2KO#D36M48B0T99
M'<!$R9KRX3N_@4[QBF?HX4DVY*43DLD7<!<+*C8`ZF0:?+6^DH;?:9=Y]Z4\
M"%<"R0>[Q%)<*^,,A_Q:W&"?K4LVA2@9/TG\YMMX/M-.>T:9F*Q2'8.'SL>S
MXZBK;Q[ORLA`?9!&=IYLA-PK3M".8O7;.UGEL8&9-I1`^XO/KX3'CM896;U>
MU\T"881++Q&SLUO[?*"!TA-&/]\3].CKFO,;WFWV$X%#I;+<5JV@DH`[`\P<
M,BK-PX@7OJZ7L=J&HU<W'M`X:0DR+D9:C,%T+"[*2`K0%T^<(&2.AKZF841"
MM5*>+4ZB%2FCU+Z\[%H`:(SHI-*E#]ND2LQKSNI\E)A`I.U\R7PNQR9D?*(F
M$QS*Z=EO:U(0L>?P/BRDVEQLAJW1DH%@F,]C&CF-9Q`=F6&QJY!H7$,O#^0T
M11C.XX"T^2,4E)K`GU0<!SI+1.G4#R.:KBCF2T3UX*U:+ZB7"T9&EU-AH-'F
M(J'^36?.:EIK`CTF'(ZR<&$Z!LWFL'6V71AA?(U9/TUBA@Y^_=T9(3TVT-#L
MRF(<NO%>CS;D*&;T:%VP3U&!XCSE"5%HI#SR#!*'7C2#"SHU]LSAI3`)3"!U
MS_I^PN790Y4EW7+6WXG5:T#9Y=&.*YNSW%'ULAB;]<""S-TO7:`Y&@$(;.(,
M6M67Z/W8H?(+H7;5>K0(JOK-9K!F=I2P6"^L1U"K_-_#[T`I2*@:CP6U2`!`
M:C@05).$X&S]@:">&M!NKA9\R+^M$=>G!G)^2P3=D&I#T9R?#@43"G/KX-%7
M%`8IU;(\ZU&UOFF1>,7$IMZP-Q6&)NRZO*?'+LY[\<<=F&3=%Q^R.F_:AYRV
MGL7H/A6A.MGSA-)\G^_:7E0=AJH2AV^I9*@N%K%R.P^-.+PH\BRQ\3PF4#V[
MLEI37DU9/T/%BL#+YG&IW\^C*SN(E.9LUA,-#]*^-S(+.:99\G-$>8*5@HG+
MW'5/8EQ<TI,T(H/\\-N5X;.'&".8`_8G50C(1]3DVNB7JL0Z+J*B>8Z('T6.
M\R4?T8OFBK%7=;)HR1+,L<^+("'-5;;!0Z<W&VWSYT_>=,$FE*G,(#1](*IG
M#OH4GE(V]:K572;D5/4C.K]P0K!4;!I+UEF:5/I`M&JMTZX,@`*(=WG*(JZ0
MU_XT[865S6/;99-%AY76F7#Q])(@AKF&NU,5)NB6UP?9-KJBJMT<.MD@Q!"Q
MG!!R9@\H9"RG@R[.I\?G%^>WYV<W:/KI%)W][?/Y[3]#!ISIB,\H8P`#\,3X
MXH2"$`94)\:W)43SY'K[Q&OCNT.Y`9!_HG\'0Z-C&&AV;T#[#*#HMAVAK'!R
M$2I.'-M$E;;`N+$^O:.FA4&+]:D=V:RD>;;8$VDX0VH0=RT\`-K-#P3I=0T&
MX^[-HX('&O.VD60#G/":2;T'K`"";RSS**OON7[$RQFF.J<-"7U"9E"[]NFH
M[%?6RC!J4'!HK=I!A%HI:!C<YMR(E@F$EAX(%!TAM&T(HT<5`]]DX2P35#%!
MW7L<JT5X"%<"1@?TH8H0>._G,M/X9D#F$=W]NC5P^!1@;CN===N84*H'`85/
M4;FF/"=VD_E.XQ`%H4<X#&LW)$TYR9>K*`,]HJ$W:QL%&JU`<(!+?GY:I#U*
M<'+\^+G`R7GV@611%O/K1G%)[E5I>[8HP"=NG*72-3`\`0\_.[^JBD"S1S2O
MV5'4\,/,06'U\Q9-H\'9B;)Q-@H[^BRSW"T*"C(:;8N&'+'S-/]2Y<15`1;T
M-O7V#MT.N>`S:8VH,A'N$_H/50'PB%5(96M?Q=TKDE6O!P7<=WC0#3@*#:!T
MB#Z=?<*.NNWZ#5-!04;AR'Y#!=@0^PT'AVZ'W%#[C4V:@RW[#54!\(A52.7:
MMK;RRX39;WC0#3@*#:!TB#Z=?<*.NNWZ#5-!04;AR'Y#!=@0^PT'AVZ'W!#Z
MC<WS&WKWMVC\XFY3L:$13/FC+E%94C);E_6VS"><WY1X.4&LB.?)M^S2PC^C
M_!YC8@B1'MQ[:H(C>=HRYFW>W=VP[-:,+P<J(ER$T]Y<8(C;$ZGTON;H^Z9.
MS=]'88B/'FWM:2UHG2T)#^S[B*12S-9=MNH`\7%4D-@).?92P$!M%>U)#2F_
M]R6NC=U%%%>E!M`Y!*(U3`0[0UH?OV[F`XE>9@TV%N1OHPG_D#PSIYLQ,/B,
M2:T4^FQ9E$CTQ2VF0KQW@;Z0\JX!(=2M8G>7=(!FML0.<@)4-;CO4CDR>;[A
M;Y?(</B$3PP;3K1AM3Q']RPQ\"1E;M:K52H>HHM25,1W.%FSD,CG?"2U)]0,
M95=X'/3JN_2.AME=6+@OPCLRP83%^$7V.BP:SG#"8KPRG;"X485%*)M>XZ#7
M"XL@MP;RK%EGDT,FZP!$0^]W_*$60A\LF\7$ZDW*KRN6;X`&^+M4(8!;UE8<
M]49-!N6#"@/;TKR5+X2PL#2_,H][M<;S=97.Y!O8I797?SC!*H!6ML3UZ73S
MK0<5I5<(#:K7-DB,LK[I`'[#8:S<U9.$L!#78J(+:K5FT#"6ERP*XX4N/3T0
MI#M"_)X`HK2V#B9#+7<RX6(5W.;5U"Y*FR?5S1,N*Y/W"9=-(B,LRAPUK&C#
M"S?C`M#&SQS+%6V;.9:3*2":S69KOW[>5=-2#>D\-I.#RG6#Q6864A/"3*!V
M*Z^O-ET+A79;KE8-%+G68R`J2@CT6H]4;/#`=\:`L;L#:;TCUWS<0Z<:"'HW
M;_]8L[2H:7TB6"5`X`^O&0W<0856.3!<*-X>,7E&1>X;'0H9="=X>`;&=8$1
M)8N[`!Z(L5E\@!6=JF!P&;M.;F'R#9VQR\WJ)<$P<#1JJ=E!>PA,\8<BSK._
MDBRQ'#A4$'K$SK!V_?9$O5$73E9LO9';"-'H"(,*D8*<Y]R^QBOFR+NHP)?S
M;M+Y:9;(+S`S@.KMAZ>6YA5?6XFH`2$KHLKAGL_1JGFH0'NDR%TUH=8VSU[!
M*N@OT)Z$VVXT;F\PR)"]G)\2?I\C2W0S9!4E0*BUJM<])KO!6%*1`D?/SF3V
M'1`*5*C`WM</$LBW^33^;4THEJ=5Q'<6]RA9`*"MDD.'EZIEX8`I[G):RL2/
M9,,(#/EGU\5W*)API8H)K0&""(XKRB<4Y>,5\T3)NB.>G7VUU"\OC2@`,G"T
M4IF;7;&35!6!ZC(F2)0R:5Z#$`6%$E9C-15L!:E?REI5[$(Y;%(.+,ZL$#5&
MG=D^(#'8&0(V'::<SS>[?>?+E?ZTUJ@B?,;A"+ETD=C,!NKQ#VRKOX6S.G@<
M:Q%X1%Y%])(*T9*_1^D:7V%ZPV]4.?E<RPR&0IU$5OQ5;ZZM(HKN.6,X,+1Y
M2`]`HS'@H2=D*:;KDHW^#"\"6YC`H-:7Q!5B4<,1#L9TKM!C2ZG]#@YLJ6HY
MQ0599(IQD@.#YX-:9FFL$+F1$)%\:,/H]7C6$W6H7Z^4.B1&'7P<RG)#5'T@
MRT'Y4%K.<_$(Z(BVJF(`;C&E%*XPDB^=AM92=DUO:R5;&H>"G<MU691L%DBR
MQ0C7M;F`4=02Q15*^88E-#PIW&$#5=\`\,BZQ0_E<6K8V=-0@R&I$<&M7PX'
M-`-+Z\'2U1$>)&(BXN0=20D&#E&]6]/R?6M,/T$O#R>'A^*_>@Q4O41_S+-(
M-"_5T\U+];T]4922W]8D$4-,.1F=H"-9%E_$BSN/A'^U?WBTF;5^C]Z]?-.N
M>C/\^KYY-#Q+VDTA*[LC;%0R>5>EN(6!7AUR?8Z.!-,ICJMOC\2WA^$$1`=5
M^F#8^!0H$'CBD/IV7Y:TSA>:K]>Y</H-%)LX^L#AG/*MY5R<UJH?`X4_%SK"
M/SV(.5D#!G)YC'%2?&"*\MM5IWBFQYB"U"NHAO5K421)>6LXJQ]]@D6.WLQ=
MJ&ATA,8&GZ%$3,U+>A.E^')N?+G>@1$(-VII#&G&5C629,KOBEWTLM&*B'0W
M\",_5S?ID&:P"C3NVO<_'?S;(0?"6%L&6_LD4)6%<C/79G@=?@8:0Z/F&J=\
M1'L5T?+1L4<;L`"AIR^'Y6"8`!"5/'R47X*^7.;B`QV(E(I#`XFWAQ_Y0VNL
M/60#MY,\37$L4OQ=SAT.DFU1$A#L',5S:L\"/*RUO4MU<!UCL)WL>K6JYB..
MRQ6OC-7\<T1IE)5G#S&F,1G>PA[+[7T_S%DTPZN-U1T-GF6?SQ/SF(@&463@
M9),M%"WS-6LM*8XQN6<_")Q6J5(1?A`5\-NHC);0:I$E7\E<GGPF^D7*4CQ/
M3G7]/MM3;3,<PG)K5`J+8:Q*2[B-N-$@W^S*C3,54,<R)Z7ALGF+P&\W4-5J
M2;<,<ZG\2>)Y[&!ZKNWU&VT5@+"G/O>HOQ]L9/&+3ZT<^O%(=59WQ9FZIUG!
M;WNZ^*(''[,!@`!US_K,//N0T]-\/2OGZW0:Q[R;-31O>A:_@-+*H7TY/D$)
MFY0$<?W3P?(]^)C5A8!/>[9WR_KG(I*#YU-2Q*PQ7U-LVRP>4X)'<(T02WL;
M4L[F11&H708DZK9P6!N$8\T"@\E5<W'-LA>B)/6*LF']+I=KC9LA[A)O?5_E
M6>3V%P)Z?'2QKE$2&M0.B^E:<B!P.RRF=X!B74OW#/*=RP\!=MM>@%%A:-`[
M[@4868#`[[@7T`&0&*66N7U/P',@/*LN$$'ALK]A-0!T<-S@F`V]$L>X:%,#
MA41+!!<$+7-:+J(%#F7,LVOQ(8"OP(P.\WUU8>!>8*;IW31C<MSC-!=+)^8L
M9V8>K]`W"*)%D.01JU[)A@L6/PY.Z*+(IG@X6#K/Q.Z#=EG?Q@6.IT84#:)^
MIJ3DFT5SWB9%\B(]?WM];R796`?]>X'<P%=VT'6M`P2[DI*8=3'\A6V^V\S^
MX:O`]U$J,H&7)Q&ECR1;F`[/CRW%+RS'B*9O^*I2Q'XP,/BV\5@/C*-M`@/.
M,B(93LXBFC%ABFD<KY=K,=8]Q7,2$_W(TLKH%8(V:;095!I"UO0)2ECDN;JC
M"S8G[6'P=8^SM?9Q@>9GKUB1=6K;(?DS+`RZ5NLZNR4^A$MO8IQ%E.2?LV*%
M8S(G#&7YD@%08V\]O4>G:X70/?Y8T4]0BP/](GE`'B!Q-G\;+&:U0="SF52:
M+T4I"'WB95"[!B@?JTE^L^R+]NH[3Z`HT9JY`P^UEH"XN,BSQ2VF2\.:EHK2
M/S+:U;M"(P!`J.RK0,1`.QA(+/@,[AJOF"'9N,;]=($+IU?(6,71=4.2$YUG
M\YPNQ2E<6!`Y>Z0+*C?]84"6LC(7/^$,TRAE$[5ILB09X8]SE>3>\IZ"([-7
MJ+E(I$6;8)Z@A62763*C3@FP\!OCJRX"G<T"`D)^YX*WM_9;*4I2GP!3U*^#
M$R=%(=TD,=FY`Q>=DB#@((N,C=QC?GQ4'OQC2+[*4S:OQX6U)W1C]@D@)XET
MD%HOEQ%]Y"O9K7+0IB!4EP0*LU$>ZP#/W3@@4*QSG%Z0#)^SC]I6:DCH$V*#
MVG5PJ@G1+YP4"5K8V;W6PAV8J!4$A<3EG"]Q?TCS+[JW=YU8(&"BD,,*&-8"
M<28DN(#?IAWC"R6,=`8`!E3S;.Y5+I.<NP-+SPH#,*T\+D#;/(=<<X<'.*NO
M-,`S&P84@/7BZ?2!6/NY#BT$Q-H"V#`U034UPQ&C#P-#*G,K03-0%10EMX;S
MV#TB"%S<&LXNMX8_@BP,'-SJ#BHK=(+Q/!N"5[?/C8F4%(1>$="O77<#G]_A
M19]P?L.L.T'G6;PODP56S'\2ER^?>@QYVPO$7M3PAW$==+HX5ZH<!M:M0S`M
M`RCVK<.M#<.?D&1!T[*D9+8NQ:Y>F?,K?:*M-`Z]GJS7/::SO,#C8L*F7B<.
MS@*,`_-HT:AN&''!VIMTG8C5&BJ&L2WPW.;\??$\*YE]4O':K_%UW1T5#AIO
MVTAL;-C#ZH,\J@<7DT^!M#E^MS;?[S?61_>;3ZKD=Q?[E@[L[&^?SV__^?L/
MCW'=W),-&4:X\$NE(\YN./.#@EPCU)CQ)2\";<I@DW!6"A+%!#2T'*EH\"--
M"QK-$6DR!DBPK6<%&SKPRU7WXJ5,6W!IZ7T&DTX([:9O38\D`RB@;!;O`,BH
M*0Q@5JM4+*)%:;WGTSI<9ANE.')[!9.32%IH;;C;37%[=Z]]^.X]+/1&^:X+
M1'<K[2#?:;NZT^J%CFJC)UN<Y,7@=),CD^?LIG:)G&!5O_XRKUE1S'F])B/=
M6I4/7:$1PTPW>3ZB$<_+"95UU!UJ=;)11U/L.@SJUX)%CE/6+Y"$1/S=()NS
MM'R0P:`3RJV9K9AE2MLV.UQ(C%2HIN?+PMV,;Q3+LX[\):9"9'Z`//T_&H7*
M(#$:9\=Q4J?+-&<Y=>4"C!&-2"X14K,BQHL:9O1)G?C42X",TV;*LPQ4)U78
M4&I5Z]/)Y!I"/%C0IHH&DR4@1O2W>+G*:40?G?;G=-0>1^P:$;37<9MW],3=
M)`8JV,.]%GNW1]TF30.`2IV!8"K2Z[MYJ\<#!YNN(+J]E9JG6HF:H)H-23Z8
M_:1G466"Q$Y20*&AQI<A0!2&""!,+C;/=<KG)C$SQ!6F8JG3S</F(N""R"B7
M!H@GK4=..XVS>`3U#`U>NU<\=\HZ4'DV)R"T.KG9`%Z[+0/`LGQ;>MH\9^L&
MDP$7'&+[HNP*I(/W=`-"ILYI!C`JS10,_L[%2\5C'%YQ0.-.BK$KS,D'FX,#
M6M<[5I"U;!(,P"XW[U^/<6^;#1IJ+5EVA;?6J^#!@4[A,2OR^B8*`'XBF=O9
M0W5L8YHD8@TD2J\BDIQG)W+=W`T&;D7!P=1)OMU`]WO^AOV;=R\G_*GZ04^M
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MZ,L=IAB)>F0/+RM#C%`\O%I$2RQ^H"*1E=SAC1!_>C;ET,V>^&3-R.VYW5LI
MJJP4Y\LE&TI5(RW@:</3<%_OX&UI+`G\2NT+5B#[F_W%/LRB`K,__@]02P,$
M%`````@`R8!J/[<VJI<:&0``AM@!`!0`'`!N8G,M,C`Q,3`Y,S!?<')E+GAM
M;%54"0`#R3R\3LD\O$YU>`L``00E#@``!#D!``#M75MSVSB6?I^J^0]:S\M.
MU<BW7#I))3/E:\HU3NRRG9G>?4E1)"1S0P%JD'+L^?4+D*(@B@`(4*0`(>CJ
M:KDE`#S?`0A\.#CGX.,_GJ?)X`G@-$;PT][1_N'>`,`013&<?-K[=C\\N3^[
MNMK[Q]___*>/_S4<#B[./Y_<#6Y@$D,PN!I^`1F.GP>_AR`!.,C`X"%X1A!-
M7P:W&*0`9D%&VAU<Q_#'*$C!WP;TO]&`?/7[Z=WUX'C_:#!XS++9AX.#GS]_
M[H-H$N`AREO?#]'T8#`<ED_^5R'CA\';_:/C_7<KO]RA.8P^#%X?AM%Q^/IX
M^.8W\&KX^DWX;O@^#,?#Z/5A\/;-V_!=$!RMU#K#H!`N(G)_&!P?'AT-R;^'
M[Q\.CS\<_O;A]>'_KI9&LQ<<3QZSP7^'?R6%#]\,:8V*/OXVN(+A_N`D209W
MM&@ZN",ZP$\@VE^TE"ST,"!*A^FGO17HSR.<[",\.2!MOSHH"^[]^4^#HO"'
MYS2N5/CYJBQ^=/#[E^O[\!%,@V$,TRR`8:4B;8Q7]>C]^_<'^:]%Z33^D.:M
M7*,P5XV"@`-A"?I_P[+8D'XU/#H>OCK:?TZCO;_3!W[$*`%W8#S(9?B0O<S`
MI[TTGLX2L+?X[A&#\:<].$IS;1^^?W5(J__E'(7S*1E=Y6<`HPN8Q=G+%1PC
M/,V%WQO0YK_=75500(#2#$SSP94MQNH!+7B@U.;!AH+?D8K?[\E;`>@C;L:7
M,22]%0?)+4IC^H2S)$C3>!R#2%=^Q5:WB.`VP$"[&S2:SAY!%H=!TCDF\AJC
M*=A`\D4#7<MU%J2/EPGZF5[!*,8@S#80L=Y6)])^11E(']"RZY9/3+\&V1R#
MF_'-C*X4I#=37>FUVNX9S7T\@60DA@',3L*0+$`963!O41*',:D!GK/3!(4_
MND.H^+R>49^#-,3QC&KX9GP'0E"1!A,D<[+VY$5[T$&KI_>LD=-Y2E;^-#U#
MTQ'YE<IV'J=A@E(R('O0@>+S>D;]&:'H9YPD)S"ZHBOE)!XEX"1-`>FD/M%K
M/K=G+2P&7WH;O`14#AB1;_`<1-=Q,(H3LF2!?M715H#>9XE1UBMNT0-ZQD6V
M-&.`,8CN,_*T'G")'M#W6D:?]HB2B.RP+OZ8$\I+R_;:@^J/[!E[P=3(KK57
MN-*G]-V[8$(_[\`,8;I0]MNO"@_K&>\=2,B?=(>0O3S@`*9!F#/"7G'K/+1G
M_(093..L6!]@=(9R=@1@V/=BI/G<OD?]?)2"/^;DSXNGGNBH^!$+;+,5$QBU
M@%5`DL(`1G2;7WQ+']:EI2(7@0A!!*H\-Z&V'82KVET\-C?@I"#<GZ"G@PC$
M!U3C](]<]</#HX7YYB_DJ^\GY-$1??QE$DS*YI)@!))/>_7?#WJ7YVR.J4W@
MDHRU(/D?$.`+&)V3ON*()BRJ)V5M3)(OOJMTSLDHS7!`M^\5T;2K]Z_44HQ"
M5;<`QRBZ)-^E'*V*RVY;3MJE:E*RDMN3<:4GR:P`KLA++A.46WQ[TA;]*'Z7
M^.6V)]\#:58B5OYS_]+D[RBUQ-!]&$><ZN];DN?EC"@`!\D566>>_PE>1'+5
MRFU-/D(9$,SW`O>/`5DM;^89/;Z@AT]B8665MB7Y.9H&,13*N/AY6])<Q@G`
M9^2]FR`L[N5JJ6W)=@<F,5VN8/8UF`I?C?5B_4MW#29!4CS[Y#GF3<#K)?J7
MB>P<Z"B^?YF.4,*1J/K[4IY5GGF"J[(%."P;(G_62&;UR&Y1XF"6GZX,P\<X
M6?+3,4;3%A2E%`;QYL$!PA'`^:DS^6=O,"-+""8-?=H[WAO,4R(JRJV]@1FP
MJHMV":ZZ)#%L1PY@6V/[#-RQ`^`$7(>!?.40R!I%9C!?.P>SLF-A0-\X`'1M
ML6#@WCH`CL\=&,;?G,%8X^@,Y#L'0(JM,@SG>P=P<HGX$N*1"_1&9<_&$-M*
M>K@[]1)B;5-@/T&5XI%W;PGN\-!>>()M6G5,EKMQW=[Z>+!NHN_7<*_HHM=Z
MGSD.TE&NX'DZG`3!K-AL@B1+RV_6=YV+K[^O>1(L9NVU+6A#X?;[X\WEIMY`
M\1.5YBO(U*3G5C&$@?IL+,^(0=H(0%#>H/0K'B=*TG/*&Y)^/IWG9[<WV2-9
MN]&4O/R/`*;Q$R@T?(W2E(R0FS%1M1B35BM&D$917$Q^MT%,!L]9,(NS8-W*
MU%3:B.2Y?Y=(T.)'<W()SO($A<S)V?!65LH8EU))J>ME34A-O:BIMP/YH&Y,
M3T&2^S]D9P'&+X01_RM(YNM&;[VZ1E")73E$6"0U3"%8[%*D7;!>S(2LYPNG
MOSNBO3/R&6=?$0REKZNTBED,3P#.&_BCH+`%<FLH?KV\2>D)IRBFQ$;R*ZMA
M&($R@Y37L0>%\F`25C.#!9.E*"/$50^*O)81)'/P@%8<,Y5P2.NXXEW07J=E
M`(9`?<N?3<BV'A%"IK:+YS"94\MD@]Q*5<U@HJZE"+\0B82RKQ1QRV^BO=Y6
M9B'"1^O1!@)=-E:S$4O#9DFYNF%L\D7?DI6^+H:Z]FW8K^JLZ?:LY%Q)U!7/
MJ6,$!0I@:3-_0*<!_-$PY(7E34C_)8;Y80I9*@$&J4CH6C$3LN8Q&TI'&;R2
M)B3.S<8+[M'T7O++&I.:PYUD@O.*FY"]&FLI,Q+Q2AJ2>!;$T<7S#,"4!ONN
M#`3Y*%>I:081F@&<O=PF-*T!C"@AF5$CHG@,2:N8P'!')CD<AV2_N(DM6+<5
M,T@SLNT$T46`(1$D73GU.@?C.(Q%?:90T02>>T#F3BK"J,%HQBEH4-YK!"</
M`$^I.'*!*R6-2/R(<$8EH'O4M#@>$(G,*VI$YM)'XUH0FR4I:%1>CD])`T56
MJFH4$R^<2E#(C)R*=@5++`G:M@/+K`5U<:[@PDIW2_,-D&&;D65T-,^*/1.E
MQPAF&"5$E$G#SJ6CQG=7+]IC8:.'F-#3`YC.$`[PB]+@%Y6V0/*2#)Y,J2N;
MFOQK=2Q`D5/9I9U=ST&I55,FG%A+@?G>0M2/M5JB9E9<.K6^LC'H01V>?+/'
M4-H8]:".4FP280AMC'=01\B.TI:(7MOH/:Z.2.W@D*&U,;1!<X3638T,GHT1
MG;JSZ"J>1?#FPHAW7:PC0EER03)$EHN\I.6:$!Q"K2I$T2S%]&5C%*@V:K[I
M@8&T,0)4&Z2V[9'AMS%(5!N_//J#@;6?."F`K;J",'#V\R4%<%)/1H;UO?Y4
M_@3P"*7`D<E<Z0QHJ:\W]O,RE;=<A.[(J86]]VA',]VLZ[VTVO,R;QN[,Y!T
MC)[G]6)W=I(N%"`-0[$[:TD7\(762KOSF'0!O6N#MMW)43J>+`0.K[7D*8ZL
MFRJ+A7CKL.XE9G<"B]9812':#.ZQH]1:3U42'TVFJA8&)0=5Q76R9$IZ[94D
M\#%B.MJ1Y5M]BN'EL&!P=V3MU3-7R&?5%DNM@V^!*#J8Z>F=UY,@&H;IJ(7Q
M:[=HFSBVH_G=XQYE'?\"I$9/:?P<`TQA.V)*T`5="^YGB'\!GJ*F+:Y[,=/3
MCG`5U9'1$.3.<.\(:5'$+0^)9ZAM/C'31MW8QRW8QPZLK&)/]OKI"L=4=FSS
MJ8(:-G6#&D-ML]E'Q]>_:DZM^M/OQLD1/PI@1U.U-H.2#6W;,[6J!QBL'6;7
M0S"9FZ3=;Z+N058U&QE#:?/II1Y*H0,W`VOS]D(/K$HP),-M\Q&E9B?K)DQE
M2K!Y!['I\>0JSK>.LLD^8HSD6N4=X+IJ*>Q?O_4,'G9?P6!RY+6+*ZS=]^#8
M'-`0/R=Q7E$,]6+;,)L'9'LUK,?ML46C[P%CYU4'M[FN'T$6AT12$UFGDP3]
M)-*!2X3/T7R4C>=)W:N\(7>V5AN&LR$3C=_@O'.B_)V\!3B_QD6`3:6F843%
M+30G\^R1O`'_88-5C*16PPH$5VDZ5Y=^4=H*R<6WMBI5,8,!$E:8T9B_JA5B
M5;O?9F2NR@NF9-820M-OR94\LF[E#*UVG^9$J5C9/"[%Z;*ADAX..$ISX0[?
MOSK,1:/7R/*><`[2>`*IVM;$4JA@BVJE\[BD@BWR-\_F3;5\VB:?MLGFM$UK
MF[+KF'Q$^0ZH&-F`</F&Z5ZK"0LP*L[Z3;6L02*=9&4UK$'0/,TV5O-1BMOV
ME="S%NQ&B*(:],;Y9#?"$5N!;5@@=B,2<8-N+B?;W8@[W``H_RICJV,&U=`V
M;0'MOEA=#VLKTX[=EZYOTMEB.\:NG/[),*L8$NR^A7WS%[DV/5L=NMH>I^"B
M^=WG5DK',[7P4S<`2]:BH]VG4\)#GMV(`6T)4O"B[@2-\I[5WK/:6D^*PK_2
MA)_$&9'N9KP(I!.>A*Z6,6%H*YUQRU7S-$CC\`1&YW$RKY\IJ=9RY;1V@UL_
M,4K36XS&PBM>5DN8N2>S]#R^))-"D2IJ3CKU9@9P_D:FIV",,%A)4+#N#DEZ
MO-I*81GX`@@UB9HO,-FF!.8TO)R,&LZH1*7-24XTOLB:>`H@$(]D46DSDA<#
M8R&*4.)J*>_/4>CE*\C8ZR307;6,<2DWN+Y$OQWS:)^"."E$7-E#+/RP\U58
M"6MS*V;NH(2HF/JIRJFP\K=87-XJZ1OF_>9Z1NZI+$5:"".:#>KEC$K;.'OQ
M2AJ[!U1WP#=4,N\.=1X_Q1'9M:5K9.9J.A._`%I-&+ISD]`9R:!:*6#H/DU`
M-OTTF_TYV4HF*+\C1CZ4Y'7,H,AWP2(=+W\V<X]DS@,^$V*+@X3H["2:QC"F
M\S/-B")7M6)E[P)H@[L<U^_VWR">/&8@.GDB/3@!7^?3$<`Y3UH8/)K\DUHV
M8M(VV+!YW5V+KJ/N6,KTLW:QD82%U#+IN0.]9BBH9?'A!A;F,LZ7$U5A;\[?
M\@-(!E5N,G5)32J#X]BM6R7TCO(8;7')=W'M\,(E3\6*9;[FB/B+CF'I!L(E
M)T95)N^2*R/'EN/ZS0::BEDU&VV4-\49U2B0!1><(8T<AKJ>\T1'Y9PS1K><
M,IGI<*.+0YSI]A:'=R[Y<:Z=L&YT^8<S8T+O$,$E1U#MP]V:;^@O.6`:O=9J
MUXGL(-BVEN?:%2%V8_<.M3OE4$OOR[Y,T$\R.T<Q!F1"-I&#+/J_^8).T^3\
MA#6$<7Z3-9M,R1Q*)"7\BRXFT>G+MY3>M;3<\9V$9+M?I#F7NV?T\B@39V<G
M4YJ7\3_YV%BZ[,,)M?2E^=29%E'9(CVH5C>2FXK>Y1Z2_199">G6*_^["$40
M>5Y+:AA#T'P;O1A+8UTG47T_M@@782,QW>J'&`0I.`?%IQ8\01,=G&'G4U00
M1^=S3'.TYL^Y1%@P^ZG4Z$(H1G.+,*\'M'@I3^<I62#3NN.9<C5S.?+2?(K,
MQ2NREB[BJT%T)!H,C?5,H"DO@]+S!F^J908)849A7%!!&*VN94(4XAH=#/QR
MCWL#N6&[X[41SO%V:=N*D2"C\9@0Q9OQQ7/X&,`)N"-L\@;R9T!!?V@UX<./
M/I,'4VIZ`YO#</AES4I]3WKR9IR[IQ2W+37*7J]A-'"&WO,;B\+GUDMU,*&L
M4X8KN'9=]^*ZV?((D+PUN:Y6[GOB3#!=M&JH&P1RLYQ3XKYIKFH'IK7+&I4!
MK=>S`PV=?"!Y6GTDJM6Q`\5RU[](T-\<]*?:@"7XZ.O-3!NRN5FQLAVX"(&:
MT;W.XM4H#[L7\YDF3J7&[,!]1Q9\'(=DCT%)E#+"M6HF(SVEZ^Q*$=,R+MYG
M22I14>DNZ`&E_S`$U3T!+-DTV=8+<X#Q:,$&K1GIAJ6\Q>8:1O\.,`[(FDY$
MO0?X*0[)=@F?)4$LC(#0:\,'%!=:NT8!++GB%T`/KP3JY10T%&S+L^4OS=W,
MEB_`H=&`W?B:HE;U&[((;['1W:`_>0W8C:]=?\H:L@@OYZQ-#R>O`;OQM>M/
MVPXEJ<L7$9,Z7.:.8#&"C3'_H@H=T*1%Z^K3H6*E[D13?[,5*YGI]0R4B_T#
M.@W@CU1*#L3EC82#YQ?P_3.F_K[2_"*<@F;D?<E-NH2GWH'9'!.2GA(:6^7E
MA,^R1-T\WK]I:R:1WXR7/H4-J%9+FI1X>:#9;+Z75K$"`UF$R+*3O=PF9+M$
MA@8]JLDCC%01B1LPE`XB!"#*??SI7'0.1N+4%IRBIF5>[F1Q<6927L?<B$!0
MT32>U=5!`46EN&G9[T!^+_AM0$:WXCBJ53&-@0Z&+T$VIQZ+]#`6)0D(\Y@9
MFGZS<?IJT5('=*KR6+I`W<P61_T+L\[%<PAP&/,=4'1J^XPU7/F>8NKNPKD5
M1BRQN(J9?#6S)6EH6`:X14W+K#!M"HN;EEUQVI16,8WA'H1SPI<5Q5\M;4^.
M*7K4169"X3335,M(#J$0P`#'Z!M,9R#,[]3F^O$TE_<9F[0N;5Q&#JA?UEBO
M8A1#.10X!R[RLF[FRNI(SOELEN0R!$G9WU=PC/`T4+G94[%V!Y1Q]5'ET7XU
M#H+#%!4J=2U::<#(R>E\E,91''"\:M3K=2Q@N9M?W<A_!3SSI4HM$T/V&\2@
M.)MG_H?G`,=/>0X1T=305,MDX%J?`565H'^]D_AEU-\KFU,J;4MY4B]VIBJ;
M@^2WI2J!_S-3DBS<?H=SO&U+O^K!A$SE-D?K;TMOC2L'4Y<LOM^/T$9--VY8
MF:9M3A&P_0F3$WK!5"5+B>4'9:.6>4?'3+DVI]':EH9D#B%+3;VV.0?$UL:2
MU(;.=&5S$JWM,>>&2%:FKA:YN9X`'J$4V)U89VL[/(V0&*9U&_<L&E'SO,32
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ME"4+%Q`H:Y;W`)$'9[^,RKX?KU(EF=..5&D7,')!9<K9=)C*;-Q'J(%6)=T,
MJXU!6-I8U1;8-S:?`*ND!>->F_ZP9O.QVC%<FCBL`D^\K=@QI+6+[[D^_[L.
MJJ&#2WB'SN!;F9*6X&Q'IY=7;GD:T10.R\:NVF+R\6`5/%'DC^+K]6\K.@'/
M&8`1NRFLIA4(4$KZ8S]$TX,L>$8035\*.I/;6![08I$(DF4?IE^I;P?-[5%L
MT!%,]QRY*->M2[,X_5055%*PDYM&1`-(>M-(8R6?+K7GI)T^DF\SZ[WJL'>(
MF,KM>YQY2'?ULXW9_!IT=".Z9@]AN8\GD&R&0NIH6<1"4TJ&DC@D6]X'\LC3
MA+I">!+3*8EQGQ2H#2O!XJM6V9,=3W8L74\\V>%B4YP4/`&R$)2K!.@<I"&.
M<^EH?&P(*H,3DS;F,"R*MJ1#W,6^U6/KRW^K9OKG3Y[-N<7F/.OQK,>S'OW3
MY':SO.<_%H)RE?^4`4!G:#HBO]('TZLE$I3.,>C``-1^%E>4C#^[*U;V5,A3
M(4^%/!7R5&@;!B#5&=T3(`M!N4J`/B,4_8R3Y"2_,2:`$QH)7"13[I0(V448
MVJ\HFOKBKSB:C7ABY(F1)T:>&+E*C'3G5$^0+`3E*D%:OR,!1HMK$E:N1;#$
M9-165/[LW[8U;U3RW,ES)\^=/'?:!G=J/>?72)1S%TYY`N8$`:.9^BTA6")1
M^$N`J+0G2)X@>8+D"9(G2-L@2,(YVUN1+`3E*HFI9IMU[CS-4X$M+:VB<<1?
M8T6E/8GQ),;2)<*3&!XVX6OO28R%H%PE,?G@>T0)09`6=R/3L@Z["7E:X\E!
M]^1@JW*JOK$B"*KU/?7QU*>?L'GU(>R/M#R1V@DB5=QY]A`\.\R=VB]:4NWP
MUREI%<__//^SB?]YAN094I<,23Y?>@N1A:!<)3;W8$(_[\`,89KDP6%^X[G!
MMM9:A3$E6(`5:GJVX]F.I<N(9SM<;"K3@2<]%H)RE?3<@83\&=T&.'MYP`%,
MR5M)'NYR_+PG/UM:>G7&%G]=UFG!DR%/ABQ=7CP9XF'3FAX\*;(0E*NDZ`Q-
MIW%6O)PP.D-YSD\`0WNBY34EY$_TFHWXT"_/_SP[\NS(LZ.MW.ZM.<-[_R%/
MKG:"7-W/1RGX8T[^O'@"[:_F\/S"\XM?B5]L4T[A&RH065C>LR//COHY2!,/
M46\ILA#4%LC,QP/ZM%&0`O(__P]02P,$%`````@`R8!J/_*\^.R3"```L$``
M`!``'`!N8G,M,C`Q,3`Y,S`N>'-D550)``/)/+Q.R3R\3G5X"P`!!"4.```$
M.0$``.U;[X_:.!/^?M+]#W[Y\MY)#8']U2[:[8D%MH=$807<V^J^5"8Q8#78
MJ>WLPG]_8R>!!$(VR>Y)7;U(53>)9Q[/S#-V;&>X^6.]\M`C$9)R=EMKUALU
M1)C#7<H6M[6_)E9[TNGW:W]\_/67F_]8%NIU/[7':,0\R@CJ6Y^)$G2-OCK$
M(P(K@J9XS1E?;=#$69(5?H=F6!(7<8:^WHT'Z*S>1&BIE-^R[:>GISIQ%UA8
MW,#5';ZRD67%7?TO-*J%KNK-L_J'1,N8!\QMH8N&XYXY%V?6Y7MR;EU<.A^L
M:\>96^Y%`U]=7CD?,&XFM#J"8`6`R`5#6^BLT6Q:\*]Q/6V<M1KO6Q>-OY/2
MW-\(NE@J])OS.P@W+BVMD0K`.]1G3AVU/0^-M:A$8R*)>"1N/4*2)@H(8LSD
M;2WA^--YG8N%#;A-^^OG01BMVJ^_H%"VM9X)CZ8T])-8Y]RF3"K,'))0`8N^
MYVCH9DU&LI,#E<BLYO7UM6U:$]*!M!88^UOY.98S(QTUV":BC:9UWDQKJ8U/
M9*:::<G68[-TP!CA4I&521*MT+@^;R3%.6/!*MM]5PE;]V2#D`521%`GJ?J\
MWH&.EG'55BT9Z4L[;$Q(.Y"O2FS2XI(X]05_M*/&["BXA&9K04.V!F6/1*IL
MI;!M7T]AL2!JB%=$^M@AQ:(.XWU%F+KG8M4E<QQXT.6/`'MT3HE;0UC!O#`+
M%$D)!&PG\E&CW&#&N#*CTMSK)[Y/V9Q'M_!`9V%+<(],@0JD+_X:]X\:J:+Y
MQ]:"=I<[@38S_HN9VV.*JDT?NA`KTW$-4?>V5DAR:U1LEDOFE%%C?K,!<PV*
MU9.7`(5"+)0`N['W$?;!`Y@X1^RCN7:PYP2>41S`?:0<2>0I^@)F)*8J:.XL
M.ZX7/8W9>1W2)F"M2:[1_)XRF.0H]AZX-*9T/"QEE&.:MC$H?"NHD,_>.5"V
M!8+KSF@X&0WZW?:TUT5W[4%[V.FAR9^]WG1RHNYEU#U@`2)+HBC$IC2/1OL9
M,B^*DXE^2YGS^XG<`N3"LH>O2#9U45L^09=Y!$VF\.=S;PCDC.[1Z*$W;D_[
M('"BI@`U'2R7]QY_DGWF4D$<E<W2H5@^85?%">NT)W^B^\'HRXFPHX0-N2)R
MRK?3W#:T<HA5(,AH/O+UA@HLDPD"2ZGE$_I>+U&H=#PN01%NIDL"FYZ5C]GF
MQ%MYWB9TP>#]Y&"FVHY9T\,.^H%[U*&@0=;JSN/.]T)<%H3*Y_?#/K^38+7"
M8H/X'"4Z0+L>4-S%B?[R]'>)=`3UM4VC^9@X),6=`(P`=NM&M%PR5`+.3XWK
M_=0(8;T-:KO<5\1-)46JBU-JE$^-NT!21J2$R74&K=JV7?3+)4-!J%SZFXU]
M^MO.CX"&R^P3P14(_L2Y^T0]K\W<OCXY6-"91]I2$AB]%8DN"9E/>'.?\!C=
M'$V,8.LCT*X7%'9S2H3RB1!-F_(!;[#FB[GP1`3$'5`\HQX82RIG1%7L_-0X
M.YP+#"A*H)XRH<IR8*:J,GU,-Y_)\WTF[S#[C@8<,_D.F<Y0E#IFU'_F0BWP
M8O?TQ')YEA\$F1,AB#M10%`YEH_IYK-\L<_R%@89G!.+%79N.G!+[KE$R!ZL
MA-1&RU8=O<71\IF^/-B_+;$@$?!_40A]HKL\W>'YY!2OJS*<"Y!/ZM4^J2&6
M_FI^>L]6&KMDH?^.B0_O,]BN5AZU!7#RJ3TX3XL@3]_\7L;PF$`(S%<?M9D*
M6,U@QVQ4JS)=!B^?\8,3M@@:&6R4!#\17Y[X#E^MJ`KW/LSM<',<19CS@CU4
M2<A\^@].T1+H9HF=PC]E0(7)/9A)\B.`R]YC^8/3X]JYO)X='(_M@%"(]'_`
MI?Y/%XN-R1R9.K"6+H2ZK4FZ\CU2BYYAX6C]_`HRVQ?<)T*?)-@Q;`QPH)TN
M63/YL1>_R*H880G[G]L:FTDK+D_Z!@KU]<J+)115NI/.#@9I'-@58\^KV3^O
MXVD6G_<;Y#/\[FY1WHC;'IX1KYC'()KA\4`#O!%G]\?X\SZ#1H;/#PF<+-=O
M[&1='=REZ^YNP'-8^"*6601XI/(4A<6M`^X8H!P5?6?%>I9^9#7/K/-F?2W=
MR,0R%NP"7<Z"6*^L!9G5G47[CA5TIY>%NLLMD#W6K>DRLR+7)IZ26RQKAU4^
M^@<%L86"L*^E(W&MP]^\>HD)B5K>DF9P-JQF25[%\PN(T4_*\O)<"7&N.5EZ
M\<V+#-FK2BYD1*RC+U[4^6%U<Z'^$VK1]1$KHI)G8X9>3\CE`Z9N-Q#Z0SRD
M$W?ON6C/I!(XKKJ"F?O;LX+AR\<4_+?@&0CU80FK%V4UA".IVYH2@7ZS&"G?
M@$R-GAN(J(R94<_3)_FQK(1U*[P>`MWZ2?#`CSNA`'_$*=C"<&:.,/M2!L2=
M<O-Q6)#XRS.1"<\*22?=`W&BL-AD.3C'GGS&P[!MACW]'H$&,J/J5?RN7KVA
MXU!-.XQ+^+N%EHJ?5XS,:\2`/E*7,-@CI#]-F'-G.9KOL:U[2X2@BO*;R(P"
MOPLX'//EM'ZB":#/'$%@B=0EX=\^V__N''X?[JU]PF!XMX%R73^0^%R\B\*K
M@+V%)#$I#9CI/&>]M;/$;*%_`]/A\&:!;0+TDQX@B6B]!.0M1&G(F:.KCL.C
M&K9H.PIF#<WRX0`J(OL3#9O(W+Y9/A1S+5?VIW+M:$5*AFO/R_Y$KF6]JN!=
M3A=,'^/OW'I.+N62:2TU],*-\>N,,5AM.(2X\E[PE;%V9)8E,+-^P4)`+S"=
M$.'0U#JNE-);F&DF@>^'#[#7C;C;3B4=+E7"^2*R;\[G:#46,@I8U*58I-[-
M!<7?FN</X7'<!G)75TCX^NF0J&R_CPK_>U[#0LA]);>_$/V3<^*V84V`%V08
MK&9$W&%)G2[U`FB(UMZ!TM.+_CW_+@I5=%\XR[UDYKZQPXT\7/X#4$L!`AX#
M%`````@`R8!J/QVA^-U\``$`5:H.`!``&````````0```*2!`````&YB<RTR
M,#$Q,#DS,"YX;6Q55`4``\D\O$YU>`L``00E#@``!#D!``!02P$"'@,4````
M"`#)@&H_+CXLS+4.```BRP``%``8```````!````I('&``$`;F)S+3(P,3$P
M.3,P7V-A;"YX;6Q55`4``\D\O$YU>`L``00E#@``!#D!``!02P$"'@,4````
M"`#)@&H_).@YQS<8```TM0$`%``8```````!````I(')#P$`;F)S+3(P,3$P
M.3,P7V1E9BYX;6Q55`4``\D\O$YU>`L``00E#@``!#D!``!02P$"'@,4````
M"`#)@&H_WV2O".,E``#UYP$`%``8```````!````I(%.*`$`;F)S+3(P,3$P
M.3,P7VQA8BYX;6Q55`4``\D\O$YU>`L``00E#@``!#D!``!02P$"'@,4````
M"`#)@&H_MS:JEQH9``"&V`$`%``8```````!````I(%_3@$`;F)S+3(P,3$P
M.3,P7W!R92YX;6Q55`4``\D\O$YU>`L``00E#@``!#D!``!02P$"'@,4````
M"`#)@&H_\KSX[),(``"P0```$``8```````!````I('G9P$`;F)S+3(P,3$P
M.3,P+GAS9%54!0`#R3R\3G5X"P`!!"4.```$.0$``%!+!08`````!@`&`!0"
(``#$<`$`````
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
